<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC2802127\results\search\drugs\results.xml">
   <result pre="of combinations of HBPG and either ACV, phosphonoformate (PFA), or" exact="cidofovir" post="(CDF) against HSV encephalitis. BALB/c mice were given ocular"/>
   <result pre="therapy of newborns with localized or disseminated HSV disease, although" exact="vidarabine" post="and phosphonoformate (PFA) have also been used. Although these"/>
   <result pre="Ocular infection Mice were anesthetized by intraperitoneal (IP) injection of" exact="ketamine" post="(200 mg/kg) and xylazine (20 mg/kg), their corneas lightly"/>
   <result pre="virus (to yield 150–250 PFU/well). Test compounds were dissolved in" exact="dimethyl sulfoxide" post="(DMSO) at 10 mg/mL, and diluted in overlay medium"/>
   <result pre="example, a ribonucleotide reductase inhibitor potentiated activity of ACV,15 and" exact="docosanol" post="was synergistic with various nucleoside analogs.16 These findings are"/>
   <result pre="Sci U S A198986105110552536930 16MarcellettiJFSynergistic inhibition of herpesvirus replication by" exact="docosanol" post="and antiviral nucleoside analogsAntivir Res20025615316612367721 17ChoCTFengKKCombined effects of acycloguanosine"/>
   <result pre="ED50, mg/kgb HSV-1 HSV-2 ACV 82 90 PFA 200 300" exact="cidofovir" post="3.2 2.4 HBPG 150 103 Notes: aOcular infection with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC2857246\results\search\drugs\results.xml">
   <result pre="cases in early phases of the outbreak demonstrated resistance to" exact="amantadine" post="and rimantadine. At present, circulating viruses appear to be"/>
   <result pre="viruses appear to be largely susceptible to the neuraminidase inhibitors" exact="oseltamivir" post="and zanamivir, although oseltamivir resistance has been observed in"/>
   <result pre="largely susceptible to the neuraminidase inhibitors oseltamivir and zanamivir, although" exact="oseltamivir" post="resistance has been observed in recent cases in Europe,"/>
   <result pre="America (1). More recently, pandemic (H1N1) 2009 virus resistance to" exact="oseltamivir" post="emerged during treatment of 2 immunosuppressed patients in the"/>
   <result pre="immunosuppressed patients in the United States. Such cases demonstrate that" exact="oseltamivir" post="resistance can emerge in infected persons treated with oseltamivir."/>
   <result pre="A recent study showed that schoolchildren may incompletely adhere to" exact="oseltamivir" post="prophylaxis instructions (3). If other groups are given oseltamivir"/>
   <result pre="to oseltamivir prophylaxis instructions (3). If other groups are given" exact="oseltamivir" post="prophylaxis, they cannot necessarily be expected to follow administration"/>
   <result pre="is difficult to enforce. Moreover, even when compliance is high," exact="oseltamivir" post="prophylaxis may fail (4). The first viable oseltamivir-resistant human"/>
   <result pre="Ecologic studies suggest a lack of association between prevalence of" exact="oseltamivir" post="use and prevalence of oseltamivir resistance (5). However, examination"/>
   <result pre="of association between prevalence of oseltamivir use and prevalence of" exact="oseltamivir" post="resistance (5). However, examination of seasonal influenza virus isolates"/>
   <result pre="examination of seasonal influenza virus isolates obtained before introduction of" exact="oseltamivir" post="showed an absence of resistance (6), leading some to"/>
   <result pre="Mortal Wkly Rep2009;58:969–7219745803 5. KramarzP, MonnetD, NicollA, YilmazC, CiancioBUse of" exact="oseltamivir" post="in 12 European countries between 2002 and 2007: lack"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3058091\results\search\drugs\results.xml">
   <result pre="a CC50 value &amp;gt;100 μg/mL. Of the five drugs, only" exact="amantadine" post="(IC50: 1 ± 0.42 μg/mL, TI: 100) and ribavirin"/>
   <result pre="only amantadine (IC50: 1 ± 0.42 μg/mL, TI: 100) and" exact="ribavirin" post="(IC50: 22 ± 1.36 μg/mL, TI: 4.55) had any"/>
   <result pre="Ribavirin was purchased from DUCHEFA (Netherlands); azidothymidine, acyclovir, amantadine, and" exact="lamivudine" post="were purchased from Sigma-Aldrich (St. Louis, MO, USA), as"/>
   <result pre="antiviral drugs at a CC50 value &amp;gt;100 μg/mL. Amantadine and" exact="ribavirin" post="exhibited antiviral activity against the Korean ECV 5 strain,"/>
   <result pre="against the Korean ECV 5 strain, though azidothymidine, acyclovir, and" exact="lamivudine" post="did not. The amantadine possessed an IC50 value of"/>
   <result pre="5 strain, though azidothymidine, acyclovir, and lamivudine did not. The" exact="amantadine" post="possessed an IC50 value of 1 ± 0.42 μg/mL"/>
   <result pre="0.42 μg/mL and a TI value of 100, while the" exact="ribavirin" post="possessed an IC50 value of 22 ± 1.36 μg/mL"/>
   <result pre="drugs tested here (azidothymidine, acyclovir, amantadine, lamivudine, and ribavirin), only" exact="amantadine" post="(IC50: 1 μg/mL) and ribavirin (IC50: 22 μg/mL) had"/>
   <result pre="amantadine, lamivudine, and ribavirin), only amantadine (IC50: 1 μg/mL) and" exact="ribavirin" post="(IC50: 22 μg/mL) had antiviral activity against Korean ECV"/>
   <result pre="22 μg/mL) had antiviral activity against Korean ECV 5, with" exact="amantadine" post="showing stronger effects than ribavirin. Therefore, the amantadine and"/>
   <result pre="5, with amantadine showing stronger effects than ribavirin. Therefore, the" exact="amantadine" post="and ribavirin could be applied to patients infected with"/>
   <result pre="amantadine showing stronger effects than ribavirin. Therefore, the amantadine and" exact="ribavirin" post="could be applied to patients infected with ECV 5."/>
   <result pre="patients infected with ECV 5. It was reported that the" exact="amantadine" post="could suppress the IRES mediated translation, and ribavirin is"/>
   <result pre="that the amantadine could suppress the IRES mediated translation, and" exact="ribavirin" post="is a nucleoside analogue with broad-spectrum antiviral activity by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3065466\results\search\drugs\results.xml">
   <result pre="stockpile of antiviral drugs, [1], [2], [3], [4], such as" exact="oseltamivir" post="and zananivir. The size of the antiviral stockpile and"/>
   <result pre="experimental human influenza.JAMA2752952998544269 6HaydenFGTreanorJJFritzaRSLoboMBettsRFet al.1999Use of the oral neuraminidase inhibitor" exact="oseltamivir" post="in experimental human influenza: randomized controlled trials for prevention"/>
   <result pre="8MosconaA2005Neuraminidase inhibitors for influenza.N Engl J Med3531363137316192481 9WelliverRMontoASCarewiczOSchattemanEHassmanMet al.2001Effectiveness of" exact="oseltamivir" post="in preventing influenza in household contacts.JAMA28574875411176912 10Hayden FG etal1997Efficacy"/>
   <result pre="contacts.JAMA28574875411176912 10Hayden FG etal1997Efficacy and safety of the neuraminidase inhibitor" exact="zanamivir" post="in the treatment of influenzavirus infections.N Engl J Med3378748809302301"/>
   <result pre="influenzavirus infections.N Engl J Med3378748809302301 11NicholsonKGAokiFYOsterhausATrottierSCarewiczOet al.2000Efficacy and safety of" exact="oseltamivir" post="in treatment of acute influenza: a randomised controlled trial.Lancet3551845185010866439"/>
   <result pre="trial.Lancet3551845185010866439 12TreanorJJet al.2000Efficacy and safety of the oral neuraminidase inhibitor" exact="oseltamivir" post="in treating acute influenza.J Am Med Assoc28310161024 13JeffersonTDemicheliVRivettiDJonesMPietrantonjCDet al.2006Antivirals"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3136400\results\search\drugs\results.xml">
   <result pre="treatment of HCV includes pegylated interferon-α (PEG IFN- α) plus" exact="ribavirin" post="(RBV) which has significant side effects depending upon the"/>
   <result pre="standard treatment pegylated interferon-α (PEG IFN- α) in combination with" exact="ribavirin" post="(RBV) have been employed with certain side effects and"/>
   <result pre="in different phases of clinical trials. Debio 025, a non-immunosuppressive" exact="cyclosporine" post="(Cs) analogue, is found to exhibit novel inhibition of"/>
   <result pre="Combined effect of HCV-796 (an NNI of HCV NS5B) and" exact="boceprevir" post="SCH 503034 (an inhibitor of NS3 serine protease) was"/>
   <result pre="for the clinical estimation of three-part combination of PEG IFN-α," exact="boceprevir" post="and HCV-796 [26]. Since RdRp is deficient in proof"/>
   <result pre="or β-D-2'-deoxy-2'-fluoro-2'- C-methylcytidine (2'-F-C-MeC; PSI-6130) with interferon-α 2b (IFN-α2b) plus" exact="ribavirin" post="(RBV) were assessed in subgenomic HCV relicon. β-D-2'-C-methylcytidine (2'-C-MeC;"/>
   <result pre="and different concentrations of compound [32]. High SVR rate of" exact="nitazoxanide" post="along with interferon suggested that nitazoxanide can be exercised"/>
   <result pre="High SVR rate of nitazoxanide along with interferon suggested that" exact="nitazoxanide" post="can be exercised instead of ribavirin to avoid side"/>
   <result pre="with interferon suggested that nitazoxanide can be exercised instead of" exact="ribavirin" post="to avoid side effect of this drug. Another newly"/>
   <result pre="process entailed for the HCVpp entry [71]. Fluphenazine, PCperazine, and" exact="trifluoperazine" post="were currently recognized as inhibitors of HCV entry [64]."/>
   <result pre="HCV entry [64]. These compounds alienated the D2 and D1" exact="dopamine" post="[65,66] and 5-HT2 serotonin receptors [67] in neural signaling"/>
   <result pre="1S385312591185 PoynardTRatziuVMcHutchisonJMannsMGoodmanZZeuzemSYounossiZAlbrechtJEffect of treatment with peginterferon or interferon alfa-2b and" exact="ribavirin" post="on steatosis in patients infected with hepatitis CHepatology200338758512829989 BurloneMEBudkowskaAHepatitis"/>
   <result pre="via clathrin-coated vesiclesJ Virol200680115711157810.1128/JVI.01717-0617005647 FeldJJHoofnagleJHMechanism of action of interferon and" exact="ribavirin" post="in treatment of hepatitis CNature200543696797210.1038/nature0408216107837 ZeuzemSFeinmanSVRasenackJHeathcoteEJLaiMYGaneEO'GradyJReichenJDiagoMLinAPeginterferon alfa-2a in patients"/>
   <result pre="dually resistant to the polymerase and protease inhibitors HCV-796 and" exact="boceprevir" post="(SCH 503034)Antimicrob Agents Chemother20095340141110.1128/AAC.01081-0818936191 LudmererSWGrahamDJBootsEMurrayEMSimcoeAMarkelEJGroblerJAFloresOAOlsenDBHazudaDJLaFeminaRLReplication fitness and NS5B drug"/>
   <result pre="BassitLGrierJBennettMSchinaziRFCombinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with" exact="ribavirin" post="in the hepatitis C virus replicon systemAntivir Chem Chemother200819253118610555"/>
   <result pre="systemAntivir Chem Chemother200819253118610555 KorbaBEElazarMLuiPRossignolJFGlennJSPotential for hepatitis C virus resistance to" exact="nitazoxanide" post="or tizoxanideAntimicrob Agents Chemother2008524069407110.1128/AAC.00078-0818710916 EinavSSobolHDGehrigEGlennJSThe hepatitis C virus (HCV)"/>
   <result pre="Chemother2008524069407110.1128/AAC.00078-0818710916 EinavSSobolHDGehrigEGlennJSThe hepatitis C virus (HCV) NS4B RNA binding inhibitor" exact="clemizole" post="is highly synergistic with HCV protease inhibitorsJ Infect Dis2026574"/>
   <result pre="virus polymerase that increase RNA binding can confer resistance to" exact="cyclosporine" post="AHepatology200950253310.1002/hep.2298719489073 YangWZhaoYFabryckiJHouXNieXSanchezAPhadkeADeshpandeMAgarwalAHuangMSelection of replicon variants resistant to ACH-806, a"/>
   <result pre="protease inhibitorAntimicrob Agents Chemother2009531377138510.1128/AAC.01058-0819171797 HopkinsSScorneauxBHuangZMurrayMGWringSSmitleyCHarrisRErdmannFFischerGRibeillYSCY-635, a novel nonimmunosuppressive analog of" exact="cyclosporine" post="that exhibits potent inhibition of hepatitis C virus RNA"/>
   <result pre="preclinical speciesBioorg Med Chem1818541865 LawitzERodriguez-TorresMMuirAJKiefferTLMcNairLKhunvichaiAMcHutchisonJGAntiviral effects and safety of telaprevir," exact="peginterferon alfa-2a," post="and ribavirin for 28 days in hepatitis C patientsJ"/>
   <result pre="Chem1818541865 LawitzERodriguez-TorresMMuirAJKiefferTLMcNairLKhunvichaiAMcHutchisonJGAntiviral effects and safety of telaprevir, peginterferon alfa-2a, and" exact="ribavirin" post="for 28 days in hepatitis C patientsJ Hepatol20084916316910.1016/j.jhep.2008.03.02718486984 ShanGZPengZGLiYHLiDLiYPMengSGaoLYJiangJDLiZRA"/>
   <result pre="USA107291296 CaiGGurdalHSmithCWangHYFriedmanEInverse agonist properties of dopaminergic antagonists at the D(1A)" exact="dopamine" post="receptor: uncoupling of the D(1A) dopamine receptor from G(s)"/>
   <result pre="antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A)" exact="dopamine" post="receptor from G(s) proteinMol Pharmacol19995698999610531405 LummisSCBakerJRadioligand binding and photoaffinity"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3184032\results\search\drugs\results.xml">
   <result pre="protein or the enzyme neuraminidase. Combination therapy with Interferon-α and" exact="ribavirin" post="remains the backbone treatment for chronic hepatitis C; the"/>
   <result pre="Some antiviral drugs possess multiple potential clinical applications, such as" exact="ribavirin" post="for the treatment of chronic hepatitis C and respiratory"/>
   <result pre="treatment of chronic hepatitis C and respiratory syncytial virus and" exact="cidofovir" post="for the treatment of cytomegalovirus and other DNA viruses."/>
   <result pre="discussed in these sections possess other potential applications, such as" exact="ribavirin" post="for the treatment of respiratory syncytial virus (RSV) and"/>
   <result pre="ribavirin for the treatment of respiratory syncytial virus (RSV) and" exact="cidofovir" post="for the treatment of cytomegalovirus (CMV) and other DNA"/>
   <result pre="of acyclovir may still be beneficial in immunocompromised patients. Short-course" exact="prednisone" post="may be added as an adjunct to acyclovir treatment"/>
   <result pre="during the early period after transplant in patients not receiving" exact="ganciclovir" post="or valganciclovir prophylaxis.14 Acyclovir is generally well tolerated. However,"/>
   <result pre="early period after transplant in patients not receiving ganciclovir or" exact="valganciclovir" post="prophylaxis.14 Acyclovir is generally well tolerated. However, IV acyclovir"/>
   <result pre="available as an IV formulation, and an oral prodrug of" exact="cidofovir" post="(known as CMX-001) is under clinical development.28 This investigational"/>
   <result pre="is under clinical development.28 This investigational lipid ester formulation of" exact="cidofovir" post="has enhanced bioavailability, resulting in improved 50% inhibitory concentrations.28"/>
   <result pre="resulting in improved 50% inhibitory concentrations.28 Direct intraocular injection of" exact="cidofovir" post="is contraindicated due to ocular hypotony.27 Serum cidofovir concentrations"/>
   <result pre="injection of cidofovir is contraindicated due to ocular hypotony.27 Serum" exact="cidofovir" post="concentrations decline rapidly after IV infusion, with a half-life"/>
   <result pre="hours. Cidofovir is eliminated by glomerular filtration and tubular secretion;" exact="probenecid" post="reduces its excretion by blocking tubular secretion.29,30 Cidofovir is"/>
   <result pre="thereby halting viral DNA synthesis.27 The major clinical indication for" exact="cidofovir" post="is the treatment of CMV retinitis in HIV-infected patients"/>
   <result pre="CMV disease resistant or unresponsive to ganciclovir.32 Because activation of" exact="cidofovir" post="does not rely on viral kinases, it retains activity"/>
   <result pre="UL97 mutation and HSV with the TK mutation.33 Resistance to" exact="cidofovir" post="occurs when the virus develops mutations in the DNA"/>
   <result pre="Famciclovir Famciclovir is a diacetyl 6-deoxy analogue of penciclovir. Oral" exact="famciclovir" post="is rapidly absorbed and achieves a bioavailability of 77%.51"/>
   <result pre="of 77%.51 Famciclovir is metabolized into penciclovir, reaching peak plasma" exact="penciclovir" post="concentrations within 1 hour. Because of extensive hepatic metabolism,"/>
   <result pre="within 1 hour. Because of extensive hepatic metabolism, virtually no" exact="famciclovir" post="is detectable in plasma.51 Famciclovir is excreted renally as"/>
   <result pre="famciclovir is detectable in plasma.51 Famciclovir is excreted renally as" exact="penciclovir" post="and its 6-deoxy precursor.9 Famciclovir is active against HSV-1,"/>
   <result pre="extent, against EBV. Its mechanism of action is through penciclovir;" exact="penciclovir" post="triphosphate inhibits herpes DNA synthesis by acting as a"/>
   <result pre="substrate for viral DNA polymerase. The major clinical indications for" exact="famciclovir" post="use are treatment of herpes zoster, recurrent genital herpes,52"/>
   <result pre="varicella in HIV-infected patients. The most common adverse effects of" exact="famciclovir" post="are headache and nausea.54 Rare adverse events include jaundice,"/>
   <result pre="of standard CMV therapies, or whose virus is resistant to" exact="ganciclovir" post="and foscarnet.55-57 The main adverse effect of fomivirsen is"/>
   <result pre="CMV diseases in immunocompromised patients, especially those unable to tolerate" exact="ganciclovir" post="and those infected with ganciclovir-resistant virus.60,61 Foscarnet is also"/>
   <result pre="CMV.65 It is available in oral and parenteral formulations. Oral" exact="ganciclovir" post="is poorly absorbed, with a bioavailability of only 5%.65"/>
   <result pre="5%.65 Management of active CMV disease is therefore with IV" exact="ganciclovir" post="or its oral valyl prodrug valganciclovir. Intravitreal ganciclovir implants"/>
   <result pre="with IV ganciclovir or its oral valyl prodrug valganciclovir. Intravitreal" exact="ganciclovir" post="implants are also available, with minimal systemic absorption. Ganciclovir"/>
   <result pre="herpes simplex keratitis, and CMV prophylaxis in transplant recipients. Intravenous" exact="ganciclovir" post="may also be used to treat other forms of"/>
   <result pre="disease, such as colitis or esophagitis. Induction therapy with IV" exact="ganciclovir" post="for CMV retinitis in patients with AIDS has an"/>
   <result pre="95% in stabilizing disease.68 Because it is poorly absorbed, oral" exact="ganciclovir" post="should not be used for induction treatment of CMV"/>
   <result pre="or progresses in patients with advanced AIDS, oral or IV" exact="ganciclovir" post="(or valganciclovir) is given as maintenance therapy until immune"/>
   <result pre="given as maintenance therapy until immune reconstitution is achieved.69 Intravitreal" exact="ganciclovir" post="may also be surgically implanted for the treatment of"/>
   <result pre="treatment should be used together with systemic therapy with IV" exact="ganciclovir" post="or oral valganciclovir therapy. Oral ganciclovir may be used"/>
   <result pre="used together with systemic therapy with IV ganciclovir or oral" exact="valganciclovir" post="therapy. Oral ganciclovir may be used to prevent CMV"/>
   <result pre="systemic therapy with IV ganciclovir or oral valganciclovir therapy. Oral" exact="ganciclovir" post="may be used to prevent CMV in patients with"/>
   <result pre="era of highly active antiretroviral therapy. Although IV and oral" exact="ganciclovir" post="have also been used to prevent CMV disease in"/>
   <result pre="also been used to prevent CMV disease in transplant recipients," exact="valganciclovir" post="is currently the preferred drug for this indication.60,61,70 Intravenous"/>
   <result pre="valganciclovir is currently the preferred drug for this indication.60,61,70 Intravenous" exact="ganciclovir" post="is also used as a first-line treatment of CMV"/>
   <result pre="creatinine and liver enzymes. Neurotoxicity may occur occasionally. Resistance to" exact="ganciclovir" post="occurs most commonly in severely immunocompromised patients with prolonged"/>
   <result pre="prolonged exposure to the drug. The most common mechanism for" exact="ganciclovir" post="resistance is UL97 gene mutation71; this mutation leads to"/>
   <result pre="viral kinase that is necessary for the initial phosphorylation of" exact="ganciclovir" post="into its active form. A less common mechanism is"/>
   <result pre="available as topical therapy for mucocutaneous herpes. For systemic use," exact="penciclovir" post="has been reformulated into the oral prodrug famciclovir. The"/>
   <result pre="reformulated into the oral prodrug famciclovir. The antiviral activity of" exact="penciclovir" post="is similar to that of acyclovir, with efficacy against"/>
   <result pre="for prevention of CMV disease in kidney transplant recipients.78 Although" exact="ganciclovir" post="is the backbone for CMV prevention in transplant recipients,"/>
   <result pre="Valganciclovir Valganciclovir is the L-valyl ester prodrug of ganciclovir. Oral" exact="valganciclovir" post="is well absorbed and converted to ganciclovir by first-pass"/>
   <result pre="of ganciclovir. Oral valganciclovir is well absorbed and converted to" exact="ganciclovir" post="by first-pass intestinal or hepatic metabolism.79 The bioavailability of"/>
   <result pre="ganciclovir by first-pass intestinal or hepatic metabolism.79 The bioavailability of" exact="ganciclovir" post="after valganciclovir administration is about 60%, and peak plasma"/>
   <result pre="first-pass intestinal or hepatic metabolism.79 The bioavailability of ganciclovir after" exact="valganciclovir" post="administration is about 60%, and peak plasma concentrations are"/>
   <result pre="CMV retinitis in patients with AIDS.83 For immediate sight-threatening lesions," exact="valganciclovir" post="is used in combination with an intravitreal ganciclovir implant."/>
   <result pre="sight-threatening lesions, valganciclovir is used in combination with an intravitreal" exact="ganciclovir" post="implant. Valganciclovir is also used for preventing CMV disease"/>
   <result pre="of kidney, heart, or kidney-pancreas transplants.61,84 In the United States," exact="valganciclovir" post="is not approved for preventing CMV disease in liver"/>
   <result pre="higher incidence of tissue-invasive CMV disease in patients who received" exact="valganciclovir" post="vs oral ganciclovir prophylaxis. In other countries, valganciclovir is"/>
   <result pre="tissue-invasive CMV disease in patients who received valganciclovir vs oral" exact="ganciclovir" post="prophylaxis. In other countries, valganciclovir is used for preventing"/>
   <result pre="who received valganciclovir vs oral ganciclovir prophylaxis. In other countries," exact="valganciclovir" post="is used for preventing CMV disease in all solid"/>
   <result pre="Valganciclovir was recently demonstrated to be as effective as IV" exact="ganciclovir" post="for treating mild to moderate CMV disease in transplant"/>
   <result pre="as diarrhea, nausea, and vomiting, may be observed. Resistance to" exact="valganciclovir" post="occurs through mechanisms identical to those underlying ganciclovir resistance,"/>
   <result pre="Resistance to valganciclovir occurs through mechanisms identical to those underlying" exact="ganciclovir" post="resistance, ie, through mutations in the UL97 gene, which"/>
   <result pre="keratitis and acute keratoconjunctivitis.90 Once phosphorylated into its active form," exact="vidarabine" post="inhibits viral DNA polymerase. Adverse effects of ophthalmic vidarabine"/>
   <result pre="form, vidarabine inhibits viral DNA polymerase. Adverse effects of ophthalmic" exact="vidarabine" post="include irritation, pain, photophobia, lacrimation, and occlusion of the"/>
   <result pre="in elderly patients and those taking neuroaffective drugs. Emergence of" exact="amantadine" post="resistance has limited its use in the clinical setting.94,95"/>
   <result pre="2 to 4 days of treatment. Because of widespread resistance," exact="amantadine" post="is no longer recommended for empiric treatment of influenza.94,95"/>
   <result pre="is excreted in the urine. The mechanism of action of" exact="rimantadine" post="is similar to that of amantadine; it inhibits the"/>
   <result pre="currently limited by drug resistance.96,97 A few trials that compared" exact="amantadine" post="and rimantadine suggested similar efficacy; however, neurologic adverse events"/>
   <result pre="by drug resistance.96,97 A few trials that compared amantadine and" exact="rimantadine" post="suggested similar efficacy; however, neurologic adverse events are less"/>
   <result pre="rimantadine. Neuraminidase Inhibitors Oseltamivir. Oseltamivir phosphate is a prodrug of" exact="oseltamivir" post="carboxylate, which is an inhibitor of neuraminidase that is"/>
   <result pre="in the replication of influenza A and B viruses.98 Oral" exact="oseltamivir" post="is well absorbed and reaches peak serum concentrations in"/>
   <result pre="and reaches peak serum concentrations in 1 hour. Bioavailability of" exact="oseltamivir" post="phosphate is at least 75%. The prodrug oseltamivir phosphate"/>
   <result pre="Bioavailability of oseltamivir phosphate is at least 75%. The prodrug" exact="oseltamivir" post="phosphate undergoes extensive hepatic metabolism via ester hydrolysis. More"/>
   <result pre="hepatic metabolism via ester hydrolysis. More than 99% of active" exact="oseltamivir" post="carboxylate is excreted renally. Oseltamivir carboxylate, the active drug"/>
   <result pre="influenza A and B, including pandemic strains. For this indication," exact="oseltamivir" post="should be started within 48 hours of exposure and"/>
   <result pre="outbreak. A systematic review reported no statistically significant difference between" exact="oseltamivir" post="and zanamivir prophylaxis for preventing symptomatic influenza among immunocompetent"/>
   <result pre="systematic review reported no statistically significant difference between oseltamivir and" exact="zanamivir" post="prophylaxis for preventing symptomatic influenza among immunocompetent adults.100 The"/>
   <result pre="influenza among immunocompetent adults.100 The most common adverse effects of" exact="oseltamivir" post="are nausea, vomiting, diarrhea, abdominal pain, insomnia, and vertigo."/>
   <result pre="the neuraminidase gene, such as R292K101 and H274Y,98 account for" exact="oseltamivir" post="resistance. Surveillance conducted during the 2009 H1N1 influenza pandemic"/>
   <result pre="is not available orally since it is poorly absorbed.106 Inhaled" exact="zanamivir" post="produces high concentrations in the respiratory tract where influenza"/>
   <result pre="influenza virus infection occurs. About 4% to 20% of inhaled" exact="zanamivir" post="is absorbed systemically, producing peak serum concentrations at 1"/>
   <result pre="is excreted in the feces.106 The mechanism of action of" exact="zanamivir" post="is similar to oseltamivir, by inhibiting neuraminidase, which is"/>
   <result pre="of newly formed viral particles from infected cells.106 For treatment," exact="zanamivir" post="is given by inhalation twice daily for 5 days,"/>
   <result pre="given IV to treat critically ill patients with influenza.107,108 Inhaled" exact="zanamivir" post="is well tolerated.106 Acute bronchospasm with decline in respiratory"/>
   <result pre="SC IFN-α.114 Likewise, SC peginterferon-α may be more effective than" exact="lamivudine" post="in hepatitis B e antigen (HBeAg)–positive and HBeAg-negative patients"/>
   <result pre="(HBeAg)–positive and HBeAg-negative patients with CHB,115-117 and the addition of" exact="lamivudine" post="to peginterferon-α did not significantly enhance efficacy.118 Interferon-α is"/>
   <result pre="patients with CHC.124-126 However, combination therapy with IFN-α and oral" exact="ribavirin" post="is more effective than either drug used alone.127 Combining"/>
   <result pre="is more effective than either drug used alone.127 Combining oral" exact="ribavirin" post="with peginterferon-α may be more effective than combining it"/>
   <result pre="of Liver Diseases130 recommends once-weekly SC peginterferon-α combined with oral" exact="ribavirin" post="as the first line of treatment of CHC. The"/>
   <result pre="rate of intolerance to a combination regimen of IFN-α and" exact="ribavirin" post="is higher and the rate of sustained virologic response"/>
   <result pre="plus ribavirin.132 A lower SVR rate to combination peginterferon-α plus" exact="ribavirin" post="therapy was observed in patients coinfected with HCV genotype"/>
   <result pre="In general, the guidelines recommend combination therapy with peginterferon-α and" exact="ribavirin" post="for 48 weeks. Interferons are generally not recommended in"/>
   <result pre="guanine, is available in oral, aerosolized, and IV formulations. Oral" exact="ribavirin" post="is absorbed extensively, but its bioavailability is only 65%"/>
   <result pre="bioavailability is only 65% because of first-pass metabolism. Peak plasma" exact="ribavirin" post="concentrations occur within 1 to 2 hours after oral"/>
   <result pre="times higher after 4 weeks of treatment. Administration of aerosolized" exact="ribavirin" post="leads to high concentrations in the respiratory tract, with"/>
   <result pre="leads to high concentrations in the respiratory tract, with some" exact="ribavirin" post="absorbed systemically. Ribavirin is mainly excreted in the urine.149"/>
   <result pre="mainly excreted in the urine.149 The mechanism of action of" exact="ribavirin" post="is known to be diverse but is not completely"/>
   <result pre="its antiviral activity is reversed by guanosine. Its triphosphorylated form," exact="ribavirin" post="triphosphate, is a potent competitive inhibitor of inosine monophosphate"/>
   <result pre="triphosphorylated form, ribavirin triphosphate, is a potent competitive inhibitor of" exact="inosine" post="monophosphate dehydrogenase, influenza virus RNA polymerase, and mRNA guanylyltransferase."/>
   <result pre="in vitro activity and its activity against human infections. Oral" exact="ribavirin" post="is approved for use, in combination with IFN-α or"/>
   <result pre="transplant recipients. When used for the treatment of RSV pneumonia," exact="ribavirin" post="is usually given by the aerosol route, which delivers"/>
   <result pre="which delivers high concentrations at the site of infection.152 Oral" exact="ribavirin" post="has also been used with good outcomes.153 Ribavirin has"/>
   <result pre="hemorrhagic fever,160,161 Bolivian hemorrhagic fever,162 and hantavirus pulmonary syndrome.163 Aerosolized" exact="ribavirin" post="can cause sudden deterioration of respiratory function and cardiovascular"/>
   <result pre="deterioration of respiratory function and cardiovascular effects. Precipitation of inhaled" exact="ribavirin" post="may occur in ventilatory tubings. Hemolytic anemia occurs commonly,154"/>
   <result pre="may occur in ventilatory tubings. Hemolytic anemia occurs commonly,154 and" exact="ribavirin" post="should not be given to patients with preexisting medical"/>
   <result pre="suicidal ideation, and relapse of drug abuse may occur, and" exact="ribavirin" post="is contraindicated in patients with a history of, or"/>
   <result pre="acidosis. Adefovir. Adefovir dipivoxil is an acyclic nucleotide analogue of" exact="adenosine" post="monophosphate.164 Oral adefovir dipivoxil is rapidly absorbed and converted"/>
   <result pre="such as lamivudine.165 However, concomitant use with the related drug" exact="tenofovir" post="disoproxil fumarate is not recommended because of the augmented"/>
   <result pre="cytidine. Although not currently approved for the treatment of CHB," exact="emtricitabine" post="has been used clinically in combination with tenofovir in"/>
   <result pre="of CHB, emtricitabine has been used clinically in combination with" exact="tenofovir" post="in HIV/HBV–coinfected patients. Emtricitabine is very similar to lamivudine,"/>
   <result pre="because of high rates of resistance development.170 The rate of" exact="emtricitabine" post="resistance among patients with HBV monoinfection is 18% at"/>
   <result pre="of patients with CHB, including those resistant to lamivudine.172 Oral" exact="entecavir" post="is extensively absorbed: peak plasma concentrations occur in 30"/>
   <result pre="and oral bioavailability is almost 100%. Despite low plasma concentrations," exact="entecavir" post="maintains its potency by the long intracellular half-life of"/>
   <result pre="potency by the long intracellular half-life of its active metabolite" exact="entecavir" post="triphosphate. Entecavir is mainly excreted by glomerular filtration and"/>
   <result pre="filtration and active tubular secretion. The mechanism of action of" exact="entecavir" post="is somewhat unique because it inhibits 3 specific functions"/>
   <result pre="liver disease.173 In randomized trials of HBeAg-positive and HBeAg-negative patients," exact="entecavir" post="demonstrated better outcomes than lamivudine, with improvement in histologic"/>
   <result pre="and normalization or improvement of ALT levels. Adverse effects of" exact="entecavir" post="are generally mild and include headache, fatigue, nausea, diarrhea,"/>
   <result pre="rtT184S/A/I/L, rtS202G/C, or rtM250L. Among nucleoside-naive patients, the rate of" exact="entecavir" post="resistance is less than 1% after 5 years, but"/>
   <result pre="but patients with preexisting rtM204V/I have a higher rate of" exact="entecavir" post="resistance (51%) after 5 years.173 Lamivudine. Lamivudine is a"/>
   <result pre="years.173 Lamivudine. Lamivudine is a nucleoside analogue of cytosine. Oral" exact="lamivudine" post="provides bioavailability of about 85%, and peak serum concentrations"/>
   <result pre="kidneys.174 Lamivudine is phosphorylated intracellularly into its active 5′-triphosphate metabolite," exact="lamivudine" post="triphosphate. When the active metabolite is incorporated into viral"/>
   <result pre="In a double-blind study involving about 350 patients with CHB," exact="lamivudine" post="was associated with substantial histologic improvement, HBeAg antibody seroconversion,"/>
   <result pre="are common once treatment is discontinued.178 The adverse effects of" exact="lamivudine" post="are mild and include abdominal pain, nausea, and headache."/>
   <result pre="include abdominal pain, nausea, and headache. The clinical utility of" exact="lamivudine" post="is limited by the rapid development of antiviral resistance."/>
   <result pre="which occurs easily and confers cross-resistance. After 4 years of" exact="lamivudine" post="monotherapy, rtM204V/I resistance develops in up to 70% and"/>
   <result pre="is a synthetic thymidine nucleoside analogue. Unlike other anti-HBV drugs," exact="telbivudine" post="has no activity against HIV. Oral telbivudine is well"/>
   <result pre="other anti-HBV drugs, telbivudine has no activity against HIV. Oral" exact="telbivudine" post="is well absorbed and achieves peak plasma concentrations after"/>
   <result pre="inhibits HBV by competitive inhibition of viral DNA polymerase. Oral" exact="telbivudine" post="is approved for the treatment of CHB in patients"/>
   <result pre="liver inflammation and fibrosis.180,181 It is considered more effective than" exact="lamivudine" post="and adefovir.182,183 Compared with lamivudine, telbivudine was associated with"/>
   <result pre="considered more effective than lamivudine and adefovir.182,183 Compared with lamivudine," exact="telbivudine" post="was associated with a higher degree of reduction in"/>
   <result pre="or anti-HBe seroconversion. The most common adverse effects reported for" exact="telbivudine" post="are dizziness, fatigue, gastrointestinal symptoms, and rash. Unique adverse"/>
   <result pre="neuropathy or myopathy is diagnosed. The rate of resistance to" exact="telbivudine" post="is 25% after 96 weeks of treatment. Tenofovir. Tenofovir"/>
   <result pre="Tenofovir disoproxil fumarate, an acyclic nucleoside phosphonate diester analogue of" exact="adenosine" post="monophosphate, is considered one of the most potent anti-HBV"/>
   <result pre="taken with a high-fat meal. The terminal elimination half-life of" exact="tenofovir" post="is 12 to 18 hours, and it is excreted"/>
   <result pre="for conversion to tenofovir. Subsequent phosphorylation by cellular enzymes forms" exact="tenofovir" post="diphosphate, which competes with the natural substrate deoxyadenosine 5′-triphosphate"/>
   <result pre="for the treatment of CHB. In a randomized trial comparing" exact="tenofovir" post="and adefovir, a higher percentage of patients receiving tenofovir"/>
   <result pre="comparing tenofovir and adefovir, a higher percentage of patients receiving" exact="tenofovir" post="achieved HBV DNA level suppression. In HBeAg-positive patients, the"/>
   <result pre="were similar for adefovir and tenofovir.185-188 The adverse effects of" exact="tenofovir" post="include gastrointestinal symptoms, dizziness, fatigue, and headache. Renal toxicities,"/>
   <result pre="syndrome), and renal failure, have been associated with tenofovir.189-193 Primary" exact="tenofovir" post="resistance mutations have not been well defined. Although viruses"/>
   <result pre="than do wild-type viruses. One study reported rtA194T as a" exact="tenofovir" post="resistance mutation; however, this pattern was not confirmed in"/>
   <result pre="current standard treatment of CHC is peginterferon-α in combination with" exact="ribavirin" post="for 24 weeks (for HCV genotype 2 or 3)"/>
   <result pre="after completion of treatment. A combination regimen of peginterferon-α and" exact="ribavirin" post="results in SVR rates between 38% and 46%, and"/>
   <result pre="serine protease inhibitors to the backbone therapies of peginterferon-α and" exact="ribavirin" post="will emerge as the standard of care for the"/>
   <result pre="(SPRINT-2 [serine protease inhibitor therapy 2] trial), the addition of" exact="boceprevir" post="for 22 weeks or 44 weeks to standard therapy"/>
   <result pre="HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2) trial evaluated" exact="boceprevir" post="for the treatment of patients who had experienced a"/>
   <result pre="rates were significantly higher for patients who received peginterferon-ribavirin plus" exact="boceprevir" post="treatment for 32 weeks (59%) or 44 weeks (66%)"/>
   <result pre="logistic regression analysis, the baseline factors associated with SVR were" exact="boceprevir" post="use, previous relapse (compared with previous nonresponder), low viral"/>
   <result pre="with peginterferon and ribavirin. The most common adverse effects of" exact="boceprevir" post="are flulike illness, fatigue, nausea, dysgeusia, and anemia.194 The"/>
   <result pre="flulike illness, fatigue, nausea, dysgeusia, and anemia.194 The addition of" exact="boceprevir" post="nearly doubled the rate of anemia compared with the"/>
   <result pre="of anemia compared with the use of standard peginterferon and" exact="ribavirin" post="therapy, with many patients requiring the use of erythropoietin.195"/>
   <result pre="binding reversibly to nonstructural 3 serine protease. After oral administration," exact="telaprevir" post="achieves peak plasma concentrations in 4 to 5 hours."/>
   <result pre="3 international randomized double-blind placebo-controlled clinical trial, the addition of" exact="telaprevir" post="to the standard treatment of peginterferon-ribavirin was associated with"/>
   <result pre="Specifically, the group of patients who received 12 weeks of" exact="telaprevir" post="combined with peginterferon-ribavirin, followed by peginterferon-ribavirin for 12 weeks"/>
   <result pre="standard therapy among patients who received only 8 weeks of" exact="telaprevir" post="combined with peginterferon-ribavirin (69% vs 44%).201 In the second"/>
   <result pre="44%).201 In the second randomized phase 3 trial that evaluated" exact="telaprevir" post="in treatment-experienced patients with HCV genotype 1 infection, the"/>
   <result pre="treatment-experienced patients with HCV genotype 1 infection, the addition of" exact="telaprevir" post="to the standard treatment regimen of peginterferon-α and ribavirin"/>
   <result pre="of telaprevir to the standard treatment regimen of peginterferon-α and" exact="ribavirin" post="was associated with significantly higher SVR rates compared with"/>
   <result pre="peginterferon-ribavirin alone.202 Collectively, these studies indicate that the addition of" exact="telaprevir" post="to standard peginterferon-ribavirin therapy can significantly improve SVR rates"/>
   <result pre="ribavirin. As a result of these findings, the FDA approved" exact="telaprevir" post="(750 mg 3 times daily) for this treatment indication."/>
   <result pre="most infections, such as acyclovir for herpes simplex virus and" exact="ganciclovir" post="for CMV. However, other of these &quot;old�? antiviral drugs"/>
   <result pre="for CMV. However, other of these &quot;old�? antiviral drugs (eg," exact="amantadine" post="and rimantadine for influenza virus infections) have lost their"/>
   <result pre="However, other of these &quot;old�? antiviral drugs (eg, amantadine and" exact="rimantadine" post="for influenza virus infections) have lost their clinical utility"/>
   <result pre="1985;151:362-3653881542 16.PerazellaMACrystal-induced acute renal failure. Am J Med. 1999;106:459-46510225250 17.HelldénALyckeJVanderTSvenssonJOOdar-CederlofIStahleLThe" exact="aciclovir" post="metabolite CMMG is detectable in the CSF of subjects"/>
   <result pre="detectable in the CSF of subjects with neuropsychiatric symptoms during" exact="aciclovir" post="and valaciclovir treatment. J Antimicrob Chemother. 2006;57:945-94916540518 18.ErnstMEFraneyRJAcyclovir- and"/>
   <result pre="the CSF of subjects with neuropsychiatric symptoms during aciclovir and" exact="valaciclovir" post="treatment. J Antimicrob Chemother. 2006;57:945-94916540518 18.ErnstMEFraneyRJAcyclovir- and ganciclovir-induced neurotoxicity."/>
   <result pre="Clin Microbiol. 2004;42:242-24914715760 23.BaconTHLevinMJLearyJJSariskyRTSuttonDHerpes simplex virus resistance to acyclovir and" exact="penciclovir" post="after two decades of antiviral therapy. Clin Microbiol Rev."/>
   <result pre="of poxvirus infections. Viruses. 2010;2:2740-276221499452 29.WolfDLRodriguezCAMucciMIngrossoADuncanBANickensDJPharmacokinetics and renal effects of" exact="cidofovir" post="with a reduced dose of probenecid in HIV-infected patients"/>
   <result pre="and renal effects of cidofovir with a reduced dose of" exact="probenecid" post="in HIV-infected patients with cytomegalovirus retinitis. J Clin Pharmacol."/>
   <result pre="Clin Pharmacol. 2003;43:43-5112520627 30.CundyKCClinical pharmacokinetics of the antiviral nucleotide analogues" exact="cidofovir" post="and adefovir. Clin Pharmacokinet. 1999;36:127-14310092959 31.KendleJBFan-HavardPCidofovir in the treatment"/>
   <result pre="of isolates from cytomegalovirus retinitis patients receiving first- or second-line" exact="cidofovir" post="therapy: relationship to clinical outcome. J Infect Dis. 1998;178:1821-18259815243"/>
   <result pre="Retinitis and Viral Resistance Study GroupIncidence of foscarnet resistance and" exact="cidofovir" post="resistance in patients treated for cytomegalovirus retinitis. Antimicrob Agents"/>
   <result pre="for cytomegalovirus retinitis. Antimicrob Agents Chemother. 1998;42:2240-22449736542 34.SnoeckRDe ClercqERole of" exact="cidofovir" post="in the treatment of DNA virus infections, other than"/>
   <result pre="Opin Investig Drugs. 2002;3:1561-1566 35.ChaSJohnstonLNatkunamYBrownJTreatment of verruca vulgaris with topical" exact="cidofovir" post="in an immunocompromised patient: a case report and review"/>
   <result pre="and review of the literature. Transpl Infect Dis. 2005;7:158-16116390407 36.LamothFPascualMErardVVenetzJPNseirGMeylanPLow-dose" exact="cidofovir" post="for the treatment of polyomavirus-associated nephropathy: two case reports"/>
   <result pre="reports and review of the literature. Antivir Ther. 2008;13:1001-100919195325 37.ToroJRSanchezSTurianskyGBlauveltATopical" exact="cidofovir" post="for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial"/>
   <result pre="1994;170:570-5728077713 39.BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous" exact="cidofovir" post="in a child. Pediatr Infect Dis J. 2001;20:1083-108611734717 40.KoppTGeusauARiegerAStinglGSuccessful"/>
   <result pre="treatment of an aciclovir-resistant herpes simplex type 2 infection with" exact="cidofovir" post="in an AIDS patient. Br J Dermatol. 2002;147:134-13812100196 41.GarveyLThomsonECTaylorGPProgressive"/>
   <result pre="a case series. AIDS. 2006;20:791-79316514320 42.MarraCMRajicicNBarkerDEet al.A pilot study of" exact="cidofovir" post="for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16:1791-179712218391 43.RazonableRRAksamitAJWrightAJWilsonJWCidofovir"/>
   <result pre="highly active antiretroviral therapy. Mayo Clin Proc. 2001;76:1171-117511702907 44.Segarra-NewnhamMVodoloKMUse of" exact="cidofovir" post="in progressive multifocal leukoencephalopathy. Ann Pharmacother. 2001;35:741-74411408993 45.ViallardJFLazaroEEllieEet al.Improvement"/>
   <result pre="Ann Pharmacother. 2001;35:741-74411408993 45.ViallardJFLazaroEEllieEet al.Improvement of progressive multifocal leukoencephalopathy after" exact="cidofovir" post="therapy in a patient with a destructive polyarthritis. Infection."/>
   <result pre="cidofovir. J Antimicrob Chemother. 2007;60:193-19417496056 49.AmbatiJWynneKBAngerameMCRobinsonMRAnterior uveitis associated with intravenous" exact="cidofovir" post="use in patients with cytomegalovirus retinitis. Br J Ophthalmol."/>
   <result pre="clinical pharmacokinetics of famciclovir. Clin Pharmacokinet. 1996;31:1-88827396 52.FaroSA review of" exact="famciclovir" post="in the management of genital herpes. Infect Dis Obstet"/>
   <result pre="review of new single-day dosing indications. Cutis. 2007;80:77-8117725069 54.SaltzmanRJurewiczRBoonRSafety of" exact="famciclovir" post="in patients with herpes zoster and genital herpes. Antimicrob"/>
   <result pre="Group; Cytomegalovirus Cooperative Study GroupA randomized, controlled study of intravenous" exact="ganciclovir" post="therapy for cytomegalovirus peripheral retinitis in patients with AIDS."/>
   <result pre="1993;168:557-5638394858 69.DrewWLIvesDLalezariJPet al.; collab: Syntex Cooperative Oral Ganciclovir Study GroupOral" exact="ganciclovir" post="as maintenance treatment for cytomegalovirus retinitis in patients with"/>
   <result pre="Transplantation Study GroupRandomised trial of efficacy and safety of oral" exact="ganciclovir" post="in the prevention of cytomegalovirus disease in liver-transplant recipients"/>
   <result pre="Lancet. 1997;350:1729-17339413463 71.EidAJArthursSKDezielPJWilhelmMPRazonableRREmergence of drug-resistant cytomegalovirus in the era of" exact="valganciclovir" post="prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22:162-17018339135 72.SariskyRTBaconTHBoonRJet"/>
   <result pre="prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22:162-17018339135 72.SariskyRTBaconTHBoonRJet al.Profiling" exact="penciclovir" post="susceptibility and prevalence of resistance of herpes simplex virus"/>
   <result pre="isolates across eleven clinical trials. Arch Virol. 2003;148:1757-176914505088 73.BaconTHBoydMRActivity of" exact="penciclovir" post="against Epstein-Barr virus. Antimicrob Agents Chemother. 1995;39:1599-16027492112 74.SpruanceSLReaTLThomingCTuckerRSaltzmanRBoonR; collab:"/>
   <result pre="Valaciclovir HSV Study GroupA large-scale, placebo-controlled, dose-ranging trial of peroral" exact="valaciclovir" post="for episodic treatment of recurrent herpes genitalis. Arch Intern"/>
   <result pre="immunocompromised hosts. Expert Rev Anti Infect Ther. 2004;2:27-4115482169 80.BrownFBankenLSaywellKArumIPharmacokinetics of" exact="valganciclovir" post="and ganciclovir following multiple oral dosages of valganciclovir in"/>
   <result pre="Expert Rev Anti Infect Ther. 2004;2:27-4115482169 80.BrownFBankenLSaywellKArumIPharmacokinetics of valganciclovir and" exact="ganciclovir" post="following multiple oral dosages of valganciclovir in HIV- and"/>
   <result pre="80.BrownFBankenLSaywellKArumIPharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of" exact="valganciclovir" post="in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37:167-17610496303 81.WiltshireHHirankarnSFarrellCet"/>
   <result pre="and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37:167-17610496303 81.WiltshireHHirankarnSFarrellCet al.Pharmacokinetic profile of" exact="ganciclovir" post="after its oral administration and from its prodrug, valganciclovir,"/>
   <result pre="organ transplant recipients. Clin Pharmacokinet. 2005;44:495-50715871635 82.CaldesAColomHArmendarizYet al.Population pharmacokinetics of" exact="ganciclovir" post="after intravenous ganciclovir and oral valganciclovir administration in solid"/>
   <result pre="Clin Pharmacokinet. 2005;44:495-50715871635 82.CaldesAColomHArmendarizYet al.Population pharmacokinetics of ganciclovir after intravenous" exact="ganciclovir" post="and oral valganciclovir administration in solid organ transplant patients"/>
   <result pre="82.CaldesAColomHArmendarizYet al.Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral" exact="valganciclovir" post="administration in solid organ transplant patients infected with cytomegalovirus."/>
   <result pre="cytomegalovirus. Antimicrob Agents Chemother. 2009;53:4816-482419738014 83.MartinDFSierra-MaderoJWalmsleySet al.A controlled trial of" exact="valganciclovir" post="as induction therapy for cytomegalovirus retinitis. N Engl J"/>
   <result pre="N Engl J Med. 2002;346:1119-112611948271 84.PayaCHumarADominguezEet al.Efficacy and safety of" exact="valganciclovir" post="vs. oral ganciclovir for prevention of cytomegalovirus disease in"/>
   <result pre="Med. 2002;346:1119-112611948271 84.PayaCHumarADominguezEet al.Efficacy and safety of valganciclovir vs. oral" exact="ganciclovir" post="for prevention of cytomegalovirus disease in solid organ transplant"/>
   <result pre="recipients. Am J Transplant. 2004;4:611-62015023154 85.KhouryJAStorchGABohlDLet al.Prophylactic versus preemptive oral" exact="valganciclovir" post="for the management of cytomegalovirus infection in adult renal"/>
   <result pre="adult renal transplant recipients. Am J Transplant. 2006;6:2134-214316780548 86.SnydmanDRUse of" exact="valganciclovir" post="for prevention and treatment of cytomegalovirus disease [editorial]. Clin"/>
   <result pre="of cytomegalovirus disease [editorial]. Clin Infect Dis. 2008;46:28-2918171209 87.EinseleHReusserPBornhauserMet al.Oral" exact="valganciclovir" post="leads to higher exposure to ganciclovir than intravenous ganciclovir"/>
   <result pre="Dis. 2008;46:28-2918171209 87.EinseleHReusserPBornhauserMet al.Oral valganciclovir leads to higher exposure to" exact="ganciclovir" post="than intravenous ganciclovir in patients following allogeneic stem cell"/>
   <result pre="al.Oral valganciclovir leads to higher exposure to ganciclovir than intravenous" exact="ganciclovir" post="in patients following allogeneic stem cell transplantation. Blood. 2006;107:3002-300816352807"/>
   <result pre="solid organ transplant recipients. Clin Infect Dis. 2008;46:20-2718171208 89.AsbergAHumarARollagHet al.Oral" exact="valganciclovir" post="is noninferior to intravenous ganciclovir for the treatment of"/>
   <result pre="Infect Dis. 2008;46:20-2718171208 89.AsbergAHumarARollagHet al.Oral valganciclovir is noninferior to intravenous" exact="ganciclovir" post="for the treatment of cytomegalovirus disease in solid organ"/>
   <result pre="in current clinical use. J Clin Virol. 2004;30:115-13315125867 92.TappendenPJacksonRCooperKet al.Amantadine," exact="oseltamivir" post="and zanamivir for the prophylaxis of influenza (including a"/>
   <result pre="clinical use. J Clin Virol. 2004;30:115-13315125867 92.TappendenPJacksonRCooperKet al.Amantadine, oseltamivir and" exact="zanamivir" post="for the prophylaxis of influenza (including a review of"/>
   <result pre="and economic evaluation. Health Technol Assess. 2009;13(11):iii,ix-xii, 1-246 93.BettsRFAmantadine and" exact="rimantadine" post="for the prevention of influenza A. Semin Respir Infect."/>
   <result pre="influenza A. Semin Respir Infect. 1989;4:304-3102697053 94.KrumbholzASchmidtkeMBergmannSet al.High prevalence of" exact="amantadine" post="resistance among circulating European porcine influenza A viruses. J"/>
   <result pre="2009;44:91-9319019729 96.HaydenFGHayAJEmergence and transmission of influenza A viruses resistant to" exact="amantadine" post="and rimantadine. Curr Top Microbiol Immunol. 1992;176:119-1301600749 97.HaydenFGSperberSJBelsheRBCloverRDHayAJPykeSRecovery of"/>
   <result pre="Chemother. 2005;55(suppl 1):i5-i2115709056 99.SugayaNTamuraDYamazakiMet al.Comparison of the clinical effectiveness of" exact="oseltamivir" post="and zanamivir against influenza virus infection in children. Clin"/>
   <result pre="1):i5-i2115709056 99.SugayaNTamuraDYamazakiMet al.Comparison of the clinical effectiveness of oseltamivir and" exact="zanamivir" post="against influenza virus infection in children. Clin Infect Dis."/>
   <result pre="a review of clinical safety. Drug Saf. 1999;21:267-28110514019 107.GaurAHBaggaBBarmanSet al.Intravenous" exact="zanamivir" post="for oseltamivir-resistant 2009 H1N1 influenza [letter]. N Engl J"/>
   <result pre="B. N Engl J Med. 2005;352:2682-269515987917 117.MarcellinPLauGKBoninoFet al.Peginterferon alfa-2a alone," exact="lamivudine" post="alone, and the two in combination in patients with"/>
   <result pre="118.JanssenHLvan ZonneveldMSenturkHet al.Pegylated Interferon alfa-2b alone or in combination with" exact="lamivudine" post="for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet."/>
   <result pre="C. Cochrane Database Syst Rev. 2010;(1):CD00544520091577 128.FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection. N Engl J"/>
   <result pre="infection. N Engl J Med. 2002;347:975-98212324553 129.MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus" exact="ribavirin" post="compared with interferon alfa-2b plus ribavirin for initial treatment"/>
   <result pre="129.MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis C: a randomised"/>
   <result pre="a randomized controlled trial. JAMA. 2004;292:2839-284815598915 132.TorrianiFJRodriguez-TorresMRockstrohJKet al.Peginterferon Alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection in HIV-infected patients."/>
   <result pre="patients. N Engl J Med. 2004;351:438-45015282351 133.ChungRTAndersenJVolberdingPet al.Peginterferon Alfa-2a plus" exact="ribavirin" post="versus interferon alfa-2a plus ribavirin for chronic hepatitis C"/>
   <result pre="2004;351:438-45015282351 133.ChungRTAndersenJVolberdingPet al.Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C in HIV-coinfected persons. N Engl"/>
   <result pre="147.AgestaNZabalaRDiaz-PerezJLAlopecia areata during interferon alpha-2b/ribavirin therapy. Dermatology. 2002;205:300-30112399683 148.WadeJRSnoeckEDuffFLambMJorgaKPharmacokinetics of" exact="ribavirin" post="in patients with hepatitis C virus. Br J Clin"/>
   <result pre="intravenously administered ribavirin. Antimicrob Agents Chemother. 1990;34:489-4902334164 150.GishRGTreating HCV with" exact="ribavirin" post="analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006;57:8-1316293677 151.GluudLLMarchesiniEIorioAPeginterferon"/>
   <result pre="analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006;57:8-1316293677 151.GluudLLMarchesiniEIorioAPeginterferon plus" exact="ribavirin" post="for chronic hepatitis C in patients with human immunodeficiency"/>
   <result pre="children. Cochrane Database Syst Rev. 2007;CD00018117253446 153.PelaezALyonGMForceSDet al.Efficacy of oral" exact="ribavirin" post="in lung transplant patients with respiratory syncytial virus lower"/>
   <result pre="Transplant. 2009;28:67-7119134533 154.KnowlesSRPhillipsEJDresserLMatukasLCommon adverse events associated with the use of" exact="ribavirin" post="for severe acute respiratory syndrome in Canada. Clin Infect"/>
   <result pre="los ReyesECet al.Treatment of severe La Crosse encephalitis with intravenous" exact="ribavirin" post="following diagnosis by brain biopsy. Pediatrics. 1997;99:261-2679024460 157.ChongHTKamarulzamanATanCTet al.Treatment"/>
   <result pre="1986;314:20-263940312 159.HugginsJWHsiangCMCosgriffTMet al.Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous" exact="ribavirin" post="therapy of hemorrhagic fever with renal syndrome. J Infect"/>
   <result pre="treated with oral ribavirin. Lancet. 1995;346:472-4757637481 161.MardaniMJahromiMKNaieniKHZeinaliMThe efficacy of oral" exact="ribavirin" post="in the treatment of Crimean-Congo hemorrhagic fever in Iran."/>
   <result pre="J Antimicrob Chemother. 2007;59:827-83217332007 170.LimSGNgTMKungNet al.A double-blind placebo-controlled study of" exact="emtricitabine" post="in chronic hepatitis B. Arch Intern Med. 2006;166:49-5616401810 171.SimsKAWoodlandAMEntecavir:"/>
   <result pre="pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41-669989342 175.DienstagJLPerrilloRPSchiffERBartholomewMVicaryCRubinMA preliminary trial of" exact="lamivudine" post="for chronic hepatitis B infection. N Engl J Med."/>
   <result pre="al.; collab: Asia Hepatitis Lamivudine Study GroupA one-year trial of" exact="lamivudine" post="for chronic hepatitis B. N Engl J Med. 1998;339:61-689654535"/>
   <result pre="ManRAHeijtinkRASchalmSWHepatitis B reactivation after lamivudine. Lancet. 1995;346:1156-11577475613 179.ZhouXJKeJSallasWMFarrellCMayersDLPentikisHSPopulation pharmacokinetics of" exact="telbivudine" post="and determination of dose adjustment for patients with renal"/>
   <result pre="on telbivudine. Int J Clin Pract. 2006;60:1295-129916981973 182.LaiCLGaneELiawYFet al.Telbivudine versus" exact="lamivudine" post="in patients with chronic hepatitis B. N Engl J"/>
   <result pre="al.Treatment of hepatitis B e antigen positive chronic hepatitis with" exact="telbivudine" post="or adefovir: a randomized trial. Ann Intern Med. 2007;147:745-75417909201"/>
   <result pre="fumarate: role in hepatitis B treatment. Hepatology. 2006;44:309-31316871562 188.ReijndersJGJanssenHLPotency of" exact="tenofovir" post="in chronic hepatitis B: mono or combination therapy?J Hepatol."/>
   <result pre="STDS. 2008;22:99-10318260800 191.SchmidSOpravilMModdelMet al.Acute interstitial nephritis of HIV-positive patients under" exact="atazanavir" post="and tenofovir therapy in a retrospective analysis of kidney"/>
   <result pre="191.SchmidSOpravilMModdelMet al.Acute interstitial nephritis of HIV-positive patients under atazanavir and" exact="tenofovir" post="therapy in a retrospective analysis of kidney biopsies. Virchows"/>
   <result pre="protease inhibitor telaprevir. Gastroenterology. 2007;132:1767-177717484874 199.McHutchisonJGEversonGTGordonSCet al.Telaprevir with peginterferon and" exact="ribavirin" post="for chronic HCV genotype 1 infection. N Engl J"/>
   <result pre="J Med. 2009;360:1827-183819403902 200.HézodeCForestierNDusheikoGet al.Telaprevir and peginterferon with or without" exact="ribavirin" post="for chronic HCV infection. N Engl J Med. 2009;360:1839-185019403903"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3185584\results\search\drugs\results.xml">
   <result pre="examples of this was data from studies of single dose" exact="nevirapine" post="(sdNVP) for prevention of mother-to-child transmission (PMTCT). Clinical trials"/>
   <result pre="subtypes, with frequencies of 69, 36, 19 and 21% against" exact="nevirapine" post="in women with subtype C, D, A, and CRF02_AG"/>
   <result pre="reveal minority species resistance, have revealed a higher incidence of" exact="nevirapine" post="resistance (K103N, Y181C) in 70–87% of individuals with subtype"/>
   <result pre="in subtype C populations failing regimens containing d4T, ddI, or" exact="tenofovir" post="(TFV) [32]. In addition, development of K65R in subtype"/>
   <result pre="subtype C and CRF01_AE has been associated with the Y181C" exact="nevirapine" post="mutation within the viral backbone [30,42]. Drug resistance selection"/>
   <result pre="subtypes A, B, and C with the second generation NNRTI," exact="etravirine" post="[50]. 2.3. PR Mutations With respect to PR, the"/>
   <result pre="first line therapy in developed countries, e.g., tenofovir, atazanavir, darunavir," exact="etravirine" post="and raltegravir. 2.5. Future Research The clinical and prognostic"/>
   <result pre="and its clinical implicationsCurr Opin Infect Dis20061959460617075337 10.ToniTDMasquelierBLazaroEDore-MbamiMBa-GomisFOTea-DiopYKouakouKDibyJSiaESoppiSet al.Characterization of" exact="nevirapine" post="(NVP) resistance mutations and HIV type 1 subtype in"/>
   <result pre="Infect Dis2005192303615942891 12.EshlemanSHChurchJDChenSGuayLAMwathaAFiscusSAMmiroFMusokePKumwendaNJacksonJBet al.Comparison of HIV-1 mother-to-child transmission after single-dose" exact="nevirapine" post="prophylaxis among African women with subtypes A, C, and"/>
   <result pre="and DJ Acquir Immune Defic Syndr20064251852116810119 13.ChaixMLEkoueviDKRouetFTonwe-GoldBVihoIBequetLPeytavinGToureHMenanHLeroyVet al.Low risk of" exact="nevirapine" post="resistance mutations in the prevention of mother-to-child transmission of"/>
   <result pre="Dis200619348248716425126 14.JohnsonJALiJFMorrisLMartinsonNGrayGMcIntyreJHeneineWEmergence of drug-resistant HIV-1 after intrapartum administration of single-dose" exact="nevirapine" post="is substantially underestimatedJ Infect Dis2005192162315942889 15.FlysTSChenSJonesDCHooverDRChurchJDFiscusSAMwathaAGuayLAMmiroFMusokePet al.Quantitative analysis of"/>
   <result pre="of HIV-1 variants with the K103N resistance mutation after single-dose" exact="nevirapine" post="in women with HIV-1 subtypes A, C, and DJ"/>
   <result pre="assays reveal long-term persistence of HIV-1 variants with the K103N" exact="nevirapine" post="(NVP) resistance mutation in some women and infants after"/>
   <result pre="AmericaAIDS2008222001201118784462 35.BrennerBGOliveiraMDoualla-BellFMoisiDDNtemgwaMFrankelFEssexMWainbergMAHIV-1 subtype C viruses rapidly develop K65R resistance to" exact="tenofovir" post="in cell cultureAIDS200620F9F1316816549 36.InvernizziCFCoutsinosDOliveiraMMoisiDBrennerBGWainbergMASignature nucleotide polymorphisms at positions 64"/>
   <result pre="46.BrennerBTurnerDOliveiraMMoisiDDetorioMCarobeneMMarlinkRGSchapiroJRogerMWainbergMAA V106M mutation in HIV-1 clade C viruses exposed to" exact="efavirenz" post="confers cross-resistance to non-nucleoside reverse transcriptase inhibitorsAIDS200317F1F512478089 47.HsuLYSubramaniamRBachelerLPatonNICharacterization of"/>
   <result pre="polymorphisms and differential development of resistance to nelfinavir, lopinavir, and" exact="atazanavir" post="in different HIV-1 subtypesAntimicrob Agents Chemother2010542878288520404123 60.SoaresROBatistaPRCostaMGDardenneLEPascuttiPGSoaresMAUnderstanding the HIV-1"/>
   <result pre="in different HIV-1 subtypesAntimicrob Agents Chemother2010542878288520404123 60.SoaresROBatistaPRCostaMGDardenneLEPascuttiPGSoaresMAUnderstanding the HIV-1 protease" exact="nelfinavir" post="resistance mutation D30N in subtypes B and C through"/>
   <result pre="C through molecular dynamics simulationsJ Mol Graph Model20102913714720541446 61.GonzalezLMBrindeiroRMAguiarRSPereiraHSAbreuCMSoaresMATanuriAImpact of" exact="nelfinavir" post="resistance mutations on in vitro phenotype, fitness, and replication"/>
   <result pre="[66] ddI, didanosine; d4T, stavudine; TFV, tenofovir; EFV, efavirenz; NVP," exact="nevirapine" post=""/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3207218\results\search\drugs\results.xml">
   <result pre="all of these act on viral proteins (Table 1). Amantadine and" exact="rimantadine" post="both target the M2 protein and are specific for"/>
   <result pre="USA. The drugs that are recommended for clinical use are" exact="oseltamivir" post="and zanamivir, which target the neuraminidase activity of the"/>
   <result pre="particle at the last step of the replication cycle. Although" exact="oseltamivir" post="is an oral drug, zanamivir is administered via inhalation."/>
   <result pre="of the replication cycle. Although oseltamivir is an oral drug," exact="zanamivir" post="is administered via inhalation. Another NA inhibitor, peramivir, obtained"/>
   <result pre="(three seasons), which was unexpected as it was believed that" exact="oseltamivir" post="resistant viruses carried a fitness deficit 29. However, evidence"/>
   <result pre="these viruses 30. Note that so far mutations that confer" exact="oseltamivir" post="resistance confer little or no resistance to zanamivir. The"/>
   <result pre="circulation. Nevertheless, if H1N1 viruses have a propensity for developing" exact="oseltamivir" post="resistance and this is acquired by the pandemic H1N1"/>
   <result pre="and who are more resistant to HIV�?1 infection 37. Admittedly," exact="maraviroc" post="has also taught us that antiviral drugs directed at"/>
   <result pre="ArmstrongRet alClinical experience in adults and children treated with intravenous" exact="peramivir" post="for 2009 influenza a (H1N1) under an emergency IND"/>
   <result pre="H274Y mutation in the influenza A/H1N1 neuraminidase active site following" exact="oseltamivir" post="phosphate treatment leave virus severely compromised both in vitro"/>
   <result pre="GongLI, BaltimoreD. Permissive secondary mutations enable the evolution of influenza" exact="oseltamivir" post="resistance. Science2010; 328: 1272–1275.20522774 31MemoliMJ, HrabalRJ, HassantoufighiAet alRapid selection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3262966\results\search\drugs\results.xml">
   <result pre="for the analysis of seven antiviral drugs, zanamivir, ribavirin, oseltamivir," exact="oseltamivir" post="carboxylate, amantadine, rimantadine and arbidol, in poultry muscle is"/>
   <result pre="of seven antiviral drugs, zanamivir, ribavirin, oseltamivir, oseltamivir carboxylate, amantadine," exact="rimantadine" post="and arbidol, in poultry muscle is reported. The antiviral"/>
   <result pre="and proved to be adequate for quantification and confirmation of" exact="zanamivir" post="and ribavirin at 10 μg kg−1, oseltamivir, oseltamivir carboxylate,"/>
   <result pre="to be adequate for quantification and confirmation of zanamivir and" exact="ribavirin" post="at 10 μg kg−1, oseltamivir, oseltamivir carboxylate, amantadine and"/>
   <result pre="confirmation of zanamivir and ribavirin at 10 μg kg−1, oseltamivir," exact="oseltamivir" post="carboxylate, amantadine and rimantadine at levels below 1.0 μg"/>
   <result pre="zanamivir and ribavirin at 10 μg kg−1, oseltamivir, oseltamivir carboxylate," exact="amantadine" post="and rimantadine at levels below 1.0 μg kg−1 and"/>
   <result pre="ribavirin at 10 μg kg−1, oseltamivir, oseltamivir carboxylate, amantadine and" exact="rimantadine" post="at levels below 1.0 μg kg−1 and for qualitative"/>
   <result pre="syndrome (SARS) [13, 14]. Furthermore, it has been shown that" exact="oseltamivir" post="carboxylate (Fig. 1) is not removed or degraded in"/>
   <result pre="Waterfowl are then in a position to ingest the active" exact="oseltamivir" post="carboxylate. This could drive the selection of resistant avian"/>
   <result pre="resistance genes and change of host [16, 17]. Finally, amantadine," exact="oseltamivir" post="and arbidol (Fig. 1) are allegedly being administered to"/>
   <result pre="antiviral drugs in chickens, turkeys and ducks: the amantadines, including" exact="amantadine" post="and rimantadine, and the neuramidase inhibitors, including zanamivir and"/>
   <result pre="amantadines, including amantadine and rimantadine, and the neuramidase inhibitors, including" exact="zanamivir" post="and oseltamivir (Fig. 1) [20]. Fig. 1 Chemical structures"/>
   <result pre="amantadine and rimantadine, and the neuramidase inhibitors, including zanamivir and" exact="oseltamivir" post="(Fig. 1) [20]. Fig. 1 Chemical structures of a"/>
   <result pre="Chemical structures of a zanamivir, b ribavirin, c oseltamivir, d" exact="oseltamivir" post="carboxylate, e rimantadine, f amantadine and g arbidol To"/>
   <result pre="b ribavirin, c oseltamivir, d oseltamivir carboxylate, e rimantadine, f" exact="amantadine" post="and g arbidol To be able to detect extra-label"/>
   <result pre="in biological matrices using mass spectrometry have been published for" exact="zanamivir" post="[21, 22], ribavirin [23–26], oseltamivir [17, 27–30] (some of"/>
   <result pre="using mass spectrometry have been published for zanamivir [21, 22]," exact="ribavirin" post="[23–26], oseltamivir [17, 27–30] (some of them including oseltamivir"/>
   <result pre="spectrometry have been published for zanamivir [21, 22], ribavirin [23–26]," exact="oseltamivir" post="[17, 27–30] (some of them including oseltamivir carboxylate [27,"/>
   <result pre="22], ribavirin [23–26], oseltamivir [17, 27–30] (some of them including" exact="oseltamivir" post="carboxylate [27, 30]), oseltamivir carboxylate only [31], amandatine [32–34],"/>
   <result pre="[17, 27–30] (some of them including oseltamivir carboxylate [27, 30])," exact="oseltamivir" post="carboxylate only [31], amandatine [32–34], some of them including"/>
   <result pre="oseltamivir carboxylate only [31], amandatine [32–34], some of them including" exact="rimantadine" post="[33, 35, 36], and arbidol [37, 38]. Recently, Chan"/>
   <result pre="drugs that are applied in poultry breeding including zanamivir, ribavirin," exact="oseltamivir" post="including its active metabolite oseltamivir carboxylate, amantadine, rimantadine and"/>
   <result pre="poultry breeding including zanamivir, ribavirin, oseltamivir including its active metabolite" exact="oseltamivir" post="carboxylate, amantadine, rimantadine and arbidol. The main difficulty in"/>
   <result pre="zanamivir, ribavirin, oseltamivir including its active metabolite oseltamivir carboxylate, amantadine," exact="rimantadine" post="and arbidol. The main difficulty in the development of"/>
   <result pre="and chemical properties. The antiviral drugs include the extremely polar" exact="zanamivir" post="and ribavirin, whereas arbidol is reasonably non-polar. Furthermore, the"/>
   <result pre="demonstrated. The method was fully validated for zanamivir, ribavirin, oseltamivir," exact="oseltamivir" post="carboxylate, amantadine, rimantadine and arbidol. This is the first"/>
   <result pre="was fully validated for zanamivir, ribavirin, oseltamivir, oseltamivir carboxylate, amantadine," exact="rimantadine" post="and arbidol. This is the first time a quantitative"/>
   <result pre="cm−1 (Millipore, Billerica, MA, USA). Rimantadine HCl (99% purity) and" exact="amantadine" post="HCl (100% purity) were obtained from Sigma-Aldrich (St. Louis,"/>
   <result pre="(99.3% purity) from Amplachem (Carmel, IN, USA). Zanamivir (100% purity)," exact="ribavirin" post="(99.5% purity), oseltamivir phosphate (98% purity) and oseltamivir carboxylate"/>
   <result pre="Amplachem (Carmel, IN, USA). Zanamivir (100% purity), ribavirin (99.5% purity)," exact="oseltamivir" post="phosphate (98% purity) and oseltamivir carboxylate (98% purity), and"/>
   <result pre="(100% purity), ribavirin (99.5% purity), oseltamivir phosphate (98% purity) and" exact="oseltamivir" post="carboxylate (98% purity), and the internal standards zanamivir-13C15N2, ribavirin-13C5,"/>
   <result pre="100 mg L−1 in MeOH. Stock solutions of zanamivir, ribavirin," exact="oseltamivir" post="carboxylate and their isotopically labelled internal standards were prepared"/>
   <result pre="the LC procedure. Z zanamivir, RB ribavirin, O oseltamivir, OC" exact="oseltamivir" post="carboxylate, AM amantadine, RM rimantadine, AB arbidol A Phenomenex"/>
   <result pre="containing fraction B was placed under the PBA cartridge and" exact="ribavirin" post="was eluted from the cartridge using 4 mL MeOH,"/>
   <result pre="and processed using MassLynx 4.1 software (Waters). Zanamivir-13C15N2, ribavirin-13C5, oseltamivir-d3," exact="oseltamivir" post="carboxylate-d3, amantadine-d15 and rimantadine-d4 were used as the internal"/>
   <result pre="levels using the developed method were compared to the indicated" exact="amantadine" post="concentration in the samples, being approximately 4 μg kg−1"/>
   <result pre="and severe matrix effects, even for late-eluting polar compounds like" exact="zanamivir" post="and ribavirin, were observed (Fig. 3). Fig. 3 Matrix"/>
   <result pre="to no matrix effects Using RP chromatography applying C18 columns," exact="zanamivir" post="eluted at the dead time of the system and"/>
   <result pre="of the system and only slight retention was obtained for" exact="ribavirin" post="(retention factor of 0.4). Although the matrix effects significantly"/>
   <result pre="of 0.4). Although the matrix effects significantly decreased for ribavirin," exact="zanamivir" post="was completely suppressed by matrix constituents (Fig. 3) and"/>
   <result pre="stationary phase, all antiviral drugs, including the most polar compounds" exact="zanamivir" post="and ribavirin obtained retention (retention factor of 3.0 and"/>
   <result pre="all antiviral drugs, including the most polar compounds zanamivir and" exact="ribavirin" post="obtained retention (retention factor of 3.0 and 4.6 respectively)."/>
   <result pre="factor of 3.0 and 4.6 respectively). The matrix suppression for" exact="zanamivir" post="decreased from 100% using zic-HILIC or C18 to 97%"/>
   <result pre="C18 to 97% (Fig. 3) resulting in the detection of" exact="zanamivir" post="in poultry muscle at a concentration of 50 μg"/>
   <result pre="the LC procedure is given in Fig. 2b. Zanamivir and" exact="ribavirin" post="are not or hardly retained by the C18 column,"/>
   <result pre="on the Hypercarb column. After that, on the Hypercarb column," exact="zanamivir" post="and ribavirin are separated from the matrix constituents using"/>
   <result pre="Hypercarb column. After that, on the Hypercarb column, zanamivir and" exact="ribavirin" post="are separated from the matrix constituents using a gradient"/>
   <result pre="compounds are retained on the C18 column. After elution of" exact="zanamivir" post="and ribavirin from the Hypercarb column, the other antiviral"/>
   <result pre="retained on the C18 column. After elution of zanamivir and" exact="ribavirin" post="from the Hypercarb column, the other antiviral drugs are"/>
   <result pre="the Strata-X C and (b) the PBA SPE cartridge Because" exact="ribavirin" post="remains neutral at pH 2, it does not interact"/>
   <result pre="type of material are hard to predict. Ribavirin, oseltamivir, amantadine," exact="rimantadine" post="and arbidol are retained by the PBA cartridge (Fig."/>
   <result pre="are retained by the PBA cartridge (Fig. 4b). Zanamivir and" exact="oseltamivir" post="carboxylate do not interact with the PBA material and"/>
   <result pre="of which is given in Fig. 2a. All compounds except" exact="ribavirin" post="were separated from matrix constituents by retaining them on"/>
   <result pre="basified, centrifuged and applied onto a PBA cartridge to retain" exact="ribavirin" post="in order to separate this drug from matrix constituents"/>
   <result pre="The most striking is the decrease in the suppression for" exact="zanamivir" post="from 85% to 29%. After the sample clean-up procedure,"/>
   <result pre="chromatography only is adequate for the analysis of ribavirin, oseltamivir," exact="oseltamivir" post="carboxylate, rimantadine, amantadine and arbidol, but the matrix effect"/>
   <result pre="adequate for the analysis of ribavirin, oseltamivir, oseltamivir carboxylate, rimantadine," exact="amantadine" post="and arbidol, but the matrix effect for zanamivir is"/>
   <result pre="carboxylate, rimantadine, amantadine and arbidol, but the matrix effect for" exact="zanamivir" post="is still very pronounced and as a result 50"/>
   <result pre="very pronounced and as a result 50 μg kg−1 of" exact="zanamivir" post="in poultry muscle is not detectable using solely RP"/>
   <result pre="blank poultry muscle sample spiked at 10 μg kg−1 with" exact="zanamivir" post="and ribavirin are presented in Fig. 6 and those"/>
   <result pre="muscle sample spiked at 10 μg kg−1 with zanamivir and" exact="ribavirin" post="are presented in Fig. 6 and those of a"/>
   <result pre="SRM chromatograms of (a) blank poultry muscle sample spiked with" exact="zanamivir" post="and ribavirin at 10 μg kg−1 including the internal"/>
   <result pre="of (a) blank poultry muscle sample spiked with zanamivir and" exact="ribavirin" post="at 10 μg kg−1 including the internal standards and"/>
   <result pre="chromatograms of (a) blank poultry muscle sample spiked with oseltamivir," exact="oseltamivir" post="carboxylate, rimantadine, amantadine and arbidol at 2.5 μg kg−1"/>
   <result pre="blank poultry muscle sample spiked with oseltamivir, oseltamivir carboxylate, rimantadine," exact="amantadine" post="and arbidol at 2.5 μg kg−1 including the internal"/>
   <result pre="Hypercarb column was tested. This solely affects the results for" exact="zanamivir" post="and ribavirin, because the RP system remains as it"/>
   <result pre="it is in the column-switch system. The matrix effects of" exact="zanamivir" post="and ribavirin were evaluated after injection of a cleaned"/>
   <result pre="in the column-switch system. The matrix effects of zanamivir and" exact="ribavirin" post="were evaluated after injection of a cleaned extract on"/>
   <result pre="be 39%. It is observed that the matrix effects for" exact="zanamivir" post="using injection on solely the Hypercarb column are increased"/>
   <result pre="set-up, which is advantageous for the analysis of zanamivir. For" exact="ribavirin" post="no statistically significant differences were observed and thus it"/>
   <result pre="39.2 55.7 15 130 61.8 64.7 For zanamivir, ribavirin, oseltamivir," exact="oseltamivir" post="carboxylate, amantadine and rimantadine the linearity in the range"/>
   <result pre="15 130 61.8 64.7 For zanamivir, ribavirin, oseltamivir, oseltamivir carboxylate," exact="amantadine" post="and rimantadine the linearity in the range of 0–20"/>
   <result pre="61.8 64.7 For zanamivir, ribavirin, oseltamivir, oseltamivir carboxylate, amantadine and" exact="rimantadine" post="the linearity in the range of 0–20 μg kg−1"/>
   <result pre="is suitable for the qualitative analysis of arbidol. For oseltamivir," exact="oseltamivir" post="carboxylate, amantadine, rimantadine and arbidol the calculated decision limits"/>
   <result pre="the qualitative analysis of arbidol. For oseltamivir, oseltamivir carboxylate, amantadine," exact="rimantadine" post="and arbidol the calculated decision limits (CCα) vary from"/>
   <result pre="confirmatory analysis of these antiviral drugs at relevant levels. For" exact="zanamivir" post="and ribavirin the calculated CCα values are 8 and"/>
   <result pre="of these antiviral drugs at relevant levels. For zanamivir and" exact="ribavirin" post="the calculated CCα values are 8 and 3 μg"/>
   <result pre="levels are still detectable. The calculated detection capabilities (CCβ) of" exact="zanamivir" post="and ribavirin are 15 and 9 μg kg−1, respectively."/>
   <result pre="still detectable. The calculated detection capabilities (CCβ) of zanamivir and" exact="ribavirin" post="are 15 and 9 μg kg−1, respectively. Even though"/>
   <result pre="9 μg kg−1, respectively. Even though the calculated CCβ for" exact="zanamivir" post="exceeds 10 μg kg−1, samples spiked at 10 μg"/>
   <result pre="10 μg kg−1, samples spiked at 10 μg kg−1 with" exact="zanamivir" post="and ribavirin were found to be non-compliant based upon"/>
   <result pre="kg−1, samples spiked at 10 μg kg−1 with zanamivir and" exact="ribavirin" post="were found to be non-compliant based upon the ion"/>
   <result pre="cases (n = 21) indicating that the calculated CCβ for at least" exact="zanamivir" post="is slightly overestimated and that the method is suitable"/>
   <result pre="and that the method is suitable for confirmatory analysis of" exact="zanamivir" post="and ribavirin at relevant levels as well. From the"/>
   <result pre="the method is suitable for confirmatory analysis of zanamivir and" exact="ribavirin" post="at relevant levels as well. From the theoretical study"/>
   <result pre="critical. The acidic methanol should be at pH ≤ 2 to retain" exact="zanamivir" post="on the Strata-X C material and the alkaline MeOH"/>
   <result pre="should be at least pH 12 for the elution of" exact="amantadine" post="and rimantadine. Incorrect pH results in a severe decrease"/>
   <result pre="sample. These levels are in good agreement with the indicated" exact="amantadine" post="concentration, being approximately 4 μg kg−1 for the poultry"/>
   <result pre="matrix interferences was critical for the detection and quantification of" exact="zanamivir" post="and ribavirin in particular. Because neither compound was sufficiently"/>
   <result pre="was critical for the detection and quantification of zanamivir and" exact="ribavirin" post="in particular. Because neither compound was sufficiently retained by"/>
   <result pre="repeatability and within-lab reproducibility were obtained for zanamivir, ribavirin, oseltamivir," exact="oseltamivir" post="carboxylate, amantadine and rimantadine. For arbidol these paramaters did"/>
   <result pre="within-lab reproducibility were obtained for zanamivir, ribavirin, oseltamivir, oseltamivir carboxylate," exact="amantadine" post="and rimantadine. For arbidol these paramaters did not comply"/>
   <result pre="presented method is suitable for the quantitative confirmatory analysis of" exact="zanamivir" post="and ribavirin at levels as low as 10 μg"/>
   <result pre="is suitable for the quantitative confirmatory analysis of zanamivir and" exact="ribavirin" post="at levels as low as 10 μg kg−1 and"/>
   <result pre="levels as low as 10 μg kg−1 and for oseltamivir," exact="oseltamivir" post="carboxylate, amantadine and rimantadine at a concentration of 1"/>
   <result pre="low as 10 μg kg−1 and for oseltamivir, oseltamivir carboxylate," exact="amantadine" post="and rimantadine at a concentration of 1 μg kg−1."/>
   <result pre="10 μg kg−1 and for oseltamivir, oseltamivir carboxylate, amantadine and" exact="rimantadine" post="at a concentration of 1 μg kg−1. Furthermore, the"/>
   <result pre="AJ Am Med Assoc2006295934936 15.GhoshGCNakadaNYamashitaNTanakaHOseltamivir carboxylate, the active metabolite of" exact="oseltamivir" post="phosphate (Tamiflu), detected in sewage discharge and river water"/>
   <result pre="with the proposed widespread use of TamifluEnviron Health Perspect200711510210617366827 17.FickJLindbergRHTysklindMHaemigPDWaldenströmJWallenstenAOlsenBAntiviral" exact="oseltamivir" post="is not removed or degraded in normal sewage water"/>
   <result pre="mass spectrometric method for the determination of the neuraminidase inhibitor" exact="zanamivir" post="(GG167) in human serumJ Chromatogr B1999732383393 22.BaughmanTMWrightWLHuttonKADetermination of zanamivir"/>
   <result pre="inhibitor zanamivir (GG167) in human serumJ Chromatogr B1999732383393 22.BaughmanTMWrightWLHuttonKADetermination of" exact="zanamivir" post="in rat and monkey plasma by positive ion hydrophilic"/>
   <result pre="23.YehLTNguyenMLourencoDLinCCA sensitive and specific method for the determination of total" exact="ribavirin" post="in monkey liver by high-performance liquid chromatography with tandem"/>
   <result pre="Biomed Anal200538344015907616 24.YehLTNguyenMDadgostariSBuWLinCCLC-MS/MS method for simultaneous determination of viramidine and" exact="ribavirin" post="levels in monkey red blood cellsJ Pharm Biomed Anal2007431057106417029670"/>
   <result pre="specific LC-MS/MS method for the simultaneous measurements of viramidine and" exact="ribavirin" post="in human plasmaJ Chromatography B20068321723 26.SvenssonJOBruchfeldASchvarczRStåhleLDetermination of ribavirin in"/>
   <result pre="viramidine and ribavirin in human plasmaJ Chromatography B20068321723 26.SvenssonJOBruchfeldASchvarczRStåhleLDetermination of" exact="ribavirin" post="in serum using highly selective solid-phase extraction and high-performance"/>
   <result pre="of a liquid chromatographic-tandem mass spectrometric method for determination of" exact="oseltamivir" post="and its metabolite oseltamivir carboxylate in plasma, saliva and"/>
   <result pre="mass spectrometric method for determination of oseltamivir and its metabolite" exact="oseltamivir" post="carboxylate in plasma, saliva and urineJ Chromatogr B Anal"/>
   <result pre="and animal plasma and urineJ Chromatogr B2000745373388 29.YamanakaTYamadaMTsujimuraKKondoTNagataSHoboSKurosawaMMatsumuraTClinical pharmacokinetics of" exact="oseltamivir" post="and its active metabolite oseltamivir carboxylate after oral administration"/>
   <result pre="Chromatogr B2000745373388 29.YamanakaTYamadaMTsujimuraKKondoTNagataSHoboSKurosawaMMatsumuraTClinical pharmacokinetics of oseltamivir and its active metabolite" exact="oseltamivir" post="carboxylate after oral administration in horsesJ Vet Med Sci20076929329617409647"/>
   <result pre="oral administration in horsesJ Vet Med Sci20076929329617409647 30.HeinigKBucheliFSensitive determination of" exact="oseltamivir" post="and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and"/>
   <result pre="in horsesJ Vet Med Sci20076929329617409647 30.HeinigKBucheliFSensitive determination of oseltamivir and" exact="oseltamivir" post="carboxylate in plasma, urine, cerebrospinal fluid and brain by"/>
   <result pre="brain by liquid chromatography-tandem mass spectrometryJ Chromatogr B2008876129136 31.BahramiGMohammadiBKianiADetermination of" exact="oseltamivir" post="carboxylic acid in human serum by solid phase extraction"/>
   <result pre="liquid chromatography with UV detectionJ Chromatogr B20088643842 32.PingWYi-ZengLBen-MeiCNengZLun-ZhaoYYanYZhi-BiaoYQuantitative determination of" exact="amantadine" post="in human plasma by liquid chromatography-mass spectrometry and the"/>
   <result pre="application in a bioequivalence studyJ Pharm Biomed Anal2007431519152517156962 33.XuMJuWXiaXTanHChenMZhangJXiongNJiangMChenLGongLDetermination of" exact="rimantadine" post="in rat plasma by liquid chromatography/electrospray mass spectrometry and"/>
   <result pre="a pharmacokinetic studyJ Chromatogr B2008864123128 34.FengSTianYZhangZZhangJHuangMChenYRapid simultaneous determination of paracetamol," exact="amantadine" post="hydrochloride, caffeine and chlorpheniramine maleate in human plasma by"/>
   <result pre="by liquid chromatography/ tandem mass spectrometryArzneim Forsch200959869519338139 35.HigashiYUemoriIFujiiYSimultaneous determination of" exact="amantadine" post="and rimantadine by HPLC in rat plasma with pre-column"/>
   <result pre="chromatography/ tandem mass spectrometryArzneim Forsch200959869519338139 35.HigashiYUemoriIFujiiYSimultaneous determination of amantadine and" exact="rimantadine" post="by HPLC in rat plasma with pre-column derivatization and"/>
   <result pre="studiesBiomed Chromatogr20051965566215803448 36.ShuangjinCFangFHanLMingMNew method for high-performance liquid chromatographic determination of" exact="amantadine" post="and its analogues in rat plasmaJ Pharm Biomed Anal2007441100110517553649"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3291404\results\search\drugs\results.xml">
   <result pre="viruses and that prophylaxis does not increase resistance. In fact," exact="amantadine" post="prophylaxis has been tested in a pandemic situation, and"/>
   <result pre="adamantanes, NAIs appear at least as efficacious. The 2 NAIs," exact="zanamivir" post="and oseltamivir, gave similar results when given daily for"/>
   <result pre="head-to-head studies have been carried out. Studies of treatment with" exact="amantadine" post="and rimantadine did not allow firm estimates of how"/>
   <result pre="have been carried out. Studies of treatment with amantadine and" exact="rimantadine" post="did not allow firm estimates of how much they"/>
   <result pre="are fully pathogenic and transmissible (27). While resistance occurs when" exact="oseltamivir" post="is used in treatment, it is far less frequent"/>
   <result pre="in contrast, is absorbed and metabolized. While human studies of" exact="oseltamivir" post="in treatment would be critical now, such studies have"/>
   <result pre="data are available. Mouse studies have already indicated that, while" exact="oseltamivir" post="is effective, it is not as effective when given"/>
   <result pre="systemic and case fatality is high, among the NAIs only" exact="oseltamivir" post="would be useful, since it is absorbed (39). Given"/>
   <result pre="prophylaxis in place rapidly in rings around cases. Supplies of" exact="oseltamivir" post="are also an issue. Will those countries with stockpiles"/>
   <result pre="LenevaIA, GoloubevaOG, BushK, WebsterRDComparison of efficacies of RWY-270201, zanamivir, and" exact="oseltamivir" post="against H5N1, H9N2, and other avian influenza viruses.Antimicrob Agents"/>
   <result pre="PoretzD, PaarD, et al.Use of the selective oral neuraminidase inhibitor" exact="oseltamivir" post="to prevent influenza.N Engl J Med. 1999;341:1336–4310.1056/NEJM19991028341180210536125 25. YounkinSW,"/>
   <result pre="26. DoyleWJ, SkonerDP, AlperCM, AllenG, MoodySA, SerokyJT, et al.Effect of" exact="rimantadine" post="treatment on clinical manifestations and otologic complications in adults"/>
   <result pre="HaydenFG, HayAJEmergence and transmission of influenza A viruses resistant to" exact="amantadine" post="and rimantadine.Curr Top Microbiol Immunol. 1992;176:119–3010.1007/978-3-642-77011-1_81600749 28. WhitleyRJ, HaydenFG,"/>
   <result pre="1992;176:119–3010.1007/978-3-642-77011-1_81600749 28. WhitleyRJ, HaydenFG, ReisingerKS, YoungN, DutkowskiR, IpeD, et al.Oral" exact="oseltamivir" post="treatment of influenza in children.Pediatr Infect Dis J. 2001;20:127–3310.1097/00006454-200102000-0000211224828"/>
   <result pre="Infect Dis. 2004;190:1627–3010.1086/42457215478068 31. KaiserL, KeeneON, HammondJMJ, ElliottM, HaydenFGImpact of" exact="zanamivir" post="on antibiotic use for respiratory events following acute influenza"/>
   <result pre="Med. 2000;160:3234–4010.1001/archinte.160.21.323411088083 32. KaiserL, WatC, MillsT, MahoneyP, WardP, HaydenFGImpact of" exact="oseltamivir" post="treatment on influenza-related lower respiratory tract complications and hospitalizations.Arch"/>
   <result pre="and hospitalizations.Arch Intern Med. 2003;163:1667–7210.1001/archinte.163.14.166712885681 33. MontoAS, MoultAB, SharpSJEffect of" exact="zanamivir" post="on duration and resolution of influenza symptoms.Clin Ther. 2000;22:1294–30510.1016/S0149-2918(00)83026-X11117654"/>
   <result pre="WebsterRG, GovorkovaEAVirulence may determine the necessary duration and dosage of" exact="oseltamivir" post="treatment for highly pathogenic A/Vietnam/1203/04 (H5N1) influenza virus in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3322031\results\search\drugs\results.xml">
   <result pre="influenza viruses A (H3N2) that exhibited reduced sensitivity to both" exact="zanamivir" post="and amantadine. These rare and naturally occurring viruses harbored"/>
   <result pre="S31N mutation in M2. Keywords: Influenza A virus H3N2 subtype" exact="zanamivir" post="amantadine antiviral drug resistance viruses Myanmar expedited dispatch Adamantanes"/>
   <result pre="mutation in M2. Keywords: Influenza A virus H3N2 subtype zanamivir" exact="amantadine" post="antiviral drug resistance viruses Myanmar expedited dispatch Adamantanes and"/>
   <result pre="(H3N2) with S31N mutation in M2 limited the effectiveness of" exact="amantadine" post="(1,2). In 2008, the emergence of subtype H1N1 with"/>
   <result pre="mutation in neuraminidase (NA) raised concerns about the use of" exact="oseltamivir" post="(3,4). On the other hand, the incidence of zanamivir-resistant"/>
   <result pre="which was isolated from an immunocompromised child who underwent prolonged" exact="zanamivir" post="treatment, was reported (6). In 2008, subtype H3N2 with"/>
   <result pre="2008, subtype H3N2 with D151A/V mutations in NA demonstrated reduced" exact="zanamivir" post="sensitivity by chemiluminescent NAI assay (5). Recently, zanamivir-resistant subtype"/>
   <result pre="an S31N mutation in M2, which respectively confer reductions in" exact="zanamivir" post="and amantadine susceptibility. In 2007 and 2008, we performed"/>
   <result pre="mutation in M2, which respectively confer reductions in zanamivir and" exact="amantadine" post="susceptibility. In 2007 and 2008, we performed phenotypic and"/>
   <result pre="assay that measures the 50% inhibitory concentration (IC50) by using" exact="zanamivir" post="and oseltamivir carboxylate (9). All samples were assayed in"/>
   <result pre="measures the 50% inhibitory concentration (IC50) by using zanamivir and" exact="oseltamivir" post="carboxylate (9). All samples were assayed in duplicates in"/>
   <result pre="NAI susceptibility assay showed 1 (1.5%) isolate (A/Myanmar/M187/2007) with a" exact="zanamivir" post="IC50 value of 59.72 nM, which was collected in"/>
   <result pre="in August 2007, and 1 (0.5%) isolate (A/Myanmar/M114/2008) with a" exact="zanamivir" post="IC50 of 33.37 nM, which was collected in July"/>
   <result pre="These isolates respectively demonstrated a 53× and 30× reduction in" exact="zanamivir" post="susceptibility (Table) and were extreme outliers (data not shown)."/>
   <result pre="subtype H3N2 viruses analyzed in this study remain sensitive to" exact="oseltamivir" post="carboxylate (Table). Table Characteristics of subtype H3N2 influenza viruses"/>
   <result pre="NA genes showed that the isolates with reduced sensitivity to" exact="zanamivir" post="belonged to 2 distinct clusters (Figure 1). These viruses"/>
   <result pre="NA gene showed that the isolates with reduced sensitivity to" exact="zanamivir" post="had a glutamine (Q) to lysine (K) substitution at"/>
   <result pre="are marked with asterisks, and isolates with reduced sensitivity to" exact="zanamivir" post="with Q136K mutation in NA are marked with squares."/>
   <result pre="S31N mutation in M2, which demonstrated reduced susceptibility to both" exact="zanamivir" post="and amantadine but remained susceptible to oseltamivir. These Q136K"/>
   <result pre="in M2, which demonstrated reduced susceptibility to both zanamivir and" exact="amantadine" post="but remained susceptible to oseltamivir. These Q136K viruses were"/>
   <result pre="the isolates in the database were obtained before introduction of" exact="zanamivir" post="into clinical practice in 1999 in Australia, New Zealand,"/>
   <result pre="unknown. Further study is needed to evaluate the effectiveness of" exact="zanamivir" post="in patients infected with Q136K mutants. Continued monitoring of"/>
   <result pre="Agents Chemother. 2008;52:3284–9210.1128/AAC.00555-0818625765 6. GubarevaLV, MatrosovichM, BrennerM, BethellR, WebsterREvidence for" exact="zanamivir" post="resistance in an immunocompromised child infected with influenza B"/>
   <result pre="from Australasia and South East Asia to the neuraminidase inhibitors" exact="zanamivir" post="and oseltamivir.Antiviral Res. 2004;62:37–4510.1016/j.antiviral.2003.11.00815026200 10. TashiroM, McKimm-BreschkinJ, SaitoT, KlimovA,"/>
   <result pre="sequence analysis and susceptibilities of influenza virus clinical isolates to" exact="zanamivir" post="and oseltamivir.Antimicrob Agents Chemother. 2003;47:2264–7210.1128/AAC.47.7.2264-2272.200312821478"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3323435\results\search\drugs\results.xml">
   <result pre="were 11 million regimens of antiviral drugs (two neuraminidase inhibitors," exact="oseltamivir" post="and zanamivir), which were later accompanied by new federal"/>
   <result pre="of pediatric formulation of oseltamivir, followed by adult formulation of" exact="oseltamivir" post="(reported by 96% and 38% of LHDs with shortages,"/>
   <result pre="and 38% of LHDs with shortages, respectively). No shortages of" exact="zanamivir" post="or peramivir were reported. Antiviral tracking and monitoring LHDs"/>
   <result pre="of LHDs with shortages, respectively). No shortages of zanamivir or" exact="peramivir" post="were reported. Antiviral tracking and monitoring LHDs were asked"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3358196\results\search\drugs\results.xml">
   <result pre="23. NgS, CowlingBJ, FangVJ, ChanKH, IpDK, ChengCK, et al.Effects of" exact="oseltamivir" post="treatment on duration of clinical illness and viral shedding"/>
   <result pre="25. WelliverR, MontoAS, CarewiczO, SchattemanE, HassmanM, HedrickJ, et al.Effectiveness of" exact="oseltamivir" post="in preventing influenza in household contacts: a randomized controlled"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3764029\results\search\drugs\results.xml">
   <result pre="used by anyone for any lawful purpose. Abstract Background While" exact="ribavirin" post="mono-therapy regimens have minimal effect on patients with chronic"/>
   <result pre="with interferon. Clinical studies show that interferon-free combination therapies containing" exact="ribavirin" post="are also efficacious, suggesting that an interferon-free therapy could"/>
   <result pre="the treatment. Therefore, understanding the mechanism of HCV resistance to" exact="ribavirin" post="and cross resistance to other antiviral drugs could be"/>
   <result pre="Methods We tested the ability of a J6/JFH1 derived HCV" exact="ribavirin" post="resistant mutant to grow in tissue cultured Huh7D cells"/>
   <result pre="mutations. Conclusions These results indicate that determinants of resistance to" exact="ribavirin" post="could also confer resistance to other anti-HCV drugs, shedding"/>
   <result pre="drugs, shedding light toward understanding the mechanism of action of" exact="ribavirin" post="and highlighting the importance of combination drug selection for"/>
   <result pre="patients consists of a combination of pegylated interferon alpha and" exact="ribavirin" post="[4]. Recently, two protease inhibitors were approved by the"/>
   <result pre="HCV infections is highly desirable. Recent studies have shown that" exact="ribavirin" post="in combination with other antiviral drugs, without interferon, can"/>
   <result pre="be efficacious [7], [8], suggesting that an interferon-free therapy containing" exact="ribavirin" post="could be adopted in the near future. However, generation"/>
   <result pre="treatment. In addition, the anti HCV mechanism of action of" exact="ribavirin" post="is not completely elucidated. Several mechanisms of action of"/>
   <result pre="ribavirin is not completely elucidated. Several mechanisms of action of" exact="ribavirin" post="against HCV were proposed including a direct effect against"/>
   <result pre="[10]. In order to study the cross-resistance of HCV to" exact="ribavirin" post="and other antiviral drugs that could have a mechanism"/>
   <result pre="we tested the ability of a J6/JFH1 [11] HCV derived" exact="ribavirin" post="resistant mutant, HCV-RR [12], to grow in the presence"/>
   <result pre="a similar lethal mutagenic effect has also been observed for" exact="ribavirin" post="on several viruses including poliovirus [17], coxsackievirus B3 [18],"/>
   <result pre="[21], and Hantaan virus [22]. It has been shown that" exact="ribavirin" post="also has a mutagenic effect on HCV, increasing its"/>
   <result pre="in vivo [25], [27]. Deep sequencing has recently revealed that" exact="ribavirin" post="exerts mutagenic activity in chronic HCV infected patients by"/>
   <result pre="cell-free biochemical assays [36]. It has also been shown that" exact="ribavirin" post="antagonizes the in vitro anti-HCV activity of 2′-C-Methylcytidine [37],"/>
   <result pre="this study we show that an HCV mutant resistant to" exact="ribavirin" post="is more resistant than parental J6/JFH1 to 5-Fluorouracil, but"/>
   <result pre="resistant than parental J6/JFH1 to 2′-C-Methylcytidine. These results indicate that" exact="ribavirin" post="resistant viruses could have elevated resistance to other inhibitors,"/>
   <result pre="light toward the understanding of the mechanism of action of" exact="ribavirin" post="and HCV resistance to this drug. In addition, the"/>
   <result pre="5-Fluorouracil In order to test the sensitivity of an HCV" exact="ribavirin" post="resistant mutant to 5-Fluorouracil, parental J6/JFH1 [11] and J6/JFH1"/>
   <result pre="of 2′-C-Methylcytidine In order to test sensitivity of an HCV" exact="ribavirin" post="resistant mutant to 2′-C-Methylcytidine, parental J6/JFH1 and HCV-RR2 were"/>
   <result pre="of the drug (Figure 4) and are still resistant to" exact="ribavirin" post="(not shown). Figure 4 Further passage of HCV in"/>
   <result pre="In this study we compared the growth of an HCV" exact="ribavirin" post="resistant mutant (HCV-RR2) to the growth of its parental"/>
   <result pre="the nucleoside analog 2′-C-Methylcytidine. We show that HCV resistant to" exact="ribavirin" post="is more resistant to 5-Fluorouracil but is not more"/>
   <result pre="along the genome (Table 1). The mechanism of action of" exact="ribavirin" post="against HCV in vitro and in vivo and the"/>
   <result pre="vitro and in vivo and the mechanism of resistance to" exact="ribavirin" post="by HCV ribavirin resistant mutants has not been completely"/>
   <result pre="vivo and the mechanism of resistance to ribavirin by HCV" exact="ribavirin" post="resistant mutants has not been completely elucidated. The differential"/>
   <result pre="fact that 5-Fluorouracil is a pyrimidine analog and 2′-C-Methylcytidine and" exact="ribavirin" post="are both nucleoside analogs. Given the nature of these"/>
   <result pre="nature of these drugs, it is tempting to speculate that" exact="ribavirin" post="acts on HCV at the RNA replication level, as"/>
   <result pre="shown for 2′-C-Methylcytidine [36]. We previously showed that an HCV" exact="ribavirin" post="resistant mutant has mutations in different positions of its"/>
   <result pre="that the RNA dependent RNA polymerase from HCV can use" exact="ribavirin" post="triphosphate as a nucleotide substrate. Once ribavirin monophosphate has"/>
   <result pre="HCV can use ribavirin triphosphate as a nucleotide substrate. Once" exact="ribavirin" post="monophosphate has been incorporated in the nascent chain, it"/>
   <result pre="RNA elongation [38], [39]. As noted above, mutagenic activity of" exact="ribavirin" post="on HCV has been observed in vivo and in"/>
   <result pre="its parental J6/JFH1. This indicates that determinants conferring resistance to" exact="ribavirin" post="also confer resistance to 5-Fluorouracil and could confer resistance"/>
   <result pre="drug treatments. Given the observed efficacy of the inclusion of" exact="ribavirin" post="in interferon free regimens in the treatment of chronic"/>
   <result pre="the treatment of chronic HCV, cross resistance of HCV to" exact="ribavirin" post="and to other antiviral drugs could be of major"/>
   <result pre="In FMDV, a single point mutation (M296I) confers resistance to" exact="ribavirin" post="[40]. This mutant was as sensitive as wild type"/>
   <result pre="the action of antiviral drugs. Of note, the concentrations of" exact="ribavirin" post="(5 mM) and 5-Fluorouracil (200 or 500 µg/ml) for"/>
   <result pre="[12]. Mutations in the finger domain have been identified in" exact="ribavirin" post="resistant mutants of poliovirus [44], [45]. Five other non-synonymous"/>
   <result pre="viral replication. Conclusion In this report, we show that a" exact="ribavirin" post="resistant mutant of HCV has differential sensitivity to other"/>
   <result pre="suggests that mutations that are responsible for HCV resistance to" exact="ribavirin" post="can be involved in the sensitivity to other drugs,"/>
   <result pre="clinically important for drug selection, since an interferon-free regimen containing" exact="ribavirin" post="for the treatment of HCV infections seems currently plausible."/>
   <result pre="10% bovine calf serum (Atlanta Biologicals), L-glutamine (Gibco), penicillin, and" exact="streptomycin" post="(Gibco). Viruses Virus J6/JFH1 was obtained from plasmid pFL-"/>
   <result pre="ShiffmanML, ReddyKR, SmithC, MarinosG, et al. (2002) Peginterferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection. N Engl J"/>
   <result pre="975–982doi:;10.1056/NEJMoa020047;347/13/97512324553 5ShermanKE, FlammSL, AfdhalNH, NelsonDR, SulkowskiMS, et al. (2011) Response-guided" exact="telaprevir" post="combination treatment for hepatitis C virus infection. N Engl"/>
   <result pre="polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus" exact="ribavirin" post="in hepatitis C. Hepatology. 55: 749–758doi:10.1002/hep.24744 8ZeuzemS, AsselahT, AngusP,"/>
   <result pre="the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and" exact="ribavirin" post="in patients with chronic HCV infection. Gastroenterology 1412047–2055: S0016–5085(11)01248-0doi:10.1053/j.gastro.2011.08.051"/>
   <result pre="LiangTJ, et al. (2008) Mechanisms of action of interferon and" exact="ribavirin" post="in chronic hepatitis C: Summary of a workshop. Hepatology47:"/>
   <result pre="ArnoldJJ, ZhongW, LauJY, et al. (2000) The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagen. Nat Med6: 1375–1379.11100123 18GraciJD,"/>
   <result pre="Curing of foot-and-mouth disease virus from persistently infected cells by" exact="ribavirin" post="involves enhanced mutagenesis. Virology 311339–349: S0042682203001442. 20Day CW, Smee"/>
   <result pre="23BrochotE, DuverlieG, CastelainS, MorelV, WychowskiC, et al. (2007) Effect of" exact="ribavirin" post="on the hepatitis C virus (JFH-1) and its correlation"/>
   <result pre="(2002) Viral RNA mutations are region specific and increased by" exact="ribavirin" post="in a full-length hepatitis C virus replication system. J"/>
   <result pre="PoltaA, HerrmannE, MihmU, KronenbergerB, et al. (2007) Mutagenic effect of" exact="ribavirin" post="on hepatitis C nonstructural 5B quasispecies in vitro and"/>
   <result pre="Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells:" exact="ribavirin" post="induces mutagenesis in HCV RNA. J Viral Hepat11: 479–487.15500548"/>
   <result pre="the hepatitis C virus NS5B in patients undergoing treatment with" exact="ribavirin" post="monotherapy. Gastroenterology132: 1757–1766.17484873 28DietzJ, SchelhornSE, FittingD, MihmU, SusserS, et"/>
   <result pre="SusserS, et al. (2013) Deep sequencing reveals mutagenic effects of" exact="ribavirin" post="during monotherapy of hepatitis C virus genotype 1-infected patients."/>
   <result pre="46094–46098.11602568 39VoNV, YoungKC, LaiMM (2003) Mutagenic and inhibitory effects of" exact="ribavirin" post="on hepatitis C virus RNA polymerase. Biochemistry42: 10462–10471.12950173 40SierraM,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC3854647\results\search\drugs\results.xml">
   <result pre="severe or with complications were considered [5]. In the Netherlands," exact="oseltamivir" post="was the drug of first choice for treatment of"/>
   <result pre="risk patients suspected of influenza during the pandemic. Treatment with" exact="zanamivir" post="was reserved for patients suspected for an infection with"/>
   <result pre="this study was therefore to investigate whether the prescription of" exact="oseltamivir" post="by general practitioners (GPs) in the Netherlands was in"/>
   <result pre="national database to estimate 1) the proportion of patients receiving" exact="oseltamivir" post="according to the guidelines in relation to patients’ and"/>
   <result pre="and 2) what proportion of patients diagnosed with influenza received" exact="oseltamivir" post="and which factors determined this prescription. Methods Practices and"/>
   <result pre="the GPs were considered. First, patients having a prescription of" exact="oseltamivir" post="(ATC-code J05AH02) between August 8 and December 31, 2009"/>
   <result pre="8 and December 31, 2009 were considered. No prescriptions of" exact="zanamivir" post="were registered. When there was more than one oseltamivir"/>
   <result pre="of zanamivir were registered. When there was more than one" exact="oseltamivir" post="prescription, only the first one was taken into account."/>
   <result pre="to take into account registration delays. However, in 88% of" exact="oseltamivir" post="prescriptions, the diagnosis was registered at the same day."/>
   <result pre="illness outside the influenza season). Patients who did not receive" exact="oseltamivir" post="were evaluated for a diagnosis of influenza. When more"/>
   <result pre="consultation was taken. Recommended treatment of high risk patients with" exact="oseltamivir" post="was based on age (&amp;lt;2 years or ≥60 years),"/>
   <result pre="– within these days), or a third trimester pregnancy (an" exact="oseltamivir" post="prescription or an influenza diagnosis between 20 to 34"/>
   <result pre="child had to be no more than 14 weeks after" exact="oseltamivir" post="prescription or influenza diagnosis). Details on ICPC- and ATC-codes"/>
   <result pre="we evaluated the proportion of patients whom had been prescribed" exact="oseltamivir" post="and whom should have been prescribed it. Univariate logistic"/>
   <result pre="analyses were performed on the association between the prescription of" exact="oseltamivir" post="and a recommendation for a prescription, as well as"/>
   <result pre="associated with the prescription of oseltamivir. Likewise, we evaluated whether" exact="oseltamivir" post="was prescribed according to the guidelines among all patients"/>
   <result pre="all patients receiving oseltamivir. Because of the recommendation to prescribe" exact="oseltamivir" post="to both very young (under two years of age)"/>
   <result pre="enlisted patients) had been prescribed oseltamivir. The total number of" exact="oseltamivir" post="prescriptions ranged between practices from 0 (11 practices) to"/>
   <result pre="geometric mean = 0.9; geometric standard distribution = 3.4). Half of the patients receiving" exact="oseltamivir" post="had a diagnosis of influenza (n = 181; 51.6%). The most"/>
   <result pre="valid ICPC-code was recorded for 23 patients (6.6%). Of all" exact="oseltamivir" post="prescriptions, 241 (68.7%) were to patients belonging to the"/>
   <result pre="shows the distribution of the underlying reasons for qualification for" exact="oseltamivir" post="in these patients. Table 1 Characteristics of 241 patients"/>
   <result pre="at high risk of severe illness who had been prescribed" exact="oseltamivir" post="n of patients (%) High risk group description  Age"/>
   <result pre="age were associated with an increased chance of having an" exact="oseltamivir" post="prescription according to the recommendations. Independently of age, a"/>
   <result pre="number of prescriptions in general were positively associated with prescribing" exact="oseltamivir" post="according to the guidelines. Table 2 Factors influencing a"/>
   <result pre="to the guidelines. Table 2 Factors influencing a prescription of" exact="oseltamivir" post="according to clinical guidelines in 351 patients with antiviral"/>
   <result pre="to 6.42) 0.001 GP = general practitioner; OR = odds ratio; CI = confidence interval. *Excluding" exact="oseltamivir" post="prescriptions. A total of 3,293 patients (1.3% of the"/>
   <result pre="(1.3% of the study population) were diagnosed with influenza and" exact="oseltamivir" post="was prescribed to 181 (5.5%). The weekly number of"/>
   <result pre="of prescriptions in 2009 were determinants of the prescription of" exact="oseltamivir" post="among influenza patients (Table 3). Patients with underlying co-morbidity"/>
   <result pre="Patients with underlying co-morbidity had the highest chance of an" exact="oseltamivir" post="prescription. All of the designated high risk groups were"/>
   <result pre="the designated high risk groups were statistically significantly associated with" exact="oseltamivir" post="prescription, except children receiving chronic aspirin therapy. Taking into"/>
   <result pre="complicated course of illness, but this was not associated with" exact="oseltamivir" post="treatment. Practice characteristics were not associated with oseltamivir prescriptions."/>
   <result pre="associated with oseltamivir treatment. Practice characteristics were not associated with" exact="oseltamivir" post="prescriptions. Table 3 Potential factors influencing the prescription of"/>
   <result pre="oseltamivir prescriptions. Table 3 Potential factors influencing the prescription of" exact="oseltamivir" post="by general practitioners to 3,293 influenza patients Prescription of"/>
   <result pre="interval. *Reference group does not have the specific co-morbidity. †Excluding" exact="oseltamivir" post="prescriptions. The results of the multilevel model with age,"/>
   <result pre="60 years or above in itself was not associated with" exact="oseltamivir" post="prescription. Independently of a high risk for severe disease"/>
   <result pre="at high risk of severe illness were not associated with" exact="oseltamivir" post="prescription, nor were age, gender, and consultation rate or"/>
   <result pre="or practice characteristics (Table 4). The only significant determinant for" exact="oseltamivir" post="prescriptions was the total number of drug prescriptions in"/>
   <result pre="to 4.32). Table 4 Potential factors influencing the prescription of" exact="oseltamivir" post="to 2,242 influenza patients not at high risk Prescription"/>
   <result pre="(0.40 to 1.82) GP = general practitioner; OR = odds ratio; CI = confidence interval. *Excluding" exact="oseltamivir" post="prescriptions. Discussion This study showed that general practitioners in"/>
   <result pre="general practitioners in the Netherlands have been restrained in prescribing" exact="oseltamivir" post="during the influenza pandemic. Only 5% of all patients"/>
   <result pre="can be considered proxies for underlying morbidity, were determinants for" exact="oseltamivir" post="prescription in addition to the high risk factors of"/>
   <result pre="[14], who found that 85% of Dutch patients with an" exact="oseltamivir" post="prescription belonged to the high risk groups. Their study"/>
   <result pre="on telephone interviews with patients who filled a prescription for" exact="oseltamivir" post="through community pharmacists. Results from other countries on prescriptions"/>
   <result pre="through community pharmacists. Results from other countries on prescriptions of" exact="oseltamivir" post="during the A(H1N1)pdm09 pandemic are scarce. In a study"/>
   <result pre="Chicago hospital, 65% of high-risk patients with influenza-like illness received" exact="oseltamivir" post="treatment [17]. These figures are much higher than in"/>
   <result pre="our study. The results of our study show that if" exact="oseltamivir" post="was prescribed, it was in accordance with the guidelines"/>
   <result pre="fairly well. But they often did not prescribe, even when" exact="oseltamivir" post="was recommended. The availability of antiviral drugs was no"/>
   <result pre="available from the national stockpile. A possible explanation for withholding" exact="oseltamivir" post="to patients at higher risk of complications might have"/>
   <result pre="this is the first study in which recommendations for prescribing" exact="oseltamivir" post="in primary care has been evaluated in detail. More"/>
   <result pre="rate more so than practice featuresPrev Med20023540140610.1006/pmed.2002.108312453719 FietjéEHPhilbertDvan GeffenECWintersNABouvyMLAdherence to" exact="oseltamivir" post="guidelines during influenza pandemic, the NetherlandsEmerg Infect Dis20121853453510.3201/eid1803.11135122377063 HershALStaffordRSAntiviral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC4066892\results\search\drugs\results.xml">
   <result pre="Tris-HCl (pH 7.5), 10mM EDTA and 10 µg/ml tRNA. After" exact="phenol" post="extraction and precipitation with ethanol, the DNA was washed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC4195804\results\search\drugs\results.xml">
   <result pre="initial outbreak of SARS, a number of medications that included" exact="ribavirin" post="with and without corticosteroids [81, 82, 83], interferon (alfacon-1)"/>
   <result pre="corticosteroids [81, 82, 83], interferon (alfacon-1) with corticosteroids [84], and" exact="ribavirin" post="with protease inhibitors [85] had some encouraging outcomes, but"/>
   <result pre="not clearly established. More recently, a combination of IFN-α2b and" exact="ribavirin" post="were shown to have some in vitro synergistic activities"/>
   <result pre="of drug abuse/overdose, bacterial infections and many others (Interferon and" exact="ribavirin" post="treatment side effects, http://www.hepatitis.va.gov/provider/reviews/treatment-side-effects.asp#S1X). Hence, with the new outbreak"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC4247767\results\search\drugs\results.xml">
   <result pre="antiviral drug combination. Combining multiple drugs such as interferon-α and" exact="ribavirin" post="is a standard therapy for enhancing the antiviral effects"/>
   <result pre="Med2012181378138510.1038/nm.289222941277 14.ZeuzemSSchmidtJMLeeJHvon WagnerMTeuberGRothWKHepatitis C virus dynamics in vivo: effect of" exact="ribavirin" post="and interferon alfa on viral turnoverHepatology19982824525210.1002/hep.5102801329657119 15.NeumannAULamNPDahariHGretchDRWileyTELaydenTJPerelsonASHepatitis C viral"/>
   <result pre="vivo and the antiviral efficacy of interferon-alpha therapyScience199828210310710.1126/science.282.5386.1039756471 16.DixitNMLayden-AlmerJELaydenTJPerelsonASModelling how" exact="ribavirin" post="improves interferon response rates in hepatitis C virus infectionNature200443292292410.1038/nature0315315602565"/>
   <result pre="decay profiles of hepatitis B virus during antiviral therapyHepatology200949323810.1002/hep.2258619065674 21.BeaucheminCAAMcSharryJJDrusanoGLNguyenJTWentGTRibeiroRMPerelsonASModeling" exact="amantadine" post="treatment of influenza A virus in vitroJ Theor Biol200825443945110.1016/j.jtbi.2008.05.03118653201"/>
   <result pre="infection dynamicsJ Theor Biol201026733034010.1016/j.jtbi.2010.08.03620831874 52.GuedjJDahariHRongLSansoneNDNettlesRECotlerSJLaydenTJUprichardSLPerelsonASModeling shows that the NS5A inhibitor" exact="daclatasvir" post="has two modes of action and yields a shorter"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC4353273\results\search\drugs\results.xml">
   <result pre="signs of spiking in several parts of Canada. NI drugs," exact="oseltamivir" post="(Tamiflu®, Hoffmann-La Roche Ltd, Canada) and zanamivir (Relenza®, GlaxoSmithKline"/>
   <result pre="Canada. NI drugs, oseltamivir (Tamiflu®, Hoffmann-La Roche Ltd, Canada) and" exact="zanamivir" post="(Relenza®, GlaxoSmithKline Inc, Canada), are the antiviral medications to"/>
   <result pre="as follows: 1. Antiviral drug therapy i. Residents: Oseltamivir or" exact="zanamivir" post="treatment should be administered as soon as the clinical"/>
   <result pre="h after illness onset. The dosage regimens for adults are" exact="oseltamivir" post="75 mg PO BID or zanamivir two inhalations BID."/>
   <result pre="regimens for adults are oseltamivir 75 mg PO BID or" exact="zanamivir" post="two inhalations BID. The treatment dose for oral oseltamivir"/>
   <result pre="or zanamivir two inhalations BID. The treatment dose for oral" exact="oseltamivir" post="for infants (younger than one year) is 3 mg/kg"/>
   <result pre="is 3 mg/kg twice a day. Given that in Canada," exact="oseltamivir" post="is currently not approved for use in infants younger"/>
   <result pre="current seasonal vaccine should be started on chemoprophylaxis with either" exact="oseltamivir" post="or zanamivir. Generally, it is preferable to wait to"/>
   <result pre="until laboratory confirmation has been received. The prophylactic doses are" exact="oseltamivir" post="75 mg PO once daily or zanamivir two inhalations"/>
   <result pre="prophylactic doses are oseltamivir 75 mg PO once daily or" exact="zanamivir" post="two inhalations once daily for adults. The prophylactic dose"/>
   <result pre="inhalations once daily for adults. The prophylactic dose for oral" exact="oseltamivir" post="for infants three months to younger than one year"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC4353274\results\search\drugs\results.xml">
   <result pre="FOR AN UPDATE? Clinical trials with the neuraminidase inhibitors (NIs)" exact="oseltamivir" post="and zanamivir and and meta-analyses of oseltamivir therapy administered"/>
   <result pre="UPDATE? Clinical trials with the neuraminidase inhibitors (NIs) oseltamivir and" exact="zanamivir" post="and and meta-analyses of oseltamivir therapy administered within 36"/>
   <result pre="neuraminidase inhibitors (NIs) oseltamivir and zanamivir and and meta-analyses of" exact="oseltamivir" post="therapy administered within 36 h to 48 h of"/>
   <result pre="treatment after onset of symptoms (4). Earlier therapy with oral" exact="oseltamivir" post="administered within 12 h of symptom onset was shown"/>
   <result pre="was shown to reduce symptoms by 3.6 days (5). Inhaled" exact="zanamivir" post="shortened the duration of major influenza symptoms by 3"/>
   <result pre="placebo in individuals who were febrile at enrollment and received" exact="zanamivir" post="within 30 h (3). In low-risk outpatients, NI treatment"/>
   <result pre="H3N2 subtype and H1N1 pandemic subtype treated in hospital with" exact="oseltamivir" post="clearly demonstrate reduction in mortality, and this benefit was"/>
   <result pre="reduction in mortality, and this benefit was still observed if" exact="oseltamivir" post="was started up to 4 to 5 days after"/>
   <result pre="the predominating H3N2 virus isolates of influenza are susceptible to" exact="oseltamivir" post="and zanamivir. All isolates of H1N1 are oseltamivir- and"/>
   <result pre="Almost all isolates of influenza B are also susceptible to" exact="oseltamivir" post="and zanamivir. C. WHAT INVESTIGATIONS ARE REQUIRED TO DIAGNOSE"/>
   <result pre="onset of influenza-like symptoms. However, in severe illness requiring hospitalization," exact="oseltamivir" post="treatment has been shown to reduce mortality even if"/>
   <result pre="virus testing, treatment should be started immediately, most frequently with" exact="oseltamivir" post="orally. For adults with normal renal function, the typical"/>
   <result pre="mg every 12 h for five days. In ventilated patients," exact="oseltamivir" post="should be administered by nasogastric tube. If zanamivir is"/>
   <result pre="ventilated patients, oseltamivir should be administered by nasogastric tube. If" exact="zanamivir" post="is required in a severely ill patient, intravenous zanamivir"/>
   <result pre="If zanamivir is required in a severely ill patient, intravenous" exact="zanamivir" post="is recommended at a dose of 600 mg every"/>
   <result pre="a dose of 600 mg every 12 h. If intravenous" exact="zanamivir" post="is needed, it can be obtained by request to"/>
   <result pre="(0830-1630 weekdays), 613-941-3061 (after hours and weekends), fax 613-941-3194). Inhaled" exact="zanamivir" post="is not advised in a severely ill patient because"/>
   <result pre="through ventilator circuits is contraindicated. The recommended dose of oral" exact="oseltamivir" post="suspension for pediatric patients is shown Table 1, as"/>
   <result pre="used by adult patients who cannot swallow a capsule. If" exact="oseltamivir" post="oral suspension is not available, oseltamivir capsules may be"/>
   <result pre="swallow a capsule. If oseltamivir oral suspension is not available," exact="oseltamivir" post="capsules may be opened and mixed with sweetened liquids"/>
   <result pre="should be sent for viral PCR and susceptibility testing for" exact="oseltamivir" post="resistance. Suspected oseltamivir resistance should prompt a switch to"/>
   <result pre="for viral PCR and susceptibility testing for oseltamivir resistance. Suspected" exact="oseltamivir" post="resistance should prompt a switch to intravenous zanamivir until"/>
   <result pre="resistance. Suspected oseltamivir resistance should prompt a switch to intravenous" exact="zanamivir" post="until results of antiviral susceptibility testing are available. Repeated"/>
   <result pre="case can be reduced by early institution of post-exposure prophylactic" exact="oseltamivir" post="or zanamivir (16). Hospitalized patients and HCW, regardless of"/>
   <result pre="be reduced by early institution of post-exposure prophylactic oseltamivir or" exact="zanamivir" post="(16). Hospitalized patients and HCW, regardless of their vaccine"/>
   <result pre="contact with a patient with ILI, may be offered either" exact="oseltamivir" post="at a dose of 75 mg once daily or"/>
   <result pre="oseltamivir at a dose of 75 mg once daily or" exact="zanamivir" post="inhalation, two puffs (10 mg) once daily for seven"/>
   <result pre="receive post-exposure antiviral prophylaxis. Pre-exposure prophylaxis Pre-exposure prophylaxis with either" exact="oseltamivir" post="or zanamivir for hospitalized patients or staff is not"/>
   <result pre="antiviral prophylaxis. Pre-exposure prophylaxis Pre-exposure prophylaxis with either oseltamivir or" exact="zanamivir" post="for hospitalized patients or staff is not routinely recommended."/>
   <result pre="Michel Laverdiere: None. References REFERENCES 1.NicholsonKAokiFYOsterhausADet al.Efficacy and safety of" exact="oseltamivir" post="in treatment of acute influenza: A randomized controlled trialLancet200035518455010866439"/>
   <result pre="Trialists) Study GroupRandomised trial of efficacy and safety of inhaled" exact="zanamivir" post="in treatment of influenza A and B virus infectionsLancet19983521877819863784"/>
   <result pre="virus infectionsLancet19983521877819863784 3.HaydenFGOsterhausADMETreanorJJet al.Efficacy and safety of the neuraminidase inhibitor" exact="zanamivir" post="in the treatment of influenzaviris infectionsNew Engl J Med1997337874809302301"/>
   <result pre="and summary of regulatory commentsBMJ2014348g254524811411 5.AokiFYMacleodMDPaggiaroPet al.Early administration of oral" exact="oseltamivir" post="increases the benefits of influenza treatmentJ Antimicrob Ther2003511239 6.AokiFYAllenUDStiverHGLaverdièreMEvansGAThe"/>
   <result pre="and pathogenicity: Observation-based trialsAm J Epidemiol20071652122117088311 TABLE 1 Oseltamivir and" exact="zanamivir" post="treatment of influenza Updated from: The use of antiviral"/>
   <result pre="prescription instructions match the dosing device. 2.The above dosage provides" exact="oseltamivir" post="exposure in children similar to that achieved by the"/>
   <result pre="for adults (13–15). The American Academy of Pediatrics recommended an" exact="oseltamivir" post="treatment dose of 3.5 mg/kg orally twice daily for"/>
   <result pre="in the case of premature infants for whom treatment with" exact="oseltamivir" post="is being considered. The current weight-based dosing recommendations are"/>
   <result pre="premature infants as they might have slower clearance of oral" exact="oseltamivir" post="because of immature renal function. The following dosing is"/>
   <result pre="disease that increase the risk of bronchospasm. TABLE 2 Recommended" exact="oseltamivir" post="regimens for prevention and treatment of adult patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC4531042\results\search\drugs\results.xml">
   <result pre="to minimize immunosuppression. The current antiviral drugs against CMV, ie," exact="ganciclovir" post="(GCV), foscarnet (PFA), and cidofovir (CDV), are associated with"/>
   <result pre="antiviral drugs against CMV, ie, ganciclovir (GCV), foscarnet (PFA), and" exact="cidofovir" post="(CDV), are associated with significant adverse effects. Moreover, there"/>
   <result pre="treatment are the nucleoside analog GCV, and its valine-ester prod-rug" exact="valganciclovir" post="(VGCV), the nucleotide analog CDV, and the pyrophosphate analog"/>
   <result pre="CMV-related disease. Often, transplant patients are receiving other drugs (eg," exact="tacrolimus" post="and calcineurin inhibitors) that augment the risk for renal"/>
   <result pre="specific sites where viral DNA will be cleaved; it produces" exact="adenosine" post="triphosphate (ATP) necessary for DNA translocation; and it combines"/>
   <result pre="CMV disease with 240 mg daily of letermovir was on" exact="tacrolimus" post="as part of his immunosuppression regimen, and no dose"/>
   <result pre="Infect Dis20094981167116819751150 5HumarALebranchuYVincentiFet al.The efficacy and safety of 200 days" exact="valganciclovir" post="cytomegalovirus prophylaxis in high-risk kidney transplant recipientsAm J Transplant20101051228123720353469"/>
   <result pre="kidney transplant recipientsAm J Transplant20101051228123720353469 6PayaCHumarADominguezEet al.Efficacy and safety of" exact="valganciclovir" post="vs oral ganciclovir for prevention of cytomegalovirus disease in"/>
   <result pre="J Transplant20101051228123720353469 6PayaCHumarADominguezEet al.Efficacy and safety of valganciclovir vs oral" exact="ganciclovir" post="for prevention of cytomegalovirus disease in solid organ transplant"/>
   <result pre="(only moderate increases in the levels of midazolam, tacrolimus, and" exact="cyclosporine" post="were observed among healthy volunteers) McCormick48 Potential future applications"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC4539848\results\search\drugs\results.xml">
   <result pre="agents compared to the single agent. Acetylcysteine was superior to" exact="ursodeoxycholic acid" post="or silibinin to reduce ALT. Ursodeoxycholic acid was superior"/>
   <result pre="the single agent. Acetylcysteine was superior to ursodeoxycholic acid or" exact="silibinin" post="to reduce ALT. Ursodeoxycholic acid was superior to acetylcysteine"/>
   <result pre="or silibinin to reduce ALT. Ursodeoxycholic acid was superior to" exact="acetylcysteine" post="or silibinin to reduce TBIL. Conclusions: Hepatoprotective agents combined"/>
   <result pre="to reduce ALT. Ursodeoxycholic acid was superior to acetylcysteine or" exact="silibinin" post="to reduce TBIL. Conclusions: Hepatoprotective agents combined with antiviral"/>
   <result pre="function. These mechanisms may be related to the ability of" exact="ursodeoxycholic acid" post="to regulate cell cycle, apoptosis and protein biosynthesis of"/>
   <result pre="and cholagogue (9). Results of long-term observational studies showed that" exact="ursodeoxycholic acid" post="can significantly reduce the development of hepatic fibrosis (8,"/>
   <result pre="with a large amount of silibinin. it is noteworthy that," exact="silibinin" post="is the main active ingredient of silymarin (14). In"/>
   <result pre="the main active ingredient of silymarin (14). In recent years," exact="silibinin" post="has been used to treat liver cirrhosis, hepatitis, liver"/>
   <result pre="of glutathione transferase and promote the detoxification of free radicals." exact="nitric oxide" post="(NO) and its metabolite can improve microcirculation, increase tissue"/>
   <result pre="not only effective to treat liver failure caused by excessive" exact="acetaminophen" post="(paracetamol), but is also useful for liver disease arising"/>
   <result pre="Using &quot;chronic hepatitis B, hepatitis B, HBV, liver fibrosis, hepatoprotective," exact="silibinin" post="(silymarin, silybin meglumine), acetylcysteine and ursodeoxycholic bile acid (UDCA)�?,"/>
   <result pre="hepatitis B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin, silybin meglumine)," exact="acetylcysteine" post="and ursodeoxycholic bile acid (UDCA)�?, the study retrieved papers"/>
   <result pre="plasma 200 ml qod or albumin 10 g qod +" exact="ranitidine" post="150 mg po tid + other symptomatic and supportive"/>
   <result pre="plasma 200 ml qod or albumin 10 g qod +" exact="ranitidine" post="150 mg po tid + other symptomatic and supportive"/>
   <result pre="Fabris et al. (25) 40 39 UDCA (0.6 g/d) +" exact="lactulose" post="(100-200 g/d) Lactulose (100 - 200 g/d) 3 w"/>
   <result pre="Flisiak et al. (31) 25 25 Silibinin (0.21 g/d) +" exact="misoprostol" post="(0.8 g/d) Placebo (unclear) 24 w ALT, AST, GGT,"/>
   <result pre="compared to UDCA and silibinin. The impact of UDCA and" exact="silibinin" post="on ALT levels in patients with hepatitis B were"/>
   <result pre="(WMD = -22.32; P = 0.03, 95% CI [-42.28, -2.36])," exact="silibinin" post="(WMD = -22.40; P = 0.11, 95% CI [-49.52,"/>
   <result pre="95 % confidence intervals. UDCA was superior over NAC and" exact="silibinin" post="to reduce TBIL in patients with hepatitis B. Meta-analysis"/>
   <result pre="[-4.95, -0.17]), UDCA (WMD = -3.48; 95% CI [-7.37, -0.31])," exact="silibinin" post="(WMD = -2.09; 95% CI [-8.70, 4.52]). However, the"/>
   <result pre="In 2006, Qureshi et al reported that large doses of" exact="ursodeoxycholic acid" post="reduces ALT levels in patients with hepatitis B (28)."/>
   <result pre="(28). The meta-analysis of the current study showed that acetylcysteine," exact="ursodeoxycholic acid" post="and silibinin significantly reduced ALT, and were a liver"/>
   <result pre="of the current study showed that acetylcysteine, ursodeoxycholic acid and" exact="silibinin" post="significantly reduced ALT, and were a liver function marker"/>
   <result pre="patients with hepatitis B. The reduction in ALT levels by" exact="acetylcysteine" post="was better than ursodeoxycholic acid and silibinin. This may"/>
   <result pre="The reduction in ALT levels by acetylcysteine was better than" exact="ursodeoxycholic acid" post="and silibinin. This may be related to the ability"/>
   <result pre="and silibinin. This may be related to the ability of" exact="acetylcysteine" post="to inhibit the expression of serum II-18, IFN-γ and"/>
   <result pre="in the patients with hepatitis B. Some studies stated that" exact="acetylcysteine" post="should be used, and that it was more beneficial"/>
   <result pre="liver disease.Clin Liver Dis.20081247334610.1016/j.cld.2008.07.00718984463 7CaoRHuXDChengHObservation on the clinical efficiency of" exact="adenosine" post="combine with ursodeoxycholic acid in the treatment of chronic"/>
   <result pre="Dis.20081247334610.1016/j.cld.2008.07.00718984463 7CaoRHuXDChengHObservation on the clinical efficiency of adenosine combine with" exact="ursodeoxycholic acid" post="in the treatment of chronic hepatitis B with severe"/>
   <result pre="Pharm Dis.2013143689 9JooSSKangHCWonTJLeeDIUrsodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1 beta and" exact="nitric oxide" post="in rat microglia.Arch Pharm Res.2003261210677314723342 10FekajEGjataAMaxhuniMThe effect of ursodeoxycholic"/>
   <result pre="nitric oxide in rat microglia.Arch Pharm Res.2003261210677314723342 10FekajEGjataAMaxhuniMThe effect of" exact="ursodeoxycholic acid" post="in liver functional restoration of patients with obstructive jaundice"/>
   <result pre="J Clin Microbiol Infect Dis.20133256576910.1007/s10096-012-1789-123247631 14RenBRZhaoYYXuBHWuJLChenJLiangCYResearch of silymarin extraction and" exact="silibinin" post="purification.Lishizhen Med Materia Med Res.20122336556 15FeherJLengyelG[Silymarin in the treatment"/>
   <result pre="paraquat-induced cytotoxicity.Toxicol Letters.199684171210.1016/0378-4274(95)03446-3 17HarrisonPWendonJWilliamsREvidence of increased guanylate cyclase activation by" exact="acetylcysteine" post="in fulminant hepatic failure.Hepatology.199623510677210.1053/jhep.1996.v23.pm00086211358621135 18McClainCJPriceSBarveSDevalarjaRShedlofskySAcetaminophen hepatotoxicity: An update.Curr Gastroenterol"/>
   <result pre="Gan Zang Bing Za Zhi.2008167487918647523 20XiaGThe clinical efficacy observation of" exact="acetylcysteine" post="injection on 58 cases of chronic severe hepatitis B.West"/>
   <result pre="B.West Chin Med J.2009245123940 21ShiXFGuoSHWuGWangZYRenHLiuQThe clinical curative effect observation of" exact="acetylcysteine" post="injection on 40 cases of chronic hepatitis B.J Chongqing"/>
   <result pre="Da Xue Xue Bao Yi Xue Ban.2010352171510.3969/j.issn.1672-7347.2010.02.01420197618 25FabrisPTosittiGMazzellaGZanettiARNicolinRPellizzerGet al.Effect of" exact="ursodeoxycholic acid" post="administration in patients with acute viral hepatitis: a pilot"/>
   <result pre="with acute viral hepatitis: a pilot study.Aliment Pharmacol Ther.199913911879310468700 26AnguloPBattsKPTherneauTMJorgensenRADicksonERLindorKDLong-term" exact="ursodeoxycholic acid" post="delays histological progression in primary biliary cirrhosis.Hepatology.1999293644710.1002/hep.51029030110051462 27CAORHuXDCHENGHHUANGSBAITGANHet al.Observation"/>
   <result pre="primary biliary cirrhosis.Hepatology.1999293644710.1002/hep.51029030110051462 27CAORHuXDCHENGHHUANGSBAITGANHet al.Observation on the clinical efficiency of" exact="adenosine" post="methionine combined with ursodeoxycholic acid in the treatment of"/>
   <result pre="al.Observation on the clinical efficiency of adenosine methionine combined with" exact="ursodeoxycholic acid" post="in the treatment of chronic hepatitis B with severe"/>
   <result pre="hepatitis B with severe jaundice.Chinese J Hos Pharm.20136019 28QureshiHMehdiIAhmedWUAlamSERole of" exact="ursodeoxycholic acid" post="in lowering ALT in chronic liver disease.J Pak Med"/>
   <result pre="of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.J Hepatol.20115451011910.1016/j.jhep.2010.08.03021145828 30FlisiakRProkopowiczDEffect of" exact="misoprostol" post="on serum beta2-microglobulin in the course of viral hepatitis"/>
   <result pre="course of viral hepatitis B.Eur J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of" exact="misoprostol" post="on the course of viral hepatitis B.Hepatogastroenterology.199744171419259356866 32GuXBYangXJHuaZLuZHZhangBZhuYFet al.Effect"/>
   <result pre="hepatitis B.J Cent Plains Med.20063315701 34BaoFYQiuPYAnalyzing the adjunctive therapy of" exact="silibinin" post="phospholipid complex treat chronic hepatitis B in 86 cases.Shandong"/>
   <result pre="36WangHZhaoYLXuKC[Clinical and pathological study on effects of Qianggan Capsule combined" exact="lamivudine" post="on hepatic fibrosis in patients with chronic hepatitis B].Zhongguo"/>
   <result pre="Za Zhi.200626119788017186724 37WuYYaoDKZhuL[Clinical observation on the safety and efficacy of" exact="ursodeoxycholic acid" post="and fuzheng huayu capsule in the treatment of primary"/>
   <result pre="hepatitis B and liver fibrosis.Pract Clin Med.2014152213 39ZhouXYGaoCGaoXCLiuXLLiLHWangXClinical effects of" exact="valsartan" post="on liver fibrosis indexes in patients with alcoholic liver"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC4542094\results\search\drugs\results.xml">
   <result pre="a resistant HCT8 colon carcinoma subline was developed by serial" exact="etoposide" post="exposure. Endoretroviral elements were detected by immunocytochemical staining, qPCR"/>
   <result pre="produce antitumoral effects. The introduction of antiviral drugs such as" exact="ribavirin" post="into the therapy of tumors with high HERV expression"/>
   <result pre="Ruhr-University of Bochum, Medical School. IC50 values and induction of" exact="etoposide" post="resistance IC50 values were determined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium"/>
   <result pre="nm. Both methods were formerly described [30, 31]. Resistance to" exact="etoposide" post="in HCT8 cells was induced in the same form"/>
   <result pre="and reported as the IC50 iCSCs/ IC50 parental ratio. Using" exact="etoposide" post="as chemoresistance-inducer it is feasible to induce a wide"/>
   <result pre="of antiviral and cytostatic drugs Amantadine, ribavirin, pleconaril, lamivudine, and" exact="doxorubicin" post="were purchased from Sigma-Aldrich, acyclovir and ganciclovir from HEXAL"/>
   <result pre="pleconaril, lamivudine, and doxorubicin were purchased from Sigma-Aldrich, acyclovir and" exact="ganciclovir" post="from HEXAL AG, Holzkirchen, Germany. Retrovir was obtained from"/>
   <result pre="Staffordshire, UK and brivudine from Berlin Chemie, Germany. Etoposide and" exact="cisplatin" post="were purchased from TEVA GmbH and 5FU from Medac,"/>
   <result pre="HERV proteins we exposure HCT8 cells to amantadine, pleconaril and" exact="ribavirin" post="alone or simultaneously at 1-fold their respective IC50-values for"/>
   <result pre="in medium containing the respective IC50 of amantadine, pleconaril, and" exact="ribavirin" post="alone or with all drugs simultaneously for 24 hours."/>
   <result pre="and HERV-FRD1 in HCT8RETO colorectal carcinoma cells The anticancer drug" exact="etoposide" post="is commonly not employed in the treatment of colorectal"/>
   <result pre="several tumors as previously described. In HCT8 colorectal carcinoma cells," exact="etoposide" post="induces characteristics for stemness, as judged by their self"/>
   <result pre="of antiproliferative effect, as defined by their IC50 values: amantadine," exact="ribavirin" post="and pleconaril (Fig. 4). All other drugs did not"/>
   <result pre="shown) and therefore were excluded from further analysis. In general," exact="amantadine" post="and pleconaril were the most active compounds in the"/>
   <result pre="cells (Fig. 4). Fig. 4 In vitro cytotoxicity of amantadine," exact="ribavirin" post="and pleconaril in HCT8WT/RETO cells. Cytotoxicity was measured over"/>
   <result pre="of at least n = 3 independent experiments Synergistic cytotoxic effects between" exact="amantadine" post="and anticancer drugs in HCT8WT/RETO cells We next questioned"/>
   <result pre="line (Fig. 5, panels a, c and e), interaction between" exact="amantadine" post="and doxorubicin was slightly synergistic (panel a), between amantadine"/>
   <result pre="5, panels a, c and e), interaction between amantadine and" exact="doxorubicin" post="was slightly synergistic (panel a), between amantadine and cisplatin"/>
   <result pre="between amantadine and doxorubicin was slightly synergistic (panel a), between" exact="amantadine" post="and cisplatin (CP) additive (panel c), and remarkable antagonistic"/>
   <result pre="and doxorubicin was slightly synergistic (panel a), between amantadine and" exact="cisplatin" post="(CP) additive (panel c), and remarkable antagonistic activity was"/>
   <result pre="additive (panel c), and remarkable antagonistic activity was observed between" exact="amantadine" post="and 5FU (panel e), respectively. In contrast, in the"/>
   <result pre="(Fig. 5, panels b, d and f), synergistic interaction between" exact="amantadine" post="and all three anticancer drugs was shown, although synergism"/>
   <result pre="(5FU) (panel f). These results indicate that antiviral compounds like" exact="amantadine" post="do not only exhibited substantial cytotoxic activity in chemoresistant"/>
   <result pre="vitro. Fig. 5 Isobologram showing the in vitro interaction between" exact="amantadine" post="and doxorubicin, cisplatin or 5FU in HCT8WT and HCT8RETO"/>
   <result pre="Isobologram showing the in vitro interaction between amantadine and doxorubicin," exact="cisplatin" post="or 5FU in HCT8WT and HCT8RETO cells. Dose-response curves"/>
   <result pre="by using their specific IC50. As expected, amantadine, pleconaril and" exact="ribavirin" post="as single drugs reduced cell survival by about 50"/>
   <result pre="%. Enhanced cytotoxicity in HCT8RETO cells was only detectable for" exact="amantadine" post="and pleconaril. In general, combination of antiviral compounds (Fig."/>
   <result pre="HCT8 colon carcinoma cells. Simultaneous incubation of HCT8WT/RETO with amantadine," exact="ribavirin" post="and pleconaril based on the IC50 values calculated for"/>
   <result pre="expressed different HERVs entities. We found that amantadine, pleconaril and" exact="ribavirin" post="alone or in combination applied simultaneously, significantly downregulated the"/>
   <result pre="upon exposure of chemo-resistant HCT8RETO cells to the antiviral compound" exact="amantadine" post="We have already shown enhanced cytotoxicity of antiviral compounds"/>
   <result pre="HCT8RETO cells in vitro (Fig. 4). Furthermore, we shown that" exact="amantadine" post="is able to reduce significantly the HERV protein expression"/>
   <result pre="c). Fig. 7 depicts the semi-quantification of the effect of" exact="amantadine" post="in HCT8WT/RETO cells as assayed by ELISA. As expected,"/>
   <result pre="the RNA levels (data not shown). Fig. 7 Effect of" exact="amantadine" post="on HERV protein expression in HCT8WT/RETO analyzed by ELISA."/>
   <result pre="of both HERV-WE1 and HERV-FRD1 is downregulated after incubation with" exact="amantadine" post="at 2 x IC50 for 24 hours. Expression is"/>
   <result pre="cancer cell lines. Among these compounds, the structurally unrelated amantadine," exact="ribavirin" post="and pleconaril were found to be the most active,"/>
   <result pre="phase of viral replication cycle. We focused our studies on" exact="amantadine" post="because we previously have been investigating several PPAP compounds"/>
   <result pre="promoters like Myc, Myb and Stat1/3 [44]. The combination of" exact="amantadine" post="with doxorubicin, cisplatin and 5FU acted synergistically in etoposide-refractory"/>
   <result pre="Myb and Stat1/3 [44]. The combination of amantadine with doxorubicin," exact="cisplatin" post="and 5FU acted synergistically in etoposide-refractory HCT8RETO, i.e. amantadine"/>
   <result pre="doxorubicin, cisplatin and 5FU acted synergistically in etoposide-refractory HCT8RETO, i.e." exact="amantadine" post="boosts the cytotoxicity of these cytostatics in resistant cells."/>
   <result pre="in resistant cells. We also addressed the combination of amantadine," exact="ribavirin" post="and pleconaril on overall cytotoxicity in HCT8WT/RETO cells. Enhanced"/>
   <result pre="Melanoma Tumor Growth In vivoCancer Res20056525889110.1158/0008-5472.CAN-04-423115805254 25.KraljacicBCArguelloMAmriACormackGBordenKInhibition of eIF4E with" exact="ribavirin" post="cooperates with common chemotherapies in primary acute myeloid leukemia"/>
   <result pre="proof-of-principle clinical trial with ribavirinBlood200911422576010.1182/blood-2009-02-20515319433856 29.AssoulineSCuljkovic-KraljacicBBergeronJCaplanSCocolakisELambertCA phase I trial of" exact="ribavirin" post="and low-dose cytarabine for the treatment of relapsed and"/>
   <result pre="with ribavirinBlood200911422576010.1182/blood-2009-02-20515319433856 29.AssoulineSCuljkovic-KraljacicBBergeronJCaplanSCocolakisELambertCA phase I trial of ribavirin and low-dose" exact="cytarabine" post="for the treatment of relapsed and refractory acute myeloid"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC4865845\results\search\drugs\results.xml">
   <result pre="models of chikungunya infection. Two of them, the calmodulin inhibitor" exact="pimozide" post="and the fatty acid synthesis inhibitor TOFA, have a"/>
   <result pre="we tested the in vivo efficacy of the calmodulin inhibitor" exact="pimozide" post="and the fatty acid synthesis inhibitor TOFA, which have"/>
   <result pre="we combined drugs to improve antiviral activity. We focused on" exact="pimozide" post="and TOFA, since they both demonstrated an antiviral effect"/>
   <result pre="with CHIKV for 1 h. In comparison with monotherapy, TOFA and" exact="pimozide" post="combination resulted in increased inhibition of CHIKV infection rate"/>
   <result pre="drug combination in vivo, in adult mice therapeutically treated with" exact="pimozide" post="and TOFA alone or in combination. Importantly, pimozide and"/>
   <result pre="treated with pimozide and TOFA alone or in combination. Importantly," exact="pimozide" post="and TOFA combination caused a significant reduction in CHIKV"/>
   <result pre="the potential for broadly active, host-directed, antiviral therapies (for example," exact="pimozide" post="that had an antiviral effect both for CHIKV and"/>
   <result pre="by keeping cells under selection medium containing blasticidine (5 μg ml−1) and" exact="puromycin" post="(2 μg ml−1) for an additional 10 days. A549 cells depleted"/>
   <result pre="which were kept under selection medium containing blasticidine (10 μg ml−1) and" exact="puromycin" post="(2.5 μg ml−1) for an additional 10 days and subsequently analysed"/>
   <result pre="50 mM stock), KH-CB19 (R&amp;amp;D Systems, 10 mM stock), bafilomycin (50 μM stock)," exact="pimozide" post="(10 mM stock), W7 (53 mM stock), TOFA (10 mM stock), BMS-303141"/>
   <result pre="mice (0.5 mg kg−1, per os) were infected as described above, whereas" exact="pimozide" post="(20 mg kg−1, via os)- and TOFA (25 mg kg−1, via intraperitoneal)-treated mice"/>
   <result pre="first dissolved in DMSO (40 mg ml−1) and then diluted in 0.5%" exact="methylcellulose" post="to a final concentration of 0.25 mg ml−1; pimozide (Sigma) was"/>
   <result pre="diluted in 0.5% methylcellulose to a final concentration of 0.25 mg ml−1;" exact="pimozide" post="(Sigma) was dissolved (25 mg ml−1) in N-methyl-2-pyrrolidone (NMP) and then"/>
   <result pre="of 5 mg ml−1. For experiments shown in Fig. 7d,e, TOFA and" exact="pimozide" post="were dissolved in DMSO (independently or in combination) to"/>
   <result pre="Oncol. Rep.13, 103–111 (2011).21318618 NelsonE. A.et al.. The STAT5 inhibitor" exact="pimozide" post="displays efficacy in models of acute myelogenous leukemia driven"/>
   <result pre="50) for 1 h and treated with cerulenin (50 μM), TOFA (25 μM)," exact="pimozide" post="(pimo, 10 μM), W7 (20 μM), tivozanib (tivo, 5 μM) or vehicle"/>
   <result pre="used and viral titres measured in C57BL/6 mice treated with" exact="pimozide" post="(pimo, per os, n=15 for both data sets) or"/>
   <result pre="days; i.p., intraperitoneal; NS, not significant. Figure 7 Impact of" exact="pimozide" post="and TOFA combination on CHIKV replication in vitro and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC5065164\results\search\drugs\results.xml">
   <result pre="costs of the two first generation direct-acting antiviral agents (DAA)," exact="boceprevir" post="and telaprevir as uncertainty existed regarding the drug of"/>
   <result pre="the two first generation direct-acting antiviral agents (DAA), boceprevir and" exact="telaprevir" post="as uncertainty existed regarding the drug of choice between"/>
   <result pre="controlled trial (RCT) at a VA Medical Center to either" exact="boceprevir" post="or telaprevir in combination with peginterferon and ribavirin, stratified"/>
   <result pre="(RCT) at a VA Medical Center to either boceprevir or" exact="telaprevir" post="in combination with peginterferon and ribavirin, stratified by the"/>
   <result pre="adjudication committee. The primary outcome was difference in tolerability between" exact="boceprevir" post="vs. telaprevir. Secondary outcomes included viral response rates and"/>
   <result pre="adverse events were seen in 10/25 (40%) patients randomized to" exact="telaprevir" post="compared to 2/25 (8%) patients randomized to boceprevir (RR:"/>
   <result pre="randomized to telaprevir compared to 2/25 (8%) patients randomized to" exact="boceprevir" post="(RR: 5; 95% CI: 1.2, 20; p&amp;lt;0.01). Cure rates"/>
   <result pre="an intention-to-treat basis, total cost per cure was $44,329 for" exact="boceprevir" post="vs. $57,115 for telaprevir. The significant side effect profile"/>
   <result pre="vs. $57,115 for telaprevir. The significant side effect profile of" exact="telaprevir" post="combined with the availability of highly efficacious second generation"/>
   <result pre="nearly 25 per 1000 person years.[9] Historically, pegylated-interferon (Peg-IFN) and" exact="ribavirin" post="(RBV) based combination therapy resulted in low cure rates"/>
   <result pre="and dose reductions.[14] The first generation nonstructural 3/4A protease inhibitors," exact="boceprevir" post="and telaprevir, were approved by the United States Food"/>
   <result pre="Peg-IFN with RBV (38–44%) in clinical trials, the addition of" exact="boceprevir" post="or telaprevir demonstrated improved cure rates between 63% to"/>
   <result pre="RBV (38–44%) in clinical trials, the addition of boceprevir or" exact="telaprevir" post="demonstrated improved cure rates between 63% to 75% for"/>
   <result pre="of these two direct-acting antiviral agents (DAA), clinicians largely preferred" exact="telaprevir" post="over boceprevir based on clinical judgment of data gathered"/>
   <result pre="two direct-acting antiviral agents (DAA), clinicians largely preferred telaprevir over" exact="boceprevir" post="based on clinical judgment of data gathered from placebo"/>
   <result pre="3 randomized controlled trials (RCT).[19, 20] The decision to use" exact="telaprevir" post="for some clinicians might have been influenced by its"/>
   <result pre="been influenced by its shorter treatment duration (12 weeks) vs." exact="boceprevir" post="(24/44 weeks). Alternatively, as direct head-to-head evidence comparing the"/>
   <result pre="guide clinicians, the Veterans Health Administration (VHA) decided to make" exact="boceprevir" post="the formulary choice presumably based on an acquisition cost"/>
   <result pre="primary objective of this RCT was to compare tolerability of" exact="boceprevir" post="vs. telaprevir in HCV treatment in treatment naïve and"/>
   <result pre="of this RCT was to compare tolerability of boceprevir vs." exact="telaprevir" post="in HCV treatment in treatment naïve and treatment experienced"/>
   <result pre="The secondary objectives were: a) to evaluate the effectiveness of" exact="boceprevir" post="vs. telaprevir in combination with peginterferon and ribavirin; b)"/>
   <result pre="objectives were: a) to evaluate the effectiveness of boceprevir vs." exact="telaprevir" post="in combination with peginterferon and ribavirin; b) to examine"/>
   <result pre="utilized to allocate subjects to one of two treatment groups," exact="boceprevir" post="or telaprevir. Allocation was concealed using serially numbered, opaque,"/>
   <result pre="eligible. Exclusion criteria were based on standard prescribing information for" exact="boceprevir" post="and telaprevir.[15, 16] These included: co-infection with Hepatitis B"/>
   <result pre="cancers), and current alcoholism or drug addiction. Treatments Boceprevir and" exact="telaprevir" post="were administered through regular clinical care without masking (open"/>
   <result pre="(375mg capsules, 750 mg TID p.o.) and Peg-IFN/RBV. Dosing for" exact="boceprevir" post="(according to product labeling): HCV treatment naïve patients and"/>
   <result pre="to product labeling): HCV treatment naïve patients and relapsers received" exact="boceprevir" post="for 24 to 44 weeks and 36 to 48"/>
   <result pre="of treatment. Prior non-responders or patients with compensated cirrhosis received" exact="boceprevir" post="for 44 weeks and Peg-IFN/RBV for 48 weeks. Dosing"/>
   <result pre="for 44 weeks and Peg-IFN/RBV for 48 weeks. Dosing for" exact="telaprevir" post="(according to product labeling): HCV treatment naïve patients/relapsers received"/>
   <result pre="telaprevir (according to product labeling): HCV treatment naïve patients/relapsers received" exact="telaprevir" post="for 12 weeks and Peg-IFN/RBV for 24 or 48"/>
   <result pre="of treatment. Non-responders and patients with compensated cirrhosis were prescribed" exact="telaprevir" post="for 12 weeks and Peg-IFN/RBV for 48 weeks. Additional"/>
   <result pre="groups: Peginterferon alfa-2a 180 mcg s.c. every week and weight-based" exact="ribavirin" post="1200 mg/day p.o. divided twice daily for patients ≥75kg"/>
   <result pre="data were used to determine cost per SVR for both" exact="boceprevir" post="and telaprevir. Statistical Analysis This study was projected to"/>
   <result pre="50 patients were randomized in a 1:1 fashion to either" exact="boceprevir" post="in combination with Peg-IFN/RBV or telaprevir and Peg-IFN/RBV. Of"/>
   <result pre="1:1 fashion to either boceprevir in combination with Peg-IFN/RBV or" exact="telaprevir" post="and Peg-IFN/RBV. Of the 50 patients randomized, 3 were"/>
   <result pre="patients randomized, 3 were lost to follow-up (1 in the" exact="boceprevir" post="group, 2 in the telaprevir group). The CONSORT study"/>
   <result pre="to follow-up (1 in the boceprevir group, 2 in the" exact="telaprevir" post="group). The CONSORT study flow diagram is shown in"/>
   <result pre="Table 1. 10.1371/journal.pone.0163945.t001Table 1 Demographic characteristics of patients randomized to" exact="boceprevir" post="and telaprevir. Boceprevir (n = 25) Telaprevir (n ="/>
   <result pre="were seen in 10 of 25 (40%) patients randomized to" exact="telaprevir" post="compared to 2 of 25 (8%) patients randomized to"/>
   <result pre="telaprevir compared to 2 of 25 (8%) patients randomized to" exact="boceprevir" post="(RR: 5; 95% CI: 1.2, 20; p&amp;lt;0.01). Eight patients"/>
   <result pre="(RR: 5; 95% CI: 1.2, 20; p&amp;lt;0.01). Eight patients discontinued" exact="telaprevir" post="treatment early due to toxicity (mostly due to rashes);"/>
   <result pre="severe anemia (Hb ≤8 g/dL). Of the two patients on" exact="boceprevir" post="who stopped treatment early, one experienced a severe rash"/>
   <result pre="and the other had severe dysgeusia. Four patients (3 on" exact="boceprevir" post="and 1 on telaprevir) discontinued treatment early due to"/>
   <result pre="each treatment group) experienced mood disturbances while two patients on" exact="boceprevir" post="experienced nausea, vomiting and flu-like symptoms. Treatment tolerability data"/>
   <result pre="data are presented in Table 2. 10.1371/journal.pone.0163945.t002Table 2 Tolerability of" exact="boceprevir" post="and telaprevir. Boceprevir (n = 25) Telaprevir (n ="/>
   <result pre="investigators decided to stop the trial early. Patients who tolerated" exact="telaprevir" post="poorly were given an option to either switch to"/>
   <result pre="3. 10.1371/journal.pone.0163945.t003Table 3 SVR24 rates based on treatment exposure to" exact="boceprevir" post="and telaprevir. Boceprevir (n = 25) Telaprevir (n ="/>
   <result pre="SVR: sustained virologic response; RR: Relative Risk. Two patients on" exact="boceprevir" post="(8%) and 1 patient on telaprevir (4%) experienced viral"/>
   <result pre="Risk. Two patients on boceprevir (8%) and 1 patient on" exact="telaprevir" post="(4%) experienced viral relapse between weeks 4 and 12"/>
   <result pre="to futility criteria as per FDA package label, 6/25 in" exact="boceprevir" post="and 0/25 in telaprevir were considered to have met"/>
   <result pre="per FDA package label, 6/25 in boceprevir and 0/25 in" exact="telaprevir" post="were considered to have met the futility criteria due"/>
   <result pre="to viral breakthrough or non-response. Resource use Patients in the" exact="boceprevir" post="group had on average 13 outpatient visits related to"/>
   <result pre="HCV treatment vs. 9 outpatient visits for those in the" exact="telaprevir" post="group (mostly due to the high percentage of early"/>
   <result pre="telaprevir). Mean cost of standard triple therapy per patient with" exact="boceprevir" post="and Peg-IFN/RBV and routine care was $18,670 ($7,958 –$32,877)"/>
   <result pre="in comparison to $26,962 ($363 –$30,505) per patient in the" exact="telaprevir" post="and Peg-IFN/RBV group. Additionally, adverse event management (additional outpatient"/>
   <result pre="medications, such as growth factors) was $14,801 vs. $24,594 for" exact="boceprevir" post="and telaprevir respectively. In the boceprevir group, 6 patients"/>
   <result pre="as growth factors) was $14,801 vs. $24,594 for boceprevir and" exact="telaprevir" post="respectively. In the boceprevir group, 6 patients received epoetin-α,"/>
   <result pre="$14,801 vs. $24,594 for boceprevir and telaprevir respectively. In the" exact="boceprevir" post="group, 6 patients received epoetin-α, 1 received filgrastim, 4"/>
   <result pre="visits and 1 patient required an ED evaluation. In the" exact="telaprevir" post="group, 7 patients received epoetin-α, 1 received filgrastim, 3"/>
   <result pre="ITT basis, total cost per SVR achieved was $44,329 for" exact="boceprevir" post="vs. $57,115 for telaprevir (Table 4). 10.1371/journal.pone.0163945.t004Table 4 Resource"/>
   <result pre="per SVR achieved was $44,329 for boceprevir vs. $57,115 for" exact="telaprevir" post="(Table 4). 10.1371/journal.pone.0163945.t004Table 4 Resource use associated with boceprevir"/>
   <result pre="for telaprevir (Table 4). 10.1371/journal.pone.0163945.t004Table 4 Resource use associated with" exact="boceprevir" post="and telaprevir. Boceprevir (n = 25) Telaprevir (n ="/>
   <result pre="SVR: Sustained virologic response. Discussion Compared to boceprevir, use of" exact="telaprevir" post="in standard triple antiviral regimens within a Midwestern VA"/>
   <result pre="not significantly different between the two treatment groups, but both" exact="telaprevir" post="and boceprevir showed substantially lower viral cure rates than"/>
   <result pre="different between the two treatment groups, but both telaprevir and" exact="boceprevir" post="showed substantially lower viral cure rates than observed in"/>
   <result pre="trials. Cost of treatment per cure was substantially higher for" exact="telaprevir" post="when compared to boceprevir. The approval of two novel"/>
   <result pre="C treatment when these drugs were approved, clinicians preferred using" exact="telaprevir" post="based triple therapy, presumably given its shorter treatment duration"/>
   <result pre="since real-world treatment experience reports were lacking.[19, 20] In contrast," exact="boceprevir" post="was the formulary choice in VHA based on its"/>
   <result pre="showed an increased incidence in SAEs including increased deaths with" exact="telaprevir" post="when compared to boceprevir, despite higher cure rates with"/>
   <result pre="side-effect profiles of the drugs in question are questionable. Although" exact="boceprevir" post="compared to telaprevir appeared attractive from an acquisition cost"/>
   <result pre="the drugs in question are questionable. Although boceprevir compared to" exact="telaprevir" post="appeared attractive from an acquisition cost perspective, implementing such"/>
   <result pre="or women. Additionally, the FDA approved two new DAAs, namely" exact="sofosbuvir" post="and simprevir in the fall of 2013, both of"/>
   <result pre="that it was unnecessary to continue treating patients with either" exact="telaprevir" post="or boceprevir. Nevertheless, our trial underscores the need for"/>
   <result pre="LeeWM, RustgiVK, et al.Interferon alfa-2b alone or in combination with" exact="ribavirin" post="as initial treatment for chronic hepatitis C. Hepatitis Interventional"/>
   <result pre="NiederauC, MinukGS, IdeoG, et al.Randomised trial of interferon alpha2b plus" exact="ribavirin" post="for 48 weeks or for 24 weeks versus interferon"/>
   <result pre="10.1056/NEJMoa101049421449783 19HezodeC, FontaineH, DorivalC, ZoulimF, LarreyD, CanvaV, et al.Effectiveness of" exact="telaprevir" post="or boceprevir in treatment-experienced patients with HCV genotype 1"/>
   <result pre="FontaineH, DorivalC, ZoulimF, LarreyD, CanvaV, et al.Effectiveness of telaprevir or" exact="boceprevir" post="in treatment-experienced patients with HCV genotype 1 infection and"/>
   <result pre="2008;337:a239010.1136/bmj.a239019001484 24AfdhalN, ZeuzemS, KwoP, ChojkierM, GitlinN, PuotiM, et al.Ledipasvir and" exact="sofosbuvir" post="for untreated HCV genotype 1 infection. N Engl J"/>
   <result pre=".24725239 25KowdleyKV, GordonSC, ReddyKR, RossaroL, BernsteinDE, LawitzE, et al.Ledipasvir and" exact="sofosbuvir" post="for 8 or 12 weeks for chronic HCV without"/>
   <result pre="SigalS, NelsonDR, CrawfordD, et al.Treatment of HCV with ABT-450/r-ombitasvir and" exact="dasabuvir" post="with ribavirin. N Engl J Med. 2014;370(17):1594–603. 10.1056/NEJMoa1315722 .24720703"/>
   <result pre=".24720703 27FerenciP, BernsteinD, LalezariJ, CohenD, LuoY, CooperC, et al.ABT-450/r-ombitasvir and" exact="dasabuvir" post="with or without ribavirin for HCV. N Engl J"/>
   <result pre="CohenD, LuoY, CooperC, et al.ABT-450/r-ombitasvir and dasabuvir with or without" exact="ribavirin" post="for HCV. N Engl J Med. 2014;370(21):1983–92. 10.1056/NEJMoa1402338 .24795200"/>
   <result pre=".24795200 28PoordadF, HezodeC, TrinhR, KowdleyKV, ZeuzemS, AgarwalK, et al.ABT-450/r-ombitasvir and" exact="dasabuvir" post="with ribavirin for hepatitis C with cirrhosis. N Engl"/>
   <result pre="HezodeC, TrinhR, KowdleyKV, ZeuzemS, AgarwalK, et al.ABT-450/r-ombitasvir and dasabuvir with" exact="ribavirin" post="for hepatitis C with cirrhosis. N Engl J Med."/>
   <result pre="LalezariJ, WangC, et al.Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and" exact="ribavirin" post="for hepatitis C in patients co-infected with HIV-1: a"/>
   <result pre="Cost-effectiveness and budget impact of hepatitis C virus treatment with" exact="sofosbuvir" post="and ledipasvir in the United States. Ann Intern Med."/>
   <result pre="32BackusLI, BelperioPS, ShahoumianTA, LoomisTP, MoleLA. Comparative effectiveness of ledipasvir/sofosbuvir +/-" exact="ribavirin" post="vs. ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in 6961 genotype"/>
   <result pre="MoleLA. Comparative effectiveness of ledipasvir/sofosbuvir +/- ribavirin vs. ombitasvir/paritaprevir/ritonavir +" exact="dasabuvir" post="+/- ribavirin in 6961 genotype 1 patients treated in"/>
   <result pre="effectiveness of ledipasvir/sofosbuvir +/- ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir +/-" exact="ribavirin" post="in 6961 genotype 1 patients treated in routine medical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC5228644\results\search\drugs\results.xml">
   <result pre="Study Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
   <result pre="This study undertaken to identify suitable candidates for peg-interferon plus" exact="ribavirin" post="(PEG-IFN/RBV) treatment by evaluating hepatocellular carcinoma (HCC) risk in"/>
   <result pre="CHC do not receive antiviral therapy.[1] Moreover, previous peg-interferon plus" exact="ribavirin" post="(PEG-IFN/RBV)-based regimens are less effective and have higher side"/>
   <result pre="FDA approved of DAAs in 2011, new drugs, such as" exact="sofosbuvir" post="and daclatasvir/asunaprevir, were recently approved with much higher SVR"/>
   <result pre="C virus infection. Lancet Infect Dis2005;5:558–67.16122679 [3]MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus" exact="ribavirin" post="compared with interferon alfa-2b plus ribavirin for initial treatment"/>
   <result pre="[3]MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis C: a randomised"/>
   <result pre="hepatitis C: a randomised trial. Lancet2001;358:958–65.11583749 [4]FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection. N Engl J"/>
   <result pre="Engl J Med2002;347:975–82.12324553 [5]KhurooMSKhurooMSDahabSTMeta-analysis: a randomized trial of peginterferon plus" exact="ribavirin" post="for the initial treatment of chronic hepatitis C genotype"/>
   <result pre="Clin Mol Hepatol2016;22:76–139.27044763 [10]HungCHLeeCMLuSNet al.Long-term effect of interferon alpha-2b plus" exact="ribavirin" post="therapy on incidence of hepatocellular carcinoma in patients with"/>
   <result pre="pegylated interferon and ribavirin. Dig Dis Sci2015;60:573–81.25236421 [17]HondaTIshigamiMMasudaHet al.Effect of" exact="peginterferon alfa-2b" post="and ribavirin on hepatocellular carcinoma prevention in older patients"/>
   <result pre="ribavirin. Dig Dis Sci2015;60:573–81.25236421 [17]HondaTIshigamiMMasudaHet al.Effect of peginterferon alfa-2b and" exact="ribavirin" post="on hepatocellular carcinoma prevention in older patients with chronic"/>
   <result pre="J Gastroenterol Hepatol2015;30:1281–7.25778783 [19]OgawaEFurusyoNKajiwaraEet al.Efficacy of pegylated interferon alpha-2b and" exact="ribavirin" post="treatment on the risk of hepatocellular carcinoma in patients"/>
   <result pre="C: a prospective, multicenter study. J Hepatol2013;58:495–501.23099187 [20]Fernandez-RodriguezCMAlonsoSMartinezSMet al.Peginterferon plus" exact="ribavirin" post="and sustained virological response in HCV-related cirrhosis: outcomes and"/>
   <result pre="predicting response. Am J Gastroenterol2010;105:2164–72.20700116 [21]CardosoACMoucariRFigueiredo-MendesCet al.Impact of peginterferon and" exact="ribavirin" post="therapy on hepatocellular carcinoma: incidence and survival in hepatitis"/>
   <result pre="sonographic study of the liver surface. Radiology1989;172:389–92.2526349 [24]AfdhalNZeuzemSKwoPet al.Ledipasvir and" exact="sofosbuvir" post="for untreated HCV genotype 1 infection. N Engl J"/>
   <result pre="effects of therapy for chronic hepatitis C. Gastroenterology2003;124:1711–9.12761728 [28]MannsMPolSJacobsonIMet al.All-oral" exact="daclatasvir" post="plus asunaprevir for hepatitis C virus genotype 1b: a"/>
   <result pre="phase 3, multicohort study. Lancet2014;384:1597–605.25078304 [29]CapraruCIKuczynskiMLaDet al.Efficacy and safety of" exact="sofosbuvir" post="plus simeprevir in patients with advanced HCV cirrhosis. Hepatology2014;60:665a."/>
   <result pre="multicohort study. Lancet2014;384:1597–605.25078304 [29]CapraruCIKuczynskiMLaDet al.Efficacy and safety of sofosbuvir plus" exact="simeprevir" post="in patients with advanced HCV cirrhosis. Hepatology2014;60:665a. [30]GonzalesGRGonzalezSANazarioHEet al.Efficacy"/>
   <result pre="Hepatology2014;60:665a. [30]GonzalesGRGonzalezSANazarioHEet al.Efficacy of Ledipasvir plus Sofosobuvir with or without" exact="ribavirin" post="in hepatitis C genotype 1 patients who failed previous"/>
   <result pre="Hepatology2015;62:775a. [31]JinYJLeeJWLeeJIet al.Multicenter comparison of PEG-IFN alpha2a or alpha2b plus" exact="ribavirin" post="for treatment-naive HCV patient in Korean population. BMC Gastroenterol2013;13:74.23627926"/>
   <result pre="in Korean population. BMC Gastroenterol2013;13:74.23627926 [32]HondaTKatanoYShimizuJet al.Efficacy of peginterferon-alpha-2b plus" exact="ribavirin" post="in patients aged 65 years and older with chronic"/>
   <result pre="the elderly. Dig Dis Sci2015;60:3170–80.26008618 [35]ModiAANazarioHTrotterJFet al.Safety and efficacy of" exact="simeprevir" post="plus sofosbuvir with or without ribavirin in patients with"/>
   <result pre="Dig Dis Sci2015;60:3170–80.26008618 [35]ModiAANazarioHTrotterJFet al.Safety and efficacy of simeprevir plus" exact="sofosbuvir" post="with or without ribavirin in patients with decompensated genotype"/>
   <result pre="al.Safety and efficacy of simeprevir plus sofosbuvir with or without" exact="ribavirin" post="in patients with decompensated genotype 1 hepatitis C cirrhosis."/>
   <result pre="hepatitis C cirrhosis. Liver Transplant2016;22:281–6. [36]MorenoCLasserLDelwaideJet al.Sofosbuvir in combination with" exact="simeprevir" post="+/− ribavirin in genotype 4 hepatitis C patients with"/>
   <result pre="cirrhosis. Liver Transplant2016;22:281–6. [36]MorenoCLasserLDelwaideJet al.Sofosbuvir in combination with simeprevir +/−" exact="ribavirin" post="in genotype 4 hepatitis C patients with advanced fibrosis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC5319548\results\search\drugs\results.xml">
   <result pre="Erratum Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
   <result pre="article &quot;Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
   <result pre="[1]LeeSHJinY-JShinJYet al.Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC5440157\results\search\drugs\results.xml">
   <result pre="Erratum Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
   <result pre="article, &quot;Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
   <result pre="Reference [1]LeeS-HJinY-JShinJ-YAssessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC5490823\results\search\drugs\results.xml">
   <result pre="are approved to treat other DNA virus infections, most frequently" exact="cidofovir" post="(CDV). CDV, however, has considerable nephrotoxicity, thus it is"/>
   <result pre="by virus replication to a larger extent. We show that" exact="valganciclovir" post="(VGCV), a drug that was shown to be active"/>
   <result pre="most serious cases [14]. Ribavirin and to a lesser extent" exact="ganciclovir" post="(GCV) have also been used (for reviews, see [3,5,6,7,8,9,10,11,15,16])."/>
   <result pre="Ad infection in immunocompromised patients, the animals are immunosuppressed by" exact="cyclophosphamide" post="[24] and then are infected intravenously (i.v.) with Ad5."/>
   <result pre="even reversed with the use of BCV [24,27], GCV [26]," exact="valganciclovir" post="(VGCV) [25], or CDV [27]. Previously, we have shown"/>
   <result pre="Infection of Hamsters with Adenovirus The animals were immunosuppressed using" exact="cyclophosphamide" post="(CP) as described before [24]. CP was administered intraperitoneally"/>
   <result pre="with human type 5 adenovirus in immunosuppressed syrian hamsters, while" exact="ribavirin" post="is largely ineffective in this modelAntivir. Res.2014112384610.1016/j.antiviral.2014.10.00525453340 28.ThomasM.A.SpencerJ.F.La ReginaM.C.DharD.TollefsonA.E.TothK.WoldW.S.Syrian"/>
   <result pre="adenovirus replication in immunocompetent syrian hamsters can be attenuated with" exact="chlorpromazine" post="or cidofovirJ. Gene Med.20101243544510.1002/jgm.145320440754 36.SoldinO.P.MattisonD.R.Sex differences in pharmacokinetics and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC5549007\results\search\drugs\results.xml">
   <result pre="thymoglobulin, MMF: micophenolate mofetil, MPD: methylprednisolone, CSA: cyclosporine, TAC: tacrolimus,AZA:" exact="azathioprine" post="Fourteen (23%) of HCV-infected patients developed clinical hepatic disease"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC5644647\results\search\drugs\results.xml">
   <result pre="infections despite aggressive management, additional treatment with antiviral drugs (e.g.," exact="plerixafor" post="and/or zidovudine) can be considered. Cats with no identifiable"/>
   <result pre="for treatment of HIV infection [13]. The anti-FIV activity of" exact="zidovudine" post="has been assessed in numerous in vitro studies in"/>
   <result pre="carried out in 1989, when North and coworkers showed that" exact="zidovudine" post="inhibited FIV replication in Crandell-Rees feline kidney (CRFK) cells."/>
   <result pre="Crandell-Rees feline kidney (CRFK) cells. The susceptibility of FIV to" exact="zidovudine" post="was similar to that of HIV [27]. There is"/>
   <result pre="the FIV gene is responsible for resistance [10]. In vivo," exact="zidovudine" post="can reduce plasma viral load, improve the immunologic and"/>
   <result pre="of life, and prolong life expectancy [16]. In placebo-controlled trials," exact="zidovudine" post="improved stomatitis and increased the CD4/CD8 ratio in naturally"/>
   <result pre="bone marrow suppression. Regular blood cell counts are necessary during" exact="zidovudine" post="treatment because non-regenerative anemia is a common side effect"/>
   <result pre="not be treated with zidovudine. Most FIV-infected cats treated with" exact="zidovudine" post="for as long as two years tolerated the drug"/>
   <result pre="in vitro [18,19,20,23,26,35,36]. Mutants of FIV that are resistant to" exact="stavudine" post="and cross-resistant to several other antivirals, including zidovudine, have"/>
   <result pre="is active against FIV in vitro [3,20,21,23,38,41]. A combination of" exact="zidovudine" post="and lamivudine had synergistic anti-FIV activities in cell cultures"/>
   <result pre="against FIV in vitro [3,20,21,23,38,41]. A combination of zidovudine and" exact="lamivudine" post="had synergistic anti-FIV activities in cell cultures [41]. FIV"/>
   <result pre="anti-FIV activities in cell cultures [41]. FIV mutants resistant to" exact="lamivudine" post="and containing a point mutation in the RT gene"/>
   <result pre="gene were selected in vitro and showed cross resistance to" exact="zidovudine" post="[23]. In one in vivo study, experimentally FIV-infected cats"/>
   <result pre="the cats with this high-dose dual-drug treatment [41]. Thus, high-dose" exact="lamivudine" post="treatment alone, or in combination with zidovudine, is not"/>
   <result pre="cats. 2.5. Emtricitabine Emtricitabine (2',3'-deoxy-5-fluoro-3'-thiacytidine, FTC) is structurally similar to" exact="lamivudine" post="and was licensed by the FDA in 2003 [40]."/>
   <result pre="had higher levels of cytotoxicity than other compounds, such as" exact="didanosine" post="and amdoxovir [16,20]. There are no in vivo studies"/>
   <result pre="only approved NtARTi for the treatment of HIV infection is" exact="tenofovir" post="disoproxil fumarate (TDF), the prodrug of tenofovir ((R)-9-(2-phosphonylmethoxypropyl)adenine, (R)-PMPA),"/>
   <result pre="HIV infection is tenofovir disoproxil fumarate (TDF), the prodrug of" exact="tenofovir" post="((R)-9-(2-phosphonylmethoxypropyl)adenine, (R)-PMPA), which is also a member of the"/>
   <result pre="of the acyclic nucleoside phosphonates [43,45]. The antiviral spectrum of" exact="tenofovir" post="(2R-1-(6-amino-9H-purin-9-yl)-propan-2-yl-oxy-methyl-phosphonic acid, PMPA) is narrower than that of adefovir;"/>
   <result pre="thereby preventing nucleotide synthesis [66]. Others, such as ribavirin, inhibit" exact="inosine" post="monophosphate dehydrogenase after intracellular phosphorylation, which in turn leads"/>
   <result pre="variety of DNA and RNA viruses [71]. Systemic administration of" exact="ribavirin" post="is limited in cats because of side effects [72]."/>
   <result pre="limited in cats because of side effects [72]. Sequestration of" exact="ribavirin" post="within erythrocytes results in hemolysis, even when low doses"/>
   <result pre="primarily on megakaryocytes, resulting in thrombocytopenia and hemorrhage. With prolonged" exact="ribavirin" post="treatment or at higher doses, the production of erythrocytes"/>
   <result pre="induce hepatic toxicity. An attempt to decrease the toxicity of" exact="ribavirin" post="by incorporating it into lecithin-containing liposomes and administering it"/>
   <result pre="vivo because of toxicity [74]. To date, the efficacy of" exact="ribavirin" post="has not been investigated in FIV-infected cats. 6. Receptor"/>
   <result pre="placebo-controlled double-blinded clinical trial, treatment of naturally FIV-infected cats with" exact="plerixafor" post="resulted in a significant decrease in proviral load in"/>
   <result pre="any clinical consequences. Development of resistance of FIV isolates to" exact="plerixafor" post="did not occur during treatment [53]. In cats, plerixafor"/>
   <result pre="to plerixafor did not occur during treatment [53]. In cats," exact="plerixafor" post="is administered at a dosage of 0.5 mg/kg every"/>
   <result pre="and further studies are needed to investigate the potential of" exact="tipranavir" post="in naturally infected cats. 7.2. Lopinavir Lopinavir (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhex-an-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide) is"/>
   <result pre="as an anti-HIV compound. Similar to lopinavir, some efficacy of" exact="atazanavir" post="was shown against FIV in vitro, but there are"/>
   <result pre="FIV in vitro [92], but FIV was less susceptible to" exact="raltegravir" post="than HIV [92]. No studies in FIV-infected cats exist"/>
   <result pre="there are no in vivo studies on the efficacy of" exact="raltegravir" post="in FIV-infected cats, the drug recently was shown to"/>
   <result pre="feline immunodeficiency virus infection: Part 1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of" exact="zidovudine" post="(ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in"/>
   <result pre="virus infection: Part 1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of zidovudine (ZDV)," exact="lamivudine" post="(3TC) and abacavir (ABC) antiretroviral therapy in suppressing in"/>
   <result pre="1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of zidovudine (ZDV), lamivudine (3TC) and" exact="abacavir" post="(ABC) antiretroviral therapy in suppressing in vitro FIV replicationAntivir."/>
   <result pre="inhibitors for the treatment of HIV: A brief history of" exact="stavudine" post="(D4T) and its comparison with other dideoxynucleosidesAntivir. Res.201085343810.1016/j.antiviral.2009.10.00619854224 35.BalzariniJ.EgberinkH.HartmannK.CahardD.VahlenkampT.ThormarH.de"/>
   <result pre="Immunol. Immunopathol.19923515516610.1016/0165-2427(92)90128-D1337395 53.HartmannK.StengelC.KleinD.EgberinkH.BalzariniJ.Efficacy and adverse effects of the antiviral compound" exact="plerixafor" post="in feline immunodeficiency virus-infected catsJ. Vet. Intern. Med./Am. Coll."/>
   <result pre="kinetic analysesProtein Sci.2007161728173710.1110/ps.07282900717656585 56.DasK.MartinezS.E.BaumanJ.D.ArnoldE.HIV-1 reverse transcriptase complex with DNA and" exact="nevirapine" post="reveals non-nucleoside inhibition mechanismNat. Struct. Mol. Biol.20121925325910.1038/nsmb.222322266819 57.AuwerxJ.NorthT.W.PrestonB.D.KlarmannG.J.De ClercqE.BalzariniJ.Chimeric"/>
   <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistanceCurr. Opin. Virol.20148101510.1016/j.coviro.2014.04.01124846716 72.LafeuilladeA.HittingerG.ChadapaudS.Increased mitochondrial toxicity with ribavirin in"/>
   <result pre="basis of ribavirin resistanceCurr. Opin. Virol.20148101510.1016/j.coviro.2014.04.01124846716 72.LafeuilladeA.HittingerG.ChadapaudS.Increased mitochondrial toxicity with" exact="ribavirin" post="in HIV/HCV coinfectionLancet200135728028110.1016/S0140-6736(00)03618-711214134 73.PoveyR.C.Effect of orally administered ribavirin on"/>
   <result pre="toxicity with ribavirin in HIV/HCV coinfectionLancet200135728028110.1016/S0140-6736(00)03618-711214134 73.PoveyR.C.Effect of orally administered" exact="ribavirin" post="on experimental feline calicivirus infection in catsAm. J. Vet."/>
   <result pre="calicivirus infection in catsAm. J. Vet. Res.19783913371341697143 74.WeissR.C.CoxN.R.BoudreauxM.K.Toxicologic effects of" exact="ribavirin" post="in catsJ. Vet. Pharmacol. Ther.19931630131610.1111/j.1365-2885.1993.tb00177.x8230401 75.WeissR.C.CoxN.R.MartinezM.L.Evaluation of free or"/>
   <result pre="in catsJ. Vet. Pharmacol. Ther.19931630131610.1111/j.1365-2885.1993.tb00177.x8230401 75.WeissR.C.CoxN.R.MartinezM.L.Evaluation of free or liposome-encapsulated" exact="ribavirin" post="for antiviral therapy of experimentally induced feline infectious peritonitisRes."/>
   <result pre="antagonistBlood20031022728273010.1182/blood-2003-02-066312855591 85.NorelliS.El DakerS.D’OstilioD.MeleF.ManciniF.TagliaF.RuggieriA.CiccozziM.CaudaR.CiervoA.et al.Response of feline immunodeficiency virus (FIV) to" exact="tipranavir" post="may provide new clues for development of broad-based inhibitors"/>
   <result pre="Res.2007536538810.2174/15701620778102396517627500 89.MouscadetJ.F.AroraR.AndreJ.LambryJ.C.DelelisO.MaletI.MarcelinA.G.CalvezV.TchertanovL.HIV-1 in alternative molecular recognition of DNA induced by" exact="raltegravir" post="resistance mutationsJ. Mol. Recognit.20092248049410.1002/jmr.97019623602 90.CattoriV.WeibelB.LutzH.Inhibition of feline leukemia virus"/>
   <result pre="of the effect of short-term treatment with the integrase inhibitor" exact="raltegravir" post="(Isentress) on the course of progressive feline leukemia virus"/>
   <result pre="type-I interferon on retrovirusesViruses2009154557310.3390/v103054521994560 100.ZeidnerN.S.MylesM.H.Mathiason-DuBardC.K.DreitzM.J.MullinsJ.I.HooverE.A.Alpha interferon (2β) in combination with" exact="zidovudine" post="for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC5753465\results\search\drugs\results.xml">
   <result pre="levels of IL-6, IL-10 and IFN-γ in mice treated with" exact="ribavirin" post="or the combination therapy of ribavirin and RDN were"/>
   <result pre="in mice treated with ribavirin or the combination therapy of" exact="ribavirin" post="and RDN were all significantly decreased than the untreated"/>
   <result pre="type I interferon and downstream interferon-stimulated responsesAntivir Res2017137495710.1016/j.antiviral.2016.11.01027847245 5.PandejpongDSaengsuriPRattarittamrongRRujipattanakulTChouriyaguneCIs excessive" exact="acetaminophen" post="intake associated with transaminitis in adult patients with dengue"/>
   <result pre="Severity of Dengue. J Infect Dis. 2015; 212(12):2011–2020. 50.YuexiaMWeiZZhongpengZMinLJianLYuguangWCombination of" exact="ribavirin" post="and reduning protects mice against severe pneumonia induced by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC5923505\results\search\drugs\results.xml">
   <result pre="a newly emerging antiviral mechanism of nucleoside analogs. nucleoside analog" exact="gemcitabine" post="antiviral drugs innate immunity interferon-stimulated gene nucleos(t)ide synthesis 1."/>
   <result pre="nucleoside analog drugs targeting specific viral polymerases (acyclovir for herpesviruses," exact="zidovudine" post="for human immunodeficiency virus (HIV), and sofosbuvir for hepatitis"/>
   <result pre="(acyclovir for herpesviruses, zidovudine for human immunodeficiency virus (HIV), and" exact="sofosbuvir" post="for hepatitis C virus (HCV)) have been successful in"/>
   <result pre="IFN-α [6]. Importantly, extensive studies on the antiviral action of" exact="ribavirin" post="have established the underlying molecular framework of nucleoside analogs."/>
   <result pre="report [1]. In the present review, we focus more on" exact="gemcitabine" post="as a nucleoside analog, which is clinically relevant and"/>
   <result pre="cancers [11,12]. However, in recent years, the antiviral activity of" exact="gemcitabine" post="has also been reported against a broad range of"/>
   <result pre="(IAV), HIV, and enteroviruses (EV) [13,14,15,16,17,18]. The antiviral activities of" exact="gemcitabine" post="against the abovementioned viruses are summarized in Table 1."/>
   <result pre="290 FDA-approved drugs in virus-infected Vero E6 cells and identified" exact="gemcitabine" post="as one of drugs with antiviral activity against both"/>
   <result pre="of 1.2 μM and 4.9 μM, respectively) [13]. More recently," exact="gemcitabine" post="was shown to effectively suppress ZIKV infection and replication"/>
   <result pre="research and development into possible treatments. Effective antiviral activities of" exact="gemcitabine" post="were also found for the replication of HCV in"/>
   <result pre="therapy [20]. In the case of HIV, the combination of" exact="gemcitabine" post="with decitabine, another nucleoside analog in clinical use for"/>
   <result pre="study, Clouser et al. further reported the antiviral effect of" exact="gemcitabine" post="against HIV-related retrovirus, murine leukemia virus (MuLV), in vitro"/>
   <result pre="in murine AIDS model [17]. A significant antiviral effect of" exact="gemcitabine" post="on IAVs was also reported for RPE cells by"/>
   <result pre="al. (EC50 of 0.068 μM) [16]. They also tested whether" exact="gemcitabine" post="had an antiviral effect on several other viruses of"/>
   <result pre="virus (MeV), and vaccinia virus [16]. The antiviral effect of" exact="gemcitabine" post="on EVs, initially performed on Coxsackievirus B3 (CVB3), was"/>
   <result pre="respectively). In the case of HRV, the antiviral effect of" exact="gemcitabine" post="was further confirmed in a virus-infected mouse model [22]."/>
   <result pre="virus-infected mouse model [22]. In this study, intranasal administration of" exact="gemcitabine" post="significantly lowered the pulmonary viral load and inflammation by"/>
   <result pre="lung infiltrating lymphocytes. More recently, Zhang et al. also identified" exact="gemcitabine" post="as the best anti-PV inhibitor from a screen of"/>
   <result pre="[15]. As previously mentioned, accumulating evidence has definitively demonstrated that" exact="gemcitabine" post="is an effective broad-spectrum inhibitor of RNA viruses and"/>
   <result pre="treatment of various virus-associated diseases. Moreover, it is possible that" exact="gemcitabine" post="is effective for other untested RNA viruses. Because gemcitabine"/>
   <result pre="that gemcitabine is effective for other untested RNA viruses. Because" exact="gemcitabine" post="is a deoxycytidine analog that interferes with DNA as"/>
   <result pre="virus classified into the Herpesviridae family, was strongly affected by" exact="gemcitabine" post="[16]. Most of the abovementioned viruses have, at best,"/>
   <result pre="their early stages of infection. In this regard, repurposing of" exact="gemcitabine" post="for the treatment of patients infected with these deadly"/>
   <result pre="is an option to treat patients with a combination of" exact="gemcitabine" post="with other antiviral agents. In this manner, an effective"/>
   <result pre="used clinically. As an example, the synergistic antiviral effect of" exact="gemcitabine" post="in combination with ribavirin, an antiviral drug currently being"/>
   <result pre="CVB3 and EV71 [18]. As previously mentioned, the combination of" exact="gemcitabine" post="with decitabine synergistically suppressed HIV infectivity both in vitro"/>
   <result pre="EV71 [18]. As previously mentioned, the combination of gemcitabine with" exact="decitabine" post="synergistically suppressed HIV infectivity both in vitro and in"/>
   <result pre="vitro and in vivo [17,21]. However, the actual use of" exact="gemcitabine" post="in virus-infected patients necessitates prior in vivo animal studies"/>
   <result pre="studies, two recent studies have reported the antiviral effects of" exact="gemcitabine" post="in murine models [17,22]. More extensive analyses of gemcitabine"/>
   <result pre="of gemcitabine in murine models [17,22]. More extensive analyses of" exact="gemcitabine" post="in animal models in the near future will accelerate"/>
   <result pre="Pyrimidine Biosynthesis Inhibitors Most studies regarding the antiviral activity of" exact="gemcitabine" post="lack experimental evidence of the mode of action. However,"/>
   <result pre="mode of action. However, our group has recently reported that" exact="gemcitabine" post="had an anti-EV effect by targeting the salvage pathway"/>
   <result pre="by targeting the salvage pathway of pyrimidine biosynthesis [23]. Moreover," exact="gemcitabine" post="strongly induced the expression of several ISGs including CXCL10,"/>
   <result pre="infection. These results were consistent with a previous report that" exact="gemcitabine" post="stimulated the production of IFN-β and IFN-γ in IAV-infected"/>
   <result pre="as summarized in Table 2 [6,10,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42]. Regarding purine biosynthesis inhibitors," exact="ribavirin" post="and mycophenolic acid (MPA) are inhibitors of inosine-5′-monophosphate (IMP)"/>
   <result pre="in Table 2 [6,10,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42]. Regarding purine biosynthesis inhibitors, ribavirin and" exact="mycophenolic acid" post="(MPA) are inhibitors of inosine-5′-monophosphate (IMP) dehydrogenase (IMPDH), which"/>
   <result pre="the stimulation of ISGs [10,30]. For the antiviral activity of" exact="ribavirin" post="against HCV, ribavirin specifically induced the expression of IRF7,"/>
   <result pre="ISGs [10,30]. For the antiviral activity of ribavirin against HCV," exact="ribavirin" post="specifically induced the expression of IRF7, IRF9, and ISG15"/>
   <result pre="classical JAK/STAT system, which is similar to that observed with" exact="ribavirin" post="[30]. Similar results were obtained with several IMPDH1 or"/>
   <result pre="was not mediated by JAK [10]. Second, IRF7 induction by" exact="ribavirin" post="was not affected by knockdown of STAT1, while that"/>
   <result pre="under the same conditions [6]. Third, our recent study with" exact="gemcitabine" post="further confirmed IFN signal-independent ISG activation by parallel studies"/>
   <result pre="signal-independent ISG activation by parallel studies comparing the effects of" exact="gemcitabine" post="and IFN-α. In our study, the phosphorylation of STAT1"/>
   <result pre="dramatically triggered by IFN-α, did not occur when treated with" exact="gemcitabine" post="[23]. Moreover, the upregulation of DDX58 mRNAs induced by"/>
   <result pre="gemcitabine [23]. Moreover, the upregulation of DDX58 mRNAs induced by" exact="gemcitabine" post="was not affected by IRF9 knockdown, which was contrary"/>
   <result pre="classical IFN signal in the activation of ISGs induced by" exact="ribavirin" post="[6]. Despite the consensus of ISG activation, each purine/pyrimidine"/>
   <result pre="than one signaling pathway involved. The synergistic antiviral activity of" exact="gemcitabine" post="and ribavirin observed in our study might be explained"/>
   <result pre="signaling pathway involved. The synergistic antiviral activity of gemcitabine and" exact="ribavirin" post="observed in our study might be explained by the"/>
   <result pre="encephalitisN. Eng. J. Med.198631414414910.1056/NEJM1986011631403033001520 4.KahnJ.O.LagakosS.W.RichmanD.D.CrossA.PettinelliC.LiouS.H.BrownM.VolberdingP.A.CrumpackerC.S.BeallG.et al.A controlled trial comparing continued" exact="zidovudine" post="with didanosine in human immunodeficiency virus infection. The niaid"/>
   <result pre="J. Med.198631414414910.1056/NEJM1986011631403033001520 4.KahnJ.O.LagakosS.W.RichmanD.D.CrossA.PettinelliC.LiouS.H.BrownM.VolberdingP.A.CrumpackerC.S.BeallG.et al.A controlled trial comparing continued zidovudine with" exact="didanosine" post="in human immunodeficiency virus infection. The niaid aids clinical"/>
   <result pre="virus cell culture modelsHepatology201153324110.1002/hep.2398521254160 7.LeyssenP.BalzariniJ.de ClercqE.NeytsJ.The predominant mechanism by which" exact="ribavirin" post="exerts its antiviral activity in vitro against flaviviruses and"/>
   <result pre="virus replicationAntimicrob. Agents Chemother.2016602834284810.1128/AAC.02700-1526926637 11.HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG.A.ToddG.C.GrindeyG.B.Evaluation of the antitumor activity of" exact="gemcitabine" post="(2′,2′-difluoro-2′-deoxycytidine)Cancer Res.199050441744222364394 12.CerqueiraN.M.FernandesP.A.RamosM.J.Understanding ribonucleotide reductase inactivation by gemcitabineChemistry2007138507851510.1002/chem.20070026017636467 13.DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.Jr.JahrlingP.B.LaidlawM.et"/>
   <result pre="respiratory syndrome coronavirus infectionAntimicrob. Agents Chemother.2014584885489310.1128/AAC.03036-1424841273 14.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.de BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and" exact="gemcitabine" post="inhibit zika virus infection in vitro and differentially affect"/>
   <result pre="and metabolismAntivir. Res.201713911712810.1016/j.antiviral.2016.12.02228049006 15.ZhangZ.YangE.HuC.ChengH.ChenC.Y.HuangD.WangR.ZhaoY.RongL.VignuzziM.et al.Cell-based high-throughput screening assay identifies 2′,2′-difluoro-2′-deoxycytidine" exact="gemcitabine" post="as a potential antipoliovirus agentACS Infect. Dis.20173455310.1021/acsinfecdis.6b0011627733043 16.DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.et al.Obatoclax,"/>
   <result pre="a potential antipoliovirus agentACS Infect. Dis.20173455310.1021/acsinfecdis.6b0011627733043 16.DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.et al.Obatoclax, saliphenylhalamide, and" exact="gemcitabine" post="inhibit influenza a virus infectionJ. Biol. Chem.2012287353243533210.1074/jbc.M112.39214222910914 17.ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O’SullivanM.G.PattersonS.E.ManskyL.M.Activity of"/>
   <result pre="Biol. Chem.2012287353243533210.1074/jbc.M112.39214222910914 17.ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O’SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of" exact="gemcitabine" post="and decitabine in a mouse model for HIV-1Antimicrob. Agents"/>
   <result pre="17.ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O’SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of gemcitabine and" exact="decitabine" post="in a mouse model for HIV-1Antimicrob. Agents Chemother.2012561942194810.1128/AAC.06161-1122271861 18.KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.et"/>
   <result pre="model for HIV-1Antimicrob. Agents Chemother.2012561942194810.1128/AAC.06161-1122271861 18.KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.et al.Synergistic antiviral activity of" exact="gemcitabine" post="and ribavirin against enterovirusesAntivir. Res.201512411010.1016/j.antiviral.2015.10.01126526589 19.BeranR.K.SharmaR.CorsaA.C.TianY.GoldeJ.LundgaardG.DelaneyW.E.t.ZhongW.GreensteinA.E.Cellular growth kinetics distinguish"/>
   <result pre="HIV-1Antimicrob. Agents Chemother.2012561942194810.1128/AAC.06161-1122271861 18.KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.et al.Synergistic antiviral activity of gemcitabine and" exact="ribavirin" post="against enterovirusesAntivir. Res.201512411010.1016/j.antiviral.2015.10.01126526589 19.BeranR.K.SharmaR.CorsaA.C.TianY.GoldeJ.LundgaardG.DelaneyW.E.t.ZhongW.GreensteinA.E.Cellular growth kinetics distinguish a cyclophilin"/>
   <result pre="of a novel HIV combination therapyJ. Virol.2010849301930910.1128/JVI.01006-1020610712 22.SongJ.H.KimS.R.HeoE.Y.LeeJ.Y.KimD.E.ChoS.ChangS.Y.YoonB.I.SeongJ.KoH.J.Antiviral activity of" exact="gemcitabine" post="against human rhinovirus in vitro and in vivoAntivir. Res.201714561310.1016/j.antiviral.2017.07.00328705625"/>
   <result pre="cultured mammalian cellsAntivir. Res.2011891810.1016/j.antiviral.2010.10.00921070810 27.TakhampunyaR.UbolS.HoungH.S.CameronC.E.PadmanabhanR.Inhibition of dengue virus replication by" exact="mycophenolic acid" post="and ribavirinJ. Gen. Virol.2006871947195210.1099/vir.0.81655-016760396 28.YingC.ColonnoR.de ClercqE.NeytsJ.Ribavirin and mycophenolic acid"/>
   <result pre="by mycophenolic acid and ribavirinJ. Gen. Virol.2006871947195210.1099/vir.0.81655-016760396 28.YingC.ColonnoR.de ClercqE.NeytsJ.Ribavirin and" exact="mycophenolic acid" post="markedly potentiate the anti-hepatitis B virus activity of entecavirAntivir."/>
   <result pre="activity of entecavirAntivir. Res.20077319219610.1016/j.antiviral.2006.10.00317098296 29.WangY.ZhouX.DebingY.ChenK.van der LaanL.J.NeytsJ.JanssenH.L.MetselaarH.J.PeppelenboschM.P.PanQ.Calcineurin inhibitors stimulate and" exact="mycophenolic acid" post="inhibits replication of hepatitis E virusGastroenterology20141461775178310.1053/j.gastro.2014.02.03624582714 30.PanQ.de RuiterP.E.MetselaarH.J.KwekkeboomJ.de JongeJ.TilanusH.W.JanssenH.L.van"/>
   <result pre="in vitro and in vivoHepatology2012551673168310.1002/hep.2556222213147 31.PanattoniA.D’AnnaF.TrioloE.Antiviral activity of tiazofurin and" exact="mycophenolic acid" post="against grapevine leafroll-associated virus 3 in vitis vinifera explantsAntivir."/>
   <result pre="vitis vinifera explantsAntivir. Res.20077320621110.1016/j.antiviral.2006.10.00717125850 32.ShirakiK.IshibashiM.OkunoT.KokadoY.TakaharaS.YamanishiK.SonodaT.TakahashiM.Effects of cyclosporine, azathioprine, mizoribine, and" exact="prednisolone" post="on replication of human cytomegalovirusTransplant. Proc.199022168216852167528 33.FurutaY.TakahashiK.FukudaY.KunoM.KamiyamaT.KozakiK.NomuraN.EgawaH.MinamiS.WatanabeY.et al.In vitro"/>
   <result pre="cultureAntimicrob. Agents Chemother.2010543686369510.1128/AAC.00561-1020606073 35.SchlapferE.FischerM.OttP.SpeckR.F.Anti-HIV-1 activity of leflunomide: A comparison with" exact="mycophenolic acid" post="and hydroxyureaAIDS2003171613162010.1097/00002030-200307250-0000512853743 36.FarasatiN.A.ShapiroR.VatsA.RandhawaP.Effect of leflunomide and cidofovir on replication"/>
   <result pre="leflunomide: A comparison with mycophenolic acid and hydroxyureaAIDS2003171613162010.1097/00002030-200307250-0000512853743 36.FarasatiN.A.ShapiroR.VatsA.RandhawaP.Effect of" exact="leflunomide" post="and cidofovir on replication of BK virus in an"/>
   <result pre="comparison with mycophenolic acid and hydroxyureaAIDS2003171613162010.1097/00002030-200307250-0000512853743 36.FarasatiN.A.ShapiroR.VatsA.RandhawaP.Effect of leflunomide and" exact="cidofovir" post="on replication of BK virus in an in vitro"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6025560\results\search\drugs\results.xml">
   <result pre="for treatment of EBV infections. Epstein–Barr virus maribavir antiviral acyclovir" exact="ganciclovir" post="1. Introduction Why is it that despite the profusion"/>
   <result pre="might be beneficial. However, in a multicenter, double-blind, placebo-controlled trial," exact="prednisolone" post="administered with ACV for treatment of IM inhibited oropharyngeal"/>
   <result pre="of the patients. 5. Ganciclovir and Valgancyclovir The effects of" exact="ganciclovir" post="(GCV) and valgancyclovir (VGCV) prophylaxis on EBV load was"/>
   <result pre="xenografts in nude mice, injection into the tumor tissue with" exact="cidofovir" post="suppressed growth of the NPC tissue [30,31]. The ribonucleotide"/>
   <result pre="of the NPC tissue [30,31]. The ribonucleotide reductase (RR) inhibitors" exact="hydroxyurea" post="and didox (3,4-dihydroxybenzohydroxamic acid) enhanced cidofovir-induced apoptosis in EBV-transformed"/>
   <result pre="authors declare no conflict of interest. References References 1.TynellE.AureliusE.BrandellA.JulanderI.WoodM.YaoQ.Y.RickinsonA.AkerlundB.AnderssonJ.Acyclovir and" exact="prednisolone" post="treatment of acute infectious mononucleosis: A multicenter, double-blind, placebo-controlled"/>
   <result pre="Transplant.20022154755410.1016/S1053-2498(01)00407-711983544 13.HierroL.Diez-DoradoR.DiazC.De la VegaA.FraucaE.CamarenaC.Munoz-BartoloG.Gonzalez de ZarateA.Lopez SantamariaM.JaraP.Efficacy and safety of" exact="valganciclovir" post="in liver-transplanted children infected with Epstein-Barr virusLiver Transpl.2008141185119310.1002/lt.2149818668670 14.GreenM.MichaelsM.G.Epstein-Barr"/>
   <result pre="deep sequencingAntimicrob. Agents Chemother.2014584697470210.1128/AAC.03214-1424890586 23.ChouS.BowlinT.L.Cytomegalovirus UL97 mutations affecting cyclopropavir and" exact="ganciclovir" post="susceptibilityAntimicrob. Agents Chemother.20115538238410.1128/AAC.01259-1021041510 24.LurainN.S.ChouS.Antiviral drug resistance of human cytomegalovirusClin."/>
   <result pre="cytomegalovirusClin. Microbiol. Rev.20102368971210.1128/CMR.00009-1020930070 25.ChouS.Cytomegalovirus UL97 mutations in the era of" exact="ganciclovir" post="and maribavirRev. Med. Virol.20081823324610.1002/rmv.57418383425 26.WangF.Z.RoyD.GershburgE.WhitehurstC.B.DittmerD.P.PaganoJ.S.Maribavir inhibits epstein-barr virus transcription"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6027266\results\search\drugs\results.xml">
   <result pre="antagonist, such as maraviroc, or integrase inhibitors (INs), such as" exact="dolutegravir" post="[17,18,19,20]. It is important to remark that long-term exposure"/>
   <result pre="both P-gp and MRP-1 [24,35,37,41,42]. The antiviral drugs amprenavir, nelfinavir," exact="indinavir" post="(PIs), and abacavir (NRTI) are known as P-gp substrates"/>
   <result pre="MRP-1 [24,35,37,41,42]. The antiviral drugs amprenavir, nelfinavir, indinavir (PIs), and" exact="abacavir" post="(NRTI) are known as P-gp substrates [43], whereas zidovudine"/>
   <result pre="and abacavir (NRTI) are known as P-gp substrates [43], whereas" exact="zidovudine" post="and didanosine appear to be transported by MRP-4 and"/>
   <result pre="(NRTI) are known as P-gp substrates [43], whereas zidovudine and" exact="didanosine" post="appear to be transported by MRP-4 and MRP-5 [32,33,38]."/>
   <result pre="and MRP-5 [32,33,38]. Finally, zidovudine, lamivudine, abacavir, zalcitabine, stavudine, and" exact="efavirenz" post="appear as BCRP substrates [44], whereas ritonavir, saquinavir, and"/>
   <result pre="efavirenz appear as BCRP substrates [44], whereas ritonavir, saquinavir, and" exact="nelfinavir" post="are known as inhibitors of this transporter [34]. Maraviroc,"/>
   <result pre="suggested to be a P-gp substrate [45,46,47], whereas the IN" exact="dolutegravir" post="appears as a P-gp and BRCP substrate [20]. Cyclosporine-A,"/>
   <result pre="as a P-gp and BRCP substrate [20]. Cyclosporine-A, verapamil, and" exact="mefloquine" post="are P-gp inhibitors; some of them have been used"/>
   <result pre="primary human brain microvascular endothelial cells (HBMVEC) to HIV-1 and" exact="saquinavir" post="induces an increased MDR-1-mediated drug efflux [51]. Moreover, it"/>
   <result pre="efflux [51]. Moreover, it has been demonstrated that the PIs" exact="ritonavir" post="and atazinavir are able to induce P-gp expression in"/>
   <result pre="endothelial cells hCMEC/D3 demonstrated that amprenavir, atazanavir, efavirenz, ritonavir, and" exact="lopinavir" post="activate hPXR, whereas abacavir, efavirenz, and nepvirapine activate hCAR."/>
   <result pre="other words, a great number of PIs are hPXR ligands:" exact="abacavir" post="and nevirapine are hCAR ligands, and efavirenz is a"/>
   <result pre="a great number of PIs are hPXR ligands: abacavir and" exact="nevirapine" post="are hCAR ligands, and efavirenz is a ligand of"/>
   <result pre="are hPXR ligands: abacavir and nevirapine are hCAR ligands, and" exact="efavirenz" post="is a ligand of both PXR and hCAR. These"/>
   <result pre="enhancement of the cytotoxicity of some anticancer drugs induced by" exact="verapamil" post="(a vasodilator) and cyclosporin A (an immunosuppressant) was revealed."/>
   <result pre="large and fluid binding cavity, the HIV reverse transcriptase inhibitor" exact="abacavir" post="was converted into a dimeric prodrug able to act"/>
   <result pre="cells overexpressing the efflux transporter. The tether length between the" exact="abacavir" post="molecules in the prodrug dimers was able to modulate"/>
   <result pre="strategy of antiviral drugs demonstrating that the ester conjugation of" exact="zidovudine" post="(AZT) with ursodeoxycholic acid, a bile acid which can"/>
   <result pre="drugs demonstrating that the ester conjugation of zidovudine (AZT) with" exact="ursodeoxycholic acid," post="a bile acid which can permeate the CNS, results"/>
   <result pre="antiretroviral drug. In this regard, it has been reported that" exact="indinavir" post="(IDV)-loaded nanoparticles, obtained by coating an IDV suspension, prepared"/>
   <result pre="Very recently, a powder formulation of agglomerates constituted by micronized" exact="ribavirin" post="and α-cyclodextrin spray-dried microparticles was nasally administered to rats."/>
   <result pre="Regarding studies on innovative nasal formulations, the development of antiretroviral" exact="efavirenz" post="(EFV)-loaded nanoparticles based on poly(ε-caprolactone) (PCL), Eudragit® RS 100"/>
   <result pre="PVP compared to chitosan gels [104]. In addition to chitosan," exact="papaverine" post="(a phosphodiesterase inhibitor) has also been considered for its"/>
   <result pre="of nasal mucosa. In particular, after intranasal administration to rats," exact="papaverine" post="appeared to be able to induce a rapid and"/>
   <result pre="associated with an approximately four-fold increase in the amounts of" exact="gemcitabine" post="(chosen as a model drug) reaching the brain, which"/>
   <result pre="surfactant and co-surfactant, respectively, was developed for brain targeting of" exact="saquinavir" post="mesylate. This type of formulation was able to induce"/>
   <result pre="the drug in the brain after intranasal administration compared to" exact="saquinavir" post="amounts obtained after intravenous administration of plain drug suspension."/>
   <result pre="efficacy of this formulation in promoting the nose-to-brain delivery of" exact="saquinavir" post="mesylate [106]. 8.3.1. Nasal Formulations for Zidovudine Administration Several"/>
   <result pre="have been studied in order to induce the uptake of" exact="zidovudine" post="(AZT) in the central nervous system. It is well-known"/>
   <result pre="[110], resulting in a poor CNS/plasma ratio (about 0.1) of" exact="zidovudine" post="[111]. It is important to underline that AZT activity"/>
   <result pre="in the CSF increased when AZT was intravenously co-administered with" exact="probenecid" post="[114], even if it is known that the concomitant"/>
   <result pre="unwanted effects [27,115]. The first studies on nasal administration of" exact="zidovudine" post="to rats were performed using formulations constituted by an"/>
   <result pre="of AZT (20 µmol/kg) or a suspension of AZT and" exact="probenecid" post="[114]. Following nasal administration, AZT showed rapid absorption in"/>
   <result pre="lower than 1 and weakly increased in the presence of" exact="probenecid" post="[114]. A thermoreversible gel, based on Poloxamer 407 (thermoreversible"/>
   <result pre="the prodrug UDCA-AZT, obtained by means of ester conjugation of" exact="zidovudine" post="with ursodeoxycholic acid [71], was loaded in micro-particulate nasal"/>
   <result pre="UDCA-AZT, obtained by means of ester conjugation of zidovudine with" exact="ursodeoxycholic acid" post="[71], was loaded in micro-particulate nasal formulations. This prodrug"/>
   <result pre="P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of" exact="lopinavir" post="in cultured CD4 T cells and primary human lymphocytesJ."/>
   <result pre="primary human lymphocytesJ. Antimicrob. Chemother.20076098799310.1093/jac/dkm35317890284 25.DalpiazA.FogagnoloM.FerraroL.CapuzzoA.PavanB.RassuG.SalisA.GiunchediP.GaviniE.Nasal chitosan microparticles target a" exact="zidovudine" post="prodrug to brain HIV sanctuariesAntivir. Res.201512314615710.1016/j.antiviral.2015.09.01326427553 26.NamanjaH.A.EmmertD.DavisD.A.CamposC.MillerD.S.HrycynaC.A.ChmielewskiJ.Toward eradicating HIV"/>
   <result pre="the brain: Inhibiting P-glycoprotein at the blood-brain barrier with prodrug" exact="abacavir" post="dimersJ. Am. Chem. Soc.20121342976298010.1021/ja206867t21866921 27.PavanB.DalpiazA.Prodrugs and endogenous transporters: Are"/>
   <result pre="al.ATP binding cassette multidrug transporters limit the anti-HIV activity of" exact="zidovudine" post="and indinavir in infected human macrophagesAntivir. Ther.2004951952815456083 34.GuptaA.ZhangY.UnadkatJ.D.MaoQ.HIV protease"/>
   <result pre="cassette multidrug transporters limit the anti-HIV activity of zidovudine and" exact="indinavir" post="in infected human macrophagesAntivir. Ther.2004951952815456083 34.GuptaA.ZhangY.UnadkatJ.D.MaoQ.HIV protease inhibitors are"/>
   <result pre="Pharmacol. Exp. Ther.200431033434110.1124/jpet.104.06534215007102 35.RonaldsonP.T.LeeG.DallasS.BendayanR.Involvement of P-glycoprotein in the transport of" exact="saquinavir" post="and indinavir in rat brain microvessel endothelial and microglia"/>
   <result pre="Ther.200431033434110.1124/jpet.104.06534215007102 35.RonaldsonP.T.LeeG.DallasS.BendayanR.Involvement of P-glycoprotein in the transport of saquinavir and" exact="indinavir" post="in rat brain microvessel endothelial and microglia cell linesPharm."/>
   <result pre="36.ParkS.SinkoP.J.P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of" exact="saquinavir" post="in miceJ. Pharmacol. Exp. Ther.20053121249125610.1124/jpet.104.07621615528451 37.BachmeierC.J.SpitzenbergerT.J.ElmquistW.F.MillerD.W.Quantitative assessment of HIV-1"/>
   <result pre="blood-brain barrierPharm. Res.2005221259126810.1007/s11095-005-5271-y16078135 38.EilersM.RoyU.MondalD.MRP (ABCC) transporters-mediated efflux of anti-HIV drugs," exact="saquinavir" post="and zidovudine, from human endothelial cellsExp. Biol. Med.20082331149116010.3181/0802-RM-5918535159 39.DallasS.MillerD.S.BendayanR.Multidrug"/>
   <result pre="and chemotherapyAAPS Pharm. Sci.20024E1410.1208/ps04031412423063 41.JannehO.OwenA.ChandlerB.HartkoornR.C.HartC.A.BrayP.G.WardS.A.BackD.J.KhooS.H.Modulation of the intracellular accumulation of" exact="saquinavir" post="in peripheral blood mononuclear cells by inhibitors of MRP1,"/>
   <result pre="MRP2, P-gp and BCRPAIDS2005192097210210.1097/01.aids.0000194793.36175.4016284458 42.MeadenE.R.HoggardP.G.NewtonP.TjiaJ.F.AldamD.CornforthD.LloydJ.WilliamsI.BackD.J.KhooS.H.P-glycoprotein and MRP1 expression and reduced" exact="ritonavir" post="and saquinavir accumulation in HIV-infected individualsJ. Antimicrob. Chemother.20025058358810.1093/jac/dkf16112356805 43.VaratharajanL.ThomasS.A.The"/>
   <result pre="and BCRPAIDS2005192097210210.1097/01.aids.0000194793.36175.4016284458 42.MeadenE.R.HoggardP.G.NewtonP.TjiaJ.F.AldamD.CornforthD.LloydJ.WilliamsI.BackD.J.KhooS.H.P-glycoprotein and MRP1 expression and reduced ritonavir and" exact="saquinavir" post="accumulation in HIV-infected individualsJ. Antimicrob. Chemother.20025058358810.1093/jac/dkf16112356805 43.VaratharajanL.ThomasS.A.The transport of"/>
   <result pre="for HIVDrug Metab. Dispos.20053358759510.1124/dmd.104.00262615650075 46.WalkerD.K.BowersS.J.MitchellR.J.PotchoibaM.J.SchroederC.M.SmallH.F.Preclinical assessment of the distribution of" exact="maraviroc" post="to potential human immunodeficiency virus (HIV) sanctuary sites in"/>
   <result pre="(CNS) and gut-associated lymphoid tissue (GALT)Xenobiotica2008381330133910.1080/0049825080244740918853388 47.RamanathanS.AbelS.TweedyS.WestS.HuiJ.KearneyB.P.Pharmacokinetic interaction of ritonavir-boosted" exact="elvitegravir" post="and maravirocJ. Acquir. Immune Defic. Syndr.20105320921410.1097/QAI.0b013e3181ba453619851115 48.Ponte-SucreA.Availability and applications"/>
   <result pre="Biotechnol.20077627928610.1007/s00253-007-1017-617522856 49.OwenA.JannehO.HartkoornR.C.ChandlerB.BrayP.G.MartinP.WardS.A.HartC.A.KhooS.H.BackD.J.In vitro synergy and enhanced murine brain penetration of" exact="saquinavir" post="coadministered with mefloquineJ. Pharmacol. Exp. Ther.20053141202120910.1124/jpet.105.08627215923343 50.KruhG.D.BelinskyM.G.The MRP family"/>
   <result pre="following co-exposure to HIV-1 and saquinavirPLoS ONE20138e7537410.1371/journal.pone.007537424098380 52.PerloffM.D.von MoltkeL.L.GreenblattD.J.Ritonavir and" exact="dexamethasone" post="induce expression of CYP3A and P-glycoprotein in ratsXenobiotica20043413315010.1080/0049825031000163021514985144 53.PerloffM.D.von"/>
   <result pre="in ratsXenobiotica20043413315010.1080/0049825031000163021514985144 53.PerloffM.D.von MoltkeL.L.FaheyJ.M.GreenblattD.J.Induction of P-glycoprotein expression and activity by" exact="ritonavir" post="in bovine brain microvessel endothelial cellsJ. Pharm. Pharmacol.20075994795310.1211/jpp.59.7.000617637189 54.ZastreJ.A.ChanG.N.Y.RonaldsonP.T.RamaswamyM.CouraudP.O.RomeroI.A.WekslerB.BendayanM.BendayanR.Up-regulation"/>
   <result pre="of human pregnane X receptor tightens the blood-brain barrier to" exact="methadone" post="through P-glycoprotein up-regulationMol. Pharmacol.2006701212121910.1124/mol.106.02379616837625 58.OttM.FrickerG.BauerB.Pregnane X receptor (PXR) regulates"/>
   <result pre="molecular basis for poly-specific drug bindingScience20093231718172210.1126/science.116875019325113 70.NamanjaH.A.EmmertD.HrycynaC.A.ChmielewskiJ.Homodimers of the antiviral" exact="abacavir" post="as modulators of P-glycoprotein transport in cell culture: Probing"/>
   <result pre="P-glycoprotein transport in cell culture: Probing tether lengthMedchemcomm201341344134910.1039/c3md00196b24273637 71.DalpiazA.PaganettoG.PavanB.FogagnoloM.MediciA.BeggiatoS.PerroneD.Zidovudine and" exact="ursodeoxycholic acid" post="conjugation: Design of a new prodrug potentially able to"/>
   <result pre="of PLGA nanoparticles as delivery systems of a prodrug of" exact="zidovudine" post="obtained by its conjugation with ursodeoxycholic acidDrug Deliv.201421221123210.3109/10717544.2013.84474424134683 73.DalpiazA.FerraroL.PerroneD.LeoE.IannuccelliV.PavanB.PaganettoG.BeggiatoS.ScaliaS.Brain"/>
   <result pre="al.Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of" exact="indinavir" post="nanoparticles in human monocyte-derived macrophagesVirology200735814815810.1016/j.virol.2006.08.01216997345 76.GorantlaS.DouH.BoskaM.DestacheC.J.NelsonJ.PoluektovaL.RabinowB.E.GendelmanH.E.MosleyR.L.Quantitative magnetic resonance and"/>
   <result pre="deliveryActa Pharm. Sin. B2016626828610.1016/j.apsb.2016.05.01327471668 78.ManfrediniS.PavanB.VertuaniS.ScagliantiM.CompagnoneD.BiondiC.ScatturinA.TanganelliS.FerraroL.PrasadP.et al.Design, synthesis and activity of" exact="ascorbic acid" post="prodrugs of nipecotic, kynurenic and diclophenamic acids, liable to"/>
   <result pre="virus type 1 encephalitisJ. Infect. Dis.200819866467210.1086/59067118662130 84.EliaG.BelloliC.CironeF.LucenteM.S.CarusoM.MartellaV.DecaroN.BuonavogliaC.OrmasP.In vitro efficacy of" exact="ribavirin" post="against canine distemper virusAntivir. Res.20087710811310.1016/j.antiviral.2007.09.00417949825 85.ColomboG.LorenziniL.ZironiE.GalligioniV.SonvicoF.BalducciA.G.PagliucaG.GiulianiA.CalzàL.ScagliariniA.Brain distribution of ribavirin"/>
   <result pre="of ribavirin against canine distemper virusAntivir. Res.20087710811310.1016/j.antiviral.2007.09.00417949825 85.ColomboG.LorenziniL.ZironiE.GalligioniV.SonvicoF.BalducciA.G.PagliucaG.GiulianiA.CalzàL.ScagliariniA.Brain distribution of" exact="ribavirin" post="after intranasal administrationAntivir. Res.20119240841410.1016/j.antiviral.2011.09.01222001322 86.GiulianiA.BalducciA.G.ZironiE.ColomboG.BortolottiF.LorenziniL.GalligioniV.PagliucaG.ScagliariniA.CalzàL.et al.In vivo nose-to-brain delivery"/>
   <result pre="Res.20119240841410.1016/j.antiviral.2011.09.01222001322 86.GiulianiA.BalducciA.G.ZironiE.ColomboG.BortolottiF.LorenziniL.GalligioniV.PagliucaG.ScagliariniA.CalzàL.et al.In vivo nose-to-brain delivery of the hydrophilic antiviral" exact="ribavirin" post="by microparticle agglomeratesDrug Deliv.20182537638710.1080/10717544.2018.142824229382237 87.MistryA.StolnikS.IllumL.Nanoparticles for direct nose-to-brain delivery"/>
   <result pre="drugsInt. J. Pharm.200937914615710.1016/j.ijpharm.2009.06.01919555750 88.HoekmanJ.D.HoR.J.Effects of localized hydrophilic mannitol and hydrophobic" exact="nelfinavir" post="administration targeted to olfactory epithelium on brain distributionAAPS PharmSciTech.20111253454310.1208/s12249-011-9614-121519984"/>
   <result pre="N-trimethyl chitosan chlorideEur. J. Pharm. Biopharm.20117722523210.1016/j.ejpb.2010.11.02221130876 96.NakamuraK.MaitaniY.LowmanA.M.TakayamaK.PeppasN.A.NagaiT.Uptake and release of" exact="budesonide" post="from mucoadhesive, pH-sensitive copolymers and their application to nasal"/>
   <result pre="the sheep nasal cavityInt. J. Pharm.200121718319110.1016/S0378-5173(01)00602-011292554 98.ZakiN.M.AwadG.A.MortadaN.D.Abd ElhadyS.S.Enhanced bioavailability of" exact="metoclopramide" post="HCl by intranasal administration of a mucoadhesive in situ"/>
   <result pre="acyclovirDrug Dev. Ind. Pharm.20093535236210.1080/0363904080236051018770068 105.KrishanM.GudelskyG.A.DesaiP.B.GenterM.B.Manipulation of olfactory tight junctions using" exact="papaverine" post="to enhance intranasal delivery of gemcitabine to the brainDrug"/>
   <result pre="olfactory tight junctions using papaverine to enhance intranasal delivery of" exact="gemcitabine" post="to the brainDrug Deliv.20142181610.3109/10717544.2013.84001724116937 106.MahajanH.S.MahajanM.S.NerkarP.P.AgrawalA.Nanoemulsion-based intranasal drug delivery system"/>
   <result pre="to the brainDrug Deliv.20142181610.3109/10717544.2013.84001724116937 106.MahajanH.S.MahajanM.S.NerkarP.P.AgrawalA.Nanoemulsion-based intranasal drug delivery system of" exact="saquinavir" post="mesylate for brain targetingDrug Deliv.20142114815410.3109/10717544.2013.83801424128122 107.PardridgeW.M.Blood-brain barrier drug targeting:"/>
   <result pre="of brain drug developmentMol. Interv.200339010510.1124/mi.3.2.9014993430 108.WongS.L.Van BelleK.SawchukR.J.Distributional transport kinetics of" exact="zidovudine" post="between plasma and brain extracellular fluid/cerebrospinal fluid in the"/>
   <result pre="fluid in the rabbit: Investigation of the inhibitory effect of" exact="probenecid" post="utilizing microdialysisJ. Pharmacol. Exp. Ther.19932648999098437131 109.TakasawaK.TerasakiT.SuzukiH.SugiyamaY.In vivo evidence for"/>
   <result pre="brain during intravenous and intracerebroventricular infusionJ. Pharm. Sci.1995787187610.1002/jps.2600840717 111.WongS.L.WangY.SawchukR.J.Analysis of" exact="zidovudine" post="distribution to specific regions in rabbit brain using microdialysisPharm."/>
   <result pre="fluid cisterns via subarachnoid velae in ratNeuroscience1996751271128810.1016/0306-4522(96)00281-38938759 114.SekiT.SatoN.HasegawaT.KawaguchiT.JuniK.Nasal absorption of" exact="zidovudine" post="and its transport to cerebrospinal fluid in ratsPharm. Bull.1994171135113710.1248/bpb.17.1135"/>
   <result pre="oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal" exact="zidovudine" post="delivery to the brainInt. J. Pharm.20114111910.1016/j.ijpharm.2011.02.04021356294 117.Al-GhananeemA.M.SmithM.CoronelM.L.TranH.Advances in brain"/>
   <result pre="and organic compounds saquinavir, ritonavir, lopinavir, amprenavir, nelfinavir, indinavir, abacavir," exact="dolutegravir" post="cyclosporine-A, verapamil, mefloquine Multidrug Resistance Protein MRP-1 ABCC1 hydrophilic"/>
   <result pre="saquinavir, ritonavir, lopinavir, amprenavir, nelfinavir, indinavir, abacavir, dolutegravir cyclosporine-A, verapamil," exact="mefloquine" post="Multidrug Resistance Protein MRP-1 ABCC1 hydrophilic anion compounds, large"/>
   <result pre="Protein MRP-1 ABCC1 hydrophilic anion compounds, large molecules saquinavir, ritonavir," exact="lopinavir" post="paclitaxel, probenecid, MK-571 MRP-4 MRP-5 ABCC4 ABCC5 small polar"/>
   <result pre="MRP-4 MRP-5 ABCC4 ABCC5 small polar compounds, nucleoside analogues Zidovudine," exact="didanosine" post="Breast-Cancer-Resistance Protein BRCP ABCG2 partially overlap with those of"/>
   <result pre="with those of P-gp zidovudine, lamivudine, abacavir, zalcitabine, stavudine, efavirenz," exact="dolutegravir" post="ritonavir, saquinavir, nelfinavir"/>
   <result pre="P-gp zidovudine, lamivudine, abacavir, zalcitabine, stavudine, efavirenz, dolutegravir ritonavir, saquinavir," exact="nelfinavir" post=""/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6439212\results\search\drugs\results.xml">
   <result pre="(Pol/RT) was modeled and docked with the active compounds, including" exact="lamivudine" post="as standard. Docking of lamivudine indicated strong interaction with"/>
   <result pre="with the active compounds, including lamivudine as standard. Docking of" exact="lamivudine" post="indicated strong interaction with the modeled HBV Pol active-site"/>
   <result pre="with HBV Pol inhibitors, the nucleot(s)ide analogs (e.g., lamivudine, adepovir," exact="entecavir" post="etc.) leads to the emergence of drug-resistance in the"/>
   <result pre="Wu, 2016, Parvez et al., 2016). Compared to interferons or" exact="lamivudine" post="treatment, some plant products are reported with similar or"/>
   <result pre="naringenin were purchased (Sigma-Aldrich, Germany). The approved anti-HBV nucleoside analog," exact="lamivudine" post="(3TC; Sigma-Aldrich, Germany) served as standard (positive control). 2.2"/>
   <result pre="grown over night. Compounds were first dissolved in 50 μl of" exact="dimethyl sulfoxide" post="(DMSO) following final preparation in culture media (1 mg/ml). Five"/>
   <result pre="for screening the binding modes of antiviral natural compounds, including" exact="lamivudine" post="(Fig. 1) in Autodock Vina and PyRx virtual screening"/>
   <result pre="used in the treatment of HIV/AIDS and CHB. Docking of" exact="lamivudine" post="(as control) to HBV Pol indicated that it was"/>
   <result pre="and two carbon-hydrogen bonds with Ala181. Other residues that surrounded" exact="lamivudine" post="were Gln182 and Ser185 as well as Tyr203 and"/>
   <result pre="delineate the binding mechanism of the anti-HBV active compounds and" exact="lamivudine" post="(ligands) to the modeled HBV Pol (receptor), we performed"/>
   <result pre="modeled HBV Pol (receptor), we performed molecular docking. Docking of" exact="lamivudine" post="indicated that it strongly interacted with the active site"/>
   <result pre="Pol ‘YMDD’ motif residues, Tyr203 and Met204 were among the" exact="lamivudine" post="surrounding amino acids. Quercetin, a widely distributed plant flavonol"/>
   <result pre="was lesser as compared to its reported higher activity to" exact="lamivudine" post="(Yi et al., 2015). In the docking analysis, menisdaurin-HBV"/>
   <result pre="in-vitro and molecular docking analysisJ. Biomol. Struct. Dyn.2017 RehmanM.T.AhmedS.KhanA.U.Interaction of" exact="meropenem" post="with 'N' and 'B' isoforms of human serum albumin:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6444013\results\search\drugs\results.xml">
   <result pre="The following reagents were purchased from Applichem: LB medium (powder)," exact="ampicillin" post="(used at 100 μg/mL) and chloramphenicol (used at 17 μg/mL), MnCl2,"/>
   <result pre="from Applichem: LB medium (powder), ampicillin (used at 100 μg/mL) and" exact="chloramphenicol" post="(used at 17 μg/mL), MnCl2, ammonium acetate, NaCl, MgCl2, ZnCl2,"/>
   <result pre="and pET16b expression vectors were obtained from Novagen. Nucleotide analogs" exact="ribavirin" post="5′-triphosphate and cordycepin 5′-triphosphate were obtained from Jena Bioscience"/>
   <result pre="E. coli cells were transformed by electroporation with pET16a-ZIKV-NS5RdRp. Single" exact="kanamycin" post="and chloramphenicol resistant colonies were cultured overnight in 10 mL"/>
   <result pre="cells were transformed by electroporation with pET16a-ZIKV-NS5RdRp. Single kanamycin and" exact="chloramphenicol" post="resistant colonies were cultured overnight in 10 mL of LB"/>
   <result pre="cordycepin 5′-triphosphate (3′dATP; a chain terminator analog of ATP48–50) and" exact="ribavirin" post="5′-triphosphate (RTP; a purine analog that inhibits but does"/>
   <result pre="and functions of RNA-directed RNA polymerasesTrends Plant Sci20061114215110.1016/j.tplants.2006.01.00316473542 22.YinZet al.An" exact="adenosine" post="nucleoside inhibitor of dengue virusProc Natl Acad Sci USA2009106204352043910.1073/pnas.090701010619918064"/>
   <result pre="activity of ribavirinJ Biol Chem2001276460944609810.1074/jbc.C10034920011602568 53.CrottySet al.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagenNat Med200061375137910.1038/8219111100123 54.AriasAet al.Determinants of"/>
   <result pre="a broad-spectrum antiviral compoundSci Rep20177581610.1038/s41598-017-04449-328725041 67.VoNVYoungKCLaiMMMutagenic and inhibitory effects of" exact="ribavirin" post="on hepatitis C virus RNA polymeraseBiochemistry200342104621047110.1021/bi034468112950173 68.Bassi, M. R.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6702965\results\search\drugs\results.xml">
   <result pre="effect of three of these cell-targeting antivirals: lauryl gallate (LG)," exact="valproic acid" post="(VPA), and cerulenin (CRL) in the multiplication of viruses"/>
   <result pre="against porcine diseases is discussed. virus porcine antiviral lauryl gallate" exact="valproic acid" post="cerulenin Funding Spanish Ministerio de Ciencia e Innovación2011-20E112 Ministerio"/>
   <result pre="have focused our studies on three compounds: lauryl gallate (LG)," exact="valproic acid" post="(VPA), and cerulenin (CRL) (Table 1) that can interfere"/>
   <result pre="Inhibition of herpes virus infection in oligodendrocyte cultured cells by" exact="valproic acid." post="Virus Res.214, 71–79. 10.1016/j.virusres.2016.01.009, PMID: 26805038 CuypersL.SnoeckJ.KerremansL.LibinP.CrabbeR.Van DoorenS.et al.."/>
   <result pre="PMID: 11254174 TerbachN.WilliamsR. S. (2009). Structure-function studies for the panacea," exact="valproic acid." post="Biochem. Soc. Trans.37, 1126–1132. 10.1042/BST0371126, PMID: 19754465 UozakiM.YamasakiH.KatsuyamaY.HiguchiM.HigutiT.KoyamaA. H."/>
   <result pre="(2013). Inhibition of multiplication of the prototypic arenavirus LCMV by" exact="valproic acid." post="Antivir. Res.99, 172–179. 10.1016/j.antiviral.2013.05.012, PMID: 23735299 Vazquez-CalvoA.SaizJ. C.SobrinoF.Martin-AcebesM. A."/>
   <result pre="(2011). Inhibition of enveloped virus infection of cultured cells by" exact="valproic acid." post="J. Virol.85, 1267–1274. 10.1128/JVI.01717-10, PMID: 21106740 YamasakiH.UozakiM.KatsuyamaY.UtsunomiyaH.ArakawaT.HiguchiM.et al.. (2007)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6724046\results\search\drugs\results.xml">
   <result pre="target hepatitis B virus transcriptionJ. Viral Hepat.20162319120110.1111/jvh.1247926456011 20.WangY.-M.LuJ.-W.LinC.-C.ChinY.-F.WuT.-Y.LinL.-I.LaiZ.-Z.KuoS.-C.HoY.-J.Antiviral activities of" exact="niclosamide" post="and nitazoxanide against chikungunya virus entry and transmissionAntivir. Res.2016135819010.1016/j.antiviral.2016.10.00327742486"/>
   <result pre="B virus transcriptionJ. Viral Hepat.20162319120110.1111/jvh.1247926456011 20.WangY.-M.LuJ.-W.LinC.-C.ChinY.-F.WuT.-Y.LinL.-I.LaiZ.-Z.KuoS.-C.HoY.-J.Antiviral activities of niclosamide and" exact="nitazoxanide" post="against chikungunya virus entry and transmissionAntivir. Res.2016135819010.1016/j.antiviral.2016.10.00327742486 21.FangJ.SunL.PengG.XuJ.ZhouR.CaoS.ChenH.SongY.Identification of"/>
   <result pre="involves both extrinsic and intrinsic pathwaysAppl. Biochem. Biotechnol.201417249750810.1007/s12010-013-0538-y24092455 25.SavignyM.R.MacintireD.K.Use of" exact="oseltamivir" post="in the treatment of canine parvoviral enteritisJ. Veter. Emerg."/>
   <result pre="enteritisJ. Veter. Emerg. Crit. Care20102013214210.1111/j.1476-4431.2009.00404.x20230441 26.LiekensS.NoppenS.GijsbersS.SienaertR.RoncaR.TobiaC.PrestaM.The broad-spectrum anti-DNA virus agent" exact="cidofovir" post="inhibits lung metastasis of virus-independent, FGF2-driven tumorsOncotarget201564633464810.18632/oncotarget.307925609197 27.HicksonS.E.MargineantuD.HockenberyD.M.SimonJ.A.GeballeA.P.Inhibition of"/>
   <result pre="Post-translational LevelJ. Boil. Chem.2009284297982980810.1074/jbc.M109.029470 32.KeeffeE.B.RossignolJ.-F.KeeffeJ.-F.E.B.RossignolO.Treatment of chronic viral hepatitis with" exact="nitazoxanide" post="and second generation thiazolidesWorld J. Gastroenterol.2009151805180810.3748/wjg.15.180519370775 33.SiddiqD.M.KooH.L.AdachiJ.A.ViolaG.M.Norovirus Gastroenteritis Successfully"/>
   <result pre="Dis.20174ofx00910.1093/ofid/ofx00928480282 39.PerelyginaL.HautalaT.SeppänenM.AdebayoA.SullivanK.E.IcenogleJ.Inhibition of rubella virus replication by the broad-spectrum drug" exact="nitazoxanide" post="in cell culture and in a patient with a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6755163\results\search\drugs\results.xml">
   <result pre="different compared with that of PHHs, as the addition of" exact="dimethyl sulfoxide" post="(DMSO) plus polyethylene glycol 8000 (PEG8000) during infection does"/>
   <result pre="vena cava under anaesthesia by intraperitoneal injection of 30 mg/kg" exact="pentobarbital" post="sodium (7). Death was confirmed by respiratory arrest, cardiac"/>
   <result pre="plates pre-coated with collagen (Gibco; Thermo Fisher Scientific, Inc.) in" exact="dimethyl sulfoxide" post="(DMSO)-free primary human hepatocyte maintenance medium (PMM) (4) containing"/>
   <result pre="supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml" exact="streptomycin" post="maintained at 37°C in a 5% CO2 incubator. Huh7D"/>
   <result pre="(DMEM supplemented with 5% FBS, 100 U/ml penicillin, 100 µg/ml" exact="streptomycin" post="and 2.5% DMSO) for 24–72 h prior to HBV"/>
   <result pre="supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml" exact="streptomycin" post="maintained at 37°C in a 5% CO2 incubator. For"/>
   <result pre="penicillin and 100 µg/ml streptomycin, 5 µg/ml insulin, 18 ng/ml" exact="hydrocortisone" post="and 2–2.5% DMSO. The culture media was collected at"/>
   <result pre="~50 nM. The less effective inhibition of HBV infection by" exact="lamivudine" post="possibly occurred due to the failure of lamivudine to"/>
   <result pre="infection by lamivudine possibly occurred due to the failure of" exact="lamivudine" post="to block HBV entry. These results indicated that HBV-infected"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6780377\results\search\drugs\results.xml">
   <result pre="for repressing Flaviviruses. Guanine biosynthesis can be inhibited through antiviral" exact="ribavirin" post="[69]. Dihydroorotate dehydrogenase (DHODH) is a mitochondrial protein that"/>
   <result pre="(HS) mimetic PI88 [80], α- d-glucan [84], GAG [85], and" exact="dextran" post="sulfate (DS, MW &amp;gt; 500,000 Da) [85] are also"/>
   <result pre="(MAPKAPK5) kinase activity and inhibit DENV propagation [108]. GNF-2 and" exact="imatinib" post="inhibit DENV but are mediated by cellular Abl kinases"/>
   <result pre="were non-detectable [142,143,144]. It has been demonstrated that IFN-γ controls" exact="nitric oxide" post="synthase II-mediated nitric oxide production that assists the host"/>
   <result pre="has been demonstrated that IFN-γ controls nitric oxide synthase II-mediated" exact="nitric oxide" post="production that assists the host in resistance against primary"/>
   <result pre="in Patients with Dengue Hemorrhagic FeverFEMS Immunol. Med. Microbiol.20002815115510.1111/j.1574-695X.2000.tb01470.x10799806 145.Neves-SouzaP.C.AzeredoE.L.ZagneS.M.Valls-de-SouzaR.ReisS.R.CerqueiraD.I.NogueiraR.M.KubelkaC.F.Inducible" exact="nitric oxide" post="synthase (iNOS) expression in monocytes during acute Dengue Fever"/>
   <result pre="Huh-7 [176] Isothiazolo[5,4-b] pyridines GAK DENV-2 Huh-7 [177] Sunitinib and" exact="erlotinib" post="AAK1 and GAK DENV-2 Huh7 [178] AR-12 PI3K/JAKT pathway"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6789623\results\search\drugs\results.xml">
   <result pre="effective antiviral drugs is a high priority. In this study," exact="lithium" post="chloride (LiCl) and diammonium glycyrrhizinate (DG), which are host-acting"/>
   <result pre="as new drugs for the treatment of PDCoV infection. PDCoV" exact="lithium" post="chloride diammonium glycyrrhizinate apoptosis 1. Introduction PDCoV, first discovered"/>
   <result pre="antiviral activity against many types of viruses [17]. For example," exact="ribavirin" post="has antiviral activity against Hantavirus [20], H1N1 influenza virus"/>
   <result pre="Assay (IFA) After infection, the cells were fixed with cold" exact="polysorbate" post="for 30 min at room temperature and permeabilized with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6792045\results\search\drugs\results.xml">
   <result pre="HFMD is currently treated with broad-spectrum antiviral drugs, such as" exact="ribavirin" post="[19, 20] and glucocorticoids [21, 22], which can cause"/>
   <result pre="1.17 pg/mL (IL-6), 1.17 pg/mL (IL-10) and 1.63 pg/mL (TNF-α). Anti-viral effects of" exact="ribavirin" post="and cytokines in vitro and in vivo RD cells"/>
   <result pre="injected 1 h after infection. At 1 dpi, the same amount of" exact="ribavirin" post="and cytokines were re-injected. The body weights, clinical scores"/>
   <result pre="negative control. In vitro and in vivo antiviral effects of" exact="ribavirin" post="and cytokines RD cells were first i.m. inoculated with"/>
   <result pre="YT226R at an MOI of 0.01, and then treated with" exact="ribavirin" post="and a cytokine panel 48 hpi. The maximum inhibition rates"/>
   <result pre="and a cytokine panel 48 hpi. The maximum inhibition rates of" exact="ribavirin" post="and different cytokines on CVA4 replication were detected by"/>
   <result pre="IFN-γ and particularly IFN-α2a had comparable anti-CVA4 effects compared with" exact="ribavirin" post="in vitro. Figure 5. Anti-CVA4 effects of ribavirin and"/>
   <result pre="compared with ribavirin in vitro. Figure 5. Anti-CVA4 effects of" exact="ribavirin" post="and cytokines in vitro. One hour after the RD"/>
   <result pre="One hour after the RD cells were challenged with YT226R," exact="ribavirin" post="and different cytokines were added, respectively. CCK8 and qRT-PCR"/>
   <result pre="and qRT-PCR were employed to determine the inhibition rates of" exact="ribavirin" post="and different cytokines on CVA4 replication (A), and the"/>
   <result pre="rate of the neonatal mice. Figure 6. Anti-CVA4 effects of" exact="ribavirin" post="and cytokines in vivo. One hour after the 3-day-old"/>
   <result pre="after the 3-day-old neonatal mice (n = 10–15) were challenged with YT226R," exact="ribavirin" post="and different cytokines were administered for the first time."/>
   <result pre="monitoring in chronic Hepatitis C patients treated with interferon and" exact="ribavirin" post="combination therapy. Pak J Pharm Sci. 2017;30(1):11–16.28603106 [25]HuangLM, ChiuCH,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6809658\results\search\drugs\results.xml">
   <result pre="used off-label on the basis of expert opinion. Nitazoxanide and" exact="ribavirin" post="show antiviral activity in a murine norovirus infection model"/>
   <result pre="GII.4 human norovirus in the presence of half-log dilutions of" exact="nitazoxanide" post="(3 µM to 100 µM), ribavirin (10 µM to"/>
   <result pre="of half-log dilutions of nitazoxanide (3 µM to 100 µM)," exact="ribavirin" post="(10 µM to 10 mM), or IVIG (1:100 to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6819294\results\search\drugs\results.xml">
   <result pre="given antiviral treatment with intravenous acyclovir 0.5 g qd and" exact="dexamethasone" post="5 mg qd to relieve pain (continuous treatment for"/>
   <result pre="of hypertension for more than 10 years, under control using" exact="nifedipine" post="controlled release tablets 30 mg bid and valsartan 80"/>
   <result pre="control using nifedipine controlled release tablets 30 mg bid and" exact="valsartan" post="80 mg bid. He was diagnosed with idiopathic chronic"/>
   <result pre="150-160/90 mmHg after antihypertensive treatment with Adalat 30 mg bid," exact="valsartan" post="80 mg bid and perindopril 8 mg qd. After"/>
   <result pre="with Adalat 30 mg bid, valsartan 80 mg bid and" exact="perindopril" post="8 mg qd. After 2 d of treatment, the"/>
   <result pre="daily for 3 d 3 d Nifedipine, irbesartan, cinacalcet, atorvastatin," exact="alfacalcidol" post="Confusion and visual hallucinations 3 d, restored after PD"/>
   <result pre="for 7 d 7 d Simvastatin, metoprolol, sevelamer, furosemide, and" exact="glimepiride" post="Hallucination, insomnia, and photosensi-tivity 7 d, improved after regular"/>
   <result pre="J Med1993942122158430717 12LinWRLinHHLeeSSTsaiHCHuangCKWannSRChenYSChiangSCYenMYLiuYCComparative study of the efficacy and safety of" exact="valaciclovir" post="versus acyclovir in the treatment of herpes zosterJ Microbiol"/>
   <result pre="serum concentrations of acyclovir and neurotoxicityJ Infect Dis19881573853883335815 27StathoulopoulouFDhillonSThodisHStathakisCVargemezisVEvaluation of" exact="valaciclovir" post="dosage reduction in continuous ambulatory peritoneal dialysis patientsNephron20029116416612021536 28TakayanagiAHashimotoJAdachiHHoritaHTwo"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6821460\results\search\drugs\results.xml">
   <result pre="2′-C-Me-A exhibits the most substantial antiviral effect relative to the" exact="dimethyl sulfoxide" post="(DMSO) control, here we compare the combination to 2′-C-Me-A"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6831721\results\search\drugs\results.xml">
   <result pre="documented in nature in the 1950s, and the effectiveness of" exact="chloroquine" post="quickly declined as resistant strains of P. falciparum spread"/>
   <result pre="strains of P. falciparum spread and evolved. Several mechanisms of" exact="chloroquine" post="resistance that emerged in nature have been documented in"/>
   <result pre="been documented in the laboratory, mostly revolving around transport of" exact="chloroquine" post="in and out of the parasite. Notably, mutations in"/>
   <result pre="out of the parasite. Notably, mutations in a P. falciparum" exact="chloroquine" post="resistance transporter gene (PfCRT) have been shown to permit"/>
   <result pre="(PfCRT) have been shown to permit the parasite to efflux" exact="chloroquine" post="at a rate 40 times that of cells lacking"/>
   <result pre="to have a protective effect against the drug, e.g., a" exact="chloroquine" post="transporter protein (CG2), and an ATP-binding cassette transporter gene"/>
   <result pre="2018). ∼1950. Mutations in transporter genes enabling efflux of chloroquine:" exact="chloroquine" post="resistance transporter (PfCRT) (Martin et al., 2009) (Haldar et"/>
   <result pre="transporter (PfCRT) (Martin et al., 2009) (Haldar et al., 2018);" exact="chloroquine" post="transporter (CG2) (Haldar et al., 2018); ABC transporter (PfMDR1)"/>
   <result pre="ABC transporter (PfMDR1) (Haldar et al., 2018). 1953 Pyrimethamine and" exact="sulfadoxine" post="inhibit folate pathway (Gregson and Plowe, 2005; Hyde, 2005)"/>
   <result pre="the parasite (Ouji et al., 2018). Antifolate drugs, such as" exact="pyrimethamine" post="and sulfadoxine, were developed and used for chloroquine-resistant parasites"/>
   <result pre="biosynthetic pathway (Gregson and Plowe, 2005; Hyde, 2005). Pyrimethamine and" exact="sulfadoxine" post="were combined for use together and have since been"/>
   <result pre="monotherapy, and was later adopted for use in combination with" exact="artemisinin" post="(Davis et al., 2005). Resistance to this combination has"/>
   <result pre="a multi-target approach did not prevent rapid viral resistance to" exact="ribavirin" post="(Pfeiffer and Kirkegaard, 2003; Vignuzzi et al., 2005; Beaucourt"/>
   <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistance. Curr. Opin. Virol.8, 10–15. 10.1016/j.coviro.2014.04.01124846716 BeheraA. K.BasuS.CherianS. S."/>
   <result pre="fitness contributed by secondary mutations in the hemagglutinin protein of" exact="oseltamivir" post="resistant H1N1 influenza viruses: modeling studies of antibody and"/>
   <result pre="I.BaltimoreD. (2010). Permissive secondary mutations enable the evolution of influenza" exact="oseltamivir" post="resistance. Science328, 1272–1275. 10.1126/science.118781620522774 BloomJ. D.NayakJ. S.BaltimoreD. (2011). A"/>
   <result pre="E virus RNA polymerase promotes its replication and associates with" exact="ribavirin" post="treatment failure in organ transplant recipients. Gastroenterology147, 1008–11.e7; quiz"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6835697\results\search\drugs\results.xml">
   <result pre="(Table 3) [26,28,29,32]. GRFT showed synergistic antiviral activity with tenofovir," exact="maraviroc" post="(a CCR5 antagonist), and enfuvirtide (a gp41 fusion peptide"/>
   <result pre="synergistic antiviral activity with tenofovir, maraviroc (a CCR5 antagonist), and" exact="enfuvirtide" post="(a gp41 fusion peptide inhibitor) [29]. The different glycosylation"/>
   <result pre="Rev. Drug Discov.2003262463410.1038/nrd115112904812 7.Abdool KarimQ.Abdool KarimS.S.FrohlichJ.A.GroblerA.C.BaxterC.MansoorL.E.KharsanyA.B.SibekoS.MlisanaK.P.OmarZ.et al.Effectiveness and safety of" exact="tenofovir" post="gel, an antiretroviral microbicide, for the prevention of HIV"/>
   <result pre="Retroviruses2012281513152310.1089/aid.2012.002622607556 29.FerirG.PalmerK.E.ScholsD.Synergistic activity profile of griffithsin in combination with tenofovir," exact="maraviroc" post="and enfuvirtide against HIV-1 clade cVirology201141725325810.1016/j.virol.2011.07.00421802104 30.HoorelbekeB.XueJ.LiWangP.J.BalzariniJ.Role of the"/>
   <result pre="activity profile of griffithsin in combination with tenofovir, maraviroc and" exact="enfuvirtide" post="against HIV-1 clade cVirology201141725325810.1016/j.virol.2011.07.00421802104 30.HoorelbekeB.XueJ.LiWangP.J.BalzariniJ.Role of the carbohydrate-binding sites"/>
   <result pre="MT-4 cells p24 HIV-1 core Ag ELISA Tenofovir, maraviroc, and" exact="enfuvirtide" post="Synergy [29] HeLa-ADA effector cells and HeLa-P5L CCR5-bearing target"/>
   <result pre="target T cells Giant cell formation Efavirenz, tenofovir, raltegravir, and" exact="elvitegravir" post="Synergy [28] Raji.DC-SIGN cells DC-SIGN mediated HIV transmission Tenofovir,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6843332\results\search\drugs\results.xml">
   <result pre="resistance in immunocompromised persons [22]. The nucleoside analogues acyclovir and" exact="ganciclovir" post="are the standard therapy for HHV-1 and CMV, respectively"/>
   <result pre="the viral kinase pUL97 and polymerase pUL54 mediate resistance to" exact="ganciclovir" post="and valganciclovir [25]. The prevalence of resistance against acyclovir"/>
   <result pre="kinase pUL97 and polymerase pUL54 mediate resistance to ganciclovir and" exact="valganciclovir" post="[25]. The prevalence of resistance against acyclovir is 5%"/>
   <result pre="marrow transplant patients [26], whereas the incidence of resistance to" exact="ganciclovir" post="is 5–10% in organ transplant recipients [27] and 40–50%"/>
   <result pre="acyclovir are typically cross-resistant to thymidine kinase-dependent drugs such as" exact="penciclovir" post="and famciclovir. They also may be cross-resistant to polymerase"/>
   <result pre="also may be cross-resistant to polymerase dependent drugs, foscarnet or" exact="cidofovir" post="[26]. Ganciclovir-resistant strains also have shown cross resistance to"/>
   <result pre="also have shown cross resistance to second-line treatments foscarnet and" exact="cidofovir" post="[28]. Targeting the DNA polymerase and thymidine kinase, while"/>
   <result pre="integrase inhibitor, exhibits efficiency against herpes viruses. The effect of" exact="raltegravir" post="on herpes viruses is attributed to an inhibition of"/>
   <result pre="as the HIV integrase [31]. Recently however, drug resistance to" exact="raltegravir" post="has been traced to HHV-1 UL42 coding for the"/>
   <result pre="not a part of the terminase, it was determined that" exact="raltegravir" post="likely inhibits DNA replication through the polymerase accessory factor"/>
   <result pre="analyzed, which may explain the resistance that has emerged against" exact="raltegravir" post="and acyclovir, respectively. Since pUL15 is one of the"/>
   <result pre="pathogenic virusesAntimicrob. Agents Chemother.2012561135113710.1128/AAC.05908-1122106211 45.Caruso BrownA.E.CohenM.N.TongS.BravermanR.S.RooneyJ.F.GillerR.LevinM.J.Pharmacokinetics and safety of intravenous" exact="cidofovir" post="for life-threatening viral infections in pediatric hematopoietic stem cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6856223\results\search\drugs\results.xml">
   <result pre="presence of proteins, enzymes, metallic ions, flavonoids, and presentment of" exact="ascorbic acid" post="preserve from sugars and oxidation (Rein, 2005). Figure 4"/>
   <result pre="cytokines and mediators including IL-1, IL-6, IL-10, TNF-a, NF-kB, inducible" exact="nitric oxide" post="synthase and COX-2)(Bowen-Forbes et al., 2010; Sodagari et al.,"/>
   <result pre="inhibitory activity against H274Y mutation. The inhibitory activity of C3S," exact="oseltamivir" post="and their mechanisms against H274Y mutant-type (MT) and wild-type"/>
   <result pre="this line, self-assembled nanoparticles were prepared by chitosan (CH) and" exact="chondroitin sulfate" post="(CS) biopolymers to enhance the biological activity of black"/>
   <result pre="nanocomplexes exhibited excellent stability against different temperature, different concentration of" exact="ascorbic acid," post="varying pH or white fluorescent light (Ge et al.,"/>
   <result pre="chitosan hydrochloride; CMC, carboxymethyl chitosan; β-Lg, β-Lactoglobulin; CH, chitosan; CS," exact="chondroitin sulfate;" post="PLGA, poly lactic-co-glycolic acid; PEG, polyethylene glycol. References References"/>
   <result pre="al. (2007). Safety and efficacy of the HIV-1 integrase inhibitor" exact="raltegravir" post="(MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase"/>
   <result pre="G.et al. (1997). Efficacy and safety of the neuraminidase inhibitor" exact="zanamivir" post="in the treatment of influenzavirus infections. N. Engl. J."/>
   <result pre="(2018). Effectiveness, safety, and costs of a treatment switch to" exact="dolutegravir" post="plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann."/>
   <result pre="safety, and costs of a treatment switch to dolutegravir plus" exact="rilpivirine" post="dual therapy in treatment-experienced HIV patients. Ann. Pharmacother.52 (1),"/>
   <result pre="SorianoV.PernoC.-F.KaiserR.CalvezV.GatellJ. M.Di PerriG.et al. (2009). When and how to use" exact="maraviroc" post="in HIV-infected patients. Aids23 (18), 2377–2385. 10.1097/QAD.0b013e328332d32d19834318 SuX.D’SouzaD. H."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6868923\results\search\drugs\results.xml">
   <result pre="fetal bovine serum (Gibco), 100 IU/ml penicillin G, 100 µg/mL" exact="streptomycin" post="at 37 °C under 5 % CO2 in a"/>
   <result pre="resistant mutationsProtein Sci20101979680720162615 9DasKMartinezSEBaumanJDArnoldEHIV-1 reverse transcriptase complex with DNA and" exact="nevirapine" post="reveals non-nucleoside inhibition mechanismNat Struct Mol Biol2012192539 10De MeyerNHaemersAMishraLPandeyHKPietersLAVandenBergheDAet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6882434\results\search\drugs\results.xml">
   <result pre="of the assay method independently, the fluorescence spectra from the" exact="tryptophan" post="of the SARS-CoV 3CLpro with candidate inhibitors were investigated20."/>
   <result pre="excitation and emission wavelengths were determined by SoftMax Pro. One" exact="tryptophan" post="of the SARS-CoV 3CLpro showed a fluorescence emission with"/>
   <result pre="Tryptophan was well known to emit its fluorescence. Therefore, if" exact="tryptophan" post="is positioned adequately in proteins, the change of fluorescence"/>
   <result pre="interaction between proteins and chemicals. The SARS-CoV 3CLpro contains one" exact="tryptophan" post="residue (Trp31) at the catalytic domain. Its backbone lines"/>
   <result pre="this study displays a fluorescence peak at 340 nm after the" exact="tryptophan" post="excitation wavelength of 290 nm. We monitored the change of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6886132\results\search\drugs\results.xml">
   <result pre="open-label randomized, controlled, phase IIb/III trialChest201715110698027884765 25MarikPEKhangooraVRiveraRHooperMHCatravasJHydrocortisone, vitamin C, and" exact="thiamine" post="for the treatment of severe sepsis and septic shock:"/>
   <result pre="ROCK signaling pathwayBiochem Biophys Res Commun201545994925712521 31KonoSKurataTSatoKOmoteYHishikawaNYamashitaTet al.Neurovascular protection by" exact="telmisartan" post="via reducing neuroinflammation in stroke-resistant spontaneously hypertensive rat brain"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6898960\results\search\drugs\results.xml">
   <result pre="pmcid: 68989601639 doi: 10.1186/s12866-019-1639-8 : Research Article Antiviral activity of" exact="mitoxantrone" post="dihydrochloride against human herpes simplex virus mediated by suppression"/>
   <result pre="of the candidates. Results Here, we identified a small molecule," exact="mitoxantrone" post="dihydrochloride, with potency against HSV-1-induced toxicity. Furthermore, the viral"/>
   <result pre="important. It has been reported that the small molecular compound" exact="mitoxantrone" post="dihydrochloride (henceforth MD) is a topoisomerase II inhibitor that"/>
   <result pre="keratitis and lethal encephalitis [5–9]. Current anti-HSV-1 drugs including acyclovir," exact="penciclovir" post="and foscarnet are viral DNA synthesis inhibitors. Acyclovir and"/>
   <result pre="penciclovir and foscarnet are viral DNA synthesis inhibitors. Acyclovir and" exact="penciclovir" post="are commonly used for the treatment of HSV-1 infection."/>
   <result pre="mechanism of action of MD against HSV-1. Conclusions In conclusion," exact="mitoxantrone" post="dihydrochloride is an interesting candidate for the development of"/>
   <result pre="infectionsN Engl J Med19813052636710.1056/NEJM1981070930502026264292 24.EarnshawDLBaconTHDarlisonSJEdmondsKPerkinsRMVere HodgeRAMode of antiviral action of" exact="penciclovir" post="in MRC-5 cells infected with herpes simplex virus type"/>
   <result pre="varicella-zoster virusAntimicrob Agents Chemother199236122747275710.1128/AAC.36.12.27471336346 25.WangSLLeeJJLiaoATComparison of efficacy and toxicity of" exact="doxorubicin" post="and mitoxantrone in combination chemotherapy for canine lymphomaCan Vet"/>
   <result pre="Agents Chemother199236122747275710.1128/AAC.36.12.27471336346 25.WangSLLeeJJLiaoATComparison of efficacy and toxicity of doxorubicin and" exact="mitoxantrone" post="in combination chemotherapy for canine lymphomaCan Vet J201657327127626933263 26.Komeili-MovahhedTFouladdelSBarzegarEAtashpourSHossein"/>
   <result pre="down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to" exact="mitoxantrone" post="chemotherapyIran J Basic Med Sci201518547247726124933 27.HouLFengQWangYYangXRenJShiYShanXYuanYWangYZhangZMultifunctional hyaluronic acid modified"/>
   <result pre="Med Sci201518547247726124933 27.HouLFengQWangYYangXRenJShiYShanXYuanYWangYZhangZMultifunctional hyaluronic acid modified graphene oxide loaded with" exact="mitoxantrone" post="for overcoming drug resistance in cancerNanotechnology201627101570110.1088/0957-4484/27/1/01570126595807 28.HouJZhangZQiangHYanJZhangXYuXTanGZhengCFengXHeSAntiviral activity of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6901432\results\search\drugs\results.xml">
   <result pre="anti-cancer effects of the nucleoside analogue 5-fluorouracil. Here, we combined" exact="omeprazole" post="with the antiviral nucleoside analogues ribavirin and acyclovir. Omeprazole"/>
   <result pre="5-fluorouracil. Here, we combined omeprazole with the antiviral nucleoside analogues" exact="ribavirin" post="and acyclovir. Omeprazole did not affect the antiviral effects"/>
   <result pre="and acyclovir. Omeprazole did not affect the antiviral effects of" exact="ribavirin" post="in non-toxic concentrations up to 80 μg/mL but increased"/>
   <result pre="reduced HSV-1-induced CPE formation by 50% (IC50). In HSV-2-infected cells," exact="omeprazole" post="80 μg/mL reduced the acyclovir IC50 by 7.3- (Vero"/>
   <result pre="7.3- (Vero cells) and 12.9-fold (HaCaT cells). In HaCaT cells," exact="omeprazole" post="80 μg/mL reduced the HSV-1 titer in the presence"/>
   <result pre="from severe complications. HSV HSV-1 HSV-2 antiviral therapy antiviral drugs" exact="ribavirin" post="proton pump inhibitors fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
   <result pre="Chemaly et al., 2019). Here, we investigated the effects of" exact="omeprazole" post="on the efficacy of the antiviral nucleoside analogues acyclovir"/>
   <result pre="influenza viruses and West Nile virus. The mechanisms by which" exact="ribavirin" post="interferes with virus replication are not clear and may"/>
   <result pre="al., 2018; Keppeke et al., 2019). Our findings show that" exact="omeprazole" post="(and other proton pump inhibitors) increase the antiviral activity"/>
   <result pre="Kärber, 1931). Drugs Acyclovir was received from GlaxoSmithKline (Munich, Germany)," exact="omeprazole" post="from AstraZeneca (Wedel, Germany), ribavirin from Valeant Pharmaceuticals Germany"/>
   <result pre="received from GlaxoSmithKline (Munich, Germany), omeprazole from AstraZeneca (Wedel, Germany)," exact="ribavirin" post="from Valeant Pharmaceuticals Germany GmbH (Eschborn, Germany), and pantoprazole,"/>
   <result pre="Results Effects of Omeprazole on Cell Viability The effects of" exact="omeprazole" post="on the viability of the investigated cell lines was"/>
   <result pre="Cells Omeprazole 80 μg/mL did not alter the effects of" exact="ribavirin" post="on CPE formation in WNV-infected Vero cells or H1N1-infected"/>
   <result pre="presence of antiviral nucleoside analogues and omeprazole. (A) Effects of" exact="omeprazole" post="(80 μg/mL) on the concentrations of antiviral nucleoside analogues"/>
   <result pre="values are presented in Supplementary Table S1. (B) Effects of" exact="omeprazole" post="and acyclovir on the expression of virus proteins in"/>
   <result pre="HSV-1- and HSV-2-infected Vero cells. HSV-1-infected cells were treated with" exact="omeprazole" post="80 μg/mL and/or acyclovir 0.31 μg/mL. HSV-2-infected cells were"/>
   <result pre="μg/mL and/or acyclovir 0.31 μg/mL. HSV-2-infected cells were treated with" exact="omeprazole" post="40 μg/mL and/or acyclovir 0.6 μg/mL. (C) HSV gB"/>
   <result pre="(C) HSV gB levels in HSV-1-infected Vero cells treated with" exact="omeprazole" post="80 μg/mL and/or acyclovir 0.31 μg/mL as determined by"/>
   <result pre="HSV-2-induced CPE formation (Supplementary Table S1). In the presence of" exact="omeprazole" post="80 μg/mL, however, acyclovir concentrations that reduced CPE formation"/>
   <result pre="HSV-2-infected Vero cells (Figure 1A and Supplementary Table S1). Further," exact="omeprazole" post="80 μg/mL reduced the acyclovir IC50s by 48-fold in"/>
   <result pre="numbers of virus-infected cells after treatment with a combination of" exact="omeprazole" post="and acyclovir compared to either single treatment (Figure 1B)."/>
   <result pre="treated with this combination (Figure 1C). Further experiments indicated that" exact="omeprazole" post="reduced acyclovir IC50s in HSV-1- and HSV-2-infected HaCaT cells"/>
   <result pre="2 and Supplementary Table S2). FIGURE 2 Concentration-dependent effects of" exact="omeprazole" post="on the acyclovir IC50 in HSV-1- or HSV-2-infected HaCaT"/>
   <result pre="combination. ∗P &amp;lt; 0.05 relative to nucleoside analogue alone. Although" exact="omeprazole" post="did not affect the HSV-1 and HSV-2 CPEs in"/>
   <result pre="of virus titers in Vero cells showed that 80 μg/mL" exact="omeprazole" post="inhibited the production of infectious HSV-1 particles and that"/>
   <result pre="of infectious HSV-1 particles and that 40 and 80 μg/mL" exact="omeprazole" post="inhibited the production of infectious HSV-2 particles. In agreement"/>
   <result pre="particles. In agreement with the findings from the CPE assays," exact="omeprazole" post="also strongly increased the anti-HSV-1 and anti-HSV-2 effects of"/>
   <result pre="omeprazole-induced increase of acyclovir activity was also seen at lower" exact="omeprazole" post="concentrations, which did not directly reduce virus titers (Figure"/>
   <result pre="virus titers (Figure 3 and Supplementary Table S3). The investigated" exact="omeprazole" post="and acyclovir concentrations did not affect cell viability, neither"/>
   <result pre="or 2 μg/mL (HSV-2) alone or in combination with varying" exact="omeprazole" post="(OME) concentrations (μg/mL) on HSV-1 and HSV-2 titres in"/>
   <result pre="acyclovir alone. Discussion Based on previous investigations that showed that" exact="omeprazole" post="increases the anti-cancer activity of the nucleoside analog 5-fluorouracil"/>
   <result pre="(Luciani et al., 2004), we here investigated the effects of" exact="omeprazole" post="on the antiviral effects of ribavirin and acyclovir. Omeprazole"/>
   <result pre="investigated the effects of omeprazole on the antiviral effects of" exact="ribavirin" post="and acyclovir. Omeprazole did not modify ribavirin-mediated effects in"/>
   <result pre="fashion in Vero and HaCaT cells. It remains unclear why" exact="omeprazole" post="increases the activity of acyclovir but not that of"/>
   <result pre="not that of ribavirin. Differences between the compounds acyclovir and" exact="ribavirin" post="including their mechanisms of action and/or differences between the"/>
   <result pre="viruses may be responsible for this. The mechanism by which" exact="omeprazole" post="enhances the activity of acyclovir seems to differ from"/>
   <result pre="of acyclovir seems to differ from the mechanism by which" exact="omeprazole" post="increases 5-fluorouracil efficacy, which was shown to be the"/>
   <result pre="lysosomal pH (Luciani et al., 2004). Lysosomotropic drugs such as" exact="chloroquine" post="and ammonium chloride are known to interfere with the"/>
   <result pre="Baines, 2011; Al-Bari, 2017; Salata et al., 2017). In agreement," exact="omeprazole" post="concentrations ≥40 μg/mL reduced HSV-1 and HSV-2 titers. However,"/>
   <result pre="μg/mL reduced HSV-1 and HSV-2 titers. However, the effects of" exact="omeprazole" post="on the anti-HSV activity of acyclovir were more pronounced"/>
   <result pre="were more pronounced than the direct antiviral effects and lower" exact="omeprazole" post="concentrations, which did not affect HSV-1 and HSV-2 replication,"/>
   <result pre="is not a direct consequence of antiviral activity exerted by" exact="omeprazole" post="and may be caused by a different mechanism. Moreover,"/>
   <result pre="omeprazole and may be caused by a different mechanism. Moreover," exact="omeprazole" post="pre-treatment was necessary to increase 5-fluorouracil activity (Luciani et"/>
   <result pre="necessary to increase 5-fluorouracil activity (Luciani et al., 2004), but" exact="omeprazole" post="and acyclovir exerted their combined activity when added at"/>
   <result pre="h post infection. This indicates that the mechanisms by which" exact="omeprazole" post="increases 5-fluorouracil and acyclovir activity differ and that omeprazole"/>
   <result pre="which omeprazole increases 5-fluorouracil and acyclovir activity differ and that" exact="omeprazole" post="increases the antiviral activity of acyclovir during the viral"/>
   <result pre="al., 2016; Nelson et al., 2017; Ghebre, 2018). In addition," exact="omeprazole" post="may inhibit DNA damage repair (Martelli et al., 1998),"/>
   <result pre="do not involve the modulation of the lysosomal pH. Since" exact="omeprazole" post="is a clinically well-established drug with a preferable safety"/>
   <result pre="not exert general immunosuppressive effects in the same way as" exact="hydrocortisone" post="but to more specifically increase acyclovir activity. In immunodeficiency"/>
   <result pre="be feasible in a severe acute disease setting. In conclusion," exact="omeprazole" post="and other proton pump inhibitors substantially enhance the antiviral"/>
   <result pre="References References Al-BariM. A. A. (2017). Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistance.Curr. Opin. Virol.810–15. 10.1016/j.coviro.2014.04.01124846716 BoukampP.PetrussevskaR. T.BreitkreutzD.HornungJ.MarkhamA.FusenigN. E. (1988). Normal"/>
   <result pre="of print]. KohC.LiangT. J. (2014). What is the future of" exact="ribavirin" post="therapy for hepatitis C?Antiviral Res.10434–39. 10.1016/j.antiviral.2014.01.00524468277 KoyamaA. H.UchidaT. (1984)."/>
   <result pre="Natl. Cancer Inst.961702–1713. 10.1093/jnci/djh30515547183 MartelliA.MattioliF.MeretoE.Brambilla CampartG.SiniD.BergamaschiG.et al. (1998). Evaluation of" exact="omeprazole" post="genotoxicity in a battery of in vitro and in"/>
   <result pre="Recent approval of Xerese in Canada: 5% acyclovir and 1%" exact="hydrocortisone" post="topical cream in the treatment of herpes labialis.Skin Therapy"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6904818\results\search\drugs\results.xml">
   <result pre="1 Rilpivirine Inhibits ZIKV by Blocking Viral RdRp (A) Proposed" exact="rilpivirine" post="binding site on ZIKV RdRp. ZIKV NS5 (PDB: 5TMH)15"/>
   <result pre="PyMOL. (B) In vivo efficacy. Treatment of ZIKV-infected mice with" exact="rilpivirine" post="suppressed viral replication and prevented animal death. First, Sariyer"/>
   <result pre="ZIKV infection of astrocytes as a screening assay, they identified" exact="rilpivirine" post="as a ZIKV inhibitor from eight FDA-approved HIV nucleoside"/>
   <result pre="killing of non-tumor cells. It remains to be tested if" exact="rilpivirine" post="also inhibits closely related flaviviruses, such as dengue, yellow"/>
   <result pre="viruses. Nevertheless, the authors have established the antiviral activity of" exact="rilpivirine" post="against ZIKV in cell culture. Second, Sariyer et al.2"/>
   <result pre="et al.2 provided five lines of evidence to support that" exact="rilpivirine" post="targets ZIKV RdRp (Figure 1A). (1) Computational docking suggests"/>
   <result pre="targets ZIKV RdRp (Figure 1A). (1) Computational docking suggests that" exact="rilpivirine" post="may bind to the palm site of RdRp protein."/>
   <result pre="site of RdRp protein. (2) Differential scanning fluorimetry showed that" exact="rilpivirine" post="binds to recombinant RdRp with a KD of 100"/>
   <result pre="cells, but not the 14-amino acid mutant protein, competed for" exact="rilpivirine" post="binding and thus alleviated compound-mediated antiviral activity. Although these"/>
   <result pre="improved potency. (2) The selection of ZIKV variants resistant to" exact="rilpivirine" post="will identify mutations that are likely mapped to the"/>
   <result pre="Third, Sariyer et al.2 demonstrated the in vivo efficacy of" exact="rilpivirine" post="in a ZIKV interferon α/β receptor (IFNAR)−/− mouse (type"/>
   <result pre="knockout) model (Figure 1B). Treatment of ZIKV-infected IFNAR−/− mice with" exact="rilpivirine" post="reduced organ viral burden and weight loss, improved clinical"/>
   <result pre="caused significant inflammation and abundant apoptotic/necrotic cell damage. Treatment with" exact="rilpivirine" post="reduced the levels of viral RNA in the brain"/>
   <result pre="but it did not eliminate inflammation. These results indicate that" exact="rilpivirine" post="suppressed viral replication and disease development. However, it was"/>
   <result pre="better in vivo efficacy. Nevertheless, the in vivo potency of" exact="rilpivirine" post="seems better than sofosbuvir, a hepatitis C virus (HCV)"/>
   <result pre="(HCV) nucleoside drug that was reported with anti-ZIKV activity.9 Specifically," exact="rilpivirine" post="completely protected ZIKV-infected mice from death, whereas sofosbuvir and"/>
   <result pre="activity.9 Specifically, rilpivirine completely protected ZIKV-infected mice from death, whereas" exact="sofosbuvir" post="and other nucleoside inhibitors only conferred partial protection.10 The"/>
   <result pre="readily advanced to clinical trials for the new indication.11 As" exact="rilpivirine" post="inhibits HIV-1 and ZIKV with EC50 in the single-digit"/>
   <result pre="to ensure clinical efficacy in patients. To achieve this goal," exact="rilpivirine" post="analogs previously synthesized during lead optimization could be tested"/>
   <result pre="with better potency for ZIKV may be identified from the" exact="rilpivirine" post="analogs. Meanwhile, efforts could be made to solve the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6907871\results\search\drugs\results.xml">
   <result pre="lytic replication, iSLK.219 cells were exposed to increasing concentrations of" exact="doxycycline" post="(Dox) (up to 4 μg/mL) and/or sodium butyrate (NaB)"/>
   <result pre="anti-KSHV drug screening. (A) The iSLK.219 cells were induced by" exact="doxycycline" post="(Dox) or sodium butyrate (NaB) alone or the combination,"/>
   <result pre="include several inhibitors targeting a series of neurotransmitter receptors, including" exact="dopamine" post="receptors, adrenergic receptors, serotonin receptors, muscarinic receptors and histamine"/>
   <result pre="results indicate that some neurotransmitter receptors, such as adrenoreceptors and" exact="dopamine" post="receptors, can regulate KSHV reactivation through related signaling pathways"/>
   <result pre="latently infected with a recombinant rKSHV.219 virus and contain a" exact="doxycycline" post="(Dox)-inducible RTA, constructed and named by Dr. Don Ganem’s"/>
   <result pre="(2004) Remission of HHV-8 and HIV-associated multicentric Castleman disease with" exact="ganciclovir" post="treatment. Blood103: 1632–1634. 10.1182/blood-2003-05-172114615380 23SeifertR, StrasserA, SchneiderEH, NeumannD, DoveS,"/>
   <result pre="et al. (2008) Regulation of Kaposi's sarcoma-associated herpesvirus reactivation by" exact="dopamine" post="receptor-mediated signaling pathways. J Acquir Immune Defic Syndr48: 531–540."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6925523\results\search\drugs\results.xml">
   <result pre="the cells ‘powerhouse’ due to their principal function in synthesizing" exact="adenosine" post="triphosphate (ATP) required for a multitude of processes and"/>
   <result pre="OXPHOS system and its functioning. Oxidative phosphorylation complexes represent reduced" exact="nicotinamide" post="adenine dinucleotide (NADH) dehydrogenase (I), succinate dehydrogenase (II), cytochrome"/>
   <result pre="such as tenofovir, which has minimal mitochondrial toxicity compared with" exact="zalcitabine" post="and didanosine [29]. Tenofovir is used in combination with"/>
   <result pre="tenofovir, which has minimal mitochondrial toxicity compared with zalcitabine and" exact="didanosine" post="[29]. Tenofovir is used in combination with other NRTI"/>
   <result pre="is used in combination with other NRTI antivirals such as" exact="abacavir" post="and lamivudine in modern HIV therapy, all of which"/>
   <result pre="in combination with other NRTI antivirals such as abacavir and" exact="lamivudine" post="in modern HIV therapy, all of which report lower"/>
   <result pre="[36]Hepatotoxicity [78] Anti-psychotic Clozapine (black box warning) Binds serotonin and" exact="dopamine" post="receptors with off-target effects on mitochondria [153] Mitochondrial membrane"/>
   <result pre="depolarization and swelling were observed [49,50]. The epileptic drug sodium" exact="valproate" post="has well documented mitochondrial toxicity showing respiratory dysfunction in"/>
   <result pre="useful new therapeutic cancer agents such as the common antibiotic" exact="doxycycline" post="with only mild mitochondrial effects [67,68] might have been"/>
   <result pre="metabolic hormesis is demonstrated in Figure 2 where two drugs" exact="bithionol" post="and meclizine are added to Ewings sarcoma cancer cell"/>
   <result pre="is demonstrated in Figure 2 where two drugs bithionol and" exact="meclizine" post="are added to Ewings sarcoma cancer cell lines. This"/>
   <result pre="function at low drug doses. At each glucose condition tested," exact="bithionol" post="and meclizine at higher doses inhibit oxygen consumption (i.e."/>
   <result pre="low drug doses. At each glucose condition tested, bithionol and" exact="meclizine" post="at higher doses inhibit oxygen consumption (i.e. little change"/>
   <result pre="function at low drug doses. In agreement with this data," exact="meclizine" post="inhibits mitochondrial respiration in vitro but has also shown"/>
   <result pre="essential in several tumour types [101,102]. The anticancer BRAF inhibitor" exact="vemurafenib" post="switches cellular metabolism from glycolysis to OXPHOS. This drug,"/>
   <result pre="in tumour progression; therefore, the inhibition of myc proteins through" exact="doxycycline" post="use, or drug-induced modulation of mitochondrial dynamics may have"/>
   <result pre="potential therapeutic benefits of mitochondrial and metabolic manipulation Abbreviations ATP" exact="adenosine" post="triphosphate ETC electron transport chain HIV human immunodeficiency virus"/>
   <result pre="325–33310.1097/01.pra.0000388627.36781.6a20859109 51KomulainenT., LodgeT., HinttalaR., BolszakM., PietiläM., KoivunenP.et al. (2015) Sodium" exact="valproate" post="induces mitochondrial respiration dysfunction in HepG2 in vitro cell"/>
   <result pre="Metab. Dis.20, 397–40010.1023/A:10053985162089266365 53KulkarniM., ZaheeruddinM., ShenoyN. and VaniH. (2006) Fetal" exact="valproate" post="syndrome. Indian J. Pediatr.73 54WillY. and DykensJ. (2014) Mitochondrial"/>
   <result pre="L2a modify susceptibility to peripheral neuropathy in Malawian adults on" exact="stavudine" post="containing highly active antiretroviral therapy. J. Acquir. Immune Defic."/>
   <result pre="(2017) Influence of mitochondrial genetics on the mitochondrial toxicity of" exact="linezolid" post="in blood cells and skin nerve fibers. Antimicrob. Agents"/>
   <result pre="97AshtonT., FokasE., Kunz-SchughartL., FolkesL., AnbalaganS., HuetherM.et al. (2016) The anti-malarial" exact="atovaquone" post="increases radiosensitivity by alleviating tumour hypoxia. Nat. Commun.710.1038/ncomms12308 98AndrzejewskiS.,"/>
   <result pre="Commun.710.1038/ncomms12308 98AndrzejewskiS., SiegelP. and St-PierreJ. (2018) Metabolic profiles associated with" exact="metformin" post="efficacy in cancer. Front. Endocrinol.9, 37210.3389/fendo.2018.00372 99LeeM., HirparaJ., EuJ.,"/>
   <result pre="Fisher-WellmanK., LinC., MaplesJ., CatheyB. and NeuferP. (2013) The anticancer agent" exact="doxorubicin" post="disrupts mitochondrial energy metabolism and redox balance in skeletal"/>
   <result pre="essential for mitochondrial membrane potential change and apoptosis induced by" exact="doxycycline" post="in melanoma cells. Br. J. Pharmacol.160, 1171–118410.1111/j.1476-5381.2010.00746.x20590610 114MohammadH., BarbashO."/>
   <result pre="Ammi-Saı¨dM., FrisdalE., ReyC.et al. (1997) Cellular and mitochondrial toxicity of" exact="zidovudine" post="(AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human"/>
   <result pre="ReyC.et al. (1997) Cellular and mitochondrial toxicity of zidovudine (AZT)," exact="didanosine" post="(ddI) and zalcitabine (ddC) on cultured human muscle cells."/>
   <result pre="Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and" exact="zalcitabine" post="(ddC) on cultured human muscle cells. J. Neurol. Sci.149,"/>
   <result pre="PayneR.M.et al. (1991) Mitochondrial ultrastructural and molecular changes induced by" exact="zidovudine" post="in rat hearts. Lab. Invest.65, 228–2361715447 137Pan-ZhouX., CuiL., ZhouX.,"/>
   <result pre="Pharmacol.740, 364–37810.1016/j.ejphar.2014.07.02525058905 149TaL., EspesetL., PodratzJ. and WindebankA. (2006) Neurotoxicity of" exact="oxaliplatin" post="and cisplatin for dorsal root ganglion neurons correlates with"/>
   <result pre="149TaL., EspesetL., PodratzJ. and WindebankA. (2006) Neurotoxicity of oxaliplatin and" exact="cisplatin" post="for dorsal root ganglion neurons correlates with platinum-DNA binding."/>
   <result pre="ChiccaM., SimoniE., OlivettoE.et al. (2013) Correlation of adverse effects of" exact="cisplatin" post="administration in patients affected by solid tumours: a retrospective"/>
   <result pre="157PonchautS., Van HoofF. and VeitchK. (1992) In vitro effects of" exact="valproate" post="and valproate metabolites on mitochondrial oxidations. Biochem. Pharmacol.43, 2435–244210.1016/0006-2952(92)90324-C1610408"/>
   <result pre="HoofF. and VeitchK. (1992) In vitro effects of valproate and" exact="valproate" post="metabolites on mitochondrial oxidations. Biochem. Pharmacol.43, 2435–244210.1016/0006-2952(92)90324-C1610408 158SangkuhlK., KleinT."/>
   <result pre="907–90910.1097/FPC.0b013e32833132cb19741567 159SouzaM., PolizelloA., UyemuraS., Castro-SilvaO. and CurtiC. (1994) Effect of" exact="fluoxetine" post="on rat liver mitochondria. Biochem. Pharmacol.48, 535–54110.1016/0006-2952(94)90283-68068040 160CurtiC., MingattoF.E.,"/>
   <result pre="and RajanR.R. (1995) Effect of long-term in vivo treatment with" exact="imipramine" post="on the oxidative energy metabolism in rat brain mitochondria."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6925545\results\search\drugs\results.xml">
   <result pre="MUD/MMUD-HCT. The incidence of EBV infection requiring pre-emptive treatment with" exact="rituximab" post="in allo-HCT children was 19.3%. In 30.8% cases of"/>
   <result pre="which did not prevent development of EBV-DNA-emia with need of" exact="rituximab" post="treatment in 81.5% cases. In 47.7% of these cases,"/>
   <result pre="(GCV) can reduce EBV replication, but neither ganciclovir/foscarnet (FCV) nor" exact="cidofovir" post="(CDV) therapy/prophylaxis have any impact on development of EBV-PTLD,"/>
   <result pre="(81.8%) cases, a significant EBV-DNA-emia has occurred and treatment with" exact="rituximab" post="was required. In 44/54 (81.5%) of these cases viral"/>
   <result pre="were treated with antiviral drugs, including: CDV (n=18), GCV (n=17)," exact="aciclovir" post="(ACV) (n=1), oseltamivir (n=1) or drug combinations (FCV+GCV, n=5;"/>
   <result pre="antiviral drugs, including: CDV (n=18), GCV (n=17), aciclovir (ACV) (n=1)," exact="oseltamivir" post="(n=1) or drug combinations (FCV+GCV, n=5; FCV+CDV, n=2; GCV+CDV,"/>
   <result pre="FCV therapies, 1/12 (8.3%) ACV therapies and 1/13 (7.7%) of" exact="oseltamivir" post="therapies. Discussion The primary causes of morbidity and non-relapse"/>
   <result pre="risk of clinically significant CMV infection.18 We have shown that" exact="ganciclovir" post="and foscarnet were the most frequently used drugs in"/>
   <result pre="disease is a challenge. Combination therapy (ganciclovir and foscarnet), cidofovir," exact="leflunomide" post="or artesunate can be considered in patients resistant or"/>
   <result pre="a challenge. Combination therapy (ganciclovir and foscarnet), cidofovir, leflunomide or" exact="artesunate" post="can be considered in patients resistant or refractory to"/>
   <result pre="severity, and the selection of antibiotic resistance.19 In our study" exact="cidofovir" post="was the most frequently used drug in the treatment"/>
   <result pre="with available antiviral drugs is currently not recommended and intravenous" exact="cidofovir" post="is currently regarded as a standard of care in"/>
   <result pre="were acquired during hospitalization.17 In the case of CARV infections," exact="ribavirin" post="and intravenous immunoglobulin are recommended in hMPV, HPIV and"/>
   <result pre="from the respiratory tract, especially broncho-alveolar lavage.23 Neuraminidase inhibitors (oral" exact="oseltamivir" post="or inhalation of zanamivir) are currently the most effective"/>
   <result pre="RV- and NoV-related gastroenterocolitis is available; however, oral immunoglobulins and" exact="nitazoxanide" post="were used in some studies.24,27 In immunocompetent individuals primary"/>
   <result pre="cases in auto-HCT setting. In 80.3% (143/175) of EBV reactivations" exact="rituximab" post="was used and 93.3% of patients survived this infection."/>
   <result pre="prevent the development of significant EBV-DNA-emia with the need of" exact="rituximab" post="treatment. This is clinically proven evidence that antiviral drugs"/>
   <result pre="immunoglobulins also have no impact in PTLD. Neither ganciclovir/foscarnet nor" exact="cidofovir" post="therapy/prophylaxis have any impact on the development of EBV-PTLD,"/>
   <result pre="PTLD.8 The following pre-emptive therapies are recommended after high-risk allo-HCT:" exact="rituximab" post="(375 mg/m2/weekly), reduction of immunosuppressive therapy (if possible), donor"/>
   <result pre="MSD. The incidence of EBV infection requiring pre-emptive treatment with" exact="rituximab" post="in allo-HSCT children was 19.3%. In 30.8% of cases"/>
   <result pre="not prevent development of significant EBV-DNA-emia with the need of" exact="rituximab" post="treatment in 81.5% of cases. This is clinically proven"/>
   <result pre="allogeneic hematopoietic cell transplant recipients: clinical course and experience using" exact="nitazoxanide" post="and enterally administered immunoglobulins. Pediatr Infect Dis J. 2018;37(2):176–181."/>
   <result pre="2013;6:94. doi:10.1186/1756-8722-6-9424341630 29.CzyzewskiK, StyczynskiJ, KrenskaA, et al. Intrathecal therapy with" exact="rituximab" post="in central nervous system involvement of post-transplant lymphoproliferative disorder."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6961902\results\search\drugs\results.xml">
   <result pre="addition, antiviral drugs associated with nephrotoxicity, such as adefovir dipivoxil," exact="tenofovir" post="and IFNs, should also be taken into consideration. These"/>
   <result pre="44 μmol/L in HIV-infected patients. Kara AV‘s study[25] found that" exact="tenofovir" post="could decrease the eGFR and that the change in"/>
   <result pre="after sensitivity analysis also confirmed that Sun’s study[17], which chose" exact="lamivudine" post="as an intervention, has a great influence on the"/>
   <result pre="7(3):177–188. 10.1016/0197-2456(86)90046-23802833 17SunLJ, ShanJP, CuiRL, YuanWJ, JiangGR. Combination therapy with" exact="lamivudine" post="and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B"/>
   <result pre="25KaraAV, YıldırımY, OzcicekF, AldemirMN, ArslanY, BayanK, et al.Effects of entecavir," exact="tenofovir" post="and telbivudine treatment on renal functions in chronic hepatitis"/>
   <result pre="OzcicekF, AldemirMN, ArslanY, BayanK, et al.Effects of entecavir, tenofovir and" exact="telbivudine" post="treatment on renal functions in chronic hepatitis B patients."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6963304\results\search\drugs\results.xml">
   <result pre="noncytotoxic concentrations [14]. In addition, it has been reported that" exact="lithium" post="chloride (LiCl) and diammonium glycyrrhizinate (DG) have good inhibitory"/>
   <result pre="(CAS 6902-91-6) was purchased from Weikeqi (China) and dissolved in" exact="dimethyl sulfoxide" post="(DMSO) at 20 mM. Lithium chloride (LiCl) (Sigma, St."/>
   <result pre="useful for clinical applications [31,32]. In particular, the germacrone and" exact="oseltamivir" post="combination has a synergistic effect on the inhibition of"/>
   <result pre="MatterACS Appl. Mater. Interfaces20157215712157910.1021/acsami.5b0687626370151 15.SuiX.YinJ.RenX.Antiviral effect of diammonium glycyrrhizinate and" exact="lithium" post="chloride on cell infection by pseudorabies herpesvirusAntivir. Res.20108534635310.1016/j.antiviral.2009.10.01419879899 16.FengJ.BaiX.CuiT.ZhouH.ChenY.XieJ.ShiQ.WangH.ZhangG.In"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6963560\results\search\drugs\results.xml">
   <result pre="by several authors; (3) An additional choice is given by" exact="rituximab" post="(RTX), which selectively targets B cells and causes depletion"/>
   <result pre="by HCV should be treated first with immunosuppressive agents (with" exact="rituximab" post="as first-line agent) with or without plasma exchange. Current"/>
   <result pre="production and cryoglobulins. Two RCTs have demonstrated the superiority of" exact="rituximab" post="mono-therapy as compared with conventional immunosuppressive therapy (i.e., corticosteroids,"/>
   <result pre="individuals also received intravenous therapy with corticosteroids (500 mg/day of" exact="methylprednisolone" post="for three consecutive days). No additional immunosuppressive medications or"/>
   <result pre="mixed cryoglobulinemia with sofosbuvir-based direct-acting antiviral agentsHepatology20166340841710.1002/hep.2829726474537 23.SaadounD.ThibaultV.AhmedS.N.S.AlricL.MalletM.GuillaudC.IzzedineH.PlaisierA.FontaineH.CostopoulosM.et al.Sofosbuvir plus" exact="ribavirin" post="for hepatitis C-associated cryoglobulinaemia vasculitis: Vascuvaldic studyAnn. Rheum. Dis.2016751777178210.1136/annrheumdis-2015-20833926567178"/>
   <result pre="cryoglobulinemiaAm. J. Gastroenterol.20171121298130810.1038/ajg.2017.4928291241 26.SaadounD.PolS.FerfarY.AlricL.HezodeC.AhmedS.N.S.de Saint MartinL.ComarmondC.BouyerA.S.MussetL.et al.Efficacy and safety of" exact="sofosbuvir" post="plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitisGastroenterology2017153495210.1053/j.gastro.2017.03.00628288791 27.BonacciM.LensS.MariñoZ.LondoñoM.C.Rodriguez-TajesS.Sánchez-TapiasJ.M.Ramos-CasalsM.Hernández-RodríguezJ.FornsX.Long-term"/>
   <result pre="Gastroenterol.20171121298130810.1038/ajg.2017.4928291241 26.SaadounD.PolS.FerfarY.AlricL.HezodeC.AhmedS.N.S.de Saint MartinL.ComarmondC.BouyerA.S.MussetL.et al.Efficacy and safety of sofosbuvir plus" exact="daclatasvir" post="for treatment of HCV-associated cryoglobulinemia vasculitisGastroenterology2017153495210.1053/j.gastro.2017.03.00628288791 27.BonacciM.LensS.MariñoZ.LondoñoM.C.Rodriguez-TajesS.Sánchez-TapiasJ.M.Ramos-CasalsM.Hernández-RodríguezJ.FornsX.Long-term outcomes of"/>
   <result pre="31.Zarębska-MichalukD.StępieńP.M.PaluchK.PabjanP.Retreatment of symptomatic HCV genotype 3 associated mixed cryoglobulinemia with" exact="sofosbuvir" post="plus ribavirin: A case reportClin. Exp. Hepatol.2018410010329904727 32.ElmowafyA.Y.El MaghrabiH.M.ZahabM.A.ElwasifS.M.BakrM.A.Sofosbuvir"/>
   <result pre="plus ribavirin: A case reportClin. Exp. Hepatol.2018410010329904727 32.ElmowafyA.Y.El MaghrabiH.M.ZahabM.A.ElwasifS.M.BakrM.A.Sofosbuvir and" exact="daclatasvir" post="in treatment of HCV-related membranoproliferative glomerulonephritis with cryoglobulinemia in"/>
   <result pre="direct-acting antiviralsIndian J. Nephrol.20182846246430647501 34.ChiaX.X.CherepanoffS.DantaM.FurlongT.Successful treatment of HCV-related glomerulonephritis with" exact="sofosbuvir" post="and daclatasvirNephrology2018333738010.1111/nep.1308729520905 35.De VitaS.QuartuccioL.IsolaM.MazzaroC.ScainiP.LenziM.CampaniniM.NaclerioC.TavoniA.PietrograndeM.et al.A randomized controlled trial of"/>
   <result pre="sofosbuvir and daclatasvirNephrology2018333738010.1111/nep.1308729520905 35.De VitaS.QuartuccioL.IsolaM.MazzaroC.ScainiP.LenziM.CampaniniM.NaclerioC.TavoniA.PietrograndeM.et al.A randomized controlled trial of" exact="rituximab" post="for the treatment of severe cryoglobulinemic vasculitisArthritis Rheum.20126484385310.1002/art.3433122147661 36.SnellerM.HuZ.LangfordC.A"/>
   <result pre="of severe cryoglobulinemic vasculitisArthritis Rheum.20126484385310.1002/art.3433122147661 36.SnellerM.HuZ.LangfordC.A randomized controlled trial of" exact="rituximab" post="following failure of antiviral therapy for hepatitis C virus"/>
   <result pre="antibodies and direct antiviral agentsOncotarget20178417644177710.18632/oncotarget.1698628454112 38.RoccatelloD.SciasciaS.BaldovinoS.RossiD.AlpaM.NarettoC.Di SimoneD.MenegattiE.Improved (4 plus 2)" exact="rituximab" post="protocol for severe cases of mixed cryoglobulinaemia: A 6-year"/>
   <result pre="observational studyAm. J. Nephrol.20164325126010.1159/00044584127161362 39.TerrierB.LaunayD.KaplanskiG.HotA.LarrocheC.CathébrasP.CombeB.De JaureguiberryJ.P.MeyerO.SchaeverbekeT.et al.Safety and efficacy of" exact="rituximab" post="in nonviral cryoglobulinemia vasculitis, data from the French Autoimmunity"/>
   <result pre="two casesWorld J. Clin. Cases2015373674210.12998/wjcc.v3.i8.73626301235 41.FabriziF.MartinP.ElliA.MontagninoG.BanfiG.PasseriniP.CampiseM.R.TarantinoA.PonticelliC.Hepatitis C virus infection and" exact="rituximab" post="therapy after renal transplantationInt. J. Artif. Organs20073044544910.1177/03913988070300051317551909 42.HamzehM.HosseinimehrS.J.KhalatbaryA.R.MohammadiH.R.DashtiA.AmiriF.T.Atorvastatin mitigates"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6968485\results\search\drugs\results.xml">
   <result pre="et al. (2016). Novel Soluplus((R))-TPGS mixed micelles for encapsulation of" exact="paclitaxel" post="with enhanced in vitro cytotoxicity on breast and ovarian"/>
   <result pre="BernabeuE, GonzalezL, et al. (2017). Mixed micelles for encapsulation of" exact="doxorubicin" post="with enhanced in vitro cytotoxicity on breast and ovarian"/>
   <result pre="GilevaA, SarychevG, KondryaU, et al. (2019). Lipoamino acid-based cerasomes for" exact="doxorubicin" post="delivery: preparation and in vitro evaluation. Mater Sci Eng"/>
   <result pre="et al. (2017). Improved oral bioavailability and therapeutic efficacy of" exact="dabigatran" post="etexilate via Soluplus-TPGS binary mixed micelles system. Drug Dev"/>
   <result pre="Agric Food Chem63:1957–66.25415840 MorettonMA, TairaC, FlorS, et al. (2014). Novel" exact="nelfinavir" post="mesylate loaded d-alpha-tocopheryl polyethylene glycol 1000 succinate micelles for"/>
   <result pre="the active ingredients. Clin Pharmacokinet52:727–49.23703577 VarmaMV, PanchagnulaR (2005). Enhanced oral" exact="paclitaxel" post="absorption with vitamin E-TPGS: effect on solubility and permeability"/>
   <result pre="WanJ, QiaoY, ChenX, et al. (2018). Structure-guided engineering of cytotoxic" exact="cabazitaxel" post="for an adaptive nanoparticle formulation: enhancing the drug safety"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6968529\results\search\drugs\results.xml">
   <result pre="doi: 10.1080/13880209.2019.16875271687527 : Article Effects of Fuzheng Huayu recipe on" exact="entecavir" post="pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats T."/>
   <result pre="cited.IPHB_58_1687527.pdf Abstract Abstract Context: Fuzheng Huayu recipe (FZHY) combined with" exact="entecavir" post="(ETV) is used to treat the cirrhosis caused by"/>
   <result pre="improve hepatic fibrosis is needed. Figure 1. Chemical structure of" exact="entecavir" post="(ETV). Fuzheng Huayu recipe (FZHY) is an anti-fibrotic agent"/>
   <result pre="study. Figure 3. Typical multiple reaction monitoring (MRM) chromatograms of" exact="entecavir" post="(m/z 277) and IS (m/z 229) separated on an"/>
   <result pre="6/5. (A) Blank serum sample; (B) blank plasma spiked with" exact="entecavir" post="(500 μg/L); (C) rat plasma 30 min after oral administration of"/>
   <result pre="HanKH2013Performance evaluation of the HepB Typer-Entecavir kit for detection of" exact="entecavir" post="resistance mutations in chronic hepatitis B. Clin Mol Hepatol."/>
   <result pre="RosmawatiM, LaoJ, Van VlierbergheH, AndersonFH, ThomasN, DehertoghD2002Entecavir is superior to" exact="lamivudine" post="in reducing hepatitis B virus DNA in patients with"/>
   <result pre="et al.2018Eight-year survival in chronic hepatitis B patients under long-term" exact="entecavir" post="or tenofovir therapy is similar to the general population."/>
   <result pre="survival in chronic hepatitis B patients under long-term entecavir or" exact="tenofovir" post="therapy is similar to the general population. J Hepatol."/>
   <result pre="Hepatol. 13(3):372–374.1808228 SuqiuP, ShuangW, GuoquanW, QienX, WeiweiY, MeirongH2013Effective observation of" exact="entecavir" post="combined with Fuzheng Huayu capsule for treating hepatic fibrosis"/>
   <result pre="MaX, KakuT, LiuK2013OAT1 and OAT3: targets of drug–drug interaction between" exact="entecavir" post="and JBP485. Eur J Pharm Sci. 48(4–5):650–657.23313623 YangT, LiuS,"/>
   <result pre="YangJ, HeY, LiuF, WangJP, DaveyAK2010Food effect on the pharmacokinetics of" exact="entecavir" post="from dispersible tablets following oral administration in healthy Chinese"/>
   <result pre="approach applied in sample pre-processing for the quantitative determination of" exact="entecavir" post="in human plasma by LC–MS. J Chromatogr B. 881–882:119–125."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6970260\results\search\drugs\results.xml">
   <result pre="was rather low (up to 3–6%), with the exception of" exact="topiramate" post="and amantadine (8.0 and 9.4%) in the physicians, and"/>
   <result pre="low (up to 3–6%), with the exception of topiramate and" exact="amantadine" post="(8.0 and 9.4%) in the physicians, and famotidine, memantine,"/>
   <result pre="in the physicians, and famotidine, memantine, levetiracetam, amiloride, venlafaxine, topiramate," exact="donepezil" post="and rivastigmine (8.2–9.2%) in the students. Table 2 Percentage"/>
   <result pre="physicians, and famotidine, memantine, levetiracetam, amiloride, venlafaxine, topiramate, donepezil and" exact="rivastigmine" post="(8.2–9.2%) in the students. Table 2 Percentage of Correct"/>
   <result pre="responses than the students for 5 drugs (furosemide, metoprolol, quetiapine," exact="omeprazole" post="and pantoprazole), and lower for 7 drugs (telmisartan, valsartan,"/>
   <result pre="fentanyl, oxycodone, tramadol, methotrexate, acyclovir, amantadine, ciprofloxacin, levofloxacin, gliclazide, metformin," exact="alendronic acid," post="and ibandronic acid), and lower for 2 drugs (atenolol"/>
   <result pre="internal medicine (Table 2). The most striking examples are sotalol," exact="metoclopramide" post="and nitrofurantoin, correctly classified as drugs that should be"/>
   <result pre="are quite commonly used in older patients.20 Frequent use of" exact="nitrofurantoin" post="in patients with CKD was reported by Farag et"/>
   <result pre="percentage of correct answers was also found for dalteparin, fluoxetine," exact="valproic acid," post="amoxicillin, and clarithromycin. Moreover, the percentage of answers &quot;no"/>
   <result pre="class was very similar regardless of the actual recommendations (eg," exact="cilazapril" post="and perindopril vs. quinapril; dalteparin vs. enoxaparin; amoxicillin and"/>
   <result pre="very similar regardless of the actual recommendations (eg, cilazapril and" exact="perindopril" post="vs. quinapril; dalteparin vs. enoxaparin; amoxicillin and clarithromycin vs."/>
   <result pre="recommendations (eg, cilazapril and perindopril vs. quinapril; dalteparin vs. enoxaparin;" exact="amoxicillin" post="and clarithromycin vs. levofloxacin). Taking unnecessary precautions may lead"/>
   <result pre="cilazapril and perindopril vs. quinapril; dalteparin vs. enoxaparin; amoxicillin and" exact="clarithromycin" post="vs. levofloxacin). Taking unnecessary precautions may lead to underdosing"/>
   <result pre="pattern could be seen for other drugs with divergent recommendations:" exact="sotalol" post="and metoclopramide. The problem of conflicting dosing information between"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6973187\results\search\drugs\results.xml">
   <result pre="plasma polymerase chain reaction (PCR). EBV was successfully treated with" exact="rituximab" post="and HSV with acyclovir. However, as the HAdV viral"/>
   <result pre="(VL) increased to 132 × 106 copies/ml, treatment with 5 mg/kg weekly intravenous" exact="cidofovir" post="with concomitant hydration only obtained a moderate decrease in"/>
   <result pre="the double haploidentical HSCT, conditioning regimens with antithymocyte globulin and" exact="rituximab" post="treatment. Without HAdV specific CD4+ helper, CD8+ cytotoxic T"/>
   <result pre="drug composition of Cidofovir and Brincidofovir. (a) The activated antiviral," exact="cidofovir" post="diphosphate, leads to chain termination as it is incorporated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6977371\results\search\drugs\results.xml">
   <result pre="the susceptibility of highly pathogenic avian influenza H5N1 viruses to" exact="oseltamivir" post="using embryonated chicken eggs TareDeeksha S.1KodeSadhana S.1HurtAeron C.3PawarShailesh D.2[1],"/>
   <result pre="OC. Antivirals embryonated chicken eggs H5N1 highly pathogenic avian influenza" exact="oseltamivir" post="The emergence of resistance among highly pathogenic avian influenza"/>
   <result pre="resistance among highly pathogenic avian influenza (HPAI) H5N1 viruses to" exact="oseltamivir" post="has been an increasing cause of concern among public"/>
   <result pre="died3. There are four neuraminidase inhibitor (NAI) antiviral drugs namely," exact="oseltamivir" post="phosphate, zanamivir, laninamivir and peramivir, of which oseltamivir phosphate"/>
   <result pre="drugs namely, oseltamivir phosphate, zanamivir, laninamivir and peramivir, of which" exact="oseltamivir" post="phosphate and zanamivir are the two currently licensed NAI"/>
   <result pre="phosphate, zanamivir, laninamivir and peramivir, of which oseltamivir phosphate and" exact="zanamivir" post="are the two currently licensed NAI drugs used for"/>
   <result pre="NAI drugs used for the treatment and prophylaxis of influenza4;" exact="peramivir" post="is licensed for use in the United States of"/>
   <result pre="the United States of America5. Recently resistance to the NAIs" exact="oseltamivir" post="and zanamivir was reported among H5N1 viruses isolated in"/>
   <result pre="States of America5. Recently resistance to the NAIs oseltamivir and" exact="zanamivir" post="was reported among H5N1 viruses isolated in India6. Due"/>
   <result pre="vivo studies include experiments in mice and ferrets. In ferrets," exact="oseltamivir" post="doses of 5.0 mg/kg twice daily had a significant"/>
   <result pre="reported12. The susceptibility of low pathogenic avian influenza viruses to" exact="oseltamivir" post="carboxylate (OC), the active metabolite of oseltamivir phosphate, has"/>
   <result pre="influenza viruses to oseltamivir carboxylate (OC), the active metabolite of" exact="oseltamivir" post="phosphate, has also been demonstrated13. The advantages of the"/>
   <result pre="A/Perth/265/2009 (pH1N1 H275Y variant) which were sensitive and resistant to" exact="oseltamivir" post="were used as controls. The experiments were carried out"/>
   <result pre="OC in humans after the prescribed 75 mg dose of" exact="oseltamivir" post="phosphate18. In a previous study, 1.75, 3.5, 7, 14,"/>
   <result pre="A/chicken/India/NIV33487/2006 and A/duck/India/TR-NIV4396/2008 with and without treatment with 14 μg/ml" exact="oseltamivir" post="carboxylate, plotted against virus dilutions. Values are mean of"/>
   <result pre="observed. dMean of EID50/ELD50 in the presence of 14 μg/ml" exact="oseltamivir" post="carboxylate, carried out in three replicates each; eMean of"/>
   <result pre="each; eMean of EID50/ELD50 in the absence of 14 μg/ml" exact="oseltamivir" post="carboxylate, carried out in three replicates each; fSince there"/>
   <result pre="a daily dose of 1 to 10 mg per kg" exact="oseltamivir" post="prevented mortality, reduced virus titres in the lungs and"/>
   <result pre="vitro and in vivo studies20. It was shown that after" exact="amantadine" post="addition in cell cultures infected with susceptible HPAI H5N1"/>
   <result pre="there was an absolute reduction in HA titres, whereas the" exact="amantadine" post="resistant viruses, which possessed the molecular signatures required for"/>
   <result pre="seen after treatment with OC for the H5N1 viruses and" exact="oseltamivir" post="sensitive wild-type control reference viruses; whereas, there was no"/>
   <result pre="In the study by Wang et al20, the antiviral drug" exact="ribavirin" post="was administered via the albumen route, while the virus"/>
   <result pre="was inoculated via the allantoic route. It was found that" exact="ribavirin" post="administered in the albumen of the egg is detectable"/>
   <result pre="study, OC which is the active metabolite of the prodrug" exact="oseltamivir" post="phosphate, was administered directly into the allantoic cavity itself"/>
   <result pre="viruses over the last decadeScientifica (Cairo)2014201443062924800107 8HurtACLowtherSMiddletonDBarrIGAssessing the development of" exact="oseltamivir" post="and zanamivir resistance in A(H5N1) influenza viruses using a"/>
   <result pre="the last decadeScientifica (Cairo)2014201443062924800107 8HurtACLowtherSMiddletonDBarrIGAssessing the development of oseltamivir and" exact="zanamivir" post="resistance in A(H5N1) influenza viruses using a ferret modelAntiviral"/>
   <result pre="to study the susceptibility of avian influenza H9N2 viruses to" exact="oseltamivir" post="carboxylateJ Virol Methods2015224677226297959 14collab: World Health OrganizationLaboratory methodologies for"/>
   <result pre="from Australasia and South East Asia to the neuraminidase inhibitors" exact="zanamivir" post="and oseltamivirAntiviral Res200462374515026200 18HaydenGGBruntonLLLazoJSParkerKLAntiviral agents (Non-retroviral)Goodman and Gilman's -"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6982504\results\search\drugs\results.xml">
   <result pre="megakaryocyte count of 8/µL. After the exclusion of malignant diseases," exact="prednisolone" post="(PSL; 1 mg/kg) was administered as a second�?line therapy"/>
   <result pre="IVIG, intravenous immunoglobulin; PC, platelet transfusion; Plt, platelet count; PSL," exact="prednisolone" post="3 DISCUSSION Herein, we described a 38�?day�?old boy with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6982783\results\search\drugs\results.xml">
   <result pre="it is a good choice of the combined arctiin with" exact="oseltamivir" post="for IAV in immunocompromised mice that were infected with"/>
   <result pre="expression in uPA-SCID chimeric mice with humanized livers during intravenous" exact="silibinin" post="monotherapyJ. Viral Hepat.20162370871710.1111/jvh.1255127272497 89.SongJ.H.ChoiH.J.Silymarin efficacy against influenza a virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6987146\results\search\drugs\results.xml">
   <result pre="and functional analyses of the second-generation integrase strand transfer inhibitor" exact="dolutegravir" post="(S/GSK1349572)Mol. Pharmacol.20118056557210.1124/mol.111.07318921719464 12.HirataYNakataHYamadaKOkuharaKNaitoTThe structure of Aureothin, a nitro compound"/>
   <result pre="enzyme inhibitorsAdv. Enzyme Regul.198422275510.1016/0065-2571(84)90007-46382953 23.FengJYet al.The triple combination of tenofovir," exact="emtricitabine" post="and efavirenz shows synergistic anti-HIV-1 activity in vitro: a"/>
   <result pre="Enzyme Regul.198422275510.1016/0065-2571(84)90007-46382953 23.FengJYet al.The triple combination of tenofovir, emtricitabine and" exact="efavirenz" post="shows synergistic anti-HIV-1 activity in vitro: a mechanism of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6996547\results\search\drugs\results.xml">
   <result pre="antigenic drifts or shifts.16 Although some antiviral drugs such as" exact="zanamivir" post="(Relenza) and oseltamivir (Tamiflu) are currently in use, the"/>
   <result pre="shifts.16 Although some antiviral drugs such as zanamivir (Relenza) and" exact="oseltamivir" post="(Tamiflu) are currently in use, the increasing emergence of"/>
   <result pre="LiuH, et al. In vivo delivery of silica nanorattle encapsulated" exact="docetaxel" post="for liver cancer therapy with low toxicity and high"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC6998849\results\search\drugs\results.xml">
   <result pre="Immun2015832836284310.1128/IAI.03101-1425916992 11.HanFZhangHXiaXXiongHSongDZongXWangYPorcine beta-defensin 2 attenuates inflammation and mucosal lesions in" exact="dextran" post="sodium sulfate-induced colitisJ Immunol20151941882189310.4049/jimmunol.140230025601921 12.TangZXuLShiBDengHLaiXLiuJSunZOral administration of synthetic porcine"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7000641\results\search\drugs\results.xml">
   <result pre="spondylitis revealed good antibody responses, regardless of the time of" exact="infliximab" post="infusion [68]. In patients prescribed both an immunomodulator and"/>
   <result pre="monotherapy with an immunomodulator, anti-TNF, or 5-ASAs [69]. In contrast," exact="vedolizumab" post="which shows gut-selective mechanism does not influence the response"/>
   <result pre="IBD who are receiving anti-TNF, such as infliximab, etanercept, or" exact="adalimumab" post="[86,92-96]. In two large, retrospective cohort studies, liver dysfunction"/>
   <result pre="listed in Table 3. Long-term moderate-to-high dose corticosteroid therapy (oral" exact="prednisone" post="≥ 10 mg/day over 4 weeks) increases the risk"/>
   <result pre="HBsAg-negative plus anti-HBc positive [98]. Long-term, low-dose corticosteroid therapy (oral" exact="prednisone" post="of less than 10 mg/day over 4 weeks) may"/>
   <result pre="which necessitates antiviral prophylaxis. In contrast, patients receiving shortterm oral" exact="prednisone" post="over 1 week are at low risk of reactivation"/>
   <result pre="do not need antiviral prophylaxis [98]. Immunophilin inhibitors such as" exact="cyclosporine" post="and tacrolimus may increase the likelihood of HBV reactivation"/>
   <result pre="need antiviral prophylaxis [98]. Immunophilin inhibitors such as cyclosporine and" exact="tacrolimus" post="may increase the likelihood of HBV reactivation [100]. However,"/>
   <result pre="the likelihood of HBV reactivation [100]. However, patients receiving methotrexate," exact="azathioprine" post="or 6-mercaptopurine do not require antiviral prophylaxis because they"/>
   <result pre="low risk of HBV reactivation [98]. Anti-TNF treatments, such as" exact="infliximab" post="and adalimumab, confer a high risk of HBV reactivation—up"/>
   <result pre="are HBsAg-positive [95,101]. Furthermore, this risk is higher when using" exact="infliximab" post="than when using etanercept, which is correlated with potency."/>
   <result pre="immunosuppressive therapy—most literature specifies 7 days before [107]. Entecavir and" exact="tenofovir" post="are preferred to other antiviral agents, because they have"/>
   <result pre="reactivation beyond 12 months reported, particularly in patients who received" exact="rituximab" post="(antiCD20 antibody) [110-112]. 5. Monitoring Statement 8 HBV status"/>
   <result pre="patients with IBDNat Rev Gastroenterol Hepatol20131027728523419290 68ElkayamOBashkinAMandelboimMet al.The effect of" exact="infliximab" post="and timing of vaccination on the humoral response to"/>
   <result pre="and future directionsGastroenterology20171521297130928219691 84LoombaRRowleyAWesleyRet al.Systematic review: the effect of preventive" exact="lamivudine" post="on hepatitis B reactivation during chemotherapyAnn Intern Med200814851952818378948 85YeoWChanPKZhongSet"/>
   <result pre="after immunosuppressive or cytotoxic chemotherapyJ Gastroenterol2016511081108926943169 92XuZDaiWWuYTet al.Prophylactic effect of" exact="lamivudine" post="on chemotherapy-induced hepatitis B virus reactivation in patients with"/>
   <result pre="anti-tumor necrosis factor-alpha therapyJ Rheumatol2009362416242019797507 95EsteveMSaroCGonzález-HuixFSuarezFFornéMViverJMChronic hepatitis B reactivation following" exact="infliximab" post="therapy in Crohn’s disease patients: need for primary prophylaxisGut2004531363136515306601"/>
   <result pre="B virus cccDNAScience20143431221122824557838 103KoskinasJTampakiMDoumbaPPRallisEHepatitis B virus reactivation during therapy with" exact="ustekinumab" post="for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patientBr"/>
   <result pre="in liver diseaseGastroenterology201414757759425066692 106MozessohnLChanKKFeldJJHicksLKHepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving" exact="rituximab" post="for lymphoma: a meta-analysisJ Viral Hepat20152284284925765930 107ZhangMYZhuGQShiKQet al.Systematic review"/>
   <result pre="prevention of chemotherapy-induced hepatitis B virus reactivationOncotarget20167306423065827121321 108YangCQinBYuanZChenLZhouHYMeta-analysis of prophylactic" exact="entecavir" post="or lamivudine against hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet"/>
   <result pre="chemotherapy-induced hepatitis B virus reactivationOncotarget20167306423065827121321 108YangCQinBYuanZChenLZhouHYMeta-analysis of prophylactic entecavir or" exact="lamivudine" post="against hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet al.Comparison of"/>
   <result pre="lamivudine against hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet al.Comparison of" exact="entecavir" post="and lamivudine in preventing HBV reactivation in lymphoma patients"/>
   <result pre="hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet al.Comparison of entecavir and" exact="lamivudine" post="in preventing HBV reactivation in lymphoma patients undergoing chemotherapy:"/>
   <result pre="Clin Pharm2016381035104327450506 110CervaCColagrossiLMaffongelliGet al.Persistent risk of HBV reactivation despite extensive" exact="lamivudine" post="prophylaxis in haematopoietic stem cell transplant recipients who are"/>
   <result pre="cyclosporine)  Low risk (&amp;lt;1%) Short-term corticosteroids (≤1 week) Noa Azathioprine/6-mercaptopurine," exact="methotrexate" post="HBsAg-negative/anti-HBc-positive  High risk (≥ 10%) Not available Yes  Moderate"/>
   <result pre="low-dose corticosteroids (prednisone &amp;lt; 10 mg/day, ≥ 4 weeks) Azathioprine/6-mercaptopurine," exact="methotrexate" post="aPreemptive therapy."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7002824\results\search\drugs\results.xml">
   <result pre="viral reservoir is resolved. To solve this problem Coumarin derivatives," exact="hymecromone" post="and scoparone which have the ability to reactivate HIV"/>
   <result pre="of latent HIV-1 in latently infected cells by coumarin compounds:" exact="hymecromone" post="and scoparoneCurr. HIV Res.201648449027697031 59SpanakisN.PitirigaV.A review of neuraminidase inhibitor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7004585\results\search\drugs\results.xml">
   <result pre=": 3800: Research ArticleStudy Protocol Systematic Review Kushenin combined with" exact="entecavir" post="for chronic hepatitis BA protocol for a systematic review"/>
   <result pre="evaluate the efficacy and safety of kushenin (KS) combined with" exact="entecavir" post="(ETV) for chronic hepatitis B. Methods: Randomized controlled trials"/>
   <result pre="for CHB. PROSPERO registration number: CRD42019124790. Keywords chronic hepatitis B" exact="entecavir" post="kushenin meta-analysis oxymatrine protocol 1 Introduction More than 240"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7005185\results\search\drugs\results.xml">
   <result pre="HBV–DNA. Twenty (37,0%) received lamivudine + adefovir, 20 (37.0%) tenofovir, 2 (3.7%)" exact="lamivudine" post="and 12 (22.2%) entecavir. Therapy median duration was 38"/>
   <result pre="compared to Group C (p = 0.00003 and p = 0.00006, respectively). Tenofovir and" exact="entecavir" post="showed less impact compared to lamivudine + adefovir. mtDNA/nDNA ratio positively"/>
   <result pre="showing significant differences in mtDNA and mtRNA levels. Tenofovir and" exact="entecavir" post="showed lower impact on alterations, compared to 1st generation"/>
   <result pre="HBeAg-antibody serological expression2. First generation Nucleos(t)ide Analogues (NAs), such as" exact="lamivudine" post="and adefovir, showed a high antiviral efficacy, but their"/>
   <result pre="HBV-DNA and with HBsAg loss, first generation NAs such as" exact="lamivudine" post="are still used for HBV reactivation prophylaxis6. A long-term"/>
   <result pre="20 (37,0%) were receiving lamivudine + adefovir, 20 (37,0%) tenofovir, 2 (3,7%)" exact="lamivudine" post="monotherapy and 12 (22,2%) entecavir monotherapy. Among NAs treated"/>
   <result pre="20 (37,0%) tenofovir, 2 (3,7%) lamivudine monotherapy and 12 (22,2%)" exact="entecavir" post="monotherapy. Among NAs treated patients, only 1/54 (4.5%) had"/>
   <result pre="currently receiving entecavir, 73 months (IQR 57–108) in those receiving" exact="tenofovir" post="and 96 months (IQR 66–150) in those treated with"/>
   <result pre="only statistically significant difference in total therapy duration was between" exact="entecavir" post="and tenofovir treated patients (p = 0.001) whereas, even if the"/>
   <result pre="significant difference in total therapy duration was between entecavir and" exact="tenofovir" post="treated patients (p = 0.001) whereas, even if the median total"/>
   <result pre="longer, only a trend toward significance was observed when comparing" exact="entecavir" post="and lamivudine + adefovir (p = 0.087). Among patients receiving tenofovir, 12/20 (60%)"/>
   <result pre="2/20 (10%) with lamivudine + entecavir and 3/10 (15%) have received only" exact="tenofovir" post="monotherapy. Among patients treated with entecavir, 5/12 (41.7%) have"/>
   <result pre="and APRI score values when considering separately patients currently receiving" exact="entecavir" post="monotherapy, tenofovir monotherapy and lamivudine + adefovir. Table 1 Demographic, clinical"/>
   <result pre="score values when considering separately patients currently receiving entecavir monotherapy," exact="tenofovir" post="monotherapy and lamivudine + adefovir. Table 1 Demographic, clinical and therapeutic"/>
   <result pre="and uninfected controls (Group C). ETV: entecavir, LAM + ADV: lamivudine + adefovir, TDF:" exact="tenofovir" post="disoproxil fumarate; data are showed as: median (point), box"/>
   <result pre="to single drug regimen after excluding the 2 patients receiving" exact="lamivudine" post="monotherapy. mtDNA/nDNA ratio levels were significantly higher in patients"/>
   <result pre="on therapy with lamivudine + adefovir (Fig. 2) compared to those receiving" exact="entecavir" post="(p = 0.025), to Group B (p = 0.00006) and Group C (p = 0.00003)."/>
   <result pre="to Group B (p = 0.00006) and Group C (p = 0.00003). Patients receiving" exact="tenofovir" post="had significantly higher mtDNA/nDNA ratio levels when compared to"/>
   <result pre="compared to patients receiving entecavir, tough not significantly. Patients receiving" exact="entecavir" post="had significantly higher levels when compared to Group C"/>
   <result pre="significantly lower mtRNA/nRNA ratio values when compared to patients receiving" exact="tenofovir" post="(p = 0.027) and entecavir (p = 0.011). Patients receiving lamivudine + adefovir had also"/>
   <result pre="ratio values when compared to patients receiving tenofovir (p = 0.027) and" exact="entecavir" post="(p = 0.011). Patients receiving lamivudine + adefovir had also significantly lower mtRNA/nRNA"/>
   <result pre="(p = 0.0039) and Group C (p = 0.0000001). Furthermore, no statistical difference between" exact="entecavir" post="and tenofovir recipients was observed (Fig. 2). mtDNA/nDNA ratio"/>
   <result pre="Group C (p = 0.0000001). Furthermore, no statistical difference between entecavir and" exact="tenofovir" post="recipients was observed (Fig. 2). mtDNA/nDNA ratio levels significantly"/>
   <result pre="treatment with lamivudine + adefovir, never changed this schedule. Instead, patients receiving" exact="tenofovir" post="or entecavir, were previously exposed to lamivudine + adefovir in 16/20"/>
   <result pre="patients receiving lamivudine + adefovir, in 3/19 (15.7%) among patients treated with" exact="tenofovir" post="and in 0/11(0%) of patients receiving entecavir. It is"/>
   <result pre="It is noteworthy that 2/3 patients with BSC currently receiving" exact="tenofovir" post="had previously been exposed to lamivudine + adefovir. When comparing the"/>
   <result pre="in CK levels was observed in 12.9% of patients receiving" exact="telbivudine" post="and in 4.1% patients of those receiving lamivudine for"/>
   <result pre="patients receiving telbivudine and in 4.1% patients of those receiving" exact="lamivudine" post="for 104 weeks (p &amp;lt; 0.001). Myopathy, has also been reported"/>
   <result pre="3 patients, all of whom had resolution of symptoms after" exact="telbivudine" post="was discontinued29. Regarding 2nd generation NAs, entecavir has been"/>
   <result pre="of symptoms after telbivudine was discontinued29. Regarding 2nd generation NAs," exact="entecavir" post="has been rarely associated with clinical signs of mitochondrial"/>
   <result pre="failed to detect an increased risk of lactic acidosis in" exact="entecavir" post="recipients30. Furthermore, to our knowledge, tenofovir has never been"/>
   <result pre="of lactic acidosis in entecavir recipients30. Furthermore, to our knowledge," exact="tenofovir" post="has never been associated with lactic acidosis in HBV-infected"/>
   <result pre="lymphoma treated with a combination of adefovir/lamivudine, when compared to" exact="lamivudine" post="alone33. Therefore, the use of 1st generation NAs also"/>
   <result pre="lamivudine + adefovir had higher levels of mtDNA, compared to those receiving" exact="entecavir" post="or tenofovir, suggesting that the impact on mitochondrial damage"/>
   <result pre="in mtDNA levels in children exposed to zidovudine/lamivudine compared to" exact="zidovudine" post="alone. This study also suggests that exposure to combination"/>
   <result pre="but no change in mtDNA levels after 4 weeks of" exact="zidovudine" post="treatment in mouse muscle cells43. In our study, the"/>
   <result pre="not appear to be critical. Among drugs, 2nd generation NA" exact="tenofovir" post="and entecavir showed a lower impact on mitochondrial alterations"/>
   <result pre="to be critical. Among drugs, 2nd generation NA tenofovir and" exact="entecavir" post="showed a lower impact on mitochondrial alterations compared to"/>
   <result pre="DNA (mtDNA/nDNA) ratio as a marker of mitochondrial toxicities of" exact="stavudine" post="containing antiretroviral therapy in HIV-infected Malawian patientsOMICS.20141843844510.1089/omi.2014.002624816082 11.MontanerJSet al.Mitochondrial"/>
   <result pre="Syndr.200334Suppl 1S859010.1097/00126334-200309011-0001314562863 12.VidalFet al.In vitro cytotoxicity and mitochondrial toxicity of" exact="tenofovir" post="alone and in combination with other antiretrovirals in human"/>
   <result pre="16.VernochetCet al.Differential effect of HIV protease inhibitors on adipogenesis: intracellular" exact="ritonavir" post="is not sufficient to inhibit differentiationAIDS.2003172177218010.1097/00002030-200310170-0000514523274 17.SmithDEet al.Thymidine analogue"/>
   <result pre="the selectivity of the mitochondrial DNA polymeraseBiochemistry.200342147111471910.1021/bi035596s14674745 19.Pérez-MolinaJADomingoPMartínezEMorenoSThe role of" exact="efavirenz" post="compared with protease inhibitors in the body fat changes"/>
   <result pre="cellular perspectiveNat. Rev. Drug. Discov.2003281282210.1038/nrd120114526384 29.LiawYFet al.2-Year GLOBE trial results:" exact="telbivudine" post="is superior to lamivudine in patients with chronic hepatitis"/>
   <result pre="Discov.2003281282210.1038/nrd120114526384 29.LiawYFet al.2-Year GLOBE trial results: telbivudine is superior to" exact="lamivudine" post="in patients with chronic hepatitis BGastroenterology.200913648649510.1053/j.gastro.2008.10.02619027013 30.LamperticoPet al.Review article:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7013637\results\search\drugs\results.xml">
   <result pre="institutions [3]. Until 2011, dual therapy using pegylated interferon and" exact="ribavirin" post="(PEG-IFN and RBV) was the standard course of treatment."/>
   <result pre="improvement in the SVR12 rate. Triple therapy with the DAA" exact="telaprevir" post="(TVR) or boceprevir (BOC) in combination with PEG-IFN and"/>
   <result pre="SVR12 rate. Triple therapy with the DAA telaprevir (TVR) or" exact="boceprevir" post="(BOC) in combination with PEG-IFN and RBV resulted in"/>
   <result pre="prior experience with treatment. The main DAA regimen used was" exact="sofosbuvir" post="(SOF) combined with ledipasvir (LDV) (±RBV) [9]. The model"/>
   <result pre="developed for treatment-naive patients treated with the DAAs SOF and/or" exact="simeprevir" post="(SMV). The ICER for Gissel et al. [43] is"/>
   <result pre="regimens and the interferon-based triple therapy, SOF with LDV and" exact="ombitasvir" post="(OBV) + paritaprevir (PTV) + ritonavir (RTV) + dasabuvir"/>
   <result pre="SOF with LDV and ombitasvir (OBV) + paritaprevir (PTV) +" exact="ritonavir" post="(RTV) + dasabuvir (DSV) ± RBV were the most"/>
   <result pre="and ombitasvir (OBV) + paritaprevir (PTV) + ritonavir (RTV) +" exact="dasabuvir" post="(DSV) ± RBV were the most cost-efficient alternatives. The"/>
   <result pre="multicenter trialJ. Viral Hepat.20152310511510.1111/jvh.1247126411532 24.SiebertU.SroczynskiG.RossolS.WasemJ.Ravens-SiebererU.KurthB.M.MannsM.P.McHutchisonJ.G.WongJ.B.Cost effectiveness of peginterferon alpha-2b plus" exact="ribavirin" post="versus interferon alpha-2b plus ribavirin for initial treatment of"/>
   <result pre="effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis CGut20035242543210.1136/gut.52.3.42512584228 25.StahmeyerJ.JacobsS.RossolS.Heinrich WedemeyerH.WirthD.BianicF.KrauthC.Cost-effectiveness"/>
   <result pre="in Health CareCologne, Germany2017 30.GrishchenkoM.GrieveR.D.SweetingM.J.De AngelisD.ThomsonB.J.RyderS.D.IrvingW.L.Cost-effectiveness of pegylated interferon and" exact="ribavirin" post="for patients with chronic hepatitis C treated in routine"/>
   <result pre="of the liverAm. J. Gastroenterol.19979266728995940 36.CardosoA.-C.MoucariR.Figueiredo-MendesC.RipaultM.-P.GiuilyN.CastelnauC.BoyerN.AsselahT.Martinot-PeignouxM.MaylinS.et al.Impact of peginterferon and" exact="ribavirin" post="therapy on hepatocellular carcinoma: Incidence and survival in hepatitis"/>
   <result pre="95.75 ** €766.19/SVR12 Percentage Point * Mean of SVR12 rates" exact="boceprevir" post="+ pegylated interferon + ribavirin non-cirrhotic + cirrhotic [14];"/>
   <result pre="* Mean of SVR12 rates boceprevir + pegylated interferon +" exact="ribavirin" post="non-cirrhotic + cirrhotic [14]; ** Mean of SVR12 rates"/>
   <result pre="ribavirin non-cirrhotic + cirrhotic [14]; ** Mean of SVR12 rates" exact="sofosbuvir" post="+ ledipasvir ± ribavirin non-cirrhotic + cirrhotic [14]; ICER—incremental"/>
   <result pre="[14]; ** Mean of SVR12 rates sofosbuvir + ledipasvir ±" exact="ribavirin" post="non-cirrhotic + cirrhotic [14]; ICER—incremental cost-effectiveness ratio."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7016755\results\search\drugs\results.xml">
   <result pre="research group screened the FDA-approved drug library and found that" exact="nifedipine" post="and benidipine hydrochloride inhibited severe fever with thrombocytopenia syndrome"/>
   <result pre="Moreover, the retrospective clinical investigation on SFTS patients showed that" exact="nifedipine" post="can significantly inhibit SFTSV infection. These studies indicate that"/>
   <result pre="high concentrations. It has been shown that verapamil, nimodipine, and" exact="diltiazem" post="also inhibit the activity of two-pore channels (TPCs) [24]."/>
   <result pre="showed that blockage of the NMDAr channel activity with FDA-approved" exact="memantine" post="or other antagonists prevents neuronal cell death and microgliosis"/>
   <result pre="by siRNA screeningDrug Dev. Res.20097025526510.1002/ddr.2030320930947 22.GehringG.RohrmannK.AtenchongN.MittlerE.BeckerS.DahlmannF.PohlmannS.VondranF.W.DavidS.MannsM.P.The clinically approved drugs amiodarone," exact="dronedarone" post="and verapamil inhibit filovirus cell entryJ. Antimicrob. Chemother.2014692123213110.1093/jac/dku09124710028 23.MadridP.B.ChopraS.MangerI.D.GilfillanL.KeepersT.R.ShurtleffA.C.GreenC.E.IyerL.V.DilksH.H.DaveyR.A.A"/>
   <result pre="screeningDrug Dev. Res.20097025526510.1002/ddr.2030320930947 22.GehringG.RohrmannK.AtenchongN.MittlerE.BeckerS.DahlmannF.PohlmannS.VondranF.W.DavidS.MannsM.P.The clinically approved drugs amiodarone, dronedarone and" exact="verapamil" post="inhibit filovirus cell entryJ. Antimicrob. Chemother.2014692123213110.1093/jac/dku09124710028 23.MadridP.B.ChopraS.MangerI.D.GilfillanL.KeepersT.R.ShurtleffA.C.GreenC.E.IyerL.V.DilksH.H.DaveyR.A.A systematic screen"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7016805\results\search\drugs\results.xml">
   <result pre="viral replication. DEAD-box helicase 3 X-linked (DDX3X) is a cellular" exact="adenosine" post="5′-triphosphate (ATP)-dependent RNA helicase that hydrolyzes ATP to unwind"/>
   <result pre="RK-33 stock was made up to 50 mM in 100%" exact="dimethyl sulfoxide" post="(DMSO). 2.2. Protein Expression and Purification Sequences encoding an"/>
   <result pre="RK-33. RK-33 (50 μM or 200 μM in 7.5% (v/v)" exact="dimethyl sulfoxide" post="(DMSO)), or an equivalent % DMSO, was titrated into"/>
   <result pre="alone (410 nm, gray) and DDX3X with an equivalent %" exact="dimethyl sulfoxide" post="(DMSO) (DDX3X alone, 290 nm, black). The residual plots"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7017049\results\search\drugs\results.xml">
   <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The thrombopoietin receptor agonist" exact="eltrombopag" post="was successfully used against human cytomegalovirus (HCMV)-associated thrombocytopenia refractory"/>
   <result pre="antiviral drugs. These effects were ascribed to the effects of" exact="eltrombopag" post="on megakaryocytes. Here, we tested whether eltrombopag may also"/>
   <result pre="the effects of eltrombopag on megakaryocytes. Here, we tested whether" exact="eltrombopag" post="may also exert direct antiviral effects. Therapeutic eltrombopag concentrations"/>
   <result pre="tested whether eltrombopag may also exert direct antiviral effects. Therapeutic" exact="eltrombopag" post="concentrations inhibited HCMV replication in human fibroblasts and adult"/>
   <result pre="activity of the mainstay drug ganciclovir. Time-of-addition experiments suggested that" exact="eltrombopag" post="interfered with HCMV replication after virus entry. Eltrombopag was"/>
   <result pre="reactivation is a major reason for transplantation failure. Since therapeutic" exact="eltrombopag" post="concentrations are effective against drug-resistant viruses, and synergistically increase"/>
   <result pre="against drug-resistant viruses, and synergistically increase the effects of ganciclovir," exact="eltrombopag" post="is also a drug-repurposing candidate for the treatment of"/>
   <result pre="the treatment of therapy-refractory HCMV disease. human cytomegalovirus antiviral therapy" exact="eltrombopag" post="thrombopietin receptor agonist drug resistance iron chelation 1. Introduction"/>
   <result pre="with severe side effects [13]. In particular, the use of" exact="ganciclovir" post="(and its prodrug valganciclovir), the mainstay treatment for cytomegalovirus"/>
   <result pre="including thrombocytopenia [14,15,16]. A case report described the use of" exact="eltrombopag" post="in an immunocompetent patient who suffered from human cytomegalovirus"/>
   <result pre="resolution of symptoms [17]. The observed effects were attributed to" exact="eltrombopag" post="overcoming HCMV-induced suppression of platelet production [17]. However, we"/>
   <result pre="the patient with HCMV-associated thrombocytopenia [17]. Indeed, we found that" exact="eltrombopag" post="exerts anti-HCMV effects via iron chelation. 2. Materials and"/>
   <result pre="Methods 2.1. Drugs Eltrombopag (the orally active ethanolamine salt of" exact="eltrombopag" post="olamine) was purchased from Selleck Chemicals (via Absource Diagnostics"/>
   <result pre="purchased from Selleck Chemicals (via Absource Diagnostics GmbH, Munich, Germany)," exact="deferasirox" post="and ganciclovir from MedChemExpress (via Hycultec, Beutelsbach, Germany), and"/>
   <result pre="Selleck Chemicals (via Absource Diagnostics GmbH, Munich, Germany), deferasirox and" exact="ganciclovir" post="from MedChemExpress (via Hycultec, Beutelsbach, Germany), and cidofovir from"/>
   <result pre="deferasirox and ganciclovir from MedChemExpress (via Hycultec, Beutelsbach, Germany), and" exact="cidofovir" post="from Cayman Chemical (via Biomol GmbH, Hamburg, Germany). 2.2."/>
   <result pre="(IC50), were calculated using Calcusyn (Biosoft, Cambridge, UK). Effects of" exact="eltrombopag" post="on murine cytomegalovirus were determined by visual scoring of"/>
   <result pre="At MOI 1, the highest MOI investigated in HFFs, the" exact="eltrombopag" post="IC50 was 3844 nM. The observed eltrombopag concentrations are"/>
   <result pre="in HFFs, the eltrombopag IC50 was 3844 nM. The observed" exact="eltrombopag" post="concentrations are within the range of therapeutic plasma concentrations,"/>
   <result pre="yield assay (Figure 2A). At a concentration of 10 µM," exact="eltrombopag" post="reduced virus titres by 1.8 × 104-fold and at"/>
   <result pre="not, or only modestly, affect virus replication. This shows that" exact="eltrombopag" post="does not primarily interfere with virus binding to host"/>
   <result pre="inhibition of HCMV immediate early antigen (IEA) expression, indicates that" exact="eltrombopag" post="inhibits the late stages of the HCMV replication cycle"/>
   <result pre="a thrombopoietin receptor agonist [1,2,3]. However, it is unlikely that" exact="eltrombopag" post="inhibits HCMV replication via thrombopoietin receptor activation, because fibroblasts"/>
   <result pre="fibroblasts do not express the thrombopoietin receptor [28]. In agreement," exact="eltrombopag" post="also inhibited murine cytomegalovirus replication in murine NIH/3T3 fibroblasts"/>
   <result pre="murine cytomegalovirus replication in murine NIH/3T3 fibroblasts (Figure 3A), although" exact="eltrombopag" post="does not target the murine thrombopoietin receptor [29]. Eltrombopag"/>
   <result pre="equimolar Fe3+ concentrations was shown to inhibit pharmacological action of" exact="eltrombopag" post="that are caused via iron chelation [31]. Hence, we"/>
   <result pre="that are caused via iron chelation [31]. Hence, we investigated" exact="eltrombopag" post="in combination with equimolar Fe(III)Cl3 concentrations to investigate whether"/>
   <result pre="to investigate whether iron chelation is the mechanism by which" exact="eltrombopag" post="exerts its anti-HCMV effects (Figure 3B). Equimolar Fe(III)Cl3 concentrations"/>
   <result pre="(Figure 3B). Equimolar Fe(III)Cl3 concentrations prevented the anti-HCMV effects of" exact="eltrombopag" post="(Figure 3B). This suggests that iron chelation is the"/>
   <result pre="is the main mechanism of eltrombopag’s anti-HCMV activity. In agreement," exact="eltrombopag" post="exerted antagonistic effects in combination with the iron chelator"/>
   <result pre="eltrombopag exerted antagonistic effects in combination with the iron chelator" exact="deferasirox" post="(Table S2), which may indicate that both compounds share"/>
   <result pre="3.3. Eltrombopag Exerts Synergistic Effects with Ganciclovir Next, we tested" exact="eltrombopag" post="in combination with ganciclovir, the mainstay of anti-HCMV therapies"/>
   <result pre="the mainstay of anti-HCMV therapies [13]. The combination of equimolar" exact="eltrombopag" post="and ganciclovir concentrations resulted in synergistic anti-HCMV effects (Figure"/>
   <result pre="of anti-HCMV therapies [13]. The combination of equimolar eltrombopag and" exact="ganciclovir" post="concentrations resulted in synergistic anti-HCMV effects (Figure 4), which"/>
   <result pre="synergistic at a CIWT of ≤0.7 [24]. The combination of" exact="eltrombopag" post="and foscarnet also displayed synergistic effects (Table S2). 3.4."/>
   <result pre="Isolates Including Drug-Resistant Ones Finally, we investigated the effects of" exact="eltrombopag" post="against a broader range of laboratory virus strains and"/>
   <result pre="polymerase UL54 (Table 1), which is known to confer combined" exact="ganciclovir" post="and cidofovir resistance [42,43]. U1 also displays a C607Y"/>
   <result pre="(Table 1), which is known to confer combined ganciclovir and" exact="cidofovir" post="resistance [42,43]. U1 also displays a C607Y mutation in"/>
   <result pre="the HCMV kinase UL97 (Table 1), which is associated with" exact="ganciclovir" post="resistance [44,45]. In agreement, U1 and U59 were characterized"/>
   <result pre="[44,45]. In agreement, U1 and U59 were characterized by high" exact="ganciclovir" post="and cidofovir IC50s (Table 1), which are typically considered"/>
   <result pre="agreement, U1 and U59 were characterized by high ganciclovir and" exact="cidofovir" post="IC50s (Table 1), which are typically considered to indicate"/>
   <result pre="considered to indicate resistance [46,47,48]. U75 also displayed resistance to" exact="ganciclovir" post="and cidofovir, although it does not harbor known resistance"/>
   <result pre="does not harbor known resistance mutations (data not shown). The" exact="eltrombopag" post="IC50s ranged from 99 nM (U1 in HFFs) to"/>
   <result pre="types, the different HCMV strains and clinical isolates displayed similar" exact="eltrombopag" post="sensitivity, apart from U1, which appeared to be particularly"/>
   <result pre="apart from U1, which appeared to be particularly sensitive to" exact="eltrombopag" post="in HFFs and ASCs (Figure 5A). The average HCMV"/>
   <result pre="HFFs and ASCs (Figure 5A). The average HCMV sensitivity to" exact="eltrombopag" post="was very similar in both cell types. To confirm"/>
   <result pre="of iron chelation as mechanism of the anti-HCMV action of" exact="eltrombopag" post="using a clinical virus isolate, U1-infected HFFs were treated"/>
   <result pre="virus isolate, U1-infected HFFs were treated with equimolar concentrations of" exact="eltrombopag" post="and Fe(III)Cl3. The presence of equimolar Fe3+ concentrations prevented"/>
   <result pre="Discussion Here, we show that the approved thrombopoietin receptor agonist" exact="eltrombopag" post="exerts anti-HCMV effects in various cell types infected with"/>
   <result pre="immunocompetent patient, who suffered from HCMV-associated thrombocytopenia and recovered after" exact="eltrombopag" post="therapy [17]. This response had originally been attributed to"/>
   <result pre="[17]. This response had originally been attributed to effects of" exact="eltrombopag" post="on platelet production [17]. The possibility that eltrombopag may"/>
   <result pre="effects of eltrombopag on platelet production [17]. The possibility that" exact="eltrombopag" post="may exert antiviral affects was not considered. Our current"/>
   <result pre="affects was not considered. Our current data show that therapeutic" exact="eltrombopag" post="levels interfere with HCMV replication, which may have contributed"/>
   <result pre="which may have contributed to the beneficial clinical outcome. Notably," exact="eltrombopag" post="has also been shown to inhibit the replication of"/>
   <result pre="of the genus Banyangvirus (Phenuiviridae) [49]. The anti-HCMV effects of" exact="eltrombopag" post="are unlikely to be caused by action on the"/>
   <result pre="to be caused by action on the thrombopoietin receptor, since" exact="eltrombopag" post="was effective in cell types that do not express"/>
   <result pre="receptor, which is expressed in hematopoietic cells [28,29]. In agreement," exact="eltrombopag" post="also exerted antiviral effects in mouse fibroblasts infected with"/>
   <result pre="fibroblasts infected with murine CMV, although the hematological effects of" exact="eltrombopag" post="are known to be species-specific and to not affect"/>
   <result pre="and clinical isolate U1-infected cells. Hence, our data suggest that" exact="eltrombopag" post="inhibits HCMV replication via Fe3+ chelation. A number of"/>
   <result pre="inhibit HCMV replication [32,33,34,35,36,37,38]. However, the iron chelators tiron and" exact="ciclopirox" post="olamine were not found to inhibit HCMV strain AD169"/>
   <result pre="of confluent fibroblasts but affected dividing cells [32]. In contrast," exact="eltrombopag" post="inhibits HCMV replication in concentrations that do not affect"/>
   <result pre="and hematopoietic stem cells [2], however, the anti-HCMV effects of" exact="eltrombopag" post="are primarily of relevance for anemia patients at risk"/>
   <result pre="for anemia patients at risk of HCMV disease, for whom" exact="eltrombopag" post="is indicated. Eltrombopag has been suggested for the treatment"/>
   <result pre="of hematopoietic stem cell transplantations [10,11,12], antiviral effects exerted by" exact="eltrombopag" post="may also contribute to improved therapy outcome. Notably, eltrombopag"/>
   <result pre="by eltrombopag may also contribute to improved therapy outcome. Notably," exact="eltrombopag" post="was effective against resistant clinical HCMV isolates, and resistance"/>
   <result pre="major challenge after stem cell transplantation [11,12]. 5. Conclusions Therapeutic" exact="eltrombopag" post="concentrations inhibit HCMV replication via chelation of Fe3+ ions."/>
   <result pre="of the mainstay anti-HCMV drug ganciclovir. The anti-HCMV activity of" exact="eltrombopag" post="may be of particular interest for its use for"/>
   <result pre="following are available online at https://www.mdpi.com/2073-4409/9/1/31/s1, Figure S1: Effects of" exact="eltrombopag" post="on HCMV immediate early antigen (IEA) expression in primary"/>
   <result pre="in primary human foreskin fibroblasts (HFFs), Table S1: Effects of" exact="eltrombopag" post="addition at different time points during the HCMV replication,"/>
   <result pre="time points during the HCMV replication, Table S2: Effects of" exact="eltrombopag" post="in combination with deferasirox and foscarnet, Table S3: Effects"/>
   <result pre="HCMV replication, Table S2: Effects of eltrombopag in combination with" exact="deferasirox" post="and foscarnet, Table S3: Effects of eltrombopag on HCMV"/>
   <result pre="in combination with deferasirox and foscarnet, Table S3: Effects of" exact="eltrombopag" post="on HCMV late antigen (LA) expression in different cell"/>
   <result pre="insights into the evolution of eltrombopagTher. Adv. Hematol.2017815917410.1177/204062071769357328473904 2.ScheinbergP.Activity of" exact="eltrombopag" post="in severe aplastic anemiaBlood Adv.201823054306210.1182/bloodadvances.201802024830425070 3.GhanimaW.CooperN.RodeghieroF.GodeauB.BusselJ.B.Thrombopoietin receptor agonists: ten"/>
   <result pre="due to poor graft functionBone Marrow. Transplant.2019541346135310.1038/s41409-019-0442-330679824 9.RiveraD.BastidaJ.M.Lopez-CorralL.Sanchez-GuijoF.CabreroM.MartinA.PerezE.Lopez-ParraM.AvendañoA.VeigaA.et al.Usefulness of" exact="eltrombopag" post="for treating thrombocytopenia after allogeneic stem cell transplantationBone Marrow."/>
   <result pre="of cytomegalovirus infection and disease in transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 15.BuscaA.de FabritiisP.GhisettiV.AlliceT.MirabileM.GentileG.LocatelliF.FaldaM.Oral" exact="valganciclovir" post="as preemptive therapy for cytomegalovirus infection post allogeneic stem"/>
   <result pre="cytomegalovirus replication in human foreskin fibroblasts and endothelial cells by" exact="ascorbic acid" post="2-phosphateAntiviral. Res.19952740541810.1016/0166-3542(95)00024-G8540759 19.BaerP.C.BrzoskaM.GeigerH.Epithelial differentiation of human adipose-derived stem cellsMethods"/>
   <result pre="the UL97 proteinJ. Med. Virol.200165707610.1002/jmv.200311505446 23.MichaelisM.PaulusC.LöschmannN.DauthS.StangeE.DoerrH.W.NevelsM.CinatlJ. Jr.The multi-targeted kinase inhibitor" exact="sorafenib" post="inhibits human cytomegalovirus replicationCell Mol. Life Sci.2011681079109010.1007/s00018-010-0510-820803231 24.ChouT.C.Theoretical basis,"/>
   <result pre="combination studiesPharmacol. Rev.20065862168110.1124/pr.58.3.1016968952 25.MatthysG.ParkJ.W.McGuireS.WireM.B.BowenC.WilliamsD.JenkinsJ.PengB.Clinical pharmacokinetics, platelet response, and safety of" exact="eltrombopag" post="at supratherapeutic doses of up to 200 mg once"/>
   <result pre="of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist" exact="eltrombopag" post="and hepatitis C virus protease inhibitors boceprevir and telaprevirAntimicrob."/>
   <result pre="thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors" exact="boceprevir" post="and telaprevirAntimicrob. Agents Chemother.2014586704670910.1128/AAC.03091-1425155600 27.ScholzM.DoerrH.W.CinatlJ.Inhibition of cytomegalovirus immediate early"/>
   <result pre="of thrombopoietin signalingJ. Thromb. Haemost.20097Suppl. S123523810.1111/j.1538-7836.2009.03419.x 29.Erickson-MillerC.L.DelormeE.TianS.S.HopsonC.B.LandisA.J.ValoretE.I.SellersT.S.RosenJ.MillerS.G.LuengoJ.I.et al.Preclinical activity of" exact="eltrombopag" post="(SB-497115), an oral, nonpeptide thrombopoietin receptor agonistStem. Cells20092742443010.1634/stemcells.2008-036619038790 30.RothM.WillB.SimkinG.NarayanagariS.BarreyroL.BartholdyB.TamariR.MitsiadesC.S.VermaA.SteidlEltrombopag"/>
   <result pre="Agents Chemother.20125619720110.1128/AAC.05559-1121968367 44.BaldantiF.UnderwoodM.R.TalaricoC.L.SimonciniL.SarasiniA.BironK.K.GernaG.The Cys607--&amp;gt;Tyr change in the UL97 phosphotransferase confers" exact="ganciclovir" post="resistance to two human cytomegalovirus strains recovered from two"/>
   <result pre="24 and Regulating Iron MetabolismJ Virol.201892e00191-1810.1128/JVI.00191-1829695420 Figure 1 Effects of" exact="eltrombopag" post="on human cytomegalovirus (HCMV) late antigen (LA) expression in"/>
   <result pre="fibroblasts (HFFs). (A) Representative dose–response curves showing the effects of" exact="eltrombopag" post="on HCMV LA expression and HFF viability (as determined"/>
   <result pre="(B) Representative photographs and Western blots demonstrating the effects of" exact="eltrombopag" post="on HCMV LA expression. In (A,B), HFFs were infected"/>
   <result pre="(C) Representative dose–response curves and IC50 values indicating effects of" exact="eltrombopag" post="on HCMV LA expression in HFFs infected with different"/>
   <result pre="as detected 120 h post infection. Figure 2 Effects of" exact="eltrombopag" post="on HCMV replication and at different stages of the"/>
   <result pre="Representative dose–response curves and IC50 values indicating the effects of" exact="eltrombopag" post="on HCMV LA expression after 24 h of pre-treatment,"/>
   <result pre="iron depletion. (A) Representative dose–response curve indicating the effects of" exact="eltrombopag" post="on cytopathogenic effect (CPE) formation (detected 120 h post"/>
   <result pre="infection), in murine cytomegalovirus (MOI 1)-infected murine, NIH/3T3 fibroblasts, and" exact="eltrombopag" post="concentration that reduces CPE formation by 50% (IC50), relative"/>
   <result pre="50% (IC50), relative to untreated control. The findings indicate that" exact="eltrombopag" post="interferes with cytomegalovirus replication by thrombopoietin-receptor-independent effects, since eltrombopag"/>
   <result pre="that eltrombopag interferes with cytomegalovirus replication by thrombopoietin-receptor-independent effects, since" exact="eltrombopag" post="does not activate the murine thrombopoietin receptor. The investigated"/>
   <result pre="eltrombopag does not activate the murine thrombopoietin receptor. The investigated" exact="eltrombopag" post="concentrations did not affect NIH/3T3 cell viability. (B) Representative"/>
   <result pre="anti-HCMV effects exerted by eltrombopag. Figure 4 Antiviral effects of" exact="eltrombopag" post="in combination with ganciclovir. (A) Effects of equimolar drug"/>
   <result pre="≤0.7 indicate synergistic effects [24]. Figure 5 Antiviral effects of" exact="eltrombopag" post="determined in different cell types infected by different HCMV"/>
   <result pre="50% (IC50). Numerical values are provided in Table S3. The" exact="eltrombopag" post="concentration that reduced ASC viability by 50% (CC50) was"/>
   <result pre="of equimolar concentrations of Fe(III)Cl3 on the anti-HCMV effects of" exact="eltrombopag" post="as indicated by HCMV LA expression in U1 (MOI"/>
   <result pre="1 Sensitivity of laboratory HCMV strains and patient isolates to" exact="ganciclovir" post="and cidofovir as indicated by HCMV LA expression in"/>
   <result pre="of laboratory HCMV strains and patient isolates to ganciclovir and" exact="cidofovir" post="as indicated by HCMV LA expression in human foreskin"/>
   <result pre="in the HCMV DNA polymerase UL54, which confers resistance to" exact="ganciclovir" post="and cidofovir [42,43]. ** mutation in the HCMV kinase"/>
   <result pre="HCMV DNA polymerase UL54, which confers resistance to ganciclovir and" exact="cidofovir" post="[42,43]. ** mutation in the HCMV kinase UL97, which"/>
   <result pre="mutation in the HCMV kinase UL97, which is associated with" exact="ganciclovir" post="resistance [44,45]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7019229\results\search\drugs\results.xml">
   <result pre="clinical use [66,67]. Brincidofovir is a lipid ester prodrug of" exact="cidofovir" post="with improved oral bioavailability and reduced toxicity that demonstrated"/>
   <result pre="be involved in the IE phase of HCMV infection include" exact="adenosine" post="monophosphate-activated protein kinase (AMPK) [173], hematopoietic cell kinase (a"/>
   <result pre="the anti-HCMV activity of natural product artemisinin, its semi-synthetic derivative" exact="artesunate" post="and various related compounds. Artemisinin is a natural product"/>
   <result pre="activity and treatment [317,318], which provided the premise for testing" exact="artesunate" post="for anti-HCMV activity [319]. Artesunate, along with various related"/>
   <result pre="potent, selective HCMV inhibitor with irreversible activity [332,333] and trimeric" exact="artesunate" post="derivative TF27 [326], which exhibits potent in vitro and"/>
   <result pre="compounds and GCV [334,335,336,337]. The mechanism of action by which" exact="artesunate" post="and the various derivatives generate their anti-HCMV activity has"/>
   <result pre="not been fully elucidated, but the general consensus is that" exact="artesunate" post="primarily interferes with the NF-κΒ pathway [319,326,331]. The NF-κΒ"/>
   <result pre="of the compound with NF-κΒ subunit RelA/p65 [319,326,331]. Interaction of" exact="artesunate" post="with a host cell factor leads to the expectation"/>
   <result pre="drug resistance would be less likely; indeed, attempts to generate" exact="artesunate" post="drug-resistant isolates in vitro have thus far been unsuccessful"/>
   <result pre="modulation of cell cycle progression, have also been proposed for" exact="artesunate" post="compounds [319,340]. Clinical use of artesunate for management of"/>
   <result pre="also been proposed for artesunate compounds [319,340]. Clinical use of" exact="artesunate" post="for management of drug-resistant HCMV infections in stem cell"/>
   <result pre="study [341] and the long and safe clinical history of" exact="artesunate" post="treatment in malaria patients [317]. The first use of"/>
   <result pre="artesunate treatment in malaria patients [317]. The first use of" exact="artesunate" post="in a clinical setting was a success with artesunate"/>
   <result pre="of artesunate in a clinical setting was a success with" exact="artesunate" post="being reported as an effective inhibitor of HCMV replication"/>
   <result pre="[342]. However, subsequent studies reported either mixed success or that" exact="artesunate" post="was ineffective in controlling HCMV infection [343,344,345]. Further studies"/>
   <result pre="clinical outcomes for artesunate-treated patients, and studies with more potent" exact="artesunate" post="derivatives may hold future promise. For example, the trimeric"/>
   <result pre="for anti-HCMV testing is the multi-targeted anti-cancer tyrosine kinase inhibitor" exact="sorafenib" post="(Nexavar), which has been shown to inhibit MIEP activity,"/>
   <result pre="later stages of HCMV replication [172]. The mechanism by which" exact="sorafenib" post="inhibits HCMV was not fully elucidated due to its"/>
   <result pre="to modulate cell signalling pathways [370]. For example, cardiac glycoside" exact="digitoxin" post="has been reported to inhibit HCMV through induction of"/>
   <result pre="vivo testing using the MCMV model, and clinical testing of" exact="artesunate" post="produced mixed clinical outcomes that warrant further investigation. Overall,"/>
   <result pre="for further study [364,381,382]. These hit compounds are deguelin (DGN)," exact="nitazoxanide" post="(NTZ), thioguanosine (TGN), alexidine dihydrochloride (AXN), manidipine dihydrochloride (MND)"/>
   <result pre="These hit compounds are deguelin (DGN), nitazoxanide (NTZ), thioguanosine (TGN)," exact="alexidine" post="dihydrochloride (AXN), manidipine dihydrochloride (MND) and berberine (BBR). All"/>
   <result pre="Med. Virol.20102020221310.1002/rmv.65520564615 36.GaneE.SalibaF.ValdecasasG.J.O’GradyJ.PescovitzM.D.LymanS.RobinsonC.A.Randomised trial of efficacy and safety of oral" exact="ganciclovir" post="in the prevention of cytomegalovirus disease in liver-transplant recipients."/>
   <result pre="Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study GroupN. Engl. J. Med.19993401462147010.1056/NEJM19990513340190310320384 38.WreghittT.G.AbelS.J.McNeilK.ParameshwarJ.StewartS.CaryN.SharplesL.LargeS.WallworkJ.Intravenous" exact="ganciclovir" post="prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant"/>
   <result pre="infected cellsProc. Natl. Acad. Sci. USA201210958859310.1073/pnas.111496610822203987 172.MichaelisM.PaulusC.LoschmannN.DauthS.StangeE.DoerrH.W.NevelsM.CinatlJ.Jr.The multi-targeted kinase inhibitor" exact="sorafenib" post="inhibits human cytomegalovirus replicationCell. Mol. Life Sci.2011681079109010.1007/s00018-010-0510-820803231 173.MukhopadhyayR.VenkatadriR.KatsnelsonJ.Arav-BogerR.Digitoxin suppresses"/>
   <result pre="silencing and genome editingCurr. Opin. Virol.201724465410.1016/j.coviro.2017.04.00128437703 317.EfferthT.RomeroM.R.WolfD.G.StammingerT.MarinJ.J.MarschallM.The antiviral activities of" exact="artemisinin" post="and artesunateClin. Infect. Dis.20084780481110.1086/59119518699744 318.HoW.E.PehH.Y.ChanT.K.WongW.S.Artemisinins: Pharmacological actions beyond anti-malarialPharmacol."/>
   <result pre="Dis.20084780481110.1086/59119518699744 318.HoW.E.PehH.Y.ChanT.K.WongW.S.Artemisinins: Pharmacological actions beyond anti-malarialPharmacol. Ther.201414212613910.1016/j.pharmthera.2013.12.00124316259 319.EfferthT.MarschallM.WangX.HuongS.M.HauberI.OlbrichA.KronschnablM.StammingerT.HuangE.S.Antiviral activity of" exact="artesunate" post="towards wild-type, recombinant, and ganciclovir-resistant human cytomegalovirusesJ. Mol. Med.20028023324210.1007/s00109-001-0300-811976732"/>
   <result pre="Med.20028023324210.1007/s00109-001-0300-811976732 320.Arav-BogerR.HeR.ChiouC.J.LiuJ.WoodardL.RosenthalA.Jones-BrandoL.FormanM.PosnerG.Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to" exact="artemisinin" post="monomersPLoS ONE20105e1037010.1371/journal.pone.001037020442781 321.ChouS.MarousekG.AuerochsS.StammingerT.MilbradtJ.MarschallM.The unique antiviral activity of artesunate is"/>
   <result pre="compared to artemisinin monomersPLoS ONE20105e1037010.1371/journal.pone.001037020442781 321.ChouS.MarousekG.AuerochsS.StammingerT.MilbradtJ.MarschallM.The unique antiviral activity of" exact="artesunate" post="is broadly effective against human cytomegaloviruses including therapy-resistant mutantsAntivir."/>
   <result pre="against human cytomegaloviruses including therapy-resistant mutantsAntivir. Res.20119236436810.1016/j.antiviral.2011.07.01821843554 322.SchnepfN.CorvoJ.PorsM.J.MazeronM.C.Antiviral activity of" exact="ganciclovir" post="and artesunate towards human cytomegalovirus in astrocytoma cellsAntivir. Res.20118918618810.1016/j.antiviral.2010.12.00221167209"/>
   <result pre="cytomegaloviruses including therapy-resistant mutantsAntivir. Res.20119236436810.1016/j.antiviral.2011.07.01821843554 322.SchnepfN.CorvoJ.PorsM.J.MazeronM.C.Antiviral activity of ganciclovir and" exact="artesunate" post="towards human cytomegalovirus in astrocytoma cellsAntivir. Res.20118918618810.1016/j.antiviral.2010.12.00221167209 323.MorereL.AndouardD.LabrousseF.SaadeF.CallisteC.A.CotinS.AubardY.RawlinsonW.D.EsclaireF.HantzS.et al.Ex"/>
   <result pre="antimalarial, antileukemia and antiviral activitiesBioorg. Med. Chem.2015235452545810.1016/j.bmc.2015.07.04826260339 325.ReiterC.FröhlichT.ZeinoM.MarschallM.BahsiH.LeidenbergerM.FriedrichO.KappesB.HampelF.EfferthT.et al.New efficient" exact="artemisinin" post="derived agents against human leukemia cells, human cytomegalovirus and"/>
   <result pre="1,2,4-trioxane-ferrocene hybridsEur. J. Med. Chem.20159716417210.1016/j.ejmech.2015.04.05325965779 326.HuttererC.NiemannI.MilbradtJ.FröhlichT.ReiterC.KadiogluO.BahsiH.ZeittragerI.WagnerS.EinsiedelJ.et al.The broad-spectrum antiinfective drug" exact="artesunate" post="interferes with the canonical nuclear factor kappa B (NF-κB)"/>
   <result pre="synergism with several antiviral agents against human cytomegalovirusAntivir. Ther.20162153553910.3851/IMP302826844400 328.Oiknine-DjianE.WeisblumY.PanetA.WongH.N.HaynesR.K.WolfD.G.The" exact="artemisinin" post="derivative artemisone is a potent inhibitor of human cytomegalovirus"/>
   <result pre="reactionsNat. Commun.201781507110.1038/ncomms1507128462939 335.FröhlichT.ReiterC.IbrahimM.M.BeutelJ.HuttererC.ZeittragerI.BahsiH.LeidenbergerM.FriedrichO.KappesB.et al.Synthesis of novel hybrids of quinazoline and" exact="artemisinin" post="with high activities against plasmodium falciparum, human cytomegalovirus, and"/>
   <result pre="mediated through cell cycle modulationAntimicrob. Agents Chemother.2015593870387910.1128/AAC.00262-1525870074 341.KapteinS.J.EfferthT.LeisM.RechterS.AuerochsS.KalmerM.BruggemanC.A.VinkC.StammingerT.MarschallM.The anti-malaria drug" exact="artesunate" post="inhibits replication of cytomegalovirus in vitro and in vivoAntivir."/>
   <result pre="transplantationClin. Infect. Dis.2008461455145710.1086/58710618419454 343.WolfD.G.ShimoniA.ResnickI.B.StammingerT.NeumannA.U.ChouS.EfferthT.CaplanO.RoseJ.NaglerA.et al.Human cytomegalovirus kinetics following institution of" exact="artesunate" post="after hematopoietic stem cell transplantationAntivir. Res.20119018318610.1016/j.antiviral.2011.03.18421443904 344.LauP.K.WoodsM.L.RatanjeeS.K.JohnG.T.Artesunate is ineffective"/>
   <result pre="valganciclovir-resistant cytomegalovirus infectionClin. Infect. Dis.20115227910.1093/cid/ciq05021288859 345.GermiR.MarietteC.AlainS.LupoJ.ThiebautA.BrionJ.P.EpaulardO.Saint RaymondC.MalvezziP.MorandP.Success and failure of" exact="artesunate" post="treatment in five transplant recipients with disease caused by"/>
   <result pre="given in italics. DGN, deguelin; NZT, nitazoxanide; TGN, thioguanosine; AXN," exact="alexidine" post="dihydrochloride; MND, manidipine dihydrochloride."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7019738\results\search\drugs\results.xml">
   <result pre="examination before they can be used in clinics [17]. Currently," exact="ganciclovir" post="is still the first treatment of choice for CMV"/>
   <result pre="[36]. However, it is not recommended to co-administer maribavir and" exact="ganciclovir" post="both in that maribavir is an inhibitor of the"/>
   <result pre="drugs because of its reduced haematotoxicity and nephrotoxicity compared with" exact="ganciclovir" post="and valganciclovir [36]. Maertens et al. used maribavir (dose-blinded)"/>
   <result pre="of its reduced haematotoxicity and nephrotoxicity compared with ganciclovir and" exact="valganciclovir" post="[36]. Maertens et al. used maribavir (dose-blinded) to treat"/>
   <result pre="least 400 mg twice daily had efficacy like that of" exact="valganciclovir" post="for removing CMV viremia. Though a higher incidence of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7019903\results\search\drugs\results.xml">
   <result pre="studies have shown that early treatments of HFRS patients with" exact="ribavirin" post="(RBV) improve prognosis. Nevertheless, there is the need for"/>
   <result pre="(1,78 log10) if compared to untreated control, the reference molecule" exact="ribavirin" post="needed to be added at 50 µM concentration. 4."/>
   <result pre="Vaccin.2011768569310.4161/hv.7.6.1519721508676 10.HugginsJ.W.HsiangC.M.CosgriT.M.GuangM.Y.SmithJ.I.WuZ.O.LeDucJ.W.ZhengZ.M.MeeganJ.M.WangQ.N.et al.Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous" exact="ribavirin" post="therapy of hemorrhagic fever with renal syndromeJ. Infect. Dis.19911641119112710.1093/infdis/164.6.11191683355"/>
   <result pre="renal syndromeJ. Infect. Dis.19911641119112710.1093/infdis/164.6.11191683355 11.MalininO.V.PlatonovA.E.Insufficient efficacy and safety of intravenous" exact="ribavirin" post="in treatment of haemorrhagic fever with renal syndrome caused"/>
   <result pre="fever with renal syndrome caused by puumala virusInfect. Dis.20174951452010.1080/23744235.2017.1293841 12.ChapmanL.E.MertzG.J.PetersC.J.Intravenous" exact="ribavirin" post="for hantavirus pulmonary syndrome: Safety and tolerance during 1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7022795\results\search\drugs\results.xml">
   <result pre="for ages in traditional Chinese medicine [8]. The sesquiterpene lactone" exact="artemisinin" post="(ART), the active principle, was discovered in the 1970s."/>
   <result pre="use of ART as an antiviral. ART, dihydroartemisinin (DHA) and" exact="artesunate" post="(AS) were compared for their anti-HCMV effect in a"/>
   <result pre="release in a culture medium. Moreover, synergism with the antiviral" exact="lamivudine" post="was demonstrated [17]. ART downregulated the oncogenic human papillomavirus"/>
   <result pre="even higher than that of classical antiviral drugs, such as" exact="ganciclovir" post="[16,25,28]. The antiviral effect was confirmed against different, multidrug-resistant"/>
   <result pre="AS was synergistic with antiviral drugs such as maribavir [27,32,33]," exact="lamivudine" post="[17], ganciclovir [34], foscarnet, cidofovir, letermovir [33]. However, in"/>
   <result pre="synergistic with antiviral drugs such as maribavir [27,32,33], lamivudine [17]," exact="ganciclovir" post="[34], foscarnet, cidofovir, letermovir [33]. However, in vitro data"/>
   <result pre="the other hand, a renal transplant recipient patient with documented" exact="valganciclovir" post="resistance mutations in HCMV was treated with AS, with"/>
   <result pre="and to prevent recrudescence. One of these combinations, AS plus" exact="amodiaquine" post="(AQ), was tested against HCMV in a clinical study"/>
   <result pre="based on transgenic viral strain. Compared to AS and/or ART," exact="artemether" post="was the most active. However, the activity was only"/>
   <result pre="effect of the aryl-aminoalcohol compounds quinine sulfate, mefloquine, halofantrine, and" exact="lumefantrine" post="on both classical and emerging viruses has been studied."/>
   <result pre="still playing a pivotal role, especially in the treatment of" exact="chloroquine" post="(CQ)-resistant Plasmodium falciparum [65,66]. Due to the benefit derived"/>
   <result pre="of the infection, with a claimed effect of MQ and" exact="mirtazapine" post="treatment [86,87,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105], and to the resolution of the infection"/>
   <result pre="difficult to determine [118,119]. MQ has also been combined with" exact="risperidone" post="[75] or risperidone and cytarabine [120], and the final"/>
   <result pre="[118,119]. MQ has also been combined with risperidone [75] or" exact="risperidone" post="and cytarabine [120], and the final outcomes were opposing,"/>
   <result pre="has also been combined with risperidone [75] or risperidone and" exact="cytarabine" post="[120], and the final outcomes were opposing, either death"/>
   <result pre="death of the patient [126]. The combined treatment MQ and" exact="mirtazapine" post="was administered to HIV-positive patients, leading to a failure"/>
   <result pre="of the three best combinations was composed of MQ with" exact="toremifene" post="(an antagonist of estrogen receptors) and the antifungal posaconazole,"/>
   <result pre="and MQ as antivirals, the same cannot be stated for" exact="halofantrine" post="and lumefantrine, which failed in the inhibition of viral"/>
   <result pre="of ~2500 compounds, were able to describe inhibition activity of" exact="halofantrine" post="on Semliki Forest virus (SFV) and DENV-2, but, due"/>
   <result pre="the treatment of different diseases. Currently, CQ and its hydroxy-analog" exact="hydroxychloroquine" post="(hydroxyCQ) cannot be used as antimalarial drugs in wide"/>
   <result pre="plasma level, although at a lower level than the antiviral" exact="zidovudine" post="[40]. In contrast, the results published in 2012 by"/>
   <result pre="infected by Newcastle disease virus [164]. It was demonstrated that" exact="primaquine" post="had an effect on the accumulation of viral hemagglutinin"/>
   <result pre="accumulation of viral hemagglutinin on the cell surface. In addition," exact="primaquine" post="inhibited protein synthesis in virus-infected cells [164]. 5. Other"/>
   <result pre="one published work reported the in vitro antiviral action of" exact="atovaquone" post="against CHIKV. Low micromolar doses inhibited the number of"/>
   <result pre="the same paper, Kottkamp and colleagues evaluated the ability of" exact="atovaquone" post="to reduce the infectivity of both a Brazilian and"/>
   <result pre="Ugandan strain [166]. 5.2. Antimicrobial Drugs Antibiotic drugs, such as" exact="doxycycline" post="and sulfonamides, are widely used in the chemoprophylaxis of"/>
   <result pre="been completely investigated. 5.2.1. Doxycycline Doxycycline (DOX) is a semisynthetic" exact="tetracycline" post="antibiotic that prevents bacterial protein synthesis by acting on"/>
   <result pre="agents with broad-spectrum bacteriostatic activity. Sulfonamides interrupt the synthesis of" exact="folic acid," post="interfering with the dihydropteroate synthase and dihydrofolate reductase enzymes"/>
   <result pre="Human cytomegalovirus HCV Hepatitis C virus HPV Human papillomavirus hydroxyCQ" exact="hydroxychloroquine" post="IL Interleukin INF Interferon KSHV Kaposi sarcoma herpesvirus MQ"/>
   <result pre="activity of artemisinin—From bench to bedsidePlanta Med.20077329930910.1055/s-2007-96713817354163 10.EfferthT.MarschallM.WangX.HuongS.M.HauberI.OlbrichA.KronschnablM.StammingerT.HuangE.S.Antiviral activity of" exact="artesunate" post="towards wild-type, recombinant, and ganciclovir-resistant human cytomegalovirusesJ. Mol. Med.20028023324210.1007/s00109-001-0300-811976732"/>
   <result pre="recombinant, and ganciclovir-resistant human cytomegalovirusesJ. Mol. Med.20028023324210.1007/s00109-001-0300-811976732 11.KapteinS.J.EfferthT.LeisM.RechterS.AuerochsS.KalmerM.BruggemanC.A.VinkC.StammingerT.MarschallM.The anti-malaria drug" exact="artesunate" post="inhibits replication of cytomegalovirus in vitro and in vivoAntivir."/>
   <result pre="transplantationClin. Infect. Dis.2008461455145710.1086/58710618419454 13.WolfD.G.ShimoniA.ResnickI.B.StammingerT.NeumannA.U.ChouS.EfferthT.CaplanO.RoseJ.NaglerA.et al.Human cytomegalovirus kinetics following institution of" exact="artesunate" post="after hematopoietic stem cell transplantationAntivir. Res.20119018318610.1016/j.antiviral.2011.03.18421443904 14.EfferthT.RomeroM.R.WolfD.G.StammingerT.MarinJ.J.MarschallM.The antiviral activities"/>
   <result pre="after hematopoietic stem cell transplantationAntivir. Res.20119018318610.1016/j.antiviral.2011.03.18421443904 14.EfferthT.RomeroM.R.WolfD.G.StammingerT.MarinJ.J.MarschallM.The antiviral activities of" exact="artemisinin" post="and artesunateClin. Infect. Dis.20084780481110.1086/59119518699744 15.EfferthT.Beyond malaria: The inhibition of"/>
   <result pre="compoundsBiotechnol. Adv.2018361730173710.1016/j.biotechadv.2018.01.00129305894 16.FlobinusA.TaudonN.DesbordesM.LabrosseB.SimonF.MazeronM.C.SchnepfN.Stability and antiviral activity against human cytomegalovirus of" exact="artemisinin" post="derivativesJ. Antimicrob. Chemother.201469344010.1093/jac/dkt34624003183 17.RomeroM.R.EfferthT.SerranoM.A.CastañoB.MaciasR.I.BrizO.MarinJ.J.Effect of artemisinin/artesunate as inhibitors of"/>
   <result pre="on HIV-1 replicationVirus Res.201015326927610.1016/j.virusres.2010.08.01820800626 24.ZengA.H.OuY.Y.GuoM.M.DaiX.ZhouD.Z.ChenR.Human embryonic lung fibroblasts treated with" exact="artesunate" post="exhibit reduced rates of proliferation and human cytomegalovirus infection"/>
   <result pre="human cytomegalovirus infection in vitroJ. Thorac. Dis.201571151115710.3978/j.issn.2072-1439.2015.07.0526380730 25.SchnepfN.CorvoJ.PorsM.J.MazeronM.C.Antiviral activity of" exact="ganciclovir" post="and artesunate towards human cytomegalovirus in astrocytoma cellsAntivir. Res.20118918618810.1016/j.antiviral.2010.12.00221167209"/>
   <result pre="infection in vitroJ. Thorac. Dis.201571151115710.3978/j.issn.2072-1439.2015.07.0526380730 25.SchnepfN.CorvoJ.PorsM.J.MazeronM.C.Antiviral activity of ganciclovir and" exact="artesunate" post="towards human cytomegalovirus in astrocytoma cellsAntivir. Res.20118918618810.1016/j.antiviral.2010.12.00221167209 26.HeR.FormanM.MottB.T.VenkatadriR.PosnerG.H.Arav-BogerR.Unique and"/>
   <result pre="diphenyl phosphate moietyAntimicrob. Agents Chemother.2013574208421410.1128/AAC.00893-1323774439 27.ChouS.MarousekG.AuerochsS.StammingerT.MilbradtJ.MarschallM.The unique antiviral activity of" exact="artesunate" post="is broadly effective against human cytomegaloviruses including therapy-resistant mutantsAntivir."/>
   <result pre="against human cytomegaloviruses including therapy-resistant mutantsAntivir. Res.20119236436810.1016/j.antiviral.2011.07.01821843554 28.ReiterC.FröhlichT.ZeinoM.MarschallM.BahsiH.LeidenbergerM.FriedrichO.KappesB.HampelF.EfferthT.et al.New efficient" exact="artemisinin" post="derived agents against human leukemia cells, human cytomegalovirus and"/>
   <result pre="1,2,4-trioxane-ferrocene hybridsEur. J. Med. Chem.20159716417210.1016/j.ejmech.2015.04.05325965779 29.HuttererC.NiemannI.MilbradtJ.FröhlichT.ReiterC.KadiogluO.BahsiH.ZeitträgerI.WagnerS.EinsiedelJ.et al.The broad-spectrum antiinfective drug" exact="artesunate" post="interferes with the canonical nuclear factor kappa B (NF-κB)"/>
   <result pre="insights into mechanisms of ActionAntimicrob. Agents Chemother.20145898699410.1128/AAC.01972-1324277030 35.CanivetC.MenasriaR.RhéaumeC.PiretJ.BoivinG.Valacyclovir combined with" exact="artesunate" post="or rapamycin improves the outcome of herpes simplex virus"/>
   <result pre="Inst. Oswaldo. Cruz.201310859659910.1590/S0074-0276201300050001023903975 37.De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On chikungunya acute infection and" exact="chloroquine" post="treatmentVector Borne Zoonotic Dis.2008883783910.1089/vbz.2008.004918620511 38.PatonN.I.LeeL.XuY.OoiE.E.CheungY.B.ArchuletaS.WongG.Wilder-SmithA.SmithA.W.Chloroquine for influenza prevention: A"/>
   <result pre="patients with human immunodeficiency virus type 1Clin. Ther.19951762263610.1016/0149-2918(95)80039-58565026 40.SperberK.ChiangG.ChenH.RossW.ChusidE.GoncharM.ChowR.LirianoO.Comparison of" exact="hydroxychloroquine" post="with zidovudine in asymptomatic patients infected with human immunodeficiency"/>
   <result pre="human immunodeficiency virus type 1Clin. Ther.19951762263610.1016/0149-2918(95)80039-58565026 40.SperberK.ChiangG.ChenH.RossW.ChusidE.GoncharM.ChowR.LirianoO.Comparison of hydroxychloroquine with" exact="zidovudine" post="in asymptomatic patients infected with human immunodeficiency virus type"/>
   <result pre="with human immunodeficiency virus type 1Clin. Ther.19971991392310.1016/S0149-2918(97)80045-89385480 41.PatonN.I.GoodallR.L.DunnD.T.FranzenS.Collaco-MoraesY.GazzardB.G.WilliamsI.G.FisherM.J.WinstonA.FoxJ.et al.Effects of" exact="hydroxychloroquine" post="on immune activation and disease progression among HIV-infected patients"/>
   <result pre="with HIV-1AIDS Res. Hum. Retrovir.20163263664710.1089/aid.2015.033626935044 43.MurrayS.M.DownC.M.BoulwareD.R.StaufferW.M.CavertW.P.SchackerT.W.BrenchleyJ.M.DouekD.C.Reduction of immune activation with" exact="chloroquine" post="therapy during chronic HIV infectionJ. Virol.201084120821208610.1128/JVI.01466-1020844049 44.RoutyJ.P.AngelJ.B.PatelM.KanagarathamC.RadziochD.KemaI.GilmoreN.AncutaP.SingerJ.JenabianM.A.Assessment of chloroquine"/>
   <result pre="with chloroquine therapy during chronic HIV infectionJ. Virol.201084120821208610.1128/JVI.01466-1020844049 44.RoutyJ.P.AngelJ.B.PatelM.KanagarathamC.RadziochD.KemaI.GilmoreN.AncutaP.SingerJ.JenabianM.A.Assessment of" exact="chloroquine" post="as a modulator of immune activation to improve CD4"/>
   <result pre="A randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly" exact="chloroquine" post="among adults on antiretroviral therapy in Malawi: Study protocol"/>
   <result pre="multidrug-resistant cytomegalovirus diseaseTranspl. Infect. Dis.20151775175510.1111/tid.1243526432076 48.GermiR.MarietteC.AlainS.LupoJ.ThiebautA.BrionJ.P.EpaulardO.Saint RaymondC.MalvezziP.MorandP.Success and failure of" exact="artesunate" post="treatment in five transplant recipients with disease caused by"/>
   <result pre="compounds in HHV-6-infected lymphoblastsJ. Clin. Virol.200637Suppl. S1S69S7510.1016/S1386-6532(06)70015-417276373 54.SharmaB.N.MarschallM.RinaldoC.H.Antiviral effects of" exact="artesunate" post="on JC polyomavirus replication in COS-7 cellsAntimicrob. Agents Chemother.2014586724673410.1128/AAC.03714-1425155602"/>
   <result pre="polyomavirus replication in COS-7 cellsAntimicrob. Agents Chemother.2014586724673410.1128/AAC.03714-1425155602 55.SharmaB.N.MarschallM.HenriksenS.RinaldoC.H.Antiviral effects of" exact="artesunate" post="on polyomavirus BK replication in primary human kidney cellsAntimicrob."/>
   <result pre="Dis.20196ofz25010.1093/ofid/ofz25031281856 61.Arav-BogerR.HeR.ChiouC.J.LiuJ.WoodardL.RosenthalA.Jones-BrandoL.FormanM.PosnerG.Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to" exact="artemisinin" post="monomersPLoS ONE20105e1037010.1371/journal.pone.001037020442781 62.MottB.T.HeR.ChenX.FoxJ.M.CivinC.I.Arav-BogerR.PosnerG.H.Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus"/>
   <result pre="anti-cancer agents: A structure-activity studyBioorg. Med. Chem.2013213702370710.1016/j.bmc.2013.04.02723673218 63.BlazquezA.G.Fernandez-DolonM.Sanchez-VicenteL.MaestreA.D.Gomez-San MiguelA.B.AlvarezM.SerranoM.A.JansenH.EfferthT.MarinJ.J.et al.Novel" exact="artemisinin" post="derivatives with potential usefulness against liver/colon cancer and viral"/>
   <result pre="targeting broad host cell pathwaysPLoS ONE20149e11063110.1371/journal.pone.011063125333287 71.BrickelmaierM.LugovskoyA.KartikeyanR.Reviriego-MendozaM.M.AllaireN.SimonK.FrisqueR.J.GorelikL.Identification and characterization of" exact="mefloquine" post="efficacy against JC virus in vitroAntimicrob. Agents Chemother.2009531840184910.1128/AAC.01614-0819258267 72.KishidaS.TanakaK.Mefloquine"/>
   <result pre="a patient with systemic lupus erythematosusIntern. Med.2012511245124710.2169/internalmedicine.51.681022687798 75.KobayashiZ.AkazaM.NumasawaY.IshiharaS.TomimitsuH.NakamichiK.SaijoM.MorioT.ShimizuN.SanjoN.et al.Failure of" exact="mefloquine" post="therapy in progressive multifocal leukoencephalopathy: Report of two Japanese"/>
   <result pre="leukoencephalopathy derived from non-Hodgkin lymphoma: Neuropathological findings and results of" exact="mefloquine" post="treatmentIntern. Med.20155496597010.2169/internalmedicine.54.230825876582 81.GarroteH.de la FuenteA.OñaR.RodríguezI.EchevarríaJ.E.SepúlvedaJ.M.GarcíaJ.F.Long-term survival in a patient"/>
   <result pre="a patient with progressive multifocal leukoencephalopathy after therapy with rituximab," exact="fludarabine" post="and cyclophosphamide for chronic lymphocytic leukemiaExp. Hematol. Oncol.20154810.1186/s40164-015-0003-425767742 82.YoshidaT.KawamotoM.TogoM.KoharaN.ItoT.NakamichiK.SaijoM.MizunoT.Progressive"/>
   <result pre="with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and" exact="cyclophosphamide" post="for chronic lymphocytic leukemiaExp. Hematol. Oncol.20154810.1186/s40164-015-0003-425767742 82.YoshidaT.KawamotoM.TogoM.KoharaN.ItoT.NakamichiK.SaijoM.MizunoT.Progressive multifocal leukoencephalopathy"/>
   <result pre="of imaging findings: A case reportJ. Neurol. Sci.20153591310.1016/j.jns.2015.10.02826671076 83.HirayamaM.NosakiY.MatsuiK.TeraoS.KuwayamaM.TateyamaH.YoshidaM.HashizumeY.Efficacy of" exact="mefloquine" post="to progressive multifocal leukoencephalopathy initially presented with parkinsonismClin. Neurol."/>
   <result pre="the outcome after natalizumab-associated progressive multifocal leukoencephalopathyFront. Neurol.201341110.3389/fneur.2013.0001123423248 94.EpperlaN.Medina-FloresR.MazzaJ.J.YaleS.H.Mirtazapine and" exact="mefloquine" post="therapy for non-AIDS-related progressive multifocal leukoencephalopathyWMJ201411324224525745699 95.KurmannR.WeisstannerC.KardasP.HirschH.H.WiestR.LämmleB.FurrerH.Du PasquierR.BassettiC.L.SturzeneggerM.et al.Progressive"/>
   <result pre="al.Progressive multifocal leukoencephalopathy in common variable immunodeficiency: Mitigated course under" exact="mirtazapine" post="and mefloquineJ. Neurovirol.20152169470110.1007/s13365-015-0340-425916731 96.BalakD.M.W.HajdarbegovicE.BramerW.M.NeumannH.A.M.ThioH.B.Progressive multifocal leukoencephalopathy associated with fumaric"/>
   <result pre="Eur. Acad. Dermatol. Venereol.2017311475148210.1111/jdv.1423628322482 97.YoshidaH.OhshimaK.TodaJ.KusakabeS.MasaieH.YagiT.IshikawaJ.Significant improvement following combination treatment with" exact="mefloquine" post="and mirtazapine in a patient with progressive multifocal leukoencephalopathy"/>
   <result pre="Dermatol. Venereol.2017311475148210.1111/jdv.1423628322482 97.YoshidaH.OhshimaK.TodaJ.KusakabeS.MasaieH.YagiT.IshikawaJ.Significant improvement following combination treatment with mefloquine and" exact="mirtazapine" post="in a patient with progressive multifocal leukoencephalopathy after allogeneic"/>
   <result pre="intravenous immunoglobulin in a patient with multiple sclerosis treated with" exact="fingolimod" post="after discontinuation of natalizumabJ. Clin. Neurosci.20152259860010.1016/j.jocn.2014.08.01625523125 99.SilverioK.A.PatelS.A.Progressive Multifocal Leukoencephalopathy"/>
   <result pre="Cancer TherapyCase Rep. Oncol. Med.2015201553452910.1155/2015/53452926788389 100.Fabis-PedriniM.J.XuW.BurtonJ.CarrollW.M.KermodeA.G.Asymptomatic progressive multifocal leukoencephalopathy during" exact="natalizumab" post="therapy with treatmentJ. Clin. Neurosci.20162514514710.1016/j.jocn.2015.08.02726541323 101.IkedaJ.MatsushimaA.IshiiW.GotoT.TakahashiK.NakamichiK.SaijoM.SekijimaY.IkedaS.I.Brain Biopsy Is More"/>
   <result pre="a 44-year old male with idiopathic CD4+ T-lymphocytopenia treated with" exact="mirtazapine" post="and mefloquineNeurol. India2017651061106410.4103/neuroindia.NI_535_1628879898 103.IshikawaY.KasuyaT.IshikawaJ.FujiwaraM.KitaY.A case of developing progressive multifocal"/>
   <result pre="India2017651061106410.4103/neuroindia.NI_535_1628879898 103.IshikawaY.KasuyaT.IshikawaJ.FujiwaraM.KitaY.A case of developing progressive multifocal leukoencephalopathy while using" exact="rituximab" post="and mycophenolate mofetil in refractory systemic lupus erythematosusTher. Clin."/>
   <result pre="107.HarelA.HorngS.GustafsonT.RamineniA.FarberR.S.FabianM.Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and" exact="maraviroc" post="in a patient with idiopathic CD4 lymphocytopeniaJ. Neurovirol.20182465265510.1007/s13365-018-0657-x29987583 108.ZhangY.WrightC.FloresA.Asymptomatic"/>
   <result pre="al.Progressive multifocal leukoencephalopathy after T-cell replete HLA-haploidentical transplantation with post-transplantation" exact="cyclophosphamide" post="graft-versus-host disease prophylaxisTranspl. Infect. Dis.201820e1285010.1111/tid.1285029359846 114.LutzM.SchulzeA.B.RebberE.WiebeS.ZoubiT.GrauerO.M.KeßlerT.KerkhoffA.LenzG.BerdelW.E.Progressive Multifocal Leukoencephalopathy after"/>
   <result pre="Response to Mefloquine TreatmentIntern. Med.2016551631163510.2169/internalmedicine.55.605127301518 121.HervásJ.V.Presas-RodríguezS.Crespo-CuevasA.M.CanentoT.Lozano-SánchezM.Massuet-VilamajóA.Ramo-TelloC.Progressive multifocal leukoencephalopathy associated to" exact="natalizumab" post="extended dosing regimenNeurodegener. Dis. Manag.2015539940210.2217/nmt.15.4226517599 122.MikitaK.MaedaT.FujikuraY.KozakiY.HaraY.KanohS.KishidaS.SaijoM.NakamichiK.KawanaA.Does anti-JCV therapy improve"/>
   <result pre="Inflammatory Syndrome (PML-IRIS): Two case reports of successful treatment with" exact="mefloquine" post="and a review of the literatureAnn. Acad. Med. Singap.20124162062423303123"/>
   <result pre="Acad. Med. Singap.20124162062423303123 124.AdachiE.KoibuchiT.ImaiK.KikuchiT.KogaM.NakamuraH.MiuraT.IwamotoA.FujiiT.Favourable outcome of progressive multifocal leukoencephalopathy with" exact="mefloquine" post="treatment in combination with antiretroviral therapy in an HIV-infected"/>
   <result pre="virus and JC virus infectionJ. Clin. Exp. Hematop.20145421121710.3960/jslrt.54.21125501112 127.MoensterR.P.JettR.A.Mirtazapine and" exact="mefloquine" post="therapy for progressive multifocal leukoencephalopathy in a patient infected"/>
   <result pre="control region rearrangements and host immunityJ. Neurovirol.20131927427910.1007/s13365-013-0167-923715894 129.CliffordD.B.NathA.CinqueP.BrewB.J.ZivadinovR.GorelikL.ZhaoZ.DudaP.A study of" exact="mefloquine" post="treatment for progressive multifocal leukoencephalopathy: Results and exploration of"/>
   <result pre="Res.201713716517210.1016/j.antiviral.2016.11.01727890675 133.NevinR.L.A serious nightmare: Psychiatric and neurologic adverse reactions to" exact="mefloquine" post="are serious adverse reactionsPharmacol. Res. Perspect.2017510.1002/prp2.32828805982 134.MazzonM.Ortega-PrietoA.M.ImrieD.LuftC.HessL.CziesoS.GroveJ.SkeltonJ.K.FarleighL.BugertJ.J.et al.Identification of"/>
   <result pre="manifestations from malaria to multifarious diseasesJ. Antimicrob. Chemother.2015701608162110.1093/jac/dkv01825693996 136.ShimizuY.YamamotoS.HommaM.IshidaN.Effect of" exact="chloroquine" post="on the growth of animal virusesArch. Gesamte Virusforsch.1972369310410.1007/BF012502994335025 137.InglotA.D.Comparison"/>
   <result pre="138.KhanM.SanthoshS.R.TiwariM.Lakshmana RaoP.V.ParidaM.Assessment of in vitro prophylactic and therapeutic efficacy of" exact="chloroquine" post="against Chikungunya virus in vero cellsJ. Med. Virol.20108281782410.1002/jmv.2166320336760 139.SourisseauM.SchilteC.CasartelliN.TrouilletC.Guivel-BenhassineF.RudnickaD.Sol-FoulonN.Le"/>
   <result pre="RouxK.PrevostM.C.FsihiH.et al.Characterization of reemerging chikungunya virusPLoS Pathog.20073e8910.1371/journal.ppat.003008917604450 140.HanY.MesplèdeT.XuH.QuanY.WainbergM.A.The antimalarial drug" exact="amodiaquine" post="possesses anti-ZIKA virus activitiesJ. Med. Virol.20189079680210.1002/jmv.2503129315671 141.DelvecchioR.HigaL.M.PezzutoP.ValadãoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an"/>
   <result pre="SARS coronavirus infection and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 146.KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob. Agents"/>
   <result pre="endocytosisJ. Virol.2006806964697210.1128/JVI.00024-0616809302 149.MizuiT.YamashinaS.TanidaI.TakeiY.UenoT.SakamotoN.IkejimaK.KitamuraT.EnomotoN.SakaiT.et al.Inhibition of hepatitis C virus replication by" exact="chloroquine" post="targeting virus-associated autophagyJ. Gastroenterol.20104519520310.1007/s00535-009-0132-919760134 150.Al-BariM.A.A.Targeting endosomal acidification by chloroquine"/>
   <result pre="by chloroquine targeting virus-associated autophagyJ. Gastroenterol.20104519520310.1007/s00535-009-0132-919760134 150.Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="Retrovir.1990648148910.1089/aid.1990.6.4811692728 152.SperberK.KalbT.H.StecherV.J.BanerjeeR.MayerL.Inhibition of human immunodeficiency virus type 1 replication by" exact="hydroxychloroquine" post="in T cells and monocytesAIDS Res. Hum. Retrovir.19939919810.1089/aid.1993.9.918427717 153.ChiangG.SassaroliM.LouieM.ChenH.StecherV.J.SperberK.Inhibition"/>
   <result pre="anti-HIV-1 activity of chloroquineJ. Clin. Virol.20012013113510.1016/S1386-6532(00)00139-611166661 155.BoelaertJ.R.PietteJ.SperberK.The potential place of" exact="chloroquine" post="in the treatment of HIV-1-infected patientsJ. Clin. Virol.20012013714010.1016/S1386-6532(00)00140-211166662 156.SavarinoA.LuciaM.B.RastrelliE.RutellaS.GolottaC.MorraE.TamburriniE.PernoC.F.BoelaertJ.R.SperberK.et"/>
   <result pre="synergism with protease inhibitorsJ. Acquir. Immune. Defic. Syndr.20043522323210.1097/00126334-200403010-0000215076236 157.NaardingM.A.BaanE.PollakisG.PaxtonW.A.Effect of" exact="chloroquine" post="on reducing HIV-1 replication in vitro and the DC-SIGN"/>
   <result pre="NucleotidesJ. Virol.20199310.1128/JVI.00389-1930894466 167.CastelliF.OdoliniS.AutinoB.FocaE.RussoR.Malaria Prophylaxis: A Comprehensive ReviewPharmaceuticals201033212323910.3390/ph3103212 168.RothanH.A.MohamedZ.PaydarM.RahmanN.A.YusofR.Inhibitory effect of" exact="doxycycline" post="against dengue virus replication in vitroArch. Virol.201415971171810.1007/s00705-013-1880-724142271 169.RothanH.A.BahraniH.MohamedZ.TeohT.C.ShankarE.M.RahmanN.A.YusofR.A combination"/>
   <result pre="against dengue virus replication in vitroArch. Virol.201415971171810.1007/s00705-013-1880-724142271 169.RothanH.A.BahraniH.MohamedZ.TeohT.C.ShankarE.M.RahmanN.A.YusofR.A combination of" exact="doxycycline" post="and ribavirin alleviated chikungunya infectionPLoS ONE201510e012636010.1371/journal.pone.012636025970853 170.WuZ.C.WangX.WeiJ.C.LiB.B.ShaoD.H.LiY.M.LiuK.ShiY.Y.ZhouB.QiuY.F.et al.Antiviral activity"/>
   <result pre="virus replication in vitroArch. Virol.201415971171810.1007/s00705-013-1880-724142271 169.RothanH.A.BahraniH.MohamedZ.TeohT.C.ShankarE.M.RahmanN.A.YusofR.A combination of doxycycline and" exact="ribavirin" post="alleviated chikungunya infectionPLoS ONE201510e012636010.1371/journal.pone.012636025970853 170.WuZ.C.WangX.WeiJ.C.LiB.B.ShaoD.H.LiY.M.LiuK.ShiY.Y.ZhouB.QiuY.F.et al.Antiviral activity of doxycycline"/>
   <result pre="and ribavirin alleviated chikungunya infectionPLoS ONE201510e012636010.1371/journal.pone.012636025970853 170.WuZ.C.WangX.WeiJ.C.LiB.B.ShaoD.H.LiY.M.LiuK.ShiY.Y.ZhouB.QiuY.F.et al.Antiviral activity of" exact="doxycycline" post="against vesicular stomatitis virus in vitroFEMS Microbiol. Lett.201536210.1093/femsle/fnv195 171.NgH.H.NarasarajuT.PhoonM.C.SimM.K.SeetJ.E.ChowV.T.Doxycycline"/>
   <result pre="metalloproteinasesExp. Mol. Pathol.20129228729510.1016/j.yexmp.2012.03.00322421441 172.ZhuJ.LiuS.LiuZ.LiY.TianJ.HuX.A highly sensitive and selective assay of" exact="doxycycline" post="by dualwavelength overlapping resonance Rayleigh scatteringSpectrochim. Acta A Mol."/>
   <result pre="liver transplantationTranspl. Infect. Dis.20121432632910.1111/j.1399-3062.2011.00709.x22260451 174.WalterM.S.FrankM.J.SatuéM.MonjoM.RønoldH.J.LyngstadaasS.P.HaugenH.J.Bioactive implant surface with electrochemically bound" exact="doxycycline" post="promotes bone formation markers in vitro and in vivoDent."/>
   <result pre="on 15 December 2019) 176.BriolantS.WurtzN.ZettorA.RogierC.PradinesB.Susceptibility of Plasmodium falciparum isolates to" exact="doxycycline" post="is associated with pftetQ sequence polymorphisms and pftetQ and"/>
   <result pre="cell linesCan. J. Physiol. Pharmacol.20169452653310.1139/cjpp-2015-048126913972 178.YangJ.M.ChenY.F.TuY.Y.YenK.R.YangY.L.Combinatorial computational approaches to identify" exact="tetracycline" post="derivatives as flavivirus inhibitorsPLoS ONE20072e42810.1371/journal.pone.000042817502914 179.BhattacharjeeM.K.Antimetabolites: Antibiotics That Inhibit"/>
   <result pre="for the evaluation of antiviral agentsAntivir. Res.20036011510.1016/S0166-3542(03)00174-814516916 188.RomeroM.R.SerranoM.A.VallejoM.EfferthT.AlvarezM.MarinJ.J.Antiviral effect of" exact="artemisinin" post="from Artemisia annua against a model member of the"/>
   <result pre="Mefloquine No PML progression [72,73,74,77,78,79,81,82,83,84,86,87] Fatal outcome [75,76,80,85,88] Mefloquine +" exact="mirtazapine" post="PML resolution with claimed effects [86,87,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105] PML resolution due"/>
   <result pre="[87,96,110,111,112,113,114,115,116] Therapy suspension due to side effects [117] Mefloquine +" exact="mirtazapine" post="+ third partner drug PML resolution [118] Fatal outcome"/>
   <result pre="partner drug PML resolution [118] Fatal outcome [119] Mefloquine +" exact="risperidone" post="Fatal outcome [75] Mefloquine + risperidone + cytarabine PML"/>
   <result pre="outcome [119] Mefloquine + risperidone Fatal outcome [75] Mefloquine +" exact="risperidone" post="+ cytarabine PML resolution [120] Mefloquine + cidofovir PML"/>
   <result pre="Mefloquine + risperidone Fatal outcome [75] Mefloquine + risperidone +" exact="cytarabine" post="PML resolution [120] Mefloquine + cidofovir PML resolution due"/>
   <result pre="Mefloquine + risperidone + cytarabine PML resolution [120] Mefloquine +" exact="cidofovir" post="PML resolution due to other factors [121] HIV positive"/>
   <result pre="Mefloquine No PML progression [122,123,124,125] Fatal outcome [126] Mefloquine +" exact="mirtazapine" post="Premature fatal outcome [127,128] Clinical Trial HIV negative versus"/>
   <result pre="HIV positive patients Standard of care (SOC) versus SOC +" exact="mefloquine" post="Lack of differences: study ended prematurely [129] microorganisms-08-00085-t003_Table 3Table"/>
   <result pre="in vitro [54] Mefloquine in vitro [71] Hepadnaviridae HBV Artemisinin," exact="artesunate" post="in vitro [17] Papillomaviridae HPV Artemisinin in vitro [18]"/>
   <result pre="Filoviridae EBOV Chloroquine in vitro [142,143] in vivo [142] Artesunate," exact="amodiaquine" post="in vivo [58] Mefloquine in vitro [132] Retroviridae HIV"/>
   <result pre="Artemisinin in vitro [23] Doxycycline in vitro [23] Mefloquine, toremifene," exact="posaconazole" post="in vitro [132] Chloroquine in vitro [151,157,158] in vivo"/>
   <result pre="vitro [132] Chloroquine in vitro [151,157,158] in vivo [155] Chloroquine," exact="hydroxychloroquine" post="in vitro [152,153,154,156] Phenuiviridae SFTSV Amodiaquine In vitro [163]"/>
   <result pre="Artesunate [52] Polyomaviridae JCPyV Artesunate [54,55] Mefloquine [72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,122,123,124,125,126] Mefloquine and" exact="mirtazapine" post="[86,87,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,127,128] Mefloquine, mirtazapine and a third drug [118,119] Mefloquine"/>
   <result pre="JCPyV Artesunate [54,55] Mefloquine [72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,122,123,124,125,126] Mefloquine and mirtazapine [86,87,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,127,128] Mefloquine," exact="mirtazapine" post="and a third drug [118,119] Mefloquine and risperidone [75]"/>
   <result pre="[86,87,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,127,128] Mefloquine, mirtazapine and a third drug [118,119] Mefloquine and" exact="risperidone" post="[75] Mefloquine, risperidone and cytarabine [120] Mefloquine and cidofovir"/>
   <result pre="and a third drug [118,119] Mefloquine and risperidone [75] Mefloquine," exact="risperidone" post="and cytarabine [120] Mefloquine and cidofovir [121] Mefloquine and"/>
   <result pre="third drug [118,119] Mefloquine and risperidone [75] Mefloquine, risperidone and" exact="cytarabine" post="[120] Mefloquine and cidofovir [121] Mefloquine and PML standard"/>
   <result pre="and risperidone [75] Mefloquine, risperidone and cytarabine [120] Mefloquine and" exact="cidofovir" post="[121] Mefloquine and PML standard of care [129] Filoviridae"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7025587\results\search\drugs\results.xml">
   <result pre="and SCD patients due to the hemolytic anemia induced by" exact="ribavirin" post="causing an increase in the number of blood transfusions."/>
   <result pre="therapy available for HCV treatment was pegylated-interferon (PEG-IFN) alpha, plus" exact="ribavirin" post="(RBV) with an administration of about 24 weeks (genotypes"/>
   <result pre="SCD patients and the use has been severely reduced because" exact="ribavirin" post="(RBV) proved to cause hemolytic anemia and to increase"/>
   <result pre="consisted of the combination with PEG-INF plus RBV. In 2013," exact="simeprevir" post="and sofosbuvir were introduced. These two drugs were proposed"/>
   <result pre="the combination with PEG-INF plus RBV. In 2013, simeprevir and" exact="sofosbuvir" post="were introduced. These two drugs were proposed to treat"/>
   <result pre="of the iron overload an iron chelation therapy was administered:" exact="deferoxamine" post="(DFO) in 29% of patients, deferiprone (DFP) in 13%"/>
   <result pre="chelation therapy was administered: deferoxamine (DFO) in 29% of patients," exact="deferiprone" post="(DFP) in 13% of patients, deferasirox (DFX) in 25%"/>
   <result pre="in 29% of patients, deferiprone (DFP) in 13% of patients," exact="deferasirox" post="(DFX) in 25% of patients, DFO + DFP in"/>
   <result pre="conflict of interest. References References AfdhalN.ZeuzemS.KwoP.ChojkierM.GitlinN.PuotiM.et al.. (2014). Ledipasvir and" exact="sofosbuvir" post="for untreated HCV genotype 1 infection. N. Engl. J."/>
   <result pre="AminizadehE.AlavianmS. M.Akbari SarmA.Ebrahimi DaryaniN.BehnavaB. (2016). Safety and efficacy of adding" exact="ribavirin" post="to interferon or peginterferon in treatment of hepatitis C"/>
   <result pre="Di MarcoV.D'AmbrosioR.BronteaF.SaraccoG.LanzaA. G.Forniet al.. (2016). Dual therapy with peg-interferon and" exact="ribavirin" post="in thalassemia major patients with chronic HCV infection: is"/>
   <result pre="al.. (2008). Safety and efficacy of pegylated interferon alpha-2a and" exact="ribavirin" post="for the treatment of hepatitis C in patients with"/>
   <result pre="(2005). Efficacy and tolerability of peginterferon alpha-2a with or without" exact="ribavirin" post="in thalassaemia major patients with chronic hepathitis C virus"/>
   <result pre="79–85.e2. 10.1016/j.jpeds.2017.06.03528735981 LiC. K.ChanP. K.LingS. C.HaS. Y. (2002). Interferon and" exact="ribavirin" post="as frontline treatment for chronic hepatitis C infection in"/>
   <result pre="Talanta174, 673–678. 10.1016/j.talanta.2017.06.04428738640 MehtaR.KabrawalaM.NandwaniS.DesaiP.BhayaniV.Patelet al.. (2018). Safety and efficacy of" exact="sofosbuvir" post="and daclatasvir for hepatitis C virus infection in patients"/>
   <result pre="10.1016/j.talanta.2017.06.04428738640 MehtaR.KabrawalaM.NandwaniS.DesaiP.BhayaniV.Patelet al.. (2018). Safety and efficacy of sofosbuvir and" exact="daclatasvir" post="for hepatitis C virus infection in patients with β-thalassemia"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7026011\results\search\drugs\results.xml">
   <result pre="at the intestinal level (54%) (Soul-Lawton et al., 1995). Later," exact="penciclovir" post="was developed with the aim of being phosphorylated more"/>
   <result pre="of 0.7 h for HSV-1 and 1 h for HSV-2," exact="penciclovir" post="has a half-life of 10 h for HSV-1 and"/>
   <result pre="and Flaherty, 1996). Famciclovir is a prodrug that derives into" exact="penciclovir" post="and has increased oral bioavailability (Hodge et al., 1989)."/>
   <result pre="well as VZV and cytomegalovirus (Ormrod et al., 2000). Furthermore," exact="famciclovir" post="is approved for treating herpes viruses, such as HSV-1"/>
   <result pre="VZV (Simpson and Lyseng-Williamson, 2006). Resistance to valacyclovir, penciclovir, and" exact="famciclovir" post="can occur. Furthermore, there is cross-resistance between valacyclovir- and"/>
   <result pre="et al., 2003). On the other hand, cross resistance to" exact="penciclovir" post="and the prodrug famciclovir may arise in acyclovir-resistant HSV-1"/>
   <result pre="the other hand, cross resistance to penciclovir and the prodrug" exact="famciclovir" post="may arise in acyclovir-resistant HSV-1 isolates in immunocompromised patients"/>
   <result pre="1993). Some studies have reported HSV-1 and HSV-2 resistance to" exact="penciclovir" post="in cell cultures and in immunocompromised patients related to"/>
   <result pre="patients (Buhles et al., 1988; Poole and James, 2018). However," exact="ganciclovir" post="has also been reported to have antiviral activity against"/>
   <result pre="of herpes simplex virus epithelial keratitis (ClinicalTrials.gov NCT03217474). Of note," exact="ganciclovir" post="has been reported to produce considerable adverse side effects"/>
   <result pre="last decades as second-line drugs that are commercially available are" exact="cidofovir" post="(an acyclic nucleotide analog) (Ashley et al., 1988; Blot"/>
   <result pre="of viral DNA than acyclovir (Ho et al., 1991). Importantly," exact="cidofovir" post="has a phosphonate group that does not require an"/>
   <result pre="study was carried out to evaluate the effectivity of topical" exact="cidofovir" post="for refractory mucocutaneous HSV-1 and HSV-2 in AIDS; However,"/>
   <result pre="In one case, three patients with bone marrow transplants received" exact="cidofovir" post="as a therapy, but nevertheless showed HSV-related diseases symptoms."/>
   <result pre="of the viral DNA polymerase (Wyles et al., 2005). Notably," exact="cidofovir" post="resistance has also been reported in children, particularly in"/>
   <result pre="cell transplants that received, in a prophylactic manner acyclovir and" exact="cidofovir" post="together, because ganciclovir produced adverse effects. Unfortunately, these children"/>
   <result pre="received, in a prophylactic manner acyclovir and cidofovir together, because" exact="ganciclovir" post="produced adverse effects. Unfortunately, these children showed HSV-related stomatitis"/>
   <result pre="produced adverse effects. Unfortunately, these children showed HSV-related stomatitis during" exact="cidofovir" post="treatment and the authors suggested that the treatment with"/>
   <result pre="cidofovir treatment and the authors suggested that the treatment with" exact="cidofovir" post="did not prevent HSV-1 reactivation in the patients (Dvorak"/>
   <result pre="HSV-1 reactivation in the patients (Dvorak et al., 2009). Nevertheless," exact="cidofovir" post="is considered a good option when encountering HSV isolates"/>
   <result pre="and foscarnet (in vitro), in which case the treatment with" exact="cidofovir" post="was effective against this drug-resistant HSV-1. Another study reporting"/>
   <result pre="foscarnet in a girl with lymphatic leukemia indicated that only" exact="cidofovir" post="treatment was successful at helping avoid recurrent oral stomatitis"/>
   <result pre="One of these alternatives is a combination of acyclovir and" exact="hydrocortisone" post="for topical use (Xerese®, Medivir). This formulation reduces the"/>
   <result pre="new drug to treat skin lesions caused by HSV-1 is" exact="docosanol" post="10% formulated as a topical cream (Abreva®, Avanir), which"/>
   <result pre="been used in both, the cosmetic and food industries. Currently," exact="docosanol" post="10% cream is approved for the treatment of HSV-1"/>
   <result pre="and Xerese® (Woo and Challacombe, 2007). One study indicates that" exact="docosanol" post="10% cream reduces the healing time of oral lesions"/>
   <result pre="h (Sacks et al., 2001). The mechanism of action of" exact="docosanol" post="would be mediated by the inhibition of the fusion"/>
   <result pre="to HSV-2 infection is Viroxyn® (Quadex Pharmaceuticals), which consists of" exact="benzalkonium chloride," post="a Category III antiseptic, that is also used for"/>
   <result pre="a ban on the sale of numerous bactericidal ingredients, leaving" exact="benzalkonium chloride" post="in a &quot;stand-by�? status until obtaining clinical results that"/>
   <result pre="Other Anti-HSV Compounds Other anti-HSV compounds, are the nucleoside analogs" exact="idoxuridine" post="and vidarabine, which are currently discontinued as there are"/>
   <result pre="better-tolerated and less-toxic compounds (Wilhelmus, 2015). On the other hand," exact="vidarabine" post="is a purine analog with fewer side-effects than idoxuridine,"/>
   <result pre="(Chono et al., 2010), pritelivir (Wald et al., 2014), and" exact="nelfinavir" post="mesylate (Kalu et al., 2014). Brincidofovir is an acyclic"/>
   <result pre="phase against HSV-1 and HSV-2 (Chono et al., 2010). Finally," exact="nelfinavir" post="mesylate, the mesylate salt of the antiviral drug nelfinavir"/>
   <result pre="Finally, nelfinavir mesylate, the mesylate salt of the antiviral drug" exact="nelfinavir" post="which has been characterized as a HIV-1 protease inhibitor"/>
   <result pre="of viral particles (Kalu et al., 2014). As a consequence," exact="nelfinavir" post="mesylate is currently being assessed in a clinical study"/>
   <result pre="J.SariskyR. T.SuttonD. (2003). Herpes simplex virus resistance to acyclovir and" exact="penciclovir" post="after two decades of antiviral therapy.Clin. Microbiol. Rev.16114–128. 10.1128/cmr.16.1.114-128.200312525428"/>
   <result pre="of an acyclovir and foscarnet-resistant herpes simplex virus infection with" exact="cidofovir" post="in a child after an unrelated bone marrow transplant.Bone"/>
   <result pre="(2001). Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous" exact="cidofovir" post="in a child.Pediatr. Infect. Dis. J.201083–1086. 10.1097/00006454-200111000-0001611734717 BuckC. B.ThompsonC."/>
   <result pre="(2009). Development of herpes simplex virus stomatitis during receipt of" exact="cidofovir" post="therapy.Clin. Infect. Dis.49e92–e95. 10.1086/60567819761410 EkorM. (2014). The growing use"/>
   <result pre="L. (2000). Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1%" exact="hydrocortisone" post="cream (ME-609) for treatment of UV radiation-induced herpes labialis.Antimicrob."/>
   <result pre="systematic review on the efficacy of topical acyclovir, penciclovir, and" exact="docosanol" post="for the treatment of herpes simplex labialis.EMJ Dermatol.6118–123. HandelS.KlinglerE."/>
   <result pre="Dis.20e12977. 10.1111/tid.1297730120866 LefloreS.AndersonP. L.FletcherC. V. (2000). A risk-benefit evaluation of" exact="aciclovir" post="for the treatment and prophylaxis of herpes simplex virus"/>
   <result pre="cytomegalovirus infection.Drugs48455–484. 10.2165/00003495-199448030-000097527763 MarkowitzM.ConantM.HurleyA.SchlugerR.DuranM.PeterkinJ.et al. (1998). A preliminary evaluation of" exact="nelfinavir" post="mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 Protease,"/>
   <result pre="M.BarbarashR. A.MikolichD. J.RuoffG. E.et al. (2001). Clinical efficacy of topical" exact="docosanol" post="10% cream for herpes simplex labialis: a multicenter, randomized,"/>
   <result pre="Penciclovir susceptibilities of herpes simplex virus isolates from patients using" exact="penciclovir" post="cream for treatment of recurrent herpes labialis.Antimicrob. Agents Chemother.462848–2853."/>
   <result pre="10.1128/aac.46.9.2848-2853.200212183237 SariskyR. T.BaconT. H.BoonR. J.DuffyK. E.EsserK. M.LearyJ.et al. (2003). Profiling" exact="penciclovir" post="susceptibility and prevalence of resistance of herpes simplex virus"/>
   <result pre="essential oils leaves.Biol. Res.481–5.25654588 SempriniA.SingerJ.BraithwaiteI.ShorttN.ThayabaranD.McConnellM.et al. (2019). Kanuka honey versus" exact="aciclovir" post="for the topical treatment of herpes simplex labialis: a"/>
   <result pre="N.WheelerW. (2012). Safety and tolerability of combination acyclovir 5% and" exact="hydrocortisone" post="1% cream in adolescents with recurrent herpes simplex labialis.Pediatr."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7026129\results\search\drugs\results.xml">
   <result pre="or newly discovered agents in vitro and in vivo, with" exact="ribavirin" post="and favipiravir being the most promising candidates. While animal"/>
   <result pre="the limited efficacy of ribavirin, it was also speculated that" exact="ribavirin" post="would be effective in patients with a viral load"/>
   <result pre="load &amp;lt;1 × 106 copies/mL. Favipiravir showed higher efficacy than" exact="ribavirin" post="against SFTSV in in vitro assays and greater efficacy"/>
   <result pre="with thrombocytopenia syndrome severe fever with thrombocytopenia syndrome virus antiviral" exact="ribavirin" post="favipiravir Funding Ministry of Health, Labour and Welfare10.13039/501100003478H25-Shinko-Shitei-009 Japan"/>
   <result pre="U/mL IFNγ IC90 = 12 ng/ml &amp;gt;2,000 ng/mL *Combination with" exact="ribavirin" post="and IFNs, virus titers were reduced from 3.2–3.6 log."/>
   <result pre="a nebulizer (Snell, 2001). The proposed mechanisms of action of" exact="ribavirin" post="against viruses are indirect (inosine monophosphate dehydrogenase inhibition and"/>
   <result pre="2006). Shimojima et al. (2014) first reported the efficacy of" exact="ribavirin" post="in vitro using three cell lines: monkey kidney-derived Vero,"/>
   <result pre="hepatoma-derived Huh7, and human osteosarcoma-derived U2OS cells. When treated with" exact="ribavirin" post="before and during infection with SFTSV, the 99% inhibitory"/>
   <result pre="during infection with SFTSV, the 99% inhibitory concentration (IC99) of" exact="ribavirin" post="was 263, 83, and 78 μM in Vero, Huh7,"/>
   <result pre="respectively (Table 1). However, when Vero cells were treated with" exact="ribavirin" post="3 days after the inoculation, the inhibitory effect was"/>
   <result pre="the inoculation, the inhibitory effect was dramatically decreased, suggesting that" exact="ribavirin" post="could be used as post-exposure prophylaxis for the prevention"/>
   <result pre="prophylaxis for the prevention of SFTS and also mentioned that" exact="ribavirin" post="could be effective as part of a combination therapy"/>
   <result pre="treat SFTS patients (Shimojima et al., 2014). The efficacy of" exact="ribavirin" post="against SFTSV replication was also observed in another study,"/>
   <result pre="1). Despite several differences in viral strains and treatment procedure," exact="ribavirin" post="suppressed SFTS replication, suggesting that it was effective against"/>
   <result pre="Shimojima et al. (2015) investigated the improvement in efficacy when" exact="ribavirin" post="was used in combination with IFNs. All IFNs showed"/>
   <result pre="U/ml, 24 U/ml, and 12 ng/ml, respectively, and that of" exact="ribavirin" post="was 43 μg/mL (Table 1). When IFNs were combined"/>
   <result pre="was 43 μg/mL (Table 1). When IFNs were combined with" exact="ribavirin" post="at IC90, significant inhibitory effects were observed, with reductions"/>
   <result pre="in viral titers. This study suggested that the combination of" exact="ribavirin" post="with IFNs or other agents that function via different"/>
   <result pre="The Chinese Ministry of Health initially approved the use of" exact="ribavirin" post="to treat SFTS based on the results of in"/>
   <result pre="the case fatality rate was similar between patients who received" exact="ribavirin" post="and those who did not (Liu et al., 2013)."/>
   <result pre="311 patients, of whom 54 died; in those who received" exact="ribavirin" post="therapy, the platelet counts did not increase and the"/>
   <result pre="significant, it was unexpectedly observed that the patients who received" exact="ribavirin" post="therapy had lower platelet counts than those who did"/>
   <result pre="study reported that two patients, in whom plasma exchange and" exact="ribavirin" post="treatment were initiated early, recovered from rapidly progressing SFTS"/>
   <result pre="patients, the platelet counts began to gradually recover after initiating" exact="ribavirin" post="treatment. Furthermore, according to a large-scale epidemiological study in"/>
   <result pre="including 2096 patients with laboratory-confirmed SFTS between 2011 and 2017," exact="ribavirin" post="therapy was effective in reducing the case fatality rate"/>
   <result pre="cells (Tani et al., 2016) was lower than that of" exact="ribavirin" post="(263 μM) (Shimojima et al., 2014). The efficacy of"/>
   <result pre="On the other hand, ~40% of the mice treated with" exact="ribavirin" post="(i.p.) at a dose of 25 or 100 mg/kg/day"/>
   <result pre="aplastic anemia (eltrombopag), and an antiprotozoal agent (broxyquinoline). Of them," exact="hexachlorophene" post="was the most potent, with an IC50 of 1.3"/>
   <result pre="antiviral drugs identified (Table 1). Furthermore, the results indicated that" exact="hexachlorophene" post="treatment interfered with SFTSV entry without affecting virus-host cell"/>
   <result pre="virus infectivity (Yuan et al., 2019). It was predicted that" exact="hexachlorophene" post="would bind to the deep hydrophobic pocket between domains"/>
   <result pre="cholinesterase inhibitor (Hsu et al., 2004). It was reported that" exact="hexachlorophene" post="inhibited the viral replication of severe acute respiratory syndrome-related"/>
   <result pre="of 700 FDA-approved drugs identified the CCBs benidipine hydrochloride and" exact="nifedipine" post="as inhibitors of SFTSV replication in vitro by impairing"/>
   <result pre="in vitro study suggested that treatment with benidipine hydrochloride or" exact="nifedipine" post="inhibited SFTSV replication by reducing virus induced Ca2+ influx."/>
   <result pre="and decreased fatality rate in the humanized mouse model. Notably," exact="nifedipine" post="is one of the most widely used drugs for"/>
   <result pre="of 2087 patients with SFTS comprising 83 nifedipine-treated, who received" exact="nifedipine" post="before admission and during hospitalization, 48 non-nifedipine-treated ones who"/>
   <result pre="before admission and during hospitalization, 48 non-nifedipine-treated ones who received" exact="nifedipine" post="before admission but not during hospitalization, and 249 general"/>
   <result pre="hospitalization, and 249 general SFTS patients who did not receive" exact="nifedipine" post="at all. The case fatality rate was decreased by"/>
   <result pre="authors clearly showed the inhibitory effect of benidipine hydrochloride or" exact="nifedipine" post="in cultured cells and an animal model. Most importantly,"/>
   <result pre="an animal model. Most importantly, it was found that the" exact="nifedipine" post="administration enhanced virus clearance and improved clinical recovery. 2′-Fluoro-2′-deoxycytidine"/>
   <result pre="(Table 1). This value was much lower than that of" exact="ribavirin" post="(49.7 μM) in the same study and favipiravir (22"/>
   <result pre="(Balasubramanian et al., 2017). The mechanism of inhibitory activity of" exact="amodiaquine" post="against malaria and those viruses remains unclear. Baba et"/>
   <result pre="remains unclear. Baba et al. (2017) investigated the effect of" exact="amodiaquine" post="and other halogen molecules (fluorine, bromine, and iodine) against"/>
   <result pre="bromine, and iodine, respectively (Table 1). Among the compounds tested," exact="amodiaquine" post="was identified as a selective inhibitor against SFTSV replication."/>
   <result pre="inhibitor against SFTSV replication. The CC50 and the IC50 of" exact="amodiaquine" post="was &amp;gt;100 and 19.1 μM, respectively. The IC50 of"/>
   <result pre="amodiaquine was &amp;gt;100 and 19.1 μM, respectively. The IC50 of" exact="amodiaquine" post="was lower than those of ribavirin (40.1 μM) and"/>
   <result pre="respectively. The IC50 of amodiaquine was lower than those of" exact="ribavirin" post="(40.1 μM) and favipiravir (25.0 μM). IFN-γ IFN-γ is"/>
   <result pre="China, 2011). The in vitro and in vivo studies on" exact="ribavirin" post="(Shimojima et al., 2014, 2015; Tani et al., 2016;"/>
   <result pre="study conducted by Liu et al. (2013), which showed that" exact="ribavirin" post="did not reduce the fatality rate of patients with"/>
   <result pre="fatality rate of patients with SFTS, discouraged us from considering" exact="ribavirin" post="treatment for treating patients with SFTS. However, Li et"/>
   <result pre="patients with SFTS. However, Li et al. (2018) reported that" exact="ribavirin" post="is effective for early-stage patients with a low viral"/>
   <result pre="for the pretreatment of exposed individuals. Nevertheless, in cases of" exact="ribavirin" post="administration, patients should be intensely monitored because of the"/>
   <result pre="intensely monitored because of the possible adverse events induced by" exact="ribavirin" post="such as anemia and hyperamylasemia (Lu et al., 2015)."/>
   <result pre="hyperamylasemia (Lu et al., 2015). Favipiravir exhibited higher effectiveness than" exact="ribavirin" post="in in vitro and in vivo studies (Tani et"/>
   <result pre="using an FDA-approved drug library (Yuan et al., 2019). Because" exact="hexachlorophene" post="can cause acute and subacute neurotoxicity in laboratory animals"/>
   <result pre="et al., 2019). Notably, retrospectively conducted clinical study suggested that" exact="nifedipine" post="remarkably reduced the case fatality rate in SFTS patients"/>
   <result pre="fatality rate in SFTS patients (Li et al., 2019). Although" exact="nifedipine" post="is administrated consistently for patients with cardiac disease, these"/>
   <result pre="therapeutics for SFTS. It is considered that the efficacy of" exact="nifedipine" post="in treating patients with SFTS should be evaluated in"/>
   <result pre="further studies are needed. Baba et al. (2017) showed that" exact="amodiaquine" post="and other halogen molecules effectively inhibited the propagation of"/>
   <result pre="can be administered at a low cost. The efficacy of" exact="amodiaquine" post="in vivo should be evaluated. The anti-SFTSV efficacy of"/>
   <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistance. Curr. Opin. Virol.8, 10–15. 10.1016/j.coviro.2014.04.01124846716 BoonyasuppayakornS.ReichertE. D.ManzanoM.NagarajanK.PadmanabhanR. (2014)."/>
   <result pre="10.1093/jac/dku20924951535 DewaldL. E.DyallJ.SwordJ. M.TorzewskiL.ZhouH.PostnikovaE.et al. (2018). The calcium channel blocker" exact="bepridil" post="demonstrates efficacy in the murine model of marburg virus"/>
   <result pre="e01942–e01916. 10.1128/JVI.01942-1627881648 GraciJ. D.CameronC. E. (2006). Mechanisms of action of" exact="ribavirin" post="against distinct viruses. Rev. Med. Virol.16, 37–48. 10.1002/rmv.48316287208 HsuJ."/>
   <result pre="J.ChoeP. G.ParkW. B.et al.. (2017). In vitro antiviral activity of" exact="ribavirin" post="against severe fever with thrombocytopenia syndrome virus. Korean J."/>
   <result pre="LiuW.LuQ. B.CuiN.LiH.WangL. Y.LiuK.et al.. (2013). Case-fatality ratio and effectiveness of" exact="ribavirin" post="therapy among hospitalized patients in china who had severe"/>
   <result pre="G.FanY. D.GuoC. T.et al.. (2015). Common adverse events associated with" exact="ribavirin" post="therapy for Severe fever with thrombocytopenia syndrome. Antiviral Res.119,"/>
   <result pre="S.HeoS. T.KimS. H.ChoiW. J.HanM. G.KimJ. Y. (2014). Plasma exchange and" exact="ribavirin" post="for rapidly progressive severe fever with thrombocytopenia syndrome. Int."/>
   <result pre="(2016). Longitudinal diffusion tensor imaging of the rat brain after" exact="hexachlorophene" post="exposure. Neurotoxicology56, 225–232. 10.1016/j.neuro.2016.08.01127555423 SaijoM. (2018). Pathophysiology of severe"/>
   <result pre="disease treatment. Science. 347, 995–998. 10.1126/science.125875825722412 SakuraiY.SakakibaraN.ToyamaM.BabaM.DaveyR. A. (2018). Novel" exact="amodiaquine" post="derivatives potently inhibit Ebola virus infection. Antiviral Res.160, 175–182."/>
   <result pre="virus infection. Virology482, 19–27. 10.1016/j.virol.2015.03.01025817401 ShimojimaM.FukushiS.TaniH.TaniguchiS.FukumaA.SaijoM. (2015). Combination effects of" exact="ribavirin" post="and interferons on severe fever with thrombocytopenia syndrome virus"/>
   <result pre="virus infection. Virol. J.12:181. 10.1186/s12985-015-0412-326527529 ShimojimaM.FukushiS.TaniH.YoshikawaT.FukumaA.TaniguchiS.et al.. (2014). Effects of" exact="ribavirin" post="on severe fever with thrombocytopenia syndrome virus in vitro."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7029664\results\search\drugs\results.xml">
   <result pre="thyroid dysfunction in children with HCV infection receiving PegIFN plus" exact="ribavirin" post="and showed that 28% of children (14 of 50)"/>
   <result pre="still widely used for treating children worldwide. Although PegIFN plus" exact="ribavirin" post="is approved for children with HCV infection (age ≥3"/>
   <result pre="virologic response rates in children with chronic hepatitis C receiving" exact="peginterferon alfa-2b" post="plus ribavirinJ Hepatol201052501720189674 5RashedYKKhalafFAKotbSEThyroid disturbances in children treated with"/>
   <result pre="and risk factors for thyroid dysfunction during peginterferon α and" exact="ribavirin" post="treatment in patients with chronic hepatitis CKorean J Intern"/>
   <result pre="https://www.hcvguidelines.org Table 1. Comparison of direct-acting antiviral and peginterferon plus" exact="ribavirin" post="in children Variable DAA PegIFN + ribavirin Administration Oral"/>
   <result pre="and peginterferon plus ribavirin in children Variable DAA PegIFN +" exact="ribavirin" post="Administration Oral PegIFN: subcutaneous injection (per week) Ribavirin: oral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7032198\results\search\drugs\results.xml">
   <result pre="required dose. In this work, two poorly soluble antiviral drugs," exact="ritonavir" post="(RTV) and efavirenz (EFV), with solubility of 1.2 µg/L and"/>
   <result pre="this work, two poorly soluble antiviral drugs, ritonavir (RTV) and" exact="efavirenz" post="(EFV), with solubility of 1.2 µg/L and 8.85 µg/L at pH"/>
   <result pre="was observed near the melting point of ritonavir, indicating that" exact="ritonavir" post="was present in an amorphous state. Similar results were"/>
   <result pre="acceptable physical stability [13], [37]. In the absence of polymer," exact="indomethacin" post="recrystallized in less than six weeks at storage temperatures"/>
   <result pre="in PVP solid dispersions, the difference between the Tg of" exact="indomethacin" post="in the formulations and the storage temperature increased to"/>
   <result pre="and the storage temperature increased to 40–50 °C, and recrystallization of" exact="indomethacin" post="was suppressed [38]. Such low glass transitions may not"/>
   <result pre="Am Chem Soc200627829116390158 27AnsellS.M.JohnstoneS.A.TardiP.G.Modulating the therapeutic activity of nanoparticle delivered" exact="paclitaxel" post="by manipulating the hydrophobicity of prodrug conjugatesJ Med Chem5120083288329618465845"/>
   <result pre="of carboxymethyl cellulose acetate butyrate containing acyclovirAppl Nanosci62016197208 35MarsacP.J.KonnoH.RumondorA.C.F.Recrystallization of" exact="nifedipine" post="and felodipine from amorphous molecular level solid dispersions containing"/>
   <result pre="cellulose acetate butyrate containing acyclovirAppl Nanosci62016197208 35MarsacP.J.KonnoH.RumondorA.C.F.Recrystallization of nifedipine and" exact="felodipine" post="from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and"/>
   <result pre="time constants for amorphous pharmaceutical systemsJ Pharm Sci89200041742710707021 38YoshiokaM.HancockB.C.ZografiG.Inhibition of" exact="indomethacin" post="crystallization in poly(vinylpyrrolidone) coprecipitatesJ Pharm Sci8419959839867500284 39FedorsR.F.A method for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7033156\results\search\drugs\results.xml">
   <result pre="and underlying malignancy. It is well-established that rituximab-containing regimens, mainly" exact="rituximab" post="with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), are strongly"/>
   <result pre="that rituximab-containing regimens, mainly rituximab with cyclophosphamide, doxorubicin, vincristine, and" exact="prednisone" post="(R-CHOP), are strongly linked to a high risk of"/>
   <result pre="malignancy: A meta-analysisHepatology (Baltimore, Md.)20176637938810.1002/hep.29082 11.HuangYHet al.Randomized controlled trial of" exact="entecavir" post="prophylaxis for rituximab-associated hepatitis B virus reactivation in patients"/>
   <result pre="therapyGastroenterology2015148221244.e22310.1053/j.gastro.2014.10.03825447852 19.Inayat, F. et al. Hepatitis B virus reactivation following" exact="imatinib" post="therapy: A comparative review of 9 cases. Journal of"/>
   <result pre="B virus reactivation in a chronic myeloid leukemia patient during" exact="imatinib" post="mesylate treatmentLeukemia &amp;amp; lymphoma20064715515710.1080/1463923050023681816321842 22.KangBWet al.Chronic myeloid leukemia patient"/>
   <result pre="patient manifesting fatal hepatitis B virus reactivation during treatment with" exact="imatinib" post="rescued by liver transplantation: case report and literature reviewInternational"/>
   <result pre="with the hepatitis B virus immune escape mutant G145R during" exact="dasatinib" post="treatment for chronic myeloid leukemiaInternational journal of hematology201510237938210.1007/s12185-015-1788-y25842192 24.ThiaTJTanHHChuahTHChowWCLuiHFImatinib"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7033915\results\search\drugs\results.xml">
   <result pre="direct-acting antivirals (DAAs). The first DAAs, the protease inhibitors (PIs)" exact="boceprevir" post="(BOC) and telaprevir (TVR), were approved in 2011 but"/>
   <result pre="The first DAAs, the protease inhibitors (PIs) boceprevir (BOC) and" exact="telaprevir" post="(TVR), were approved in 2011 but had several limitations."/>
   <result pre="new DAAs have been developed. Approval of the polymerase inhibitor" exact="sofosbuvir" post="(SOF) in January 2014 allowed for IFN-free therapy, which"/>
   <result pre="considered, especially in the ritonavir-based regimen [20–23]. When looking at" exact="ritonavir" post="in particular, a strong inhibition of CYP 3A4 affects"/>
   <result pre="analyzed as a single medication. The following DAAs were assessed:" exact="boceprevir" post="(BOC), telaprevir (TVR), daclatasvir (DAC), simeprevir (SIM), sofosbuvir (SOF),"/>
   <result pre="a single medication. The following DAAs were assessed: boceprevir (BOC)," exact="telaprevir" post="(TVR), daclatasvir (DAC), simeprevir (SIM), sofosbuvir (SOF), ombitasvir + paritaprevir + ritonavir ± dasabuvir (OBV/PTV/r ± DSV),"/>
   <result pre="medication. The following DAAs were assessed: boceprevir (BOC), telaprevir (TVR)," exact="daclatasvir" post="(DAC), simeprevir (SIM), sofosbuvir (SOF), ombitasvir + paritaprevir + ritonavir ± dasabuvir (OBV/PTV/r ± DSV), ledipasvir (LDV) + sofosbuvir"/>
   <result pre="following DAAs were assessed: boceprevir (BOC), telaprevir (TVR), daclatasvir (DAC)," exact="simeprevir" post="(SIM), sofosbuvir (SOF), ombitasvir + paritaprevir + ritonavir ± dasabuvir (OBV/PTV/r ± DSV), ledipasvir (LDV) + sofosbuvir (SOF), glecaprevir"/>
   <result pre="were assessed: boceprevir (BOC), telaprevir (TVR), daclatasvir (DAC), simeprevir (SIM)," exact="sofosbuvir" post="(SOF), ombitasvir + paritaprevir + ritonavir ± dasabuvir (OBV/PTV/r ± DSV), ledipasvir (LDV) + sofosbuvir (SOF), glecaprevir (GLE) + pibrentasvir (PIB),"/>
   <result pre="DDIs were analyzed for pegylated interferon α (PEG-IFN α) and" exact="ribavirin" post="(RBV). 2. Real-world incidence of DDIs due to antiviral"/>
   <result pre="contrast, patients with kidney transplantation receiving sirolimus, everolimus, cyclosporine, or" exact="tacrolimus" post="increased over time (A: 0.0%, B: 2.3%, C: 4.0%;"/>
   <result pre="2 (0–19) Kidney transplant patients receiving sirolimus, everolimus, cyclosporine, or" exact="tacrolimus" post="16 (2.4) 0 (0) 6 (2.3) 10 (4.0) Abbreviations:"/>
   <result pre="description provided by the patient. Pantoprazole (22.0%), levothyroxine (14.4%), and" exact="spironolactone" post="(12.3%) were used most frequently. Overall, the top most"/>
   <result pre="medications, antiepileptic drugs (carbamazepine [5 patients], eslicarbazepine [1 patient], and" exact="oxcarbazepine" post="[1 patient]), St. John’s wort (1 patient), and rifampicin"/>
   <result pre="and oxcarbazepine [1 patient]), St. John’s wort (1 patient), and" exact="rifampicin" post="(1 patient) were identified as the medications with the"/>
   <result pre="ELB/GRZ (n = 73), were proton pump inhibitors (PPIs), metamizole, statins, and" exact="carvedilol" post="(Supplementary Table 6). More precise information on relevant DDIs"/>
   <result pre="with first-generation PIs used from 2011 or the combinations with" exact="ritonavir" post="booster used from 2014 [10, 20]. However, our work"/>
   <result pre="EversonGT, GordonSC, et al.collab: PROVE1 Study TeamTelaprevir with peginterferon and" exact="ribavirin" post="for chronic HCV genotype 1 infection. N Engl J"/>
   <result pre="3.FosterGR, HézodeC, BronowickiJP, et al.Telaprevir alone or with peginterferon and" exact="ribavirin" post="reduces HCV RNA in patients with chronic genotype 2"/>
   <result pre="et al.collab: PROVE2 Study TeamTelaprevir and peginterferon with or without" exact="ribavirin" post="for chronic HCV infection. N Engl J Med2009; 360:1839–50.19403903"/>
   <result pre="Int2015; 35:1845–1852.25556625 15.AfdhalN, ZeuzemS, KwoP, et al.collab: ION-1 InvestigatorsLedipasvir and" exact="sofosbuvir" post="for untreated HCV genotype 1 infection. N Engl J"/>
   <result pre="Med2014; 370:1889–98.24725239 16.AfdhalN, ReddyKR, NelsonDR, et al.collab: ION-2 InvestigatorsLedipasvir and" exact="sofosbuvir" post="for previously treated HCV genotype 1 infection. N Engl"/>
   <result pre="Med2014; 370:1483–93.24725238 17.KowdleyKV, GordonSC, ReddyKR, et al.collab: ION-3 InvestigatorsLedipasvir and" exact="sofosbuvir" post="for 8 or 12 weeks for chronic HCV without"/>
   <result pre="18.FeldJJ, KowdleyKV, CoakleyE, et al.Treatment of HCV with ABT-450/r-ombitasvir and" exact="dasabuvir" post="with ribavirin. N Engl J Med2014; 370:1594–603.24720703 19.PoordadF, HezodeC,"/>
   <result pre="Engl J Med2014; 370:1594–603.24720703 19.PoordadF, HezodeC, TrinhR, et al.ABT-450/r-ombitasvir and" exact="dasabuvir" post="with ribavirin for hepatitis C with cirrhosis. N Engl"/>
   <result pre="Med2014; 370:1594–603.24720703 19.PoordadF, HezodeC, TrinhR, et al.ABT-450/r-ombitasvir and dasabuvir with" exact="ribavirin" post="for hepatitis C with cirrhosis. N Engl J Med2014;"/>
   <result pre="al.Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor" exact="simeprevir" post="and frequently used concomitant medications. Br J Clin Pharmacol2018;"/>
   <result pre="Dis2014; 46:67–71.24125691 35.CharltonM, EversonGT, FlammSL, et al.collab: SOLAR-1 InvestigatorsLedipasvir and" exact="sofosbuvir" post="plus ribavirin for treatment of HCV infection in patients"/>
   <result pre="35.CharltonM, EversonGT, FlammSL, et al.collab: SOLAR-1 InvestigatorsLedipasvir and sofosbuvir plus" exact="ribavirin" post="for treatment of HCV infection in patients with advanced"/>
   <result pre="Gastroenterology2015; 149:649–59.25985734 36.MannsM, SamuelD, GaneEJ, et al.collab: SOLAR-2 InvestigatorsLedipasvir and" exact="sofosbuvir" post="plus ribavirin in patients with genotype 1 or 4"/>
   <result pre="36.MannsM, SamuelD, GaneEJ, et al.collab: SOLAR-2 InvestigatorsLedipasvir and sofosbuvir plus" exact="ribavirin" post="in patients with genotype 1 or 4 hepatitis C"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7036343\results\search\drugs\results.xml">
   <result pre="causal relationship between laboratory results and therapeutic effects. Lopinavir and" exact="ritonavir" post="(LPV/r) is considered a promising treatment option for COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7036541\results\search\drugs\results.xml">
   <result pre="same sites. The flares had begun within hours of ingesting" exact="nicardipine" post="hydrochloride, amlodipine besilate, candesartan cilexetil and atenolol for the"/>
   <result pre="The flares had begun within hours of ingesting nicardipine hydrochloride," exact="amlodipine" post="besilate, candesartan cilexetil and atenolol for the first time"/>
   <result pre="had begun within hours of ingesting nicardipine hydrochloride, amlodipine besilate," exact="candesartan" post="cilexetil and atenolol for the first time despite showing"/>
   <result pre="hours of ingesting nicardipine hydrochloride, amlodipine besilate, candesartan cilexetil and" exact="atenolol" post="for the first time despite showing a low level"/>
   <result pre="fixed drug eruption Parapsoriasis en plaque Pegylated interferon α-2b plus" exact="ribavirin" post="fig-count: table-count: ref-count: page-count: Introduction Although it has been"/>
   <result pre="alleviate sustained virologic responses [4], pegylated IFN (PEG-IFN) concomitant with" exact="ribavirin" post="is used in patients with HCV genotype 1b [5,"/>
   <result pre="cascade [7, 8], adverse effects of treatment with IFN plus" exact="ribavirin" post="are attributed to IFN. Accordingly, since IFN can stimulate"/>
   <result pre="hypertension and over several years had been sequentially treated with" exact="nicardipine" post="hydrochloride, amlodipine besilate, and candesartan cilexetil. Because her blood"/>
   <result pre="over several years had been sequentially treated with nicardipine hydrochloride," exact="amlodipine" post="besilate, and candesartan cilexetil. Because her blood pressure control"/>
   <result pre="had been sequentially treated with nicardipine hydrochloride, amlodipine besilate, and" exact="candesartan" post="cilexetil. Because her blood pressure control was poor, her"/>
   <result pre="she had been started on combination therapy of PEG-IFNα-2b plus" exact="ribavirin" post="administered subcutaneously to treat progressive liver disease, but treatment"/>
   <result pre="did not ameliorate the skin lesions. Meanwhile, following PEG-IFNα-2b plus" exact="ribavirin" post="therapy, her ALT level decreased but remained above normal,"/>
   <result pre="decreased but remained above normal, whereas discontinuation of PEG-IFNα-2b plus" exact="ribavirin" post="resulted in an increase in the HCV RNA level."/>
   <result pre="HCV RNA level. Because the patient refused further PEG-IFN-α-2b plus" exact="ribavirin" post="therapy complaining of fatigue and headache, she stopped taking"/>
   <result pre="of fatigue and headache, she stopped taking all medications except" exact="ursodeoxycholic acid," post="900 mg daily. Gradual improvement in skin lesions was"/>
   <result pre="possibility that her skin lesions had been a reaction to" exact="candesartan" post="cilexetil, she was asked to avoid this medicine, and"/>
   <result pre="candesartan cilexetil, she was asked to avoid this medicine, and" exact="amlodipine" post="besilate was re-administered to control her hypertension. However, a"/>
   <result pre="to control her hypertension. However, a few days later on" exact="amlodipine" post="besilate, her skin lesions worsened again (Fig. 3a), so"/>
   <result pre="amlodipine besilate, her skin lesions worsened again (Fig. 3a), so" exact="amlodipine" post="besilate was discontinued. By 8 weeks later, in August"/>
   <result pre="pressure was high (165/110), the patient consented to start oral" exact="atenolol" post="daily. Thereafter, the patient's course was complicated by additional"/>
   <result pre="recurrences that appeared within a month of starting treatment with" exact="atenolol" post="gradually subsided, HCV RNA levels increased. Thus, there was"/>
   <result pre="before the start of taking atenolol, she consented to retake" exact="amlodipine" post="besilate. Within 24 h, a small oval erythematous plaque"/>
   <result pre="levels increased, but her blood pressure control was poor, so" exact="candesartan" post="cilexetil was added again in June 2012. Oral challenge"/>
   <result pre="was added again in June 2012. Oral challenge tests of" exact="atenolol" post="were performed with no observed recurrences in January 2013."/>
   <result pre="responses. A report of multiple FDE triggered by IFN +" exact="ribavirin" post="in a patient with HCV infection supports this argument"/>
   <result pre="Baker [13] reported a case of chronic FDE caused by" exact="acetaminophen" post="that simulated parapsoriasis en plaque. Interestingly, the lesions recurred"/>
   <result pre="hepatitis infection be complicated by malignant lymphoma?Lancet199511346(8987)14267 4ReddyKRBourlièreMSulkowskiMOmataMZeuzemSFeldJJet al.Ledipasvir and" exact="sofosbuvir" post="in patients with genotype 1 hepatitis C virus infection"/>
   <result pre="inhibition of intracellular hepatitis C virus replication by combination of" exact="ribavirin" post="and interferon- αJ Infect Dis20044189(7)11293915031779 7GuttermanJUCytokine therapeutics: lessons from"/>
   <result pre="�?, ALT; ▲, HCV RNA; ↓, oral challenge test with" exact="amlodipine" post="besilate; ↡, oral challenge test with atenolol. Fig. 2"/>
   <result pre="the neck and trunk resembling parapsoriasis. Fig. 3 a Taking" exact="amlodipine" post="besilate in May 2011. b Erythematous plaque reappearance at"/>
   <result pre="reappearance at the previously affected site after clinical challenge with" exact="amlodipine" post="besilate. Table 1 Results of lymphocyte transformation tests with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7038234\results\search\drugs\results.xml">
   <result pre="selectivity indexes over 1,000. The results indicated that ouabain and" exact="digoxin" post="blocked the JEV infection at the replication stage by"/>
   <result pre="drug. KEYWORDS high-content screening (HCS) Japanese encephalitis virus (JEV) ouabain" exact="digoxin" post="Na+/K+-ATPase Funding National Key Research and Development Program of"/>
   <result pre="(8), N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) (9), indirubin (10), manidipine (11)," exact="chlorpromazine" post="(12), etanercept (13), and minocycline (14), few therapies beyond"/>
   <result pre="derivative (SCH 16) (9), indirubin (10), manidipine (11), chlorpromazine (12)," exact="etanercept" post="(13), and minocycline (14), few therapies beyond intensive supportive"/>
   <result pre="(9), indirubin (10), manidipine (11), chlorpromazine (12), etanercept (13), and" exact="minocycline" post="(14), few therapies beyond intensive supportive care to treat"/>
   <result pre="selected for the second screening because of their solubility in" exact="dimethyl sulfoxide" post="(DMSO) at room temperature and absence of any obvious"/>
   <result pre="(Fig. 2A and B). Among the 8 compounds, ouabain and" exact="digoxin" post="were subjected to further investigation because of their high"/>
   <result pre="at least two independent experiments. Antiviral effects of ouabain and" exact="digoxin" post="in different cell lines and viruses. For AT31 infection"/>
   <result pre="cell lines and viruses. For AT31 infection of Vero cells," exact="digoxin" post="(392 nM) and ouabain (196 nM) displayed inhibition rates &amp;gt;90%; the"/>
   <result pre="SA14 reproduction could be greatly inhibited when the concentration of" exact="digoxin" post="and ouabain reached 392 nM and 98 nM, respectively, Simultaneously, the"/>
   <result pre="FIG 3 Validation of the antiviral effects of ouabain and" exact="digoxin" post="in different cell lines and virus strains. The antiviral"/>
   <result pre="different cell lines and virus strains. The antiviral effects of" exact="digoxin" post="and ouabain against two JEV strains (AT31 and SA14)"/>
   <result pre="assessed by qRT-PCR. (G to J) The antiviral effects of" exact="digoxin" post="and ouabain against two JEV strains in Huh-7 cells"/>
   <result pre="*, P &amp;lt; 0.05. Under the same conditions of infection, ouabain and" exact="digoxin" post="robustly inhibited AT31 and SA14 virus production in a"/>
   <result pre="the two cell lines (Fig. 3G to J). Ouabain and" exact="digoxin" post="inhibit JEV infection during viral RNA synthesis. To determine"/>
   <result pre="was performed (Fig. 4A). As shown in Fig. 4B, neither" exact="digoxin" post="nor ouabain showed suppression of JEV in virucidal treatments"/>
   <result pre="during treatment. Most importantly, when added posttreatment, both ouabain and" exact="digoxin" post="exerted full inhibitory effects on JEV infection, suggesting that"/>
   <result pre="illustration of the time-of-addition experiment. (B) The inhibitory effects of" exact="digoxin" post="and ouabain with the indicated concentration in each group,"/>
   <result pre="Huh-7 cells transfected with the JEV replicon were treated with" exact="digoxin" post="and ouabain, respectively, and luciferase activities were determined as"/>
   <result pre="infection at the replication stage. JEV inhibition with ouabain and" exact="digoxin" post="occurs via Na+/K+-ATPase. Na+/K+-ATPase is the only target of"/>
   <result pre="experimental conditions, the results of ouabain action were consistent with" exact="digoxin" post="(Fig. 5C and D), which indicated that the JEV-inhibiting"/>
   <result pre="correlated with KCl. These results confirm that both ouabain and" exact="digoxin" post="exert the antiviral effect by targeting the Na+/K+-ATPase. FIG"/>
   <result pre="by targeting the Na+/K+-ATPase. FIG 5 Inhibition of JEV with" exact="digoxin" post="and ouabain occurs via Na+/K+-ATPase. Vero cells infected with"/>
   <result pre="arrhythmias and hypotension for more than 200 years. Recently, ouabain and" exact="digoxin" post="have been proven to inhibit different kinds of viruses,"/>
   <result pre="variants by serial passaging of JEV using increasing concentrations of" exact="digoxin" post="and ouabain, respectively. However, no adaptive mutant was found"/>
   <result pre="the associated Harmony 3.5 software. Antiviral effects of ouabain and" exact="digoxin" post="with different cell lines and virus strains. Vero, Huh-7,"/>
   <result pre="for 1 h (0 to 1 h). Ouabain (10 μM) and" exact="digoxin" post="(10 μM) were incubated with the cells for 1 h"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7040080\results\search\drugs\results.xml">
   <result pre="and prophylaxis of influenza (De Clercq, 2006). The M2 inhibitors," exact="amantadine" post="and rimantadine blocks the activity of M2 proteins that"/>
   <result pre="of influenza (De Clercq, 2006). The M2 inhibitors, amantadine and" exact="rimantadine" post="blocks the activity of M2 proteins that are ion"/>
   <result pre="binding to the NA and obstructing its enzymatic activity. Since" exact="oseltamivir" post="does not inhibit influenza virus replication, it is not"/>
   <result pre="replication, leading to a poor prognosis. A rapid rise in" exact="oseltamivir" post="resistance was detected amongst seasonal A/H1N1 isolates before the"/>
   <result pre="the 50 mM drug stock solution was formulated with the" exact="dimethyl sulfoxide." post="Ribavirin was purchased from Sigma Chemical Company (Sigma-Aldrich, St."/>
   <result pre="Co., Ltd. (Charles River laboratories China). Mice were anesthetized with" exact="pentobarbital" post="sodium and then infected with the influenza virus through"/>
   <result pre="replication of IAV RNA. We found that the reference drug" exact="ribavirin" post="inhibits the replication of cRNA and vRNA but not"/>
   <result pre="primers that initiate viral-RNA transcription.Cell23847–858. 10.1016/0092-8674(81)90449-904496261960 RenaudC.KuypersJ.EnglundJ. A. (2011). Emerging" exact="oseltamivir" post="resistance in seasonal and pandemic influenza A/H1N1.J. Clin. Virol.5270–78."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7045215\results\search\drugs\results.xml">
   <result pre="by HSV2.11 In a cell-culture model, the antiviral medications acyclovir," exact="penciclovir" post="and foscarnet reduced HSV1 particles and Aβ and phosphorylated"/>
   <result pre="zoster and chickenpox.30 No other antiviral drug, including acyclovir (intravenous)," exact="famciclovir" post="and ganciclovir, is superior to valacyclovir in the treatment"/>
   <result pre="the patient will be eligible. Use of cholinesterase inhibitors and" exact="memantine" post="is permitted. Doses of these medications need to be"/>
   <result pre="(other than benzodiazepines prescribed at a dose equivalent of 2 mg" exact="lorazepam" post="daily or higher) and other medications prescribed for medical"/>
   <result pre="valacyclovir as per FDA package insert). Use of benzodiapezines in" exact="lorazepam" post="equivalent doses equal to or greater than 2 mg daily."/>
   <result pre="&amp;lt;60.41 If a patient is receiving a cholinesterase inhibitor and/or" exact="memantine" post="to treat AD, the dose needs to be stable"/>
   <result pre="there is any evidence of randomisation imbalance. Cholinesterase inhibitors and/or" exact="memantine" post="that are permitted during the trial may be related"/>
   <result pre="10.1053/j.ajkd.2012.12.00823312723 40WangLH, SchultzM, WellerS, et al.Pharmacokinetics and safety of multiple-dose" exact="valaciclovir" post="in geriatric volunteers with and without concomitant diuretic therapy."/>
   <result pre="44RogersSL, FarlowMR, DoodyRS, et al.A 24-week, double-blind, placebo-controlled trial of" exact="donepezil" post="in patients with Alzheimer's disease. Neurology1998;50:136–45. 10.1212/WNL.50.1.1369443470 45LinM, GongP,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7048954\results\search\drugs\results.xml">
   <result pre="first drugs used in combination with conventional pegylated interferon and" exact="ribavirin" post="therapies and significantly improved treatment outcomes.5–7 Second generation protease"/>
   <result pre="156 are &quot;hot spots�? for linear antivirals, such as first-generation" exact="telaprevir" post="and boceprevir. Additionally, mutations at position 156 also arise"/>
   <result pre="156 also arise after treatment with next-generation anti-proteases such as" exact="simeprevir" post="and grazoprevir.35 Enzyme constructs containing these mutations were tested"/>
   <result pre="J Med. 2011;364(13):1195–1206. doi:10.1056/NEJMoa101049421449783 7.ShermanKE, FlammSL, AfdhalNH, et al. Response-guided" exact="telaprevir" post="combination treatment for hepatitis C virus infection. N Engl"/>
   <result pre="treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without" exact="ribavirin" post="for hepatitis C virus genotype 1 infection in previously"/>
   <result pre="treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without" exact="ribavirin" post="in patients with hepatitis C virus genotype 1 mono-infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7049240\results\search\drugs\results.xml">
   <result pre="analysis. Opioid substitution treatment (OST) programs included substitution therapies with" exact="buprenorphine" post="or methadone in a structured program under the supervision"/>
   <result pre="substitution treatment (OST) programs included substitution therapies with buprenorphine or" exact="methadone" post="in a structured program under the supervision of a"/>
   <result pre="use. Four patients (2.3%) had HBsAg detectable and were receiving" exact="tenofovir" post="fumarate 245 mg daily, while 8 (4.6%) patients with"/>
   <result pre="Anemia (hemoglobin &amp;lt;10 g/dL) was reported in 2 patients receiving" exact="ribavirin" post="and resolved after dose reduction in both cases. One"/>
   <result pre="patients needed to discontinue treatment and their anemia improved with" exact="ribavirin" post="dose reduction. In addition, none of the treated PWID"/>
   <result pre="who inject drugsSubst Use Misuse2016511218122327219274 10BaruaSGreenwaldRGrebelyJDoreGJSwanTTaylorLERestrictions for Medicaid reimbursement of" exact="sofosbuvir" post="for the treatment of hepatitis C virus infection in"/>
   <result pre="Med201616562563427537841 14GrebelyJMaussSBrownAet al.Efficacy and safety of ledipasvir/sofosbuvir with and without" exact="ribavirin" post="in patients with chronic HCV genotype 1 infection receiving"/>
   <result pre="al.Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and" exact="dasabuvir" post="for the treatment of chronic hepatitis C virus infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7049568\results\search\drugs\results.xml">
   <result pre="a majority of circulating viruses during 2008 became resistant to" exact="oseltamivir" post="prior to the 2009 pandemic.4, 5, 6, 7 Circulation"/>
   <result pre="viral polymerase inhibitor (baloxavir marboxil [Xofluza] approved in 2018).2,3,36 However," exact="amantadine" post="and its derivatives are no longer used because 100%"/>
   <result pre="old (Jackson Laboratories, Bar Harbor, ME, USA), were anesthetized with" exact="isoflurane" post="and administered (5 mice/group) 25 μg of 5′-PPP-NS1shRNA, capped-NS1shRNA,"/>
   <result pre="States—2017–2018 influenza seasonhttps://www.cdc.gov/flu/about/burden/2017-2018.htm2018 2HaydenF.G.AtmarR.L.SchillingM.JohnsonC.PoretzD.PaarD.HusonL.WardP.MillsR.G.Use of the selective oral neuraminidase inhibitor" exact="oseltamivir" post="to prevent influenzaN. Engl. J. Med.34119991336134310536125 3HeoY.A.Baloxavir: First Global"/>
   <result pre="and EFTA countries: an updateEuro Surveill.132008803218445425 5LackenbyA.HungnesO.DudmanS.G.MeijerA.PagetW.J.HayA.J.ZambonM.C.Emergence of resistance to" exact="oseltamivir" post="among influenza A(H1N1) viruses in EuropeEuro Surveill.132008802618445375 6HaugeS.H.DudmanS.BorgenK.LackenbyA.HungnesO.Oseltamivir-resistant influenza"/>
   <result pre="global seasonal influenza-associated respiratory mortality: a modelling studyLancet39120181285130029248255 36WendelH.A.SnyderM.T.PellS.Trial of" exact="amantadine" post="in epidemic influenzaClin. Pharmacol. Ther.7196638435325584 37collab: Centers for Disease"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7049676\results\search\drugs\results.xml">
   <result pre="EASL European Association for the Study of the Liver ETV" exact="entecavir" post="HBeAg hepatitis B e antigen HBsAg hepatitis HBV surface"/>
   <result pre="PWID people who inject drugs SVR sustained virologic response TAF" exact="tenofovir" post="alafenamide TDF tenofovir disoproxil fumarate Viral hepatitis continues to"/>
   <result pre="inject drugs SVR sustained virologic response TAF tenofovir alafenamide TDF" exact="tenofovir" post="disoproxil fumarate Viral hepatitis continues to contribute to the"/>
   <result pre="of decompensation. In patients with eGFR &amp;lt; 30 mL/min/1.73 m2," exact="sofosbuvir" post="should only be used if no alternative treatment approved"/>
   <result pre="(C) John Wiley &amp;amp; Sons, Ltd, Since the approval of" exact="telaprevir" post="and boceprevir in 2011 with SVR rates of 65%"/>
   <result pre="Wiley &amp;amp; Sons, Ltd, Since the approval of telaprevir and" exact="boceprevir" post="in 2011 with SVR rates of 65% to 75%,"/>
   <result pre="high�?fold resistance variants to NS5A Severe renal impairment GT3: Add" exact="sofosbuvir" post="for PEG/RBV experienced with compensated cirrhosis Not for decompensated"/>
   <result pre="cirrhosis 24�?week duration and add RBV for decompensated cirrhosis with" exact="sofosbuvir" post="failure Following liver transplant with/without cirrhosis (compensated or decompensated)"/>
   <result pre="lung and 8 heart transplants) who received 4 weeks of" exact="sofosbuvir" post="and velpatasvir immediately after transplantation. The authors found that,"/>
   <result pre="long�?term (up to 8 years) rates of HBV resistance to" exact="entecavir" post="(ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF)."/>
   <result pre="to 8 years) rates of HBV resistance to entecavir (ETV)," exact="tenofovir" post="disoproxil fumarate (TDF), and tenofovir alafenamide (TAF). Thus, these"/>
   <result pre="HBV resistance to entecavir (ETV), tenofovir disoproxil fumarate (TDF), and" exact="tenofovir" post="alafenamide (TAF). Thus, these three antiviral drugs have become"/>
   <result pre="treatments Abbreviations: eGFR, estimated glomerular filtration rate; ETV, entecavir; TAF," exact="tenofovir" post="alafenamide; TDF, tenofovir disoproxil fumarate. (C) John Wiley &amp;amp;"/>
   <result pre="estimated glomerular filtration rate; ETV, entecavir; TAF, tenofovir alafenamide; TDF," exact="tenofovir" post="disoproxil fumarate. (C) John Wiley &amp;amp; Sons, Ltd, Future"/>
   <result pre="alpha. Additionally, additional NAs are currently in development, including other" exact="tenofovir" post="prodrugs besifovir and metacavir.63 Unfortunately, even though NAs effectively"/>
   <result pre="24PoordadF, SchiffER, VierlingJM, LandisC, FontanaRJ, YangR, et al. Daclatasvir with" exact="sofosbuvir" post="and ribavirin for hepatitis C virus infection with advanced"/>
   <result pre="VierlingJM, LandisC, FontanaRJ, YangR, et al. Daclatasvir with sofosbuvir and" exact="ribavirin" post="for hepatitis C virus infection with advanced cirrhosis or"/>
   <result pre="FlisiakR, TrinhH, PetersenJ, GurelS, et al. Long term treatment with" exact="tenofovir" post="disoproxil fumarate for chronic hepatitis B infection is safe"/>
   <result pre="SetoWK, LimY�?S, FungS, MarcellinP, et al. 96 weeks treatment of" exact="tenofovir" post="alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus"/>
   <result pre="MarcellinP, et al. 96 weeks treatment of tenofovir alafenamide vs." exact="tenofovir" post="disoproxil fumarate for hepatitis B virus infection. J Hepatol2018;68:672�?681.29756595"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7050564\results\search\drugs\results.xml">
   <result pre="HoepelmanAI, LampirisH, HirschelB, TebasP, RaffiF, TrottierBet al.: Subgroup analyses of" exact="maraviroc" post="in previously treated R5 HIV-1 infection. N Engl J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7054408\results\search\drugs\results.xml">
   <result pre="7054408282 doi: 10.1038/s41422-020-0282-0 : Letter to the Editor Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat," exact="chloroquine" post="and two well-known broad-spectrum antiviral drugs remdesivir (GS-5734) and"/>
   <result pre="seven tested drugs, high concentrations of three nucleoside analogs including" exact="ribavirin" post="(half-maximal effective concentration (EC50) = 109.50 μM, half-cytotoxic concentration (CC50) &amp;gt; 400 μM, selectivity index"/>
   <result pre="(half-maximal effective concentration (EC50) = 109.50 μM, half-cytotoxic concentration (CC50) &amp;gt; 400 μM, selectivity index (SI) &amp;gt; 3.65)," exact="penciclovir" post="(EC50 = 95.96 μM, CC50 &amp;gt; 400 μM, SI &amp;gt; 4.17) and favipiravir (EC50 = 61.88 μM, CC50 &amp;gt; 400 μM, SI &amp;gt; 6.46) were"/>
   <result pre="is recommended. Notably, two compounds remdesivir (EC50 = 0.77 μM; CC50 &amp;gt; 100 μM; SI &amp;gt; 129.87) and" exact="chloroquine" post="(EC50 = 1.13 μM; CC50 &amp;gt; 100 μM, SI &amp;gt; 88.50) potently blocked virus infection at low-micromolar"/>
   <result pre="for the treatment of Ebola virus infection.6 Remdesivir is an" exact="adenosine" post="analogue, which incorporates into nascent viral RNA chains and"/>
   <result pre="of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that" exact="chloroquine" post="functioned at both entry, and at post-entry stages of"/>
   <result pre="Vero E6 cells (Fig. 1c, d). Besides its antiviral activity," exact="chloroquine" post="has an immune-modulating activity, which may synergistically enhance its"/>
   <result pre="body, including lung, after oral administration. The EC90 value of" exact="chloroquine" post="against the 2019-nCoV in Vero E6 cells was 6.90 μM,"/>
   <result pre="applicable against the 2019-nCoV. Our findings reveal that remdesivir and" exact="chloroquine" post="are highly effective in the control of 2019-nCoV infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7057540\results\search\drugs\results.xml">
   <result pre="al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with" exact="sorafenib" post="(KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol2018;19:940–52.10.1016/S1470-2045(18)30351-629875066"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7059311\results\search\drugs\results.xml">
   <result pre="The following regimens were administered based on international recommendations [17]:" exact="sofosbuvir" post="(SOF) plus ribavirin (RBV); SOF plus simeprevir (SMV) ± RBV; SOF"/>
   <result pre="were administered based on international recommendations [17]: sofosbuvir (SOF) plus" exact="ribavirin" post="(RBV); SOF plus simeprevir (SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV;"/>
   <result pre="international recommendations [17]: sofosbuvir (SOF) plus ribavirin (RBV); SOF plus" exact="simeprevir" post="(SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV; SOF plus daclatasvir (DCV) ± RBV;"/>
   <result pre="SOF plus simeprevir (SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV; SOF plus" exact="daclatasvir" post="(DCV) ± RBV; ombitasvir (OBV), paritaprevir/ritonavir (PTV/r) ± dasabuvir(DSV) ± RBV, glecaprevir (GLE) plus pibrentasvir"/>
   <result pre="simeprevir (SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV; SOF plus daclatasvir (DCV) ± RBV;" exact="ombitasvir" post="(OBV), paritaprevir/ritonavir (PTV/r) ± dasabuvir(DSV) ± RBV, glecaprevir (GLE) plus pibrentasvir (PIB), grazoprevir"/>
   <result pre="(83.3%) patients were in treatment with protease inhibitors: one with" exact="atazanavir" post="unboosted, two with lopinavir/ritonavir, two with darunavir/ritonavir. Of the"/>
   <result pre="sustained virological response after treatment with pegylated interferon α-2a and" exact="ribavirin" post="in patients infected with HCV genotypes 2 and 3PLoS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7064180\results\search\drugs\results.xml">
   <result pre="KozbialK, LaferlH, SchützA, ReibergerT, SchwablP, et al.Efficacy of ledipasvir/sofosbuvir plus" exact="ribavirin" post="for 12 weeks in patients with chronic hepatitis C"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7067438\results\search\drugs\results.xml">
   <result pre="of respiratory syncytial virus infection RCT of an antiviral and" exact="ibuprofen" post="in bovine respiratory syncytial virus infection http://orcid.org/0000-0003-4059-7115WalshPaulConceptualizationData curationFormal analysisFunding"/>
   <result pre="RSV and an important bovine pathogen. Very early administration of" exact="ibuprofen" post="and GS-561937, a fusion protein inhibitor (FPI), have separately"/>
   <result pre="Our aims were to determine how long after RSV inoculation" exact="ibuprofen" post="and GS-561937 can be administered with clinical benefit and"/>
   <result pre="Ibuprofen alone started on day 3 increased, and FPI with" exact="ibuprofen" post="started on day 3 decreased, viral shedding. Conclusion Dual"/>
   <result pre="where long-acting parenteral agents are preferred, 10-day courses of oral" exact="ibuprofen" post="appear reasonably well-tolerated in pre-ruminant calves, although abomasal ulcers"/>
   <result pre="score but also increased viral shedding in bovine calves when" exact="ibuprofen" post="rather than placebo was initiated on the day following"/>
   <result pre="and answer two questions: How long after RSV inoculation can" exact="ibuprofen" post="and FPI be administered with clinical benefit? Does dual"/>
   <result pre="be administered with clinical benefit? Does dual therapy with both" exact="ibuprofen" post="and FPI improve outcomes compared with either drug alone?"/>
   <result pre="by a veterinarian and consisted of an overdose of sodium" exact="pentobarbital" post="administered through the jugular vein. Two of the 36"/>
   <result pre="and the cause of death for all animals was sodium" exact="pentobarbital" post="overdose. The interventions Calves were randomized to receive either"/>
   <result pre="determine if there was a benefit beyond antipyresis in the" exact="ibuprofen" post="treatment arms. We used the same approach when estimating"/>
   <result pre="successfully randomized; 34 completed the protocol. Two, one in the" exact="ibuprofen" post="starting on day 3 treatment arm, and one in"/>
   <result pre="rate when treatment was initiated earlier, and the combination of" exact="ibuprofen" post="and FPI was better than either drug alone. The"/>
   <result pre="FPI was better than either drug alone. The benefit of" exact="ibuprofen" post="treatment demonstrated by decreased clinical scores in the ibuprofen"/>
   <result pre="of ibuprofen treatment demonstrated by decreased clinical scores in the" exact="ibuprofen" post="only groups extends beyond what would be explained by"/>
   <result pre="benefit when treatment was initiated earlier, and the combination of" exact="ibuprofen" post="and FPI was better than either drug alone (Table"/>
   <result pre="4 Mean daily viral load (copies) for each replicate. Both" exact="ibuprofen" post="and FPI decreased clinical scores compared to placebo. This"/>
   <result pre="of clinical scores. CI, confidence interval. Discussion We found that" exact="ibuprofen" post="and FPI decreased clinical severity of illness. The combination"/>
   <result pre="to better clinical scores than either drug alone. We found" exact="ibuprofen" post="increased and FPI decreased viral shedding but that dual"/>
   <result pre="Richardson et al found some benefit using 20 mg of" exact="indomethacin" post="in a cotton rat model.[9] Treatment within a day"/>
   <result pre="cotton rat model.[9] Treatment within a day of inoculation using" exact="ibuprofen" post="in a bovine RSV model did not decrease histopathological"/>
   <result pre="retrospective study using propensity scores to simulate an RCT of" exact="ibuprofen" post="and acetaminophen in human bronchiolitis found that both drugs"/>
   <result pre="using propensity scores to simulate an RCT of ibuprofen and" exact="acetaminophen" post="in human bronchiolitis found that both drugs decreased wheezing"/>
   <result pre="despite diverging viral loads, +174, (95% CI -303, +651) in" exact="ibuprofen" post="monotherapy started on day 5 group) and -146, (95%"/>
   <result pre="Infect Dis. 1996;173(3):598–608. 10.1093/infdis/173.3.598 .8627023 12SalichsM, SabateD, HomedesJ. Efficacy of" exact="ketoprofen" post="administered in drinking water at a low dose for"/>
   <result pre="Medicine. 1984;77(1, Part 1):25–34. 10.1016/S0002-9343(84)80015-7. 19WalshP, RothenbergSJ, BangH. Safety of" exact="ibuprofen" post="in infants younger than six months: A retrospective cohort"/>
   <result pre="One. 2018;13(6):e0199493 Epub 2018/06/28. 10.1371/journal.pone.019949329953460 20AshrafE; FordL.RGCS. Safety profile of" exact="ibuprofen" post="suspension in young children. InflammoPharmacology. 1999;7(3):219–25. 10.1007/s10787-999-0005-017638093 21WalshP, Carvallo"/>
   <result pre="McEligotH, GunnarsonB, et al.Adverse effects of a 10-day course of" exact="ibuprofen" post="in Holstein calves. J Vet Pharmacol Ther. 2016 Epub"/>
   <result pre="McEligotH, AgrawalK, NewmanJW, et al.A Randomized placebo controlled trial of" exact="ibuprofen" post="for Respiratory Syncytial Virus infection in a bovine model."/>
   <result pre="Epub 2012/09/18. 10.1136/bmj.e584022983531 30WalshP, RothenbergSJ. Wheezing after the use of" exact="acetaminophen" post="and or ibuprofen for first episode of bronchiolitis or"/>
   <result pre="30WalshP, RothenbergSJ. Wheezing after the use of acetaminophen and or" exact="ibuprofen" post="for first episode of bronchiolitis or respiratory tract infection."/>
   <result pre="[cited 9/6/2014]. http://www.merckmanuals.com/vet/respiratory_system/respiratory_diseases_of_cattle/viral_respiratory_tract_infections_in_cattle.html. 32LockwoodPW, JohnsonJC, KatzTL. Clinical efficacy of flunixin," exact="carprofen" post="and ketoprofen as adjuncts to the antibacterial treatment of"/>
   <result pre="http://www.merckmanuals.com/vet/respiratory_system/respiratory_diseases_of_cattle/viral_respiratory_tract_infections_in_cattle.html. 32LockwoodPW, JohnsonJC, KatzTL. Clinical efficacy of flunixin, carprofen and" exact="ketoprofen" post="as adjuncts to the antibacterial treatment of bovine respiratory"/>
   <result pre="ShawKN, HolubkovR, ReevesSD, et al.A multicenter, randomized, controlled trial of" exact="dexamethasone" post="for bronchiolitis. New England Journal of Medicine. 2007;357(4):33110.1056/NEJMoa07125517652648 48BuckinghamSC,"/>
   <result pre="CarubelliCM, SheeranP, HardyRD, et al.A randomized, double-blind, placebo-controlled trial of" exact="dexamethasone" post="in severe respiratory syncytial virus (RSV) infection: effects on"/>
   <result pre=".12001038 49SomersCC, AhmadN, MejiasA, BuckinghamSC, CarubelliC, KatzK, et al.Effect of" exact="dexamethasone" post="on respiratory syncytial virus-induced lung inflammation in children: results"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7070519\results\search\drugs\results.xml">
   <result pre="found in several medicines such as acetazolamide, methazolamide, cefazolin, cefazedone," exact="sulfamethizole" post="or megazol [20,25,26,27]. The 1,3,4-thiadiazole nucleus provides the compounds"/>
   <result pre="inhibitors (NRTIs) such as zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir," exact="tenofovir" post="or emtricitabine interact competitively with the catalytic site of"/>
   <result pre="such as zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, tenofovir or" exact="emtricitabine" post="interact competitively with the catalytic site of the RT,"/>
   <result pre="have been approved for the treatment of HIV infection: nevirapine," exact="delavirdine" post="and efavirenz as the first generation drugs and etravirine"/>
   <result pre="approved for the treatment of HIV infection: nevirapine, delavirdine and" exact="efavirenz" post="as the first generation drugs and etravirine (Intelence tablets,"/>
   <result pre="nevirapine, delavirdine and efavirenz as the first generation drugs and" exact="etravirine" post="(Intelence tablets, Janssen Therapeutics Company, 2008) and rilpivirine (Edurant"/>
   <result pre="drugs and etravirine (Intelence tablets, Janssen Therapeutics Company, 2008) and" exact="rilpivirine" post="(Edurant tablets, Janssen Therapeutics Company, 2011) as the next-generation"/>
   <result pre="[53]. Doravirine demonstrated antiretroviral activity and immunological effects similar to" exact="efavirenz" post="with significantly fewer central nervous system adverse events [54]."/>
   <result pre="as a once-daily fixed-dose combination single tablet of doravirine with" exact="lamivudine" post="and tenofovir disoproxil fumarate [55]. On 30 August 2018,"/>
   <result pre="once-daily fixed-dose combination single tablet of doravirine with lamivudine and" exact="tenofovir" post="disoproxil fumarate [55]. On 30 August 2018, FDA approved"/>
   <result pre="tablets (doravirine 100 mg) and Delstrigo tablets (doravirine 100 mg," exact="lamivudine" post="300 mg and tenofovir disoproxil fumarate 300 mg) [56,57]."/>
   <result pre="and Delstrigo tablets (doravirine 100 mg, lamivudine 300 mg and" exact="tenofovir" post="disoproxil fumarate 300 mg) [56,57]. Several NNRTIs (e.g., fosdevirine,"/>
   <result pre="or low half-maximal effective concentration (EC50) values in comparison to" exact="efavirenz" post="(EC50 value of 0.003 μg/mL). The best results were"/>
   <result pre="activity and selectivity of derivative 6 are limited compared to" exact="efavirenz" post="(EC50 value of 0.003 μg/mL and SI ≈ 13333),"/>
   <result pre="Although they exhibited less anti-HIV-1 activity compared to standard drug" exact="zidovudine" post="(half-maximal inhibitory concentration IC50 = 0.016 μM), these compounds"/>
   <result pre="HIV-1 was tested on MT-4 cells by MTT assay using" exact="efavirenz" post="as a standard drug [64]. Except for derivative 11"/>
   <result pre="drugs recommended for the treatment of HCMV infection are intravenous" exact="ganciclovir" post="or orally administered valganciclovir [83]. Although tolerability of ganciclovir"/>
   <result pre="treatment of HCMV infection are intravenous ganciclovir or orally administered" exact="valganciclovir" post="[83]. Although tolerability of ganciclovir and valganciclovir is acceptable,"/>
   <result pre="intravenous ganciclovir or orally administered valganciclovir [83]. Although tolerability of" exact="ganciclovir" post="and valganciclovir is acceptable, hematological or neurological side effects"/>
   <result pre="or orally administered valganciclovir [83]. Although tolerability of ganciclovir and" exact="valganciclovir" post="is acceptable, hematological or neurological side effects can occur."/>
   <result pre="therapy with these drugs. Serum creatinine levels may increase during" exact="ganciclovir" post="therapy, which requires monitoring of renal function [84]. Encephalopathy"/>
   <result pre="of renal function [84]. Encephalopathy is the neurotoxic effect of" exact="ganciclovir" post="and valganciclovir [85]. Foscarnet is also a very effective"/>
   <result pre="function [84]. Encephalopathy is the neurotoxic effect of ganciclovir and" exact="valganciclovir" post="[85]. Foscarnet is also a very effective anti-HCMV drug,"/>
   <result pre="[85]. Foscarnet is also a very effective anti-HCMV drug, and" exact="cidofovir" post="is a broad-spectrum antiviral with good activity against HCMV."/>
   <result pre="selectivity index SI of 1111 compared to the standard drug" exact="lamivudine" post="(IC50 value of 0.1μM). From these results, it can"/>
   <result pre="(GSK2248761)Antivir. Ther.201419697810.3851/IMP2689 59.VernazzaP.WangC.PozniakA.WeilE.PulikP.CooperD.A.KaplanR.LazzarinA.ValdezH.GoodrichJ.et al.Efficacy and safety of lersivirine (UK-453,061) versus" exact="efavirenz" post="in antiretroviral treatment-naive HIV-1 infected patients: week 48 primary"/>
   <result pre="in the United StatesArch. Intern. Med.200316348749410.1001/archinte.163.4.48712588210 93.JohnsonD.S.LiJ.J.Neuraminidase inhibitors for influenza:" exact="oseltamivir" post="phosphate (Tamiflu) and zanamivir (Relenza)The art of drug synthesisJohnsonD.S.LiJ.J.Wiley"/>
   <result pre="Intern. Med.200316348749410.1001/archinte.163.4.48712588210 93.JohnsonD.S.LiJ.J.Neuraminidase inhibitors for influenza: oseltamivir phosphate (Tamiflu) and" exact="zanamivir" post="(Relenza)The art of drug synthesisJohnsonD.S.LiJ.J.Wiley Interscience, John Wiley and"/>
   <result pre="Dis.200814414710.3201/eid1401.07051018258075 101.KucukguzelS.G.KucukguzelI.TatarE.RollasS.SahinF.GulluceM.De ClercqE.KabasakalL.Synthesis of some novel heterocyclic compounds derived from" exact="diflunisal" post="hydrazide as potential anti-infective and anti-inflammatory agentsEur. J. Med."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7073089\results\search\drugs\results.xml">
   <result pre="polymerase, such as ganciclovir, valganciclovir, cidofovir, and foscarnet. At present," exact="ganciclovir" post="remains to be the first line drug for the"/>
   <result pre="line drug for the treatment of CMV infections. Ganciclovir and" exact="valganciclovir" post="are mainly used for both preemptive therapy and prophylaxis"/>
   <result pre="[62]. However, it is not recommended to co-administer maribavir and" exact="ganciclovir" post="because maribavir is an inhibitor of the UL97 enzyme"/>
   <result pre="is commonly used when patients present with drug resistance (e.g.," exact="ganciclovir" post="and valganciclovir) [62,69]. Additionally, it is likely to be"/>
   <result pre="compounds because of its reduced haematotoxicity and nephrotoxicity, compared with" exact="ganciclovir" post="and valganciclovir [62]. Maribavir has been used to treat"/>
   <result pre="of its reduced haematotoxicity and nephrotoxicity, compared with ganciclovir and" exact="valganciclovir" post="[62]. Maribavir has been used to treat hematopoietic cell"/>
   <result pre="Brincidofovir Brincidofovir (CMX001) is an orally bioavailable lipid prodrug of" exact="cidofovir" post="which is less renal toxic than the parent compound."/>
   <result pre="is poor despite surgical resection, high-dose radiation, and chemotherapy with" exact="temozolomide" post="[88,89]. Activation of the immune system against tumor cells"/>
   <result pre="tissues. Batich et al. evaluated pp65-specific cellular responses following dose-intensified" exact="temozolomide" post="(DI-TMZ) with pp65- DCs and determined the effects on"/>
   <result pre="[94]. Following tumor resection, the patient received radiation therapy and" exact="temozolomide" post="combined therapy that was complicated by CMV colitis and"/>
   <result pre="foscarnet therapy remodels thymidine analogue mutations and alters resistance to" exact="zidovudine" post="and lamivudine in HIV-1Antivir. Ther.20071233534317591023 60.StuppR.MasonW.P.van den BentM.J.WellerM.FisherB.TaphoornM.J.BelangerK.BrandesA.A.MarosiC.BogdahnU.et al.Radiotherapy"/>
   <result pre="remodels thymidine analogue mutations and alters resistance to zidovudine and" exact="lamivudine" post="in HIV-1Antivir. Ther.20071233534317591023 60.StuppR.MasonW.P.van den BentM.J.WellerM.FisherB.TaphoornM.J.BelangerK.BrandesA.A.MarosiC.BogdahnU.et al.Radiotherapy plus concomitant"/>
   <result pre="HIV-1Antivir. Ther.20071233534317591023 60.StuppR.MasonW.P.van den BentM.J.WellerM.FisherB.TaphoornM.J.BelangerK.BrandesA.A.MarosiC.BogdahnU.et al.Radiotherapy plus concomitant and adjuvant" exact="temozolomide" post="for glioblastomaN. Engl. J. Med.200535298799610.1056/NEJMoa04333015758009 61.OrnaghiS.HsiehL.S.BordeyA.VerganiP.PaidasM.J.van den PolA.N.Valnoctamide Inhibits"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7073332\results\search\drugs\results.xml">
   <result pre="cell lines. We further identify three potential drug combinations (e.g.," exact="sirolimus" post="plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin)"/>
   <result pre="further identify three potential drug combinations (e.g., sirolimus plus dactinomycin," exact="mercaptopurine" post="plus melatonin, and toremifene plus emodin) captured by the"/>
   <result pre="drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and" exact="toremifene" post="plus emodin) captured by the &quot;Complementary Exposure�? pattern: the"/>
   <result pre="specific drug. Mesalazine (an approved drug for inflammatory bowel disease)," exact="sirolimus" post="(an approved immunosuppressive drug), and equilin (an approved agonist"/>
   <result pre="symptoms) achieved the highest GSEA scores of 3, followed by" exact="paroxetine" post="and melatonin with GSEA scores of 2. We next"/>
   <result pre="the highest GSEA scores of 3, followed by paroxetine and" exact="melatonin" post="with GSEA scores of 2. We next selected 16"/>
   <result pre="drugs. b–e Inferred mechanism-of-action networks for four selected drugs: b" exact="toremifene" post="(first-generation nonsteroidal-selective estrogen receptor modulator), c irbesartan (an angiotensin"/>
   <result pre="selected drugs: b toremifene (first-generation nonsteroidal-selective estrogen receptor modulator), c" exact="irbesartan" post="(an angiotensin receptor blocker), d mercaptopurine (an antimetabolite antineoplastic"/>
   <result pre="estrogen receptor modulator), c irbesartan (an angiotensin receptor blocker), d" exact="mercaptopurine" post="(an antimetabolite antineoplastic agent with immunosuppressant properties), and e"/>
   <result pre="mercaptopurine (an antimetabolite antineoplastic agent with immunosuppressant properties), and e" exact="melatonin" post="(a biogenic amine for treating circadian rhythm sleep disorders)."/>
   <result pre="established cell lines17,38. Compared to the classical ESR1-related antiviral pathway," exact="toremifene" post="prevents fusion between the viral and endosomal membrane by"/>
   <result pre="and eventually inhibiting viral replication39. As shown in Fig. 5b," exact="toremifene" post="potentially affects several key host proteins associated with HCoV,"/>
   <result pre="and human immunodeficiency virus (ZEBOV-GP/HIV)18. Altogether, network-predicted SERMs (such as" exact="toremifene" post="and equilin) offer candidate repurposable drugs for 2019-nCoV/SARS-CoV-2. Angiotensin"/>
   <result pre="proteins in the human interactome. As shown in Fig. 5c," exact="irbesartan" post="targets SLC10A1, encoding the sodium/bile acid cotransporter (NTCP) protein"/>
   <result pre="release effectively50. Indeed, the latest study revealed the clinical application:" exact="sirolimus" post="reduced MERS-CoV infection by over 60%51. Moreover, sirolimus usage"/>
   <result pre="clinical application: sirolimus reduced MERS-CoV infection by over 60%51. Moreover," exact="sirolimus" post="usage in managing patients with severe H1N1 pneumonia and"/>
   <result pre="roles in viral maturation and antagonism to interferon stimulation53,54. Mechanistically," exact="mercaptopurine" post="potentially target several host proteins in HCoVs, such as"/>
   <result pre="play essential roles in viral infections56,57. As a biogenic amine," exact="melatonin" post="(N-acetyl-5-methoxytryptamine) (Z = –1.72 and GSEA score = 2) plays a key role"/>
   <result pre="on the function of multiple organs60. The antioxidant effect of" exact="melatonin" post="makes it a putative candidate drug to relieve patients’"/>
   <result pre="to relieve patients’ clinical symptoms in antiviral treatment, even though" exact="melatonin" post="cannot eradicate or even curb the viral replication or"/>
   <result pre="the viral replication or transcription61,62. In addition, the application of" exact="melatonin" post="may prolong patients’ survival time, which may provide a"/>
   <result pre="and eventually eradicate the virus. As shown in Fig. 5e," exact="melatonin" post="indirectly targets several HCoV cellular targets, including ACE2, BCL2L1,"/>
   <result pre="effect as melatonin. By inhibiting mast-cell-derived proteinases and suppressing fibrosis," exact="eplerenone" post="can improve survival of mice infected with encephalomyocarditis virus63."/>
   <result pre="Inferred mechanism-of-action networks for three selected pairwise drug combinations: b" exact="sirolimus" post="(a potent immunosuppressant with both antifungal and antineoplastic properties)"/>
   <result pre="(a potent immunosuppressant with both antifungal and antineoplastic properties) plus" exact="dactinomycin" post="(an RNA synthesis inhibitor for treatment of various tumors),"/>
   <result pre="(an RNA synthesis inhibitor for treatment of various tumors), c" exact="toremifene" post="(first-generation nonsteroidal-selective estrogen receptor modulator) plus emodin (an experimental"/>
   <result pre="experimental drug for the treatment of polycystic kidney), and d" exact="melatonin" post="(a biogenic amine for treating circadian rhythm sleep disorders)"/>
   <result pre="(a biogenic amine for treating circadian rhythm sleep disorders) plus" exact="mercaptopurine" post="(an antimetabolite antineoplastic agent with immunosuppressant properties). Sirolimus plus"/>
   <result pre="treatment of various cancer types. An early study showed that" exact="dactinomycin" post="(1 μg/ml) inhibited the growth of feline enteric CoV67. As"/>
   <result pre="As shown in Fig. 6b, our network analysis shows that" exact="sirolimus" post="and dactinomycin synergistically target HCoV-associated host protein subnetwork by"/>
   <result pre="in Fig. 6b, our network analysis shows that sirolimus and" exact="dactinomycin" post="synergistically target HCoV-associated host protein subnetwork by &quot;Complementary Exposure�?"/>
   <result pre="pattern, offering potential combination regimens for treatment of HCoV. Specifically," exact="sirolimus" post="and dactinomycin may inhibit both mTOR signaling and RNA"/>
   <result pre="potential combination regimens for treatment of HCoV. Specifically, sirolimus and" exact="dactinomycin" post="may inhibit both mTOR signaling and RNA synthesis pathway"/>
   <result pre="the Ebola virus glycoprotein39. In vitro assays have demonstrated that" exact="toremifene" post="inhibited growth of MERS-CoV17,69 and SARA-CoV38 (Table 1). Emodin,"/>
   <result pre="Altogether, network analyses and published experimental data suggested that combining" exact="toremifene" post="and emdoin offered a potential therapeutic approach for 2019-nCoV/SARS-CoV-2"/>
   <result pre="plus Melatonin As shown in Fig. 5a, targets of both" exact="mercaptopurine" post="and melatonin showed strong network proximity with HCoV-associated host"/>
   <result pre="As shown in Fig. 5a, targets of both mercaptopurine and" exact="melatonin" post="showed strong network proximity with HCoV-associated host proteins in"/>
   <result pre="interactome network. Recent in vitro and in vivo studies identified" exact="mercaptopurine" post="as a selective inhibitor of both SARS-CoV and MERS-CoV"/>
   <result pre="in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically," exact="melatonin" post="was reported to inhibit calmodulin and calmodulin interacts with"/>
   <result pre="in HCoV infectious bronchitis virus74. As shown in Fig. 6d," exact="mercaptopurine" post="and melatonin may synergistically block c-Jun signaling by targeting"/>
   <result pre="infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and" exact="melatonin" post="may synergistically block c-Jun signaling by targeting multiple cellular"/>
   <result pre="signaling by targeting multiple cellular targets. In summary, combination of" exact="mercaptopurine" post="and melatonin may offer a potential combination therapy for"/>
   <result pre="targeting multiple cellular targets. In summary, combination of mercaptopurine and" exact="melatonin" post="may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by"/>
   <result pre="(Fig. 6d). However, further experimental observations on ACE2 pathways by" exact="melatonin" post="in 2019-nCoV/SARS-CoV-2 are highly warranted. Discussion In this study,"/>
   <result pre="studies showed the potential pulmonary toxicities (including pneumonia) associated with" exact="mesalazine" post="usage81,82. Integration of lung-specific gene expression23 of 2019-nCoV/SARS-CoV-2 host"/>
   <result pre="Ebola virus infectionSci. Transl. Med.20135190ra17910.1126/scitranslmed.3005471 19.HeSet al.Repurposing of the antihistamine" exact="chlorcyclizine" post="and related compounds for treatment of hepatitis C virus"/>
   <result pre="Top. Med. Chem.200441433145410.2174/156802604338781815379656 43.SekoYEffect of the angiotensin II receptor blocker" exact="olmesartan" post="on the development of murine acute myocarditis caused by"/>
   <result pre="Na(+)-dependent taurocholate cotransporting polypeptide activityAntivir. Res.201512014014610.1016/j.antiviral.2015.06.00726086883 46.KoCet al.The FDA-approved drug" exact="irbesartan" post="inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate"/>
   <result pre="deubiquitinating and deISGylating enzymeAntivir. Chem. Chemother.20091915115610.1177/09563202090190040219374142 54.ChengKWet al.Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
   <result pre="Metab. Immune Drug Discov.20126303910.2174/18722141279901531722264213 60.TanDXKorkmazAReiterRJManchesterLCEbola virus disease: potential use of" exact="melatonin" post="as a treatmentJ. Pineal Res.20145738138410.1111/jpi.1218625262626 61.TanDXManchesterLCTerronMPFloresLJReiterRJOne molecule, many derivatives:"/>
   <result pre="Pineal Res.20145738138410.1111/jpi.1218625262626 61.TanDXManchesterLCTerronMPFloresLJReiterRJOne molecule, many derivatives: a never-ending interaction of" exact="melatonin" post="with reactive oxygen and nitrogen species?J. Pineal Res.200742284210.1111/j.1600-079X.2006.00407.x17198536 62.GalanoATanDXReiterRJOn"/>
   <result pre="melatonin’s metabolites, AFMK and AMKJ. Pineal Res.20135424525710.1111/jpi.1201022998574 63.XiaoJShimadaMLiuWHuDMatsumoriAAnti-inflammatory effects of" exact="eplerenone" post="on viral myocarditisEur. J. Heart Fail.20091134935310.1093/eurjhf/hfp02319213804 64.WangManliCaoRuiyuanZhangLeikeYangXinglouLiuJiaXuMingyueShiZhengliHuZhihongZhongWuXiaoGengfuRemdesivir and chloroquine"/>
   <result pre="of eplerenone on viral myocarditisEur. J. Heart Fail.20091134935310.1093/eurjhf/hfp02319213804 64.WangManliCaoRuiyuanZhangLeikeYangXinglouLiuJiaXuMingyueShiZhengliHuZhihongZhongWuXiaoGengfuRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Gen. Virol.1992733285328810.1099/0022-1317-73-12-32851335030 68.ZhouWBDingQChenLLiuXAWangSToremifene is an effective and safe alternative to" exact="tamoxifen" post="in adjuvant endocrine therapy for breast cancer: results of"/>
   <result pre="its ectodomainFEBS Lett.200858238539010.1016/j.febslet.2007.11.08518070603 73.DaiJInschoEWYuanLHillSMModulation of intracellular calcium and calmodulin by" exact="melatonin" post="in MCF-7 human breast cancer cellsJ. Pineal Res.20023211211910.1034/j.1600-079x.2002.1844.x12071468 74.FungTSLiuDXActivation"/>
   <result pre="Viruses10, 55 (2018). 81.KimJHet al.Acute eosinophilic pneumonia related to a" exact="mesalazine" post="suppositoryAsia Pac. Allergy2013313613910.5415/apallergy.2013.3.2.13623667838 82.GuptaAGulatiSMesalamine induced eosinophilic pneumoniaRespir. Med. Case"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7076467\results\search\drugs\results.xml">
   <result pre="chitosan nanoparticles for nose-to-brain delivery [3]. Rotigotine is a non-ergoline" exact="dopamine" post="D1/D2/D3 agonist that is used in the therapy of"/>
   <result pre="structural damages. The results obtained by this work show that" exact="rotigotine" post="loaded chitosan nanoparticles represent a potential formulation for nose-to-brain"/>
   <result pre="chitosan niosomes. The model drug that has been chosen is" exact="pentamidine" post="which is an example of old drug (antiprotozoal discovered"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7076512\results\search\drugs\results.xml">
   <result pre="selective and effective antivirals, from which only acyclovir (ACV) and" exact="ganciclovir" post="(GCV) were incorporated into nanomaterials; a complete classification of"/>
   <result pre="used, either alone or in combination [57]. These include also" exact="amantadine" post="and neuraminidase inhibitors (zanamivir and oseltamivir), that have been"/>
   <result pre="against influenza virus infection [58,59,60]. Briefly, the antiviral mechanism of" exact="amantadine" post="is based on nterference with the viral protein, M2"/>
   <result pre="it is taken inside the cell by endocytosis [61]. Also," exact="oseltamivir" post="carboxylate mechanism implies a selective inhibition of influenza virus"/>
   <result pre="included/encapsulated/incorporated into nanomaterials. The representative nucleoside reverse transcriptase inhibitor (NRTI)" exact="zidovudine" post="(AZT) is phosphorylated intracellular by kinases specific to AZT"/>
   <result pre="41, 44, 67, 70, 210, 215, and 219 [72]. Also," exact="lamivudine" post="(LAM), another NRTI agent, enters cells by passive diffusion,"/>
   <result pre="by deoxycytidine monophosphate kinase and nucleoside diphosphate kinase to yield" exact="lamivudine" post="5′-triphosphate, which is the active anabolite [73]. Tenofovir disoproxil"/>
   <result pre="the active anabolite [73]. Tenofovir disoproxil is a derivative of" exact="adenosine" post="5′-monophosphate lacking a complete ribose ring, and it is"/>
   <result pre="active against HIV-1, HIV-2 and HBV. After a rapid hydrolysis," exact="tenofovir" post="is formed, being then phosphorylated by cellular kinases to"/>
   <result pre="being then phosphorylated by cellular kinases to its active metabolite," exact="tenofovir" post="diphosphate which is a competitive inhibitor of viral reverse"/>
   <result pre="infectious form [77,78]. Only SQV, indinavir, ATV, RTV, NFV and" exact="lopinavir" post="are currently employed in nanotechnology research. There are two"/>
   <result pre="HSV treatment in this case for the topical form of" exact="trifluridine" post="(TFT) and ganciclovir (ACV analog) gels, is denoted by"/>
   <result pre="this case for the topical form of trifluridine (TFT) and" exact="ganciclovir" post="(ACV analog) gels, is denoted by low retention time"/>
   <result pre="on the membrane [113]; transferrin-conjugated quantum rod nanoparticles conjugated with" exact="saquinavir" post="crossed an in vitro BBB model by exploiting a"/>
   <result pre="with PMA amphiphilic polymer and functionalized with the antiretroviral peptide" exact="enfuvirtide" post="crossed the BBB by a passive diffusion, probably mediated"/>
   <result pre="this drawback. Patel et al. [156] obtained nanosuspensions—NS based on" exact="povidone" post="polymer- polyvinylpyrrolidone (PVP) K30, poloxamers steric stabilizer (188 and"/>
   <result pre="and RTV and also LNPs containing ATV + RTV +" exact="tenofovir" post="(TFV—an HIV NRTIs), the last ones being prepared in"/>
   <result pre="RNA; ssDNA: single stranded DNA; ssRNA: single stranded RNA; TAF:" exact="tenofovir" post="alafenamide; TEM: transmission electron microscopy; Tf: transferrin; TFV: tenofovir;"/>
   <result pre="foscarnet therapy remodels thymidine analogue mutations and alters resistance to" exact="zidovudine" post="and lamivudine in HIV-1Antivir. Ther.20071233534317591023 50.LeungD.T.SacksS.L.Docosanol: A topical antiviral"/>
   <result pre="remodels thymidine analogue mutations and alters resistance to zidovudine and" exact="lamivudine" post="in HIV-1Antivir. Ther.20071233534317591023 50.LeungD.T.SacksS.L.Docosanol: A topical antiviral for herpes"/>
   <result pre="A (H5N1) InfectionN. Engl. J. Med.20053532667267210.1056/NEJMoa05451216371632 64.TeH.S.RandallG.JensenD.M.Mechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterol. Hepatol.20073218225 65.Kre�?merováM.Amino"/>
   <result pre="DNA Virus and Retrovirus InfectionsClin. Microbiol. Rev.20031656959610.1128/CMR.16.4.569-596.200314557287 67.LeeH.W.ParkJ.Y.AhnS.H.An evaluation of" exact="entecavir" post="for the treatment of chronic hepatitis B infection in"/>
   <result pre="112.KuoY.-C.ChenH.-H.Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate–sulfopropylmethacrylate on the permeability of" exact="zidovudine" post="and lamivudine across the in vitro blood–brain barrierInt. J."/>
   <result pre="nanoparticulate polybutylcyanoacrylate and methylmethacrylate–sulfopropylmethacrylate on the permeability of zidovudine and" exact="lamivudine" post="across the in vitro blood–brain barrierInt. J. Pharm.200632716016910.1016/j.ijpharm.2006.07.04416939704 113.MishraV.MahorS.RawatA.GuptaP.N.DubeyP.KhatriK.VyasS.P.Targeted"/>
   <result pre="HIV reservoirsEur. J. Pharm. Biopharm.2019138486310.1016/j.ejpb.2018.06.00229879528 125.ShenY.TuJ.Preparation and ocular pharmacokinetics of" exact="ganciclovir" post="liposomesAAPS J.20079E37110.1208/aapsj090304418170984 126.FengM.CaiQ.ShiX.HuangH.ZhouP.GuoX.Recombinant high-density lipoprotein complex as a targeting"/>
   <result pre="therapy significantly enhanced by targeted liposome deliveryAIDS2008221961196910.1097/QAD.0b013e32830efd9618753929 131.GagnéJ.-F.DésormeauxA.PerronS.TremblayM.J.BergeronM.G.Targeted delivery of" exact="indinavir" post="to HIV-1 primary reservoirs with immunoliposomesBBA Biomembr.2002155819821010.1016/S0005-2736(01)00432-1 132.ClaytonR.OhagenA.NicolF.Del VecchioA.M.JonckersT.H.M.GoethalsO.Van"/>
   <result pre="of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with" exact="amantadine" post="through ROS-mediated AKT signaling pathwaysIJN2018132005201610.2147/IJN.S15599429662313 136.LiY.LinZ.GuoM.XiaY.ZhaoM.WangC.XuT.ChenT.ZhuB.Inhibitory activity of selenium"/>
   <result pre="AKT signaling pathwaysIJN2018132005201610.2147/IJN.S15599429662313 136.LiY.LinZ.GuoM.XiaY.ZhaoM.WangC.XuT.ChenT.ZhuB.Inhibitory activity of selenium nanoparticles functionalized with" exact="oseltamivir" post="on H1N1 influenza virusIJN2017125733574310.2147/IJN.S14093928848350 137.LiY.LinZ.ZhaoM.GuoM.XuT.WangC.XiaH.ZhuB.Reversal of H1N1 influenza virus-induced"/>
   <result pre="Administration in RatsPLoS ONE201510e014039910.1371/journal.pone.014039926461917 141.KirimlioğluG.Y.ÖztürkA.A.Preparation and in vitro characterization of" exact="lamivudine" post="loaded nanoparticles prepared by acid and/or ester terminated PLGA"/>
   <result pre="inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapyNanomedicine20161210912210.1016/j.nano.2015.09.00926472049 148.SavageA.C.TathamL.M.SiccardiM.ScottT.VourvahisM.ClarkA.RannardS.P.OwenA.Improving" exact="maraviroc" post="oral bioavailability by formation of solid drug nanoparticlesEur. J."/>
   <result pre="Templating for the Topical Treatment of Herpesviruses InfectionsPharmaceutics2018104610.3390/pharmaceutics10020046 156.PatelG.V.PatelV.B.PathakA.RajputS.J.Nanosuspension of" exact="efavirenz" post="for improved oral bioavailability: Formulation optimization, in vitro, in"/>
   <result pre="HIV treatmentJ. Nanopart. Res.201315204010.1007/s11051-013-2040-4 180.ReddyP.P.ReddyB.M.PrakashJ.LathaK.PrashanthiD.Formulation and characterisation of chitosan based" exact="lamivudine" post="nanoparticlesEJPMR20144377383 181.SanchezC.G.MolinskiS.V.GongoraR.SosulskiM.FuselierT.MacKinnonS.S.MondalD.LaskyJ.A.The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy"/>
   <result pre="and DSC; EFV [146] - Folic acid-conjugated-P407 NPs based on" exact="folic acid" post="conjugated with P407 with inclusion of ATV and RTV"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7076579\results\search\drugs\results.xml">
   <result pre="patients planned to be treated with traditional agents, such as" exact="cyclophosphamide" post="and glucocorticoids, particularly in the setting of resolved HBV"/>
   <result pre="(HR) has been reported at 5.1.25 Peak doses of &amp;gt;40 mg" exact="prednisolone" post="equivalents were associated with an adjusted HR for HBVr"/>
   <result pre="1 year and 5.5% at 10 years. GC peak daily dose &amp;gt;20 mg" exact="prednisolone" post="equivalents and treatment duration for &amp;gt;4 weeks were independent risk"/>
   <result pre="and expert advice suggests that daily doses of GCs &amp;gt;20 mg" exact="prednisolone" post="equivalents for treatment durations &amp;gt;4 weeks should be considered as"/>
   <result pre="of MTX).35 With regards to other non-biologic agents such as" exact="leflunomide" post="(LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and azathioprine (AZA), cases"/>
   <result pre="With regards to other non-biologic agents such as leflunomide (LEF)," exact="sulfasalazine" post="(SSZ), hydroxychloroquine (HCQ), and azathioprine (AZA), cases of HBVr"/>
   <result pre="to other non-biologic agents such as leflunomide (LEF), sulfasalazine (SSZ)," exact="hydroxychloroquine" post="(HCQ), and azathioprine (AZA), cases of HBVr are extremely"/>
   <result pre="agents such as leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and" exact="azathioprine" post="(AZA), cases of HBVr are extremely rare, and these"/>
   <result pre="rheumatology field are limited, Li and colleagues compared a standard" exact="prednisone" post="regimen (1 mg/kg daily) versus MMF (500–1000 mg twice daily) and"/>
   <result pre="regimen (1 mg/kg daily) versus MMF (500–1000 mg twice daily) and lower" exact="prednisone" post="dose (0.5 mg/kg daily) in HBsAg-positive patients with idiopathic nephrotic"/>
   <result pre="in 64% (14/22) and 37% (7/19) of patients on standard" exact="prednisone" post="monotherapy and MMF/lower prednisone combination, respectively (p = 0.047), highlighting the"/>
   <result pre="37% (7/19) of patients on standard prednisone monotherapy and MMF/lower" exact="prednisone" post="combination, respectively (p = 0.047), highlighting the role of high GC"/>
   <result pre="experienced HBVr. CYC-induced HBVr occurred earlier than that associated with" exact="rituximab" post="(RTX) or tumor necrosis factor inhibitors (TNFi) (8 versus"/>
   <result pre="main driver of HBVr in this cohort was an average" exact="prednisolone" post="daily dose of &amp;gt;5 mg. From these limited data, it"/>
   <result pre="as 53%, but was essentially nullified by the use of" exact="lamivudine" post="or entecavir. 63–65 In the setting of rheumatic diseases,"/>
   <result pre="and case series showing no safety signals for HBVr with" exact="secukinumab" post="(a human IgG1k anti-IL17A monoclonal antibody)89–92 or ixekizumab (a"/>
   <result pre="(a humanized monoclonal anti-IL17A antibody).93,94 The risk for HBVr with" exact="secukinumab" post="was studied in a multicenter prospective cohort study of"/>
   <result pre="these data, it appears that the risk for HBVr with" exact="ustekinumab" post="is similar to that of TNF inhibitors and the"/>
   <result pre="with another currently under investigation (filgotinib). As for psoriatic arthritis," exact="tofacitinib" post="is the only JAK inhibitor currently approved for use"/>
   <result pre="is the only JAK inhibitor currently approved for use after" exact="methotrexate" post="or other csDMARD failure. Data for their HBVr potential"/>
   <result pre="the HBsAg positive patients were prophylactically treated with antivirals upon" exact="tofacitinib" post="initiation and did not experience HBVr. Amongst the four"/>
   <result pre="antivirals, two had HBVr after 6 and 12 months of" exact="tofacitinib" post="therapy, with one having only virological and the other"/>
   <result pre="were being cotreated with low-dose corticosteroids (5 and 10 mg of" exact="prednisolone" post="daily, respectively). Patients who were HBsAg negative/anti-HBc positive did"/>
   <result pre="of drug-related hepatotoxicity should be also of concern (especially for" exact="methotrexate" post="and leflunomide) and, thus, screening should be performed in"/>
   <result pre="antigen; HBV-DNA, HBV-deoxyribonucleic acid; HBVr, hepatitis B virus reactivation; TAF," exact="tenofovir" post="alafenamide; TDF, tenofovir disoproxil fumarate. Table 4. Risk of"/>
   <result pre="acid; HBVr, hepatitis B virus reactivation; TAF, tenofovir alafenamide; TDF," exact="tenofovir" post="disoproxil fumarate. Table 4. Risk of HBVr stratified per"/>
   <result pre="analogues (NAs) with high barrier to genetic resistance, such as" exact="entecavir" post="(ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF)"/>
   <result pre="with high barrier to genetic resistance, such as entecavir (ETV)," exact="tenofovir" post="disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are the"/>
   <result pre="resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and" exact="tenofovir" post="alafenamide (TAF) are the antiviral agents of choice (Figure"/>
   <result pre="al.A randomized, controlled trial of interferon alfa-2b alone and after" exact="prednisone" post="withdrawal for the treatment of chronic hepatitis B. The"/>
   <result pre="et al.Prednisolone priming enhances Th1 response and efficacy of subsequent" exact="lamivudine" post="therapy in patients with chronic hepatitis B. Hepatology2000; 32:"/>
   <result pre="B. Hepatology2000; 32: 604–609.10960456 22HoofnagleJHDavisGLPappasSC, et al.A short course of" exact="prednisolone" post="in chronic type B hepatitis. Report of a randomized,"/>
   <result pre="the tip of the iceberg?Hepatology2015; 61: 703–711.25412906 34LaohapandCArromdeeETanwandeeTLong-term use of" exact="methotrexate" post="does not result in hepatitis B reactivation in rheumatologic"/>
   <result pre="in vitro. J Viral Hepat1999; 6: 229–236.10607235 39YingCDe ClercqENeytsJRibavirin and" exact="mycophenolic acid" post="potentiate the activity of guanine- and diaminopurine-based nucleoside analogues"/>
   <result pre="suppressing hepatitis B virus replication in liver recipients who developed" exact="lamivudine" post="resistance-no beneficial effect. Transplantation2001; 71: 154–156.11211184 42LiXTianJWuJ, et al.A"/>
   <result pre="Transplantation2001; 71: 154–156.11211184 42LiXTianJWuJ, et al.A comparison of a standard-dose" exact="prednisone" post="regimen and mycophenolate mofetil combined with a lower prednisone"/>
   <result pre="standard-dose prednisone regimen and mycophenolate mofetil combined with a lower" exact="prednisone" post="dose in chinese adults with idiopathic nephrotic syndrome who"/>
   <result pre="Intern Med2016; 164: 30–40.26595058 63HsuCHsiungCASuIJ, et al.A revisit of prophylactic" exact="lamivudine" post="for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a"/>
   <result pre="47: 844–853.18302293 64LauGKKYiuHHYFongDYT, et al.Early is superior to deferred preemptive" exact="lamivudine" post="therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology2003; 125:"/>
   <result pre="patients undergoing chemotherapy. Gastroenterology2003; 125: 1742–1749.14724827 65HuangHLiXZhuJ, et al.Entecavir vs" exact="lamivudine" post="for prevention of hepatitis B virus reactivation among patients"/>
   <result pre="66PyrpasopoulouADoumaSVassiliadisT, et al.Reactivation of chronic hepatitis B virus infection following" exact="rituximab" post="administration for rheumatoid arthritis. Rheumatol Int2011; 31: 403–404.19830433 67HuiC-KCheungWWWZhangH-Y,"/>
   <result pre="Ann Hematol2011; 90: 1219–1223.21520001 71HuangY-HHsiaoL-THongY-C, et al.Randomized controlled trial of" exact="entecavir" post="prophylaxis for rituximab-associated hepatitis B virus reactivation in patients"/>
   <result pre="J Clin Oncol2013; 31: 2765–2772.23775967 72MitroulisIHatzaraCKandiliA, et al.Long-term safety of" exact="rituximab" post="in patients with rheumatic diseases and chronic or resolved"/>
   <result pre="risk of hepatitis B virus reactivation in HBsAg-negative/anti-HBc-positive carriers receiving" exact="rituximab" post="for rheumatoid arthritis: a retrospective multicenter italian study. J"/>
   <result pre="characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving" exact="rituximab" post="for rheumatoid arthritis. Clin Exp Rheumatol35: 831–836.28375829 77KimPSHoGYPretePE, et"/>
   <result pre="Clin Exp Rheumatol35: 831–836.28375829 77KimPSHoGYPretePE, et al.Safety and efficacy of" exact="abatacept" post="in eight rheumatoid arthritis patients with chronic hepatitis B."/>
   <result pre="B. Arthritis Care Res2012; 64: 1265–1268. 78PadovanMFilippiniMTincaniA, et al.Safety of" exact="abatacept" post="in rheumatoid arthritis with serologic evidence of past or"/>
   <result pre="68: 738–743. 79FanouriakisAVassilopoulosDRepaA, et al.Hepatitis B reactivation following treatment with" exact="abatacept" post="in a patient with past hepatitis B virus infection."/>
   <result pre="agents targeting interleukins, immunoglobuli. Clin Microbiol Infect2018; 24: S21–S40.29447987 83NagashimaTMinotaSLong-term" exact="tocilizumab" post="therapy in a patient with rheumatoid arthritis and chronic"/>
   <result pre="1838–1840. 84TsuboiHTsujiiANampeiA, et al.A patient with rheumatoid arthritis treated with" exact="tocilizumab" post="together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis"/>
   <result pre="al.A patient with rheumatoid arthritis treated with tocilizumab together with" exact="lamivudine" post="prophylaxis after remission of infliximab-reactivated hepatitis B. Mod Rheumatol2011;"/>
   <result pre="infliximab-reactivated hepatitis B. Mod Rheumatol2011; 21: 701–705.21626075 85KishidaDOkudaYOnishiM, et al.Successful" exact="tocilizumab" post="treatment in a patient with adult-onset Still’s disease complicated"/>
   <result pre="amyloid A amyloidosis. Mod Rheumatol2011; 21: 215–218.20931272 86ChenL-FMoY-QJingJ, et al.Short-course" exact="tocilizumab" post="increases risk of hepatitis B virus reactivation in patients"/>
   <result pre="Int J Rheum Dis2017; 20: 859–869.28160426 87AhnSSJungSMSongJJ, et al.Safety of" exact="tocilizumab" post="in rheumatoid arthritis patients with resolved hepatitis B virus"/>
   <result pre="vulgaris in a hepatitis B virus carrier successfully treated with" exact="secukinumab" post="and entecavir combination therapy. Eur J Dermatol2017; 27: 185–186.27965188"/>
   <result pre="a hepatitis B virus carrier successfully treated with secukinumab and" exact="entecavir" post="combination therapy. Eur J Dermatol2017; 27: 185–186.27965188 91FeasterBClineAFeldmanSRSecukinumab for"/>
   <result pre="JAAD Case Reports2019; 5: 150–152.30733983 95ChiuHHuiRHuangY, et al.Safety Profile of" exact="secukinumab" post="in treatment of patients with psoriasis and concurrent hepatitis"/>
   <result pre="Derm Venereol2018; 98: 829–834.29972221 96ChiuH-YChenC-HWuM-S, et al.The safety profile of" exact="ustekinumab" post="in the treatment of patients with psoriasis and concurrent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7076747\results\search\drugs\results.xml">
   <result pre="others use T-cell depletion of the graft, for example, by" exact="alemtuzumab" post="(anti-CD52) &quot;in the bag.�? In both cases, the depleting"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7076820\results\search\drugs\results.xml">
   <result pre="al. found that four organic acids (syringic acid, 2-amino-benzoic acid," exact="salicylic acid," post="benzoic acid) from Radix isatidis could inhibit the growth"/>
   <result pre="fetal bovine serum (HyClone, UT, USA), 100 U/mL penicillin, and 100 U/mL" exact="streptomycin" post="(HyClone, UT, USA) at 37 °C with 5% CO2. Determination"/>
   <result pre="pseudorabies virus genomeJ Virol200478142444010.1128/JVI.78.1.424-440.200414671123 5.SuiXYinJRenXAntiviral effect of diammonium glycyrrhizinate and" exact="lithium" post="chloride on cell infection by pseudorabies herpesvirusAntivir Res201085234635310.1016/j.antiviral.2009.10.01419879899 6.MullerTHahnECTottewitzFKramerMKluppBGMettenleiterTCFreulingCPseudorabies"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7077210\results\search\drugs\results.xml">
   <result pre="was preloaded in a syringe, animals were anesthetized with 1.5–5%" exact="isoflurane" post="using a vaporizer, and the microchip was injected subcutaneously"/>
   <result pre="24 h for 10 days. Animals were anesthetized with 1.5–5%" exact="isoflurane" post="for IP and IV administration. For IV administration, the"/>
   <result pre="days. On day 1, all animals were anesthetized with 1.5–5%" exact="isoflurane" post="and infected IM in the gluteal muscle of the"/>
   <result pre="daily for clinical signs of rabies. Animals were euthanized by" exact="isoflurane" post="overdose at the first clinical signs of rabies (e.g.,"/>
   <result pre="Clin. Oncol.20022027428110.1200/JCO.20.1.27411773179 12.VogelzangN.TaubR.ShinD.CostanziJ.PassH.GutheilJ.GeorgiadisM.McAndrewP.KellyK.ChunH.Phase III randomized trial of onconase (ONC) vs." exact="doxorubicin" post="(DOX) in patients (pts) with unresectable malignant mesothelioma (UMM):"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7077228\results\search\drugs\results.xml">
   <result pre="One type pertains to the M2 ion channel inhibitors, including" exact="amantadine" post="and rimantadine, which block the release of viral RNA"/>
   <result pre="cytoplasm [4]. The others are neuraminidase (NA) inhibitors, including zanamivir," exact="oseltamivir" post="and peramivir, which prevent progeny virus from being released"/>
   <result pre="(Dalian, China) with purities ≥98%. Oleanane-type triterpenoids were dissolved in" exact="dimethyl sulfoxide" post="(DMSO) and diluted with PBS to &amp;lt;0.4% DMSO for"/>
   <result pre="Beit Haemek, Israel), 100 U/mL of penicillin and 100 µg/mL" exact="streptomycin" post="in a humidified atmosphere with 5% CO2. All cells"/>
   <result pre="(0.1 MOI) for 1 h at 37 °C. OA-10 or" exact="ribavirin" post="or peramivir was added before, during or after IAV"/>
   <result pre="for 1 h at 37 °C. OA-10 or ribavirin or" exact="peramivir" post="was added before, during or after IAV infection. For"/>
   <result pre="in fresh medium. In total, 80 µM of OA-10 or" exact="ribavirin" post="or peramivir was then added for 0 to 2,"/>
   <result pre="medium. In total, 80 µM of OA-10 or ribavirin or" exact="peramivir" post="was then added for 0 to 2, 2 to"/>
   <result pre="in this study. Our results showed that 15 μM of" exact="peramivir" post="exhibited a significant inhibition on IAV infections in the"/>
   <result pre="antiviral effects during virus entry. In these assays, 15 μM" exact="peramivir" post="exhibited more significant inhibition on H5N1 IAV’s replication in"/>
   <result pre="replication in both co-treatment and post-treatment modes, while 30 μM" exact="ribavirin" post="exhibited inhibition only in the post-treatment mode, and its"/>
   <result pre="addition, the combination of 40 μM OA-10 and 15 μM" exact="ribavirin" post="treatment showed a synergistic effect on reducing progeny virus"/>
   <result pre="inhibition when added after 4 hpi. On the other hand," exact="peramivir" post="blocks progeny virus release from infected cells, and did"/>
   <result pre="entry by OA-10 (earlier step) and polymerase-mediated RNA replication by" exact="ribavirin" post="(later step). It is expected that using an inhibitor"/>
   <result pre="is expected that using an inhibitor like OA-10 together with" exact="ribavirin" post="or NA inhibitors would not only enhance antiviral effects"/>
   <result pre="fresh medium containing various concentrations of OA-10 or 15 µM" exact="peramivir" post="(Per). At 24 hpi, the cells were fixed with"/>
   <result pre="was used to digitize image OD. Results from OA-10 or" exact="peramivir" post="or ribavirin treated samples were compared to those from"/>
   <result pre="to digitize image OD. Results from OA-10 or peramivir or" exact="ribavirin" post="treated samples were compared to those from corresponding DMSO-treated"/>
   <result pre="for 1 h. After two washes with PBS, OA-10 or" exact="ribavirin" post="or peramivir was added at the indicated time points"/>
   <result pre="h. After two washes with PBS, OA-10 or ribavirin or" exact="peramivir" post="was added at the indicated time points and removed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7077276\results\search\drugs\results.xml">
   <result pre="[11,12]. GAGs include heparan sulfate (HS), keratan sulfate (KS), and" exact="chondroitin sulfate" post="(CS), which are characterized by disaccharide units forming blocks"/>
   <result pre="proteinJ. Gen. Virol.2000812281228710.1099/0022-1317-81-9-228110950986 10.MisinzoG.DelputteP.L.MeertsP.LefebvreD.J.NauwynckH.J.Porcine circovirus 2 uses heparan sulfate and" exact="chondroitin sulfate" post="B glycosaminoglycans as receptors for its attachment to host"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7077318\results\search\drugs\results.xml">
   <result pre="chain with a larger volume. The compound was dissolved in" exact="dimethyl sulfoxide" post="(DMSO) at a concentration of 100 mM and stored"/>
   <result pre="coronavirus main protease 3CL(pro)Chem. Biol. Drug Des.200872344910.1111/j.1747-0285.2008.00679.x18611220 15.ChengK.W.ChengS.C.ChenW.Y.LinM.H.ChuangS.J.ChengI.H.SunC.Y.ChouC.Y.Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7078228\results\search\drugs\results.xml">
   <result pre="We have recently reported that two drugs, remdesivir (GS-5734) and" exact="chloroquine" post="(CQ) phosphate, efficiently inhibited SARS-CoV-2 infection in vitro1. Remdesivir"/>
   <result pre="have no conflict of interest. References References 1.WangMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="toxicity of chloroquineBull. World Health197979906 4.McChesneyEWAnimal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateAm. J. Med.198375111810.1016/0002-9343(83)91265-26408923 5.MautheMet al.Chloroquine inhibits autophagic flux by"/>
   <result pre="erythematosus. A clinical study with determination of serum concentrations of" exact="chloroquine" post="and hydroxychloroquineScand. J. rheumatol.1974310310810.3109/030097474091158094608161 12.HuangCet al.Clinical features of patients"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7081067\results\search\drugs\results.xml">
   <result pre="showed that several HIV inhibitors such as lopinavir, ritonavir, and" exact="saquinavir" post="produce strong interaction with the active site of SARS-CoV-2"/>
   <result pre="and in vivo to block coronavirus replication. Lopinavir (LPV) and" exact="ritonavir" post="(RTV) are protease inhibitors currently used in HIV therapy"/>
   <result pre="SARS-CoV and MERS-CoV main proteases (Savarino 2005[13]). The combination of" exact="lopinavir" post="or ritonavir with ribavirin was associated with improvement in"/>
   <result pre="MERS-CoV main proteases (Savarino 2005[13]). The combination of lopinavir or" exact="ritonavir" post="with ribavirin was associated with improvement in clinical outcome,"/>
   <result pre="proteases (Savarino 2005[13]). The combination of lopinavir or ritonavir with" exact="ribavirin" post="was associated with improvement in clinical outcome, compared with"/>
   <result pre="ribavirin was associated with improvement in clinical outcome, compared with" exact="ribavirin" post="alone, in SARS-CoV-infected patients (Lai, 2005[5]). During the MERS-CoV"/>
   <result pre="code 1UJ1/2GX4 and 6LU7 respectively. Also, HIV-1 protease bounded to" exact="lopinavir" post="under PDB code 1MIU and Bat HKU4 coronavirus PDB"/>
   <result pre="manually and then verified by a priori docking approach with" exact="lopinavir" post="by using the Achilles Blind Docking server (Sánchez-Linares et"/>
   <result pre="are showing that patients infected with SARS-CoV-2 and treated with" exact="lopinavir" post="could achieve viral clearance (Lim et al., 2020[6]). Our"/>
   <result pre="Commun202011122231924756 15SonoikiENsanzabanaCLegacJSindheKMDeRisiJRosenthalPJAltered Plasmodium falciparum sensitivity to the antiretroviral protease inhibitor" exact="lopinavir" post="associated with polymorphisms in pfmdr1Antimicrob Agents Chemother20176110194901916 16ValdiviesoERangelAMorenoJSaugarJMCañavateCAlvarJet al.Effects"/>
   <result pre="all-atom additive biological force fieldsJ Comput Chem20101671690 18WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7089181\results\search\drugs\results.xml">
   <result pre="activity in the central nervous system (CNS) cells compared to" exact="sofosbuvir" post="(Bugert-MBDC-2018-GO3), novel protease inhibitors for Zika virus as surrogate"/>
   <result pre="detail elsewhere [133]. Further candidate anti-poxvirus drugs include kinase inhibitors" exact="imatinib" post="(Gleevec/STI-571; [122, 123]) and olomoucine [61], terameprocol [119], mitoxandrone"/>
   <result pre="these two Mabs for all further treatments [150]. Remdesivir (GS-5734;1-cyano-substituted" exact="adenosine" post="nucleotide analogue), a nucleoside-analogue prodrug and lead compound of"/>
   <result pre="shown the efficacy of favipiravir [13, 14]). While extensively tested," exact="ribavirin" post="is not FDA approved for EBOV [65]. Other promising"/>
   <result pre="alleviating peripheral symptoms but not providing cure [1, 3]. Intranasal" exact="ribavirin" post="may be more effective. Ribavirin resolves joint swelling in"/>
   <result pre="FDA approval is pending [49]. An in vitro comparison between" exact="ribavirin" post="and favipiravir revealed that efficacy is cell-type dependent [45]."/>
   <result pre="[141]. Compounds with known cellular targets include the cancer drugs" exact="mefenamic acid" post="and sorafenib, inhibiting replication of CHIKV and other alphaviruses"/>
   <result pre="clinical trials were unable to show significant beneficial effects of" exact="ribavirin" post="versus CCHFV [70, 78]. Further interesting candidates for virus-specific"/>
   <result pre="by the FDA (Table 1), the most promising candidate is" exact="sofosbuvir" post="[18]. Sofosbuvir was initially developed and approved by FDA"/>
   <result pre="of influenza B viruses [42]. Anti-orthomyxovirus drugs. FDA-approved neuraminidase inhibitors" exact="oseltamivir" post="(Tamiflu®), zanamivir (Relenza®), laninamivir (Inavir®), and peramivir have marginal"/>
   <result pre="B viruses [42]. Anti-orthomyxovirus drugs. FDA-approved neuraminidase inhibitors oseltamivir (Tamiflu®)," exact="zanamivir" post="(Relenza®), laninamivir (Inavir®), and peramivir have marginal clinical benefits"/>
   <result pre="FDA-approved neuraminidase inhibitors oseltamivir (Tamiflu®), zanamivir (Relenza®), laninamivir (Inavir®), and" exact="peramivir" post="have marginal clinical benefits only when given early but"/>
   <result pre="the polymerase PA-PB1 subunits of influenza virus [106]. Alicyclic amines/aminoadamantanes" exact="amantadine" post="and rimantadine, first described in 1985 as M2 protein"/>
   <result pre="Cochrane review found no evidence for efficacy or safety of" exact="amantadine" post="for the treatment of influenza A [6]. However, their"/>
   <result pre="combinations of antiviral compounds with similar or different MoA are" exact="ribavirin" post="with vitamin A in measles infections [12], ribavirin with"/>
   <result pre="MoA are ribavirin with vitamin A in measles infections [12]," exact="ribavirin" post="with favipiravir in Zika virus infections [75], and ribavirin"/>
   <result pre="[12], ribavirin with favipiravir in Zika virus infections [75], and" exact="ribavirin" post="with mefenamic acid in infections with Chikungunya virus [126]."/>
   <result pre="with favipiravir in Zika virus infections [75], and ribavirin with" exact="mefenamic acid" post="in infections with Chikungunya virus [126]. Antiviral drug combinations"/>
   <result pre="viruses in mice [134]. Previously thought as a one-family-broad-spectrum compound," exact="sofosbuvir" post="(Sovaldi™, Soforal™) has in vitro and in vivo activity"/>
   <result pre="in extracts [27]. Treatment of viral hemorrhagic fevers (VHF) with" exact="ribavirin" post="Viral hemorrhagic fevers (VHFs) cause the highest mortality in"/>
   <result pre="VHF and is used under compassionate use protocols only. Intravenous" exact="ribavirin" post="reduces mortality of HFRS if combined with hemodialysis and"/>
   <result pre="bunyaviruses (HFRS, Crimean-Congo fever, and Rift Valley fever). However, intravenous" exact="ribavirin" post="does not show any benefits for the treatment of"/>
   <result pre="by mitoxantroneAntivir Res20129330530810.1016/j.antiviral.2011.12.00122182595 6.Alves GalvãoMGRocha Crispino SantosMAAlves da CunhaAJAmantadine and" exact="rimantadine" post="for influenza A in children and the elderlyCochrane Database"/>
   <result pre="616 antiviral activity against chikungunya virusAntivir Res201398121810.1016/j.antiviral.2013.01.00223380636 10.BazMCarbonneauJRhéaumeCCavanaghM-HBoivinGCombination therapy with" exact="oseltamivir" post="and favipiravir delays mortality but does not prevent oseltamivir"/>
   <result pre="with oseltamivir and favipiravir delays mortality but does not prevent" exact="oseltamivir" post="resistance in immunodeficient mice infected with pandemic A(H1N1) Influenza"/>
   <result pre="BeinekeABaumgärtnerWWohlseinPCross-species transmission of canine distemper virus—an updateOne Health20151495910.1016/j.onehlt.2015.09.00228616465 12.BichonAAubryCBenarousLDrouetHZandottiCParolaPLagierJ-CCase report:" exact="ribavirin" post="and vitamin A in a severe case of measlesMedicine"/>
   <result pre="hazards in the Kosovo warNephrol Dial Transpl1999141843184410.1093/ndt/14.8.1843 18.Bullard-FeibelmanKMGoveroJZhuZSalazarVVeselinovicMDiamondMSGeissBJThe FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntivir Res201713713414010.1016/j.antiviral.2016.11.02327902933 19.CallawayE‘Make Ebola a thing"/>
   <result pre="CDCGlobal measles mortality, 2000–2008MMWR2009581321132619959985 23.ChanJF-WChikKK-HYuanSYipCC-YZhuZTeeK-MTsangJO-LChanCC-SPoonVK-MLuGZhangAJLaiK-KChanK-HKaoRY-TYuenK-YNovel antiviral activity and mechanism of" exact="bromocriptine" post="as a Zika virus NS2B-NS3 protease inhibitorAntivir Res.2017141293710.1016/j.antiviral.2017.02.00228185815 24.ChanJF-WZhuZChuHYuanSChikKK-HChanCC-SPoonVK-MYipCC-YZhangXTsangJO-LZouZTeeK-MShuaiHLuGYuenK-YThe"/>
   <result pre="bromocriptine as a Zika virus NS2B-NS3 protease inhibitorAntivir Res.2017141293710.1016/j.antiviral.2017.02.00228185815 24.ChanJF-WZhuZChuHYuanSChikKK-HChanCC-SPoonVK-MYipCC-YZhangXTsangJO-LZouZTeeK-MShuaiHLuGYuenK-YThe" exact="celecoxib" post="derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via"/>
   <result pre="yearsClin Microbiol Rev20162969574710.1128/CMR.00102-1527281742 33.de FreitasCSHigaLMSacramentoCQFerreiraACReisPADelvecchioRMonteiroFLBarbosa-LimaGJames-WestgarthHVieiraYRMattosMRochaNHoelzLVBLemeRPPBastosMMRodriguesGOLLopesCEMQueiroz-JuniorCMLimaCXCostaVVTeixeiraMMBozzaFABozzaPTBoechatNTanuriASouzaTMLYellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl Trop Dis.201913707210.1371/journal.pntd.0007072"/>
   <result pre="Epidemiological Report for 2016. https://www.ecdc.europa.eu/en/publications-data/hantavirus-infection-annual-epidemiological-report-2016 39.EyerLZouharováDŠirmarováJFojtíkováMŠtefánikMHaviernikJNenckaRde ClercqERůžekDAntiviral activity of the" exact="adenosine" post="analogue BCX4430 against West Nile virus and tick-borne flavivirusesAntivir"/>
   <result pre="weapons-a primer for microbiologistsAnnu Rev Microbiol20015523525310.1146/annurev.micro.55.1.23511544355 59.HawmanDWHaddockEMeade-WhiteKWilliamsonBHanleyPWRosenkeKKomenoTFurutaYGowenBBFeldmannHFavipiravir (T-705) but not" exact="ribavirin" post="is effective against two distinct strains of Crimean-Congo hemorrhagic"/>
   <result pre="and control strategy in admitted patientsCasp J Intern Med20123443444 69.JeulinHVenardVCarapitoDFinanceCKedzierewiczFEffective" exact="ribavirin" post="concentration in mice brain using cyclodextrin as a drug"/>
   <result pre="protein against a small-molecule membrane fusion inhibitorVirus Res2019259283710.1016/j.virusres.2018.10.00330296457 75.KimJ-ASeongR-KKumarMShinOSFavipiravir and" exact="ribavirin" post="inhibit replication of Asian and African strains of Zika"/>
   <result pre="drug screening in primary human cellsAntivir Res2018150202910.1016/j.antiviral.2017.12.00529224735 78.KoksalIYilmazGAksoyFAydinHYavuzIIskenderSAkcayKErensoySCaylanRAydinKThe efficacy of" exact="ribavirin" post="in the treatment of Crimean-Congo hemorrhagic fever in Eastern"/>
   <result pre="89.LubySPThe pandemic potential of Nipah virusAntivir Res2013100384310.1016/j.antiviral.2013.07.01123911335 90.LundbergLBrahmsAHooperICareyBLinS-CDahalBNarayananAKehn-HallKRepurposed FDA-Approved drug" exact="sorafenib" post="reduces replication of Venezuelan equine encephalitis virus and other"/>
   <result pre="Lassa virus antiviral targets an arenavirus virulence determinantPLoS Pathog201814e100743910.1371/journal.ppat.100743930576397 92.MalinoskiFJHastySEUsseryMADalrympleJMProphylactic" exact="ribavirin" post="treatment of dengue type 1 infection in rhesus monkeysAntivir"/>
   <result pre="virus serotypes in AG129 mouse models: proof-of-concept studies with the" exact="adenosine" post="nucleoside inhibitor NITD-008Antivir Res201815410410910.1016/j.antiviral.2018.04.01229665374 102.MohrELMcMullanLKLoMKSpenglerJRBergeronÉAlbariñoCGShrivastava-RanjanPChiangC-FNicholSTSpiropoulouCFFlintMInhibitors of cellular kinases with"/>
   <result pre="virus (smallpox)Antimicrob Agents Chemother201357126246625310.1128/aac.00977-1324100494 105.MumtazNJimmersonLCBushmanLRKiserJJAronGReuskenCBEMKoopmansMPGvan KampenJJACell-line dependent antiviral activity of" exact="sofosbuvir" post="against Zika virusAntivir Res.201714616116310.1016/j.antiviral.2017.09.00428912011 106.NannettiGMassariSMercorelliBBertagninCDesantisJPalùGTabarriniOLoregianAPotent and broad-spectrum cycloheptathiophene-3-carboxamide compounds"/>
   <result pre="biological and chemical (NBC) defensive operations—part II 108.NelsonDRet al.Balapiravir plus" exact="peginterferon alfa-2a" post="(40KD)/ribavirin in a randomized trial of hepatitis C genotype"/>
   <result pre="of GTP pool is not the predominant mechanism by which" exact="ribavirin" post="exerts its antiviral effect on Lassa virusAntivir Res201191899310.1016/j.antiviral.2011.05.00621616094 113.OoARausaluKMeritsAHiggsSVanlandinghamDBakarSAZandiKDeciphering"/>
   <result pre="116.ParkerSTouchetteEOberleCAlmondMRobertsonATrostLCLampertBPainterGBullerRMEfficacy of therapeutic intervention with an oral ether-lipid analogue of" exact="cidofovir" post="(CMX001) in a lethal mousepox modelAntivir Res.200877394910.1016/j.antiviral.2007.08.00317904231 117.PetersenEKanteleAKoopmansMAsogunDYinka-OgunleyeAIhekweazuCZumlaAHuman monkeypox:"/>
   <result pre="infection in macaquesEmerg Infect Dis2018241696169910.3201/eid2409.18023329882740 126.RothanHABahraniHAbdulrahmanAYMohamedZTeohTCOthmanSRashidNNRahmanNAYusofRMefenamic acid in combination with" exact="ribavirin" post="shows significant effects in reducing chikungunya virus infection In"/>
   <result pre="members of the family BunyaviridaeVirus Adapt Treat2010292010.2147/VAAT.S6903 136.TaylorRKotianPWarrenTPanchalRBavariSJulanderJDoboSRoseAEl-KattanYTaubenheimBBabuYSheridanWPBCX4430—a broad-spectrum antiviral" exact="adenosine" post="nucleoside analog under development for the treatment of Ebola"/>
   <result pre="Afr Med J Suid-Afr Tydskr Vir Geneeskd198568718721 141.VargheseFSKaukinenPGläskerSBespalovMHanskiLWennerbergKKümmererBMAholaTDiscovery of berberine," exact="abamectin" post="and ivermectin as antivirals against chikungunya and other alphavirusesAntivir"/>
   <result pre="J Suid-Afr Tydskr Vir Geneeskd198568718721 141.VargheseFSKaukinenPGläskerSBespalovMHanskiLWennerbergKKümmererBMAholaTDiscovery of berberine, abamectin and" exact="ivermectin" post="as antivirals against chikungunya and other alphavirusesAntivir Res201612611712410.1016/j.antiviral.2015.12.01226752081 142.WaltonTEJohnsonKMMonathTPVenezuelan"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7089605\results\search\drugs\results.xml">
   <result pre="activity of the IMP dehydrogenase inhibitor VX-497: a comparison with" exact="ribavirin" post="and demonstration of antiviral additivity with alpha interferonAntimicrob. Agents"/>
   <result pre="of antiviral additivity with alpha interferonAntimicrob. Agents Chemother.44200085986610722482 30WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="PSI-7851 and its diastereoisomer PSI-7977J. Biol. Chem.2852010343373434720801890 49Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.The FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntivir. Res.137201713414027902933 50SacramentoC.Q.de MeloG.R.RochaN.LVBH.MesquitaM.de FreitasC.S.The clinically"/>
   <result pre="virus infectionAntivir. Res.137201713414027902933 50SacramentoC.Q.de MeloG.R.RochaN.LVBH.MesquitaM.de FreitasC.S.The clinically approved antiviral drug" exact="sofosbuvir" post="impairs Brazilian zika virus replicationSci Rep.720174092028098253 51Cretton-ScottE.PerigaudC.PeyrottesS.LickliderL.CamireM.LarssonM.588 in vitro"/>
   <result pre="diisobutyryl prodrug (R7128) are better than their parent nucleotides and" exact="ribavirin" post="in hepatitis C virus inhibition: a molecular modeling studyJ."/>
   <result pre="C virus, in healthy subjectsAntimicrob. Agents Chemother.552011768121060109 54GaneE.J.StedmanC.A.HylandR.H.DingX.SvarovskaiaE.SymondsW.T.Nucleotide polymerase inhibitor" exact="sofosbuvir" post="plus ribavirin for hepatitis CN. Engl. J. Med.3682013344423281974 55GlueP.The"/>
   <result pre="in healthy subjectsAntimicrob. Agents Chemother.552011768121060109 54GaneE.J.StedmanC.A.HylandR.H.DingX.SvarovskaiaE.SymondsW.T.Nucleotide polymerase inhibitor sofosbuvir plus" exact="ribavirin" post="for hepatitis CN. Engl. J. Med.3682013344423281974 55GlueP.The Clinical Pharmacology"/>
   <result pre="Pharmacology of Ribavirin. Seminars in Liver Disease19991724 56MannsM.P.McHutchisonJ.G.GordonS.C.RustgiV.K.ShiffmanM.ReindollarR.Peginterferon alfa-2b plus" exact="ribavirin" post="compared with interferon alfa-2b plus ribavirin for initial treatment"/>
   <result pre="Disease19991724 56MannsM.P.McHutchisonJ.G.GordonS.C.RustgiV.K.ShiffmanM.ReindollarR.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis C: a randomised"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7090514\results\search\drugs\results.xml">
   <result pre="pharmaceutical care of the five antiviral treatments (IFN-α, lopinavir/ritonavir, ribavirin," exact="chloroquine" post="diphosphate and arbidol) in children with COVID-19 (Table 1)."/>
   <result pre="in patients with liver dysfunction IFN-α interferon-α, LPVr lopinavir/ritonavir, CD" exact="chloroquine" post="diphosphate, COVID-19 coronavirus disease 2019, CrCl creatinine clearance, SCr"/>
   <result pre="these symptoms should be closely monitored in children. For LPVr," exact="lopinavir" post="is a substrate of CYP3A enzyme, and ritonavir is"/>
   <result pre="For LPVr, lopinavir is a substrate of CYP3A enzyme, and" exact="ritonavir" post="is a strong inhibitor of CYP3A enzyme. LPVr should"/>
   <result pre="and DNA viruses. Different dosage forms and age restrictions of" exact="ribavirin" post="can be seen in China and other countries. In"/>
   <result pre="can be seen in China and other countries. In China," exact="ribavirin" post="is available in injections, oral dosage forms (capsules, granules,"/>
   <result pre="out in children under 6 years in China, so oral" exact="ribavirin" post="is not recommended to be used in children younger"/>
   <result pre="in children aged 3 years or older. Intravenous infusion of" exact="ribavirin" post="injections at a dose of 10 mg/kg every time"/>
   <result pre="function. In patients with creatinine clearance (CrCl) below 50 mL/min," exact="ribavirin" post="is not recommended. In patients with serum creatinine (SCr)"/>
   <result pre="In patients with serum creatinine (SCr) higher than 2 mg/dL," exact="ribavirin" post="should be discontinued. The most common adverse reactions of"/>
   <result pre="ribavirin should be discontinued. The most common adverse reactions of" exact="ribavirin" post="in children include fever (80%), headache (62%), neutropenia (33%),"/>
   <result pre="could lead to hemolytic anemia [21, 22]. Large doses of" exact="ribavirin" post="could cause decreased hemoglobin and serious heart damage. Children"/>
   <result pre="diseases should be suggested to avoid using ribavirin. If necessary," exact="ribavirin" post="should not be given at a high dose and"/>
   <result pre="of 50 mg/kg according to the instruction. A report regarded" exact="chloroquine" post="concentration &amp;gt; 25 μmol/L as a fatal predictor [25]. Extreme caution"/>
   <result pre="Accessed 19 Feb 2020. 2.FalzaranoDde WitERasmussenALFeldmannFOkumuraAScottDPet al.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat Med2013191313131710.1038/nm.336224013700 3.ShangXYHuangYLiuEMChenQCaoLLuMet al.A"/>
   <result pre="of the clinical efficacy and safety of interferon nebulization and" exact="ribavirin" post="in the treatment of infantile herpes anginaChin Med Pharm201778082"/>
   <result pre="(the second edition)J ZheJiang Univ (Med Sci)202010.3785/j.issn.1008-9292.2020.02.01 18.DailyMed. Kaletra-lopinavir and" exact="ritonavir" post="tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fa34341-1dce-4bad-b97e-f466e96a0bbe. Accessed 1 Feb 2020. 19.UpToDate."/>
   <result pre="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04d2b6f4-bd9b-4871-9527-92c81aa2d4d0. Accessed 11 Feb 2020. 21.De FranceschiLFattovichGTurriniFAyiKBrugnaraCManzatoFet al.Hemolytic anemia-induced by" exact="ribavirin" post="therapy in patients with chronic hepatitis C virus infection:"/>
   <result pre="review of 182 casesEva Ana Drug Use Hosp Chin200745256 23.GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="on printing and distributing the adjustment of dosage regimen of" exact="chloroquine" post="diphosphate in COVID-19. https://www.nhc.gov.cn/yzygj/s7653p/202002/0293d017621941f6b2a4890035243730.shtml. Accessed 28 Feb 2020. 25.RiouBBarriotPRimailhoABaudFJTreatment"/>
   <result pre="in COVID-19. https://www.nhc.gov.cn/yzygj/s7653p/202002/0293d017621941f6b2a4890035243730.shtml. Accessed 28 Feb 2020. 25.RiouBBarriotPRimailhoABaudFJTreatment of severe" exact="chloroquine" post="poisoningN Engl J Med19883181610.1056/NEJM1988010731801013336379 26.collab: Multicenter Collaboration Group of"/>
   <result pre="Chloroquine in the Treatment of Novel Coronavirus PneumoniaExpert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumoniaChin J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7090748\results\search\drugs\results.xml">
   <result pre="efficiency of the FDA-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat," exact="chloroquine" post="(CQ) and two well-known broad-spectrum antiviral drugs remdesivir (RDV,"/>
   <result pre="clinical drugs for treatment of 2019-nCoV infections. RDV is an" exact="adenosine" post="analogue prodrug and can be incorporated into nascent chains"/>
   <result pre="Republic of China (2020) http://www.nhc.gov.cn/xcs/yqfkdt/202001/e71bd2e7a0824ca69f87bbf1bef2a3c9.shtml RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="China (2020) http://www.nhc.gov.cn/xcs/yqfkdt/202001/e71bd2e7a0824ca69f87bbf1bef2a3c9.shtml RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="systemic lupus erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology20152323126910.1007/s10787-015-0239-y26246395 SavarinoABoelaertJRCassoneAMajoriGCaudaRobertoEffects of" exact="chloroquine" post="on viral infections: an old drug against today's diseasesLancet"/>
   <result pre="inhibits both epidemic and zoonotic coronavirusesSci Trans Med201710.1126/scitranslmed.aal3653 WangMCaoRZhangLYangXLiuJXuMShiZLHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7091034\results\search\drugs\results.xml">
   <result pre="baloxavirEmerg Infect Dis2019251969197210.3201/eid2510.19060731287050 23.SugayaNOhashiYLong-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus" exact="oseltamivir" post="as treatment for children with influenza virus infectionAntimicrob Agents"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7091927\results\search\drugs\results.xml">
   <result pre="from marine sponges and subsequently contributed to the synthesis of" exact="vidarabine" post="(arabinosyladenine), which is used for the treatment of herpes"/>
   <result pre="2 (M2) inhibitors (amantadine and rimantadine), NA inhibitors (zanamivir, oseltamivir," exact="peramivir" post="and laninamivir octanoate) and viral RNA-dependent RNA polymerase inhibitors"/>
   <result pre="1966 to treat influenza A virus infections. The target of" exact="amantadine" post="is M2 integral membrane protein, which exhibits H+ ion"/>
   <result pre="of the viral genome into the cytoplasm35 (Figure 1). However," exact="amantadine" post="and rimantadine, a derivative of amantadine, are not currently"/>
   <result pre="with viral membrane proteins (HA, NA and M2). Amantadine and" exact="rimantadine" post="inhibit M2 ion channel activity, and therefore, inhibit release"/>
   <result pre="viral mRNA by binding to viral polymerase complex. Favipiravir and" exact="ribavirin" post="inhibit viral RNA synthesis. Zanamivir, oseltamivir, peramivir and laninamivir"/>
   <result pre="complex. Favipiravir and ribavirin inhibit viral RNA synthesis. Zanamivir, oseltamivir," exact="peramivir" post="and laninamivir octanoate all inhibit neuraminidase activity of NA"/>
   <result pre="various influenza A and B viruses.40 The guanidine group in" exact="zanamivir" post="is suggested to form salt bridges with Glu119 in"/>
   <result pre="interactions with Glu227 of NA. Because of poor oral bioavailability," exact="zanamivir" post="is administered by inhalation. To improve oral bioavailability, novel"/>
   <result pre="is an ethylester prodrug of GS4071. The oral bioavailability of" exact="oseltamivir" post="was improved compared with that of GS4071.42 After zanamivir"/>
   <result pre="of oseltamivir was improved compared with that of GS4071.42 After" exact="zanamivir" post="and oseltamivir, two NA inhibitors, peramivir and laninamivir octanoate,"/>
   <result pre="that of GS4071.42 After zanamivir and oseltamivir, two NA inhibitors," exact="peramivir" post="and laninamivir octanoate, were launched.43, 44 Peramivir is administered"/>
   <result pre="influenza A and influenza B virus infections. Two approved drugs," exact="ribavirin" post="and T-705 (favipiravir), inhibit influenza viral RNA synthesis (Figure"/>
   <result pre="(interferon-α and pegylated interferon-α) and nucleos(t)ide analogs (lamivudine, adefovir, telbivudine," exact="entecavir" post="and tenofovir), which are useful for therapeutic treatment to"/>
   <result pre="an indispensable drug target for HBV treatment. Indeed, a new" exact="tenofovir" post="derivative, tenofovir alafenamide (Vemlidy), was recently approved and its"/>
   <result pre="drug target for HBV treatment. Indeed, a new tenofovir derivative," exact="tenofovir" post="alafenamide (Vemlidy), was recently approved and its improved pharmacological"/>
   <result pre="and is currently in phase II clinical trials.79, 80 Recently," exact="cyclosporine" post="A, a fungal cyclic polypeptide, and its analogs have"/>
   <result pre="Hendra and Nipah viruses.88, 89, 90 The potential activity of" exact="ribavirin" post="against broad-spectrum RNA viruses can be exerted by both"/>
   <result pre="decreasing intracellular GTP levels.91 Nucleotide pool imbalances that result from" exact="ribavirin" post="treatment could cause a reduction of viral polymerase activity"/>
   <result pre="cyclophilins have been semi-synthesized.118 A CsA derivative, alisporivir (DEB025), with" exact="ribavirin" post="has been studied as an anti-HCV drug and is"/>
   <result pre="formycin BJ. Antibiot. (Tokyo)1966192862876013241 5SawaTFukagawaYHommaITakeuchiTUmezawaHMode of inhibition of coformycin on" exact="adenosine" post="deaminaseJ. Antibiot. (Tokyo)1967202272316072897 6ShimadaNOxanosine, a novel nucleoside from actinomycetesJ."/>
   <result pre="and its relativesJ. Antibiot. (Tokyo)1974278018044457528 19KunimotoTHoriMUmezawaHModes of action of phleomycin," exact="bleomycin" post="and formycin on HeLa S3 cells in synchronized cultureJ."/>
   <result pre="1,2,4-triazole- 3-carboxamideScience19721777057064340949 49ErikssonBInhibition of influenza virus ribonucleic acid polymerase by" exact="ribavirin" post="triphosphate inhibition of influenza virus ribonucleic acid polymerase by"/>
   <result pre="ribavirin triphosphate inhibition of influenza virus ribonucleic acid polymerase by" exact="ribavirin" post="triphosphateAntimicrob. Agents Chemother.197711946951879760 50FurutaYIn vitro and in vivo activities"/>
   <result pre="by quantitative real-time PCR of RNA accumulation, the effect of" exact="ribavirin" post="and the attenuation of transcriptionArch. Virol.200515052153215526144 89ChangK-OGeorgeDWInterferons and Ribavirin"/>
   <result pre="norwalk virus replication in replicon-bearing cellsJ. Virol.200781121111211817855555 90KoffWCElmJLHalsteadSBAntiviral effects if" exact="ribavirin" post="and 6-mercapto-9-tetrahydro-2-furylpurine against dengue viruses in vitroAntiviral Res.1982269797201778 91StreeterDGMechanism"/>
   <result pre="against Ebola virus in rhesus monkeysNature201653138138526934220 96EyerLAntiviral activity of the" exact="adenosine" post="analogue BCX4430 against West Nile virus and tick-borne flavivirusesAntiviral"/>
   <result pre="their potential for combination therapy with interferonHepatology20064411712516799963 103PengJProtective effect of" exact="fluvastatin" post="on influenza virus infectionMol. Med. Rep.201492221222624676773 104GiguèreJTremblayMJStatin compounds reduce"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7092597\results\search\drugs\results.xml">
   <result pre="and H1N1 present resistance to M2 ion channel inhibitors, including" exact="amantadine" post="and rimantadine [4]. Furthermore, recent influenza strains, including those"/>
   <result pre="present resistance to M2 ion channel inhibitors, including amantadine and" exact="rimantadine" post="[4]. Furthermore, recent influenza strains, including those responsible for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7092853\results\search\drugs\results.xml">
   <result pre="Economic and Technological Development Zone, China), was dissolved in 100%" exact="dimethyl sulfoxide" post="(DMSO) as a 20 mM stock solution and stored"/>
   <result pre="infection period, the cells were overlaid with DMEM containing 1.5%" exact="methylcellulose" post="and 2% FBS, and then incubated for two days."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7093024\results\search\drugs\results.xml">
   <result pre="United States), 1000 units/mL of penicillin, and 100 μg/mL of" exact="streptomycin" post="(Invitrogen, Carlsbad, CA, United States). Infections were performed in"/>
   <result pre="Figure 2A, at a concentration of 12.5 μM, corilagin and" exact="ellagic acid" post="showed about 40% inhibition, while CHLA, CHLI, and 1,2,3,4,6-pentagalloyllucose"/>
   <result pre="CHLI, and 1,2,3,4,6-pentagalloyllucose (PGG) showed &amp;gt; 90% inhibition. Since corilagin," exact="ellagic acid," post="and PGG have been well characterized for their antiviral"/>
   <result pre="virus release in a dose-dependent manner, like the positive control" exact="oseltamivir" post="phosphate (Figure 4A). FIGURE 4 CHLA and CHLI block"/>
   <result pre="potency of CHLA and CHLI with the marketed NA inhibitor" exact="oseltamivir" post="carboxylate, a yield reduction assay was performed with six"/>
   <result pre="CHLI (1.58 μM) upon A/H1N1/PR8 were lower than that of" exact="oseltamivir" post="carboxylate (3.92 μM), suggesting their comparable activities (Figure 5A)."/>
   <result pre="CHLI (Figures 5D,E).Interestingly, NA/H274Y in A/H1N1/pdm(09) virus conferred resistance to" exact="oseltamivir" post="carboxylate, but the potency of CHLA and CHLI was"/>
   <result pre="FIGURE 5 Dose–response curves of CHLA, CHLI, and reference compound" exact="oseltamivir" post="acid against virus replication in a yield reduction assay."/>
   <result pre="for the prophylaxis and treatment of influenza virus infections, including" exact="oseltamivir" post="(Shobugawa et al., 2012), zanamivir (von Itzstein et al.,"/>
   <result pre="of influenza virus infections, including oseltamivir (Shobugawa et al., 2012)," exact="zanamivir" post="(von Itzstein et al., 1993), peramivir (Alame et al.,"/>
   <result pre="(Shobugawa et al., 2012), zanamivir (von Itzstein et al., 1993)," exact="peramivir" post="(Alame et al., 2016), and laninamivir (Kashiwagi et al.,"/>
   <result pre="2016), and laninamivir (Kashiwagi et al., 2016). Among these drugs," exact="oseltamivir" post="remains a first-line therapy since it was approved in"/>
   <result pre="therapy since it was approved in 1999. However, resistance to" exact="oseltamivir" post="has constantly been reported due to its wide use"/>
   <result pre="NAs (Li et al., 2010; Air, 2012). Upon binding of" exact="oseltamivir" post="or zanamivir, the open 150-loop of group 1 NAs"/>
   <result pre="a deficient 150-cavity in its crystal structure, conferring resistance to" exact="oseltamivir" post="(Li et al., 2010). In addition, another auxiliary binding"/>
   <result pre="G.Rocha Crispino SantosM. A.Alves da CunhaA. J. (2014). Amantadine and" exact="rimantadine" post="for influenza A in children and the elderly.Cochrane Database"/>
   <result pre="activity of strictinin from Pu′er tea after thermal degradation to" exact="ellagic acid" post="and gallic acid.J. Food Drug Anal.23116–123. 10.1016/j.jfda.2014.07.00728911434 ColmanP. M."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7093072\results\search\drugs\results.xml">
   <result pre="resulting in over 3000 deaths. Potential therapeutic strategies, including remdesivir," exact="chloroquine" post="phosphate, abidol, lopinavir/ritonavir, plasma, antibody, vaccine and stem cells"/>
   <result pre="need for effective therapeutic intervention. Coronavirus 2019-nCoV SARS-COV-2 COVID-19 remdesivir" exact="chloroquine" post="phosphate abidol lopinavir/ ritonavir plasma. 1. Introduction Since the"/>
   <result pre="intervention. Coronavirus 2019-nCoV SARS-COV-2 COVID-19 remdesivir chloroquine phosphate abidol lopinavir/" exact="ritonavir" post="plasma. 1. Introduction Since the beginning of December 2019,"/>
   <result pre="In addition, other antiviral nucleotide analogs such as fapivir and" exact="ribavirin" post="are undergoing clinical trials. Fapivir is a drug approved"/>
   <result pre="virus replication7. The results from in vitro studies suggest that" exact="chloroquine" post="can actively inhibit SARS-COV-24. Both animal experiments and clinical"/>
   <result pre="currently in progress. Results from preliminary clinical trials show that" exact="chloroquine" post="phosphate has promising effects on patients with COVID-19. Of"/>
   <result pre="patients with COVID-19. Of note, it has been reported that" exact="chloroquine" post="may cause adverse reactions such as ocular disorders, immune"/>
   <result pre="treatment. Lopinavir inhibits viral protease resulting in immature/non-infectious virus particles;" exact="ritonavir" post="inhibits the degradation of lopinavir in the liver and"/>
   <result pre="resulting in immature/non-infectious virus particles; ritonavir inhibits the degradation of" exact="lopinavir" post="in the liver and thereby extends lopinavir’s half-life. Results"/>
   <result pre="soon in a hospital in Wuhan, China. In addition, since" exact="darunavir" post="(trade name: Prozekal) is another protease inhibitor used for"/>
   <result pre="another protease inhibitor used for HIV treatment, a combination of" exact="darunavir" post="and ritonavir could also be a potential treatment of"/>
   <result pre="inhibitor used for HIV treatment, a combination of darunavir and" exact="ritonavir" post="could also be a potential treatment of COVID-19, especially"/>
   <result pre="could also be a potential treatment of COVID-19, especially since" exact="darunavir" post="has been approved in China since 2018 for HIV"/>
   <result pre="MTranchevaIvaFengJoy YBarauskasOnaXuYiliWongPamelaBraunMolly RFlintMikeMcMullanLaura KChenShan-ShanFearnsRachelSwaminathanSwamiMayersDouglas LSpiropoulouChristina FLeeWilliam ANicholStuart TCihlarTomasBavariSinaNature531201626934220 4Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="GNicholStuart TVirology journal2200516115318 8Chloroquine.Drugs.com, Accessed in March 2020.https://www.drugs.com/pro/chloroquine.html 9Abidol and" exact="darunavir" post="effectively inhibit coronavirus.Tengxun News, February 4, 20202020https://new.qq.com/omn/NEW20200/NEW2020020401256700.html?pgv_ref=aio2015. 10ClinicalTrials.govU.S. National"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7093363\results\search\drugs\results.xml">
   <result pre="Looking back on the medications used to fight SARS-CoV, initially" exact="ribavirin" post="was recognized as a widely active antiviral drug that"/>
   <result pre="little use to SARS patients. The in vitro activities of" exact="ribavirin" post="on the replication of SARS-CoV are highly variable, depending"/>
   <result pre="assays. Many SARS patients were treated with a combination of" exact="ribavirin" post="and corticosteroids, given such poor prognosis linked to drug"/>
   <result pre="previous anti-SARS studies and computer simulations, older drugs, like cinnamon" exact="thiamine" post="and cyclosporin A (CsA), could be effective against 2019-nCoV."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7093748\results\search\drugs\results.xml">
   <result pre="denied prior history of chicken pox. He took immunosuppressants including" exact="methotrexate" post="(12.5 mg per week), azathioprine (100 mg per day) and prednisolone"/>
   <result pre="chicken pox. He took immunosuppressants including methotrexate (12.5 mg per week)," exact="azathioprine" post="(100 mg per day) and prednisolone (10 mg per day) for"/>
   <result pre="including methotrexate (12.5 mg per week), azathioprine (100 mg per day) and" exact="prednisolone" post="(10 mg per day) for his underlying cutaneous leukocytoclastic vasculitis"/>
   <result pre="Under the impression of varicella zoster complicated with hepatitis, oral" exact="famciclovir" post="500 mg three times per day was prescribed and his"/>
   <result pre="serious infection in immunocompromised hosts [9]. The administration of oral" exact="famciclovir" post="treatment in immunocompromised patients with disseminated cutaneous and visceral"/>
   <result pre="chicken pox after recent contact with diseased patients and oral" exact="famciclovir" post="was prescribed incorrectly for disseminated infection in immunocompromised host"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7094090\results\search\drugs\results.xml">
   <result pre="to potential antiviral drug candidates such as remdesivir, baricitinib, and" exact="chloroquine" post="for the treatment of this disease. Table 1 Notable"/>
   <result pre="Cancer, Imperial College London, UK 13 Cell Research Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="target these proteases in other viruses such as HIV drugs," exact="lopinavir" post="and ritonavir, have been explored.19 RdRp is the RNA"/>
   <result pre="inhibitors that may inhibit the viral proteases: 3CLpro or PLpro" exact="lopinavir" post="and ritonavir are approved drug combination for HIV infection"/>
   <result pre="may inhibit the viral proteases: 3CLpro or PLpro lopinavir and" exact="ritonavir" post="are approved drug combination for HIV infection ritonavir19,37c 155213-67-5"/>
   <result pre="of selected similar substance Registry Number of selected similar substance" exact="ribavirin" post="(36791-04-5) 1520 viramidine 119567-79-2 galidesivir (249503-25-1) 502 (2R,3S,5R)-5-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-hydroxy-2-pyrrolidinemethanol 1610426-50-0"/>
   <result pre="119567-79-2 galidesivir (249503-25-1) 502 (2R,3S,5R)-5-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-hydroxy-2-pyrrolidinemethanol 1610426-50-0 (2S,4R,5S)-5-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-4-hydroxy-2-pyrrolidinemethanol 872534-76-4 (2R,3R,4S,5S)-5-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-hydroxy-4-methoxy-2-pyrrolidinemethanol 1610426-51-1" exact="chloroquine" post="(54-05-7) 21176 hydroxychloroquine 118-42-3 (±)-chloroquine diphosphate 50-63-5 chloroquine hydrochloride"/>
   <result pre="502 (2R,3S,5R)-5-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-hydroxy-2-pyrrolidinemethanol 1610426-50-0 (2S,4R,5S)-5-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-4-hydroxy-2-pyrrolidinemethanol 872534-76-4 (2R,3R,4S,5S)-5-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-hydroxy-4-methoxy-2-pyrrolidinemethanol 1610426-51-1 chloroquine (54-05-7) 21176" exact="hydroxychloroquine" post="118-42-3 (±)-chloroquine diphosphate 50-63-5 chloroquine hydrochloride 3545-67-3 chloroquine sulfate"/>
   <result pre="(2R,3R,4S,5S)-5-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-hydroxy-4-methoxy-2-pyrrolidinemethanol 1610426-51-1 chloroquine (54-05-7) 21176 hydroxychloroquine 118-42-3 (±)-chloroquine diphosphate 50-63-5" exact="chloroquine" post="hydrochloride 3545-67-3 chloroquine sulfate 132-73-0 favipiravir (259793-96-9) 309 6-bromo-3,4-dihydro-3-oxo-2-pyrazine-5-d-carboxamide"/>
   <result pre="(54-05-7) 21176 hydroxychloroquine 118-42-3 (±)-chloroquine diphosphate 50-63-5 chloroquine hydrochloride 3545-67-3" exact="chloroquine" post="sulfate 132-73-0 favipiravir (259793-96-9) 309 6-bromo-3,4-dihydro-3-oxo-2-pyrazine-5-d-carboxamide 1476773-04-2 6-fluoro-3,4-dihydro-3-oxo-2-pyrazine-5-d-carboxamide 1492021-26-7"/>
   <result pre="CaoR.; ZhangL.; YangX.; LiuJ.; XuM.; ShiZ.; HuZ.; ZhongW.; XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7094151\results\search\drugs\results.xml">
   <result pre="considerations include sialic acid analogs, cold atmospheric plasma, N-chlorotaurine, and" exact="benzalkonium chloride." post="Continued investigation and evaluation of treatment are warranted to"/>
   <result pre="use in clinical the clinical setting.30 However, combining iodine with" exact="povidone" post="allowed for this antiseptic to be safely and routinely"/>
   <result pre="ophthalmic gel, interferon eye drops, a tobramycin-dexamethasone combo, and topical" exact="diclofenac" post="sodium. In this study, interferon was administered with the"/>
   <result pre="side effects, such as inflammation, congestion, and edema, tobramycin-dexamethasone and" exact="diclofenac" post="sodium treatments were also employed. This combination of drugs"/>
   <result pre="a challenge in the treatment of adenoviral keratoconjunctivitis.47 Ribavirin and" exact="cidofovir" post="have also been shown to exhibit antiviral activity against"/>
   <result pre="polymerase, causing viral DNA chain termination and viral inhibition.13,44 Intravenous" exact="cidofovir" post="is often used in transplant clinics with only mild"/>
   <result pre="ocular toxicity around the skin of eyelids and conjunctiva.46 Similarly," exact="ribavirin" post="also results in poor systemic side effects and safety"/>
   <result pre="infiltrates. This study showed great promise in the future of" exact="cidofovir" post="for the treatment of ocular HAdV infections in the"/>
   <result pre="therapeutic use. Gordon et al described the effects of topical" exact="cidofovir" post="in uninfected animals, determining that there was consistent clinically"/>
   <result pre="Even at lower and presumably ineffective dosages, 3.5 mg of" exact="cidofovir" post="continued exhibit significant ocular surface toxicity in vivo.52 Resistance"/>
   <result pre="to be an ophthalmic form.13,44 When antiviral comparison is made," exact="ganciclovir" post="appears to be the most favorable in terms of"/>
   <result pre="Nwanegbo et al found that Ig was actually comparable to" exact="cidofovir" post="in its antiviral activity. While cidofovir acts intracellularly to"/>
   <result pre="was actually comparable to cidofovir in its antiviral activity. While" exact="cidofovir" post="acts intracellularly to block DNA replication, Ig neutralizes the"/>
   <result pre="neutralizes the virus on the ocular surface. In comparison to" exact="cidofovir" post="and saline titers, Ig was more effective during the"/>
   <result pre="be beneficial in prophylaxis to prevent clinical infections. Though both" exact="cidofovir" post="and Ig were effective in this study, cidofovir demonstrated"/>
   <result pre="Though both cidofovir and Ig were effective in this study," exact="cidofovir" post="demonstrated a significantly shorter duration of viral shedding. This"/>
   <result pre="be helpful in such cases.63 In a study comparing topical" exact="loteprednol" post="with dexamethasone, similar outcomes in SEI treatment were observed."/>
   <result pre="the first to investigate NSAID effects on adenoviral replication, specifically" exact="ketorolac" post="tromethamine and diclofenac sodium ophthalmic solutions. During both the"/>
   <result pre="investigate NSAID effects on adenoviral replication, specifically ketorolac tromethamine and" exact="diclofenac" post="sodium ophthalmic solutions. During both the early and late"/>
   <result pre="did it affect the duration of viral shedding. In contrast," exact="prednisolone" post="treatment was shown to prolong viral shedding.73 As it"/>
   <result pre="viral shedding.73 As it pertained to sub-epithelial infiltrates, treatment with" exact="diclofenac" post="or ketorolac did not yield a statistically significant reduction"/>
   <result pre="As it pertained to sub-epithelial infiltrates, treatment with diclofenac or" exact="ketorolac" post="did not yield a statistically significant reduction when compared"/>
   <result pre="a statistically significant reduction when compared to control groups, whereas" exact="prednisolone" post="did. This study suggests that NSAIDs are not likely"/>
   <result pre="of using corticosteroids or to limit associated corticosteroid complications. Topical" exact="cyclosporine" post="(both 1% and 2% concentrations) is an alternative option"/>
   <result pre="3–4 weeks.64,66,69,78 Okumus et al studied the efficacy of 0.05%" exact="cyclosporine" post="(Restasis®, Allergan, Irvine, California, USA) once per day or"/>
   <result pre="due to subsequent, elevated IOP. After one month of 0.05%" exact="cyclosporine" post="treatment, 81.75% of eyes had cleared SEIs while the"/>
   <result pre="treatment options for acute adenoviral keratoconjunctivitis using either topical 1%" exact="prednisolone" post="acetate in conjunction with non-preserved artificial tears, topical 2%"/>
   <result pre="In comparison to artificial tears alone, both the corticosteroid and" exact="cyclosporine" post="groups exhibited improvement in symptoms as well as a"/>
   <result pre="well as a shorter duration. Both the Cyclosporine A and" exact="prednisolone" post="groups were also similarly effective in preventing the development"/>
   <result pre="to prevent rejection in organ transplants. However, despite similar effects," exact="tacrolimus" post="and cyclosporine differ in their chemical makeup. Cyclosporine is"/>
   <result pre="rejection in organ transplants. However, despite similar effects, tacrolimus and" exact="cyclosporine" post="differ in their chemical makeup. Cyclosporine is a cyclic"/>
   <result pre="calcineurin inhibitors, an enzyme necessary for T cell replication.82,83 When" exact="cyclosporine" post="and tacrolimus enter T cells, they bind to their"/>
   <result pre="an enzyme necessary for T cell replication.82,83 When cyclosporine and" exact="tacrolimus" post="enter T cells, they bind to their respective immunophilins,"/>
   <result pre="survival of CD4+ T cells and CD8+ T cells.70,84-86 Topical" exact="tacrolimus" post="0.03% has ophthalmic uses, mainly in the treatment of"/>
   <result pre="vernal keratoconjunctivitis. With regards to its effect on HAdV keratoconjunctivitis," exact="tacrolimus" post="was more effective than dexamethasone in the reduction of"/>
   <result pre="its effect on HAdV keratoconjunctivitis, tacrolimus was more effective than" exact="dexamethasone" post="in the reduction of SEIs, and subsequently in the"/>
   <result pre="of vision and symptomology. This study is significant in that" exact="tacrolimus" post="was not only superior to topical corticosteroids in the"/>
   <result pre="Generally, for SEIs that are resistant to tapering of corticosteroid," exact="tacrolimus" post="0.03% was proven to be an effective corticosteroid-sparing agent.87"/>
   <result pre="antiviral use appears to be synergistic and efficacious.44 Cardiotonic steroids" exact="digoxin" post="and digitoxin have been suggested to offer a new"/>
   <result pre="appears to be synergistic and efficacious.44 Cardiotonic steroids digoxin and" exact="digitoxin" post="have been suggested to offer a new strategy to"/>
   <result pre="ATPase is an important cell signaling molecule, where binding with" exact="digoxin" post="or digitoxin initiates multiple signaling cascades, influencing gene expression."/>
   <result pre="an important cell signaling molecule, where binding with digoxin or" exact="digitoxin" post="initiates multiple signaling cascades, influencing gene expression. These drugs"/>
   <result pre="viral shedding.52 When comparing PVI/dexamethasone combination treatment with that of" exact="dexamethasone" post="alone, combination drops not only increase recovery but also,"/>
   <result pre="sialic acid analogs, cold atmospheric plasma (CAP), N-chlorotaurine, and even" exact="benzalkonium chloride" post="(BAK). Sialic acid plays a role in initial attachment"/>
   <result pre="rare cases of lacrimal canalicularblockade in rabbit models.107 Ganciclovir 3%" exact="ganciclovir" post="reduced HAdV 5 replication and pathogenesis in animal models.108"/>
   <result pre="EKC symptoms and Persistent adenoviral SEIs.2,63 Glaucoma and cataracts.116 Topical" exact="cyclosporine" post="Effective against persistent adenoviral SEIs.66,69,117–119 Transient or long-lasting burning"/>
   <result pre="ocular pain/irritation, redness; eyelid swelling in Steven Johnsons patients.121 Topical" exact="tacrolimus" post="Superior to dexamethasone in reducing symptomology and SEIs70 as"/>
   <result pre="eyelid swelling in Steven Johnsons patients.121 Topical tacrolimus Superior to" exact="dexamethasone" post="in reducing symptomology and SEIs70 as well as a"/>
   <result pre="ganciclovir, cidofovir, PVI irrigation Poor bioavailability and high toxicity of" exact="cidofovir" post="Lipid-linked derivative brincidofovir and potential development of ophthalmic formulation"/>
   <result pre="(ie, elevated IOP and cataract formation) Immunotherapy such as topical" exact="cyclosporine" post="or tacrolimus Corticosteroids prolonging viral shedding Combination PVI/dexamethasone ophthalmic"/>
   <result pre="IOP and cataract formation) Immunotherapy such as topical cyclosporine or" exact="tacrolimus" post="Corticosteroids prolonging viral shedding Combination PVI/dexamethasone ophthalmic solution Conjunctival"/>
   <result pre="2008;34(6):845–855. doi:10.1016/j.burns.2007.11.01418378399 34.YazarH, YarbagA, BalciM, TekerB, TanyeriP. The effects of" exact="povidone" post="iodine (pH 4.2) on patients with adenoviral conjunctivitis. J"/>
   <result pre="42.KimSJ, KimK, ParkSB, HongDJ, JhunBW. Outcomes of early administration of" exact="cidofovir" post="in non-immunocompromised patients with severe adenovirus pneumonia. PLoS One."/>
   <result pre="BoeckhM. Adenovirus infection in hematopoietic stem cell transplantation: effect of" exact="ganciclovir" post="and impact on survival. Biol Blood Marrow Transplant. 2003;9(5):341–352."/>
   <result pre="Marrow Transplant. 2003;9(5):341–352. doi:10.1016/S1083-8791(03)00102-212766884 46.HuangJ, KadonosonoK, UchioE. Antiadenoviral effects of" exact="ganciclovir" post="in types inducing keratoconjunctivitis by quantitative polymerase chain reaction"/>
   <result pre="doi:10.1016/0166-3542(95)00962-08811201 49.RomanowskiEG, YatesKA, GordonYJ. Antiviral prophylaxis with twice daily topical" exact="cidofovir" post="protects against challenge in the adenovirus type 5/New Zealand"/>
   <result pre="al. Clinical and antiviral efficacy of an ophthalmic formulation of" exact="dexamethasone" post="povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis. Invest"/>
   <result pre="2000;19(1):69–85. doi:10.1016/S1350-9462(99)00004-X10614681 64.HillenkampJ, ReinhardT, RossRS, et al. The effects of" exact="cidofovir" post="1% with and without cyclosporin a 1% as a"/>
   <result pre="et al. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2%" exact="cidofovir" post="and 1% cyclosporine: a controlled clinical pilot study. Arch"/>
   <result pre="doi:10.1001/archopht.119.10.148711594949 66.LevingerE, SlomovicA, SansanayudhW, BaharI, SlomovicAR. Topical treatment with 1%" exact="cyclosporine" post="for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea. 2010;29(6):638–640."/>
   <result pre="pilot study]. Ophthalmologe. 2000;97(11):764–768. German. doi:10.1007/s003470070025.11130165 68.KilicA, GurlerB. Topical 2%" exact="cyclosporine" post="A in preservative-free artificial tears for the treatment of"/>
   <result pre="of the safety and efficacy of topical Tacrolimus (0.03%) versus" exact="dexamethasone" post="(0.05%) for subepithelial infiltrates after adenoviral conjunctivitis. Indian J"/>
   <result pre="CevherS, MatE. Symptomatic treatment of subepithelial infiltrates after viral conjunctivitis:" exact="loteprednol" post="or dexamethasone?Ocul Immunol Inflamm. 2017;25(5):649–653. doi:10.3109/09273948.2016.114959327015587 72.AsenaL, Singar OzdemirE,"/>
   <result pre="uses. Surv Ophthalmol. 1986;31(3):159–169. doi:10.1016/0039-6257(86)90035-43544293 78.RomanowskiEG, PlessP, YatesKA, GordonYJ. Topical" exact="cyclosporine" post="A inhibits subepithelial immune infiltrates but also promotes viral"/>
   <result pre="experimental adenovirus models. Cornea. 2005;24(1):86–91. doi:10.1097/01.ico.0000127481.23714.b615604872 79.LiegnerJT, YeeRW, WildJH. Topical" exact="cyclosporine" post="therapy for ulcerative keratitis associated with rheumatoid arthritis. Am"/>
   <result pre="inflammatory disease. Cornea. 1993;12(5):413–419. doi:10.1097/00003226-199309000-000088306663 81.PerryHD, Doshi-carnevaleS, DonnenfeldED, KornsteinHS. Topical" exact="cyclosporine" post="A 0.5% as a possible new treatment for superior"/>
   <result pre="Pharmacokinet. 1993;24(6):472–495. doi:10.2165/00003088-199324060-000048513650 83.ThomsonAW, BonhamCA, ZeeviA. Mode of action of" exact="tacrolimus" post="(FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6):584–591."/>
   <result pre="Monit. 1995;17(6):584–591. doi:10.1097/00007691-199512000-000078588225 84.BarbarinoJM, StaatzCE, VenkataramananR, KleinTE, AltmanRB. PharmGKB summary:" exact="cyclosporine" post="and tacrolimus pathways. Pharmacogenet Genomics. 2013;23(10):563–585. doi:10.1097/FPC.0b013e328364db8423922006 85.BoymanO, SprentJ."/>
   <result pre="doi:10.1097/00007691-199512000-000078588225 84.BarbarinoJM, StaatzCE, VenkataramananR, KleinTE, AltmanRB. PharmGKB summary: cyclosporine and" exact="tacrolimus" post="pathways. Pharmacogenet Genomics. 2013;23(10):563–585. doi:10.1097/FPC.0b013e328364db8423922006 85.BoymanO, SprentJ. The role"/>
   <result pre="of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and" exact="dexamethasone" post="0.1% drops: a clinical prospective controlled randomized study. Acta"/>
   <result pre="PhillipsJ, NarendranN, YangYC. Ocular surface effects of repeated application of" exact="povidone" post="iodine in patients receiving frequent intravitreal injections. Cutan Ocul"/>
   <result pre="with human type 5 adenovirus in immunosuppressed Syrian hamsters, while" exact="ribavirin" post="is largely ineffective in this model. Antiviral Res. 2014;112:38–46."/>
   <result pre="Cornea. 2011;30(9):958–961. doi:10.1097/ICO.0b013e31820cd60721673568 118.MuftuogluIK, AkovaYA, GungorSG. Effect of 0.05% topical" exact="cyclosporine" post="for the treatment of symptomatic subepithelial infiltrates due to"/>
   <result pre="119.BayraktutarBN, UcakhanOO. Comparison of efficacy of two different topical 0.05%" exact="cyclosporine" post="a formulations in the treatment of adenoviral keratoconjunctivitis-related subepithelial"/>
   <result pre="CaputoR, MoriF, et al. Long-term safety and efficacy of topical" exact="cyclosporine" post="in 156 children with vernal keratoconjunctivitis. Int J Immunopathol"/>
   <result pre="J Immunopathol Pharmacol. 2010;23(3):865–871. doi:10.1177/03946320100230032220943058 121.SchultzC. Safety and efficacy of" exact="cyclosporine" post="in the treatment of chronic dry eye. Ophthalmol Eye"/>
   <result pre="Eye Dis. 2014;6:37–42. doi:10.4137/OED.S1606725002818 122.LevingerE, TrivizkiO, ShacharY, LevingerS, TopicalVD. 0.03%" exact="tacrolimus" post="for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Graefes Arch"/>
   <result pre="Riestra AyoraAC, Lisa FernandezC, Chacon RodriguezM, Merayo-llovesJ, Alfonso SanchezJF. Topical" exact="tacrolimus" post="for corneal subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea."/>
   <result pre="124.BarotRK, ShitoleSC, BhagatN, PatilD, SawantP, PatilK. Therapeutic effect of 0.1%" exact="tacrolimus" post="eye ointment in allergic ocular diseases. J Clin Diagn"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7095077\results\search\drugs\results.xml">
   <result pre="to maintain blood pressure, fluids given to manage diarrhoea and" exact="ibuprofen" post="provided for pain relief in mild cases [10]. Active"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7095524\results\search\drugs\results.xml">
   <result pre="a family clusterLancet202039551452310.1016/S0140-6736(20)30154-931986261 10.SakabeMYoshiokaRFujikiASick sinus syndrome induced by interferon and" exact="ribavirin" post="therapy in a patient with chronic hepatitis CJ. Cardiol."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7097340\results\search\drugs\results.xml">
   <result pre="of hypodermic syringes. Classic antiviral drugs such as interferon and" exact="ribavirin" post="are effective in vitro against most viruses, but often"/>
   <result pre="and the solubility-permeability interplayEur J Pharm Sci201577737810.1016/j.ejps.2015.05.02426006306 163.BeigAMillerJMDahanAThe interaction of" exact="nifedipine" post="with selected cyclodextrins and the subsequent solubility-permeability trade-offEur J"/>
   <result pre="lipophilic drugs for oral delivery: the effects of urea and" exact="nicotinamide" post="on carbamazepine solubility-permeability interplayFront Pharmacol2016737910.3389/fphar.2016.0037927826241 169.DahanABeigALindleyDMillerJMThe solubility-permeability interplay and"/>
   <result pre="for oral delivery: the effects of urea and nicotinamide on" exact="carbamazepine" post="solubility-permeability interplayFront Pharmacol2016737910.3389/fphar.2016.0037927826241 169.DahanABeigALindleyDMillerJMThe solubility-permeability interplay and oral drug"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7097833\results\search\drugs\results.xml">
   <result pre="mg tablets, 1 tablet q12, during 14 days. ** Before" exact="chloroquine" post="and hydrossichloroquine administration, G6PD deficiency test should be performed."/>
   <result pre="mg tablets, 1 tablet q12, during 14 days. ** Before" exact="chloroquine" post="and hydroxychloroquine administration, G6PD deficiency test should be performed"/>
   <result pre="1 tablet q12, during 14 days. ** Before chloroquine and" exact="hydroxychloroquine" post="administration, G6PD deficiency test should be performed ° Do"/>
   <result pre="days and, lastly, 10 mg daily for 2 days, or" exact="dexamethasone" post="20 mg daily intravenously for 5 days, followed by"/>
   <result pre="mg tablets, 1 tablet q12, during 14 days. ** Before" exact="chloroquine" post="and hydrossichloroquine administration, G6PD deficiency test should be performed"/>
   <result pre="days and, lastly, 10 mg daily for 2 days, or" exact="dexamethasone" post="20 mg daily intravenously for 5 days, followed by"/>
   <result pre="are based on anecdotal experiences and expert opinions. Chloroquine and" exact="hydroxychloroquine" post="Chloroquine is an old and widely used anti-malarial drug"/>
   <result pre="of Action It has been postulated that antiviral action of" exact="chloroquine" post="may depend by several mechanisms such as the change"/>
   <result pre="on SARS-COV2 A recent study has demonstrated invitro efficacy of" exact="chloroquine" post="and remdesivir in inhibiting replication of SARS-COV2. Moreover, emerging"/>
   <result pre="replication of SARS-COV2. Moreover, emerging reports from China suggests that" exact="chloroquine" post="has shown a superiority in reducing both the severity"/>
   <result pre="this results, an expert consensus group in China has recommended" exact="chloroquine" post="for COVID-19 treatment. Dosage The recommended dosage for SARSCoV-"/>
   <result pre="treatment. Dosage The recommended dosage for SARSCoV- 2 infection is" exact="chloroquine" post="500 mg bid or hydroxychloroquine 200 mg bid for"/>
   <result pre="for SARSCoV- 2 infection is chloroquine 500 mg bid or" exact="hydroxychloroquine" post="200 mg bid for 10 days in combination with"/>
   <result pre="antiviral activity by inhibiting viral replication. As in HIV infection," exact="ritonavir" post="only acts boosting lopinavir plasma levels. Available data on"/>
   <result pre="viral replication. As in HIV infection, ritonavir only acts boosting" exact="lopinavir" post="plasma levels. Available data on SARS-COV2 Although only limited"/>
   <result pre="SARS-COV2 A recent study exploring in-vitro activity of remdesivir and" exact="chloroquine" post="has demonstrated efficacy of the drugs in inhibiting replication"/>
   <result pre="Syndrome Coronavirus (MERS-CoV). Travel Med Infect Dis2019;30:9-18..31252170 WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="SARS coronavirus infection and spread. J Virol2005;2:69. YanYZouZSunYet al.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="infection in an animal model. Cell Res2013;23:300-2.23208422 WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumonia. [Expert consensus"/>
   <result pre="in the treatment of novel coronavirus pneumonia. [Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua"/>
   <result pre="ihttps://www.ema.europa.eu/en/documents/product-information/roactemraepar-product-information_it.pdf (Last Access 10th March 2020) LeRQLiLYuanWet al.FDA approval summary:" exact="tocilizumab" post="for treatment of chimeric antigen receptor T cell induced"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7098069\results\search\drugs\results.xml">
   <result pre="this brief review, we summarize the broad antiviral activity of" exact="niclosamide" post="and highlight its potential clinical use in the treatment"/>
   <result pre="highlight its potential clinical use in the treatment of COVID-19." exact="niclosamide" post="broad antiviral agents coronavirus SARS-CoV MERS-CoV SARS-CoV-2 (COVID-19) flavivirus"/>
   <result pre="exerts its anticestodal effect by inhibiting oxidative phosphorylation and stimulating" exact="adenosine" post="triphosphatase activity in the mitochondria.12 Over the past several"/>
   <result pre="triphosphatase activity in the mitochondria.12 Over the past several years," exact="niclosamide" post="has been identified as a multifunctional drug via drug"/>
   <result pre="viral infections,19−22 and metabolic diseases.23 These broad biological activities of" exact="niclosamide" post="including relevant cell signaling pathways were briefly reviewed by"/>
   <result pre="review, we focus on summarizing the broad antiviral activities of" exact="niclosamide" post="(Figure 1) and highlighting its therapeutic potential in combating"/>
   <result pre="need for new drug discovery. Wu et al. found that" exact="niclosamide" post="was able to inhibit SARS-CoV replication and totally abolished"/>
   <result pre="was discovered as potent inhibitors against SARS-CoV 3CL protease. Interestingly," exact="niclosamide" post="showed no obvious inhibitory activity against SARS-CoV 3CL protease"/>
   <result pre="and affected the autophagic flux in the MERS-CoV-infected cells.33 Since" exact="niclosamide" post="is a multifunctional drug, we cannot exclude the possibility"/>
   <result pre="used caspase-3 activity as the primary screening assay and discovered" exact="niclosamide" post="as a potent inhibitor of ZIKV infection, displaying an"/>
   <result pre="the intracellular ZIKV RNA level.22 The time-of-addition studies indicated that" exact="niclosamide" post="inhibits ZIKV infection at a postentry stage, probably in"/>
   <result pre="a viral RNA replication step. Our research team also identified" exact="niclosamide" post="as a potent anti-ZIKV inhibitor through an independent quantitative"/>
   <result pre="an independent quantitative high-throughput screening (qHTS) campaign and found that" exact="niclosamide" post="directly inhibits flavivirus NS2B-NS3 interactions.14 Protease complex NS2B-NS3 is"/>
   <result pre="essential for flaviviral polyprotein processing.39−41 Our team also found that" exact="niclosamide" post="is a broad-spectrum inhibitor against other flaviviruses including DENV-2,"/>
   <result pre="HTS assay to screen 1280 pharmacologically active compounds and identified" exact="niclosamide" post="as a potent JEV inhibitor with micromolar potency.42 The"/>
   <result pre="JEV inhibitor with micromolar potency.42 The time-of-addition studies showed that" exact="niclosamide" post="inhibits JEV at the stage of replication. Niclosamide and"/>
   <result pre="the host cell process similar to that of its derivatives" exact="nitazoxanide" post="and tizoxanide.45−47 However, chronic HCV infection requires long-term (several"/>
   <result pre="in past outbreaks. Through a systematic screen of FDA-approved drugs," exact="niclosamide" post="was identified as one of the most potent EBOV"/>
   <result pre="available to treat these infections. Three salicylanilide anthelmintic drugs including" exact="niclosamide" post="were screened out as potent anti-HAdV inhibitors. Niclosamide showed"/>
   <result pre="μM in the plaque assay. Subsequent mechanistic studies indicated that" exact="niclosamide" post="inhibits the transport of the HAdV particle from the"/>
   <result pre="Hodgkin’s lymphoma, and nasopharyngeal carcinoma.53 Huang et al. demonstrated that" exact="niclosamide" post="inhibits EBV lytic replication in lymphoma cells and epithelial"/>
   <result pre="single oral doses of 0.5, 1, and 2 g of" exact="niclosamide" post="are recommended for children under 2 years, children between"/>
   <result pre="were eliminated by 5–7 daily doses of 2 g of" exact="niclosamide" post="each, while the treatment of Hymenolepis nana infection requires"/>
   <result pre="nana infection requires one or several 5–7 day courses of" exact="niclosamide" post="treatment. One 7 day course regimen for adults is"/>
   <result pre="7 day course regimen for adults is 2 g of" exact="niclosamide" post="on day 1 followed by 1 g daily for"/>
   <result pre="of 2000 mg of niclosamide, the maximum serum concentration of" exact="niclosamide" post="was equivalent to 0.25–6.0 μg/mL (0.76–18.3 μM). The wide"/>
   <result pre="in human.10 Through a series of drug repurposing screening campaigns," exact="niclosamide" post="was found to be effective against a variety of"/>
   <result pre="infections. Currently, there are four ongoing human clinical trials of" exact="niclosamide" post="in ulcerative colitis, prostate carcinoma, and colorectal cancer in"/>
   <result pre="colorectal cancer in the ClinicalTrails.gov clinical trials registry.56 Of note," exact="niclosamide" post="has several weaknesses such as unneglectable cytotoxicity and limited"/>
   <result pre="group has made substantial efforts in medicinal chemistry based on" exact="niclosamide" post="as a lead compound and discovered a series of"/>
   <result pre="orally bioavailable anticancer agents with improved aqueous solubility16 and diversified" exact="salicylamide" post="derivatives as potent anti-HAdV inhibitors with increased potency (submicromolar"/>
   <result pre="in the HAdV life cycle.58 The ester derivative prodrug of" exact="niclosamide" post="was also reported to increase its systemic drug exposure"/>
   <result pre="useful strategy for improving the pharmacological and pharmacokinetic properties of" exact="niclosamide" post="and maximizing its therapeutic potential for clinical applications.60−62 The"/>
   <result pre="a prodrug of tizoxanide, which shares considerable structural similarity with" exact="niclosamide" post="as a salicylamide derivative.47 Notably, niclosamide displays promising inhibitory"/>
   <result pre="tizoxanide, which shares considerable structural similarity with niclosamide as a" exact="salicylamide" post="derivative.47 Notably, niclosamide displays promising inhibitory activity against SARS-CoV"/>
   <result pre="considerable structural similarity with niclosamide as a salicylamide derivative.47 Notably," exact="niclosamide" post="displays promising inhibitory activity against SARS-CoV replication with an"/>
   <result pre="activity is validated in animal models or human clinical trials," exact="niclosamide" post="and its optimized analogues may be developed as effective"/>
   <result pre="ChuL.; ZhangY.; TerryK.; LiuH.; ShenQ.; ZhouJ. (2013) Discovery of O-alkylamino-tethered" exact="niclosamide" post="derivatives as potent and orally bioavailable anticancer agents. ACS"/>
   <result pre="ZhangY.; ChelluriR.; BoufraqechM.; NilubolN.; PatelD.; ShenM.; KebebewE. (2016) Identification of" exact="niclosamide" post="as a novel anticancer agent for adrenocortical carcinoma. Clin."/>
   <result pre="ClayT. M.; ChenW.; MorseM. A.; LyerlyH. K. (2011) Antihelminth compound" exact="niclosamide" post="downregulates Wnt signaling and elicits antitumor responses in tumors"/>
   <result pre="XuJ.; Pachón-IbáñezM. E.; Cebrero-CangueiroT.; ChenH.; Sánchez-CéspedesJ.; ZhouJ. (2019) Discovery of" exact="niclosamide" post="and its O-alkylamino-tethered derivatives as potent antibacterial agents against"/>
   <result pre="D.; EndsleyJ. J.; ZhouJ.; EndsleyM. A. (2019) Dual activity of" exact="niclosamide" post="to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis"/>
   <result pre="GlennJ. S. (2008) Potential for hepatitis C virus resistance to" exact="nitazoxanide" post="or tizoxanide. Antimicrob. Agents Chemother.52, 4069–4071. 10.1128/AAC.00078-08.18710916 YonC.; ViswanathanP.;"/>
   <result pre="in HCV non-structural genes do not contribute to resistance to" exact="nitazoxanide" post="in replicon-containing cells. Antiviral Res.91, 233–240. 10.1016/j.antiviral.2011.05.017.21703309 de CarvalhoL."/>
   <result pre="ChinY.-F.; WuT.-Y.; LinL.-I.; LaiZ.-Z.; KuoS.-C.; HoY.-J. (2016) Antiviral activities of" exact="niclosamide" post="and nitazoxanide against chikungunya virus entry and transmission. Antiviral"/>
   <result pre="LinL.-I.; LaiZ.-Z.; KuoS.-C.; HoY.-J. (2016) Antiviral activities of niclosamide and" exact="nitazoxanide" post="against chikungunya virus entry and transmission. Antiviral Res.135, 81–90."/>
   <result pre="ChangY.-W.; YehT.-K.; LinK.-T.; ChenW.-C.; YaoH.-T. (2006) Pharmacokinetics of anti-SARS-CoV agent" exact="niclosamide" post="and its analogs in rats. J. Food Drug Anal.14,"/>
   <result pre="ChenH.; PachónJ.; ZhouJ.; Sanchez-CespedesJ. (2020) Structure-activity relationship studies on diversified" exact="salicylamide" post="derivatives as potent inhibitors of human adenovirus infection. J."/>
   <result pre="BiancaR.; SorrentinoR.; MiroA.; QuagliaF.; ImperiF.; LeoniL.; UngaroF. (2015) Toward repositioning" exact="niclosamide" post="for antivirulence therapy of Pseudomonas aeruginosa lung infections: Development"/>
   <result pre="YangX.; LiuJ.; XuM.; ShiZ.; HuZ.; ZhongW.; XiaoG. (2020) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7100427\results\search\drugs\results.xml">
   <result pre="treatments. The recommended antiviral drugs are interferon-α (IFN-α), lopinavir/ritonavir, ribavirin," exact="chloroquine" post="diphosphate and arbidol [2] which have been used in"/>
   <result pre="circumstances. However, children are particularly sensitive to the accumulation of" exact="chloroquine" post="phosphate in the body, which could possibly induce severe"/>
   <result pre="safety, experts have not reached on an agreement on using" exact="ribavirin" post="in the pediatric population. Guidelines for diagnosis and treatment"/>
   <result pre="children (Second Edition) recommend the use of IFN-α, lopinavir/ritonavir and" exact="ribavirin" post="in children, without specifying age limitation [10]. The recommended"/>
   <result pre="children, without specifying age limitation [10]. The recommended dosage of" exact="ribavirin" post="infusion varies in different medical literatures. Some suggest intravenous"/>
   <result pre="varies in different medical literatures. Some suggest intravenous infusion of" exact="ribavirin" post="administered at a dose of 10 mg/kg every time"/>
   <result pre="the China Clinical Trial Registry Center; another clinical trial of" exact="darunavir" post="and cobicistat for treatment of COVID-19 in children has"/>
   <result pre="Clinical Trial Registry Center; another clinical trial of darunavir and" exact="cobicistat" post="for treatment of COVID-19 in children has been registered"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7100484\results\search\drugs\results.xml">
   <result pre="(~4 μM), on par with the well known lysosomotropic compound" exact="chloroquine" post="(Fig. 3). Others have shown that the tilorone induced"/>
   <result pre="Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="models of infectionCell Rep201718381682928099857 45.MartinREMarchettiRVCowanAIHowittSMBroerSKirkKChloroquine transport via the malaria parasite's" exact="chloroquine" post="resistance transporterScience.200932559481680168219779197 46.GuptaDKGieselmannVHasilikAvon FiguraKTilorone acts as a lysosomotropic agent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7101875\results\search\drugs\results.xml">
   <result pre="of human-to-human disease transmission. Similarly, after the media reported that" exact="chloroquine" post="phosphate can inhibit SARS-CoV-2 in vitro, there were reports"/>
   <result pre="patient who was not infected with SARS-CoV-2 but self-medicated with" exact="hydroxychloroquine" post="sulfate tablets (1.8 g, 24 h). The patient subsequently"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7102518\results\search\drugs\results.xml">
   <result pre="influenza viruses.17 Exemplifying the scope of the problem, the adamantanes," exact="amantadine" post="and, subsequently, rimantadine, were the first drugs approved for"/>
   <result pre="after treatment.25 In addition to seasonal influenza virus strains, signature" exact="amantadine" post="resistance mutations were detected in highly pathogenic avian H5N1"/>
   <result pre="other antivirals Neuraminidase inhibitors Of the NAIs in clinical use," exact="oseltamivir" post="(Fig 1 ), peramivir, and zanamivir, oseltamivir carboxylate is"/>
   <result pre="in clinical use, oseltamivir (Fig 1 ), peramivir, and zanamivir," exact="oseltamivir" post="carboxylate is the most frequently prescribed and considered standard-of-care"/>
   <result pre="impairs virion release and dissemination.31 Fig 1 Chemical structures of" exact="oseltamivir" post="carboxylate, baloxavir marboxil, favipiravir, EIDD-2801, and pimodivir. Oseltamivir is"/>
   <result pre="progression to severe disease in the 2009/2010 pandemic.38 Resistance to" exact="oseltamivir" post="can develop rapidly in both experimental settings and the"/>
   <result pre="or N294S (predominant in H3N2 viruses).39,40 Major resistance mutations to" exact="zanamivir" post="are NA substitutions Q136K and I223R (H1N1 viruses) and"/>
   <result pre="adults and childrenCochrane Database Syst Rev3482014CD008965 9AokiF.Y.MacleodM.D.PaggiaroP.Early administration of oral" exact="oseltamivir" post="increases the benefits of influenza treatmentJ Antimicrob Chemother51200312312912493796 10TreanorJ.J.HaydenF.G.VroomanP.S.Efficacy"/>
   <result pre="Antimicrob Chemother51200312312912493796 10TreanorJ.J.HaydenF.G.VroomanP.S.Efficacy and safety of the oral neuraminidase inhibitor" exact="oseltamivir" post="in treating acute influenza: a randomized controlled trial. US"/>
   <result pre="trial. US Oral Neuraminidase Study GroupJAMA.28320001016102410697061 11NicholsonK.G.AokiF.Y.OsterhausA.D.Efficacy and safety of" exact="oseltamivir" post="in treatment of acute influenza: a randomised controlled trial."/>
   <result pre="approaches for diagnosis of influenza virus infections in humansViruses820169627077877 13JacksonR.J.CooperK.L.TappendenP.Oseltamivir," exact="zanamivir" post="and amantadine in the prevention of influenza: a systematic"/>
   <result pre="diagnosis of influenza virus infections in humansViruses820169627077877 13JacksonR.J.CooperK.L.TappendenP.Oseltamivir, zanamivir and" exact="amantadine" post="in the prevention of influenza: a systematic reviewJ Infect622011142520950645"/>
   <result pre="virus: the epidemiology and managementInfect Drug Resist10201712113428458567 18JingX.MaC.OhigashiY.Functional studies indicate" exact="amantadine" post="binds to the pore of the influenza A virus"/>
   <result pre="22AbedY.GoyetteN.BoivinG.Generation and characterization of recombinant influenza A (H1N1) viruses harboring" exact="amantadine" post="resistance mutationsAntimicrob Agents Chemother49200555655915673732 23KrumbholzA.SchmidtkeM.BergmannS.High prevalence of amantadine resistance"/>
   <result pre="viruses harboring amantadine resistance mutationsAntimicrob Agents Chemother49200555655915673732 23KrumbholzA.SchmidtkeM.BergmannS.High prevalence of" exact="amantadine" post="resistance among circulating European porcine influenza A virusesJ Gen"/>
   <result pre="resistant strains of avian fluBMJ331200510 25YouX.YangS.ZhaoJ.Study on the abuse of" exact="amantadine" post="in tissues of broiler chickens by HPLC-MS/MSJ Vet Pharmacol"/>
   <result pre="treatment: pros, cons and future perspectivesExpert Opin Pharmaco20201917111718 36EbellM.H.Oseltamivir and" exact="zanamivir" post="have limited effect on symptoms and do not reduce"/>
   <result pre="mitochondrial replication and functionAntimicrob Agents Chemother642020 116SmeeD.F.BarnardD.L.JonesS.M.Activities of JNJ63623872 and" exact="oseltamivir" post="against influenza A H1N1pdm and H3N2 virus infections in"/>
   <result pre="study of pimodivir (JNJ-63623872) as monotherapy or in combination with" exact="oseltamivir" post="for treatment of acute uncomplicated seasonal influenza A: TOPAZ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7102522\results\search\drugs\results.xml">
   <result pre="41, 44. On the other hand, the patients who received" exact="ribavirin" post="(1), lopinavir (10, see Fig. 4 )- ritonavir (2)"/>
   <result pre="On the other hand, the patients who received ribavirin (1)," exact="lopinavir" post="(10, see Fig. 4 )- ritonavir (2) and a"/>
   <result pre="who received ribavirin (1), lopinavir (10, see Fig. 4 )-" exact="ritonavir" post="(2) and a corticosteroid had lower 21-day acute respiratory"/>
   <result pre="distress syndrome (ARDS) and death rates than those who received" exact="ribavirin" post="and a corticosteroid 54, 55 combination therapy using interferon"/>
   <result pre="corticosteroid alone (uncontrolled study) [56]. The use of the corticosteroid," exact="methylprednisolone" post="(3, Fig. 3) as a therapeutic intervention for SARS"/>
   <result pre="weeks 2-3 of the illness were higher in patients given" exact="hydrocortisone" post="(n = 10) than those given normal saline (n"/>
   <result pre="phase of the illness, suggesting that early use of pulsed" exact="methylprednisolone" post="(3) might prolong viremia. In the case of patients"/>
   <result pre="In the case of patients with MERS, the combination of" exact="ritonavir" post="(2) + interferon α2a or interferon α-2b resulted in"/>
   <result pre="on coronaviruses infections. Retrospective analyses showed that the combination of" exact="ritonavir" post="(2) + interferon β-1a had no significant effect on"/>
   <result pre="on clinical outcome [48]. In another study, the combination of" exact="ribavirin" post="(1), ritonavir (2) + interferon α-2a resolved viremia within"/>
   <result pre="outcome [48]. In another study, the combination of ribavirin (1)," exact="ritonavir" post="(2) + interferon α-2a resolved viremia within 2 days"/>
   <result pre="severe MERS. Patients with severe MERS who were treated with" exact="methylprednisolone" post="(3) with or without antivirals and interferons had no"/>
   <result pre="and dosing regimens. Drugs including interferon α, β, and γ," exact="ribavirin" post="(1) and inhibitors of cyclophilin 60, 61, 62 were"/>
   <result pre="discovered using this approach. The combination therapy of interferon and" exact="ribavirin" post="showed the best result in treating MERS-CoV infection. Also,"/>
   <result pre="coronaviruses, see Table 2[64]. They identified seven compounds (lycorine, emetine," exact="monensin" post="sodium, mycophenolate mofetil, mycophenolic acid, phenazopyridine, and pyrvinium pamoate)"/>
   <result pre="They identified seven compounds (lycorine, emetine, monensin sodium, mycophenolate mofetil," exact="mycophenolic acid," post="phenazopyridine, and pyrvinium pamoate) from HTS screening as broad-spectrum"/>
   <result pre="as high as of their inhibitions, phenazopyridine, pyrvinium pamoate, and" exact="monensin" post="sodium displayed less CC50 values. Further, in vivo studies"/>
   <result pre="CoVs, de Wilde et al identified four drugs such as" exact="chloroquine" post="(7), chlorpromazine (8), loperamide (9) and lopinavir (10) from"/>
   <result pre="Wilde et al identified four drugs such as chloroquine (7)," exact="chlorpromazine" post="(8), loperamide (9) and lopinavir (10) from the screening"/>
   <result pre="al identified four drugs such as chloroquine (7), chlorpromazine (8)," exact="loperamide" post="(9) and lopinavir (10) from the screening of FDA"/>
   <result pre="drugs such as chloroquine (7), chlorpromazine (8), loperamide (9) and" exact="lopinavir" post="(10) from the screening of FDA approved drugs library"/>
   <result pre="[72] and other coronavirus SARS-CoV [73]. The mechanistic study of" exact="chlorpromazine" post="(8) on MERS-CoV indicated that it inhibited the virus"/>
   <result pre="5 and the activities in Table 3 ). Antidiarrheal agent" exact="loperamide" post="(9), or anti-HIV-1 agent lopinavir (10) were able to"/>
   <result pre="Table 3 ). Antidiarrheal agent loperamide (9), or anti-HIV-1 agent" exact="lopinavir" post="(10) were able to inhibit both MERS-and SARS-CoVs infection"/>
   <result pre="linear with the study by de Wilde et al.[79]. Antiparasitics," exact="mefloquine" post="(20), and amodiaquine dihydrochloride (21) or antibacterial, emetine dihydrochloride"/>
   <result pre="study by de Wilde et al.[79]. Antiparasitics, mefloquine (20), and" exact="amodiaquine" post="dihydrochloride (21) or antibacterial, emetine dihydrochloride hydrate (19) in"/>
   <result pre="MERS-CoV and SARS-CoV at the entry stage. The neurotransmitter inhibitor" exact="triflupromazine" post="(33) inhibited both SARS-CoV and MERS-CoV. In addition to"/>
   <result pre="both SARS-CoV and MERS-CoV. In addition to that, other neurotransmitters" exact="fluphenazine" post="(29) and promethazine (30) were reported to inhibit MERS-CoVs"/>
   <result pre="MERS-CoV. In addition to that, other neurotransmitters fluphenazine (29) and" exact="promethazine" post="(30) were reported to inhibit MERS-CoVs protein-mediated cell-cell fusion"/>
   <result pre="20 and 29 μM, respectively [81]. Kinase signaling pathway inhibitors" exact="imatinib" post="mesylate (35) and dasatinib (36) are known inhibitors of"/>
   <result pre="respectively [81]. Kinase signaling pathway inhibitors imatinib mesylate (35) and" exact="dasatinib" post="(36) are known inhibitors of the Abelson murine leukemia"/>
   <result pre="inhibitor 5.46 2.10 The identified DNA synthesis inhibitors (for example," exact="gemcitabine" post="hydrochloride, 23) those were active against at least one"/>
   <result pre="drug used to prevent rejection in organ transplantation. It inhibits" exact="inosine" post="monophosphate dehydrogenase, a key rate-limiting enzyme in the de"/>
   <result pre="enzyme in the de novo purine synthesis pathway which converts" exact="inosine" post="monophosphate to guanosine monophosphate [83]. The active molecule, mycophenolic"/>
   <result pre="converts inosine monophosphate to guanosine monophosphate [83]. The active molecule," exact="mycophenolic acid" post="(46, see for structure Table 4 ), exhibits broad-spectrum"/>
   <result pre="virus (HBV), hepatitis C virus (HCV) and arboviruses [82]. Recently," exact="mycophenolic acid" post="was identified as a potential anti-MERS-CoV drug by a"/>
   <result pre="result as the treatment of MERS-CoV infected common marmosets with" exact="mycophenolic acid" post="had a worse outcome than untreated animals did [84]."/>
   <result pre="(44) and N-ethylmaleimide (45) as well as the immunosuppressive drug," exact="mycophenolic acid" post="(46), were all independently able to inhibit the proteolytic"/>
   <result pre="(45), 6-mercaptopurine (43), 6-thioguanine (44) were more effective inhibitors, while" exact="mycophenolic acid" post="(46) was a less effective inhibitor against the MERS-CoV"/>
   <result pre="by reacting with cysteine residues, suggesting broad-spectrum characteristics [95]. Notably," exact="disulfiram" post="(47) has been reported as an allosteric inhibitor of"/>
   <result pre="combinations of interferon- α or-β with other antivirals such as" exact="ribavirin" post="and/or lopinavir-ritonavir have been used to treat patients with"/>
   <result pre="SARS or MERS. Overall, combination treatments consisting of interferons and" exact="ribavirin" post="did not consistently improve outcomes 47, 48, 49, 136,"/>
   <result pre="the T cell-mediated adaptive immune response [142]. The calcineurin inhibitor" exact="cyclosporine" post="(90, Fig. 13) inhibits a broad range of CoVs"/>
   <result pre="at standard therapeutic dosages limit its clinical application. Trametinib (91)," exact="selumetinib" post="(92), everolimus, rapamycin, dasatinib, and imatinib are examples of"/>
   <result pre="clinical application. Trametinib (91), selumetinib (92), everolimus, rapamycin, dasatinib, and" exact="imatinib" post="are examples of inhibitors of kinase signaling pathways, which"/>
   <result pre="and SARS-CoV S-mediated cell-cell fusion in vitro[148]. Neurotransmitter inhibitors including" exact="chlorpromazine" post="(8), fluphenazine (29), and promethazine (30), were reported to"/>
   <result pre="S-mediated cell-cell fusion in vitro[148]. Neurotransmitter inhibitors including chlorpromazine (8)," exact="fluphenazine" post="(29), and promethazine (30), were reported to inhibit cell-cell"/>
   <result pre="in vitro[148]. Neurotransmitter inhibitors including chlorpromazine (8), fluphenazine (29), and" exact="promethazine" post="(30), were reported to inhibit cell-cell fusion in a"/>
   <result pre="the entry [158]. Subsequently, cholesterol-binding or depleting agents such as" exact="nystatin" post="(104, Fig. 13) or methyl-β-cyclodextrin (MβCD) (105, Fig. 13)"/>
   <result pre="crystallography and functional assays. Examples include the viroporin inhibitor hexamethylene" exact="amiloride" post="(6, Fig. 1), which reduces the ion channel activity"/>
   <result pre="and MERS-CoV viruses. Inosine monophosphate dehydrogenase (IMPDH) inhibitors such as" exact="ribavirin" post="and mycophenolic acid inhibit an important step in de"/>
   <result pre="viruses. Inosine monophosphate dehydrogenase (IMPDH) inhibitors such as ribavirin and" exact="mycophenolic acid" post="inhibit an important step in de novo synthesis of"/>
   <result pre="infections [169] Mizoribine exerts its activity through selective inhibition of" exact="inosine" post="monophosphate synthetase and guanosine monophosphate synthetase, resulting in the"/>
   <result pre="of guanine nucleotide synthesis without incorporation into nucleotides. The chemotherapeutic" exact="gemcitabine" post="has shown in vitro activity against MERS-CoV and SARS-CoV"/>
   <result pre="of two casesAntivir. Ther.202015879124831606 49ShalhoubS.IFN-α2a or IFN-β1a in combination with" exact="ribavirin" post="to treat Middle East respiratory syndrome coronavirus pneumonia: a"/>
   <result pre="of Middle East respiratorysyndromecoronavirus replication in cell cultureAntimicrobAgentsChemother58201448754884 66SavarinoA.Effects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseases?Lancet"/>
   <result pre="mechanisms of action, and self-potentiationSemin. Oncol.221995310 78KangH.Synergistic antiviral activity of" exact="gemcitabine" post="and ribavirin against enterovirusesAntivir. Res.124201511026526589 79BrassA.L.The IFITM proteins mediate"/>
   <result pre="action, and self-potentiationSemin. Oncol.221995310 78KangH.Synergistic antiviral activity of gemcitabine and" exact="ribavirin" post="against enterovirusesAntivir. Res.124201511026526589 79BrassA.L.The IFITM proteins mediate cellular resistance"/>
   <result pre="and inhibition by designed antiviral compoundsAntiviral Res.1152015213825554382 92ChengK.W.Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
   <result pre="pneumocytes against SARS coronavirus infection in macaquesNat. Med.10200429029314981511 131HartB.J.Interferon-β and" exact="mycophenolic acid" post="are potent inhibitors of Middle East respiratory syndrome coronavirus"/>
   <result pre="a first-in-class broad-spectrum antiviral agentAntiviral Res.11020149410325108173 133FalzaranoD.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat. Med.1920131313131724013700 134CinatlJ.Treatment of"/>
   <result pre="the Middle East respiratory syndromeCurr. Opin. Pulm. Med.20201423324124626235 140HaffizullaJ.Effect of" exact="nitazoxanide" post="in adults and adolescents with acute uncomplicated influenza: a"/>
   <result pre="Infect. Dis.14201460961824852376 141RossignolJ.F.Clinical trial: randomized, double blind, placebo-controlled study of" exact="nitazoxanide" post="monotherapy for the treatment of patients with chronic hepatitis"/>
   <result pre="of the SARS coronavirus envelope protein ion channelPLoS Pathog.52009e1000511 162WilsonL.Hexamethylene" exact="amiloride" post="blocks E protein ion channels and inhibits coronavirus replicationVirology353200629430616815524"/>
   <result pre="and HR2 domainsInt. J. Mol. Sci.192018487 169MorenoC.Efficacy and safety of" exact="simeprevir" post="with PegIFN/ribavirin in naïve or experienced patients infected with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7102548\results\search\drugs\results.xml">
   <result pre="powder of raw material of LH was first dissolved in" exact="dimethyl sulfoxide" post="(DMSO) to 240 mg/mL. After shaking for 30 min"/>
   <result pre="via suppression of host TLR3 signaling in vitroMolecules2212017 17WangM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7102570\results\search\drugs\results.xml">
   <result pre="cures all mice in a lethal influenza infection model, while" exact="oseltamivir" post="fails to cure the animals. Thus, favipiravir contributes to"/>
   <result pre="2009). Favipiravir shows better efficacy in treating influenza infections than" exact="oseltamivir" post="(Tamiflu) (Takahashi et al., 2003; Tanaka et al., 2017),"/>
   <result pre="Guanosine, inosine, and AICAR are biosynthesized in the body, and" exact="ribavirin" post="and ribosyl favipiravir are synthesized nucleoside analogues. They have"/>
   <result pre="influenza A(H7N9) (Li et al., 2014). A combination therapy with" exact="oseltamivir" post="has been used to treat patients with severe influenza"/>
   <result pre="and conducted experiments to compare the efficacy of favipiravir with" exact="oseltamivir" post="(Tamiflu). Based on its chemical structure, favipiravir should inhibit"/>
   <result pre="in Japan (Yasukawa, 2016) and as a combination therapy with" exact="oseltamivir" post="to treat patients with severe influenza in China (Cao,"/>
   <result pre="(EC50 = 63.7 μM) of adenine, guanine, adenosine, guanosine, and" exact="inosine" post="in the assay medium abolishes the anti-influenza virus activity"/>
   <result pre="1998; Kurokawa, Brown, Kagawa, &amp;amp; Shiraki, 2003). Cinnamyl compounds and" exact="clarithromycin" post="increase the levels of IL-12 on day 2 and"/>
   <result pre="we have experience in conducting a pharmacological study for a" exact="famciclovir" post="approval application in Japan, the efficacy and validation studies"/>
   <result pre="shows one of the comparisons of efficacy between favipiravir and" exact="oseltamivir" post="in the influenza virus infection model established with a"/>
   <result pre="of experiments, and the better efficacy of favipiravir compared with" exact="oseltamivir" post="was observed in an animal with a severe lethal"/>
   <result pre="a high viral load (Takahashi et al., 2003). Favipiravir and" exact="oseltamivir" post="show similar efficacy in low-dose infections, but the efficacy"/>
   <result pre="favipiravir as an influenza drug is clearly increased compared with" exact="oseltamivir" post="in high-titer virus infections (Fig. 3). Mice in the"/>
   <result pre="die on day 3 after a high-dose infection, and an" exact="oseltamivir" post="treatment prolongs the survival period for three days but"/>
   <result pre="infection, and all mice survive. Favipiravir exhibits better efficacy than" exact="oseltamivir" post="after a delayed administration beginning 1, 24, 48, or"/>
   <result pre="2003). Fig. 3 Comparison of the efficacy of favipiravir and" exact="oseltamivir" post="in lethal influenza virus infection. Mice were infected with"/>
   <result pre="of influenza A/PR/8/34 virus and were orally administered favipiravir and" exact="oseltamivir" post="at doses of 200 and 400 mg/kg/day for 5"/>
   <result pre="from a representative experiment. *P &amp;lt; .01 compared to 0.5%" exact="methylcellulose" post="solution-treated controls and oseltamivir-treated groups (log-rank test). The authors"/>
   <result pre="to correspond to human seasonal infection models. In this model," exact="oseltamivir" post="and favipiravir are equally effective and do not differ"/>
   <result pre="to correspond to a novel influenza infection in humans. Although" exact="oseltamivir" post="is ineffective in this model, favipiravir effectively improves survival"/>
   <result pre="macrophage-derived P388D1 cells, and the suppressive effects of favipiravir and" exact="oseltamivir" post="were compared in this P388D1 cell-based system. Favipiravir significantly"/>
   <result pre="influenza virus-infected P388D1 cells compared with the active form of" exact="oseltamivir" post="(Tanaka et al., 2017). TNF-α appears first and disappears"/>
   <result pre="effects of favipiravir treatment on alleviating influenza infection compared with" exact="oseltamivir" post="treatment. Favipiravir displays superior properties to oseltamivir in mouse"/>
   <result pre="infection compared with oseltamivir treatment. Favipiravir displays superior properties to" exact="oseltamivir" post="in mouse models, and we confirmed its efficacy in"/>
   <result pre="to the placebo in alleviating influenza symptoms and to both" exact="oseltamivir" post="and placebo in reducing the viral load 1 day"/>
   <result pre="clearance, and baloxavir-resistant viruses were not cross-resistant to favipiravir and" exact="oseltamivir" post="(Omoto et al., 2018). Baloxavir-resistant viruses were identified after"/>
   <result pre="drugs ineffective during prolonged viral growth in patients treated with" exact="oseltamivir" post="or baloxavir. Although drug-resistant viruses may have a reduced"/>
   <result pre="severe influenza infections characterized by a high viral load than" exact="oseltamivir" post="(Takahashi et al., 2003), and a favipiravir-resistant virus does"/>
   <result pre="exploited in treating patients with severe influenza in combination with" exact="oseltamivir" post="in China (Cao, 2018; Wang et al., 2019). Favipiravir"/>
   <result pre="in China (Cao, 2018; Wang et al., 2019). Favipiravir and" exact="oseltamivir" post="combination therapy accelerated clinical recovery compared to oseltamivir monotherapy"/>
   <result pre="Favipiravir and oseltamivir combination therapy accelerated clinical recovery compared to" exact="oseltamivir" post="monotherapy in severe influenza. The dose of favipiravir used"/>
   <result pre="other existing therapies is also an option and favipiravir and" exact="oseltamivir" post="combination therapy showed accelerated clinical recovery compared to oseltamivir"/>
   <result pre="and oseltamivir combination therapy showed accelerated clinical recovery compared to" exact="oseltamivir" post="monotherapy in severe influenza in China (Cao, 2018; Wang"/>
   <result pre="different from the range of 0.014–0.55 μg/mL in medium without" exact="adenosine" post="and guanosine and 10 μg/mL, respectively (Furuta et al.,"/>
   <result pre="x EC50 (63.7 μM) of adenine, guanine, adenosine, guanosine, and" exact="inosine" post="in the assay medium abolishes the anti-influenza virus activity"/>
   <result pre="strand cannot be completed. In contrast, the anti-RNA virus drug" exact="ribavirin" post="is incorporated into the replicating strand, which further elongates"/>
   <result pre="accumulates mismatched nucleotides at the incorporated sites. Base pairing with" exact="ribavirin" post="in the complementary strand during replication, transcription, and translation"/>
   <result pre="and infectious viruses with mutations in viral RdRp that affect" exact="ribavirin" post="incorporation are produced, drug-resistant viruses can be selected in"/>
   <result pre="to elongate until completion. Next, the RNA strand with multiple" exact="ribavirin" post="incorporation sites further incorporates ribavirin or serves as mRNA"/>
   <result pre="the RNA strand with multiple ribavirin incorporation sites further incorporates" exact="ribavirin" post="or serves as mRNA for viral protein synthesis. The"/>
   <result pre="serves as mRNA for viral protein synthesis. The incorporation of" exact="ribavirin" post="in the viral RNA causes the mismatch of base"/>
   <result pre="(Jin et al., 2013; Sangawa et al., 2013). Favipiravir-RTP and" exact="ribavirin" post="TP inhibit the RdRp activity in a dose-dependent manner,"/>
   <result pre="and a low IC50 (0.14 μM). On the other hand," exact="ribavirin" post="induces competitive inhibition with GTP, and incorporation results in"/>
   <result pre="incorporate labeled GTP without stopping at the incorporation site. Thus," exact="ribavirin" post="has a high IC50 value (2.4 μM) because its"/>
   <result pre="al., 2007; Talarico, Phelps, &amp;amp; Biron, 1993). Penciclovir (famciclovir) and" exact="ganciclovir" post="(valganciclovir), which are guanosine analogues, function as an anti-herpes"/>
   <result pre="activity causes a lower mutation frequency in subjects treated with" exact="penciclovir" post="and ganciclovir than in subjects treated with acyclovir. If"/>
   <result pre="a lower mutation frequency in subjects treated with penciclovir and" exact="ganciclovir" post="than in subjects treated with acyclovir. If favipiravir induces"/>
   <result pre="of favipiravir into viral RNA followed by elongation, similar to" exact="ribavirin" post="or acyclovir (Fig. 5). Favipiravir is unlikely to induce"/>
   <result pre="mutagens such as ribavirin. Ribavirin reduces GTP levels by inhibiting" exact="inosine" post="monophosphate dehydrogenase, but favipiravir has little effect on GTP"/>
   <result pre="assess the emergence of favipiravir-resistant virus, but the appearance of" exact="oseltamivir" post="or baloxavir resistance might be observed in clinical trials"/>
   <result pre="might be observed in clinical trials of influenza treatment with" exact="oseltamivir" post="and baloxavir with a similar number of patients, as"/>
   <result pre="after the start of treatment. Time from illness onset to" exact="oseltamivir" post="treatment in avian influenza A(H7N9) virus infection is 6"/>
   <result pre="respiratory tract of miceActa Virologica53200923324019941386 HawmanD.W.HaddockE.Meade-WhiteK.WilliamsonB.HanleyP.W.RosenkeK. …FeldmannH.Favipiravir (T-705) but not" exact="ribavirin" post="is effective against two distinct strains of Crimean-Congo hemorrhagic"/>
   <result pre="of Dermatological Science232000637210699766 IdaM.KageyamaS.SatoH.KamiyamaT.YamamuraJ.KurokawaM. …ShirakiK.Emergence of resistance to acyclovir and" exact="penciclovir" post="in varicella-zoster virus and genetic analysis of acyclovir-resistant variantsAntiviral"/>
   <result pre="in influenza virus-infected miceChem Pharm Bull (Tokyo)461998144414479775439 KurosakiK.MiwaN.YoshidaY.KurokawaM.KurimotoM.EndoS.ShirakiK.Therapeutic basis of" exact="vidarabine" post="on adenovirus-induced haemorrhagic cystitisAntiviral Chemistry &amp;amp; Chemotherapy15200428128515535050 LaiS.QinY.CowlingB.J.RenX.WardropN.A.GilbertM. …YuH.Global"/>
   <result pre="of Medicine370201452053223614499 LinaB.BoucherC.OsterhausA.MontoA.S.SchuttenM.WhitleyR.J.Nguyen-Van-TamJ.S.Five years of monitoring for the emergence of" exact="oseltamivir" post="resistance in patients with influenza A infections in the"/>
   <result pre="hemorrhagic feverPLoS Neglected Tropical Diseases52011e1342 MiwaN.KurosakiK.YoshidaY.KurokawaM.SaitoS.ShirakiK.Comparative efficacy of acyclovir and" exact="vidarabine" post="on the replication of varicella-zoster virusAntiviral Research652005495515652971 MoriH.ShirakiK.KatoT.HayakawaY.YamanishiK.TakahashiM.Molecular analysis"/>
   <result pre="Research1052014172124583123 OestereichL.RiegerT.LudtkeA.RuibalP.WurrS.PallaschE. …GuntherS.Efficacy of Favipiravir alone and in combination with" exact="ribavirin" post="in a lethal, Immunocompetent mouse model of Lassa feverThe"/>
   <result pre="(H1N1) infectionFrontiers in Immunology102019216131572376 RaabeV.N.KannG.RibnerB.S.MoralesA.VarkeyJ.B.MehtaA.K. …Emory Serious Communicable DiseasesU.Favipiravir and" exact="ribavirin" post="treatment of epidemiologically linked cases of Lassa feverClinical Infectious"/>
   <result pre="fever virus infection and reduces delayed-onset neurologic disease observed with" exact="ribavirin" post="treatmentAntiviral Research1042014849224486952 ShimadaY.SuzukiM.ShirasakiF.SaitoE.SogoK.HasegawaM. …ShirakiK.Genital herpes due to acyclovir-sensitive herpes"/>
   <result pre="TakahashiK.FurutaY.FukudaY.KunoM.KamiyamaT.KozakiK. …ShirakiK.In vitro and in vivo activities of T-705 and" exact="oseltamivir" post="against influenza virusAntiviral Chemistry &amp;amp; Chemotherapy14200323524114694986 TakashitaE.EjimaM.OgawaR.FujisakiS.NeumannG.FurutaY. …OdagiriT.Antiviral susceptibility"/>
   <result pre="(IL)-12 level in the airway of mice administered orally with" exact="clarithromycin" post="or intranasally with IL-12 results in alleviation of influenza"/>
   <result pre="Jan 1434635531309975 VanderlindenE.VranckenB.Van HoudtJ.RajwanshiV.K.GillemotS.AndreiG. …NaesensL.Distinct effects of T-705 (Favipiravir) and" exact="ribavirin" post="on influenza virus replication and viral RNA synthesisAntimicrobial Agents"/>
   <result pre="implicationsVirus Research107200517318115649563 WangY.FanG.SalamA.HorbyP.HaydenF.G.ChenC. …NetworkC. A.-C.Comparative effectiveness of combined favipiravir and" exact="oseltamivir" post="therapy versus oseltamivir monotherapy in critically ill patients with"/>
   <result pre="…NetworkC. A.-C.Comparative effectiveness of combined favipiravir and oseltamivir therapy versus" exact="oseltamivir" post="monotherapy in critically ill patients with influenza virus infectionJ"/>
   <result pre="patients with influenza virus infectionJ Infect Dis2019jiz65610.1093/infdis/jiz65631822885 WestoverJ.B.SefingE.J.BaileyK.W.Van WettereA.J.JungK.H.DagleyA. …GowenB.B.Low-dose" exact="ribavirin" post="potentiates the antiviral activity of favipiravir against hemorrhagic fever"/>
   <result pre="deoxyribonucleoside triphosphate accumulation in Escherichia coliDNA Repair (Amst)420051450145616207537 WhitleyR.J.HaydenF.G.ReisingerK.S.YoungN.DutkowskiR.IpeD. …WardP.Oral" exact="oseltamivir" post="treatment of influenza in childrenThe Pediatric Infectious Disease Journal20200112713311224828"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7102586\results\search\drugs\results.xml">
   <result pre="and gastrointestinal disease. Results We discuss evidence regarding role of" exact="chloroquine" post="and hydroxychloroquine in treatment and prophylaxis, use of inhibitors"/>
   <result pre="disease. Results We discuss evidence regarding role of chloroquine and" exact="hydroxychloroquine" post="in treatment and prophylaxis, use of inhibitors of the"/>
   <result pre="relevant cross references from the search results. 3 Role of" exact="chloroquine" post="and hydroxychloroquine (HCQ) Antiviral properties of chloroquine in vitro"/>
   <result pre="references from the search results. 3 Role of chloroquine and" exact="hydroxychloroquine" post="(HCQ) Antiviral properties of chloroquine in vitro have been"/>
   <result pre="3 Role of chloroquine and hydroxychloroquine (HCQ) Antiviral properties of" exact="chloroquine" post="in vitro have been observed for more than half"/>
   <result pre="immune reaction seen with viral infections. In vitro activity of" exact="chloroquine" post="(CQ) has been demonstrated against several viruses including Vesicular"/>
   <result pre="concentrate in target tissues. Also 50% effective concentration [EC50] of" exact="chloroquine" post="for anti-viral effects is about three times higher than"/>
   <result pre="this study of 36 patients, 20 patients were treated with" exact="hydroxychloroquine" post="(HCQ), out of which 6 also received azithromycin, and"/>
   <result pre="100%, 57% and 12.%% for those treated with HCQ and" exact="azithromycin" post="combination, HCQ only and controls, respectively [13].Though this is"/>
   <result pre="[15]. Though there is no evidence of the role of" exact="chloroquine" post="in prophylaxis against CVID-19, Indian Council of Medical Research"/>
   <result pre="lhousehold contacts of laboratory confirmed cases [16]. 4 Use of" exact="ibuprofen" post="and other NSAIDs A doctor from France cited four"/>
   <result pre="disease. This observation prompted the advice against the use of" exact="ibuprofen" post="in this condition [17]. World Health Organisation (WHO) first"/>
   <result pre="condition [17]. World Health Organisation (WHO) first recommended against using" exact="ibuprofen" post="in COVID-19, however went back against its own advice"/>
   <result pre="evidence Overall, it seems reasonable, but not mandatory, to avoid" exact="ibuprofen" post="and other NSAIDs in COVID-19 infection and use acetaminophen"/>
   <result pre="avoid ibuprofen and other NSAIDs in COVID-19 infection and use" exact="acetaminophen" post="instead for control of fever and pain. 5 Use"/>
   <result pre="injury showed improvement when treated with an angiotensin receptor blocker," exact="losartan" post="[22].As far as CVID-19 infection is concerned, the data"/>
   <result pre="times of COVID-19 epidemicDiabetes Metab Syndr1432020 Mar 1021121232172175 2ShimizuY.YamamotoS.HommaM.IshidaN.Effect of" exact="chloroquine" post="on the growth of animal virusesArch Gesamte Virusforsch3611972931044335025 3SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects"/>
   <result pre="on the growth of animal virusesArch Gesamte Virusforsch3611972931044335025 3SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseases?Lancet"/>
   <result pre="Natl Acad Sci U S A7861981360536096115382 5KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newbornmiceAntimicrob Agents Chemother53820093416342110.1128/AAC.01509-0819506054"/>
   <result pre="placebo controlled trialLancet Infect Dis119201167768310.1016/S1473-3099(11)70065-221550310 8TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.TranH.T.SimmonsC.P.A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adultsPLoS Negl"/>
   <result pre="Negl Trop Dis482010 Aug 10e78510.1371/journal.pntd.000078520706626 9RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.GrasG.LebonP.NgL.F.P.de LamballerieX.Le GrandR.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses1052018E26810.3390/v10050268pii29772762 10De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On"/>
   <result pre="chikungunya virus infectionViruses1052018E26810.3390/v10050268pii29772762 10De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On chikungunya acute infection and" exact="chloroquine" post="treatmentVector Borne Zoonotic Dis86200883783910.1089/vbz.2008.004918620511 11SavarinoA.Use of chloroquine in viral"/>
   <result pre="acute infection and chloroquine treatmentVector Borne Zoonotic Dis86200883783910.1089/vbz.2008.004918620511 11SavarinoA.Use of" exact="chloroquine" post="in viral diseasesLancet Infect Dis119201165365410.1016/S1473-3099(11)70092-521550312 12WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and chloroquine effectively"/>
   <result pre="11SavarinoA.Use of chloroquine in viral diseasesLancet Infect Dis119201165365410.1016/S1473-3099(11)70092-521550312 12WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="recently emerged novel coronavirus (2019-nCoV) in vitroCell Res303202026927110.1038/s41422-020-0282-010-028232020029 13GautretHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="clinical trialInt J Antimicrob Agents202010.1016/j.ijantimicag.2020.105949In Press 17 March 2020 14GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="Clin Res RevMarch 22, 2020 16Recommendations for empiric use of" exact="hydroxychloroquine" post="for prophylaxis of SARS CoV-2 infectionhttps://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf 17DayM.Covid-19:Ibuprofen should not"/>
   <result pre="and scientistsBMJ3682020 Mar 17m108610.1136/bmj.m108632184201 18Updated: WHO now doesn’t recommend avoiding" exact="ibuprofen" post="for COVID-19 symptomshttps://www.sciencealert.com/who-recommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms 19VoiriotG.PhilippotQ.ElabbadiA.ElbimC.ChalumeauFartoukhM.Risks related to the use of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7102587\results\search\drugs\results.xml">
   <result pre="Elsevier Ltd. pmcid: 7102587S1871-4021(20)30051-5 doi: 10.1016/j.dsx.2020.03.011 : Article Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
   <result pre="been tried. In view of recent studies and discussion on" exact="chloroquine" post="and hydroxychloroquine (HCQ), we aimed to review existing literature"/>
   <result pre="In view of recent studies and discussion on chloroquine and" exact="hydroxychloroquine" post="(HCQ), we aimed to review existing literature and relevant"/>
   <result pre="March 21, 2020 and retrieved all the articles published on" exact="chloroquine" post="and HCQ and COVID-19. Results Two small human studies"/>
   <result pre="the treatment for COVID-19 that includes a low-cost antimalarial drug" exact="chloroquine" post="and its derivative hydroxychloroquine (HCQ), along with several other"/>
   <result pre="that includes a low-cost antimalarial drug chloroquine and its derivative" exact="hydroxychloroquine" post="(HCQ), along with several other antiviral drugs. Because HCQ"/>
   <result pre="evidences that have emerged so far on the efficacy of" exact="chloroquine" post="and hydroxychloroquine, in the treatment of patients with COVID-19,"/>
   <result pre="PubMed database up till March 21, 2020 using key words" exact="chloroquine" post="AND COVID-19, and hydroxychloroquine AND COVID-19 and retrieved a"/>
   <result pre="March 21, 2020 using key words chloroquine AND COVID-19, and" exact="hydroxychloroquine" post="AND COVID-19 and retrieved a total of 13 articles."/>
   <result pre="both these compounds from ClinicalTrials.gov. 3 Results 3.1 Studies of" exact="chloroquine" post="and hydroxychloroquine conducted in vitro Experimental studies have suggested"/>
   <result pre="compounds from ClinicalTrials.gov. 3 Results 3.1 Studies of chloroquine and" exact="hydroxychloroquine" post="conducted in vitro Experimental studies have suggested that chloroquine"/>
   <result pre="and hydroxychloroquine conducted in vitro Experimental studies have suggested that" exact="chloroquine" post="is a proven anti-malarial drug that has the capability"/>
   <result pre="micro-organisms including coronaviruses in vitro. It is also believed that" exact="chloroquine" post="may have a varied mechanism of action which may"/>
   <result pre="been increasingly learnt that the anti-viral and anti-inflammatory activities of" exact="chloroquine" post="may have a role in the treatment of patients"/>
   <result pre="has the potential to block viral infection [7]. In addition," exact="chloroquine" post="also inhibits the quinone reductase-2, which is involved in"/>
   <result pre="and orthomyxoviruses uses sialic acid moieties as a receptor. Moreover," exact="chloroquine" post="changes the pH of lysosomes and likely inhibits cathepsins,"/>
   <result pre="formation of the autophagosome which cleaves SARS-CoV-2 spike protein. Furthermore," exact="chloroquine" post="through the inhibition of MAP-kinase interferes with SARS-CoV-2 molecular"/>
   <result pre="M protein [7,8]. Previous experimental studies have also demonstrated that" exact="chloroquine" post="has potent anti-SARS-CoV-1 effects in vitro, primarily attributable to"/>
   <result pre="utilizes the similar surface receptor ACE2, it is believed that" exact="chloroquine" post="can also interfere with ACE2 receptor glycosylation thus prevents"/>
   <result pre="[7], [8], [9]]. Chinese researchers who studied the effect of" exact="chloroquine" post="in vitro (using Vero E6 cell line infected by"/>
   <result pre="vitro (using Vero E6 cell line infected by SARS-CoV-2) found" exact="chloroquine" post="to be highly effective in reducing viral replication that"/>
   <result pre="lung [6,10]. Since the structure and mechanism of action of" exact="chloroquine" post="and hydroxychloroquine (HCQ) are exactly same except an additional"/>
   <result pre="Since the structure and mechanism of action of chloroquine and" exact="hydroxychloroquine" post="(HCQ) are exactly same except an additional hydroxy moiety"/>
   <result pre="transport and the post-entry stages of SARS-CoV-2, similar to the" exact="chloroquine" post="and one study found HCQ to be a more"/>
   <result pre="study found HCQ to be a more potent agent than" exact="chloroquine" post="in inhibiting SARS-CoV-2 in vitro [12,13]. In addition, HCQ"/>
   <result pre="lesser risk of retinal toxicity with HCQ, as compared to" exact="chloroquine" post="[16]. Furthermore, the narrow therapeutic and safety index margin"/>
   <result pre="[16]. Furthermore, the narrow therapeutic and safety index margin with" exact="chloroquine" post="makes HCQ a safer option than chloroquine. An additional"/>
   <result pre="of HCQ with less drug-drug interactions. 3.2 Studies conducted with" exact="chloroquine" post="and hydroxychloroquine in human COVID-19 The anti-viral and anti-inflammatory"/>
   <result pre="with less drug-drug interactions. 3.2 Studies conducted with chloroquine and" exact="hydroxychloroquine" post="in human COVID-19 The anti-viral and anti-inflammatory actions of"/>
   <result pre="hydroxychloroquine in human COVID-19 The anti-viral and anti-inflammatory actions of" exact="chloroquine" post="have led to numerous trials urgently in the face"/>
   <result pre="Chinese study involving more than 100 patients of COVID-19 found" exact="chloroquine" post="superior to the control group in reducing symptom duration,"/>
   <result pre="[18]. This represents the first human trial ever conducted with" exact="chloroquine" post="against COVID-19. Although the detailed results of this trial"/>
   <result pre="letter form, interestingly, this early result led China to include" exact="chloroquine" post="in the prevention and treatment of COVID-19 pneumonia. Moreover,"/>
   <result pre="Commission of the People’s Republic of China recommended inclusion of" exact="chloroquine" post="in the next version of the Guidelines for the"/>
   <result pre="and Treatment of Pneumonia Caused by COVID-19. In this study," exact="chloroquine" post="was given in dose of 500 mg of chloroquine"/>
   <result pre="study, chloroquine was given in dose of 500 mg of" exact="chloroquine" post="twice daily in mild to severe COVID-19 pneumonia (see"/>
   <result pre="al. found that HCQ alone and combination of HCQ plus" exact="azithromycin" post="was highly and significantly effective in clearing viral nasopharyngeal"/>
   <result pre="(p &amp;lt; 0.001). This data suggests a synergistic effect of" exact="azithromycin" post="with HCQ. Indeed, azithromycin has shown an antiviral effect"/>
   <result pre="data suggests a synergistic effect of azithromycin with HCQ. Indeed," exact="azithromycin" post="has shown an antiviral effect against Zika and Ebola"/>
   <result pre="institutions and or organizations have already recognized the utility of" exact="chloroquine" post="and HCQ [20]. The expert consensus from the Department"/>
   <result pre="(based on in vitro evidence and still unpublished clinical experience)" exact="chloroquine" post="phosphate tablet at a dose of 500 mg twice"/>
   <result pre="Korea who have treated 27 cases of COVID-19 recommend using" exact="lopinavir" post="400mg/Ritonavir 100 mg BID or Chloroquine 500 mg orally"/>
   <result pre="public document on its website, also suggested the use of" exact="chloroquine" post="in those having severe COVID-19 infection admitted in the"/>
   <result pre="Insufficient evidence to issue a recommendation on the use of" exact="chloroquine" post="or hydroxychloroquine in critically ill adults with COVID-19 at"/>
   <result pre="to issue a recommendation on the use of chloroquine or" exact="hydroxychloroquine" post="in critically ill adults with COVID-19 at this point"/>
   <result pre="later followed by 300 mg BID for 5 days (Consider" exact="lopinavir" post="400 mg/ritonavir 100 mg BID for 14 days as"/>
   <result pre="14 days as a second choice only if HCQ and" exact="chloroquine" post="is contraindicated, provided it can be administered within 10"/>
   <result pre="days (lopinavir/ritonavir as second option)Critical COVID-19:Remdesivir for 10 days plus" exact="chloroquine" post="for 5 day Gautret et al., Marseille, France19 Hydroxychloroquine"/>
   <result pre="reaction, i.v - intravenous. 4 Discussion The antiviral activity of" exact="chloroquine" post="and HCQ have been identified in the in vitro"/>
   <result pre="Zika virus and influenza A H5N1. However, no benefit of" exact="chloroquine" post="was seen in the prevention of influenza and dengue"/>
   <result pre="infection in a randomized, double-blind, placebo-controlled, clinical trial [29,30]. Similarly," exact="chloroquine" post="was active in ex vivo studies but not in"/>
   <result pre="ebolavirus, nipah and influenza viruses [[31], [32], [33]]. Data of" exact="chloroquine" post="against chikungunya virus is even more intriguing. While chloroquine"/>
   <result pre="of chloroquine against chikungunya virus is even more intriguing. While" exact="chloroquine" post="had satisfactory antiviral activity against chikungunya in vitro, animal"/>
   <result pre="of fever and incomplete viral clearance [34]. Human trials of" exact="chloroquine" post="showed no improvement in chikungunya acute illness and rather"/>
   <result pre="post-illness period, compared to the controls [35]. The role of" exact="chloroquine" post="against Human Immunodeficiency Virus was inconclusive [36]. The only"/>
   <result pre="Immunodeficiency Virus was inconclusive [36]. The only viral disease where" exact="chloroquine" post="was modestly effective so far before COVID-19 era was"/>
   <result pre="C suggesting an increased virological response to pegylated interferon plus" exact="ribavirin" post="[37]. Therefore, the results of chloroquine and HCQ so"/>
   <result pre="to pegylated interferon plus ribavirin [37]. Therefore, the results of" exact="chloroquine" post="and HCQ so far done against COVID-19, more promising"/>
   <result pre="countries where malaria is endemic. 4.1 Cautions and contraindication with" exact="chloroquine" post="and hydroxychloroquine Expectedly, some precautions will be needed while"/>
   <result pre="malaria is endemic. 4.1 Cautions and contraindication with chloroquine and" exact="hydroxychloroquine" post="Expectedly, some precautions will be needed while using both"/>
   <result pre="the QTc interval (such as anti-arrhythmic, anti-depressants, anti-psychotics, anti-histaminic, teneligliptin," exact="ondansetron" post="and moxifloxacin etc.) must be avoided [38,39]. Moreover, addition"/>
   <result pre="interval (such as anti-arrhythmic, anti-depressants, anti-psychotics, anti-histaminic, teneligliptin, ondansetron and" exact="moxifloxacin" post="etc.) must be avoided [38,39]. Moreover, addition of azithromycin"/>
   <result pre="and moxifloxacin etc.) must be avoided [38,39]. Moreover, addition of" exact="azithromycin" post="to HCQ as done in French trial by Gautret"/>
   <result pre="is not contraindicated in pregnancy. 5 Conclusion Although evidence of" exact="chloroquine" post="and HCQ is limited (based on the experimental data"/>
   <result pre="small human trials), considering the potentially favorable benefit-risk balance of" exact="chloroquine" post="and HCQ in absence of any other valid treatment"/>
   <result pre="of management in Table 3 . The low cost of" exact="chloroquine" post="and HCQ could also be an effective strategy to"/>
   <result pre="the benefit-risk ratio as well as the low cost of" exact="chloroquine" post="and hydroxychloroquine in Indian context, we propose the following"/>
   <result pre="ratio as well as the low cost of chloroquine and" exact="hydroxychloroquine" post="in Indian context, we propose the following regime, until"/>
   <result pre="of intervention Proposed Chemoprophylaxis •No conclusive evidence so far; however," exact="chloroquine" post="or HCQ could be researched as a prophylactic agent"/>
   <result pre="HCQ-hydroxychloroquine, BID – twice daily. Table 4 Ongoing trials with" exact="chloroquine" post="and hydroxychloroquine as of March 21, 2020. [alt-text] Table"/>
   <result pre="– twice daily. Table 4 Ongoing trials with chloroquine and" exact="hydroxychloroquine" post="as of March 21, 2020. [alt-text] Table 4 Study"/>
   <result pre="planned for COVID-19: Several trials are currently underway with both" exact="chloroquine" post="and HCQ in patients with COVID-19 at different doses."/>
   <result pre="ClinicalTrial.org database dated March 21, 2020 showed 4 trials with" exact="chloroquine" post="and 3 trials with HCQ which is currently under"/>
   <result pre="area which needs to be explored further is resistance to" exact="chloroquine" post="and HCQ that may be present with different strains"/>
   <result pre="for the 2019-new coronavirus (2019-nCoV)Biosci Trends2020 Jan 2810.5582/bst.2020.01020 7WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV)J Biol Chem29120169218e3226953343 10ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents2020"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Mar 910.1093/cid/ciaa237pii: ciaa237, [Epub ahead of print] 14RaoultD.DrancourtM.VestrisG.Bactericidal effect of" exact="doxycycline" post="associated with lysosomotropic agents on Coxiella burnetii in P388D1"/>
   <result pre="Antimicrob Agents. 16MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.American academy of ophthalmology. Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy2016Revision 17HuangC.WangY.LiX.RenL.ZhaoJ.HuY.Clinical features of patients infected with"/>
   <result pre="16MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.American academy of ophthalmology. Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy2016Revision 17HuangC.WangY.LiX.RenL.ZhaoJ.HuY.Clinical features of patients infected with 2019 novel"/>
   <result pre="24. Ophthalmology. 2016 Jun;123(6):1386-94. doi:10.1016/j.ophtha.2016.01.058. Epub 2016 Mar 1631986264 18GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci Trends202010.5582/bst.2020.01047 19GautretP.LagieraJ.C.ParolaaP.HoangaV.T.MeddebaL.MailheaM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open"/>
   <result pre="clinical trialInt J Antimicrob Agents17 March 202010.1016/j.ijantimicag.2020.105949In Press 20TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antivir Res1772020 Mar 510476210.1016/j.antiviral.2020.104762[Epub ahead of print]32147496 21Multicenter"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumonia. Expert consensus"/>
   <result pre="in the treatment of novel coronavirus pneumonia. Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]Zhonghua Jiehe"/>
   <result pre="controlled trialLancet Infect Dis1192011 Sep67768321550310 30TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adultsPLoS Neglected"/>
   <result pre="Neglected Trop Dis42010e78510.1371/journal.pntd.0000785 31FalzaranoD.SafronetzD.PrescottJ.MarziA.FeldmannF.FeldmannH.Lack of protection against ebola virus from" exact="chloroquine" post="in mice and hamstersEmerg Infect Dis2120151065106725988934 32VigerustD.J.McCullersJ.A.Chloroquine is effective"/>
   <result pre="in malaria-endemic areasAm J Trop Med Hyg61199918018610463664 35RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses1052018 May 1710.3390/v10050268pii: E268"/>
   <result pre="May 1710.3390/v10050268pii: E268 36ChauhanA.TikooA.The enigma of the clandestine association between" exact="chloroquine" post="and HIV-1 infectionHIV Med16201558559026238012 37HelalG.K.GadM.A.Abd-EllahM.F.EidM.S.Hydroxychloroquine augments early virological response"/>
   <result pre="Med16201558559026238012 37HelalG.K.GadM.A.Abd-EllahM.F.EidM.S.Hydroxychloroquine augments early virological response to pegylated interferon plus" exact="ribavirin" post="in genotype-4 chronic hepatitis C patientsJ Med Virol881220162170217827183377 38Chloroquine"/>
   <result pre="39Chloroquine US prescribing information(Last accessed March 21, 2020)https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf 40LiuD.LiX.ZhangY.KwongJ.S.W.LiL.ZhangY.Chloroquine and" exact="hydroxychloroquine" post="are associated with reduced cardiovascular risk: a systematic review"/>
   <result pre="Ther12201816851695 41CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care202020 Mar 10303903039710.1016/j.jcrc.2020.03.005pii:"/>
   <result pre="S0883-9441https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf[Epub ahead of print]. 42: Recommendations for empiric use of" exact="hydroxychloroquine" post="for prophylaxis of SARS CoV-2 infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7102605\results\search\drugs\results.xml">
   <result pre="of three representative independent experiments. 4 Discussion The anti-depressant drug" exact="lithium" post="is a well-known Food and Drug Administration-approved drug for"/>
   <result pre="mechanism of action of lithiumMol. Psychiatr.41999117128 7WonE.KimY.K.An oldie but goodie:" exact="lithium" post="in the treatment of bipolar disorder through neuroprotective and"/>
   <result pre="neuroprotective and neurotrophic mechanismsInt. J. Mol. Sci.182017 8ChenY.YanH.ZhengH.ShiY.SunL.WangC.Antiviral effect of" exact="lithium" post="chloride on infection of cells by porcine parvovirusArch. Virol.16020151015102025663217"/>
   <result pre="Pathol.36200710911417479370 10LiJ.YinJ.SuiX.LiG.RenX.Comparative analysis of the effect of glycyrrhizin diammonium and" exact="lithium" post="chloride on infectious bronchitis virus infection in vitroAvian Pathol.38200921522119468938"/>
   <result pre="infectious bronchitis virus infection in vitroAvian Pathol.38200921522119468938 11RenX.MengF.YinJ.LiG.LiX.WangC.Action mechanisms of" exact="lithium" post="chloride on cell infection by transmissible gastroenteritis coronavirusPloS One62011e18669"/>
   <result pre="cell infection by transmissible gastroenteritis coronavirusPloS One62011e18669 12SkinnerG.R.HartleyC.BuchanA.HarperL.GallimoreP.The effect of" exact="lithium" post="chloride on the replication of herpes simplex virusMed. Microbiol."/>
   <result pre="simplex virusMed. Microbiol. Immunol.16819801391486256617 13SuiX.YinJ.RenX.Antiviral effect of diammonium glycyrrhizinate and" exact="lithium" post="chloride on cell infection by pseudorabies herpesvirusAntivir. Res.85201034635319879899 14ZhouP.FuX.YanZ.FangB.HuangS.FuC.Antiviral"/>
   <result pre="on cell infection by pseudorabies herpesvirusAntivir. Res.85201034635319879899 14ZhouP.FuX.YanZ.FangB.HuangS.FuC.Antiviral effect of" exact="lithium" post="chloride on infection of cells by canine parvovirusArch. Virol.16020152799280526315688"/>
   <result pre="inflammationMed. Microbiol. Immunol.2072018273829043433 18KleinP.S.MeltonD.A.A molecular mechanism for the effect of" exact="lithium" post="on developmentProc. Natl. Acad. Sci. U. S. A.931996845584598710892 19YanagitaT.MarutaT.UezonoY.SatohS.YoshikawaN.NemotoT.Lithium"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7102647\results\search\drugs\results.xml">
   <result pre="is required for IAV replication, and adamantane-based M2 inhibitors including" exact="amantadine" post="(1) and rimantadine (2; Fig. 1 ) were historically"/>
   <result pre="IAV replication, and adamantane-based M2 inhibitors including amantadine (1) and" exact="rimantadine" post="(2; Fig. 1 ) were historically used as influenza"/>
   <result pre="of adamantane-resistant M2. Fig. 1 The two FDA approved adamantanes" exact="amantadine" post="(1) and rimantadine (2). Recent advances in molecular and"/>
   <result pre="Fig. 1 The two FDA approved adamantanes amantadine (1) and" exact="rimantadine" post="(2). Recent advances in molecular and structural biology, electrophysiology,"/>
   <result pre="WT M2 is effectively antagonized by two FDA-approved adamantane-class drugs," exact="amantadine" post="(1) and rimantadine (2) (Fig. 1), in addition to"/>
   <result pre="effectively antagonized by two FDA-approved adamantane-class drugs, amantadine (1) and" exact="rimantadine" post="(2) (Fig. 1), in addition to numerous other adamantane"/>
   <result pre="μMV27A:31.3 μM A/Udorn/72 NR Wang et al. (2011b) 23 Hexamethylene" exact="amiloride" post="[alt-text] Image 23 SEVC WT: 1.3 μMS31N: 10% inhibition"/>
   <result pre="2000). Additionally, the molecular mechanism describing a direct link between" exact="amantadine" post="and virus inhibition was not described until more than"/>
   <result pre="under the brand name Flumadine, is a methylated derivative of" exact="amantadine" post="which was licensed by FDA for the same indications"/>
   <result pre="5 ). In the first reported crystallographic structure of M2-bound" exact="amantadine" post="at pH 5.3 (PDB: 3C9J), Stouffer et al. (2008)"/>
   <result pre="pH 5.3 (PDB: 3C9J), Stouffer et al. (2008) suggested that" exact="amantadine" post="binds in a pocket located inside the intraluminal cavity"/>
   <result pre="by decreasing the pore size and occluding stable access of" exact="amantadine" post="to the pore (Stouffer et al., 2008). Fig. 5"/>
   <result pre="2009; Schnell and Chou, 2008, Fig. 5B). In these studies," exact="rimantadine" post="was found to bind to Asp44 on the C-terminal,"/>
   <result pre="drug binding pocket as a result of Ser31Asn mutation rendered" exact="rimantadine" post="incapable of effectively binding to the allosteric site (Pielak"/>
   <result pre="to alanine, Jing and coworkers continued to observe inhibition by" exact="amantadine" post="in both electrophysiological and antiviral plaque assays, suggesting that"/>
   <result pre="substitution with the M2 transmembrane domain from influenza A restored" exact="amantadine" post="sensitivity (Jing et al., 2008). Using solid-state NMR, Cady"/>
   <result pre="channel pore was the preferred binding site (PDB: 2KQT), where" exact="amantadine" post="preferentially localized to a hydrophobic cage formed by Ala30,"/>
   <result pre="adamantane cage were also observed, and the ammonium group of" exact="amantadine" post="showed hydrogen bonding to water molecules and pore-facing residues"/>
   <result pre="with the allosteric binding site were observed only at high" exact="amantadine" post="concentrations and were thus less probable as the primary"/>
   <result pre="Asp44Asn, Asp44Phe, Asp44Gly, and Asp44Thr) did not affect inhibition by" exact="amantadine" post="(Balannik et al., 2010). Notably, in further testing their"/>
   <result pre="testing their initial hypothesis of an allosteric binding site of" exact="amantadine" post="to M2, Pielak et al. (2011) next generated an"/>
   <result pre="proposed allosteric binding mechanism, using solution NMR, they described the" exact="rimantadine" post="binding pocket to be preserved within the pore of"/>
   <result pre="allosteric binding site, although the latter did remain sensitive to" exact="amantadine" post="(Rosenberg and Casarotto, 2010). Another computational study using small"/>
   <result pre="al., 2018, 2019). Taken together, these follow-up studies support that" exact="amantadine" post="inhibits IAV M2 by plugging the pore (Fig. 5A)."/>
   <result pre="the binding affinities of the R and S enantiomers of" exact="rimantadine" post="to M2 have also been questioned. Surprisingly, by comparing"/>
   <result pre="amantadine, M2 sequences containing Ser31Asn can still be inhibited by" exact="amantadine" post="in vitro, albeit with approximately 200-fold higher concentrations in"/>
   <result pre="changes between the observed interactions of the Ser31Asn channel and" exact="amantadine" post="when compared to WT M2 (Gleed et al., 2015)."/>
   <result pre="(A) X-ray crystal structure of M2-WT (22–46) in complex with" exact="amantadine" post="(1) (PDB: 6BKK; Thomaston et al., 2018). (B) Solution"/>
   <result pre="(Leu26Phe, Val27Ala, or Ser31Asn) with efficacies comparable or better than" exact="amantadine" post="against WT M2. While several other compounds are reported"/>
   <result pre="at low or sub-micromolar concentrations, which approximate the activities of" exact="amantadine" post="and rimantadine in these assays with wild-type M2. Clearly,"/>
   <result pre="or sub-micromolar concentrations, which approximate the activities of amantadine and" exact="rimantadine" post="in these assays with wild-type M2. Clearly, the efficacy"/>
   <result pre="that installation of aromatic groups to the amine group of" exact="amantadine" post="might also improve inhibitory activity against Ser31Asn M2 while"/>
   <result pre="design hypothesis lead to the synthesis and discovery of benzyl-substituted" exact="amantadine" post="derivatives, among which a benzdiol (7) was reported as"/>
   <result pre="Ser31Asn, respectively, as measured by TEVC. Compound 8 additionally inhibited" exact="amantadine" post="sensitive and resistant viruses with EC50 values of 4.6"/>
   <result pre="helix. Interestingly, Leu46Pro did not significantly change proton conductance or" exact="amantadine" post="sensitivity on its own in WT M2. However, in"/>
   <result pre="2019). Taken together, these results suggest that when compared to" exact="amantadine" post="and WT M2, the genetic barrier for drug resistance"/>
   <result pre="inhibited virus strains with resistance to the licensed neuramindase inhibitor" exact="oseltamivir" post="(Hu et al., 2017a; Ma et al., 2016; Wang"/>
   <result pre="2011b). Another notably explored chemical class is exemplified by hexamethylene" exact="amiloride" post="(HMA, 23), an amiloride-based compound which is reported to"/>
   <result pre="single electrode voltage clamp (SEVC) experiments, which was comparable to" exact="amantadine" post="in these studies (IC50 0.2 μM vs 0.6 μM),"/>
   <result pre="M2 channel of influenza B (~60%). Salinomycin also synergized with" exact="oseltamivir" post="in vitro. However, while salinomycin on its own exhibited"/>
   <result pre="it did rescue mice treated with a sub-optimal concentration of" exact="oseltamivir" post="and lethally-infected with oseltamivir sensitive or resistant viruses. (Jang"/>
   <result pre="treated with a sub-optimal concentration of oseltamivir and lethally-infected with" exact="oseltamivir" post="sensitive or resistant viruses. (Jang et al., 2018). 4.3"/>
   <result pre="of M2 inhibitors. As shown by Balgi and Roberge (2009)," exact="amantadine" post="restored the growth of yeast expressing WT M2 from"/>
   <result pre="has historically been an effective antiviral target for drugs like" exact="amantadine" post="and rimantadine. However, mutations in M2, particularly lining the"/>
   <result pre="inhibit viruses with major resistance to other IAV antivirals like" exact="oseltamivir" post="(5, 8, 10, 16) and/or synergize with oseltamivir (5,"/>
   <result pre="antivirals like oseltamivir (5, 8, 10, 16) and/or synergize with" exact="oseltamivir" post="(5, 16, 28), exhibit high genetic barriers to resistance"/>
   <result pre="bilayers from magic-angle-spinning solid-state NMR: the role of Ser31 in" exact="amantadine" post="bindingJ. Mol. Biol.38520091127114110.1016/j.jmb.2008.11.02219061899 CadyS.D.Schmidt-RohrK.WangJ.SotoC.S.DegradoW.F.HongM.Structure of the amantadine binding site"/>
   <result pre="of Ser31 in amantadine bindingJ. Mol. Biol.38520091127114110.1016/j.jmb.2008.11.02219061899 CadyS.D.Schmidt-RohrK.WangJ.SotoC.S.DegradoW.F.HongM.Structure of the" exact="amantadine" post="binding site of influenza M2 proton channels in lipid"/>
   <result pre="in mouse erythroleukaemia cellsJ. Physiol.494Pt 219963293368841994 ChuangG.Y.KozakovD.BrenkeR.BeglovD.GuarnieriF.VajdaS.Binding hot spots and" exact="amantadine" post="orientation in the influenza A virus M2 proton channelBiophys."/>
   <result pre="and drug-resistant mutant of the influenza A virus10.1016/j.ejmech.2015.12.0132016 DrakopoulosA.TzitzoglakiC.MaC.FreudenbergerK.HoffmannA.HuY.GauglitzG.SchmidtkeM.WangJ.KolocourisA.Affinity of" exact="rimantadine" post="enantiomers against influenza A/M2 protein revisitedACS Med. Chem. Lett.8201714515010.1021/acsmedchemlett.6b0031128217261"/>
   <result pre="viruses from different species: mechanisms for emergence and spread of" exact="amantadine" post="resistanceAntimicrob. Agents Chemother.5320094457446310.1128/AAC.00650-0919651904 GanS.-W.TanE.LinX.YuD.WangJ.TanG.M.-Y.VararattanavechA.YeoC.Y.SoonC.H.SoongT.W.PervushinK.TorresJ.The small hydrophobic protein of the"/>
   <result pre="copper complexes as influenza A M2 inhibitorsAntivir. Res.147201710010610.1016/j.antiviral.2017.10.00929032206 GrambasS.BennettM.S.HayA.J.Influence of" exact="amantadine" post="resistance mutations on the pH regulatory function of the"/>
   <result pre="2 function VACCINES ANDjvi.asm.org 1 J. Virol.9220181441145910.1128/JVI.01441-18 JingX.MaC.OhigashiY.OliveiraF.A.JardetzkyT.S.PintoL.H.LambR.A.Functional studies indicate" exact="amantadine" post="binds to the pore of the influenza A virus"/>
   <result pre="oocytesPLoS One132018e019922710.1371/journal.pone.0199227 KeyserL.A.KarlM.NafzigerA.N.BertinoJ.S.Comparison of central nervous system Adverse effects of" exact="amantadine" post="and rimantadine used as sequential prophylaxis of influenza A"/>
   <result pre="KeyserL.A.KarlM.NafzigerA.N.BertinoJ.S.Comparison of central nervous system Adverse effects of amantadine and" exact="rimantadine" post="used as sequential prophylaxis of influenza A in elderly"/>
   <result pre="influenza A M2 channelBiochem. Biophys. Res. Commun.4012010586310.1016/j.bbrc.2010.09.00820833142 PielakR.M.OxenoidK.ChouJ.J.Structural investigation of" exact="rimantadine" post="inhibition of the AM2-BM2 chimera channel of influenza virusesStructure1920111655166310.1016/j.str.2011.09.00322078564"/>
   <result pre="candidate influenza a M2 ion-channel inhibitorsFront. Cell. Infect. Microbiol.920196710.3389/fcimb.2019.0006730972303 RenaudC.KuypersJ.EnglundJ.A.Emerging" exact="oseltamivir" post="resistance in seasonal and pandemic influenza A/H1N1J. Clin. Virol.522011707810.1016/j.jcv.2011.05.01921684202"/>
   <result pre="virus M 2 proton channel is formed by a single" exact="tryptophan" post="residueJ. Biol. Chem.2772002398803988610.1074/jbc.M20658220012183461 TataridisD.FytasG.KolocourisA.FytasC.KolocourisN.FoscolosG.B.PadalkoE.NeytsJ.De ClercqE.Influence of an additional 2-amino"/>
   <result pre="substituent of the 1-aminoethyl pharmacophore group on the potency of" exact="rimantadine" post="against influenza virusA. Bioorg. Med. Chem. Lett.17200769269610.1016/j.bmcl.2006.10.09217113287 ThielG.BaumeisterD.SchroederI.KastS.M.Van EttenJ.L.MoroniA.Minimal"/>
   <result pre="activity of influenza A virus M2 protein: characterization of the" exact="amantadine" post="blockJ. Virol.671993558555947688826 WangJ.CadyS.D.BalannikV.PintoL.H.DeGradoW.F.HongM.Discovery of spiro-piperidine inhibitors and their modulation"/>
   <result pre="channel HHS public accessJ. Am. Chem. Soc.1412019116671167610.1021/jacs.9b0513631264413 WingfieldW.L.PollackD.GrunertR.R.Therapeutic efficacy of" exact="amantadine" post="HCl and rimantadine HCl in naturally occurring influenza A2"/>
   <result pre="accessJ. Am. Chem. Soc.1412019116671167610.1021/jacs.9b0513631264413 WingfieldW.L.PollackD.GrunertR.R.Therapeutic efficacy of amantadine HCl and" exact="rimantadine" post="HCl in naturally occurring influenza A2 respiratory illness in"/>
   <result pre="respiratory illness in manN. Engl. J. Med.281196957958410.1056/NEJM1969091128111024897137 WrightA.K.BatsomboonP.DaiJ.HungI.ZhouH.-X.DudleyG.B.CrossT.A.Differential binding of" exact="rimantadine" post="enantiomers to influenza A M2 proton channelJ. Am. Chem."/>
   <result pre="cytotoxic concentration EC50 50% effective concentration HA hemagglutinin HMA hexamethylene" exact="amiloride" post="IAV influenza A virus IC50 50% inhibitory concentration MDCK"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7102657\results\search\drugs\results.xml">
   <result pre="in 2003. Shortly after the emergence of MERS-CoV, researchers identified" exact="lopinavir" post="and ritonavir as MERS-CoV inhibitors. The national expert group"/>
   <result pre="Shortly after the emergence of MERS-CoV, researchers identified lopinavir and" exact="ritonavir" post="as MERS-CoV inhibitors. The national expert group has recommended"/>
   <result pre="ritonavir as MERS-CoV inhibitors. The national expert group has recommended" exact="lopinavir" post="and ritonavir as effective anti-COVID-19 agents in China, and"/>
   <result pre="MERS-CoV inhibitors. The national expert group has recommended lopinavir and" exact="ritonavir" post="as effective anti-COVID-19 agents in China, and most clinical"/>
   <result pre="on COVID-19 select both drugs as positive controls. Emtricitabine and" exact="tenofovir" post="alafenamide are reverse transcriptase inhibitors that were approved to"/>
   <result pre="clarified in the near future. Chloroquine and its derivatives including" exact="hydroxychloroquine" post="and chloroquine phosphate have elicited antiviral effects on several"/>
   <result pre="the near future. Chloroquine and its derivatives including hydroxychloroquine and" exact="chloroquine" post="phosphate have elicited antiviral effects on several viruses such"/>
   <result pre="rarely occurring adverse reactions, a series of clinical trials on" exact="chloroquine" post="and its derivatives have been advancing rapidly. Presently, Chinese"/>
   <result pre="have been advancing rapidly. Presently, Chinese government authorities have approved" exact="chloroquine" post="phosphate to be used to treat adult patients suffering"/>
   <result pre="of biological rationale, such as the anti-influenza drugs umifenovir and" exact="oseltamivir" post="targeting neuraminidase, baloxavirmarboxil targeting cap-dependent endonuclease that is not"/>
   <result pre=", ASC09 targeting protease with no anti-coronavirus research reported, and" exact="cobicistat" post="targeting CYP3A4 with only unpersuasive predicted activity by computer"/>
   <result pre="some of them can cause serious adverse reactions. For example," exact="hydroxychloroquine" post="has the side effect of arrhythmia, which can itself"/>
   <result pre="coronavirus: implications for virus origins and receptor bindingLancet395202056557432007145 3WangM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7103671\results\search\drugs\results.xml">
   <result pre="MERS in the MIRACLE trial.75 The same two protease inhibitors" exact="lopinavir" post="and ritonavir, when combined with ribavirin, were found to"/>
   <result pre="these repurposed drugs in COVID-19, a controlled trial of ritonavir-boosted" exact="lopinavir" post="and interferon-α 2b therapy has been registered for hospitalized"/>
   <result pre="in China (ChiCTR2000029308).76 Oral administration of neuraminidase inhibitors such as" exact="oseltamivir" post="has been used as an empirical drug for COVID-19"/>
   <result pre="of approved drugs such as ribavirin, penciclovir, nitazoxanide, nafamostat, and" exact="chloroquine" post="was compared with that of the two broad-spectrum antiviral"/>
   <result pre="favipiravir for COVID-19. Among the evaluated drugs, both remdesivir and" exact="chloroquine" post="were found to be highly effective in controlling COVID-19"/>
   <result pre="to reduce the viral infection in vitro. Both remdesivir and" exact="chloroquine" post="are being used for the treatment of other diseases"/>
   <result pre="study against COVID-19 are promising since the drugs remdesivir and" exact="chloroquine" post="were found to be highly effective in controlling the"/>
   <result pre="CaoR, ZhangL, YangX, LiuJ, XuM, ShiZ, HuZ, ZhongW, XiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="ScottDP, BriningD, BushmakerT, MartellaroC, BaselerL, et alTreatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–17."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7103900\results\search\drugs\results.xml">
   <result pre="clinical trials [6]. Chloroquine (CQ) and its less toxic derivative" exact="hydroxychloroquine" post="(HCQ) are well known for their immunomodulating effects in"/>
   <result pre="patients and that its efficacy is enhanced in combination with" exact="azithromycin" post="[11]. HCQ low costs and relative safety profile may"/>
   <result pre="evidence from a small uncontrolled trial in China proves that" exact="tocilizumab" post="in addition to routine therapy is effective for decreasing"/>
   <result pre="inhibiting SARS-CoV-2 infection in vitroCell Discov20206161410.1038/s41421-020-0156-031934347 8.SchrezenmeierEDörnerTMechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol20201615516610.1038/s41584-020-0372-x32034323 9.RolainJMColsonPRaoultDRecycling of"/>
   <result pre="hydroxychloroquine and chloroquine: implications for rheumatologyNat Rev Rheumatol20201615516610.1038/s41584-020-0372-x32034323 9.RolainJMColsonPRaoultDRecycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="COVID-19 associated pneumonia in clinical studiesBiosci Trends2020141727310.5582/bst.2020.0104732074550 11.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="of an open-label non-randomized clinical trialInt J Antimicrob Agents202010.1016/j.ijantimicag.2020.105949 12.ChangRSunWZRepositioning" exact="chloroquine" post="as ideal antiviral prophylactic against COVID-19-time is nowPreprints202010.20944/preprints202003.0279.v1 13.RuanQYangKWangWJiangLSongJClinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7103910\results\search\drugs\results.xml">
   <result pre="be noted that some of the most administered drugs, particularly" exact="chloroquine" post="and hydroxychloroquine, have well-known antiviral effects [4], being also"/>
   <result pre="lupus erythematosus patients: susceptibility factors and preventive strategiesLupus201322121286129410.1177/096120331349303224098001 5.ColsonPRolainJMLagierJCBrouquiPRaoultDChloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.10593232205204"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7104000\results\search\drugs\results.xml">
   <result pre="a recent possible exposure to SARS-CoV-2. For example, PEP with" exact="rifampicin" post="is given to people exposed to index cases of"/>
   <result pre="people exposed to index cases of invasive meningococcal infection, and" exact="oseltamivir" post="has been recommended by WHO for people at high"/>
   <result pre="concentrations and in vitro drug testing suggest that prophylaxis with" exact="hydroxychloroquine" post="at approved doses could prevent SARS-CoV-2 infection and ameliorate"/>
   <result pre="prevent SARS-CoV-2 infection and ameliorate viral shedding.5 Clinical trials of" exact="hydroxychloroquine" post="treatment for COVID-19 pneumonia are underway in China (NCT04261517"/>
   <result pre="anyone found to be infected, and the efficacy of prophylactic" exact="hydroxychloroquine" post="in preventing secondary SARS-CoV-2 infections and disease symptoms among"/>
   <result pre="1286 of their close contactsmedRxiv2020published online March 4.10.1101/2020.03.03.20028423(preprint). 3WelliverRMontoASCarewiczOEffectiveness of" exact="oseltamivir" post="in preventing influenza in household contacts: a randomized controlled"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020published online March 9.10.1093/cid/ciaa237 5TettSECutlerDJDayROBrownKFBioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteersBr J Clin Pharmacol2719897717792757893 6Henao-RestrepoAMCamachoALonginiIMEfficacy and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7104317\results\search\drugs\results.xml">
   <result pre="to provide an intracellular codelivery, PolyI:PolyC and the third-generation bisphosphonate" exact="zoledronic acid" post="(ZOL), Chen et al. [92] obtained lipid coated calcium"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7105343\results\search\drugs\results.xml">
   <result pre="to challenging decision-making about treatment of critically unwell patients. Low-dose" exact="prednisolone" post="and tacrolimus may have beneficial impacts on COVID-19. The"/>
   <result pre="decision-making about treatment of critically unwell patients. Low-dose prednisolone and" exact="tacrolimus" post="may have beneficial impacts on COVID-19. The mycophenolate mofetil"/>
   <result pre="There is no definitive evidence that specific cytotoxic drugs, low-dose" exact="methotrexate" post="for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFα"/>
   <result pre="relation to specific treatments: Although HIV protease inhibitors such as" exact="lopinavir" post="has been suggested as a low-micromolar inhibitor of MERS-CoV,"/>
   <result pre="Currently, there is no scientific evidence of the interaction between" exact="methotrexate" post="and COVID-19. Low-dose steroids and NSAIDs Since the outbreak"/>
   <result pre="identify any strong evidence for or against the use of" exact="ibuprofen" post="for treatment of COVID-19 specifically. One study did however"/>
   <result pre="downregulation of angiotensin converting enzyme-2 (ACE2) which is upregulated by" exact="ibuprofen" post="[12]. The authors of this study were investigating the"/>
   <result pre="investigate a non-steroidal anti-inflammatory drug was one which looked at" exact="indomethacin" post="[13]. This study suggested that indomethacin exhibited potent antiviral"/>
   <result pre="one which looked at indomethacin [13]. This study suggested that" exact="indomethacin" post="exhibited potent antiviral activity against canine coronavirus (dramatically inhibiting"/>
   <result pre="laboratory study which treated porcine respiratory coronavirus infected pigs with" exact="dexamethasone" post="suggested that one or two doses of the corticosteroid"/>
   <result pre="TNFa can be achieved with a monoclonal antibody, such as" exact="infliximab" post="(Remicade), adalimumab (Humira), certolizumab pegol (Cimzia) and golimumab (Simponi),"/>
   <result pre="be achieved with a monoclonal antibody, such as infliximab (Remicade)," exact="adalimumab" post="(Humira), certolizumab pegol (Cimzia) and golimumab (Simponi), or with"/>
   <result pre="with a monoclonal antibody, such as infliximab (Remicade), adalimumab (Humira)," exact="certolizumab pegol" post="(Cimzia) and golimumab (Simponi), or with the receptor fusion"/>
   <result pre="such as infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia) and" exact="golimumab" post="(Simponi), or with the receptor fusion protein etanercept (Enbrel)."/>
   <result pre="(Cimzia) and golimumab (Simponi), or with the receptor fusion protein" exact="etanercept" post="(Enbrel). Results A total of three studies were identified,"/>
   <result pre="receptor antibody was developed. Other approved anti IL-6 drugs are" exact="siltuximab" post="(Sylvant) and sarilumab. Several agents are in clinical trials:olokizumab"/>
   <result pre="of human nasal and tracheal epithelial cells with glycopyrronium or" exact="formoterol" post="decreased viral RNA levels and/or titers, the expression of"/>
   <result pre="of the cells with a combination of three drugs (glycopyrronium," exact="formoterol" post="and budesonide) exerted additive inhibitory effects on viral titers"/>
   <result pre="further clinical data becomes available. In vitro treatment with glycopyrronium," exact="formoterol" post="and budesonide exerted additive inhibitory effects on viral titers"/>
   <result pre="data becomes available. In vitro treatment with glycopyrronium, formoterol and" exact="budesonide" post="exerted additive inhibitory effects on viral titers and cytokine"/>
   <result pre="Those patients with more severe disease were treated with pulsed" exact="methylprednisolone" post="and IL-1β levels returned to normal after 7 days."/>
   <result pre="human coronaviruses. Mycophenolate Mycophenolate mofetil (which is a derivative of" exact="mycophenolic acid" post="(MPA)) is an immune suppressant, antineoplastic and antiviral mediation."/>
   <result pre="the cohort who received a variety of antiviral agents including" exact="ribavirin" post="and IFN-a, steroids and antibiotics. Therefore, the results must"/>
   <result pre="Overall, the literature appeared to suggest a potential role for" exact="tacrolimus" post="in the treatment of human coronaviruses. In a case"/>
   <result pre="patient who was being treated with an immunosuppressive regimen of" exact="tacrolimus" post="underwent full recovery whilst the other patient (who was"/>
   <result pre="of SARS-CoV non-structural protein 1. Subsequently, the authors investigated whether" exact="tacrolimus" post="inhibits viral replication of human coronaviruses. VeroFM cells infected"/>
   <result pre="and disadvantages associated with using one of these medications. Low-dose" exact="prednisolone" post="and tacrolimus therapy may have beneficial impacts on the"/>
   <result pre="associated with using one of these medications. Low-dose prednisolone and" exact="tacrolimus" post="therapy may have beneficial impacts on the course of"/>
   <result pre="There is no definitive evidence that specific cytotoxic drugs, low-dose" exact="methotrexate" post="for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFa"/>
   <result pre="it has high cytotoxicity. HIV protease inhibitor nelfinavir, antihelminthic drug" exact="niclosamide" post="and antimalarial agent chloroquine have also showed strong inhibitory"/>
   <result pre="HIV protease inhibitor nelfinavir, antihelminthic drug niclosamide and antimalarial agent" exact="chloroquine" post="have also showed strong inhibitory activity against SARS-CoV replication."/>
   <result pre="Lu China 2020 No evidence given for or against using" exact="ibuprofen" post="only that ‘anti-inflammatory drugs (such as hormones and other"/>
   <result pre="various viruses including Dengue, Ebola and SARS-CoV. They stated that" exact="ribavirin" post="(an antiviral) is the most frequently used drug to"/>
   <result pre="study which treated porcine respiratory coronavirus infected pigs with corticosteroid" exact="dexamethasone" post="as a model for SARS.Goal to define whether corticosteroid"/>
   <result pre="pig lung lesions.Confirmed infection model applicable and resembled SARS.Treatment with" exact="dexamethasone" post="suppressed early local IL-6 levels but increased later on"/>
   <result pre="at early infection stage but not later.Results also suggest that" exact="dexamethasone" post="induced reduction of IL-6 might play a role in"/>
   <result pre="with corticosteroids).Overall findings suggest that 1 or 2 doses of" exact="dexamethasone" post="in acute phase of infection may effectively alleviate early"/>
   <result pre="against several RNA viruses to investigate effect of COX inhibitor" exact="indomethacin" post="on coronavirus replication.Indomethacin is common NSAID.Report describes how indomethacin"/>
   <result pre="inhibitor indomethacin on coronavirus replication.Indomethacin is common NSAID.Report describes how" exact="indomethacin" post="was unexpectedly found to possess potent antiviral activity against"/>
   <result pre="cytokines.Numerous papers published outcomes of patients administered corticosteroids (mostly IV" exact="hydrocortisone" post="or methylprednisolone) in either early low-dose or pulsed-dose strategies."/>
   <result pre="hypokalaemia, hypertension, gastrointestinal haemorrhage and avascular necrosis (AVN). [33] High-dose" exact="hydrocortisone" post="reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10"/>
   <result pre="CXCL8 and CXCL10 in human intestinal epithelial cells.High concentrations of" exact="hydrocortisone" post="prevented DNA binding activity of AP-1 and NF-kappabeta and"/>
   <result pre="use of high-dose steroids in combination with a quinolone plus" exact="azithromycin" post="gave the best outcome with improvement of clinical signs"/>
   <result pre="H5N1 influenza and SARS coronavirus. In humans, anti-TNF therapy utilising" exact="etanercept" post="has been reported to be beneficial for treatment of"/>
   <result pre="of virus-endotoxin-induced respiratory disease.The study demonstrates that after intratracheal administration" exact="etanercept" post="is able to successfully block TNF-α activity in vivo"/>
   <result pre="including viral infections. [40] Inhibitory effects of glycopyrronium, formoterol, and" exact="budesonide" post="on coronavirus HCoV-229E replication and cytokine production by primary"/>
   <result pre="coronavirus. Pretreatment of HNE and HTE cells with glycopyrronium or" exact="formoterol" post="decreased viral RNA levels and/or titers, the expression of"/>
   <result pre="link between viral load, ribavirin, proinflammatory cytokines, and clinical progression." exact="ribavirin" post="was not effective in reducing the SARS coronavirus load"/>
   <result pre="Country of study Year Summary of results [68] Interferon-β and" exact="mycophenolic acid" post="are potent inhibitors of middle east respiratory syndrome coronavirus"/>
   <result pre="of 2.87 mM. This drug may provide an alternative to" exact="ribavirin" post="for treatment of MERS-CoV. In conclusion, IFN-b, MPA or"/>
   <result pre="drugsMultiple inhibition assays also support a kinetic mechanism by which" exact="disulfiram" post="together with 6TG and/or MPA can synergistically inhibit MERS-CoV"/>
   <result pre="mode of inhibition, SARS-CoV PLpro.Synergistic inhibition of MERS-CoV PLpro by" exact="disulfiram" post="and 6-thioguanine or mycophenolic acid implies the potential for"/>
   <result pre="PLpro.Synergistic inhibition of MERS-CoV PLpro by disulfiram and 6-thioguanine or" exact="mycophenolic acid" post="implies the potential for combination treatments using these three"/>
   <result pre="using these three clinically available drugs. [70] Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
   <result pre="target MERS-CoV PLpro. The authors report that the immunosuppressive drug" exact="mycophenolic acid," post="was able to inhibit MERS-CoV PLpro.MPA is a non-competitive"/>
   <result pre="vitro)The authors assessed the anti-MERS-CoV activities of several compounds. Only" exact="mycophenolic acid" post="exhibited low EC50 and high selectivity index.They found that"/>
   <result pre="EC50 and high selectivity index.They found that a combination of" exact="mycophenolic acid" post="and IFN-b1b lowered the EC50 of each drug by"/>
   <result pre="the salt mycophenolate sodium, and could be given orally.Interferon-b1b with" exact="mycophenolic acid" post="should be considered in treatment trials of MERS. [72]"/>
   <result pre="They concluded that they had identified seven compounds (lycorine, emetine," exact="monensin" post="sodium, mycophenolate mofetil, mycophenolic acid, phenazopyridine, and pyrvinium pamoate)"/>
   <result pre="had identified seven compounds (lycorine, emetine, monensin sodium, mycophenolate mofetil," exact="mycophenolic acid," post="phenazopyridine, and pyrvinium pamoate) as broad-spectrum inhibitors according to"/>
   <result pre="of all CoVs with EC50 values of 5μm.Mycophenolate mofetil and" exact="mycophenolic acid," post="showed a similar antiviral effect on the four CoVs"/>
   <result pre="only)The authors assessed the antiviral activities of ribavirin, 6-azauridine, pyrazofurin," exact="mycophenolic acid," post="and glycyrrhizin against two clinical isolates of coronavirus (FFM-1"/>
   <result pre="of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including" exact="ribavirin" post="Barnard et al USA 2006 In vivo study in"/>
   <result pre="and autoimmune diseases such as systemic lupus erythematosus.The use of" exact="mycophenolic acid" post="monotherapy has not been reported in MERS. IFN-b and"/>
   <result pre="acid monotherapy has not been reported in MERS. IFN-b and" exact="mycophenolic acid" post="combination therapy was described in a retrospective observational study"/>
   <result pre="patients; all of the 8 patients who received IFN-b and" exact="mycophenolic acid" post="survived.Corticosteroids, ribavirin monotherapy and mycophenolic acid are likely to"/>
   <result pre="the 8 patients who received IFN-b and mycophenolic acid survived.Corticosteroids," exact="ribavirin" post="monotherapy and mycophenolic acid are likely to cause more"/>
   <result pre="who received IFN-b and mycophenolic acid survived.Corticosteroids, ribavirin monotherapy and" exact="mycophenolic acid" post="are likely to cause more harm than benefit.There are"/>
   <result pre="than benefit.There are no clinical data on the efficacy of" exact="mycophenolic acid" post="in SARS or MERS. However, it led to severe"/>
   <result pre="disease Chan et al Hong Kong/China 2015 (Review)The combination of" exact="mycophenolic acid" post="and interferon beta 1b shows synergistic activity against MERS-CoV"/>
   <result pre="activity against MERS-CoV in Vero cells. The desirable pharmacokinetics of" exact="mycophenolic acid" post="compared to ribavirin warrants further evaluation, although the potential"/>
   <result pre="Vero cells. The desirable pharmacokinetics of mycophenolic acid compared to" exact="ribavirin" post="warrants further evaluation, although the potential inhibitory effect on"/>
   <result pre="infectious bronchitis virusVirology2011420210611610.1016/j.virol.2011.09.00321959016 42.YamayaMNishimuraHDengXet al.Inhibitory effects of glycopyrronium, formoterol, and" exact="budesonide" post="on coronavirus HCoV-229E replication and cytokine production by primary"/>
   <result pre="papain-like proteases via different modesAntiviral Res201815015516310.1016/j.antiviral.2017.12.01529289665 54.ChengKWChengSCChenWYet al.Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
   <result pre="of potent broad-spectrum inhibitors of coronavirusesJ Virol2019931210.1128/JVI.00023-19 57.HartBJDyallJPostnikovaEet al.Interferon-beta and" exact="mycophenolic acid" post="are potent inhibitors of Middle East respiratory syndrome coronavirus"/>
   <result pre="coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive" exact="cyclosporine" post="A-derivatives including AlisporivirVirus Res2014184445310.1016/j.virusres.2014.02.01024566223 References References 1.ZhuWJWangJHeXHet al.[The differential"/>
   <result pre="for severe acute respiratory syndromeExpert Rev Anti-infect Ther20053225126210.1586/14787210.3.2.25115918782 33.CinatlJMichaelisMMorgensternBet al.High-dose" exact="hydrocortisone" post="reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10"/>
   <result pre="Regul Homeost Agents2020342pii:1 40.YamayaMNishimuraHDengXet al.Inhibitory effects of glycopyrronium, formoterol, and" exact="budesonide" post="on coronavirus HCoV-229E replication and cytokine production by primary"/>
   <result pre="Agents2020341 67.ZhuMSARS immunity and vaccinationCell Mol Immunol20041319319816219167 68.HartBJDyallJPostnikovaEet al.Interferon-beta and" exact="mycophenolic acid" post="are potent inhibitors of Middle East respiratory syndrome coronavirus"/>
   <result pre="papain-like proteases via different modesAntiviral Res201815015516310.1016/j.antiviral.2017.12.01529289665 70.ChengKWChengSCChenWYet al.Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
   <result pre="coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive" exact="cyclosporine" post="A-derivatives including AlisporivirVirus Res184445324566223 Table 1. Search terms and"/>
   <result pre="COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (anti-inflammatory or" exact="ibuprofen" post="or isobutylphenylpropionic acid or cortisone or non-steroidal anti-inflammatory) 13/58"/>
   <result pre="AND (TNF blocker or Anti-TNF therapy or TNFα inhibitor or" exact="infliximab" post="or etanercept or Certolizumab or Golimumab or adalimumab)) 2/3"/>
   <result pre="blocker or Anti-TNF therapy or TNFα inhibitor or infliximab or" exact="etanercept" post="or Certolizumab or Golimumab or adalimumab)) 2/3 IL-6 blockade"/>
   <result pre="interlukin-6 blockage or IL 6 blockage or IL-6 blockage or" exact="tocilizumab" post="or siltuximab or Sylvant or sarilumab or olokizumab or"/>
   <result pre="or IL 6 blockage or IL-6 blockage or tocilizumab or" exact="siltuximab" post="or Sylvant or sarilumab or olokizumab or CDP6038 or"/>
   <result pre="or interlukin 6 or Anti-IL-6 therapy or IL-6 blockage or" exact="tocilizumab" post="or siltuximab)) 023/108 JAK inhibitors ((SARS-CoV-2 or coronavirus or"/>
   <result pre="SARS-CoV) and (JAK or JAK1 or JAK2 or TYK3 or" exact="tofacitinib" post="or baricitinib or filgotinib or peficitinib or ABT494 or"/>
   <result pre="MERS-CoV or SARS-CoV) AND (Interleukin-1 or IL-1 or IL-1RA or" exact="canakinumab" post="or anti-IL-1 or IL-1 antagonists or IL-1 blockers or"/>
   <result pre="canakinumab or anti-IL-1 or IL-1 antagonists or IL-1 blockers or" exact="rilonacept" post="or IL-1 trap or ACZ885 or anakinra) 9/37 Mycophenylate"/>
   <result pre="betacoronavirus or MERS-CoV or SARS-CoV) AND (envarsus or tacni or" exact="tacrolimus" post="or prograf or FK506) 3/18 Anti-CD20 ((SARS-CoV-2 or coronavirus"/>
   <result pre="MERS-CoV or SARS-CoV) AND (anti-cd20 monoclonal antibodies or anti-cd20 or" exact="rituximab" post="or truxima or zevalin or ruxience or rituxan or"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7106583\results\search\drugs\results.xml">
   <result pre="from Merck (Darmstadt, Germany). ABTS, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), DPPH, Folin–Ciocalteu" exact="phenol" post="reagent, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), sodium carbonate, and 2,4,6-tri-pyridyl-s-triazine"/>
   <result pre="Line Stably Expressing the Goat Signaling Lymphocyte Activation Molecule2016114 31.SlinkardKSingletonVLTotal" exact="phenol" post="analysis: automation ans comparison with manual methodsAm J Enol"/>
   <result pre="modified version for simultaneous measurement of total antioxidant power and" exact="ascorbic acid" post="concentration. In: Oxidants and Antioxidants Part A: Academic; 1999."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7108130\results\search\drugs\results.xml">
   <result pre="and autoimmune conditions. We propose that the immunomodulatory effect of" exact="hydroxychloroquine" post="also may be useful in controlling the cytokine storm"/>
   <result pre="Currently, there is no evidence to support the use of" exact="hydroxychloroquine" post="in SARS-CoV-2 infection. Methods The pharmacological activity of chloroquine"/>
   <result pre="of hydroxychloroquine in SARS-CoV-2 infection. Methods The pharmacological activity of" exact="chloroquine" post="and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells."/>
   <result pre="in SARS-CoV-2 infection. Methods The pharmacological activity of chloroquine and" exact="hydroxychloroquine" post="was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic"/>
   <result pre="by integrating their in vitro data. Using the PBPK models," exact="hydroxychloroquine" post="concentrations in lung fluid were simulated under 5 different"/>
   <result pre="Hydroxychloroquine (EC50=0.72 μM) was found to be more potent than" exact="chloroquine" post="(EC50=5.47 μM) in vitro. Based on PBPK models results,"/>
   <result pre="results, a loading dose of 400 mg twice daily of" exact="hydroxychloroquine" post="sulfate given orally, followed by a maintenance dose of"/>
   <result pre="SARS-CoV-2 infection, as it reached three times the potency of" exact="chloroquine" post="phosphate when given 500 mg twice daily 5 days"/>
   <result pre="advance. Conclusions Hydroxychloroquine was found to be more potent than" exact="chloroquine" post="to inhibit SARS-CoV-2 in vitro. Chloroquine Hydroxychloroquine SARS-CoV-2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7110269\results\search\drugs\results.xml">
   <result pre="in vitro. They found that EC90 of a remdesivir, an" exact="adenosine" post="analogue, as 1.76 μM which can be achieved in"/>
   <result pre="liver cancer (Huh-7) cells. Some clinical trials with remdesivir, ritonavir-boosted" exact="lopinavir" post="monotherapy, have been launched (ChiCTR2000029308, NCT04257656). Xia et al."/>
   <result pre="of SARS-CoV. In a recent study, it was shown that" exact="chloroquine" post="efficiently inhibits the COVID-19 viral infection in Vero E6"/>
   <result pre="Vero E6 cells at entry and post-entry stages [5]. As" exact="chloroquine" post="is cheap and safe drug and is being used"/>
   <result pre="for COVID-19 infection? Lancet Respir Med. 2020. 10.1016/S2213-2600(20)30116-8. 5.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7113931\results\search\drugs\results.xml">
   <result pre="ranging from 10 to 20%. In 1998, the oral drug" exact="ribavirin" post="was added to interferon. The therapeutic response rates increased"/>
   <result pre="this drug. In 2011, two protease inhibitors were introduced namely" exact="boceprevir" post="and telaprevir.[47] Treatment of chronic HCV with PEG-IFN and"/>
   <result pre="boceprevir and telaprevir.[47] Treatment of chronic HCV with PEG-IFN and" exact="ribavirin" post="and, more recently, with PEG-IFN plus ribavirin and first-generation"/>
   <result pre="with PEG-IFN and ribavirin and, more recently, with PEG-IFN plus" exact="ribavirin" post="and first-generation protease inhibitors (Telaprevir and Boceprevir) for HCV-1,"/>
   <result pre="may interact with HIV antiretrovirals (nucleoside reverse transcriptase inhibitors) and" exact="ribavirin" post="Can cause mitochondrial toxicity Nucleos(t) ide analog NS5B polymerase"/>
   <result pre="management by impacting the duration of therapy and/or inclusion of" exact="ribavirin" post="or result in selection of alternative therapy. However, at"/>
   <result pre="for 12 weeks of sofosbuvir/velpatasvir. If Y93H is present, weight-based" exact="ribavirin" post="should be added or sofosbuvir/velpatasvir/voxilaprevir should be used. I,"/>
   <result pre="added or sofosbuvir/velpatasvir/voxilaprevir should be used. I, A Daclatasvir plus" exact="sofosbuvir" post=" NS5A RAS testing is recommended for genotype 3-infected, treatment-experienced"/>
   <result pre="treatment-experienced patients without cirrhosis being considered for 12 weeks of" exact="daclatasvir" post="plus sofosbuvir. If Y93H is present, weight-based ribavirin should"/>
   <result pre="weeks of daclatasvir plus sofosbuvir. If Y93H is present, weight-based" exact="ribavirin" post="should be added.  NS5A RAS testing is recommended for"/>
   <result pre="treatment-naive patients with cirrhosis being considered for 24 weeks of" exact="daclatasvir" post="plus sofosbuvir. If Y93H is present, treatment should include"/>
   <result pre="I, A Paritaprevir/ritonavir/ombitasvir with dasabuvir±weight-based ribavirin, or paritaprevir/ritonavir/ombitasvir + weight-based" exact="ribavirin" post=" RAS testing is not recommended for genotype 1- or"/>
   <result pre="-experienced patients being considered for therapy with paritaprevir/ritonavir/ombitasvir with dasabuvir±weight-based" exact="ribavirin" post="or paritaprevir/ritonavir/ombitasvir + weight-based ribavirin, respectively. I, A Sofosbuvir/velpatasvir"/>
   <result pre="resistance in genotype 1-6 hepatitis C virus-infected subjects treated with" exact="sofosbuvir" post="in phase 2 and 3 clinical trialsClin Infect Dis20145916667425266287"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7114107\results\search\drugs\results.xml">
   <result pre="S6 phosphorylation by HSV-1 infection, and our subsequent finding that" exact="ribavirin" post="antagonizes this upregulation of S6 phosphorylation. We go on"/>
   <result pre="through the FSC technique (a mixture of ACV with either" exact="ribavirin" post="(RIB) or interferons (IFNs)) could both effectively inhibit HSV-1"/>
   <result pre="DMEM was purchased from CELLGRO (Manassas, VA), and penicillin and" exact="streptomycin" post="were obtained from GIBCO (Grand Island, NY). Paraformaldehyde (PFA)"/>
   <result pre="for combinatorial drug discoverySci. Transl. Med.52052013205rv1 TeH.S.RandallG.JensenD.M.Mechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterol Hepatol (N"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7114176\results\search\drugs\results.xml">
   <result pre="of antiviral activity in live mice. Additionally, we validated that" exact="chloroquine" post="strongly inhibited rOC43-ns2DelRluc replication in vivo. These results provide"/>
   <result pre="mice infected by human coronavirus OC43Virology3152003203314592756 KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob. Agents"/>
   <result pre="for estimating fifty percent endpointsAm. J. Hyg.371938 SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Antiviral effects of" exact="chloroquine" post="Effects of chloroquine on viral infections : an old drug"/>
   <result pre="percent endpointsAm. J. Hyg.371938 SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Antiviral effects of chloroquine Effects of" exact="chloroquine" post="on viral infections : an old drug against today ’"/>
   <result pre="features of coronavirus HKU1-associated community-acquired pneumoniaJ. Infect. Dis.19220051898190716267760 YiwuY.ZhenZ.YangS.XiaoL.Kai-FengX.YuquanW.NingyiJ.ChengyuJ.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7114304\results\search\drugs\results.xml">
   <result pre="recruited by the GTase, transfers the methyl group from S-adenosyl-" exact="l-methionine" post="(AdoMet) to the cap guanine to form the cap-0"/>
   <result pre="PPi (II) PPPi (III) 6-chloropurine-ribose-5′-triphosphate. GTase inhibitors: (I) foscarnet (II)" exact="ribavirin" post="triphosphate. MTase inhibitors: (I) sinefungin (II) dAPPMA 2′-O MTase"/>
   <result pre="GTase inhibitors: (I) foscarnet (II) ribavirin triphosphate. MTase inhibitors: (I)" exact="sinefungin" post="(II) dAPPMA 2′-O MTase inhibitors: (III) aurintricaboxylic acid (IV)"/>
   <result pre="ribose 2′-OH position by 2′-O MTase (see Fig. 1). S-adenosyl-" exact="l-methionine" post="(SAM) is the methyl donor for both the N-7"/>
   <result pre="capping started in the dsDNA Poxviridae field. A SAM analogue," exact="sinefungin" post="(Fig. 6, MTase inhibitor I), was reported as the"/>
   <result pre="MTase activity was shown to be inhibited by the GTP-analogue" exact="ribavirin" post="triphosphate (Benarroch et al., 2004a), sinefungin, and SAH (Selisko"/>
   <result pre="antiviral therapy or prevention: a monoclonal antibody (Palivizumab, Synagis) and" exact="ribavirin" post="(Empey et al., 2010, Vigant and Lee, 2011). The"/>
   <result pre="of PRNTase inhibitors, but the precise mechanism of action of" exact="ribavirin" post="(i.e., capping, error catastrophe, IMP dehydrogenase, or else (Leyssen"/>
   <result pre="al., 2003). In the case of alphaviruses, resistance mutants to" exact="ribavirin" post="were mapped into the GTase domain of the nsP1"/>
   <result pre="protein (Scheidel et al., 1987, Scheidel and Stollar, 1991) suggesting" exact="ribavirin" post="interferes with the GTase activity. Nevertheless, the ribavirin action"/>
   <result pre="1991) suggesting ribavirin interferes with the GTase activity. Nevertheless, the" exact="ribavirin" post="action mode remains controversial. Ribavirin also reduces the intracellular"/>
   <result pre="The same group extended the family of interesting compounds with" exact="thalidomide" post="derivatives, active through their 3,4-dihydroxyphenethyl moieties, and later with"/>
   <result pre="inhibition of the NS5 dengue virus mRNA 2′-O-methyltransferase domain by" exact="ribavirin" post="5′-triphosphateJ. Biol. Chem.2792004356383564315152003 BenarrochD.SeliskoB.LocatelliG.A.MagaG.RometteJ.-L.CanardB.The RNA helicase, nucleotide 5′-triphosphatase, and"/>
   <result pre="as multisubstrate adductsJ. Pharm. Sci.7519861421453958922 BougieI.BisaillonM.The broad spectrum antiviral nucleoside" exact="ribavirin" post="as a substrate for a viral RNA capping enzymeJ."/>
   <result pre="as a targetAntiviral Res.8020089410118674567 LeyssenP.BalzariniJ.De ClercqE.NeytsJ.The predominant mechanism by which" exact="ribavirin" post="exerts its antiviral activity in vitro against flaviviruses and"/>
   <result pre="IMP dehydrogenaseJ. Virol.7920051943194715650220 LeyssenP.De ClercqE.NeytsJ.The anti-yellow fever virus activity of" exact="ribavirin" post="is independent of error-prone replicationMol Pharmacol6920061461146716421290 LiY.I.ChenY.J.HsuY.H.MengM.Characterization of the"/>
   <result pre="polymeraseJ. Virol.792005131051311516189012 LivonesiM.C.De SousaR.L.BadraS.J.FigueiredoL.T.In vitro and in vivo studies of" exact="ribavirin" post="action on Brazilian OrthobunyavirusAm. J. Trop. Med. Hyg.7520061011101617124004 LugariA.BetziS.DecrolyE.BonnaudE.HermantA.GuillemotJ.-C.DebarnotC.BorgJ.-P.BouvetM.CanardB.MorelliX.LecineP.Molecular"/>
   <result pre="of GTP pool is not the predominant mechanism by which" exact="ribavirin" post="exerts its antiviral effect on Lassa virusAntiviral Res.912011899321616094 PlotchS.J.BouloyM.KrugR.M.Transfer"/>
   <result pre="for viral cap-dependent transcriptionPLoS Pathog.692010e100110120862319 ScheidelL.M.DurbinR.K.StollarV.Sindbis virus mutants resistant to" exact="mycophenolic acid" post="and ribavirinVirology1581987173033882 ScheidelL.M.StollarV.Mutations that confer resistance to mycophenolic acid"/>
   <result pre="to mycophenolic acid and ribavirinVirology1581987173033882 ScheidelL.M.StollarV.Mutations that confer resistance to" exact="mycophenolic acid" post="and ribavirin on Sindbis virus map to the nonstructural"/>
   <result pre="and ribavirinVirology1581987173033882 ScheidelL.M.StollarV.Mutations that confer resistance to mycophenolic acid and" exact="ribavirin" post="on Sindbis virus map to the nonstructural protein nsP1Virology18119914904991826574"/>
   <result pre="of viruses by cytoplasmic sensorsCurr. Opin. Immunol.222010414720061127 ZhouS.LiuR.BaroudyB.M.MalcolmB.A.ReyesG.R.The effect of" exact="ribavirin" post="and IMPDH inhibitors on hepatitis C virus subgenomic replicon"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7114316\results\search\drugs\results.xml">
   <result pre="NSC343256 showed better EC50 values than the broad-spectrum antiviral drug" exact="ribavirin" post="and the protease inhibitor lopinavir, under all the test"/>
   <result pre="cultured in 5 mL of LB broth containing 100 μg/mL" exact="ampicillin" post="overnight at 37 °C. The correct constructs were subsequently"/>
   <result pre="purine analog with antiviral activity. The mechanism of action of" exact="ribavirin" post="is still unclear and highly variable among patients (Cameron"/>
   <result pre="hepatitis C virus (Dixit and Perelson, 2006). The activity of" exact="ribavirin" post="is enhanced by using its combination with interferons or"/>
   <result pre="drugs that synergistically inhibit the viruses, rather than treatment with" exact="ribavirin" post="alone, as reported for the MERS-CoV and SARS-CoV regimens"/>
   <result pre="in several studies. In our pre- and post-viral entry experiments," exact="ribavirin" post="showed less antiviral effect on FIPV, compared to compounds"/>
   <result pre="of HIV protease, has been commonly used in combination with" exact="ritonavir" post="for treatment of HIV. The booted forms of lopinavir"/>
   <result pre="with ritonavir for treatment of HIV. The booted forms of" exact="lopinavir" post="and ritonavir have exhibited antiviral activities in some clinical"/>
   <result pre="for treatment of HIV. The booted forms of lopinavir and" exact="ritonavir" post="have exhibited antiviral activities in some clinical cases of"/>
   <result pre="al., 2004; Chan et al., 2003). It was expected that" exact="lopinavir" post="could possibly inhibit 3CLpro activity. However, lopinavir and its"/>
   <result pre="was expected that lopinavir could possibly inhibit 3CLpro activity. However," exact="lopinavir" post="and its derivatives partially inhibited the 3CLpro of SARS-CoV,"/>
   <result pre="~25 μM, respectively (Wu et al., 2004). We observed that" exact="lopinavir" post="effectively inhibited FIPV during the stage of viral entry"/>
   <result pre="viral entry (EC50 = 5.38–31.70 μM). It is possible that" exact="lopinavir" post="may have higher inhibitory activity toward other proteases when"/>
   <result pre="other host proteases such as furin protease, the action of" exact="lopinavir" post="might involve the blocking of furin-mediated cleavage during viral"/>
   <result pre="cleavage during viral entry. Therefore, the mechanism of action of" exact="lopinavir" post="on FIPV requires further investigation. The selectivity index, defined"/>
   <result pre="Biol.1263201524325025618350 DixitN.M.PerelsonA.S.The metabolism, pharmacokinetics and mechanisms of antiviral activity of" exact="ribavirin" post="against hepatitis C virusCell. Mol. Life Sci.63200683284216501888 FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.BriningD.BushmakerT.MartellaroC.BaselerL.BeneckeA.G.KatzeM.G.MunsterV.J.FeldmannH.Treatment"/>
   <result pre="C virusCell. Mol. Life Sci.63200683284216501888 FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.BriningD.BushmakerT.MartellaroC.BaselerL.BeneckeA.G.KatzeM.G.MunsterV.J.FeldmannH.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV–infected rhesus macaquesNat. Med.192013131324013700 HerreweghA.A.P.M.De GrootR.J.CepicaA.EgberinkH.F.HorzinekM.C.RottierP.J.M.Detection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7114806\results\search\drugs\results.xml">
   <result pre="a credit line to the data. Abstract Background Interferon and" exact="ribavirin" post="have been used as therapeutic agents for chronic hepatitis"/>
   <result pre="administration was started. Following steroid pulse therapy, treatment with oral" exact="prednisolone" post="tablets was gradually tapered. The patient’s symptoms were relieved"/>
   <result pre="Interstitial lung disease Drug-induced lung disease Background Interferon (IFN) and" exact="ribavirin" post="have been used as the standard treatment of chronic"/>
   <result pre="an adverse effect of DAAs were the spontaneous report of" exact="simeprevir" post="sodium [5] used in combination with IFN and the"/>
   <result pre="used in combination with IFN and the simultaneous administration of" exact="daclatasvir" post="hydrochloride and asunaprevir [6]. LDV/SOF does not specify interstitial"/>
   <result pre="discontinued, and steroid administration was started. Steroid pulse therapy with" exact="methylprednisolone" post="sodium succinate was performed for 3 days starting the day"/>
   <result pre="after hospitalization (day 17, June 3, 20XX). After changing to" exact="prednisolone" post="tablets for oral administration, the dose was gradually tapered."/>
   <result pre="hospitalization were tested to rule out respiratory infection, and prophylactic" exact="azithromycin" post="infusion was given until the results were known. An"/>
   <result pre="and sputum culture showed no viable microbes and administration of" exact="azithromycin" post="was discontinued after it had been administered for 5 days."/>
   <result pre="they have no competing interests. References References 1.MizokamiMYokosukaOTakeharaTSakamotoNKorenagaMMochizukiHet al.Ledipasvir and" exact="sofosbuvir" post="fixed-dose combination with and without ribavirin for 12 weeks"/>
   <result pre="References 1.MizokamiMYokosukaOTakeharaTSakamotoNKorenagaMMochizukiHet al.Ledipasvir and sofosbuvir fixed-dose combination with and without" exact="ribavirin" post="for 12 weeks in treatment-naive and previously treated Japanese"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7115022\results\search\drugs\results.xml">
   <result pre="transplant recipients. Neuraminidase inhibitor therapy has been suggested for influenza," exact="ribavirin" post="for RSV, and cidofovir for adenovirus infections. However, there"/>
   <result pre="therapy has been suggested for influenza, ribavirin for RSV, and" exact="cidofovir" post="for adenovirus infections. However, there is no evidence supporting"/>
   <result pre="transplant recipients, and patients with chronic lymphocytic leukaemia treated with" exact="fludarabine" post="combined with CD52 monoclonal antibodies [88, 89]. In allogeneic"/>
   <result pre="channel inhibitors and neuraminidase inhibitors. The M2 ion channel inhibitors," exact="amantadine" post="and rimantadine, act by inhibiting the M2 protein needed"/>
   <result pre="influenza A strains [122]. The neuraminidase inhibitors (Table 21.3), oral" exact="oseltamivir" post="and inhaled zanamivir, are sialic acid analogues that competitively"/>
   <result pre="every 2 weeks according to the clinical response cHyperhydratation and" exact="probenecide" post="may help to prevent cidofovir nephrotoxicity dHaemolytic anaemia may"/>
   <result pre="the clinical response cHyperhydratation and probenecide may help to prevent" exact="cidofovir" post="nephrotoxicity dHaemolytic anaemia may be readily controlled by blood"/>
   <result pre="drug for Paramyxoviridae infection (Table 21.3). The efficacy of aerosolized" exact="ribavirin" post="was variable in uncontrolled cohorts of patients with RSV-related"/>
   <result pre="132]. Again, the results must be interpreted with caution. Early" exact="ribavirin" post="therapy, introduced before the onset of respiratory failure, seemed"/>
   <result pre="al. [132]. This observation led some authors to evaluate pre-emptive" exact="ribavirin" post="therapy, characterised by ribavirin treatment of RSV URTI to"/>
   <result pre="led some authors to evaluate pre-emptive ribavirin therapy, characterised by" exact="ribavirin" post="treatment of RSV URTI to prevent progression to pneumonia"/>
   <result pre="et al. is the only randomised controlled trial evaluating pre-emptive" exact="ribavirin" post="therapy in patients with RSV infection [133]. Unfortunately, the"/>
   <result pre="enrol a sufficient number of patients to produce conclusions. Intravenous" exact="ribavirin" post="has also been evaluated and found unhelpful [29, 135]."/>
   <result pre="has also been evaluated and found unhelpful [29, 135]. Combining" exact="ribavirin" post="with intravenous immunoglobulins or RSV-specific immunoglobulins produced variable levels"/>
   <result pre="was evaluated only in a small cohort [138]. In vitro," exact="ribavirin" post="exhibits mild antiviral activity against PIV [58]. No clear"/>
   <result pre="antiviral activity against PIV [58]. No clear efficacy of aerosolized" exact="ribavirin" post="was found in small, uncontrolled cohorts of patients with"/>
   <result pre="cohorts of patients with HM [34, 139]. Early initiation of" exact="ribavirin" post="therapy has been proposed to enhance efficacy [140]. No"/>
   <result pre="titres of PIV-specific immunoglobulins. An in vitro study suggests that" exact="ribavirin" post="may be of interest for treating human MPV-related pneumonia,"/>
   <result pre="treatment of adenoviral disease in patients with HM. Ribavirin and" exact="cidofovir" post="have been suggested for the treatment of adenoviral infections,"/>
   <result pre="uncontrolled cohort studies are available to support their use. Intravenous" exact="ribavirin" post="therapy failed to demonstrate benefits in available studies [89,"/>
   <result pre="also been reported in some small series [155, 156]. Early" exact="cidofovir" post="treatment seems associated with a better outcome [151]. Weekly"/>
   <result pre="screening for adenovirus viraemia has been suggested to guide pre-emptive" exact="cidofovir" post="therapy [91–94, 153, 157]. The exact threshold above which"/>
   <result pre="therapy [91–94, 153, 157]. The exact threshold above which pre-emptive" exact="cidofovir" post="therapy should be initiated is unknown. Randomised controlled trials"/>
   <result pre="proposed to prevent common respiratory virus infections. Intravenous immunoglobulins and" exact="palivizumab" post="have been suggested for RSV infection prevention, but have"/>
   <result pre="have not been evaluated in patients with HM. Prophylactic post-exposure" exact="oseltamivir" post="therapy is currently recommended in patients with HM [176]."/>
   <result pre="HSCT recipients [177]. Considering the lack of proven benefits of" exact="oseltamivir" post="therapy and the growing concern about the emergence of"/>
   <result pre="the growing concern about the emergence of oseltamivir-resistant influenza strains," exact="oseltamivir" post="therapy should be carefully evaluated before it is suggested"/>
   <result pre="the 20th century: a period analysisLancet200236093401131113512387961 4.CoiffierBet al.CHOP chemotherapy plus" exact="rituximab" post="compared with CHOP alone in elderly patients with diffuse"/>
   <result pre="95.BrunoBet al.Adenovirus infection in hematopoietic stem cell transplantation: effect of" exact="ganciclovir" post="and impact on survivalBiol Blood Marrow Transplant20039534135212766884 96.HaleGAet al.Adenovirus"/>
   <result pre="recipientsTranspl Infect Dis200911429830319453994 121.Jefferson TO et al (2002) Amantadine and" exact="rimantadine" post="for preventing and treating influenza A in adults. Cochrane"/>
   <result pre="Trialists) Study GroupRandomised trial of efficacy and safety of inhaled" exact="zanamivir" post="in treatment of influenza A and B virus infectionsLancet19983529144187718819863784"/>
   <result pre="A and B virus infectionsLancet19983529144187718819863784 124.NicholsonKGet al.Efficacy and safety of" exact="oseltamivir" post="in treatment of acute influenza: a randomised controlled trial."/>
   <result pre="GroupLancet200035592181845185010866439 125.TreanorJJet al.Efficacy and safety of the oral neuraminidase inhibitor" exact="oseltamivir" post="in treating acute influenza: a randomised controlled trial. US"/>
   <result pre="US Oral Neuraminidase Study GroupJAMA200028381016102410697061 126.MontoASWebsterAKeeneORandomized, placebo-controlled studies of inhaled" exact="zanamivir" post="in the treatment of influenza A and B: pooled"/>
   <result pre="efficacy analysisJ Antimicrob Chemother199944Suppl B232910877459 127.AokiFYet al.Early administration of oral" exact="oseltamivir" post="increases the benefits of influenza treatmentJ Antimicrob Chemother200351112312912493796 128.McGeerAet"/>
   <result pre="bone marrow transplantationBone Marrow Transplant200434211111415094755 132.WhimbeyEet al.Combination therapy with aerosolized" exact="ribavirin" post="and intravenous immunoglobulin for respiratory syncytial virus disease in"/>
   <result pre="recipientsBone Marrow Transplant19951633933998535312 133.BoeckhMet al.Randomized controlled multicenter trial of aerosolized" exact="ribavirin" post="for respiratory syncytial virus upper respiratory tract infection in"/>
   <result pre="marrow transplant recipients with breast cancer: combination therapy with aerosolized" exact="ribavirin" post="and parenteral immunoglobulinsBone Marrow Transplant200128327127511535995 135.LewinsohnDMet al.Phase I study"/>
   <result pre="parenteral immunoglobulinsBone Marrow Transplant200128327127511535995 135.LewinsohnDMet al.Phase I study of intravenous" exact="ribavirin" post="treatment of respiratory syncytial virus pneumonia after marrow transplantationAntimicrob"/>
   <result pre="adult blood and marrow transplant recipients: combination therapy with aerosolized" exact="ribavirin" post="and intravenous immunoglobulinBone Marrow Transplant200025775175510745261 138.BoeckhMet al.Phase 1 evaluation"/>
   <result pre="al.Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody" exact="palivizumab" post="in recipients of hematopoietic stem cell transplantsJ Infect Dis2001184335035411443562"/>
   <result pre="3 infections in hematopoetic stem cell transplant recipients: response to" exact="ribavirin" post="therapyClin Infect Dis20003161516151811096028 141.WydePRet al.Comparison of the inhibition of"/>
   <result pre="the inhibition of human metapneumovirus and respiratory syncytial virus by" exact="ribavirin" post="and immune serum globulin in vitroAntiviral Res2003601515914516921 142.BordigoniPet al.Treatment"/>
   <result pre="adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous" exact="ribavirin" post="therapyBone Marrow Transplant199923111209121110382964 144.GavinPJKatzBZIntravenous ribavirin treatment for severe adenovirus"/>
   <result pre="marrow transplantation: failure of intravenous ribavirin therapyBone Marrow Transplant199923111209121110382964 144.GavinPJKatzBZIntravenous" exact="ribavirin" post="treatment for severe adenovirus disease in immunocompromised childrenPediatrics20021101 Pt"/>
   <result pre="treatment with intravenous ribavirinBone Marrow Transplant19931244094128275042 146.MannDet al.Failure of intravenous" exact="ribavirin" post="in the treatment of invasive adenovirus infection following allogeneic"/>
   <result pre="allogeneic bone marrow transplantation: a case reportJ Infect19983622272289570662 147.MiyamuraKet al.Successful" exact="ribavirin" post="therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow"/>
   <result pre="Marrow Transplant200025554554810713633 148.HoffmanJAet al.Adenoviral infections and a prospective trial of" exact="cidofovir" post="in pediatric hematopoietic stem cell transplantationBiol Blood Marrow Transplant20017738839411529489"/>
   <result pre="Transplant20017738839411529489 149.LegrandFet al.Early diagnosis of adenovirus infection and treatment with" exact="cidofovir" post="after bone marrow transplantation in childrenBone Marrow Transplant200127662162611319592 150.LjungmanPet"/>
   <result pre="Full textMed Mal Infect200535Suppl 4S24527316535783 177.VuDet al.Safety and tolerability of" exact="oseltamivir" post="prophylaxis in hematopoietic stem cell transplant recipients: a retrospective"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7117595\results\search\drugs\results.xml">
   <result pre="Clinical Trial Registry Identifier: ChiCTR2000029544) [10]. Finally, preclinical studies of" exact="ribavirin" post="(ribonucleic analog) has shown in vitro activity against SARS-CoV-2"/>
   <result pre="2293–2303 (2019).31774950 8.collab: NIH Clinical Trials. Efficacy and safety of" exact="hydroxychloroquine" post="for treatment of pneumonia caused by 2019-nCoV (HC-nCoV) (2020)."/>
   <result pre="(HC-nCoV) (2020). https://clinicaltrials.gov/ct2/show/NCT04261517 9.WangM , CaoR , ZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="DeMorais ATSet al.Structural and molecular basis of mismatch correction and" exact="ribavirin" post="excision from coronavirus RNA. Proc. Natl Acad. Sci. USA115(2),"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7118351\results\search\drugs\results.xml">
   <result pre="pmid: 31964466 doi: 10.5483/BMBRep.2020.53.3.175BMB-53-166 : Article Antiviral activity of sertindole," exact="raloxifene" post="and ibutamoren against transcription and replication-competent Ebola virus-like particles"/>
   <result pre="structure, the compounds were divided into three groups, diphenylmethane derivatives," exact="promazine" post="derivatives and chemicals with no conserved skeletons. The third"/>
   <result pre="previous reports of GPCR modulators as anti-EBOV compounds (19-21). Particularly," exact="sertindole" post="(EC50, 0.7 μM; SI, &amp;gt; 45.8), raloxifene hydrochloride (raloxifene;"/>
   <result pre="compounds (19-21). Particularly, sertindole (EC50, 0.7 μM; SI, &amp;gt; 45.8)," exact="raloxifene" post="hydrochloride (raloxifene; EC50, 0.5 μM; SI, 47.1) and ibutamoren"/>
   <result pre="comparable or superior to the known anti-EBOV compounds such as" exact="ribavirin" post="(RBV) and T-705 in their inhibitory effects. To establish"/>
   <result pre="inhibitory effects. To establish this finding, we purchased highly purified" exact="sertindole" post="(≥ 97.5%), raloxifene (≥ 98%), and ibutamoren (≥ 98%)"/>
   <result pre="establish this finding, we purchased highly purified sertindole (≥ 97.5%)," exact="raloxifene" post="(≥ 98%), and ibutamoren (≥ 98%) and repeated the"/>
   <result pre="minigenome-derived VP40 was downregulated in a dose-dependent manner by sertindole," exact="raloxifene" post="and ibutamoren as well as RBV, a positive control,"/>
   <result pre="spots was reduced significantly in the presence of 10 μM" exact="sertindole" post="(by 84.7%), raloxifene (by 69.1%), or ibutamoren (by 74.2%)"/>
   <result pre="significantly in the presence of 10 μM sertindole (by 84.7%)," exact="raloxifene" post="(by 69.1%), or ibutamoren (by 74.2%) as well as"/>
   <result pre="dose-dependent manner (Fig. 3C). These data strongly suggested that sertindole," exact="raloxifene" post="and ibutamoren not only prevent trVLP-derived EBOV viral replication"/>
   <result pre="relationships (Supplementary Fig. 3). Diphenylmethane derivatives belong to group I," exact="promazine" post="derivatives to group II and other compounds to group"/>
   <result pre="I and II carry distinct chemical skeletons as diphenylmethane and" exact="promazine" post="cores, respectively, these structural features might be preferred for"/>
   <result pre="the antiviral efficacy of the three active compounds including sertindole," exact="raloxifene" post="and ibutamoren against other human RNA viruses, such as"/>
   <result pre="(the Korea Chemical Bank) deposited by domestic chemists. Highly purified" exact="sertindole" post="(≥ 97.5%) and ibutamoren (≥ 98%) were purchased from"/>
   <result pre="97.5%) and ibutamoren (≥ 98%) were purchased from Sigma-Aldrich, and" exact="raloxifene" post="(≥ 98%) from Santa Cruz Biotechnology. Control antiviral compounds,"/>
   <result pre="microarray analysisBMC Genomics121410.1186/1471-2164-12-1421214938 25JungENamSOhHet al.2019Neutralization of acidic intracellular vesicles by" exact="niclosamide" post="inhibits multiple steps of the dengue virus life cycle"/>
   <result pre="the trVLP system in the presence of increasing concentrations of" exact="sertindole" post="(A), raloxifene (B) or ibutamoren (C) using RBV (D)"/>
   <result pre="system in the presence of increasing concentrations of sertindole (A)," exact="raloxifene" post="(B) or ibutamoren (C) using RBV (D) as a"/>
   <result pre="μM RBV, or 10 μM of each hit compound (sertindole," exact="raloxifene" post="or ibutamoren). On day 1 p.i., cells were fixed"/>
   <result pre="0.7 ± 0.2 17.4 ± 0.6 27.7 ± 9.2 Postsynaptic" exact="dopamine" post="2 receptor inhibitor 13 Ibutamoren mesylate &amp;lt; 0.4 &amp;gt;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7118362\results\search\drugs\results.xml">
   <result pre="patients infected by SARS-CoV-2. It has been previously reported that" exact="chloroquine" post="could inhibit SARS-CoV and is studied for treating COVID-19"/>
   <result pre="and colleagues report that, in more than 100 patients, the" exact="chloroquine" post="phosphate is better compared to the control treatment in"/>
   <result pre="Italy with some encouraging results (25). However, the hypothesis that" exact="tocilizumab" post="can restore T cell counts in COVID-19 disease patients,"/>
   <result pre="COVID-19 associated pneumonia in clinical studiesBiosci Trends2020141727310.5582/bst.2020.0104732074550 24.YanYZouZSunYet al.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7118423\results\search\drugs\results.xml">
   <result pre="[50]. Recently, scientists screened out four small-molecule drugs (prulifloxacin, tegobuvir," exact="nelfinavir" post="and bictegravir) with strong binding affinity to the main"/>
   <result pre="of China, antiviral therapy can be tried with interferon, lopinavir/ritonavir," exact="chloroquine" post="phosphate and umifenovir. These and other potentially effective drugs"/>
   <result pre="[67]. It has been shown in in vitro experiments that" exact="ribavirin" post="inhibits the replication of MERS-CoV and HCoV-OC43, but the"/>
   <result pre="[68]. Simultaneous use of interferon can reduce the dose of" exact="ribavirin" post="[69]. In a primate model, clinical symptoms of MERS"/>
   <result pre="symptoms of MERS could be improved by the combination of" exact="ribavirin" post="and type I interferon [70]. However, side effects of"/>
   <result pre="syndrome [72,73]. Therefore, further studies are needed to determine whether" exact="ribavirin" post="can effectively treat novel coronavirus pneumonia (COVID-19), and ribavirin"/>
   <result pre="whether ribavirin can effectively treat novel coronavirus pneumonia (COVID-19), and" exact="ribavirin" post="and interferon are still in clinical trials (Chinese Clinical"/>
   <result pre="(HIV) [74]. Lopinavir inhibits cleavage of the gag-pol protein, whilst" exact="ritonavir" post="inhibits cleavage of the gag-pol protein precursor and lopinavir"/>
   <result pre="whilst ritonavir inhibits cleavage of the gag-pol protein precursor and" exact="lopinavir" post="metabolism to increase the concentration of lopinavir [75]. It"/>
   <result pre="protein precursor and lopinavir metabolism to increase the concentration of" exact="lopinavir" post="[75]. It has been shown that lopinavir/ritonavir could inhibit"/>
   <result pre="with virus–receptor binding by ACE2 terminal glycosylation [83,84]. In vitro," exact="chloroquine" post="can enhance the effects of other antiviral drugs [38]."/>
   <result pre="the viral polymerase and the proofreading exoribonucleasemBio9201810.1128/mBio.00221-18pii: e00221-18 66WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="coronavirus (2019-nCoV) in vitroCell Res30202026927110.1038/s41422-020-0282-032020029 67ElfikyA.A.Ribavirin, remdesivir, sofosbuvir, galidesivir, and" exact="tenofovir" post="against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular"/>
   <result pre="of interferon-α2b and ribavirinSci Rep32013168610.1038/srep0168623594967 70FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat Med1920131313131710.1038/nm.336224013700 71ZumlaA.ChanJ.F.AzharE.I.HuiD.S.YuenK.Y.Coronaviruses—drug discovery"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7118541\results\search\drugs\results.xml">
   <result pre="remdesivir, and Kaletra were predicted to inhibit SARS-CoV-2. •Rapamycin and" exact="tiotropium bromide" post="may also be effective for SARS-CoV-2. Abstract The infection"/>
   <result pre="against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM)," exact="efavirenz" post="(199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM)."/>
   <result pre="3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM)," exact="ritonavir" post="(204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir,"/>
   <result pre="remdesivir (113.13 nM), efavirenz (199.17 nM), ritonavir (204.05 nM), and" exact="dolutegravir" post="(336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all"/>
   <result pre="(204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and" exact="darunavir" post="are all designed to target viral proteinases. However, in"/>
   <result pre="analysis. The SARS-CoV-2 3C-like proteinase was predicted to bind with" exact="atazanavir" post="(Kd 94.94 nM), followed by remdesivir, efavirenz, ritonavir, and"/>
   <result pre="studies have been identified. For example, a docking study of" exact="lopinavir" post="along with other HIV proteinase inhibitors of the CoV"/>
   <result pre="HIV proteinase inhibitors of the CoV proteinase (PDBID 1UK3) suggests" exact="atazanavir" post="and ritonavir, which are listed in the present prediction"/>
   <result pre="the CoV proteinase in line with the inhibitory potency of" exact="lopinavir" post="[27]. According to the prediction, viral proteinase-targeting drugs were"/>
   <result pre="O)N1CC2C(C1C( O)NC(CC1CCC1)C( O)C(N) O)C2(C)C)C(C)(C)C 433.93 101 Among the prediction results," exact="atazanavir" post="was predicted to have a potential binding affinity to"/>
   <result pre="of the COVID-19 replication complex may be inhibited simultaneously by" exact="atazanavir" post="(Table 2, Table 3, Table 4, Table 5, Table"/>
   <result pre="2, Table 3, Table 4, Table 5, Table 6). Also," exact="ganciclovir" post="was predicted to bind to three subunits of the"/>
   <result pre="anti-HIV drug, Prezcobix of Johnson &amp;amp; Johnson, which consists of" exact="darunavir" post="and cobicistat, was to be sent to China [29],"/>
   <result pre="and cobicistat, was to be sent to China [29], and" exact="darunavir" post="is also predicted to have a Kd of 90.38"/>
   <result pre="3). However, there was no current supporting literature found for" exact="darunavir" post="to be used as a CoV therapeutic. Although remdesivir"/>
   <result pre="by inhibiting some aspects of SARS-CoV-2. For example, remdesivir and" exact="chloroquine" post="showed inhibitory effects against SARS-CoV-2 in vitro[31]. Another in-vitro"/>
   <result pre="effects against SARS-CoV-2 in vitro[31]. Another in-vitro study showed that" exact="hydroxychloroquine" post="was found to be more potent than chloroquine for"/>
   <result pre="showed that hydroxychloroquine was found to be more potent than" exact="chloroquine" post="for inhibiting SARS-CoV-2 [32]. Remdesivir and lopinavir/ritonavir (Kaletra) also"/>
   <result pre="but some differences were observed. For example, atazanavir, remdesivir, and" exact="efavirenz" post="were the top three predicted drugs that may bind"/>
   <result pre="that these drugs may be effective in inhibiting SARS-CoV-2. Lastly," exact="atazanavir" post="appears to be effective in the treatment of COVID-19"/>
   <result pre="issue)17145705 15PaoliniG.V.ShaplandR.H.van HoornW.P.MasonJ.S.HopkinsA.L.Global mapping of pharmacological spaceNat Biotechnol247200680581516841068 16WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="treatment of SARS: initial virological and clinical findingsThorax593200425225614985565 31WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7118644\results\search\drugs\results.xml">
   <result pre="virus infection [8], remdesivir is a prodrug of the parent" exact="adenosine" post="analog, GS-441524 (Fig. 1b), both of which are metabolized"/>
   <result pre="host metabolizes remdesivir into active NTP, the metabolite competes with" exact="adenosine" post="triphosphate (ATP; the natural nucleotide normally used in this"/>
   <result pre="inhibiting SARS-CoV-2. EC50 values ranged widely from 109.5 μM for" exact="ribavirin" post="to 1.13 μM for choloquine and 0.77 μM for"/>
   <result pre="that is being evaluated in multiple trials against COVID-19 is" exact="chloroquine" post="(or hydroxychloroquine), which is already approved as an antimalarial"/>
   <result pre="naturally occurring feline infectious peritonitisJ. Feline Med. Surg.214201927128130755068 17WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7118659\results\search\drugs\results.xml">
   <result pre="10.1016/j.ijantimicag.2020.105938105938 : Article New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19? DevauxChristian A.christian.devaux@mediterranee-infection.comabc�?�RolainJean-MarcacColsonPhilippeacRaoultDidierac[a],"/>
   <result pre="potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of" exact="chloroquine" post="repurposing in the treatment of COVID-19 in China have"/>
   <result pre="several new trials. Here we discuss the possible mechanisms of" exact="chloroquine" post="interference with the SARS-CoV-2 replication cycle. Keywords COVID-19 SARS-CoV-2"/>
   <result pre="the previous drug of choice against malaria [3]. For decades," exact="chloroquine" post="was a front-line drug for the treatment and prophylaxis"/>
   <result pre="most prescribed drugs worldwide [4]. Chloroquine and the 4-aminoquinoline drug" exact="hydroxychloroquine" post="belong to the same molecular family. Hydroxychloroquine differs from"/>
   <result pre="hydroxychloroquine belong to the same molecular family. Hydroxychloroquine differs from" exact="chloroquine" post="by the presence of a hydroxyl group at the"/>
   <result pre="molecule is available for oral administration in the form of" exact="hydroxychloroquine" post="sulfate. Hydroxychloroquine has pharmacokinetics similar to that of chloroquine,"/>
   <result pre="of these drugs slightly differ. In malaria, the indication for" exact="chloroquine" post="was a high dose for a short period of"/>
   <result pre="of time. Hydroxychloroquine was reported to be as active as" exact="chloroquine" post="against Plasmodium falciparum malaria and less toxic, but it"/>
   <result pre="and less toxic, but it is much less active than" exact="chloroquine" post="against chloroquine-resistant P. falciparum owing to its physicochemical properties."/>
   <result pre="falciparum owing to its physicochemical properties. What is advantageous with" exact="hydroxychloroquine" post="is that it can be used in high doses"/>
   <result pre="long periods with very good tolerance. Unfortunately, the efficacy of" exact="chloroquine" post="gradually declined due to the continuous emergence of chloroquine-resistant"/>
   <result pre="tolerability, rare toxicity reports, inexpensive cost and immunomodulatory properties [11]," exact="chloroquine" post="repurposing was explored against human immunodeficiency virus (HIV) and"/>
   <result pre="possibility of a SARS-CoV-2 pandemic, the broad-spectrum antiviral effects of" exact="chloroquine" post="warranted particular attention for repurposing this drug in the"/>
   <result pre="SARS-CoV-2, named coronavirus disease 2019 (COVID-19). 2 Antiviral properties of" exact="chloroquine" post="In vitro, chloroquine appears as a versatile bioactive agent"/>
   <result pre="disease 2019 (COVID-19). 2 Antiviral properties of chloroquine In vitro," exact="chloroquine" post="appears as a versatile bioactive agent reported to possess"/>
   <result pre="virus [40] and herpes simplex virus [41].The antiviral properties of" exact="chloroquine" post="described in vitro have sometimes been confirmed during treatment"/>
   <result pre="in clinical trials depending on the disease, the concentration of" exact="chloroquine" post="used, the duration of treatment and the clinical team"/>
   <result pre="of the trial. Regarding coronaviruses, the potential therapeutic benefits of" exact="chloroquine" post="were notably reported for SARS-CoV-1 [11,42]. Chloroquine was also"/>
   <result pre="mice with the HCoV-O43 coronavirus could be averted by administering" exact="chloroquine" post="through the mother's milk. In vitro experiments also showed"/>
   <result pre="In vitro experiments also showed a strong antiviral effect of" exact="chloroquine" post="on a recombinant HCoV-O43 coronavirus [45]. Although chloroquine was"/>
   <result pre="effect of chloroquine on a recombinant HCoV-O43 coronavirus [45]. Although" exact="chloroquine" post="was reported to be active against Middle East respiratory"/>
   <result pre="this observation remains controversial [47]. 3 Potential antiviral effect of" exact="chloroquine" post="against SARS-CoV-2 Because of its broad spectrum of action"/>
   <result pre="any known efficient therapy to investigate the possible effect of" exact="chloroquine" post="against SARS-CoV-2. A recent paper reported that both chloroquine"/>
   <result pre="of chloroquine against SARS-CoV-2. A recent paper reported that both" exact="chloroquine" post="and the antiviral drug remdesivir inhibited SARS-CoV-2 in vitro"/>
   <result pre="Recently, the China National Center for Biotechnology Development indicated that" exact="chloroquine" post="is one of the three drugs with a promising"/>
   <result pre="Chinese authorities suggesting that approximately 100 infected patients treated with" exact="chloroquine" post="experienced a more rapid decline in fever and improvement"/>
   <result pre="serious adverse effects, the Chinese medical advisory board has suggested" exact="chloroquine" post="inclusion in the SARS-CoV-2 treatment guidelines. As a result,"/>
   <result pre="chloroquine inclusion in the SARS-CoV-2 treatment guidelines. As a result," exact="chloroquine" post="is probably the first molecule to be used in"/>
   <result pre="this drug in malaria therapy demonstrates the safety of acute" exact="chloroquine" post="administration to humans, one cannot ignore the minor risk"/>
   <result pre="reports on cardiomyopathy as a severe adverse effect caused by" exact="chloroquine" post="[53,54]. A survey of SARS-CoV-2-infected patients for adverse effects"/>
   <result pre="[53,54]. A survey of SARS-CoV-2-infected patients for adverse effects of" exact="chloroquine" post="therapy remains to be performed. However, chloroquine is currently"/>
   <result pre="adverse effects of chloroquine therapy remains to be performed. However," exact="chloroquine" post="is currently among the best available candidates to impact"/>
   <result pre="in humans. Currently, at least ten clinical trials are testing" exact="chloroquine" post="as an anti-COVID-19 therapy [55]. 4 Mode of action"/>
   <result pre="as an anti-COVID-19 therapy [55]. 4 Mode of action of" exact="chloroquine" post="Chloroquine has multiple mechanisms of action that may differ"/>
   <result pre="are critical components of ligand recognition. The possible interference of" exact="chloroquine" post="with sialic acid biosynthesis could account for the broad"/>
   <result pre="acid moieties as receptors [58]. The potent anti-SARS-CoV-1 effects of" exact="chloroquine" post="in vitro were considered attributable to a deficit in"/>
   <result pre="or Chikungunya virus [60,61]. Due to the alkalisation of endosomes," exact="chloroquine" post="was an effective in vitro treatment against Chikungunya virus"/>
   <result pre="require a low pH. For HIV, the antiretroviral effect of" exact="chloroquine" post="is attributable to a post-transcriptional inhibition of glycosylation of"/>
   <result pre="infectivity is impaired. In the herpes simplex virus (HSV) model," exact="chloroquine" post="inhibited budding with accumulation of non-infectious HSV-1 particles in"/>
   <result pre="site of virion budding [67], suggesting a possible action of" exact="chloroquine" post="on SARS-CoV-2 at this step of the replication cycle."/>
   <result pre="[68]. Beside affecting the virus maturation process, pH modulation by" exact="chloroquine" post="can impair the proper maturation of viral protein [32]"/>
   <result pre="endosomal acidification [69]. On the contrary, other proposed effects of" exact="chloroquine" post="on the immune system include increasing the export of"/>
   <result pre="[70]. In the influenza virus model, it was reported that" exact="chloroquine" post="improve the cross-presentation of non-replicating virus antigen by dendritic"/>
   <result pre="receptor was also reported in U937 monocytic cells treated with" exact="chloroquine" post="[84]. In the Dengue virus model, chloroquine was found"/>
   <result pre="cells treated with chloroquine [84]. In the Dengue virus model," exact="chloroquine" post="was found to inhibit interferon-alpha (IFNα), IFNβ, IFNγ, TNFα,"/>
   <result pre="replication of several coronaviruses. Recent publications support the hypothesis that" exact="chloroquine" post="can improve the clinical outcome of patients infected by"/>
   <result pre="patients infected by SARS-CoV-2. The multiple molecular mechanisms by which" exact="chloroquine" post="can achieve such results remain to be further explored."/>
   <result pre="SARS-CoV-1 [85,86] (Table 1 ), it may be hypothesised that" exact="chloroquine" post="also interferes with ACE2 receptor glycosylation thus preventing SARS-CoV-2"/>
   <result pre="on some cell subtypes, this interaction will be affected by" exact="chloroquine" post="treatment [87,88]. Today, preliminary data indicate that chloroquine interferes"/>
   <result pre="affected by chloroquine treatment [87,88]. Today, preliminary data indicate that" exact="chloroquine" post="interferes with SARS-CoV-2 attempts to acidify the lysosomes and"/>
   <result pre="molecular crosstalk with its target cell can be altered by" exact="chloroquine" post="through inhibition of kinases such as MAPK. Chloroquine could"/>
   <result pre="[98]. Fig. 1 Schematic representation of the possible effects of" exact="chloroquine" post="on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"/>
   <result pre="vesicles and are released by exocytosis. It is possible that" exact="chloroquine" post="interferes with ACE2 receptor glycosylation, thus preventing SARS-CoV-2 binding"/>
   <result pre="of SARS-CoV-2. If binding of some viral particles is achieved," exact="chloroquine" post="may modulate the acidification of endosomes thereby inhibiting formation"/>
   <result pre="autophagosome. Through reduction of cellular mitogen-activated protein (MAP) kinase activation," exact="chloroquine" post="may also inhibit virus replication. Moreover, chloroquine could alter"/>
   <result pre="(MAP) kinase activation, chloroquine may also inhibit virus replication. Moreover," exact="chloroquine" post="could alter M protein maturation and interfere with virion"/>
   <result pre="virion assembly and budding. With respect to the effect of" exact="chloroquine" post="on the immune system, see the elegant review by"/>
   <result pre="of us emphasised in this journal the possibility of using" exact="chloroquine" post="to fight orphan viral infections [10]. The worldwide ongoing"/>
   <result pre="our institute [90], will verify whether the hopes raised by" exact="chloroquine" post="in the treatment of COVID-19 can be confirmed. References"/>
   <result pre="research in the post-genomic eraNature455200875175618843360 2ParhizgarA.R.TahghighiA.Introducing new antimalarial analogues of" exact="chloroquine" post="and amodiaquine: a narrative reviewIran J Med Sci42201711512828360437 3editorBruce-ChwattL.J.Chemotherapy"/>
   <result pre="of SLE and lupus nephritisNat Rev Nephrol7201171872910.1038/nrneph.2011.15022009248 7RaoultD.DrancourtM.VestrisG.Bactericidal effect of" exact="doxycycline" post="associated with lysosomotropic agents on Coxiella burnetii in P388D1"/>
   <result pre="8RaoultD.HoupikianP.TissotD.H.RissJ.M.Arditi-DjianeJ.BrouquiP.Treatment of Q fever endocarditis: comparison of 2 regimens containing" exact="doxycycline" post="and ofloxacin or hydroxychloroquineArch Intern Med159199916717310.1001/archinte.159.2.1679927100 9BoulosA.RolainJ.M.RaoultD.Antibiotic susceptibility of"/>
   <result pre="Q fever endocarditis: comparison of 2 regimens containing doxycycline and" exact="ofloxacin" post="or hydroxychloroquineArch Intern Med159199916717310.1001/archinte.159.2.1679927100 9BoulosA.RolainJ.M.RaoultD.Antibiotic susceptibility of Tropheryma whipplei"/>
   <result pre="of Tropheryma whipplei in MRC5 cellsAntimicrob Agents Chemother48200474775214982759 10RolainJ.M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="infection in the 21st centuryInt J Antimicrob Agents30200729730817629679 11SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="drug against today's diseases?Lancet Infect Dis3200372272714592603 12BoelaertJ.R.PietteJ.SperberK.The potential place of" exact="chloroquine" post="in the treatment of HIV-1-infected patientsJ Clin Virol20200113714011166662 13HuangC.WangY.LiX.RenL.ZhaoJ.HuY.Clinical"/>
   <result pre="potential bat origin. bioRxiv2020 Jan 23. doi:10.1101/2020.01.22.914952. 16TsiangH.SupertiF.Ammonium chloride and" exact="chloroquine" post="inhibit rabies virus infection in neuroblastoma cellsArch Virol8119843773826148053 17KronenbergerP.VrijsenR.BoeyéA.Chloroquine"/>
   <result pre="Retroviruses6199048148910.1089/aid.1990.6.4811692728 19SavarinoA.GenneroL.SperberK.BoelaertJ.R.The anti-HIV-1 activity of chloroquineJ Clin Virol20200113113511166661 20RomanelliF.SmithK.M.HovenA.D.Chloroquine and" exact="hydroxychloroquine" post="as inhibitors of human immunodeficiency virus (HIV-1) activityCurr Pharm"/>
   <result pre="A virus uncoatingIntervirology41199826127110325536 23MizuiT.YamashinaS.TanidaI.TakeiY.UenoT.SakamotoN.Inhibition of hepatitis C virus replication by" exact="chloroquine" post="targeting virus-associated autophagyJ Gastroenterol45201019520319760134 24MillerD.K.LenardJ.Antihistaminics, local anesthetics, and other"/>
   <result pre="a randomised, double-blind, placebo controlled trialLancet Infect Dis11201167768321550310 28YanY.ZouZ.SunY.LiX.XuK.F.WeiY.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="an animal modelCell Res23201330030210.1038/cr.2012.16523208422 29De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On Chikungunya acute infection and" exact="chloroquine" post="treatmentVector Borne Zoonotic Dis8200883784010.1089/vbz.2008.004918620511 30KhanM.SanthoshS.R.TiwariM.Lakshmana RaoP.V.ParidaM.Assessment of in vitro"/>
   <result pre="30KhanM.SanthoshS.R.TiwariM.Lakshmana RaoP.V.ParidaM.Assessment of in vitro prophylactic and therapeutic efficacy of" exact="chloroquine" post="against Chikungunya virus in Vero cellsJ Med Virol82201081782420336760 31DeloguI.de"/>
   <result pre="virus in Vero cellsJ Med Virol82201081782420336760 31DeloguI.de LamballerieX.Chikungunya disease and" exact="chloroquine" post="treatmentJ Med Virol8320111058105921503920 32RandolphV.B.WinklerG.StollarV.Acidotropic amines inhibit proteolytic processing of"/>
   <result pre="to identification of a promising candidate for therapyJ Virol8320095148515519264786 37FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined" exact="chloroquine" post="and ribavirin treatment does not prevent death in a"/>
   <result pre="of a promising candidate for therapyJ Virol8320095148515519264786 37FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined chloroquine and" exact="ribavirin" post="treatment does not prevent death in a hamster model"/>
   <result pre="RembertA.Paranhos-BaccalaG.Evaluation of Crimean–Congo hemorrhagic fever virus in vitro inhibition by" exact="chloroquine" post="and chlorpromazine, two FDA approved moleculesAntiviral Res1182015758110.1016/j.antiviral.2015.03.00525796972 39DowallS.D.BosworthA.WatsonR.BewleyK.TaylorI.RaynerE.Chloroquine inhibited"/>
   <result pre="1 by ammonium chloride and chloroquineVirology13819843323356093369 42KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob Agents"/>
   <result pre="the endo-/lysosomal pathway in a proteolysis-dependent mannerPLoS Pathog102014e1004502 49WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res30202026927110.1038/s41422-020-0282-032020029 50GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumoniaExpert consensus on"/>
   <result pre="chloroquine in the treatment of novel coronavirus pneumoniaExpert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia [in"/>
   <result pre="Xi Za Zhi432020E01910.3760/cma.j.issn.1001-0939.2020.001932075365 52BernsteinH.N.Ocular safety of hydroxychloroquineAnn Ophthalmol2319912922961952638 53RatliffN.B.EstesM.L.MylesJ.L.ShireyE.K.McMahonJ.T.Diagnosis of" exact="chloroquine" post="cardiomyopathy by endomyocardial biopsyN Engl J Med31619871911933796692 54CuberoG.J.Rodriguez RegueroJ.J.Rojo"/>
   <result pre="coronavirus infection and spreadVirol J220056910.1186/1743-422X-2-6916115318 60TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adultsPLoS Negl"/>
   <result pre="T cell-mediated immune responses to whole inactivated influenza virus by" exact="chloroquine" post="treatment in vivoVaccine3120131717172410.1016/j.vaccine.2013.01.03723380456 72SteizM.ValbrachtJ.QuachJ.LotzM.Gold sodium thiomalate and chloroquine inhibit"/>
   <result pre="virus by chloroquine treatment in vivoVaccine3120131717172410.1016/j.vaccine.2013.01.03723380456 72SteizM.ValbrachtJ.QuachJ.LotzM.Gold sodium thiomalate and" exact="chloroquine" post="inhibit cytokine production in monocytic THP-1 cells through distinct"/>
   <result pre="proinflammatory cytokine levels in systemic lupus erythematosus patientsLupus15200626827516761500 78SharmaO.P.Effectiveness of" exact="chloroquine" post="and hydroxychloroquine in treating selected patients with sarcoidosis with"/>
   <result pre="levels in systemic lupus erythematosus patientsLupus15200626827516761500 78SharmaO.P.Effectiveness of chloroquine and" exact="hydroxychloroquine" post="in treating selected patients with sarcoidosis with neurological involvementArch"/>
   <result pre="the SARS-coronavirus spike-protein for cell–cell and virus–cell fusionVirology413201126527410.1016/j.virol.2011.02.02021435673 90ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents2020"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7120377\results\search\drugs\results.xml">
   <result pre="have been described [52, 54]. Several cases were treated with" exact="ganciclovir" post="or with valganciclovir, some with fatal outcome despite therapy."/>
   <result pre="measurements of CMV in blood samples. Emerging strains resistant to" exact="ganciclovir" post="pose a therapeutic challenge for which foscarnet or cidofovir"/>
   <result pre="to ganciclovir pose a therapeutic challenge for which foscarnet or" exact="cidofovir" post="may become alternative antiviral agents [58]. Valganciclovir has recently"/>
   <result pre="reduced in liver transplant recipients who receive antiviral prophylaxis with" exact="valganciclovir" post="or oral ganciclovir for the first 3 months following"/>
   <result pre="transplant recipients who receive antiviral prophylaxis with valganciclovir or oral" exact="ganciclovir" post="for the first 3 months following liver transplantation. CMV"/>
   <result pre="infection to full-blown clinical disease [67]. Preemptive therapy with oral" exact="ganciclovir" post="or intravenous ganciclovir or valganciclovir resulted in reduction of"/>
   <result pre="clinical disease [67]. Preemptive therapy with oral ganciclovir or intravenous" exact="ganciclovir" post="or valganciclovir resulted in reduction of CMV disease by"/>
   <result pre="[67]. Preemptive therapy with oral ganciclovir or intravenous ganciclovir or" exact="valganciclovir" post="resulted in reduction of CMV disease by 70 %"/>
   <result pre="very rapid [66]. For antiviral prophylaxis, antiviral drugs such as" exact="ganciclovir" post="and valganciclovir are administered to patients at risk of"/>
   <result pre="[66]. For antiviral prophylaxis, antiviral drugs such as ganciclovir and" exact="valganciclovir" post="are administered to patients at risk of CMV disease"/>
   <result pre="as anti-CMV prophylaxis after liver transplantation has been supplanted by" exact="ganciclovir" post="and valganciclovir because of their superior efficacy [71, 76,"/>
   <result pre="prophylaxis after liver transplantation has been supplanted by ganciclovir and" exact="valganciclovir" post="because of their superior efficacy [71, 76, 77]. Prophylactic"/>
   <result pre="antiviral treatment of CMV disease after liver transplantation is intravenous" exact="ganciclovir" post="along with a reduction in the degree of pharmacologic"/>
   <result pre="disease, treatment options include foscarnet, cidofovir, CMV hyperimmune globulins, or" exact="leflunomide" post="[69]. Compartmentalized CMV disease refers to clinical syndromes wherein"/>
   <result pre="indicated for end organ disease and includes foscarnet, ganciclovir, and" exact="cidofovir" post="[86]. Varicella Zoster Virus Primary varicella infection is usually"/>
   <result pre="No specific therapy for adenovirus hepatitis is currently available, and" exact="cidofovir" post="has been recently suggested as an optional treatment [1]."/>
   <result pre="infectionHerpesviridae20112110.1186/2042-4280-2-121429244 12.LevitskyVMasucciMGManipulation of immune responses by Epstein-Barr virusVirus Res200288718610.1016/S0168-1702(02)00121-112297328 13.KagoyaYHangaishiATakahashiTImaiYKurokawaMHigh-dose" exact="dexamethasone" post="therapy for severe thrombocytopenia and neutropenia induced by EBV"/>
   <result pre="transplantationLancet20003552032610.1016/S0140-6736(00)02350-310885354 67.WalkerJKScholzLMScheetzMHGallonLGKaufmanDBRachwalskiEJAbecassisMMet al.Leukopenia complicates cytomegalovirus prevention after renal transplantation with" exact="alemtuzumab" post="inductionTransplantation2007838748210.1097/01.tp.0000257923.69422.4d17460557 68.HodsonEMJonesCAWebsterACStrippoliGFBarclayPGKableKVimalachandraDet al.Antiviral medications to prevent cytomegalovirus disease and"/>
   <result pre="in liver transplantation: a randomized trial comparing a combination of" exact="ganciclovir" post="and acyclovir to acyclovir. NIDDK Liver Transplantation DatabaseTransplantation199764667310.1097/00007890-199707150-000139233703 71.GaneESalibaFValdecasasGJO’GradyJPescovitzMDLymanSRobinsonCARandomised"/>
   <result pre="Transplantation DatabaseTransplantation199764667310.1097/00007890-199707150-000139233703 71.GaneESalibaFValdecasasGJO’GradyJPescovitzMDLymanSRobinsonCARandomised trial of efficacy and safety of oral" exact="ganciclovir" post="in the prevention of cytomegalovirus disease in liver-transplant recipients."/>
   <result pre="organ transplant recipientsClin Infect Dis2002358667210.1086/34238512228824 77.PayaCHumarADominguezEWashburnKBlumbergEAlexanderBFreemanRet al.Efficacy and safety of" exact="valganciclovir" post="vs. oral ganciclovir for prevention of cytomegalovirus disease in"/>
   <result pre="Infect Dis2002358667210.1086/34238512228824 77.PayaCHumarADominguezEWashburnKBlumbergEAlexanderBFreemanRet al.Efficacy and safety of valganciclovir vs. oral" exact="ganciclovir" post="for prevention of cytomegalovirus disease in solid organ transplant"/>
   <result pre="disease in solid organ transplant recipientsAm J Transplant200446112010.1111/j.1600-6143.2004.00382.x15023154 78.AsbergAHansenCNReubsaetLDetermination of" exact="ganciclovir" post="in different matrices from solid organ transplanted patients treated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7120516\results\search\drugs\results.xml">
   <result pre="from the substrate envelope. Similarly prolonged therapy against HBV with" exact="lamivudine" post="is associated with an increased incidence of viral resistance."/>
   <result pre="reduces viral burden in chronic HBV carriers. Long-term treatment with" exact="lamivudine" post="may, however, lead to resistance as the result of"/>
   <result pre="RNA-dependent DNA polymerase activity. It has similar therapeutic effects to" exact="lamivudine" post="and is responsible for the emergence of mutants usually"/>
   <result pre="B domain of the polymerase gene. However, mutants resistant to" exact="famciclovir" post="appear to be less common than those induced by"/>
   <result pre="famciclovir appear to be less common than those induced by" exact="lamivudine" post="(Pichoud et al. 1999). The X gene protein exhibits"/>
   <result pre="or antiviral nucleoside/nucleotide analogues such as lamivudine, adefovir dipivoxil, and" exact="ribavirin" post="(Marcellin et al. 2002; Chander et al. 2002) and"/>
   <result pre="et al. 2002; Chander et al. 2002) and IFN or" exact="lamivudine" post="alone can control hepatitis B in about one-third of"/>
   <result pre="et al. 2002; Liaw 2002). A combination of IFN with" exact="ribavirin" post="is standard therapy for hepatitis C and has resulted"/>
   <result pre="Liver diseases severity increases in C and D IFN and" exact="ribavirin" post="Farci and Purcell (2000) Genotype 1 and genotype 2"/>
   <result pre="via the JAK–STAT pathway; IFN-alpha-induced genes with antiviral properties, including" exact="adenosine" post="deaminase/eukaryotic translation initiation factor 2A-alpha kinase 2/NFKB1/myxovirus resistance 1/2′5′-oligoadenylate"/>
   <result pre="excellent agreement; 0.4 &amp;lt; kappa &amp;lt; 0.75, good agreement; kappa &amp;lt; 0.4, poor agreement Nevirapine and" exact="tipranavir" post="(Boehringer Ingelheim, http://www.boehringer-ingelheim.com) Saquinavir (Roche, http//www.roche.com) Amprenavir (Glaxo Wellcome,"/>
   <result pre="Adverse effects NRTIs Zidovudine Anemia, nausea, rash, myopathy, dyslipidemia Stavudine," exact="didanosine" post="Nausea, lipoatrophy, dyslipidemia, pancreatitis, lactic acidosis, hepatic steatosis Abacavir"/>
   <result pre="dyslipidemia, diarrhea, insulin resistance Atazanavir Jaundice, sclera icterus, nephrolithiasis Lopinavir," exact="fosamprenavir" post="Heart disease Integrase inhibitors Raltegravir Headache, insomnia, dizziness, fatigue"/>
   <result pre="analogue mutations. Associated with resistance to most nucleoside analogue except" exact="lamivudine" post="M41L, D67N In vitro cause high-level resistance to zidovudine"/>
   <result pre="except lamivudine M41L, D67N In vitro cause high-level resistance to" exact="zidovudine" post="and low-level resistance to stavudine, didanosine, and abacavir K70R,"/>
   <result pre="resistance to zidovudine and low-level resistance to stavudine, didanosine, and" exact="abacavir" post="K70R, L210W Segregate in two pathways, one comprising T215Y"/>
   <result pre="Pathway comprising T215Y and L210W associated with decreased responsiveness to" exact="tenofovir" post="M184V Observed in most viruses resistant to treatment with"/>
   <result pre="tenofovir M184V Observed in most viruses resistant to treatment with" exact="lamivudine" post="Confers high-level resistance to lamivudine in vitro Can interfere"/>
   <result pre="viruses resistant to treatment with lamivudine Confers high-level resistance to" exact="lamivudine" post="in vitro Can interfere with resistance to zidovudine and"/>
   <result pre="resistance to lamivudine in vitro Can interfere with resistance to" exact="zidovudine" post="and stavudine when the number of thymidine analogue mutations"/>
   <result pre="lamivudine in vitro Can interfere with resistance to zidovudine and" exact="stavudine" post="when the number of thymidine analogue mutations is small"/>
   <result pre="analogue mutations is small Increase the level of resistance to" exact="didanosine" post="and abacavir owing to thymidine analogue mutations Q151M Rare"/>
   <result pre="is small Increase the level of resistance to didanosine and" exact="abacavir" post="owing to thymidine analogue mutations Q151M Rare pathway for"/>
   <result pre="In vitro, cause high-level resistance to most nucleoside analogues except" exact="lamivudine" post="and tenofovir 69 Insertional mutations Insertion of two or"/>
   <result pre="cause high-level resistance to most nucleoside analogues except lamivudine and" exact="tenofovir" post="69 Insertional mutations Insertion of two or more amino"/>
   <result pre="all nucleoside analogues K65R Selected for by zalcitabine, abacavir, and" exact="tenofovir" post="therapy Y115F Selected for by abacavir therapy L74V Selected"/>
   <result pre="by zalcitabine, abacavir, and tenofovir therapy Y115F Selected for by" exact="abacavir" post="therapy L74V Selected for by didanosine therapy, usually when"/>
   <result pre="Y115F Selected for by abacavir therapy L74V Selected for by" exact="didanosine" post="therapy, usually when didanosine is the only nucleoside analogue"/>
   <result pre="abacavir therapy L74V Selected for by didanosine therapy, usually when" exact="didanosine" post="is the only nucleoside analogue Mutations conferring resistance to"/>
   <result pre="resistance to NNRTIs K103N Mutation most frequently selected for by" exact="efavirenz" post="therapy Occasionally selected for by nevirapine therapy Confers high-level"/>
   <result pre="frequently selected for by efavirenz therapy Occasionally selected for by" exact="nevirapine" post="therapy Confers high-level resistance to all available NNRTIs Y181C"/>
   <result pre="to all available NNRTIs Y181C Mutations most frequently selected by" exact="nevirapine" post="Y188C Confers high-level resistance to nevirapine but lower-level resistance"/>
   <result pre="most frequently selected by nevirapine Y188C Confers high-level resistance to" exact="nevirapine" post="but lower-level resistance to efavirenz Y108I Y188L, unlike Y188C,"/>
   <result pre="Y188C Confers high-level resistance to nevirapine but lower-level resistance to" exact="efavirenz" post="Y108I Y188L, unlike Y188C, seen mostly with efavirenz therapy"/>
   <result pre="resistance to efavirenz Y108I Y188L, unlike Y188C, seen mostly with" exact="efavirenz" post="therapy L100I, V106A, G190A, G190S Mutations that accumulate during"/>
   <result pre="with most protease inhibitors Mutation most frequently selected for by" exact="saquinavir" post="therapy V82A, V82T, V82F Common resistance mutations Can emerge"/>
   <result pre="with most protease inhibitors Mutations most frequently selected for by" exact="ritonavir" post="and indinavir therapy D30N Mutations most frequently selected for"/>
   <result pre="protease inhibitors Mutations most frequently selected for by ritonavir and" exact="indinavir" post="therapy D30N Mutations most frequently selected for by nelfinavir"/>
   <result pre="and indinavir therapy D30N Mutations most frequently selected for by" exact="nelfinavir" post="therapy N88D, N88S D30N always first L101, L10F, K20R,K20M,"/>
   <result pre="resistance to most protease inhibitors G48V Exclusively selected for by" exact="saquinavir" post="therapy Associated with high-level resistance to saquinavir L24I Emerges"/>
   <result pre="selected for by saquinavir therapy Associated with high-level resistance to" exact="saquinavir" post="L24I Emerges occasionally during failure of indinavir therapy Also"/>
   <result pre="high-level resistance to saquinavir L24I Emerges occasionally during failure of" exact="indinavir" post="therapy Also found with lopinavir therapy I47V, I50V Most"/>
   <result pre="Emerges occasionally during failure of indinavir therapy Also found with" exact="lopinavir" post="therapy I47V, I50V Most often selected for by amprenavir"/>
   <result pre="with lopinavir therapy I47V, I50V Most often selected for by" exact="amprenavir" post="therapy Also found with lopinavir therapy V32I, F53L Rare"/>
   <result pre="Most often selected for by amprenavir therapy Also found with" exact="lopinavir" post="therapy V32I, F53L Rare mutations Confer high-level resistance to"/>
   <result pre="analogues Same as nucleoside analogues K65 R impairs incorporation of" exact="tenofovir" post="into DNA thymidine analogue mutations often associated with cross-resistance"/>
   <result pre="into DNA thymidine analogue mutations often associated with cross-resistance to" exact="tenofovir" post="Tenofovir Nucleoside reverse transcriptase inhibitors Bind a hydrophobic pocket"/>
   <result pre="transcriptase and is the main mutation that confers resistance to" exact="lamivudine" post="(Boucher et al. 1993). Methionine 184 is located at"/>
   <result pre="a different side chain, interferes with the proper positioning of" exact="lamivudine" post="triphosphate within the catalytic site (Sarafianos et al. 1999)."/>
   <result pre="mutation induces very high levels of resistance to lamivudine. When" exact="lamivudine" post="is used as a single agent, resistant strains overtake"/>
   <result pre="in a few weeks (Schuurman et al. 1995), and when" exact="lamivudine" post="is used as part of a failing regimen of"/>
   <result pre="for in the course of the failure of regimens containing" exact="stavudine" post="and didanosine. This pathway always starts with the Q151M"/>
   <result pre="can confer high-level resistance to most but not all (e.g.," exact="lamivudine" post="and tenofovir) analogues (Iversen et al. 1996). Interestingly, the"/>
   <result pre="nucleoside or nucleotide analogues fails, especially when the regimen includes" exact="tenofovir" post="or abacavir. This mutation appears to confer resistance to"/>
   <result pre="failure of drug combinations that include thymidine analogues, such as" exact="zidovudine" post="and stavudine, but they can promote resistance to almost"/>
   <result pre="promote resistance to almost all nucleoside and nucleotide analogues, including" exact="tenofovir" post="(Larder and Kemp 1989; Picard et al. 2001). These"/>
   <result pre="most frequently are somewhat drug dependent (Table 28.12). Resistance to" exact="nevirapine" post="is often associated with the Y181C mutation, but other"/>
   <result pre="Y188C, K103N, G190A, and V106A, also occur. Initial resistance to" exact="efavirenz" post="is generally characterized by the K103N mutation, but the"/>
   <result pre="HR1 and blocks the infectivity of HIV-1. Viral resistance to" exact="enfuvirtide" post="usually results from mutations located in a stretch of"/>
   <result pre="probably explain the remarkably wide range of natural susceptibility to" exact="enfuvirtide" post="among HIV-1 strains (Derdeyn et al. 2001; Reeves et"/>
   <result pre="Gilead Sciences (Borroto-Esoda et al. 2004). Study FTC-301A compared once-daily" exact="emtricitabine" post="(Emtriva) to once-daily stavudine (Zerit), both combined with didanosine"/>
   <result pre="al. 2004). Study FTC-301A compared once-daily emtricitabine (Emtriva) to once-daily" exact="stavudine" post="(Zerit), both combined with didanosine (Videx) and efavirenz (Sustiva),"/>
   <result pre="once-daily emtricitabine (Emtriva) to once-daily stavudine (Zerit), both combined with" exact="didanosine" post="(Videx) and efavirenz (Sustiva), in 571 treatment-naïve patients from"/>
   <result pre="to once-daily stavudine (Zerit), both combined with didanosine (Videx) and" exact="efavirenz" post="(Sustiva), in 571 treatment-naïve patients from North America, Latin"/>
   <result pre="the incidence of virologic failure was 12 % in the" exact="stavudine" post="group and 5 % in the emtricitabine group. Among"/>
   <result pre="% in the stavudine group and 5 % in the" exact="emtricitabine" post="group. Among patients with drug-resistant virus at baseline, virologic"/>
   <result pre="at baseline, virologic failure occurred in 32 % of the" exact="stavudine" post="group and 13 % of the emtricitabine group. Mutations"/>
   <result pre="% of the stavudine group and 13 % of the" exact="emtricitabine" post="group. Mutations The K65R Mutation Perhaps the most widely"/>
   <result pre="In this study, 345 patients were randomized to receive either" exact="tenofovir" post="or efavirenz, combined with a fixed-dose combination tablet containing"/>
   <result pre="efavirenz, combined with a fixed-dose combination tablet containing 600 mg" exact="abacavir" post="and 300 mg lamivudine, all to be taken once"/>
   <result pre="5.4 % patients in the efavirenz-based arm. Tenofovir, abacavir, and" exact="lamivudine" post="can all select for the K65R mutation. Among 21"/>
   <result pre="10 (48 %) had the K65R mutation. Tenofovir, abacavir, and" exact="lamivudine" post="all exert concerted pressure on the 65 locus, and,"/>
   <result pre="is believed to be the primary mechanism of resistance to" exact="zidovudine" post="and stavudine, the process is not drug specific in"/>
   <result pre="drug binding and incorporation; there are data suggesting that concurrent" exact="zidovudine" post="use can prevent the emergence of the K65R mutation"/>
   <result pre="initiating therapy for the first time, tenofovir-inclusive regimens not involving" exact="zidovudine" post="were much more likely to fail in association with"/>
   <result pre="addition of a second protease inhibitor to a regimen containing" exact="amprenavir" post="(Agenerase) improved the 24-week response to salvage therapy (Mellors"/>
   <result pre="amprenavir. In addition, subjects were randomized to receive either placebo," exact="nelfinavir" post="(Viracept), saquinavir (Fortovase), or indinavir (Crixivan). There were no"/>
   <result pre="addition, subjects were randomized to receive either placebo, nelfinavir (Viracept)," exact="saquinavir" post="(Fortovase), or indinavir (Crixivan). There were no statistically significant"/>
   <result pre="randomized to receive either placebo, nelfinavir (Viracept), saquinavir (Fortovase), or" exact="indinavir" post="(Crixivan). There were no statistically significant differences between the"/>
   <result pre="common TAM pattern and is associated with high-level resistance to" exact="zidovudine" post="and with cross-resistance to other NRTIs, including tenofovir and"/>
   <result pre="resistance to zidovudine and with cross-resistance to other NRTIs, including" exact="tenofovir" post="and abacavir. In contrast, the D67N/K70R/K219Q pathway isolate is"/>
   <result pre="there was a substantial growth advantage in the presence of" exact="zidovudine" post="(Hu et al. 2004). Thus, it was concluded that"/>
   <result pre="T215Y pathway is more common and confers higher-level resistance to" exact="zidovudine" post="and other NRTIs, whereas viruses carrying T215F have lower"/>
   <result pre="confers a significant advantage to HIV in the presence of" exact="zidovudine" post="and that this mutation plays a much larger role"/>
   <result pre="mutation plays a much larger role in the development of" exact="zidovudine" post="resistance than is usually considered (Kuritzkes 2004). Perhaps the"/>
   <result pre="is M184V, which is known to cause high-level resistance to" exact="lamivudine" post="and emtricitabine. However, there have been studies suggesting that"/>
   <result pre="However, there have been studies suggesting that high-level resistance to" exact="lamivudine" post="does not necessarily mean that the drug is rendered"/>
   <result pre="terms of maintaining the less-fit virus. One more study discontinued" exact="lamivudine" post="in four highly treatment-experienced patients with no viable alternative"/>
   <result pre="us that, even in the presence of the M184V mutation," exact="lamivudine" post="was still contributing to HIV RNA suppression. Reversion of"/>
   <result pre="increase in viral load of 0.3 log10 copies/ml. Upon resuming" exact="lamivudine" post="therapy, the M184V mutation reappeared within 8 weeks in"/>
   <result pre="regimen, approximately half of the patients were randomized to continue" exact="lamivudine" post="therapy, with the remaining patients randomized to discontinue lamivudine"/>
   <result pre="continue lamivudine therapy, with the remaining patients randomized to discontinue" exact="lamivudine" post="treatment. Forty-eight weeks later, there were no significant differences"/>
   <result pre="in CYP2B6 signals a longer half-life and increased levels of" exact="efavirenz" post="(Haas et al. 2004). Other haplotypes within CYP2B6 have"/>
   <result pre="within CYP2B6 have been associated with a longer half-life for" exact="nevirapine" post="(Chantarangsu 2009). The genetic variant associated with Gilbert’s disease,"/>
   <result pre="genotype as a predictor of virological failure in patients receiving" exact="emtricitabine" post="once daily or stavudine twice daily in combination with"/>
   <result pre="of virological failure in patients receiving emtricitabine once daily or" exact="stavudine" post="twice daily in combination with didanosine and efavirenz [Abstract"/>
   <result pre="emtricitabine once daily or stavudine twice daily in combination with" exact="didanosine" post="and efavirenz [Abstract 672]. In: 11th conference on retroviruses"/>
   <result pre="daily or stavudine twice daily in combination with didanosine and" exact="efavirenz" post="[Abstract 672]. In: 11th conference on retroviruses and opportunistic"/>
   <result pre="Young RK, Johnson SC et al (2003) Antiviral activity of" exact="lamivudine" post="in persons infected with HIV-1 that has M184V and"/>
   <result pre="takeover of YMDD motif mutant hepatitis B virus during long-term" exact="lamivudine" post="therapy and re-takeover by wild type after cessation of"/>
   <result pre="open-label, multi-center trial to evaluate safety and efficacy of continued" exact="lamivudine" post="twice daily versus discontinuation of lamivudine in HIV-1-infected adults"/>
   <result pre="and efficacy of continued lamivudine twice daily versus discontinuation of" exact="lamivudine" post="in HIV-1-infected adults with virological failure on ongoing combination"/>
   <result pre="Rodriguez AE, Weinberg W et al (2003) Early non-response to" exact="tenofovir" post="DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized"/>
   <result pre="al (2003) Early non-response to tenofovir DF (TDF) + abacavir (ABC) and" exact="lamivudine" post="(3TC) in a randomized trial compared to efavirenz (EFV) + ABC"/>
   <result pre="(ABC) and lamivudine (3TC) in a randomized trial compared to" exact="efavirenz" post="(EFV) + ABC and 3TC: ESS30009[Abstract 1722a]. In: 43rd interscience conference"/>
   <result pre="genomics to emerging zoonotic viral diseasesPLoS Pathog2009510e100055719855817 HaasDRibaudoHKimRet al.Pharmacogenetics of" exact="efavirenz" post="and central nervous system side effectsAIDS2004182391240015622315 HannaGJD’AquilaRTClinical use of"/>
   <result pre="hepatitis B patients: a pilot studyHepatology2002361416142412447867 KleinTEet al.Estimation of the" exact="warfarin" post="dose with clinical and pharmacogenetic dataN Engl J Med200936075376419228618"/>
   <result pre="LarderBAKempSDMultiple mutations in HIV-1 reverse transcriptase confer high-level resistance to" exact="zidovudine" post="(AZT)Science1989246115511582479983 LarderBAKempSDHarriganPRPotential mechanism for sustained antiretroviral efficacy of AZT-3TC"/>
   <result pre="infectionJ Virol20057918116931170416140747 McHutchisonJGGordonSCSchiffERet al.Interferon alfa-2b alone or in combination with" exact="ribavirin" post="as initial treatment for chronic hepatitis C. Hepatitis Interventional"/>
   <result pre="human immunodeficiency virus type 1 isolates from patients treated with" exact="stavudine" post="and didanosine or zidovudine and lamivudineJ Infect Dis200118478178411517441 PichoudCSeigne`resBWangZTrepoCZoulimFTransient"/>
   <result pre="virus type 1 isolates from patients treated with stavudine and" exact="didanosine" post="or zidovudine and lamivudineJ Infect Dis200118478178411517441 PichoudCSeigne`resBWangZTrepoCZoulimFTransient selection of"/>
   <result pre="1 isolates from patients treated with stavudine and didanosine or" exact="zidovudine" post="and lamivudineJ Infect Dis200118478178411517441 PichoudCSeigne`resBWangZTrepoCZoulimFTransient selection of a hepatitis"/>
   <result pre="polymerase gene mutant associated with a decreased replication capacity and" exact="famciclovir" post="resistanceHepatology1999292302379862871 Pirmohamed M (2001) The pharmacogenomics of HIV therapy."/>
   <result pre="RamseyLBet al.Rare versus common variants in pharmacogenetics: SLCO1B1 variation and" exact="methotrexate" post="dispositionGenome Res2012221822147369 RauchAKutalikZDescombesPet al.Genetic variation in IL28B is associated"/>
   <result pre="persistence and cervical precancer/cancerPLoS One201274e3361922496757 SagreiyaHet al.Extending and evaluating a" exact="warfarin" post="dosing algorithm that includes CYP4F2 and pooled rare variants"/>
   <result pre="Acad Sci USA199996100271003210468556 SchapiroJMWintersMALawrenceJMeriganTCClinical cross-resistance between the HIV-1 protease inhibitors" exact="saquinavir" post="and indinavir and correlations with genotypic mutationsAIDS19991335936510199226 SchiffmanMCastlePEJeronimoJRodriguezACWacholderSHuman papillomavirus"/>
   <result pre="USA199996100271003210468556 SchapiroJMWintersMALawrenceJMeriganTCClinical cross-resistance between the HIV-1 protease inhibitors saquinavir and" exact="indinavir" post="and correlations with genotypic mutationsAIDS19991335936510199226 SchiffmanMCastlePEJeronimoJRodriguezACWacholderSHuman papillomavirus and cervical"/>
   <result pre="and appearance of drug-resistant virus populations in persons treated with" exact="lamivudine" post="(3TC)J Infect Dis1995171141114197539472 Shafer, R (2003) Human immunodeficiency virus"/>
   <result pre="al.First large, multicenter, open label study utilizing HLA-B*5701 screening for" exact="abacavir" post="hypersensitivity in North AmericaAIDS2008221673167518670229 StevensWHorsfieldPScottLEEvaluation of the performance of"/>
   <result pre="is associated with response to chronic hepatitis C interferon-alpha and" exact="ribavirin" post="therapyNat Genet200941101100110419749758 TanakaYNishidaNSugiyamaMet al.Genome-wide association of IL28B with response"/>
   <result pre="al.Genome-wide association of IL28B with response to pegylated interferon-a and" exact="ribavirin" post="therapy for chronic hepatitis CNat Genet20091011051111 ThioCLThomasDLInterleukin-28b: a key"/>
   <result pre="interferon alpha pathway genes and response to pegylated interferon-Alpha2a plus" exact="ribavirin" post="for treatment of chronic hepatitis C virus infection in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7120554\results\search\drugs\results.xml">
   <result pre="with cascade principle for treatment of animal diseases (e.g. acyclovir," exact="idoxuridine" post="and trifluridine against feline herpesvirus-1 ocular infection in cats)"/>
   <result pre="principle for treatment of animal diseases (e.g. acyclovir, idoxuridine and" exact="trifluridine" post="against feline herpesvirus-1 ocular infection in cats) (Thiry et"/>
   <result pre="infections in humans (Fenner et al. 2014). It is an" exact="adenosine" post="analogue that is converted by cellular enzymes to its"/>
   <result pre="is converted by cellular enzymes to its active intracellular derivate," exact="vidarabine" post="triphosphate. Obtained triphosphate form further acts as competitive inhibitor"/>
   <result pre="shown it to be less potent against feline herpesviruses than" exact="trifluridine" post="and idoxuridine (Nasisse 1990). In vitro activity has also"/>
   <result pre="to be less potent against feline herpesviruses than trifluridine and" exact="idoxuridine" post="(Nasisse 1990). In vitro activity has also been demonstrated"/>
   <result pre="upon which it gets rapidly metabolized to acyclovir. Acyclovir and" exact="entecavir" post="had the ability to block nucleic acid synthesis (Fig."/>
   <result pre="and Boyd 1996). Because of penciclovir’s poor oral bioavailability (&amp;lt;5%)," exact="famciclovir" post="was developed as the oral formulation (Salvaggio and Gnann"/>
   <result pre="the oral formulation (Salvaggio and Gnann 2017). The use of" exact="penciclovir" post="will be further described along with famciclovir. Famciclovir Famciclovir"/>
   <result pre="following oral administration, gets rapidly converted to its active metabolite" exact="penciclovir" post="by di-deacetylation and oxidation. However, the pharmacokinetics of penciclovir"/>
   <result pre="metabolite penciclovir by di-deacetylation and oxidation. However, the pharmacokinetics of" exact="penciclovir" post="and famciclovir in cats appears to be nonlinear (saturable)"/>
   <result pre="by di-deacetylation and oxidation. However, the pharmacokinetics of penciclovir and" exact="famciclovir" post="in cats appears to be nonlinear (saturable) and absorption"/>
   <result pre="by the observation that administration of the same doses of" exact="famciclovir" post="to cats and other species resulted in much lower"/>
   <result pre="plasma concentrations in cats (Thomasy et al. 2007). Thus, limited" exact="famciclovir" post="metabolism stems from deficiency of hepatic aldehyde oxidase enzyme"/>
   <result pre="deficiency of hepatic aldehyde oxidase enzyme in cats, which converts" exact="famciclovir" post="to its active form (Dick et al. 2005). Even"/>
   <result pre="to its active form (Dick et al. 2005). Even though" exact="famciclovir" post="has to be administered in high oral doses to"/>
   <result pre="mg famciclovir/kg to cats resulted in equivalent serum and tear" exact="penciclovir" post="concentrations, implying that 40 mg/kg is equally effective against"/>
   <result pre="higher dose (Thomasy et al. 2012). In rats and dogs," exact="famciclovir" post="absorption and metabolism appear to be similar to those"/>
   <result pre="previously reported in people, despite the observed slower conversion of" exact="famciclovir" post="to penciclovir in both species (Filer et al. 1994)."/>
   <result pre="in people, despite the observed slower conversion of famciclovir to" exact="penciclovir" post="in both species (Filer et al. 1994). Ribavirin As"/>
   <result pre="Ribavirin As first described by Witkowski et al. in 1972," exact="ribavirin" post="(1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a triazole nucleoside analogue that inhibits replication"/>
   <result pre="2007). It has several possible mechanisms of action. Firstly, as" exact="ribavirin" post="monophosphate, generated by adenosine kinase-mediated phosphorylation, it can indirectly"/>
   <result pre="possible mechanisms of action. Firstly, as ribavirin monophosphate, generated by" exact="adenosine" post="kinase-mediated phosphorylation, it can indirectly inhibit the synthesis of"/>
   <result pre="GTP to RNA polymerase (Riviere and Papich 2013). Orally administered" exact="ribavirin" post="has been shown to worsen the condition of cats"/>
   <result pre="infectious peritonitis virus (FIPV), treatment with neither free nor liposomal" exact="ribavirin" post="improved survival rate and, similarly to animals infected with"/>
   <result pre="(Riviere and Papich 2013; Weiss et al. 1993). Activity of" exact="ribavirin" post="has also been demonstrated against bovine viral diarrhoea virus,"/>
   <result pre="biological activities. Biologically active compounds such as vitamin B12, albendazole," exact="mebendazole" post="and thiabendazole contain a benzimidazole nucleus in their structure"/>
   <result pre="Biologically active compounds such as vitamin B12, albendazole, mebendazole and" exact="thiabendazole" post="contain a benzimidazole nucleus in their structure (Fig. 22.2)"/>
   <result pre="of benzimidazole derivatives are available in the market such as" exact="omeprazole" post="and rabeprazole used for gastric ulcers, telmisartan and candesartan"/>
   <result pre="derivatives are available in the market such as omeprazole and" exact="rabeprazole" post="used for gastric ulcers, telmisartan and candesartan for hypertension,"/>
   <result pre="market such as omeprazole and rabeprazole used for gastric ulcers," exact="telmisartan" post="and candesartan for hypertension, astemizole and mizolastine for allergic"/>
   <result pre="as omeprazole and rabeprazole used for gastric ulcers, telmisartan and" exact="candesartan" post="for hypertension, astemizole and mizolastine for allergic rhinitis, and"/>
   <result pre="rabeprazole used for gastric ulcers, telmisartan and candesartan for hypertension," exact="astemizole" post="and mizolastine for allergic rhinitis, and albendazole, oxibendazole and"/>
   <result pre="astemizole and mizolastine for allergic rhinitis, and albendazole, oxibendazole and" exact="mebendazole" post="for parasitosis (Wang et al. 2015). Benzimidazoles readily interact"/>
   <result pre="rifamycins isolated from bacteria, the most widely used derivative of" exact="rifampicin" post="(rifampin) is a semisynthetic rifamycin. Rifamycins are preferable as"/>
   <result pre="interacting with type II topoisomerase (Zakaryan and Revilla 2016). Rifampicin," exact="rifapentine" post="and rifabutin (Fig. 22.5) are semisynthetic and water-soluble derivatives"/>
   <result pre="type II topoisomerase (Zakaryan and Revilla 2016). Rifampicin, rifapentine and" exact="rifabutin" post="(Fig. 22.5) are semisynthetic and water-soluble derivatives of 3-formylrifamycin"/>
   <result pre="against a number of ailments. It is a synthetic second-generation" exact="tetracycline" post="derivative with immunomodulatory and anti-inflammatory action and widely used"/>
   <result pre="of acne, rheumatoid arthritis and UTIs. Potential antiviral action of" exact="minocycline" post="against human immunodeficiency virus, Japanese encephalitis virus and West"/>
   <result pre="to their antibacterial and anticancer activity. Particularly the antimalarial drugs" exact="chloroquine" post="and amodiaquine displayed activity against viruses like dengue virus,"/>
   <result pre="antibacterial and anticancer activity. Particularly the antimalarial drugs chloroquine and" exact="amodiaquine" post="displayed activity against viruses like dengue virus, West Nile"/>
   <result pre="and replication (Savoia 2016). On the other hand, the compound" exact="teicoplanin" post="isolated from an Actinobacteria member, Actinoplanes teichomyceticus, is a"/>
   <result pre="action through inhibiting bacterial cell wall biosynthesis. This semisynthetic glycopeptide" exact="teicoplanin" post="showed a significant inhibitory activity against Ebola envelope pseudotyped"/>
   <result pre="viruses in Vero cells when used in the clinic. Besides," exact="teicoplanin" post="and other glycopeptide antibiotics, including dalbavancin, oritavancin and telavancin,"/>
   <result pre="the clinic. Besides, teicoplanin and other glycopeptide antibiotics, including dalbavancin," exact="oritavancin" post="and telavancin, but not vancomycin, had inhibitory action against"/>
   <result pre="have been isolated from marine cyanobacteria. Marketed marine products include" exact="cytarabine" post="(Cytosar) for non-Hodgkin’s lymphoma, the antiviral vidarabine (Vira-A), ziconotide"/>
   <result pre="marine products include cytarabine (Cytosar) for non-Hodgkin’s lymphoma, the antiviral" exact="vidarabine" post="(Vira-A), ziconotide (Prialt) and trabectedin (Yondelis) (Demain 2014). Herbal"/>
   <result pre="include cytarabine (Cytosar) for non-Hodgkin’s lymphoma, the antiviral vidarabine (Vira-A)," exact="ziconotide" post="(Prialt) and trabectedin (Yondelis) (Demain 2014). Herbal Antiviral The"/>
   <result pre="for non-Hodgkin’s lymphoma, the antiviral vidarabine (Vira-A), ziconotide (Prialt) and" exact="trabectedin" post="(Yondelis) (Demain 2014). Herbal Antiviral The history of herbal"/>
   <result pre="with Ebola virus-like particle entry-blocking activity including the macrolide antibiotics" exact="azithromycin" post="and clarithromycin, which block bacterial protein synthesis (Kouznetsova et"/>
   <result pre="methyltransferase inhibitor and repurposed drugs. Repurposed drugs such as chloroquine," exact="azithromycin" post="and niclosamide are used for the treatment of Zika"/>
   <result pre="and repurposed drugs. Repurposed drugs such as chloroquine, azithromycin and" exact="niclosamide" post="are used for the treatment of Zika virus infection"/>
   <result pre="with Zika virus infection. Therefore, blocking of NMDAR channels with" exact="memantine" post="and/or other antagonists helps to lessen the neuronal damage"/>
   <result pre="that possess antiviral properties, such as indoleamine 2,3-dioxygenase and inducible" exact="nitric oxide" post="synthase (Moraes et al. 2007). One of the most"/>
   <result pre="nucleotide analogues have been reported for topical administration, such as" exact="vidarabine" post="that affects DNA polymerase and subsequently disrupts DNA synthesis,"/>
   <result pre="vidarabine that affects DNA polymerase and subsequently disrupts DNA synthesis," exact="trifluridine" post="which acts as a fluorinated nucleoside analogue of thymidine"/>
   <result pre="which acts as a fluorinated nucleoside analogue of thymidine and" exact="cidofovir" post="which is a cytosine analogue acting on two host-mediated"/>
   <result pre="the enzyme (Hartmann et al. 2015). The first among them," exact="zidovudine" post="(AZT), has been reported to improve the immunologic and"/>
   <result pre="marrow suppression (Hartmann 1998). Another drug acting as RTI is" exact="stavudine" post="that has been shown to be active against FIV"/>
   <result pre="FIV in vitro, however with many resistant strains arisen. Similarly," exact="didanosine" post="and lamivudine have shown potency against FIV in in"/>
   <result pre="vitro, however with many resistant strains arisen. Similarly, didanosine and" exact="lamivudine" post="have shown potency against FIV in in vitro conditions"/>
   <result pre="vitro conditions (Schwartz et al. 2014). Additionally, a combination of" exact="zidovudine" post="and lamivudine has been investigated, resulting in synergistic anti-FIV"/>
   <result pre="(Schwartz et al. 2014). Additionally, a combination of zidovudine and" exact="lamivudine" post="has been investigated, resulting in synergistic anti-FIV effects in"/>
   <result pre="of infected cats (de Mari et al. 2004). Idoxuridine and" exact="trifluridine" post="are structurally similar thymidine analogues that inhibit synthesis of"/>
   <result pre="(Collinson et al. 1994). It has also been reported that" exact="idoxuridine" post="in the concentration of 0.1% and 0.3% trifluridine can"/>
   <result pre="reported that idoxuridine in the concentration of 0.1% and 0.3%" exact="trifluridine" post="can limit the viral replication but do not kill"/>
   <result pre="clinical trialsNat Prod Rep200825347551610.1039/b514294f18497896 CanonicoPGEfficacy, toxicology and clinical applications of" exact="ribavirin" post="against virulent RNA viral infectionsAntivir Res19855758110.1016/S0166-3542(85)80011-53160302 ChenJJet al.Synthesis and"/>
   <result pre="recombinant feline interferon omegaRes Vet Sci201599879510.1016/j.rvsc.2015.02.00825747956 LeelaSLet al.Drug repurposing of" exact="minocycline" post="against dengue virus infectionBiochem Biophys Res Commun2016478141041610.1016/j.bbrc.2016.07.02927396621 LiuYet al.Identification"/>
   <result pre="MalikRet al.Treatment of feline herpesvirus-1 associated disease in cats with" exact="famciclovir" post="and related drugsJ Feline Med Surg2009111404810.1016/j.jfms.2008.11.01219154974 MaoJ-HRobishawEEOverbyLInhibition of DNA"/>
   <result pre="2, 5, 6-trichloro-1-(β-D-ribofuranosyl) benzimidazoleJ Med Chem19984181252126210.1021/jm970559i9548815 PoveyREffect of orally administered" exact="ribavirin" post="on experimental feline calicivirus infection in catsAm J Vet"/>
   <result pre="diseases2013St LouisElsevier5465 SzaboCBissellMJCalvinMInhibition of infectious Rous sarcoma virus production by" exact="rifamycin" post="derivativeJ Virol197618244545358073 SzymańskiPMarkowiczMMikiciuk-OlasikEAdaptation of high-throughput screening in drug discovery—toxicological"/>
   <result pre="and emerging strategiesNat Rev Drug Discov2002186710.1038/nrd93712415247 TeHSRandallGJensenDMMechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterol Hepatol200733218 ThiryEet"/>
   <result pre="feline herpesvirus type 1Vet Ophthalmol20161911913010.1111/vop.1237527091747 ThomasySMet al.Pharmacokinetics and safety of" exact="penciclovir" post="following oral administration of famciclovir to catsAm J Vet"/>
   <result pre="ThomasySMet al.Pharmacokinetics and safety of penciclovir following oral administration of" exact="famciclovir" post="to catsAm J Vet Res200768111252125810.2460/ajvr.68.11.125217975982 ThomasySMet al.Pharmacokinetics of famciclovir"/>
   <result pre="of famciclovir to catsAm J Vet Res200768111252125810.2460/ajvr.68.11.125217975982 ThomasySMet al.Pharmacokinetics of" exact="famciclovir" post="and penciclovir in tears following oral administration of famciclovir"/>
   <result pre="to catsAm J Vet Res200768111252125810.2460/ajvr.68.11.125217975982 ThomasySMet al.Pharmacokinetics of famciclovir and" exact="penciclovir" post="in tears following oral administration of famciclovir to cats:"/>
   <result pre="of famciclovir and penciclovir in tears following oral administration of" exact="famciclovir" post="to cats: a pilot studyVet Ophthalmol201215529930610.1111/j.1463-5224.2011.00984.x22339892 TomeiLet al.Mechanism of"/>
   <result pre="review (2013–2014)Expert Opin Ther Pat201525559561210.1517/13543776.2015.101598725887338 WeissRCoxNMartinezMEvaluation of free or liposome-encapsulated" exact="ribavirin" post="for antiviral therapy of experimentally induced feline infectious peritonitisRes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7120890\results\search\drugs\results.xml">
   <result pre="of capsid (amantadine derivatives, pleconaril), replication (reverse transcriptase inhibitors like" exact="zidovudine" post="or abacavir, nevirapine, etc.), integrase inhibitors, DNA or RNA"/>
   <result pre="proteinase involved in viral polyprotein precursors and assembly/maturation inhibitors (indinavir," exact="ritonavir" post="and rimantadine, etc.). Based on this strategy, numerous compounds"/>
   <result pre="formazan product. After removal of the medium, 100 μl of" exact="dimethyl sulfoxide" post="(DMSO) is added to dissolve the formazan crystals. After"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7120914\results\search\drugs\results.xml">
   <result pre="and kills the parasite just like the famous antimalarial drug" exact="chloroquine" post="(Orjih et al. 1981; Kayembe et al. 2012). Hemin"/>
   <result pre="against the W2 strain of , which is resistant to" exact="chloroquine" post="(Boyom et al. 2010). Of particular interest is the"/>
   <result pre="inhibiting the neuronal uptake of mood regulators such as serotonin," exact="dopamine" post="and norepinephrine. In addition, it also has its own"/>
   <result pre="variations of this drug are used now in chemotherapy —conventional" exact="paclitaxel" post="and albumin-bound paclitaxel (see footnote 13). The advantage of"/>
   <result pre="drug are used now in chemotherapy —conventional paclitaxel and albumin-bound" exact="paclitaxel" post="(see footnote 13). The advantage of the latter is"/>
   <result pre="However due to the slow growing nature of yew tree," exact="paclitaxel" post="nowadays is produced by coalescing the products of endophytic"/>
   <result pre="BoissJ Med Plant Res200935413419 AlqareerAet al.The effect of clove and" exact="benzocaine" post="versus placebo as topical anestheticsJ Dent2006341074775010.1016/j.jdent.2006.01.00916530911 Appleton, J. &quot;Lavender"/>
   <result pre="acute bronchitis: a placebo-controlled double-blind trialCough2013912510.1186/1745-9974-9-2524261680 FormanLJet al.Diabetes induced by" exact="streptozocin" post="results in a decrease in immunoreactive beta-endorphin levels in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7121112\results\search\drugs\results.xml">
   <result pre="infection with the hepatitis B virus are lamivudine, adefovir, telbivudine," exact="tenofovir" post="and entecavir. One mutation, called the YMDD motive, is"/>
   <result pre="now has been replaced by other more potent antivirals, like" exact="entecavir" post="and tenofovir. Entecavir, however, is less effective in patients"/>
   <result pre="is less effective in patients who have been pretreated with" exact="lamivudine" post="and who carry the YMDD variant of hepatitis B."/>
   <result pre="assay, but sequence-based assays have also been developed. First-generation protease-inhibitors" exact="telaprevir" post="and boceprevir are active against hepatitis C genotype 1,"/>
   <result pre="sequence-based assays have also been developed. First-generation protease-inhibitors telaprevir and" exact="boceprevir" post="are active against hepatitis C genotype 1, but they"/>
   <result pre="patients that receive treatment with acyclovir, or similar medications like" exact="valaciclovir" post="and famciclovir, become resistant. Up to 95% of resistance"/>
   <result pre="in UL54 are associated with higher levels of resistance to" exact="ganciclovir" post="or cross-resistance to cidofovir or foscarnet. Influenza Virus Influenza"/>
   <result pre="with higher levels of resistance to ganciclovir or cross-resistance to" exact="cidofovir" post="or foscarnet. Influenza Virus Influenza is a member of"/>
   <result pre="treatment. Most influenza A and B strains are sensitive to" exact="oseltamivir" post="and zanamivir, two neuraminidase inhibitors. Occasionally, resistant strains are"/>
   <result pre="long-term treatment of influenza infection in immunocompromised patients. Resistance to" exact="oseltamivir" post="has also been reported during the 2007–2008-winter season, due"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7121811\results\search\drugs\results.xml">
   <result pre="good ARV activity with nonsevere toxic effects in comparison with" exact="nevirapine" post="as the standard drug in positive control group (Ardestani"/>
   <result pre="use was summarized by Gao et al. (2018). For example," exact="tenofovir" post="(TFV) alafenamide and elvitegravir (EVG) loaded NPs subcutaneously administered"/>
   <result pre="Gao et al. (2018). For example, tenofovir (TFV) alafenamide and" exact="elvitegravir" post="(EVG) loaded NPs subcutaneously administered to female humanized CD34+-NSG"/>
   <result pre="Jiang et al. (2015) incorporated ARV drugs maraviroc, etravirine, and" exact="raltegravir" post="into poly(lactic-co-glycolic) acid (PLGA) NPs and found that ARV"/>
   <result pre="in vitro was estimated mainly for ARV NPs combinations involving" exact="etravirine" post="NPs, whereby the combinations that showed large dose-reduction were"/>
   <result pre="a biodegradable carrier for loading with TFV in combination with" exact="efavirenz" post="or saquinavir, which resulted in pronounced combination drug effects,"/>
   <result pre="(0.01861 and 0.033 μg/mL, respectively) and showed comparable activity with" exact="emtricitabine" post="solution. Based on prolonged intracellular drug concentration and inhibition"/>
   <result pre="and reduced toxicity of ARV bioactives. Surface-functionalized mannosylated-PLGA NPs of" exact="lamivudine" post="(LVD) administered by intravenous route in a dose of"/>
   <result pre="(MP) delivery system (NiMDS) comprised of pure NPs of the" exact="darunavir" post="(DRV) and its boosting agent ritonavir (RTV) encapsulated within"/>
   <result pre="pure NPs of the darunavir (DRV) and its boosting agent" exact="ritonavir" post="(RTV) encapsulated within film-coated MPs was reported, in which"/>
   <result pre="succinate derivatives of NRTIs with cholesteryl-ε-polylysine nanogels. Nanogel conjugates of" exact="zidovudine" post="(ZDV), LVD, and abacavir demonstrated tenfold suppression of reverse"/>
   <result pre="with cholesteryl-ε-polylysine nanogels. Nanogel conjugates of zidovudine (ZDV), LVD, and" exact="abacavir" post="demonstrated tenfold suppression of reverse transcriptase activity in HIV-infected"/>
   <result pre="constructed CD4-targeted SLNPs providing selective binding and efficient delivery of" exact="indinavir" post="to CD4+-HIV host cells (whereby inclusion of PEG in"/>
   <result pre="use in HIV/AIDS therapy (Joshy et al. 2018b). ZDV-loaded core-shell" exact="dextran" post="hybrid nanosystem expressed enhanced cellular internalization of drug-loaded hybrid"/>
   <result pre="Retained intracytoplasmic nanoformulations consisting of a hydrophobic and lipophilic modified" exact="dolutegravir" post="prodrug encapsulated into poloxamer released the drug from macrophages"/>
   <result pre="of a hydrophobic and lipophilic modified dolutegravir prodrug encapsulated into" exact="poloxamer" post="released the drug from macrophages and suppressed viral replication"/>
   <result pre="the living cells (Amirkhanov et al. 2015). SeNPs decorated by" exact="ribavirin" post="(RBV), a broad-spectrum antiviral drug, protected cells during H1N1"/>
   <result pre="(Tang et al. 2018). Biomimetic supramolecular hexagonal-shaped nanoassemblies composed of" exact="chondroitin sulfate" post="formed by mixing hydrophobically modified chondroitin sulfate with α-cyclodextrin"/>
   <result pre="nanoassemblies composed of chondroitin sulfate formed by mixing hydrophobically modified" exact="chondroitin sulfate" post="with α-cyclodextrin in water showed improved antiviral activity against"/>
   <result pre="showed improved antiviral activity against HSV-2 compared to hydrophobically modified" exact="chondroitin sulfate" post="(Galus et al. 2016). ACV was found to increasingly"/>
   <result pre="C (Hang et al. 2015). Multifunctional SeNPs with baicalin and" exact="folic acid" post="surface-modifications designed for the targeted treatment of HBV-infected liver"/>
   <result pre="immune responses (Yang et al. 2016b). HBsAg-loaded trimethyl CS (TMC)/hydroxypropyl" exact="methylcellulose" post="(hypromellose) phthalate (HPMCP) NPs with particle size of 158"/>
   <result pre="delivery system prepared by conjugating the liver-targeting peptide to PEGylated" exact="cyclosporine" post="A-encapsulated PLGA NPs effectively inhibited viral replication in vitro"/>
   <result pre="in mice and non-human primatesNPJ Vaccines201834610.1038/s41541-018-0086-030302284 BelgamwarAKhanSYeolePIntranasal chitosan-g-HPβCD nanoparticles of" exact="efavirenz" post="for the CNS targetingArtif Cells Nanomed Biotechnol20184637438610.1080/21691401.2017.131326628423949 BernasconiVBernocchiBYeLLeMQOmokanyeACarpentierRSchonKSaelensXStaeheliPBetbederDLyckeNPorous nanoparticles"/>
   <result pre="doseProc Natl Acad Sci U S A2016113E4133E414210.1073/pnas.160029911327382155 ChaowanachanTKrogstadEBallCWoodrowKADrug synergy of" exact="tenofovir" post="and nanoparticle-based antiretrovirals for HIV prophylaxisPLoS One20138e6141610.1371/journal.pone.006141623630586 ChatziprodromidouIPArvanitidouMGuitianJApostolouTVantarakisGApostolos VantarakisAGlobal"/>
   <result pre="type 1Bioconjug Chem2017281115112210.1021/acs.bioconjchem.7b0003028177606 DesaiJThakkarHEnhanced oral bioavailability and brain uptake of" exact="darunavir" post="using lipid nanoemulsion formulationColloids Surf B: Biointerfaces201917514314910.1016/j.colsurfb.2018.11.05730529999 DeyPBergmannTCuellar-CamachoJLEhrmannSChowdhuryMSZhangMZDahmaniIHaagRAzadWMultivalent flexible"/>
   <result pre="disease and H9N2 AI virusesVet World20171018719310.14202/vetworld.2017.187-19328344402 EndsleyANHoRJYEnhanced anti-HIV efficacy of" exact="indinavir" post="after inclusion in CD4-targeted lipid nanoparticlesJ Acquir Immune Defic"/>
   <result pre="3Int J Nanomedicine201384303431424235828 GaldieroSFalangaAVitielloMCantisaniMMarraVGaldieroMSilver nanoparticles as potential antiviral agentsMolecules2011168894891810.3390/molecules1610889422024958 GalusAMalletJMLemboDCagnoVDjabourovMLortat-JacobHBouchemalKHexagonal-shaped" exact="chondroitin sulfate" post="self-assemblies have exalted anti-HSV-2 activityCarbohydr Polym201613611312010.1016/j.carbpol.2015.08.05426572336 GaoYKraftJCYuDHoRJYRecent developments of"/>
   <result pre="against HIV infection in the brainNanomedicine20141017718510.1016/j.nano.2013.06.01223845925 GongYuqingChowdhuryPallabitaMiddeNarasimha M.RahmanMohammad A.YallapuMurali M.KumarSantoshNovel" exact="elvitegravir" post="nanoformulation approach to suppress the viral load in HIV-infected"/>
   <result pre="for the formulation and optimization of solid lipid nanoparticles of" exact="efavirenz" post="by high pressure homogenization using design of experiments for"/>
   <result pre="transmitted infection—an updateMicrobial Cell2016342043710.15698/mic2016.09.52728357379 IshiharaTKanekoKIshiharaTMizushimaTDevelopment of biodegradable nanoparticles for liver-specific" exact="ribavirin" post="deliveryJ Pharm Sci20141034005401110.1002/jps.2421925335768 IshwaryaRVaseeharanBAnuradhaRRekhaRGovindarajanMAlharbiNSKadaikunnanSKhaledJMBenelliGEco-friendly fabrication of Ag nanostructures using"/>
   <result pre="and nanoparticle vaccines against the respiratory syncytial virusVaccine201644510.3390/vaccines4040045 JoshyKSAlexSMSnigdhaSKalarikkalNPothenLAThomasSEncapsulation of" exact="zidovudine" post="in PF-68 coated alginate conjugate nanoparticles for anti-HIV drug"/>
   <result pre="nanoparticles for anti viral drug deliveryChem Phys Lipids2018210828910.1016/j.chemphyslip.2017.11.00329129570 JoshyKSGeorgeASnigdhaSJosephBKalarikkalNPothenLAThomasSNovel core-shell" exact="dextran" post="hybrid nanosystem for anti-viral drug deliveryMater Sci Eng C"/>
   <result pre="carboxy methyl cellulose and compritol-PEG for antiretroviral drug deliveryCellulose2017244759477110.1007/s10570-017-1446-z JyothiKRBeloorJJoAMinhNNChoiTGKimJHAkterSLeeSKMaengCHBaikHHKangIHaJKimSSLiver-targeted" exact="cyclosporine" post="A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus"/>
   <result pre="of influenza infectionVet Sci201857110.3390/vetsci50300716165133 KumarPLakshmiYSBhaskarCGollaKKondapiAKImproved safety, bioavailability and pharmacokinetics of" exact="zidovudine" post="through lactoferrin nanoparticles during oral administration in ratsPLoS One201510e014039910.1371/journal.pone.014039926461917"/>
   <result pre="transcriptase inhibitory potentialJ Clust Sci20172835936710.1007/s10876-016-1100-1 KumarPLakshmiYSKondapiAKTriple drug combination of zidovudine," exact="efavirenz" post="and lamivudine loaded lactoferrin nanoparticles: an effective nano first-line"/>
   <result pre="potentialJ Clust Sci20172835936710.1007/s10876-016-1100-1 KumarPLakshmiYSKondapiAKTriple drug combination of zidovudine, efavirenz and" exact="lamivudine" post="loaded lactoferrin nanoparticles: an effective nano first-line regimen for"/>
   <result pre="of H1N1 influenza virus infection by selenium nanoparticles loaded with" exact="ribavirin" post="via resisting caspase-3 apoptotic pathwayInt J Nanomedicine2018135787579710.2147/IJN.S17765830310281 LuLSunRWYChenRHuiCKHoCMLukJMLauGKKCheCMSilver nanoparticles"/>
   <result pre="treatment of HIV infectionAntimicrob Agents Chemother201761e01475e0141610.1128/AAC.01475-1627821449 MandalSPrathipatiPKKangGBZhouYYuanZFanWJLiQSDestacheCJTenofovir alafenamide and and" exact="elvitegravir" post="loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmissionAIDS20173146947610.1097/QAD.000000000000134928121666"/>
   <result pre="Biol Rev20056946250010.1128/MMBR.69.3.462-500.200516148307 PrathipatiPKMandalSPonGVivekanandanRDestacheCJPharmacokinetic and tissue distribution profile of long acting" exact="tenofovir" post="alafenamide and elvitegravir loaded nanoparticles in humanized mice modelPharm"/>
   <result pre="and tissue distribution profile of long acting tenofovir alafenamide and" exact="elvitegravir" post="loaded nanoparticles in humanized mice modelPharm Res2017342749275510.1007/s11095-017-2255-728905173 QiMZhangXESunXXZhangXWYaoYFLiuSLChenZLiWZhangZPChenJJCuiZIntranasal nanovaccine"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7121845\results\search\drugs\results.xml">
   <result pre="and HSP60). Interestingly, heme oxygenase-1, vascular endothelial growth factor and" exact="nitric oxide" post="level were also increased in Hippophae salicifolia pretreated rats"/>
   <result pre="prophylactically along with tab aspirin 150 mg once daily, tab" exact="pentoxifylline" post="400 mg and tab vit C 500 mg three"/>
   <result pre="properties and has been shown to be way better than" exact="silver sulfadiazine" post="and other iodine-based ointments. The safety and toxicological studies"/>
   <result pre="and has been shown to be way better than silver" exact="sulfadiazine" post="and other iodine-based ointments. The safety and toxicological studies"/>
   <result pre="back thousands of years. Catha (khat) contains a monoaminealkaloid –" exact="cathinone" post="(an amphetamine-like stimulant), which causes excitement, appetite loss and"/>
   <result pre="use as a precursor for the semi-synthetic anticancer drugs etoposide," exact="teniposide" post="and etopophos and other antiarthritic drugs. These drugs and"/>
   <result pre="tannins supported anti-adhesion, anti-quorum sensing and anti-biofilm potential activities. Besides," exact="nitric oxide" post="and superoxide scavenging activity correlated with anti-quorum sensing activity."/>
   <result pre="meropenem, colistin and augmentin. The lead combination of PTRC-31911-A + ertapenem or" exact="meropenem" post="showed maximum augmentative potential at a dose of 50"/>
   <result pre="that the antibacterial combinations of PTRC-31911-A and ertapenem, meropenem, colistin," exact="tigecycline" post="or augmentin are more effective than monotherapy with either"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7122247\results\search\drugs\results.xml">
   <result pre="(Turk 2006), as well as the neprilysin (enkephalinase) inhibitor prodrugs" exact="sacubitril" post="(Howell and Cameron 2016) and racecadotril (acetorphan) target Zn2+-dependent"/>
   <result pre="and racecadotril (acetorphan) target Zn2+-dependent metalloproteases. The ACE blockers and" exact="sacubitril" post="are suitable for long-term usage as antihypertensive drugs, whereas"/>
   <result pre="synthetic inhibitors of the trypsin-like serine proteases (TLSP) thrombin (argatroban," exact="dabigatran" post="etexilate, bivalirudin) and factor Xa (rivaroxaban, apixaban, edoxaban, betrixaban)"/>
   <result pre="to an enhanced insulin secretion (Scheen 2015). The proteasome inhibitors" exact="bortezomib" post="(Adams 2004) and carfilzomib (Kortuem and Stewart 2013) are"/>
   <result pre="secretion (Scheen 2015). The proteasome inhibitors bortezomib (Adams 2004) and" exact="carfilzomib" post="(Kortuem and Stewart 2013) are used in patients with"/>
   <result pre="approved drugs targeting threonine proteases. Meanwhile, two additional proteasome inhibitors," exact="ixazomib" post="and oprozomib, obtained orphan drug status (Manasanch and Orlowski"/>
   <result pre="antiviral strategy was supported by studies with the broad-spectrum inhibitor" exact="aprotinin" post="(1) in mice (Ovcharenko and Zhirnov 1994; Zhirnov et"/>
   <result pre="trypsin is shown in Fig. 11.1. Fig. 11.1 Structure of" exact="aprotinin" post="(1) in complex with trypsin (PDB, 3FP6). Trypsin is"/>
   <result pre="(PDB, 3FP6). Trypsin is shown with its surface in beige," exact="aprotinin" post="as cartoon in green. Only the aprotinin residues in"/>
   <result pre="surface in beige, aprotinin as cartoon in green. Only the" exact="aprotinin" post="residues in direct contact to the trypsin surface (Pro13-Cys-Lys-Ala-Arg17"/>
   <result pre="after reexposure (Levy and Adkinson 2008). However, the application of" exact="aprotinin" post="against influenza in form of an aerosol at significantly"/>
   <result pre="minimize side effects (Zhirnov et al. 2011). In addition, an" exact="aprotinin" post="variant with stronger kallikrein and similar plasmin inhibition has"/>
   <result pre="the secretory pathway. Despite this limitation, an aerosol formulation of" exact="aprotinin" post="has been developed and approved in Russia for the"/>
   <result pre="et al. 2010, 2013). This suggests that small amounts of" exact="aprotinin" post="can reach intracellular targets and achieve an antiviral efficacy"/>
   <result pre="used for the development of the orally available thrombin inhibitor" exact="ximelagatran" post="(Gustafsson et al. 2004). The conversion of the P1-amidine"/>
   <result pre="due to the discovery of more suited non-covalent inhibitors, like" exact="melagatran" post="containing the 4-Amba residue. The arginal derivative 14 acylated"/>
   <result pre="1999) (WX-UK1, Fig. 11.9) in combination with the 5-fluorouracil prodrug" exact="capecitabine" post="reached clinical development for tumor therapy (Setyono-Han et al."/>
   <result pre="et al. 2013), respectively. Surprisingly, also the mucolytic cough suppressant" exact="bromhexine" post="30 was described as TMPRSS2 inhibitor (IC50 = 0.75"/>
   <result pre="plasmin. Further modification of the P3 position by tert-leucine or" exact="penicillamine" post="provided inhibitors with enhanced potencies (Becker et al. 2011;"/>
   <result pre="Podsiadlo et al. 2004; Sielaff et al. 2011b) Furthermore, furin-inhibiting" exact="dicoumarol" post="derivatives could be identified by HTS. Some of these"/>
   <result pre="Sci20119915010.1016/B978-0-12-385504-6.00001-421238933 ApelerHPetersJSchröderWSchneiderKHLemmGHinzVRossouwGJDembowskyKExpression, purification, biochemical and pharmacological characterization of a recombinant" exact="aprotinin" post="variantArzneimittelforschung20045448349715460216 AscenziPBocediABolognesiMSpallarossaAColettaMDe CristofaroRMenegattiEThe bovine basic pancreatic trypsin inhibitor (Kunitz"/>
   <result pre="protease inhibitorsJ Enzyme Inhib Med Chem20132846847810.3109/14756366.2011.65146622380780 FergussonDAHebertPCMazerCDFremesSMacAdamsCMurkinJMTeohKDukePCArellanoRBlajchmanMAet al.A comparison of" exact="aprotinin" post="and lysine analogues in high-risk cardiac surgeryN Engl J"/>
   <result pre="its receptor CD26Nature201350022723110.1038/nature1232823831647 LuYHardesKDahmsSOBöttcher-FriebertshäuserESteinmetzerTThanMEKlenkHDGartenWPeptidomimetic furin inhibitor MI-701 in combination with" exact="oseltamivir" post="and ribavirin efficiently blocks propagation of highly pathogenic avian"/>
   <result pre="CD26Nature201350022723110.1038/nature1232823831647 LuYHardesKDahmsSOBöttcher-FriebertshäuserESteinmetzerTThanMEKlenkHDGartenWPeptidomimetic furin inhibitor MI-701 in combination with oseltamivir and" exact="ribavirin" post="efficiently blocks propagation of highly pathogenic avian influenza viruses"/>
   <result pre="of highly pathogenic avian influenza viruses and delays high level" exact="oseltamivir" post="resistance in MDCK cellsAntiviral Res20151208910010.1016/j.antiviral.2015.05.00626022200 LucasJMHeinleinCKimTHernandezSAMalikMSTrueLDMorrisseyCCoreyEMontgomeryBMostaghelEet al.The androgen-regulated protease"/>
   <result pre="and reduction of primary tumour growth by the small synthetic" exact="urokinase" post="inhibitor WX-UK1Thromb Haemost20059377978615841327 ShiratoKazuyaKanouKazuhikoKawaseMiyukiMatsuyamaShutokuClinical Isolates of Human Coronavirus 229E"/>
   <result pre="Med Chem1997403091309910.1021/jm960668h9301673 StürzebecherJViewegHSteinmetzerTSchweinitzAStubbsMTRenatusMWikströmP3-Amidinophenylalanine-based inhibitors of urokinaseBioorg Med Chem Lett199993147315210.1016/S0960-894X(99)00541-710560742 StürzebecherJSchweinitzASchmalixWAWikströmPSynthetic" exact="urokinase" post="inhibitors as potential anti-invasive drugsIDrugs2001467768316001312 SwedbergJEHarrisJMPlasmin substrate binding site"/>
   <result pre="complex with Sunflower trypsin inhibitor-1BMC Struct Biol2011113010.1186/1472-6807-11-3021693064 ZeslawskaESchweinitzAKarcherASondermannPSperlSStürzebecherJJacobUCrystals of the" exact="urokinase" post="type plasminogen activator variant beta(c)-uPAin complex with small molecule"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7122610\results\search\drugs\results.xml">
   <result pre="use compulsory license Oseltamivir phosphate Taiwan Compulsory license CD-R and" exact="oseltamivir" post="phosphate Brazil In 2005, Brazil began negotiations to issue"/>
   <result pre="of those receiving ARV treatment in Brazil will be using" exact="efavirenz" post="by the end of 2007. Efavirenz (in tablets of"/>
   <result pre="threatened Merck with a compulsory license unless Brazil could sell" exact="efavirenz" post="at a rate equal to or less than the"/>
   <result pre="[18, 19], the Thai government issued a compulsory license for" exact="efavirenz" post="on December 6, 2006, and began the local production"/>
   <result pre="nationwide anthrax scare in USA resulting in rising demands for" exact="ciprofloxacin" post="(Cipro). Anecdotally, many health professionals believe that &quot;it is"/>
   <result pre="cost of the ARV drugs. For instance, the price of" exact="lamivudine" post="(3TC) could be reduced to one-tenth of the current"/>
   <result pre="reduced to one-tenth of the current price in China and" exact="nevirapine" post="to one-tenth of its international price. Trizivir would only"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7122614\results\search\drugs\results.xml">
   <result pre="contained the His275Tyr mutation and were therefore highly resistant to" exact="oseltamivir" post="while retaining susceptibility to zanamivir. All currently circulating A/H1N1"/>
   <result pre="acids in the M2 gene result in cross-resistance to both" exact="amantadine" post="and rimantadine. Resistance emergence during therapy with neuraminidase inhibitors"/>
   <result pre="[17]. There are currently two approved M2 ion channel inhibitors," exact="amantadine" post="and rimantadine. Early studies demonstrated that influenza variants with"/>
   <result pre="Early studies demonstrated that influenza variants with high-level resistance to" exact="amantadine" post="and rimantadine could be selected in the laboratory though"/>
   <result pre="demonstrated that influenza variants with high-level resistance to amantadine and" exact="rimantadine" post="could be selected in the laboratory though in vitro"/>
   <result pre="of influenza A/H1N1, A/H2N2, and A/H3N2 were initially susceptible to" exact="amantadine" post="and rimantadine [19, 24, 39, 42]. Even after licensure"/>
   <result pre="A/H1N1, A/H2N2, and A/H3N2 were initially susceptible to amantadine and" exact="rimantadine" post="[19, 24, 39, 42]. Even after licensure of the"/>
   <result pre="the M2 inhibitors, possibly related to increased use of over-the-counter" exact="amantadine" post="after the emergence of severe acute respiratory syndrome (SARS)"/>
   <result pre="EIA enzyme immunoassay aAll resistant viruses from family members receiving" exact="rimantadine" post="bOver 80 % of tested isolates were H3N2 subtype"/>
   <result pre="resistant virus could be detected in 50 % of six" exact="rimantadine" post="recipients by day 3 of treatment, although the nasal"/>
   <result pre="33 % of 24 adult and pediatric household members receiving" exact="rimantadine" post="shed resistant virus on day 5 of treatment; none"/>
   <result pre="found emergence of resistant virus in 27 % of 37" exact="rimantadine" post="recipients, including 45 % of those still virus positive"/>
   <result pre="positive on day 7, compared to 6 % of 32" exact="acetaminophen" post="recipients [23]. Resistant virus was detected as early as"/>
   <result pre="on days 5–7. A study of Japanese children treated with" exact="amantadine" post="found that 30 % of 81 in the 1999–2000"/>
   <result pre="80 % of 15 hospitalized children during or immediately after" exact="amantadine" post="treatment [41]. Nine (75 %) of 12 children had"/>
   <result pre="randomized study patients hospitalized with influenza were to receive either" exact="rimantadine" post="alone or rimantadine plus nebulized zanamivir [54]. Rimantadine-resistant virus"/>
   <result pre="hospitalized with influenza were to receive either rimantadine alone or" exact="rimantadine" post="plus nebulized zanamivir [54]. Rimantadine-resistant virus was detected in"/>
   <result pre="were to receive either rimantadine alone or rimantadine plus nebulized" exact="zanamivir" post="[54]. Rimantadine-resistant virus was detected in 2/20 (10 %)"/>
   <result pre="[54]. Rimantadine-resistant virus was detected in 2/20 (10 %) of" exact="rimantadine" post="monotherapy patients, while non-resistant variants were detected in the"/>
   <result pre="(38 %) H3N2 Englund et al. [28] 1993–1994 Immunocompromised Amantadine," exact="rimantadine" post="15 5 (33 %) H3N2 Saito et al. [53]"/>
   <result pre="Contact birds shedding resistant virus due to earlier incorporation of" exact="amantadine" post="in the drinking water of donors (4 days only)"/>
   <result pre="of four experiments over four cumulative transmission cycles. Households Both" exact="amantadine" post="and rimantadine are effective for postexposure prophylaxis of illness"/>
   <result pre="experiments over four cumulative transmission cycles. Households Both amantadine and" exact="rimantadine" post="are effective for postexposure prophylaxis of illness due to"/>
   <result pre="reduction in secondary influenza illness in household contacts receiving either" exact="amantadine" post="or rimantadine for postexposure prophylaxis, when the ill index"/>
   <result pre="secondary influenza illness in household contacts receiving either amantadine or" exact="rimantadine" post="for postexposure prophylaxis, when the ill index cases received"/>
   <result pre="a persistent or an increasing number of virus-positive patients despite" exact="amantadine" post="prophylaxis. The recovery of the same genotype of resistant"/>
   <result pre="nursing home outbreak [58]. The frequency of instances in which" exact="amantadine" post="or rimantadine has failed to control outbreaks because of"/>
   <result pre="outbreak [58]. The frequency of instances in which amantadine or" exact="rimantadine" post="has failed to control outbreaks because of resistance emergence"/>
   <result pre="occasional patients wild-type virus replaces resistant variants after cessation of" exact="amantadine" post="[41]. As noted for some avian A/H7 viruses, this"/>
   <result pre="when resistance emerges as well [23]. Treatment Alternatives Amantadine and" exact="rimantadine" post="share susceptibility and resistance, so that resistance to one"/>
   <result pre="of suspected M2 inhibitor-resistant infections. Clinical studies suggest that both" exact="oseltamivir" post="and zanamivir are successful in terminating institutional outbreaks where"/>
   <result pre="M2 inhibitor-resistant infections. Clinical studies suggest that both oseltamivir and" exact="zanamivir" post="are successful in terminating institutional outbreaks where amantadine resistance"/>
   <result pre="oseltamivir and zanamivir are successful in terminating institutional outbreaks where" exact="amantadine" post="resistance is proven or highly probable [58, 62, 63]."/>
   <result pre="62, 63]. In vitro testing suggests that the synthetic nucleosides" exact="ribavirin" post="and favipiravir are also inhibitory for M2 inhibitor-resistant influenza"/>
   <result pre="be an option. A small study randomized hospitalized adults to" exact="rimantadine" post="monotherapy or rimantadine-nebulized zanamivir combination therapy. The combination arm"/>
   <result pre="small study randomized hospitalized adults to rimantadine monotherapy or rimantadine-nebulized" exact="zanamivir" post="combination therapy. The combination arm had a trend to"/>
   <result pre="therapy [54]. Recently, a triple combination of amantadine, oseltamivir, and" exact="ribavirin" post="has been studied in vitro, in vivo, and in"/>
   <result pre="determine the genetic antiviral resistance profiles of the NA inhibitors" exact="zanamivir" post="and oseltamivir were initiated shortly after their development (reviewed"/>
   <result pre="genetic antiviral resistance profiles of the NA inhibitors zanamivir and" exact="oseltamivir" post="were initiated shortly after their development (reviewed in [70,"/>
   <result pre="late 1990s that served as the basis for approval of" exact="zanamivir" post="and oseltamivir in 1999 and, more recently, for approval"/>
   <result pre="that served as the basis for approval of zanamivir and" exact="oseltamivir" post="in 1999 and, more recently, for approval of laninamivir"/>
   <result pre="in 1999 and, more recently, for approval of laninamivir and" exact="peramivir" post="[83–87]. Although zanamivir and oseltamivir have been available in"/>
   <result pre="more recently, for approval of laninamivir and peramivir [83–87]. Although" exact="zanamivir" post="and oseltamivir have been available in many countries since"/>
   <result pre="for approval of laninamivir and peramivir [83–87]. Although zanamivir and" exact="oseltamivir" post="have been available in many countries since 1999, their"/>
   <result pre="182) had significantly fewer days of fever if treated with" exact="oseltamivir" post="(n = 64) as compared to non-treated patients (n"/>
   <result pre="an oseltamivir-resistant viruses (n = 44) did not benefit from" exact="oseltamivir" post="treatment (n = 43; P = 0.5) [91]. Similar"/>
   <result pre="patterns of cross-resistance are found for particular NA mutations. Importantly," exact="zanamivir" post="and laninamivir retain full inhibitory activity against variants with"/>
   <result pre="resistance [115–117]. Table 71.4 Effects of NA mutations that confer" exact="oseltamivir" post="resistance on viral fitness measures in clinical isolates of"/>
   <result pre="patients (1.9 %) receiving an antiviral, emergence of resistance to" exact="oseltamivir" post="could be detected during treatment, in most cases children"/>
   <result pre="an His274Tyr are a reason for concern [122–124]. Resistance to" exact="zanamivir" post="was reported due to an amino change Gln136Lys [125,"/>
   <result pre="causing an 80-fold and sevenfold increase of the IC50 for" exact="oseltamivir" post="and zanamivir, respectively [134–137]. This Asn295Ser change has also"/>
   <result pre="in China since 2013 causes high NA inhibitor resistance to" exact="oseltamivir" post="and peramivir and reduced resistance to zanamivir [138, 139]."/>
   <result pre="since 2013 causes high NA inhibitor resistance to oseltamivir and" exact="peramivir" post="and reduced resistance to zanamivir [138, 139]. Unlike A/H3N2"/>
   <result pre="inhibitor resistance to oseltamivir and peramivir and reduced resistance to" exact="zanamivir" post="[138, 139]. Unlike A/H3N2 viruses carrying the Arg292Lys amino"/>
   <result pre="to oseltamivir, zanamivir, and peramivir. Table 71.5 Representative studies of" exact="oseltamivir" post="and zanamivir susceptibility of field isolates of influenza A"/>
   <result pre="zanamivir, and peramivir. Table 71.5 Representative studies of oseltamivir and" exact="zanamivir" post="susceptibility of field isolates of influenza A and B"/>
   <result pre="chain reaction aOne B/Perth/211/2001 isolate had ninefold reduced susceptibility to" exact="zanamivir" post="and 14-fold to oseltamivir compared to the mean inhibitory"/>
   <result pre="isolate had ninefold reduced susceptibility to zanamivir and 14-fold to" exact="oseltamivir" post="compared to the mean inhibitory concentrations of influenza B"/>
   <result pre="analysis of samples from over 2500 influenza patients treated with" exact="oseltamivir" post="as outpatients indicated that the frequency of resistance detection"/>
   <result pre="Japanese children reported high frequencies of 16 and 18 %" exact="oseltamivir" post="resistance emergence during oseltamivir therapy [8, 147]. The use"/>
   <result pre="frequencies of 16 and 18 % oseltamivir resistance emergence during" exact="oseltamivir" post="therapy [8, 147]. The use of weight-based dosing for"/>
   <result pre="a replication advantage over viruses with human receptor preference during" exact="oseltamivir" post="use in humans. Interestingly, amino acid changes in the"/>
   <result pre="change [149, 150]. Table 71.6 Frequency of resistance emergence to" exact="oseltamivir" post="or zanamivir during treatment Drug/study Population Assay Virus type"/>
   <result pre="150]. Table 71.6 Frequency of resistance emergence to oseltamivir or" exact="zanamivir" post="during treatment Drug/study Population Assay Virus type No. isolates"/>
   <result pre="0 aThese pediatric studies used a 2 mg/kg dose of" exact="oseltamivir" post="that has been shown to give reduced drug exposure"/>
   <result pre="impact on therapy is unclear for such moderate increase in" exact="oseltamivir" post="resistance; however viruses with the combination of Ile223Arg and"/>
   <result pre="the combination of Ile223Arg and His275Tyr are highly resistant to" exact="oseltamivir" post="in vitro (1750-fold) [160]. In the past, emergence of"/>
   <result pre="for influenza A/H3N2 and influenza B virus-infected patients treated with" exact="oseltamivir" post="and zanamivir with mutations in both the viral HA"/>
   <result pre="A/H3N2 and influenza B virus-infected patients treated with oseltamivir and" exact="zanamivir" post="with mutations in both the viral HA and NA"/>
   <result pre="have been suggested to have facilitated the emergence of this" exact="oseltamivir" post="resistance change. The Asp344Asn amino acid change, which appeared"/>
   <result pre="compensate for the loss of fitness due to the Glu119Val" exact="oseltamivir" post="resistance mutation [170, 171]. The observed community clusters of"/>
   <result pre="inhibitor cross-resistance vary by virus type and subtype, such that" exact="zanamivir" post="retains inhibitory activity for the most common resistant variants"/>
   <result pre="common resistant variants that emerge during the therapeutic use of" exact="oseltamivir" post="or peramivir. Zanamivir is fully inhibitory for oseltamivir-resistant variants"/>
   <result pre="in N1 [102, 172]. Depending on the virus and assay," exact="zanamivir" post="is partially inhibitory for resistant variants with Arg292Lys substitution"/>
   <result pre="type [102, 172–174]. There is controversy about the role of" exact="peramivir" post="in the management of variants that are resistant to"/>
   <result pre="peramivir in the management of variants that are resistant to" exact="oseltamivir" post="as in vitro and in vivo models have given"/>
   <result pre="mutation in influenza B NA that confers reduced susceptibility to" exact="zanamivir" post="[178]. Given these findings, most experts recommend using zanamivir"/>
   <result pre="to zanamivir [178]. Given these findings, most experts recommend using" exact="zanamivir" post="for the treatment of patients who develop resistance or"/>
   <result pre="patients who develop resistance or virologic failure to oseltamivir. Inhaled" exact="zanamivir" post="has been utilized in a few patients with variable"/>
   <result pre="is less likely in patients with influenza pneumonia [179–182]. Intravenous" exact="zanamivir" post="has been utilized most frequently for patients with proven"/>
   <result pre="prior exposure to numerous interventions [183–186]. Other NA inhibitors and" exact="zanamivir" post="dimers that have prolonged duration of antiviral effect after"/>
   <result pre="experimentally infected with influenza A, the combination of orally administered" exact="ribavirin" post="and peramivir was associated with improved survival relative to"/>
   <result pre="with influenza A, the combination of orally administered ribavirin and" exact="peramivir" post="was associated with improved survival relative to ribavirin alone"/>
   <result pre="ribavirin and peramivir was associated with improved survival relative to" exact="ribavirin" post="alone but not to peramivir alone [189]. A more"/>
   <result pre="with improved survival relative to ribavirin alone but not to" exact="peramivir" post="alone [189]. A more recent study found that a"/>
   <result pre="[189]. A more recent study found that a combination of" exact="ribavirin" post="and oseltamivir was no more effective than ribavirin alone"/>
   <result pre="more recent study found that a combination of ribavirin and" exact="oseltamivir" post="was no more effective than ribavirin alone against a"/>
   <result pre="combination of ribavirin and oseltamivir was no more effective than" exact="ribavirin" post="alone against a lethal influenza A(H1N1) infection but superior"/>
   <result pre="M2 inhibitor-resistant viruses. Recently, triple combinations of amantadine, ribavirin, and" exact="oseltamivir" post="have been studied in vitro, in vivo, and in"/>
   <result pre="therapy. Given its slightly broader activity against most oseltamivir-resistant variants," exact="zanamivir" post="would be the preferred therapy for patients with proven"/>
   <result pre="polymerase inhibitor favipiravir [191], the receptor-destroying sialidase DAS181 [199], and" exact="nitazoxanide" post="[200]. Neutralizing antibodies and convalescent plasma need to be"/>
   <result pre="Pt B):159–73. 6.GovorkovaEAet al.Comparison of efficacies of RWJ-270201, zanamivir, and" exact="oseltamivir" post="against H5N1, H9N2, and other avian influenza virusesAntimicrob Agents"/>
   <result pre="nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virusJAMA2009301101042610.1001/jama.2009.29719255111 12.GubarevaLVet al.Evidence for" exact="zanamivir" post="resistance in an immunocompromised child infected with influenza B"/>
   <result pre="of influenza pandemic preparedness in developing countriesEmerg Infect Dis20081468758010.3201/eid1406.07083918507896 17.HaydenFGAokiFYBarriereSLAmantadine," exact="rimantadine" post="and related agentsAntimicrobial therapy and vaccines1999Baltimore, MDWilliams and Wilkins134465"/>
   <result pre="vaccines1999Baltimore, MDWilliams and Wilkins134465 18.BelsheRBet al.Genetic basis of resistance to" exact="rimantadine" post="emerging during treatment of influenza virus infectionJ Virol19886251508123282079 19.HayAJRichmanDDAmantadine"/>
   <result pre="treatment with rimantadinePediatrics1987802275823302925 24.BelsheRBet al.Resistance of influenza A virus to" exact="amantadine" post="and rimantadine: results of one decade of surveillanceJ Infect"/>
   <result pre="N1 neuraminidase subtypeJ Virol201084199800910.1128/JVI.00296-1020660186 35.MarjukiHet al.Neuraminidase mutations conferring resistance to" exact="oseltamivir" post="in influenza A(H7N9) virusesJ Virol2015891054192610.1128/JVI.03513-1425740997 36.MarjukiHet al.Characterization of drug-resistant"/>
   <result pre="and H3N2J Clin Microbiol20034152164510.1128/JCM.41.5.2164-2165.200312734269 54.IsonMGet al.Safety and efficacy of nebulized" exact="zanamivir" post="in hospitalized patients with serious influenzaAntivir Ther2003831839012924534 55.KlimovAIet al.Prolonged"/>
   <result pre="Rocha Crispino Santos, and A.J. Alves da Cunha, Amantadine and" exact="rimantadine" post="for influenza A in children and the elderly. Cochrane"/>
   <result pre="amantadine-resistant influenza a viruses (H3N2) from patients following administration of" exact="amantadine" post="in JapanJ Clin Microbiol20013941652310.1128/JCM.39.4.000-000.200111283109 61.DegelauJet al.Amantadine-resistant influenza A in"/>
   <result pre="A in a nursing facilityArch Intern Med19921522390210.1001/archinte.1992.004001401280271739371 62.BowlesSKet al.Use of" exact="oseltamivir" post="during influenza outbreaks in Ontario nursing homes, 1999–2000J Am"/>
   <result pre="Ontario nursing homes, 1999–2000J Am Geriatr Soc20025046081610.1046/j.1532-5415.2002.50153.x11982659 63.HirjiZet al.Utility of" exact="zanamivir" post="for chemoprophylaxis of concomitant influenza A and B in"/>
   <result pre="T-705Antimicrob Agents Chemother20024649778110.1128/AAC.46.4.977-981.200211897578 65.NguyenJTet al.Triple combination of amantadine, ribavirin, and" exact="oseltamivir" post="is highly active and synergistic against drug resistant influenza"/>
   <result pre="One201052e933210.1371/journal.pone.000933220179772 66.NguyenJTet al.Efficacy of combined therapy with amantadine, oseltamivir, and" exact="ribavirin" post="in vivo against susceptible and amantadine-resistant influenza A virusesPLoS"/>
   <result pre="virusesPLoS Pathog2014104e100406510.1371/journal.ppat.100406524699865 80.BloomJDGongLIBaltimoreDPermissive secondary mutations enable the evolution of influenza" exact="oseltamivir" post="resistanceScience201032859831272510.1126/science.118781620522774 81.LiYet al.Single hemagglutinin mutations that alter both antigenicity"/>
   <result pre="R Soc Interface201411922013108310.1098/rsif.2013.108324430126 83.SugayaNet al.Efficacy, safety, and pharmacokinetics of intravenous" exact="peramivir" post="in children with 2009 pandemic H1N1 influenza A virus"/>
   <result pre="Chemother20125613697710.1128/AAC.00132-1122024821 84.KohnoSet al.Phase III randomized, double-blind study comparing single-dose intravenous" exact="peramivir" post="with oral oseltamivir in patients with seasonal influenza virus"/>
   <result pre="III randomized, double-blind study comparing single-dose intravenous peramivir with oral" exact="oseltamivir" post="in patients with seasonal influenza virus infectionAntimicrob Agents Chemother2011551152677610.1128/AAC.00360-1121825298"/>
   <result pre="inhibitorExpert Opin Pharmacother20151612188990010.1517/14656566.2015.106633626153242 86.WatanabeAet al.Long-acting neuraminidase inhibitor laninamivir octanoate versus" exact="oseltamivir" post="for treatment of influenza: a double-blind, randomized, noninferiority clinical"/>
   <result pre="trialClin Infect Dis2010511011677510.1086/65680220936975 87.SugayaNOhashiYLong-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus" exact="oseltamivir" post="as treatment for children with influenza virus infectionAntimicrob Agents"/>
   <result pre="II clinical efficacy studiesJ Antimicrob Chemother.2000441788710.1128/AAC.44.1.78-87.2000 89.KawaiNet al.Clinical effectiveness of" exact="oseltamivir" post="and zanamivir for treatment of influenza A virus subtype"/>
   <result pre="efficacy studiesJ Antimicrob Chemother.2000441788710.1128/AAC.44.1.78-87.2000 89.KawaiNet al.Clinical effectiveness of oseltamivir and" exact="zanamivir" post="for treatment of influenza A virus subtype H1N1 with"/>
   <result pre="and 2008–2009 influenza seasonsClin Infect Dis2009491218283510.1086/64842419911968 90.KawaiNet al.Clinical effectiveness of" exact="oseltamivir" post="for influenza A(H1N1) virus with H274Y neuraminidase mutationJ Infect20095932071210.1016/j.jinf.2009.07.00219619898"/>
   <result pre="A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of" exact="oseltamivir" post="and zanamivirVirol J201075310.1186/1743-422X-7-5320202225 93.SaitoRet al.Reduced effectiveness of oseltamivir in"/>
   <result pre="effectiveness of oseltamivir and zanamivirVirol J201075310.1186/1743-422X-7-5320202225 93.SaitoRet al.Reduced effectiveness of" exact="oseltamivir" post="in children infected with oseltamivir-resistant influenza A (H1N1) viruses"/>
   <result pre="influenza viruses A (H1N1), Norway, 2007–08Emerg Infect Dis20091521556210.3201/eid1502.08103119193257 95.BesselaarTGet al.Widespread" exact="oseltamivir" post="resistance in influenza A viruses (H1N1), South AfricaEmerg Infect"/>
   <result pre="Interface20129696485610.1098/rsif.2011.042721865253 97.CarrJet al.Influenza virus carrying neuraminidase with reduced sensitivity to" exact="oseltamivir" post="carboxylate has altered properties in vitro and is compromised"/>
   <result pre="99.BazMet al.Effect of the neuraminidase mutation H274Y conferring resistance to" exact="oseltamivir" post="on the replicative capacity and virulence of old and"/>
   <result pre="assays for quantitative and qualitative detection of influenza virus and" exact="oseltamivir" post="resistance mutationsJ Mol Diagn20131533475410.1016/j.jmoldx.2012.11.00723597879 108.DeydeVMet al.Pyrosequencing as a tool"/>
   <result pre="virus resistance to neuraminidase inhibitorsVirus Res20041031–219920310.1016/j.virusres.2004.02.03415163510 113.CollinsPJet al.Structural basis for" exact="oseltamivir" post="resistance of influenza virusesVaccine2009274563172310.1016/j.vaccine.2009.07.01719840667 114.SamsonMet al.Characterization of drug-resistant influenza"/>
   <result pre="influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with" exact="oseltamivir" post="and zanamivirJ Infect Dis2015212812091310.1093/infdis/jiv24525943200 116.NguyenHTet al.Recovery of a multidrug-resistant"/>
   <result pre="al.A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to" exact="oseltamivir" post="and peramivir in Japan, November to December 2013Euro Surveill.20141912066610.2807/1560-7917.ES2014.19.1.2066624434172"/>
   <result pre="cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and" exact="peramivir" post="in Japan, November to December 2013Euro Surveill.20141912066610.2807/1560-7917.ES2014.19.1.2066624434172 125.HurtACet al.Zanamivir-resistant"/>
   <result pre="a Q136K mutation in the neuraminidase gene is resistant to" exact="zanamivir" post="but exhibits reduced fitness in the guinea pig transmission"/>
   <result pre="patients infected with I221V influenza B virus variants with reduced" exact="oseltamivir" post="susceptibility—North Carolina and South Carolina, 2010–2011J Infect Dis201320769667310.1093/infdis/jis77623242536 146.RobertsNATreatment"/>
   <result pre="fitness contributed by secondary mutations in the hemagglutinin protein of" exact="oseltamivir" post="resistant H1N1 influenza viruses: modeling studies of antibody and"/>
   <result pre="cancerPediatr Infect Dis J2011304284810.1097/INF.0b013e3181ff863b21048522 158.FraaijPLet al.Viral shedding and susceptibility to" exact="oseltamivir" post="in hospitalized immunocompromised patients with influenza in the Influenza"/>
   <result pre="H274Y mutation in the influenza A/H1N1 neuraminidase active site following" exact="oseltamivir" post="phosphate treatment leave virus severely compromised both in vitro"/>
   <result pre="N1 and N2 genetic backgroundsAntivir Ther2006118971617302366 173.MishinVPet al.Evaluation of methyl" exact="inosine" post="monophosphate (MIMP) and peramivir activities in a murine model"/>
   <result pre="backgroundsAntivir Ther2006118971617302366 173.MishinVPet al.Evaluation of methyl inosine monophosphate (MIMP) and" exact="peramivir" post="activities in a murine model of lethal influenza A"/>
   <result pre="fitness and transmissibilityAntimicrob Agents Chemother2005491040758410.1128/AAC.49.10.4075-4084.200516189083 175.Abed Y et al. Parenteral" exact="peramivir" post="treatment for Oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses."/>
   <result pre="Infect Dis. 2011;204(10):1641–2; author’s reply 1642–3. 176.AbedYPizzornoABoivinGTherapeutic activity of intramuscular" exact="peramivir" post="in mice infected with a recombinant influenza A/WSN/33 (H1N1)"/>
   <result pre="(H1N1) 2009, United StatesEmerg Infect Dis2011172255710.3201/eid1702.10172421291599 181.JohnyAAet al.The use of" exact="zanamivir" post="to treat influenza A and B infection after allogeneic"/>
   <result pre="stem cell transplantationBone Marrow Transplant2002292113510.1038/sj.bmt.170334311850704 182.PetersenEet al.Failure of combination oral" exact="oseltamivir" post="and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated"/>
   <result pre="Marrow Transplant2002292113510.1038/sj.bmt.170334311850704 182.PetersenEet al.Failure of combination oral oseltamivir and inhaled" exact="zanamivir" post="antiviral treatment in ventilator- and ECMO-treated critically ill patients"/>
   <result pre="A (H1N1)vScand J Infect Dis2011436–749550310.3109/00365548.2011.55614421309638 183.Chan-TackKMet al.Clinical experience with intravenous" exact="zanamivir" post="under an emergency investigational new drug program in the"/>
   <result pre="the United StatesJ Infect Dis20132071196810.1093/infdis/jis63723089591 184.Chan-TackKMet al.Clinical experience with intravenous" exact="zanamivir" post="under an Emergency IND program in the United States"/>
   <result pre="States (2011–2014)Antivir Ther2015205561410.3851/IMP294425667992 185.FraaijPLet al.Evaluation of the antiviral response to" exact="zanamivir" post="administered intravenously for treatment of critically ill patients with"/>
   <result pre="the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirinChemotherapy2002482889310.1159/00005766812011541 189.SmeeDFet al.Activities of" exact="oseltamivir" post="and ribavirin used alone and in combination against infections"/>
   <result pre="neuraminidase inhibitor RWJ-270201 and ribavirinChemotherapy2002482889310.1159/00005766812011541 189.SmeeDFet al.Activities of oseltamivir and" exact="ribavirin" post="used alone and in combination against infections in mice"/>
   <result pre="and B virusesAntivir Chem Chemother20061741859210.1177/09563202060170040317066897 190.SeoSet al.Combination therapy with amantadine," exact="oseltamivir" post="and ribavirin for influenza A infection: safety and pharmacokineticsAntivir"/>
   <result pre="virusesAntivir Chem Chemother20061741859210.1177/09563202060170040317066897 190.SeoSet al.Combination therapy with amantadine, oseltamivir and" exact="ribavirin" post="for influenza A infection: safety and pharmacokineticsAntivir Ther20131833778610.3851/IMP247523264438 191.FurutaYet"/>
   <result pre="sialidase therapy for respiratory viral infectionsAntiviral Res2013983401910.1016/j.antiviral.2013.04.01223602850 200.HaffizullaJet al.Effect of" exact="nitazoxanide" post="in adults and adolescents with acute uncomplicated influenza: a"/>
   <result pre="pneumonia: a future H5N1 treatment?Ann Intern Med2006145859960910.7326/0003-4819-145-8-200610170-0013916940336 202.ValetteMet al.Susceptibilities to" exact="rimantadine" post="of influenza A/H1N1 and A/H3N2 viruses isolated during the"/>
   <result pre="and 1989 to 1990Antimicrob Agents Chemother1993371022394010.1128/AAC.37.10.22398257151 203.ZieglerTet al.Low incidence of" exact="rimantadine" post="resistance in field isolates of influenza A virusesJ Infect"/>
   <result pre="influenza A virusesJ Infect Dis19991804935910.1086/31499410479115 204.DawsonJNeuraminidase inhibitor and amantadineLancet20003559222225410.1016/S0140-6736(05)72755-010881922 205.SuzukiHSaitoROshitaniHExcess" exact="amantadine" post="use and resistant virusesLancet20013589296191010.1016/S0140-6736(01)06919-711741673 206.ShihSRet al.Amantadine-resistant influenza A virus"/>
   <result pre="studyLancet1969276291026810.1016/S0140-6736(69)90639-44187541 209.BricaireFet al.Prevention of influenza A. Effectiveness and tolerance of" exact="rimantadine" post="hydrochloridePresse Med.199019269722137233 210.MontoASet al.Zanamivir prophylaxis: an effective strategy for"/>
   <result pre="A and B within householdsJ Infect Dis2002186111582810.1086/34572212447733 211.WelliverRet al.Effectiveness of" exact="oseltamivir" post="in preventing influenza in household contacts: a randomized controlled"/>
   <result pre="epidemic in the family environmentBull World Health Organ1969413677824908342 213.HaydenFGet al.Inhaled" exact="zanamivir" post="for the prevention of influenza in families. Zanamivir Family"/>
   <result pre="al.Management of influenza in households: a prospective, randomized comparison of" exact="oseltamivir" post="treatment with or without postexposure prophylaxisJ Infect Dis20041893440910.1086/38112814745701 215.McKimm-BreschkinJet"/>
   <result pre="sequence analysis and susceptibilities of influenza virus clinical isolates to" exact="zanamivir" post="and oseltamivirAntimicrob Agents Chemother200347722647210.1128/AAC.47.7.2264-2272.200312821478 216.HurtACet al.Susceptibility of human influenza"/>
   <result pre="from Australasia and South East Asia to the neuraminidase inhibitors" exact="zanamivir" post="and oseltamivirAntiviral Res2004621374510.1016/j.antiviral.2003.11.00815026200 217.BoivinGGoyetteNSusceptibility of recent Canadian influenza A"/>
   <result pre="the 2000–2002 influenza seasonsVirus Res20041031-2195710.1016/j.virusres.2004.02.03315163509 219.FerrarisOKesslerNLinaBSensitivity of influenza viruses to" exact="zanamivir" post="and oseltamivir: a study performed on viruses circulating in"/>
   <result pre="seasons. Wkly Epidemiol Rec, 2007. 82(17): p. 149-50. 223.WhitleyRJet al.Oral" exact="oseltamivir" post="treatment of influenza in childrenPediatr Infect Dis J20012021273310.1097/00006454-200102000-0000211224828 224.WardPet"/>
   <result pre="influenza pandemicJ Antimicrob Chemother200555Suppl 1i52110.1093/jac/dki01815709056 225.StephensonIet al.Neuraminidase inhibitor resistance after" exact="oseltamivir" post="treatment of acute influenza A and B in childrenClin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7122828\results\search\drugs\results.xml">
   <result pre="possibility of being consumed by pregnant women. These advantages made" exact="chloroquine" post="the first choice in the treatment of malaria (Robert"/>
   <result pre="tropical diseases, especially malaria. In the 1970s, Chinese researchers presented" exact="artemisinin" post="and its semisynthetic derivatives (Artemether, Arteether, Artesunate, Artemisinic acid,"/>
   <result pre="species; however, these drugs may act as hemozoin production inhibitors," exact="folic acid" post="synthesis inhibitors, transcription inhibitors or inhibitors of the mitochondrial"/>
   <result pre="Artemisin Artemether Arteether Artesunate Artenilic acid Dihydroartemisin Biguanides and derivatives:" exact="folic acid" post="synthesis inhibitors Chloroproguanil Cyclochloroproguanil Naphthoquinones: mitochondrial respiratory chain inhibitors"/>
   <result pre="modifiers Amodiaquine Primaquine Chloroquine Etaquine Hydroxychloroquine Plasmoquine Sulfones: inhibitors of" exact="folic acid" post="synthesis Dapsone Sulfadoxine Sulfalene The importance of drugs with"/>
   <result pre="in vitro studies demonstrated that the compounds verapamil, desipramine, and" exact="promethazine" post="may reverse the resistance of P. falciparum to chloroquine;"/>
   <result pre="exhibit anticancer, anti-allergic, and antiparasitic potential, as they correspond to" exact="nitric oxide" post="donors for vascular relaxation induction (Donnici et al. 2009;"/>
   <result pre="purpose. According to the literature, the binuclear complex of Ru(II)" exact="chloroquine" post="[RuCQCl2]2 (complex 1, Fig. 8.3) was five times more"/>
   <result pre="1, Fig. 8.3) was five times more potent than standard" exact="chloroquine" post="against P. berghei and P. falciparum strains. The mechanism"/>
   <result pre="et al. 2013). Fig. 8.3 Gold and ruthenium complexes of" exact="chloroquine" post="Sanches-Delgado et al. (1996) synthesized the first class of"/>
   <result pre="was investigated (Martínez et al. 2011). Another promising class of" exact="chloroquine" post="complexes for the development of therapeutic agents are gold"/>
   <result pre="of possible ligands that can be coordinated to CQ or" exact="chloroquine" post="diphosphate (CQDP), allowing the investigation of antimalarial properties of"/>
   <result pre="the antimalarial activities of iron, cobalt, and nickel complexes containing" exact="chloroquine" post="(CQ) and Mefloquine (Mef) as ligands. The complexes of"/>
   <result pre="tests revealed that the mixed metal complexes of Mefloquine and" exact="chloroquine" post="[Co(Mef)(CQ)Cl2] and [Fe(Mef)(CQ)Cl3)] exhibited higher antimalarial potential. Furthermore, toxicity"/>
   <result pre="therapy. This compound was described in 1997 as the first" exact="chloroquine" post="derivative containing a ferrocene molecule, incorporating the ferrocene to"/>
   <result pre="molecule, incorporating the ferrocene to the lateral side chain of" exact="chloroquine" post="(Biot et al. 1997). Although there are structural similarities"/>
   <result pre="(Biot et al. 1997). Although there are structural similarities between" exact="chloroquine" post="and FQ, the in vitro activities against P. falciparum"/>
   <result pre="Lett2007176434643810.1016/j.bmcl.2007.10.00317949976 Biot C, Delhaes L, Maclejewski AL (2000) Synthetic ferrocene" exact="mefloquine" post="and quinine analogues as potential antimalarial agents. Eur J"/>
   <result pre="Camus D, Dive D, Brocard S J (2000) Synthetic ferrocenic" exact="mefloquine" post="and quinine analogues as potential antimalarial agentes. Eur J"/>
   <result pre="the role of the covalent linkage of ferrocene into a" exact="chloroquine" post="template. J Med Chem 49:4707–4714 BlackieALMChibaleKMetallocene antimalarials: the continuing"/>
   <result pre="vitro of new heterobimetallic complexes: Rh and Au derivatives of" exact="chloroquine" post="and a series of ferrocenyl-4-amino-7-chloroquines and a series of"/>
   <result pre="Clin Biol Res19893131191492506579 SeuanesGCMoreiraMBPettaTMoraesDMPFMoraesLABOliveiraARMNaalGZMRNikolaouSNovel binuclear μ-oxo diruthenium complexes combined with" exact="ibuprofen" post="and ketoprofen: interaction with relevant target biomolecules and anti-allergic"/>
   <result pre="biomolecules and anti-allergic potentialJ Inorg Biochem201515317818510.1016/j.jinorgbio.2015.08.00426298864 SharmaVTherapeutic drugs for targeting" exact="chloroquine" post="resistance in malariaMini-Rev Med Chem2005533735110.2174/138955705354402915853624 Sibley CH, Ringwald PA"/>
   <result pre="murine malaria parasite Plasmodium bergheiJ Inorg Biochem20171661410.1016/j.jinorgbio.2016.10.00427815977 Van SchalkuykDAWalderJCSmithPJReversal of" exact="chloroquine" post="resistance in Plasmodium falciparum using combinations of chemosensitizersAntimicrob Agents"/>
   <result pre="of actionJ Inorg Biochem20091031300130610.1016/j.jinorgbio.2009.02.01119361864 Wallace DJ (1989) The use of" exact="quinacrine" post="(atrabine) in rheumatic diseases: a reexamination. Semin Arthritis Rheu"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7123767\results\search\drugs\results.xml">
   <result pre="are drug components of traditional Chinese herbs. The finding of" exact="artemisinin" post="extracted from Artemisia annua as an effective antimalarial drug"/>
   <result pre="against 3a channel protein of coronavirusPlanta Med.20148017718210.1055/s-0033-136027724458263 TuYYThe discovery of" exact="artemisinin" post="(qinghaosu) and gifts from Chinese medicineNature Medicine2011171217122010.1038/nm.247121989013 WangKXieSSunBViral proteins"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7124147\results\search\drugs\results.xml">
   <result pre="A. annua, one active compound, a sesquiterpene lactone endoperoxide called" exact="artemisinin" post="has been identified and is currently being used, as"/>
   <result pre="artemisinin has been identified and is currently being used, as" exact="artemisinin" post="derivatives, as a first-line treatment for malaria (De Ridder"/>
   <result pre="an inexpensive treatment for malaria, as opposed to the WHO-recommended" exact="artemisinin" post="derivatives. The traditional use of A. annua has caused"/>
   <result pre="amount of controversy, and it is feared that resistance against" exact="artemisinin" post="might develop because of the traditional use of the"/>
   <result pre="of the main active compound artemisinin, they have concluded that" exact="artemisinin" post="combination therapies (ACTs) are the only way to approach"/>
   <result pre="a tea infusion due to the low natural abundance of" exact="artemisinin" post="in A. annua (Liu et al. 2006 and WHO,"/>
   <result pre="the use of A. annua versus the WHO-recommended use of" exact="artemisinin" post="derivatives, van der Kooy and Sullivan (2013) should be"/>
   <result pre="remains to be difficult, and therefore the main source of" exact="artemisinin" post="remains to be isolation and purification from the A."/>
   <result pre="various approaches have been taken. To increase the yield of" exact="artemisinin" post="in A. annua, classical plant breeding techniques have been"/>
   <result pre="improved (Liu et al. 2011a), and the chemical synthesis of" exact="artemisinin" post="has been successful to some degree (Dietrich et al."/>
   <result pre="(API) in order to reduce the overall production cost of" exact="artemisinin" post="(Lubbe et al. 2012). In order to do this,"/>
   <result pre="The outcome of this study is important to note as" exact="artemisinin" post="was not identified as the virus inhibitor. The pure"/>
   <result pre="was not identified as the virus inhibitor. The pure compound" exact="artemisinin" post="also showed significant activity towards the bovine viral diarrhoea"/>
   <result pre="BVDV virus and treated with artemisinin. It was found that" exact="artemisinin" post="is an inhibitor of flaviviridae viruses, with a possible"/>
   <result pre="hosts DNA. Paeshuyse et al. (2006) confirmed this by testing" exact="artemisinin" post="against HCV and found it to be active at"/>
   <result pre="the host cells, indicating a pronounced synergistic antiviral activity when" exact="artemisinin" post="and hemin were combined. A further understanding of how"/>
   <result pre="of HIV. Romero et al. (2005) studied the activity of" exact="artemisinin" post="against hepatitis B virus (HBV), noting IC50 values of"/>
   <result pre="B envelope protein surface antigen and HBV-DNA release, respectively. Interestingly," exact="artemisinin" post="proved to be a more effective antiviral than its"/>
   <result pre="regarding the in vitro anti-HIV activity of A. annua and" exact="artemisinin" post="is rather limited. Chang and Woo (2003) tested the"/>
   <result pre="b; Zhang 2003; and Chen 2007). The first report on" exact="artemisinin" post="derivatives being used as anti-HIV agents was published by"/>
   <result pre="Jung and Schinazi (1994) who embarked on a study of" exact="artemisinin" post="trioxane derivatives. They concluded that anti-HIV activity was common"/>
   <result pre="trioxane derivatives. They concluded that anti-HIV activity was common in" exact="artemisinin" post="trioxane derivatives and, given their results, further evaluation was"/>
   <result pre="A. annua having an IC50 of 2.0 μg/mL, whereas pure" exact="artemisinin" post="showed no inhibition even at 25 μg/mL. Artemisia afra"/>
   <result pre="even at 25 μg/mL. Artemisia afra which does not contain" exact="artemisinin" post="showed a similar level of activity against HIV, indicating"/>
   <result pre="of reducing the price and the accompanying price fluctuations of" exact="artemisinin" post="by identifying a second API in A. annua. A"/>
   <result pre="this activity caused by artemisinin? In order to test if" exact="artemisinin" post="was responsible for the reported in vivo anti-HIV activity,"/>
   <result pre="similar to A. annua but, importantly, it does not contain" exact="artemisinin" post="(Liu et al. 2010; van der Kooy et al."/>
   <result pre="of A. afra was done in order to determine whether" exact="artemisinin" post="was responsible for any observed anti-HIV activity, or whether"/>
   <result pre="for any observed anti-HIV activity, or whether a combination of" exact="artemisinin" post="and other components can explain any observed activity (synergism)."/>
   <result pre="of cultivation, year of harvest, plant parts used and the" exact="artemisinin" post="content of all the samples are given. The IC50"/>
   <result pre="Another possible explanation for the anti-HIV activity is synergism between" exact="artemisinin" post="and other compounds in the extract. With the inclusion"/>
   <result pre="and the observed activity of this sample, it appears that" exact="artemisinin" post="had a very limited role to play, if any."/>
   <result pre="species are chemically closely related with the major exception that" exact="artemisinin" post="has not yet been detected in any A. afra"/>
   <result pre="have also focussed only on the extraction and quantification of" exact="artemisinin" post="without conducting a complete chemical profile on the A."/>
   <result pre="extracts, mainly consisting of caffeic acid derivatives, flavonoids, coumarins and" exact="artemisinin" post="(van der Kooy and Sullivan 2013). The influence of"/>
   <result pre="inactive. Coumarins are however known for their anticoagulation properties with" exact="warfarin" post="being the best example. This possible influence on blood"/>
   <result pre="viruses. Efferth (2008) reported on the broad antiviral activity of" exact="artemisinin" post="and its semi-synthetic derivative artesunate. Artesunate showed inhibition of"/>
   <result pre="of 600 nM, but no reports on the activity of" exact="artemisinin" post="against HIV was given. Jung and Schinazi (1994) reported"/>
   <result pre="greater than 100 μM. Benedikt et al. (2005) have patented" exact="artemisinin" post="and some of its derivatives against various viruses. In"/>
   <result pre="against various viruses. In the patent description, the activity of" exact="artemisinin" post="was given to be insignificant against HIV-1 and HIV-2."/>
   <result pre="insignificant against HIV-1 and HIV-2. Lubbe et al. (2012) found" exact="artemisinin" post="to be inactive against HIV at a concentration of"/>
   <result pre="We therefore have some conflicting reports on the activity of" exact="artemisinin" post="against HIV probably caused by the different bioassays used."/>
   <result pre="cancer (Anamed). Lui et al. (2011b) have recently shown that" exact="artemisinin" post="does indeed show selective action against breast cancer cell"/>
   <result pre="classical swine fever virus. US Patent 20050059647 BrownGDThe biosynthesis of" exact="artemisinin" post="(Qinghaosu) and the phytochemistry of Artemisia annua L. (Qinghao)Molecules2010157603769810.3390/molecules1511760321030913"/>
   <result pre="in developing countriesJ Ethnopharmacol200812030231410.1016/j.jep.2008.09.01718977424 DietrichJAYoshikuniYFisherKJet al.A novel semi-biosynthetic route for" exact="artemisinin" post="production using engineered substrate-promiscuous P450BM3ACS Chem Biol2009426126710.1021/cb900006h19271725 EfferthTThe antiviral"/>
   <result pre="using engineered substrate-promiscuous P450BM3ACS Chem Biol2009426126710.1021/cb900006h19271725 EfferthTThe antiviral activities of" exact="artemisinin" post="and artesunateClin Infect Dis20084780481110.1086/59119518699744 Farnsworth NR (1985) Medicinal plants"/>
   <result pre="R Soc Trop Med Hyg200610050550810.1016/j.trstmh.2005.09.02016566952 JansenFHThe herbal tea approach for" exact="artemisinin" post="as a therapy for malaria?Trans R Soc Trop Med"/>
   <result pre="Hyg200610028528610.1016/j.trstmh.2005.08.00416274712 JungMSchinaziRFSynthesis and in vitro anti-human immunodeficiency virus activity of" exact="artemisinin" post="(qinghaosu)-related trioxanesBioorg Med Chem Lett1994493193410.1016/S0960-894X(01)80266-3 KaramoddiniMKAntiviral activities of aerial"/>
   <result pre="data analysisJ Ethnopharmacol201012823023510.1016/j.jep.2010.01.02020079415 LiuNQSchuehlyWVon FreyholdMet al.A novel purification method of" exact="artemisinin" post="from Artemisia annuaInd Crops Prod2011341084108810.1016/j.indcrop.2011.03.023 LiuNQPrager-van der SmissenWOzturkBet al.Molecular"/>
   <result pre="endemic in Costa RicaJ Pharm Pharmacol2005571109111510.1211/jpp.57.9.000616105232 RäthKTaxisKWalzGet al.Pharmacokinetic study of" exact="artemisinin" post="after oral intake of a traditional preparation of Artemisia"/>
   <result pre="an &quot;in vitro�? replicative systemAntiviral Res200568758310.1016/j.antiviral.2005.07.00516122816 RomeroMRSerranoMAVallejoMet al.Antiviral effect of" exact="artemisinin" post="from Artemisia annua against a model member of the"/>
   <result pre="plant extractsS Afr J Bot20087418618910.1016/j.sajb.2007.10.004 Van der KooyFVerpoorteRThe Content of" exact="artemisinin" post="in the Artemisia annua tea infusionPlanta Med2011771754175610.1055/s-0030-127106521544776 Van der"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7125728\results\search\drugs\results.xml">
   <result pre="HIV pandemic, for example, FDG-PET was used to demonstrate that" exact="zidovudine" post="therapy had a beneficial effect in patients with HIV-related"/>
   <result pre="example, PET was used to study the pharmacokinetics of the" exact="tenofovir" post="analogue 18F-PMPA in rats, revealing increased concentrations in the"/>
   <result pre="al., 2008). Although a study of the pharmacokinetics of 11C-labeled" exact="stavudine" post="in rats was based on measuring radioactivity in excised"/>
   <result pre="imaging. Examples include: •a recombinant vaccinia virus encoding the human" exact="norepinephrine" post="transporter, which enables PET imaging by causing124I-meta-iodobenzylguanidine (MIBG) to"/>
   <result pre="been inoculated with a recombinant vaccinia virus encoding the human" exact="norepinephrine" post="transporter. The probe, 124I-MIBG, is taken up by the"/>
   <result pre="(2009b), with permission. •a recombinant vaccinia virus encoding the type-2" exact="somatostatin" post="receptor, which binds the somatostatin analog 111In-pentetreotide on the"/>
   <result pre="vaccinia virus encoding the type-2 somatostatin receptor, which binds the" exact="somatostatin" post="analog 111In-pentetreotide on the cell surface, so that virus-infected"/>
   <result pre="herpesvirus-induced cancers, such as Burkitt's lymphoma, with the anti-cancer drug" exact="bortezomib" post="triggers expression of the viral TK, making it possible"/>
   <result pre="tumors to be visualized by PET, but potentially treated with" exact="ganciclovir" post="(Fu et al., 2007). As noted above, poxviruses also"/>
   <result pre="directly to virions to inhibit their replication are the adamantanes," exact="amantadine" post="and rimantidine, which block the M2 ion channel, preventing"/>
   <result pre="nature of this interaction suggests that small doses of radiolabeled" exact="amantadine" post="or rimantadine could be used to localize an influenza"/>
   <result pre="this interaction suggests that small doses of radiolabeled amantadine or" exact="rimantadine" post="could be used to localize an influenza virus infection"/>
   <result pre="both in laboratory animals and in humans. •Two licensed drugs," exact="oseltamivir" post="and zanamivir, inhibit the cell-to-cell spread of influenza A"/>
   <result pre="Opin. Biol. Ther.7200759559717477798 CassL.M.BrownJ.PickfordM.FayinkaS.NewmanS.P.JohanssonC.J.ByeA.Pharmacoscintigraphic evaluation of lung deposition of inhaled" exact="zanamivir" post="in healthy volunteersClin. Pharmacokinet.36Suppl. 11999213110429837 ChakrabartiB.K.MaitraR.K.MaX.Z.KestlerH.W.A candidate live inactivatable"/>
   <result pre="E2PLoS One42009e814219997645 ChenN.ZhangQ.YuY.A.StritzkerJ.BraderP.SchirbelA.SamnickS.SerganovaI.BlasbergR.FongY.SzalayA.A.A novel recombinant vaccinia virus expressing the human" exact="norepinephrine" post="transporter retains oncolytic potential and facilitates deep-tissue imagingMol. Med.15200914415119287510"/>
   <result pre="of RNA virusesAntiviral Res.78200892518313769 LivniE.BerkerM.HillierS.WallerS.C.OganM.D.DiscordiaR.P.RienhartJ.K.RubinR.H.FischmanA.J.Preparation and pharmacokinetics of 11C labeled" exact="stavudine" post="(d4T)Nucl. Med. Biol.31200461362115219280 LomholtS.Pharmacology of bismuth, with reference to"/>
   <result pre="cytomegalovirus pneumoniaClin. Nucl. Med.29200456957115311128 McCartJ.A.MehtaN.ScollardD.ReillyR.M.CarrasquilloJ.A.TangN.DengH.MillerM.XuH.LibuttiS.K.AlexanderH.R.BartlettD.L.Oncolytic vaccinia virus expressing the human" exact="somatostatin" post="receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotideMol."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7126206\results\search\drugs\results.xml">
   <result pre="while it takes 60mins under temperature control techniques. JZ-1 and" exact="penciclovir" post="showed significant anti-HSV-2 effects, with improved host cell morphologies"/>
   <result pre="be detected after treatment for 6 h while that of" exact="penciclovir" post="was not obvious until treatment for 12 h. JZ-1"/>
   <result pre="The anti-HSV-2 effect of JZ-1 was superior to that of" exact="penciclovir" post="and berberine in vitro, and was mainly mediated by"/>
   <result pre="4 h. The supernatant was discarded and 100 μL of" exact="dimethyl sulfoxide" post="(DMSO) (Servicebio Technology Co., China) was added to each"/>
   <result pre="group, JV sands for JZ-1 treatment group, PV stands for" exact="penciclovir" post="treatment group, BV stands for berberine treatment group. Data"/>
   <result pre="control group. The morphologies and cell numbers in JZ-1 and" exact="penciclovir" post="groups were significantly improved compare to HSV-2 alone group."/>
   <result pre="in JZ-1 groups (12.5, 6.25, and 3.125 mg/mL) and the" exact="penciclovir" post="groups (0.3125, 0.15625, and 0.078125 mg/mL) was significantly increased."/>
   <result pre="group at 6 h, while there were no differences compare" exact="penciclovir" post="and berberine groups with HSV-2 alone group. Compared with"/>
   <result pre="with HSV-2 alone group, expression of gD in JZ-1 and" exact="penciclovir" post="groups was significantly reduced at 12 h, 18 h,"/>
   <result pre="observed in cell membrane and intracellular regions in JZ-1 and" exact="penciclovir" post="groups were significantly lower than HSV-2 alone group. The"/>
   <result pre="morphology by light microscopy and TEM indicates that JZ-1 and" exact="penciclovir" post="could inhibit HSV-2 infection in vitro and reduce damage"/>
   <result pre="The results of MTT assays also demonstrated that JZ-1 and" exact="penciclovir" post="could significantly inhibit HSV-2 infection and improve cell viability"/>
   <result pre="Only JZ-1 showed an antiviral effect at 6 h, while" exact="penciclovir" post="and berberine showed no such effect. However, JZ-1 and"/>
   <result pre="penciclovir and berberine showed no such effect. However, JZ-1 and" exact="penciclovir" post="both showed anti-HSV-2 effects in vitro at 12 h,"/>
   <result pre="group, JV stands for JZ-1 treatment group, PV stands for" exact="penciclovir" post="treatment group, BV stands for berberine treatment group.*P &amp;lt;"/>
   <result pre="there was no significant difference in expression of gD compare" exact="penciclovir" post="and berberine groups with HSV-alone group, indicating that JZ-1"/>
   <result pre="compared with HSV-2 adhesion and penetration groups. By contrast, in" exact="penciclovir" post="and berberine groups, expression of gD, gB, VP16, and"/>
   <result pre="adhesion group. The cell morphologies and numbers of virions in" exact="penciclovir" post="and berberine groups were not significantly different from HSV-2"/>
   <result pre="inhibit HSV-2 adhesion and penetration into VK2/E6E7 in vitro, while" exact="penciclovir" post="and berberine had no such effects. Expression of the"/>
   <result pre="VK2/E6E7 in vitro and improved health of the cells, while" exact="penciclovir" post="and berberine showed no such effects. 4 Discussion The"/>
   <result pre="2017). At present, nucleoside drugs such as acyclovir, ganciclovir, and" exact="penciclovir" post="are commonly used to treat HSV-2 infections. These drugs"/>
   <result pre="of VK2/E6E7. Firstly, we explored the anti-HSV-2 effects of JZ-1," exact="penciclovir" post="and berberine at 6 h, 12 h, 18 h,"/>
   <result pre="vital role in the early stages of viral infection. Both" exact="penciclovir" post="and JZ-1 showed apparent antiviral effects at the treatment"/>
   <result pre="state, intercellular space, and intercellular junctions) in the JZ-1 and" exact="penciclovir" post="groups were superior to those of HSV-2 alone group."/>
   <result pre="count by TEM confirmed the anti-HSV-2 effects of JZ-1 and" exact="penciclovir" post="in vitro. Cells in the HSV-2 alone group became"/>
   <result pre="other organelle damage. The morphology of cells in JZ-1 and" exact="penciclovir" post="groups was similar to the control group, suggesting that"/>
   <result pre="organelles. As a nucleoside antiviral drug, the anti-HSV-2 mechanism of" exact="penciclovir" post="is competitive inhibition of the HSV-2 polymerase, thus selectively"/>
   <result pre="al., 2017). The antiviral effect of JZ-1 was superior to" exact="penciclovir" post="at the treatment of 12 h, 18 h, and"/>
   <result pre="virions attached to the cell surface and cell morphologies in" exact="penciclovir" post="group were closer to the virus adhesion group, suggesting"/>
   <result pre="group were closer to the virus adhesion group, suggesting that" exact="penciclovir" post="had no effect on the adhesion stage of HSV-2."/>
   <result pre="effect of JZ-1 was superior to that of chemical drug" exact="penciclovir" post="while using alone of berberine, the main component of"/>
   <result pre="Inflamm.2019201912 PingX.U.ZhuoC.LijunX.U.FuerL.U.Spermicidal effect of jieze No. 1 in combination with" exact="nonoxynol-9" post="in vitroJ. Huazhong Univ. Sci. Technol. Sci.252005225228 QianC.C.[Distinguishing some"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7126217\results\search\drugs\results.xml">
   <result pre="chicken red blood cells DMEM Dulbecco's Modified Eagle Medium DMSO" exact="dimethyl sulfoxide" post="EID50 50% egg infective dose FBS fetal bovine serum"/>
   <result pre="progoitrin, epigoitrin and goitrin were dissolved in 1 mL of" exact="dimethyl sulfoxide" post="(DMSO) and diluted with sodium chloride injection to get"/>
   <result pre="injection (Shijiazhuang Siyao Co., Ltd.), phosphate buffered saline (PBS, Hyclone)," exact="dimethyl sulfoxide" post="(DMSO, Sigma), Alsever's solution (pH 6.1) an isotonic solution"/>
   <result pre="experiments with virus concentration of 50 EID50. 3 mg/mL of" exact="peramivir" post="was used as the positive control and sodium chloride"/>
   <result pre="activity of the drugs. As shown in Table 2 ," exact="peramivir" post="presented dose-dependent NA inhibitory activity with IC50 value of"/>
   <result pre="Medical Science PressBeijing CorreiaV.SantosL.A.GiriaM.Almeida-SantosM.M.Rebelo-de-AndradeH.Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to" exact="oseltamivir" post="and zanamivir antiviral drugsJ. Med. Virol.872015455625042157 CourtinN.FotsoA.F.FautradP.MasF.AlessiM.C.RiteauB.Antiviral activity of"/>
   <result pre="PressBeijing CorreiaV.SantosL.A.GiriaM.Almeida-SantosM.M.Rebelo-de-AndradeH.Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and" exact="zanamivir" post="antiviral drugsJ. Med. Virol.872015455625042157 CourtinN.FotsoA.F.FautradP.MasF.AlessiM.C.RiteauB.Antiviral activity of formyl peptide"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7127009\results\search\drugs\results.xml">
   <result pre="with the cytokine storm in severe cases and use of" exact="tocilizumab" post="has shown good outcomes in a small cohort. Baricitinib"/>
   <result pre="commonly used immunosuppressive drugs such as JAK kinase inhibitors and" exact="tocilizumab" post="have been proposed and/or used for the treatment of"/>
   <result pre="that hydroxychloroquine, which shares the same mechanism of action as" exact="chloroquine" post="but has a better safety profile and is frequently"/>
   <result pre="connective tissue disease, has a more potent anti-viral effect than" exact="chloroquine" post="in vitro. From the results of physiologically-based pharmacokinetic models,"/>
   <result pre="daily for four days reaches three times the potency of" exact="chloroquine" post="and is therefore a promising drug for both the"/>
   <result pre="clinical trials that are ongoing to study the efficacy of" exact="chloroquine" post="or hydroxychloroquine in CoViD-19 patients. Hydroxychloroquine is thus being"/>
   <result pre="that are ongoing to study the efficacy of chloroquine or" exact="hydroxychloroquine" post="in CoViD-19 patients. Hydroxychloroquine is thus being used in"/>
   <result pre="or life-threatening cytokine release syndrome [12]. A single dose of" exact="tocilizumab" post="was used in 21 patients in China suffering from"/>
   <result pre="with crowded places. Smart working is encouraged. 3- Chloroquine and" exact="hydroxychloroquine" post="seem to have some efficacy on SARS-CoV2 infection. 4-"/>
   <result pre="biologic drugs, must be guaranteed for rheumatic patients. This includes" exact="tocilizumab" post="and baricitinib availability for patients chronically taking these compounds,"/>
   <result pre="biologic therapies which are available only in some hospitals. As" exact="tocilizumab" post="and baricitinib may start to be used to treat"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="monocyte-derived macrophages and dendritic cellsJ. Virol.837200930393048Epub 2008/11/1219004938 12LeR.Q.LiL.YuanW.ShordS.S.NieL.HabtemariamB.A.FDA approval summary:" exact="tocilizumab" post="for treatment of chimeric antigen receptor T cell-induced severe"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7127693\results\search\drugs\results.xml">
   <result pre="restrict HIV-1 infection by binding to the capsid core and" exact="cyclosporine" post="A (CsA), which can effectively turn off restriction (Hulme"/>
   <result pre="ganciclovir, penciclovir) (De Clercq and Li, 2016). In the body," exact="ganciclovir" post="is phosphorylated by cellular kinases and penciclovir and acyclovir"/>
   <result pre="In the body, ganciclovir is phosphorylated by cellular kinases and" exact="penciclovir" post="and acyclovir by virus-encoded thymidine kinases to the active"/>
   <result pre="in murine leukemia virusJ. Biol. Chem.291392016206302064227514744 DongH.ChangD.C.HuaM.H.C.LimS.P.ChionhY.H.HiaF.LeeY.H.KukkaroP.LokS.-M.DedonP.C.ShiP.-Y.2′-O methylation of internal" exact="adenosine" post="by flavivirus NS5 methyltransferasePLoS Pathog.842012e100264222496660 DriscollM.D.RentergentJ.HayS.A quantitative fluorescence-based steady-state"/>
   <result pre="simplex virus type 1 thymidine kinase mutants engineered for improved" exact="ganciclovir" post="or acyclovir activityProtein Sci.11920022267227212192082 KonvalinkaJ.KräusslichH.-G.MüllerB.Retroviral proteases and their roles"/>
   <result pre="activityJ. Virol.79212005133731338416227259 LiJ.ChorbaJ.S.WhelanS.P.Vesicular stomatitis viruses resistant to the methylase inhibitor" exact="sinefungin" post="upregulate RNA synthesis and reveal mutations that affect mRNA"/>
   <result pre="SOCS genes, the negative regulators of cytokine signalingMicrobiol. Immunol.615201715916728419615 SchäferlingM.WolfbeisO.S.Europium" exact="tetracycline" post="as a luminescent probe for nucleoside phosphates and its"/>
   <result pre="phosphorylated motifsJ. Biol. Chem.277422002393793938712151408 ZhangZ.YangE.HuC.ChengH.ChenC.Y.HuangD.WangR.ZhaoY.RongL.VignuzziM.ShenH.ShenL.ChenZ.W.Cell-based high-throughput screening assay identifies 2′,2′-difluoro-2′-deoxycytidine" exact="gemcitabine" post="as a potential antipoliovirus agentACS Infect. Dis.312017455327733043 ZhaoQ.LiS.XueF.ZouY.ChenC.BartlamM.RaoZ.Structure of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7128205\results\search\drugs\results.xml">
   <result pre="initiate clinical trials. For example, novel anti-ZIKV activities of enoxacin," exact="amodiaquine" post="and niclosamide were discovered recently using human neural progenitor"/>
   <result pre="trials. For example, novel anti-ZIKV activities of enoxacin, amodiaquine and" exact="niclosamide" post="were discovered recently using human neural progenitor cells, human"/>
   <result pre="also known as T-705, was approved against FLUAV in Japan;" exact="cidofovir" post="is an injectable antiviral medication used as a treatment"/>
   <result pre="are undergoing surveillance studies (phase IV). Azithromycin, chloroquine, cyclosporine, ezetimibe," exact="mycophenolic acid," post="nitazoxanide and rapamycin progressed to phase IV studies without"/>
   <result pre="surveillance studies (phase IV). Azithromycin, chloroquine, cyclosporine, ezetimibe, mycophenolic acid," exact="nitazoxanide" post="and rapamycin progressed to phase IV studies without approvals"/>
   <result pre="other coronaviruses (Figure 5 ). For example, teicoplanin, oritavancin, dalbavancin," exact="monensin" post="and emetine could be repurposed for treatment of COVID-19."/>
   <result pre="emetine could be repurposed for treatment of COVID-19. Teicoplanin, ritavancin," exact="dalbavancin" post="and monensin are approved antibiotics, whereas emetine is an"/>
   <result pre="be repurposed for treatment of COVID-19. Teicoplanin, ritavancin, dalbavancin and" exact="monensin" post="are approved antibiotics, whereas emetine is an anti-protozoal drug."/>
   <result pre="corona- as well as some other viral infections . Moreover," exact="chloroquine" post="and remdesivir were shown to effectively inhibit SARS-CoV-2 infection"/>
   <result pre="addition, clinical investigations into the effectiveness of lopinavir, ritonavir, remdesivir," exact="hydroxychloroquine" post="and arbidol against COVID-19 have started recently (NCT04252664; NCT0425487;"/>
   <result pre="viral strains. For example, a cocktail of nitazoxanide, favipiravir, and" exact="niclosamide" post="could be developed for the treatment of viruses belonging"/>
   <result pre="the protection of patients from the secondary infections. For example," exact="azithromycin" post="could be used against FLUAV and Chlamydophila pneumoniae, Haemophilus"/>
   <result pre="some agents, such as doxycycline, artesunate, omeprazole, nitazoxanide, suramin, azithromycin," exact="minocycline" post="and chloroquine, could have novel antibacterial, antiprotozoal, antifungal or"/>
   <result pre="its cost (Table S1). For example, the concomitant actions of" exact="ezetimibe" post="and statins could be beneficial for treatment of both"/>
   <result pre="of antivirals: broad-spectrum inhibitorsCurr Opin Infect Dis28201559660226524332 DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.Obatoclax, saliphenylhalamide, and" exact="gemcitabine" post="inhibit influenza a virus infectionJ Biol Chem2872012353243533222910914 DiseaseG.B.D.InjuryI.PrevalenceC.Global, regional,"/>
   <result pre="One82013e78425 FerreiraA.C.ReisP.A.de FreitasC.S.SacramentoC.Q.Villas Boas HoelzL.BastosM.M.Beyond members of the flaviviridae family," exact="sofosbuvir" post="also inhibits chikungunya virus replicationAntimicrob Agents Chemother632019 FinkS.L.VojtechL.WagonerJ.SlivinskiN.S.J.JacksonK.J.WangR.The antiviral"/>
   <result pre="acidic endosomes with broad antiviral effectsPLoS Pathog82012e1002976 KaoJ.C.HuangFuW.C.TsaiT.T.HoM.R.JhanM.K.ShenT.J.The antiparasitic drug" exact="niclosamide" post="inhibits dengue virus infection by interfering with endosomal acidification"/>
   <result pre="of slow proliferating HepG2-NTCP cellsJ Hepatol71201928930031077792 KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.Obatoclax, saliphenylhalamide and" exact="gemcitabine" post="inhibit Zika virus infection in vitro and differentially affect"/>
   <result pre="Zika virusNat Commun92018209029844387 SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.MirandaM.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci Rep720174092028098253 Sarzotti-KelsoeM.BailerR.T.TurkE.LinC.L.BilskaM.GreeneK.M.Optimization and validation of"/>
   <result pre="and tagging of every replicase proteinPLoS One112016e0151616 WangY.M.LuJ.W.LinC.C.ChinY.F.WuT.Y.LinL.I.Antiviral activities of" exact="niclosamide" post="and nitazoxanide against chikungunya virus entry and transmissionAntiviral Res1352016819027742486"/>
   <result pre="of every replicase proteinPLoS One112016e0151616 WangY.M.LuJ.W.LinC.C.ChinY.F.WuT.Y.LinL.I.Antiviral activities of niclosamide and" exact="nitazoxanide" post="against chikungunya virus entry and transmissionAntiviral Res1352016819027742486 WatanabeM.ButhJ.E.VishlaghiN.de la"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7128376\results\search\drugs\results.xml">
   <result pre="et al., 2013; Markland et al., 2000) 2. Ritonavir and" exact="lopinavir" post="SARS, MERS (Chu et al., 2004) 3. Ribavirin RSV"/>
   <result pre="1984) 4. Reverse transcriptase inhibitors: zidovudine, didanosine, zalcitabine, stavudine, lamivudine," exact="abacavir" post="and emtricitabine. SARS (De Clercq, 2007) 5. Nucleotide reverse"/>
   <result pre="emtricitabine. SARS (De Clercq, 2007) 5. Nucleotide reverse transcriptase inhibitor:" exact="tenofovir" post="disoproxil fumarate. SARS (De Clercq, 2007) 6. Non-nucleoside reverse"/>
   <result pre="(De Clercq, 2007) 6. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): nevirapine," exact="delavirdine" post="and efavirenz. SARS De Clercq, 2007 7. Protease Inhibitors"/>
   <result pre="7. Protease Inhibitors (PIs): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir," exact="atazanavir" post="and fosamprenavir. SARS De Clercq, 2007 8. Fusion inhibitor:"/>
   <result pre="by HIV protease. This drug along with another flu drug" exact="oseltamivir" post="was reported to result in complete recovery after showing"/>
   <result pre="2020b). 10.4 Remidesivir (anti-viral peptide) This particular drug is an" exact="adenosine" post="nucleotide analog, which was used in treatments against Ebola,"/>
   <result pre="Sun Yat-Sen University 17. A study for the efficacy of" exact="hydroxychloroquine" post="for mild and moderate COVID-19 infectious diseases Hydroxychloroquine –"/>
   <result pre="randomized, open-label, parallel controlled trial for the preventive effect of" exact="hydroxychloroquine" post="on medical personnel after exposure to COVID-19 Hydroxychloroquine –"/>
   <result pre="Ritonavir in the Treatment of Novel Coronavirus Infection Ganovo with" exact="ritonavir" post="+/-Interferon Recruiting The Ninth Hospital of NanchangNanchang, Jiangxi, China"/>
   <result pre="Minneapolis, Minnesota, United States 35. The efficacy and safety of" exact="pirfenidone" post="capsules in the treatment of severe new coronavirus pneumonia"/>
   <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistanceCurr. Opin. Virol.82014101510.1016/j.coviro.2014.04.01124846716 BeckB.R.ShinB.ChoiY.ParkS.KangK.Predicting commercially availableantiviral drugs that may"/>
   <result pre="and with clinical specimensJ. Clin. Microbiol.202010.1128/JCM.00310-20 CheemaS.U.R.RehmanM.S.HussainG.CheemaS.S.GilaniN.Efficacy and tolerability of" exact="sofosbuvir" post="and daclatasvir for treatment of hepatitis C genotype 1"/>
   <result pre="clinical specimensJ. Clin. Microbiol.202010.1128/JCM.00310-20 CheemaS.U.R.RehmanM.S.HussainG.CheemaS.S.GilaniN.Efficacy and tolerability of sofosbuvir and" exact="daclatasvir" post="for treatment of hepatitis C genotype 1 &amp;amp; 3"/>
   <result pre="fusionJ. Virol.8220082883289410.1128/JVI.01805-0718199653 HsiehL.E.LinC.N.SuB.L.JanT.R.ChenC.M.WangC.H.LinD.S.LinC.T.ChuehL.L.Synergistic antiviral effect of Galanthus nivalis agglutinin and" exact="nelfinavir" post="against feline coronavirusAntivir. Res.882010253010.1016/j.antiviral.2010.06.01020603153 HuF.JiangJ.YinP.Prediction of Potential Commercially Inhibitors"/>
   <result pre="in the viral replication cycleAntivir. Res.75200717918710.1016/j.antiviral.2007.03.00317428553 KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob. Agents"/>
   <result pre="disease (COVID-19) infectionJ. Inf. Secur.202010.1016/j.jinf.2020.03.016 LewinsohnD.M.BowdenR.A.MattsonD.CrawfordS.W.Phase I study of intravenous" exact="ribavirin" post="treatment of respiratory syncytial virus pneumonia after marrow transplantationAntimicrob."/>
   <result pre="activity of the IMP dehydrogenase inhibitor VX-497: a comparison with" exact="ribavirin" post="and demonstration of antiviral additivity with alpha interferonAntimicrob. Agents"/>
   <result pre="McIntoshK.KurachekS.C.CairnsL.M.BurnsJ.C.GoodspeedB.Treatment of respiratory viral infection in an immunodeficient infant with" exact="ribavirin" post="aerosolAm. J, Dis. Child.13819843053086322573 MengelingW.WLM.ADB.AER.Characteristics of a coronavirus (strain"/>
   <result pre="resistance-inducing protein isolated from Clerodendrum inerme Gaertn. Is a polynucleotide:" exact="adenosine" post="glycosidase (ribosome-inactivating protein)FEBS Lett.39619961321348914973 OtakeT.MoriH.MorimotoM.UebaN.SutardjoS.KusumotoI.T.HattoriM.NambaT.Screening of Indonesian plant extracts"/>
   <result pre="with 2019 novel coronavirus–infected pneumonia in Wuhan, ChinaJama32320201061106910.1001/jama.2020.1585 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="coronavirus SARS-CoV-2Eur. J. Nucl. Med. and Mol. Imaging20201610.1007/s00259-020-04735-9 YanY.ZouZ.SunY.LiX.XuK.-F.WeiY.JinN.JiangC.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="the absence of growth factorsBiochem. J.392200513514310.1042/BJ2005069816048439 YaoT.T.QianJ.D.ZhuW.Y.WangY.WangG.Q.A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-A possible reference"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7128395\results\search\drugs\results.xml">
   <result pre="5 of the patients with CKD) received antiviral therapy and" exact="hydroxychloroquine" post="as per our protocol. Dexamethasone and tocilizumab have been"/>
   <result pre="antiviral therapy and hydroxychloroquine as per our protocol. Dexamethasone and" exact="tocilizumab" post="have been used, respectively, in 11 and 6 of"/>
   <result pre="effect, and antiviral drugs may be considered (e.g., chloroquine-hydroxychloroquine, lopinavir/ritonavir," exact="darunavir" post="ritonavir, and darunavir/cobicistat). The second phase of the disease"/>
   <result pre="evidence seems to support the role of antiviral activity of" exact="chloroquine" post="toward the SARS and avian influenza viruses in in"/>
   <result pre="molecular structure, a well-known immunomodulating effect,10 and better safety profile," exact="hydroxychloroquine" post="may be considered as an option in this context,11"/>
   <result pre="study performed on patients with COVID-19 infection and treated with" exact="hydroxychloroquine" post="demonstrated that combination with azithromycin was associated with a"/>
   <result pre="COVID-19 infection and treated with hydroxychloroquine demonstrated that combination with" exact="azithromycin" post="was associated with a higher probability of showing a"/>
   <result pre="the therapy compared with controls and with those who received" exact="hydroxychloroquine" post="alone.12 Corticosteroids The use of corticosteroids would be contraindicated"/>
   <result pre="to have in the development of the cytokine release syndrome,17" exact="tocilizumab" post="could play a role in the management of selected"/>
   <result pre="During this phase, treatment with glucocorticoid and the interleukin-6 inhibitor" exact="tocilizumab" post="should be considered, especially in patients with rapid clinical"/>
   <result pre="2019 pandemic and kidneys. Kidney Int, in press. 7WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumonia[Expert consensus on"/>
   <result pre="chloroquine in the treatment of novel coronavirus pneumonia[Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]Zhonghua Jie"/>
   <result pre="al. A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19 [e-pub ahead of print]."/>
   <result pre="https://doi.org/10.1016/j.jcrc.2020.03.005. Accessed March 23, 2020. 10van den BorneB.E.DijkmansB.A.de RooijH.H.Chloroquine and" exact="hydroxychloroquine" post="equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma"/>
   <result pre="Tong Q. COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression [e-pub ahead of print]."/>
   <result pre="12Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7128473\results\search\drugs\results.xml">
   <result pre="ongoing to further evaluate efficacy in affected patients. Although ritonavir-boosted" exact="lopinavir" post="showed some antiviral effect on SARS-CoV-2 in vitro, a"/>
   <result pre="compared to no treatment.28 Other drugs currently under evaluation include" exact="chloroquine" post="phosphate or hydroxychloroquine.29 Chloroquine has shown antiviral efficacy against"/>
   <result pre="with certain immunosuppressive therapies where drug levels of cyclosporine, tacrolimus," exact="sirolimus" post="or everolimus will have to be closely monitored. In"/>
   <result pre="immunosuppressive therapies where drug levels of cyclosporine, tacrolimus, sirolimus or" exact="everolimus" post="will have to be closely monitored. In addition, patients"/>
   <result pre="hepatitis B and C •Liver toxicity (↑ALT) possible Chloroquine/Hydroxychloroquine35 ±" exact="azithromycin" post="•Interference with the cellular receptor ACE224 •Endosomal acidification fusion"/>
   <result pre="AST possible. •No data in cirrhosis available Sofosbuvir∗maybe combination with" exact="ribavirin" post="•Nucleotide analogue, RdRp-inhibitor •Approved for treatment of chronic hepatitis"/>
   <result pre="(see Table 1 for guidance with regards to CLD) •Prevent" exact="acetaminophen" post="overdosing (2–3 g/day is considered safe in patients with"/>
   <result pre="molecule GS-5734 against Ebola virus in rhesus monkeysNature531201638138526934220 24WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="in adults hospitalized with severe Covid-19N Engl J Med2020 29GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="to treat coronavirus disease 2019 (COVID-19)Drug Discoveries Ther1420205860 32GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="challengeMayo Clinic Proc852010451458 34COVID-19 Drug interactions2020Available from:http://www.covid19-druginteractions.org/ 35[Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]Zhonghua Jie"/>
   <result pre="He He Hu Xi Za Z432020E019 36Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="in SingaporeJAMA2020[Epub ahead of print] 38CasadoJ.L.Del PalacioM.MoyaJ.RodriguezJ.M.MorenoA.Perez-ElíasM.J.Safety and pharmacokinetics of" exact="lopinavir" post="in HIV/HCV coinfected patients with advanced liver diseaseHIV Clin"/>
   <result pre="diseaseHIV Clin Trials12201123524322180521 39GenoveseM.C.KremerJ.M.van VollenhovenR.F.AltenR.ScaliJ.J.KelmanA.Transaminase levels and hepatic events during" exact="tocilizumab" post="treatment: pooled analysis of long-term clinical trial safety data"/>
   <result pre="long-term clinical trial safety data in rheumatoid arthritisArthritis Rheumatol6920171751176128597609 40ChenL.-F.MoY.-Q.JingJ.MaJ.-D.ZhengD.-H.DaiL.Short-course" exact="tocilizumab" post="increases risk of hepatitis B virus reactivation in patients"/>
   <result pre="pancreatitis (TACTIC)Trials20201950131412955 50Press release on planned clinical trials to evaluate" exact="anakinra" post="and emapalumab in COVID-19. 2020. Available from: https://www.sobi.com/en/press-releases/sobi-initiate-clinical-study-evaluate-whether-anakinra-and-emapalumab-may-relieve. [Accessed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7128678\results\search\drugs\results.xml">
   <result pre="molecular modelling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infection FantiniJacquesjacques.fantini@univ-amu.frab�?�Di ScalaCoraliecChahinianHenriabYahiNouaraab[a], [b], [c],"/>
   <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infection FantiniJacquesjacques.fantini@univ-amu.frab�?�Di ScalaCoraliecChahinianHenriabYahiNouaraab[a], [b], [c], �?�Corresponding author."/>
   <result pre="SARS�?CoV�?2 poses a global health emergency. •Promising results suggest that" exact="chloroquine" post="could stop the spread of SARS�?CoV�?2. •In-silico studies confirm"/>
   <result pre="the antiviral properties of chloroquine. •New mechanism of action of" exact="chloroquine" post="elucidated. •Hydroxychloroquine is more potent than chloroquine. Abstract The"/>
   <result pre="of structural and molecular modelling approaches, this study showed that" exact="chloroquine" post="(CLQ), one of the drugs currently under investigation for"/>
   <result pre="in the presence of CLQ [or its more active derivative," exact="hydroxychloroquine" post="(CLQ-OH)], the viral S protein is no longer able"/>
   <result pre="delay [2,3]. Several drugs have already been tested, among which" exact="chloroquine" post="(CLQ), a well-known antimalarial drug, is one of the"/>
   <result pre="In addition, the antiviral potential of CLQ and its derivative" exact="hydroxychloroquine" post="(CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found"/>
   <result pre="interaction of -79 kJ.mol−1Fig. 1(f). Fig. 1 Chemical structure of" exact="chloroquine" post="(CLQ) and hydroxychloroquine (CLQ-OH). (a) CLQ. (b) CLQ-OH. (c)"/>
   <result pre="kJ.mol−1Fig. 1(f). Fig. 1 Chemical structure of chloroquine (CLQ) and" exact="hydroxychloroquine" post="(CLQ-OH). (a) CLQ. (b) CLQ-OH. (c) CLQ-OH extended conformer."/>
   <result pre="and van der Waals interactions. Fig. 2 Molecular modelling of" exact="chloroquine" post="(CLQ) interaction with sialic acids. (a,b) Surface representation of"/>
   <result pre="obtained for CLQ (-45 kJ.mol−1). Fig. 3 Molecular modelling of" exact="hydroxychloroquine" post="(CLQ-OH) interaction with sialic acids. (a,b) Surface representation of"/>
   <result pre="or bound to gangliosides. Fig. 4 Molecular modelling simulations of" exact="chloroquine" post="(CLQ) and hydroxychloroquine (CLQ-OH) binding to ganglioside GM1. The"/>
   <result pre="gangliosides. Fig. 4 Molecular modelling simulations of chloroquine (CLQ) and" exact="hydroxychloroquine" post="(CLQ-OH) binding to ganglioside GM1. The surface electrostatic potential"/>
   <result pre="of the NTD to the gangliosides is particularly obvious. As" exact="chloroquine" post="also interacts with the saccharide part of GM1, its"/>
   <result pre="of which with lipid rafts can be efficiently prevented by" exact="chloroquine" post="and hydroxychloroquine. 3.7 Molecular mechanism of CLQ and CLQ-OH"/>
   <result pre="too high to occur. Fig. 9 Mechanism of action of" exact="hydroxychloroquine" post="(CLQ-OH). The N-terminal domain (NTD) bound to GM1 was"/>
   <result pre="for the 2019 novel coronavirus SARS-CoV-2Int J Antimicrob Agents552020105923 4GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="functional cholesterol-binding domains in membrane proteinsMethods Mol Biol1583201771928205163 12ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents2020"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7128679\results\search\drugs\results.xml">
   <result pre="for patients who are in life-threatening situations. Third, surfactant, inhaled" exact="nitric oxide," post="various ventilation methods, and extracorporeal life support cannot be"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7128742\results\search\drugs\results.xml">
   <result pre="for prospective clinical trials to test the post-exposure potential of" exact="hydroxychloroquine" post="against COVID-19 PicotStephanestephane.picot@univ-lyon1.frab�?�MartyAileencBienvenuAnne-LiseadBlumbergLucille H.eDupouy-CametJeanfCarnevalePierregKanoShigeyukihJonesMalcolm K.iDaniel-RibeiroCláudio TadeujMas-ComaSantiagok[a], [b], [c], [d],"/>
   <result pre="for high-quality evaluation protocols of the potential beneficial effect of" exact="hydroxychloroquine" post="(HCQ) as a post-exposure drug for exposed people. In"/>
   <result pre="raised by publicity both regarding the potential beneficial effect of" exact="hydroxychloroquine" post="(HCQ) as well as potential risks from HCQ, we"/>
   <result pre="paucity of clinical evidences of an unequivocal beneficial effect of" exact="chloroquine" post="on COVID-19, the absence of an effective treatment so"/>
   <result pre="far, the untimely publicity given to the potential effect of" exact="chloroquine" post="and the consequent social and political pressure raised the"/>
   <result pre="clinical trials to answer the question: can prophylactic doses of" exact="hydroxychloroquine" post="decrease the risk of clinical infection in documented exposed"/>
   <result pre="for high-quality evaluation protocols of the potential beneficial effect of" exact="hydroxychloroquine" post="(HCQ) as post-exposure drug for exposed people, meaning people"/>
   <result pre="Here we provide information that justifies a clinical trial of" exact="hydroxychloroquine" post="[1] as a post-exposure drug together with the background"/>
   <result pre="virus. 2.4 Why Hydroxychloroquine is a more soluble hydroxy-analogue of" exact="chloroquine" post="(CQ), which was first synthesized by Hans Andersag in"/>
   <result pre="in endemic areas [5]. In the 1990s studies revealed that" exact="hydroxychloroquine" post="(HCQ), has immunomodulatory properties; leading to its use in"/>
   <result pre="early as the 1990s, researchers noted the antiviral effect of" exact="hydroxychloroquine" post="[7]. Currently, there are over 123 references on PubMed"/>
   <result pre="hydroxychloroquine�? similarly, web of science reveals a high interest in" exact="hydroxychloroquine" post="and its role in viral diseases since the early"/>
   <result pre="role in viral diseases since the early 1990s. Hydroxychloroquine and" exact="chloroquine" post="have demonstrated in vitro antiviral effectiveness against Herpes simplex"/>
   <result pre="some studies suggested, at least in vitro, some efficacy of" exact="chloroquine" post="on the SARS-CoV virus [12,13] or MERS-CoV [17]. Using"/>
   <result pre="et al. showed that Hydroxychloroquine (HCQ) was more potent than" exact="chloroquine" post="(EC50 = 0.72 and EC50 = 5.47 μM respectively)"/>
   <result pre="to diffuse in the brain [27]. Based on this observation," exact="hydroxychloroquine" post="may reach antiviral concentrations in the brain, leading to"/>
   <result pre="which may persist after recovery from COVID-19. 3 Benefits/risks of" exact="hydroxychloroquine" post="against the virus 3.1 Benefits Hydroxychloroquine has a wide"/>
   <result pre="appropriate oral, administration [30]. The risk of retinopathy associated with" exact="hydroxychloroquine" post="treatment has been well documented for decades. It was"/>
   <result pre="but considering the lack of evidence for safety of post-exposure" exact="hydroxychloroquine" post="during pregnancy, we consider that pregnant women should be"/>
   <result pre="antiviral effect of chloroquine/hydroxychloroquine The exact mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against the virus has not been clearly"/>
   <result pre="of chloroquine/hydroxychloroquine The exact mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against the virus has not been clearly depicted; however,"/>
   <result pre="the cellular receptor for SARS-CoV-1 and SARS-CoV-2. In cell culture" exact="chloroquine" post="effectively prevents the spread of SARS CoV and works"/>
   <result pre="Experimental data from the Wuhan Institute of Virology demonstrated that" exact="chloroquine" post="inhibits the replication of the SARS-CoV-2, in part because"/>
   <result pre="prevents endocytosis-mediated uptake of SARS-CoV-2. There is also data that" exact="chloroquine" post="interferes with organelle acidification, which may lead to hindering"/>
   <result pre="which may lead to hindering fusion of viral particles, when" exact="chloroquine" post="treatment was used for different emerging or non-emerging virus"/>
   <result pre="[40], needed for receptor binding. 4.Immunomodulation: At the cellular level," exact="chloroquine" post="and hydroxychloroquine inhibit immune activation by reducing signaling by"/>
   <result pre="for receptor binding. 4.Immunomodulation: At the cellular level, chloroquine and" exact="hydroxychloroquine" post="inhibit immune activation by reducing signaling by Pattern Recognition"/>
   <result pre="preventing TLR signaling and cGAS–stimulator of interferon genes (STING) signaling," exact="hydroxychloroquine" post="can reduce the production of pro-inflammatory cytokines, including type"/>
   <result pre="means to control the outbreak become urgent. The use of" exact="hydroxychloroquine" post="as a post-exposure means to reduce sickness and transmission"/>
   <result pre="to test the hypothesis: ‘Does a post-exposure non-toxic dose of" exact="hydroxychloroquine" post="significantly alter SARS-CoV-2 replication in people exposed to a"/>
   <result pre="strategy for prevention is clearly achievable considering the safety of" exact="hydroxychloroquine" post="for a short period of time, its demonstrated antiviral"/>
   <result pre="of pharmaceutical companies, already ongoing, for increasing the production of" exact="hydroxychloroquine" post="specifically for COVID-19. Other initiative such as the &quot;Defense"/>
   <result pre="References References 1ZhouD.DaiS.-M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother.20 mars 202010.1093/jac/dkaa114"/>
   <result pre="Rheum Dis.201910.1136/annrheumdis-2019-215573Published Online First: 02 May 2019 4TettS.E.CutlerD.J.BeckC.DayR.O.Concentration-effect relationship of" exact="hydroxychloroquine" post="in patients with rheumatoid arthritis--a prospective, dose ranging studyJ"/>
   <result pre="6LandewéR.B.Goei ThèH.S.van RijthovenA.W.BreedveldF.C.DijkmansB.A.A randomized, double-blind, 24-week controlled study of low-dose" exact="cyclosporine" post="versus chloroquine for early rheumatoid arthritisArthritis Rheum. Mai3751994637643 7GoldringJ.P.NemaoraniS.Antimalarial"/>
   <result pre="RijthovenA.W.BreedveldF.C.DijkmansB.A.A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus" exact="chloroquine" post="for early rheumatoid arthritisArthritis Rheum. Mai3751994637643 7GoldringJ.P.NemaoraniS.Antimalarial drugs modulate"/>
   <result pre="metabolites are potent Zika virus inhibitorsJ. Med. Virol.91720191182119030801742 11SavarinoA.Use of" exact="chloroquine" post="in viral diseasesLancet Infect Dis. Sept1192011653654 12VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a"/>
   <result pre="infection and spreadVirol J.222 août 20056916115318 13KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob Agents"/>
   <result pre="null, Sahoo GC, Madhukar M, et al.Molecular docking studies of" exact="chloroquine" post="and its derivatives against P23pro-zbd domain of chikungunya virus:"/>
   <result pre="Oct1201020191829818308 15HelalG.K.GadM.A.Abd-EllahM.F.EidM.S.Hydroxychloroquine augments early virological response to pegylated interferon plus" exact="ribavirin" post="in genotype-4 chronic hepatitis C patientsJ. Med. Virol.881220162170217827183377 16SalataC.CalistriA.ParolinC.BaritussioA.PalùG.Antiviral"/>
   <result pre="licensed drugs in human monocyte-derived antigen-presenting cellsPLoS One1332018e0194868 18WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="C-terminal sorting motifsJ Virol. Oct812020071152011525 26RosenfeldM.R.YeX.SupkoJ.G.DesideriS.GrossmanS.A.BremS.A phase I/II trial of" exact="hydroxychloroquine" post="in conjunction with radiation therapy and concurrent and adjuvant"/>
   <result pre="hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant" exact="temozolomide" post="in patients with newly diagnosed glioblastoma multiformeAutophagy. Août108201413591368 27OlafuyiO.BadhanR.K.S.Dose"/>
   <result pre="patients with newly diagnosed glioblastoma multiformeAutophagy. Août108201413591368 27OlafuyiO.BadhanR.K.S.Dose optimization of" exact="chloroquine" post="by pharmacokinetic modeling during pregnancy for the treatment of"/>
   <result pre="in patients with Sjögren syndromeQJM112101 oct 201975776231218368 30KrishnaS.WhiteN.J.Pharmacokinetics of quinine," exact="chloroquine" post="and amodiaquineClinical Implications. Clin Pharmacokinet. Avr3041996263299 31JorgeA.UngC.YoungL.H.MellesR.B.ChoiH.K.Hydroxychloroquine retinopathy -"/>
   <result pre="review of the literatureJ Rheumatol. Déc3812201125042508 33Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="of emerging viral diseasesPharmacol. Res. Perspect.512017e00293 34HuT.Y.FriemanM.WolframJ.Insights from nanomedicine into" exact="chloroquine" post="efficacy against COVID-19Nat Nanotechnol.23 mar 202010.1038/s41565-020-0674-9[Epub ahead of print]"/>
   <result pre="against COVID-19Nat Nanotechnol.23 mar 202010.1038/s41565-020-0674-9[Epub ahead of print] 35MallucciL.Effect of" exact="chloroquine" post="on lysosomes and on growth of mouse hepatitis virus"/>
   <result pre="on growth of mouse hepatitis virus (MHV-3)Virology. Mars2831966355362 36TakanoT.KatohY.DokiT.HohdatsuT.Effect of" exact="chloroquine" post="on feline infectious peritonitis virus infection in vitro and"/>
   <result pre="infection in vitro and in vivoAntiviral Res. Août9922013100107 37YanY.ZouZ.SunY.LiX.XuK.-F.WeiY.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza a H5N1"/>
   <result pre="glycoproteins into coronavirus virionsViruses743 avr 20151700172525855243 41SchrezenmeierE.DörnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol. Mars1632020155166 42LiuJ.CaoR.XuM.WangX.ZhangH.HuH.Hydroxychloroquine,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7129111\results\search\drugs\results.xml">
   <result pre="recommended by the latest Chinese guidance7 include interferon-α, lopinavir-ritonavir, arbidol," exact="chloroquine" post="phosphate and ribavirin. And favipiravir is recommended to be"/>
   <result pre="treatment, lopinavir-ritonavir treatment and control group (P &amp;gt; 0.05). For" exact="hydroxychloroquine" post="sulfate: an open-label, non-randomized clinical trial18 suggested, compared with"/>
   <result pre="nucleic acid turning negative of control group (12.5%), combination of" exact="hydroxychloroquine" post="sulfate and azithromycin (100%) and monotherapy of hydroxychloroquine sulfate"/>
   <result pre="negative of control group (12.5%), combination of hydroxychloroquine sulfate and" exact="azithromycin" post="(100%) and monotherapy of hydroxychloroquine sulfate (57.1%) significantly improved"/>
   <result pre="combination of hydroxychloroquine sulfate and azithromycin (100%) and monotherapy of" exact="hydroxychloroquine" post="sulfate (57.1%) significantly improved the rate of viral nucleic"/>
   <result pre="nucleic acid turning negative (P &amp;lt; 0.001). The effect of" exact="hydroxychloroquine" post="sulfate is reinforced by azithromycin. And such combination may"/>
   <result pre="turning negative were not significant. In addition, remdesivir, favipiravir, ribavirin," exact="chloroquine" post="phosphate and other antiviral drugs are still in ongoing"/>
   <result pre="Use Authorization (EUA) for emergency use of oral formulations of" exact="chloroquine" post="phosphate and hydroxychloroquine sulfate for the treatment of COVID-19.20"/>
   <result pre="for emergency use of oral formulations of chloroquine phosphate and" exact="hydroxychloroquine" post="sulfate for the treatment of COVID-19.20 Hospital pharmacists should"/>
   <result pre="to current antiviral drugs recommended by the latest Chinese guidance,7" exact="tocilizumab" post="is recommended for severe patients with extensive lung disease"/>
   <result pre="closely and dosage should be adjusted if necessary, for example," exact="ribavirin" post="may reduce the anticoagulant effect of warfarin, lopinavir-ritonavir may"/>
   <result pre="of novel coronavirus pneumoniaChin J of Infect Dis2020 18GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="non-randomized clinical trialInt J Antimicrob Agents2020 19ChenJ.LiuD.P.LiuL.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)Journal"/>
   <result pre="Food &amp;amp; Drug AdministrationLetter of emergency use authorization to allow" exact="hydroxychloroquine" post="sulfate and chloroquine phosphate to be distributed and used"/>
   <result pre="AdministrationLetter of emergency use authorization to allow hydroxychloroquine sulfate and" exact="chloroquine" post="phosphate to be distributed and used for certain hospitalized"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7129535\results\search\drugs\results.xml">
   <result pre="efficacy than standard care. However, the regimen of LPV/RTV plus" exact="ribavirin" post="was shown to be effective against SARS-CoV in vitro."/>
   <result pre="be effective against SARS-CoV in vitro. Another promising alternative is" exact="hydroxychloroquine" post="(200 mg thrice daily) plus azithromycin (500 mg on"/>
   <result pre="Another promising alternative is hydroxychloroquine (200 mg thrice daily) plus" exact="azithromycin" post="(500 mg on day 1, followed by 250 mg"/>
   <result pre="COVID-19 patients and anti-SARS-CoV-2 potency in vitro. The roles of" exact="teicoplanin" post="(which inhibits the viral genome exposure in cytoplasm) and"/>
   <result pre="some viral hemorrhagic fevers. The in vitro antiviral activity of" exact="ribavirin" post="against SARS-CoV was estimated to be at a concentration"/>
   <result pre="are papain-like protease and 3C-like protease.30 The antiviral activity of" exact="lopinavir" post="(LPV; Abbott Laboratories, Lake Bluff, Illinois, US) against MERS-CoV"/>
   <result pre="patients with SARS-CoV-2 infections in 2020 (ChiCTR2000029308). The role of" exact="darunavir" post="(Janssen Pharmaceutica, Beerse, Belgium), also a promising PI against"/>
   <result pre="a rhesus macaque model.35 Additionally, the regimen of LPV/RTV plus" exact="ribavirin" post="was shown to be effective against SARS-CoV in patients"/>
   <result pre="SARS-CoV in patients and in tissue culture.36 Chloroquine, hydroxychloroquine, and" exact="azithromycin" post="Chloroquine is active against malaria as well as autoimmune"/>
   <result pre="cellular receptors of SARS-CoV.38,39 Although the in vitro data of" exact="chloroquine" post="is promising (EC90 of 6.90 μM, using Vero E6"/>
   <result pre="Vero E6 cells infected by SARS-CoV-2), an extensive prescription of" exact="chloroquine" post="in clinical treatment of SARS-CoV-2 is a completely off-label"/>
   <result pre="phase SARS-CoV-2 infected patients.41 Hydroxychloroquine is significantly more potent than" exact="chloroquine" post="in vitro (EC50 values: 0.72 and 5.47 μM, respectively)"/>
   <result pre="potential for drug–drug interactions than chloroquine. Pharmacokinetic models demonstrate that" exact="hydroxychloroquine" post="sulfate is significant superior (5 days in advance) to"/>
   <result pre="hydroxychloroquine sulfate is significant superior (5 days in advance) to" exact="chloroquine" post="phosphate in inhibiting SARS-CoV-2 in vitro.41 The Taiwan CDC"/>
   <result pre="phosphate in inhibiting SARS-CoV-2 in vitro.41 The Taiwan CDC declared" exact="hydroxychloroquine" post="as an important anti-SARS-CoV-2 agent on 26 March, 2020."/>
   <result pre="of glucose-6-phosphatase, QTc prolongation in electrocardiograms, history of allergy to" exact="hydroxychloroquine" post="or who are pregnant or breastfeeding are contraindicated for"/>
   <result pre="or who are pregnant or breastfeeding are contraindicated for receiving" exact="hydroxychloroquine" post="therapy.42 Azithromycin (Pfizer Inc., Manhattan, New York City, NY,"/>
   <result pre="shown to be active in vitro against Ebola viruses.43 Furthermore," exact="azithromycin" post="is thought to have good potential in preventing severe"/>
   <result pre="to patients suffering viral infection.44 According to one recent study," exact="azithromycin" post="(500 mg on day 1, followed by 250 mg"/>
   <result pre="day 2–5) was shown to significantly reinforce the efficacy of" exact="hydroxychloroquine" post="(200 mg three times per day for 10 days)"/>
   <result pre="the treatment of 20 patients with severe COVID-19. Mean serum" exact="hydroxychloroquine" post="concentration was 0.46 ± 0.20 μg/mL. The good clinical"/>
   <result pre="after administration of this combination therapy.42 Consequently, the regimen of" exact="hydroxychloroquine" post="in combination with azithromycin might be a promising alternative"/>
   <result pre="combination therapy.42 Consequently, the regimen of hydroxychloroquine in combination with" exact="azithromycin" post="might be a promising alternative to remdesivir in the"/>
   <result pre="particles in the low micromolar range (IC50, 330 nM).45 Moreover," exact="teicoplanin" post="is able to block the MERS and SARS envelope"/>
   <result pre="SARS envelope pseudotyped viruses as well.45 Mechanistic investigations revealed that" exact="teicoplanin" post="specifically inhibits the activities of host cell's cathepsin L"/>
   <result pre="and subsequent release into the cytoplasm of host cells.46,47 Thus," exact="teicoplanin" post="blocks Ebola virus entry in the late endosomal pathway."/>
   <result pre="late endosomal pathway. These studies indicate the potential role of" exact="teicoplanin" post="and its derivatives (dalbavancin, oritavancin, and telavancin) as novel"/>
   <result pre="(camostat mesylate) Inhibition of endosomal acidification (early endosomal pathway) Chloroquine," exact="hydroxychloroquine" post="(azithromycin is reported to greatly enhance the anti-SARS-CoV-2 activity"/>
   <result pre="dalbavancin, oritavancin, and telavancin) Enhancement of the anti-SARS-CoV-2 activity of" exact="hydroxychloroquine" post="Azithromycin Monoclonal or polyclonal antibodies and other therapies Monoclonal"/>
   <result pre="against COVID-19 has been under evaluation in China recently. Additionally," exact="tocilizumab" post="(Roche Pharmaceuticals, Basel, Switzerland) is a monoclonal antibody that"/>
   <result pre="between 10 and 22 days after admission. Antiviral agents and" exact="methylprednisolone" post="were also administered. Following plasma transfusions, improvements in clinical"/>
   <result pre="receptors.66 For critically ill adults with COVID-19 who develop fever," exact="acetaminophen" post="might be a better choice for temperature control than"/>
   <result pre="by Wu et al. (2020), treatment of COVID-19 patients with" exact="methylprednisolone" post="was shown to decrease the case-fatality risk (HR, 0.38;"/>
   <result pre="(HR, 0.38; 95% CI, 0.20–0.72).68 However, the administered dose of" exact="methylprednisolone" post="is not specified in that investigation. Despite a lack"/>
   <result pre="therapy in adults with COVID-19 and refractory shock (e.g., intravenous" exact="hydrocortisone" post="200 mg per day, as a &quot;shock-reversal�? strategy).68 Moreover,"/>
   <result pre="most promising agent. In addition, favipiravir and combination therapy with" exact="hydroxychloroquine" post="plus azithromycin appear to be acceptable alternatives for treatment"/>
   <result pre="agent. In addition, favipiravir and combination therapy with hydroxychloroquine plus" exact="azithromycin" post="appear to be acceptable alternatives for treatment of COVID-19"/>
   <result pre="ARB need to be prescribed with caution. Compared with NSAIDs," exact="acetaminophen" post="might be a safer agent for treating fever in"/>
   <result pre="USA2020 Feb 1310.1073/pnas.1922083117pii: 201922083 26WangY.FanG.SalamA.HorbyP.HaydenF.G.ChenC.Comparative effectiveness of combined favipiravir and" exact="oseltamivir" post="therapy versus oseltamivir monotherapy in critically ill patients with"/>
   <result pre="201922083 26WangY.FanG.SalamA.HorbyP.HaydenF.G.ChenC.Comparative effectiveness of combined favipiravir and oseltamivir therapy versus" exact="oseltamivir" post="monotherapy in critically ill patients with influenza virus infectionJ"/>
   <result pre="for effective therapyN Engl J Med2020 Mar 1810.1056/NEJMe2005477 34NewsAbidol and" exact="darunavir" post="can effectively inhibit coronavirushttp://www.sd.chinanews.com/2/2020/0205/70145.html[in Chinese] 35FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.Treatment with interferon-α2b"/>
   <result pre="can effectively inhibit coronavirushttp://www.sd.chinanews.com/2/2020/0205/70145.html[in Chinese] 35FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat Med1920131313131724013700 36ChuC.M.ChengV.C.HungI.F.WongM.M.ChanK.H.ChanK.S.Role of"/>
   <result pre="treatment of SARS: initial virological and clinical findingsThorax59200425225614985565 37YanY.ZouZ.SunY.LiX.XuK.F.WeiY.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="inhibitor of SARS coronavirus infection and spreadVirol J220056910.1186/1743-422X-2-6916115318 39WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Res30202026927132020029 40CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care2020 Mar 1010.1016/j.jcrc.2020.03.005pii:"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii: S1684-1182 42GautretP.LagierJ.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="virus inhibitors for drug repurposingACS Infect Dis1201531732627622822 44BacharierL.B.GuilbertT.W.MaugerD.T.BoehmerS.BeigelmanA.FitzpatrickA.M.Early administration of" exact="azithromycin" post="and prevention of severe lower respiratory tract illnesses in"/>
   <result pre="scientific evidence that NSAID use worsens COVID-19 symptomsFrom:https://www.drugtopics.com/latest/fda-no-scientific-evidence-nsaid- use-worsens-covid-19-symptoms 66DayM.COVID-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7129715\results\search\drugs\results.xml">
   <result pre="ACE-2 receptors. There have been some anecdotal reports of successful" exact="chloroquine" post="treatment from China, and the guidelines of the Italian"/>
   <result pre="of COVID-19, but there is a question as to whether" exact="chloroquine" post="and hydroxychloroquine can play a prophylactic role as a"/>
   <result pre="but there is a question as to whether chloroquine and" exact="hydroxychloroquine" post="can play a prophylactic role as a randomised, double-blind,"/>
   <result pre="prophylactic role as a randomised, double-blind, placebo-controlled clinical trial of" exact="chloroquine" post="found that it did not prevent influenza infection [5]."/>
   <result pre="a trial involving 21 patients in China [6] found that" exact="tocilizumab" post="(an IL-6 receptor antagonist) quickly resolved some of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7130072\results\search\drugs\results.xml">
   <result pre="have been touted as promising therapies against COVID-19, such as" exact="chloroquine" post="and hydroxychloroquine.5 In fact, due to off-label prescriptions and"/>
   <result pre="and hydroxychloroquine.5 In fact, due to off-label prescriptions and hoarding," exact="hydroxychloroquine" post="is now difficult to obtain for patients without COVID-19"/>
   <result pre="Even more worrisome is the shortage of sedatives such as" exact="midazolam" post="and propofol which are needed for patients who are"/>
   <result pre="worrisome is the shortage of sedatives such as midazolam and" exact="propofol" post="which are needed for patients who are being intubated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7131061\results\search\drugs\results.xml">
   <result pre="China have given a combination of two HIV drugs –" exact="lopinavir" post="and ritonavir – to &quot;quite a number�? of people"/>
   <result pre="given a combination of two HIV drugs – lopinavir and" exact="ritonavir" post="– to &quot;quite a number�? of people with covid-19."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7131140\results\search\drugs\results.xml">
   <result pre="four existing, approved drugs that might also work: prulifloxacin, bictegravir," exact="nelfinavir" post="and tegobuvir (bioRxiv, doi.org/dk2z). Most promisingly, doctors in Wuhan,"/>
   <result pre="two randomised controlled trials. One will test two drugs called" exact="lopinavir" post="and ritonavir given together. These are already used to"/>
   <result pre="controlled trials. One will test two drugs called lopinavir and" exact="ritonavir" post="given together. These are already used to treat HIV,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7132016\results\search\drugs\results.xml">
   <result pre="that an acute ingestion of &amp;gt;7.5 to 10 g of" exact="acetaminophen" post="in adults or 150 to 200 mg/kg in children"/>
   <result pre="has proposed a decrease in the maximum daily dosage of" exact="acetaminophen" post="from 4 to 3 g, and the maximum individual"/>
   <result pre="with acute respiratory distress syndromeLancet Respir Med202010.1016/s2213-2600(20)30076-x 24HodgmanMJGarrardARA review of" exact="acetaminophen" post="poisoningCrit Care Clin20122849951610.1016/j.ccc.2012.07.00622998987 25KrenzelokEPThe FDA Acetaminophen Advisory Committee Meeting"/>
   <result pre="Acetaminophen Advisory Committee Meeting - what is the future of" exact="acetaminophen" post="in the United States? The perspective of a committee"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7132364\results\search\drugs\results.xml">
   <result pre="ResAntiviral Research0166-35421872-9096Elsevier B.V. pmcid: 7132364S0166-3542(20)30114-5 doi: 10.1016/j.antiviral.2020.104762104762 : Article Of" exact="chloroquine" post="and COVID-19 TouretFranckfranck.touret@univ-amu.frde LamballerieXavierxavier.de-lamballerie@univ-amu.fr∗[], ∗Corresponding author. xavier.de-lamballerie@univ-amu.fr pmc-release: 2020-3-3ppub:"/>
   <result pre="should consider this information in light of previous experiments with" exact="chloroquine" post="in the field of antiviral research. Highlights •In vitro"/>
   <result pre="field of antiviral research. Highlights •In vitro data suggest that" exact="chloroquine" post="inhibits SARS Cov-2 replication. •In past research, chloroquine has"/>
   <result pre="suggest that chloroquine inhibits SARS Cov-2 replication. •In past research," exact="chloroquine" post="has shown in vitro activity against many different viruses,"/>
   <result pre="without success. •The outcomes of some current clinical trials of" exact="chloroquine" post="in China have been announced, without access to the"/>
   <result pre="should consider this information in light of previous experiments with" exact="chloroquine" post="in the field of antiviral research. The sulfate and"/>
   <result pre="field of antiviral research. The sulfate and phosphate salts of" exact="chloroquine" post="have both been commercialised as antimalarial drugs. Hydroxychloroquine has"/>
   <result pre="autoimmune diseases such as lupus and rheumatoid arthritis. Of note," exact="chloroquine" post="and hydroxychloroquine are considered to be safe and side-effects"/>
   <result pre="such as lupus and rheumatoid arthritis. Of note, chloroquine and" exact="hydroxychloroquine" post="are considered to be safe and side-effects are generally"/>
   <result pre="margin between the therapeutic and toxic dose is narrow and" exact="chloroquine" post="poisoning has been associated with cardiovascular disorders that can"/>
   <result pre="that can be life-threatening (Frisk-Holmberg et al., 1983). Chloroquine and" exact="hydroxychloroquine" post="use should therefore be subject to strict rules, and"/>
   <result pre="self-treatment is not recommended. The in vitro antiviral activity of" exact="chloroquine" post="has been identified since the late 1960's (Inglot, 1969;"/>
   <result pre="different viruses can be inhibited in cell culture by both" exact="chloroquine" post="and hydroxychloroquine, including the SARS coronavirus (Keyaerts et al.,"/>
   <result pre="2017) and influenza A H5N1 (Yan et al., 2013). However," exact="chloroquine" post="did not prevent influenza infection in a randomized, double-blind,"/>
   <result pre="The case of chikungunya virus (CHIKV) is of specific interest:" exact="chloroquine" post="showed promising antiviral activity in vitro (Coombs et al.,"/>
   <result pre="probably because of the immune modulation and anti-inflammatory properties of" exact="chloroquine" post="in vivo (Connolly et al., 1988; Katz and Russell,"/>
   <result pre="al., 2003). In a nonhuman primate model of CHIKV infection," exact="chloroquine" post="treatment was shown to exacerbate acute fever and delay"/>
   <result pre="chikungunya outbreak in 2006 in Réunion Island showed that oral" exact="chloroquine" post="treatment did not improve the course of the acute"/>
   <result pre="date, no acute virus infection has been successfully treated by" exact="chloroquine" post="in humans. Chloroquine has also been tested in chronic"/>
   <result pre="panel recommended for HIV treatment. The only modest effect of" exact="chloroquine" post="in the therapy of human virus infection was found"/>
   <result pre="increase of the early virological response to pegylated interferon plus" exact="ribavirin" post="(Helal et al., 2016) and, in a small sample"/>
   <result pre="al., 2016) were observed. This was not enough to include" exact="chloroquine" post="in the standardised therapeutic protocols for hepatitis C patients."/>
   <result pre="ChiCTR2000029761, ChiCTR2000029760, ChiCTR2000029741, ChiCTR2000029740, ChiCTR2000029609, ChiCTR2000029559, ChiCTR2000029542) propose to use" exact="chloroquine" post="or hydroxychloroquine in the treatment of COVID-19 (&quot;Chinese Clinical"/>
   <result pre="ChiCTR2000029741, ChiCTR2000029740, ChiCTR2000029609, ChiCTR2000029559, ChiCTR2000029542) propose to use chloroquine or" exact="hydroxychloroquine" post="in the treatment of COVID-19 (&quot;Chinese Clinical Trial Register&quot;"/>
   <result pre="briefing&quot;, &quot;results from more than 100 patients have demonstrated that" exact="chloroquine" post="phosphate is superior to the control treatment in inhibiting"/>
   <result pre="disease course&quot;. This would represent the first successful use of" exact="chloroquine" post="in humans for the treatment of an acute viral"/>
   <result pre="to know if the observed efficacy is associated specifically with" exact="chloroquine" post="phosphate, or if this includes other salts (e.g., sulfate)"/>
   <result pre="It is also necessary to determine if the benefit of" exact="chloroquine" post="therapy depends on the age class, the clinical presentation"/>
   <result pre="stage of the disease. In conclusion, the option of using" exact="chloroquine" post="in the treatment of SARS-CoV-2 should be examined with"/>
   <result pre="practice. References References ChauhanA.TikooA.The enigma of the clandestine association between" exact="chloroquine" post="and HIV-1 infectionHIV Med.16201558559026238012 Chinese Clinical Trial Register (ChiCTR)The"/>
   <result pre="rats treated with disease modifying antirheumatic drugsAgents Actions251988941053142230 CoombsK.MannE.EdwardsJ.BrownD.T.Effects of" exact="chloroquine" post="and cytochalasin B on the infection of cells by"/>
   <result pre="stomatitis virusJ. Virol.371981106010656262524 De LamballerieX.BoissonV.ReynierJ.-C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On chikungunya acute infection and" exact="chloroquine" post="treatmentVector Borne Zoonotic82008837839 DeloguI.de LamballerieX.Chikungunya disease and chloroquine treatmentJ."/>
   <result pre="infection and chloroquine treatmentVector Borne Zoonotic82008837839 DeloguI.de LamballerieX.Chikungunya disease and" exact="chloroquine" post="treatmentJ. Med. Virol.8320111058105921503920 DowallS.D.BosworthA.WatsonR.BewleyK.TaylorI.RaynerE.HunterL.PearsonG.EasterbrookL.PitmanJ.HewsonR.CarrollM.W.Chloroquine inhibited Ebola virus replication in"/>
   <result pre="modelJ. Gen. Virol.9620153484349226459826 FalzaranoD.SafronetzD.PrescottJ.MarziA.FeldmannF.FeldmannH.Lack of protection against ebola virus from" exact="chloroquine" post="in mice and hamstersEmerg. Infect. Dis.2120151065106725988934 Frisk-HolmbergM.BergqvistY.EnglundU.Chloroquine intoxication [letter]Br."/>
   <result pre="hamstersEmerg. Infect. Dis.2120151065106725988934 Frisk-HolmbergM.BergqvistY.EnglundU.Chloroquine intoxication [letter]Br. J. Clin. Pharmacol.1519835025036849790 GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="Trends2020 HelalG.K.GadM.A.Abd-EllahM.F.EidM.S.Hydroxychloroquine augments early virological response to pegylated interferon plus" exact="ribavirin" post="in genotype-4 chronic hepatitis C patientsJ. Med. Virol.8820162170217827183377 InglotA.D.Comparison"/>
   <result pre="new mechanisms of actionCurr. Opin. Rheumatol.23201127828121448012 KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob. Agents"/>
   <result pre="controlled trialLancet Infect. Dis.11201167768321550310 PeymaniP.YeganehB.SabourS.GeramizadehB.FattahiM.R.KeyvaniH.AzarpiraN.CoombsK.M.GhavamiS.LankaraniK.B.New use of an old drug:" exact="chloroquine" post="reduces viral and ALT levels in HCV non-responders (a"/>
   <result pre="pilot trial)Can. J. Physiol. Pharmacol.94201661361926998724 RoquesP.ThibervilleS.-D.Dupuis-MaguiragaL.LumF.-M.LabadieK.MartinonF.GrasG.LebonP.NgL.F.P.de LamballerieX.Le GrandR.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses102018 SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine"/>
   <result pre="of chloroquine treatment in enhancing chikungunya virus infectionViruses102018 SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseasesLancet"/>
   <result pre="implications in malaria-endemic areasAm. J. Trop. Med. Hyg.61199918018610463664 ShimizuY.YamamotoS.HommaM.IshidaN.Effect of" exact="chloroquine" post="on the growth of animal virusesArch. Gesamte Virusforsch.361972931044335025 TanY.W.YamW.K.SunJ.ChuJ.J.H.An"/>
   <result pre="the growth of animal virusesArch. Gesamte Virusforsch.361972931044335025 TanY.W.YamW.K.SunJ.ChuJ.J.H.An evaluation of" exact="chloroquine" post="as a broad-acting antiviral against hand, foot and mouth"/>
   <result pre="foot and mouth diseaseAntivir. Res.149201814314929175128 TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.TranH.T.SimmonsC.P.A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adultsPLoS Neglected"/>
   <result pre="vitro but not in vivo. Influenza Other RespirViruses12007189192 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.20201331802008 YanY.ZouZ.SunY.LiX.XuK.-F.WeiY.JinN.JiangC.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7134866\results\search\drugs\results.xml">
   <result pre="chloroquine. We had 20 years ago proposed to systematically test" exact="chloroquine" post="in viral infections because it had been shown to"/>
   <result pre="tested to assess their effectiveness against this virus. Among these," exact="teicoplanin" post="[7], an antistaphylococcal agent, had proven efficacy in vitro,"/>
   <result pre="fact, all Europeans visiting malaria-endemic geographic areas for decades received" exact="chloroquine" post="prophylaxis and continued it for 2 months after their"/>
   <result pre="2 months after their return. In addition, local residents took" exact="chloroquine" post="continuously, and treatment of malaria has long been based"/>
   <result pre="malaria has long been based on this drug. In addition," exact="hydroxychloroquine" post="has been used for decades at much higher doses"/>
   <result pre="into the antiviral effects of chloroquineLancet Infect Dis62006676916439323 4RolainJ.M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="Amoy Gardens: completing the incomplete legacyClin Infect Dis58201468368624319085 12WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7135139\results\search\drugs\results.xml">
   <result pre="Elsevier B.V. pmcid: 7135139S0924-8579(20)30082-0 doi: 10.1016/j.ijantimicag.2020.105932105932 : Article Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19 ColsonPhilippeabRolainJean-MarcabLagierJean-ChristopheabBrouquiPhilippeabRaoultDidierdidier.raoult@gmail.comab�?�[a], [b], �?�Corresponding"/>
   <result pre="by virologists, as we experienced when reporting the effectiveness of" exact="azithromycin" post="for Zika virus [2]. A response has come from"/>
   <result pre="recent publication of results showing the in vitro activity of" exact="chloroquine" post="against SARS-CoV-2 [3], data have been reported on the"/>
   <result pre="obtained from more than 100 patients showed the superiority of" exact="chloroquine" post="compared with treatment of the control group in terms"/>
   <result pre="side effects [4,5]. This has led in China to include" exact="chloroquine" post="in the recommendations regarding the prevention and treatment of"/>
   <result pre="[4,6]. There is a strong rationality for the use of" exact="chloroquine" post="to treat infections with intracellular micro-organisms. Thus, malaria has"/>
   <result pre="with this molecule [7]. In addition, our team has used" exact="hydroxychloroquine" post="for the first time for intracellular bacterial infections since"/>
   <result pre="[8,9]. Since then, we have also shown the activity of" exact="hydroxychloroquine" post="on Tropheryma whipplei, the agent of Whipple's disease, which"/>
   <result pre="of Whipple's disease, which is another intracellular bacterium for which" exact="hydroxychloroquine" post="has become a reference drug [10,11]. Altogether, one of"/>
   <result pre="Regarding viruses, for reasons probably partly identical involving alkalinisation by" exact="chloroquine" post="of the phagolysosome, several studies have shown the effectiveness"/>
   <result pre="coronavirus [1,12,13] (Table 1 ). We previously emphasised interest in" exact="chloroquine" post="for the treatment of viral infections in this journal"/>
   <result pre="the discovery in China of the in vitro activity of" exact="chloroquine" post="against SARS-CoV-2, discovered during culture tests on Vero E6"/>
   <result pre="and also aroused great enthusiasm among us. They showed that" exact="chloroquine" post="could reduce the length of hospital stay and improve"/>
   <result pre="[4,6], leading to recommend the administration of 500 mg of" exact="chloroquine" post="twice a day in patients with mild, moderate and"/>
   <result pre="COVID-19 pneumonia. At such a dosage, a therapeutic concentration of" exact="chloroquine" post="might be reached. With our experience on 2000 dosages"/>
   <result pre="might be reached. With our experience on 2000 dosages of" exact="hydroxychloroquine" post="during the past 5 years in patients with long-term"/>
   <result pre="assessed in the coming days. For us, the activity of" exact="hydroxychloroquine" post="on viruses is probably the same as that of"/>
   <result pre="hydroxychloroquine on viruses is probably the same as that of" exact="chloroquine" post="since the mechanism of action of these two molecules"/>
   <result pre="Table 1 Main results of studies on the activity of" exact="chloroquine" post="or hydroxychloroquine on coronavirusesa [alt-text] Table 1 Reference Compound(s)"/>
   <result pre="Main results of studies on the activity of chloroquine or" exact="hydroxychloroquine" post="on coronavirusesa [alt-text] Table 1 Reference Compound(s) Targeted virus"/>
   <result pre="E6 cells EC50 = 4.4 ± 1.0 μM [17] Chloroquine," exact="chloroquine" post="monophosphate, chloroquine diphosphate SARS-CoV (four strains) Vero 76 cells"/>
   <result pre="EC50 = 4.4 ± 1.0 μM [17] Chloroquine, chloroquine monophosphate," exact="chloroquine" post="diphosphate SARS-CoV (four strains) Vero 76 cells Chloroquine: EC50"/>
   <result pre="diphosphate: EC50 = 3–4 μM BALB/c mice Intraperitoneal or intranasal" exact="chloroquine" post="administration, beginning 4 h prior to virus exposure: 50"/>
   <result pre="CCID50/g at Day 3 (considered as not significant) [18] Chloroquine," exact="hydroxychloroquine" post="SARS-CoV Vero cells Chloroquine: EC50 = 6.5 ± 3.2"/>
   <result pre="cells EC50 = 0.306 ± 0.0091 μM Newborn C57BL/6 mice;" exact="chloroquine" post="administration transplacentally and via maternal milk 100%, 93%, 33%"/>
   <result pre="catus whole fetus-4 cells FIPV replication was inhibited in a" exact="chloroquine" post="concentration-dependent manner [22] Chloroquine SARS-CoV Vero E6 cells EC50"/>
   <result pre="[1] (Table 1) for additional references. References References 1RolainJ.M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="inhibits the replication of Zika virusJ Antivir Antiretrovir10201861110.4172/1948-5964.1000173 3WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="(2019-nCoV) in vitroCell Res2020 Feb 410.1038/s41422-020-0282-0[Epub ahead of print] 4GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="Chloroquine in the Treatment of Novel Coronavirus PneumoniaExpert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia [in"/>
   <result pre="from malaria to multifarious diseasesJ Antimicrob Chemother7020151608162110.1093/jac/dkv01825693996 8RaoultD.DrancourtM.VestrisG.Bactericidal effect of" exact="doxycycline" post="associated with lysosomotropic agents on Coxiella burnetii in P388D1"/>
   <result pre="DupontH.RissJ.M.Arditi-DjianeJ.BrouquiP.Treatment of Q fever endocarditis: comparison of 2 regimens containing" exact="doxycycline" post="and ofloxacin or hydroxychloroquineArch Intern Med159199916717310.1001/archinte.159.2.1679927100 10BoulosA.RolainJ.M.RaoultD.Antibiotic susceptibility of"/>
   <result pre="Q fever endocarditis: comparison of 2 regimens containing doxycycline and" exact="ofloxacin" post="or hydroxychloroquineArch Intern Med159199916717310.1001/archinte.159.2.1679927100 10BoulosA.RolainJ.M.RaoultD.Antibiotic susceptibility of Tropheryma whipplei"/>
   <result pre="of p38 MAPK and ERKAntiviral Res77200815015210.1016/j.antiviral.2007.10.01118055026 20KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob Agents"/>
   <result pre="coronavirus OC43 infection in newborn miceAntimicrob Agents Chemother5320093416342110.1128/AAC.01509-0819506054 21TakanoT.KatohY.DokiT.HohdatsuT.Effect of" exact="chloroquine" post="on feline infectious peritonitis virus infection in vitro and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7135364\results\search\drugs\results.xml">
   <result pre="due to coronaviruses. Several pre-existing and potential drug candidates, including" exact="chloroquine" post="and remdesivir, have been considered [10], [11], [12]. The"/>
   <result pre="fleximer analogues [12]. Remdesivir (GS-5734), the phosphoramidate prodrug of an" exact="adenosine" post="C‑nucleoside [13], has a similar structure to tenofovir alafenamide,"/>
   <result pre="of an adenosine C‑nucleoside [13], has a similar structure to" exact="tenofovir" post="alafenamide, which is a nucleotide analogue of adenosine 5-monophosphate"/>
   <result pre="structure to tenofovir alafenamide, which is a nucleotide analogue of" exact="adenosine" post="5-monophosphate with antiviral activity against hepatitis B virus and"/>
   <result pre="demonstrated that nucleoside triphosphate works as an incorporation competitor with" exact="adenosine" post="triphosphate, confuses viral RdRp, acts as a delayed RNA"/>
   <result pre="the viral polymerase and the proofreading exoribonucleasemBio9201810.1128/mBio.00221-18pii: e00221-18 18WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7136267\results\search\drugs\results.xml">
   <result pre="after treatment with pigments or standard viral drugs (sofosbuvir and" exact="lamivudine" post="for HCV and HBV, respectively) at their safe doses"/>
   <result pre="21.65 ± 0.25 and 4.99 ± 0.13 µg/ml, respectively, in comparison with 59.87 ± 4.59 µg/ml (HCV) for" exact="sofosbuvir" post="and 1.642 ± 0.49 µg/ml (HBV) for lamivudine. This result suggests that"/>
   <result pre="higher inhibitory effect on HCV RNA-dependent RNA polymerase (NS5B) than" exact="sofosbuvir" post="did (p &amp;lt; 0.05). Meanwhile, this pigment revealed a lower suppressor"/>
   <result pre="a lower suppressor impact on HBV DNA-dependent DNA polymerase than" exact="lamivudine" post="did (p &amp;lt; 0.05). Discussion Haloarchaea, such as Natrialba sp., are"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7136311\results\search\drugs\results.xml">
   <result pre="others, but a strong trend toward significance was found in" exact="telbivudine" post="and tenofovir, of which had the highest probability of"/>
   <result pre="weeks. Conclusion This network meta-analysis recommended the earlier use of" exact="telbivudine" post="or tenofovir, tends to be better to prevent MTCT"/>
   <result pre="risk of transmission, particularly in Asian countries [5]. Lamivudine (LAM)," exact="telbivudine" post="(LDT), and tenofovir (TDF) are the oral anti-HBV drugs"/>
   <result pre="particularly in Asian countries [5]. Lamivudine (LAM), telbivudine (LDT), and" exact="tenofovir" post="(TDF) are the oral anti-HBV drugs approved by FDA."/>
   <result pre="(Fig. 3), a strong trend toward significance was found in" exact="telbivudine" post="and tenofovir, of which had the highest probability of"/>
   <result pre="perinatal transmission of hepatitis BN Engl J Med201837891192329514030 10.ZhangHPanCQPangQTianRYanMLiuXTelbivudine or" exact="lamivudine" post="use in late pregnancy safely reduces perinatal transmission of"/>
   <result pre="12.YiWLiMHXieYet al.Prospective cohort study on the efficacy and safety of" exact="telbivudine" post="used throughout pregnancy in blocking mother-to-child transmission of hepatitis"/>
   <result pre="B virusJ Viral Hepat201724Suppl 1495629082650 13.LiuYWangMYaoSet al.Efficacy and safety of" exact="telbivudine" post="in different trimesters of pregnancy with high viremia for"/>
   <result pre="Off J Jpn Soc Hepatol201646E181E188 14.HeTBaiYCaiHet al.Safety and efficacy of" exact="lamivudine" post="or telbivudine started in early pregnancy for mothers with"/>
   <result pre="Jpn Soc Hepatol201646E181E188 14.HeTBaiYCaiHet al.Safety and efficacy of lamivudine or" exact="telbivudine" post="started in early pregnancy for mothers with active chronic"/>
   <result pre="J Int Assoc Study Liver20183812121219 17.HuYXuCXuBet al.Safety and efficacy of" exact="telbivudine" post="in late pregnancy to prevent mother-to-child transmission of hepatitis"/>
   <result pre="B virus endemic regionJ Viral Hepat201623152226192022 19.ChenHLLeeCNChangCHet al.Efficacy of maternal" exact="tenofovir" post="disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B"/>
   <result pre="transmission of hepatitis B virusHepatology20156237538625851052 20.GreenupAJTanPKNguyenVet al.Efficacy and safety of" exact="tenofovir" post="disoproxil fumarate in pregnancy to prevent perinatal transmission of"/>
   <result pre="transmission of hepatitis B virusJ Hepatol20146150250724801414 21.AyresAYuenLJacksonKMet al.Short duration of" exact="lamivudine" post="for the prevention of hepatitis B virus transmission in"/>
   <result pre="selection of resistance mutationsJ Viral Hepat20142180981724329944 22.ZhangLJWangLBlocking intrauterine infection by" exact="telbivudine" post="in pregnant chronic hepatitis B patientsChin J Hepatol200917561563 23.YangSLiuMWangLEffect"/>
   <result pre="studyWorld J Gastroenterol200391501150312854150 26.PengBAZhaoYYangXFMiaoMFZhuLHYuHYEvaluation of the efficacy and safety of" exact="telbivudine" post="in preventing mother-to-infant HBV transmissionChin Pharm J201247855857 27.ShengQJWangSJWuYYDouXGDingYHepatitis B"/>
   <result pre="women in Shenyang, China: an observational studyMedicine201897e1093129851831 28.LinYLiuYDingGet al.Efficacy of" exact="tenofovir" post="in preventing perinatal transmission of HBV infection in pregnant"/>
   <result pre="with high viral loadsSci Rep201881551430341345 29.CelenMKMertDAyMet al.Efficacy and safety of" exact="tenofovir" post="disoproxil fumarate in pregnancy for the prevention of vertical"/>
   <result pre="B virusWorld Chin J Digestol20162435173522 31.LiuJWangJYanTet al.Efficacy and safety of" exact="telbivudine" post="and tenofovir disoproxil fumarate in preventing hepatitis B vertical"/>
   <result pre="Chin J Digestol20162435173522 31.LiuJWangJYanTet al.Efficacy and safety of telbivudine and" exact="tenofovir" post="disoproxil fumarate in preventing hepatitis B vertical transmission: a"/>
   <result pre="B vertical transmission: a real-life practiceJ Viral Hepat2019261170117731177596 32.ZengJZhengCLiHEffectiveness of" exact="tenofovir" post="or telbivudine in preventing HBV vertical transmission for pregnancyMedicine201998e1509230946367"/>
   <result pre="transmission: a real-life practiceJ Viral Hepat2019261170117731177596 32.ZengJZhengCLiHEffectiveness of tenofovir or" exact="telbivudine" post="in preventing HBV vertical transmission for pregnancyMedicine201998e1509230946367 33.ZhangBFChengMLZhangQet al.Clinical"/>
   <result pre="trimester of pregnancyChin J Hepatol201523912 35.ZhouYZhengJPanHLuCLong-term efficacy and safety of" exact="telbivudine" post="in the treatment of childbearing patients with chronic hepatitis"/>
   <result pre="chronic hepatitis BChin J Hepatol201422573576 36.HanGRJiangHXYueXet al.Efficacy and safety of" exact="telbivudine" post="treatment: an open-label, prospective study in pregnant women for"/>
   <result pre="gestational stages for the prevention of mother-to-child transmission: outcomes of" exact="telbivudine" post="treatment during pregnancyMedicine201695e484727749537 41.SunWMaLHaoAet al.Predictive value of telbivudine in"/>
   <result pre="outcomes of telbivudine treatment during pregnancyMedicine201695e484727749537 41.SunWMaLHaoAet al.Predictive value of" exact="telbivudine" post="in preventing mother-to-infant transmission of hepatitis B virus in"/>
   <result pre="Gastroenterol Off Publ Pan-Arab Assoc Gastroenterol201920813 43.DengYWuWZhangDet al.The safety of" exact="telbivudine" post="in preventing mother-to-infant transmission of hepatitis B virus in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7136878\results\search\drugs\results.xml">
   <result pre="For patients with mild disease, it is recommended to take" exact="moxifloxacin" post="or azithromycin orally or intravenously according to the patient's"/>
   <result pre="with mild disease, it is recommended to take moxifloxacin or" exact="azithromycin" post="orally or intravenously according to the patient's condition. For"/>
   <result pre="chest imaging. The dose exceed 1–2 mg kg/·d equivalent of" exact="methylprednisolone" post="is not recommended. – The second edition Change:There is"/>
   <result pre="progress of chest imaging. The dose exceed 1~2mg·kg/·d equivalent of" exact="methylprednisolone" post="is not recommended. – The Third Edition Same as"/>
   <result pre="heart rate should be monitored. Triazoles Combination is not recommended:" exact="voriconazole" post="and high-dose itraconazole(&amp;gt;200mg/d) Immunosuppressant Careful combination. It may increase"/>
   <result pre="during the combined use. Hepatotoxic drugs Combined with antiepileptics, erythromycin," exact="minocycline" post="and other hepatotoxic drugs may rise potential risk of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7136885\results\search\drugs\results.xml">
   <result pre="were released into the market], pegylated interferon (IFN)-α combined with" exact="ribavirin" post="was used as a standard therapy, with aviraemia 24"/>
   <result pre="eventually led to the licensing in 2011 of first-generation DAAs" exact="boceprevir" post="and telaprevir, both NS3/4A protease inhibitors. Replicons were used"/>
   <result pre="and optimisation of candidates, reviewed in Refs. 28, 29. However," exact="boceprevir" post="and telaprevir act on HCV genotype 1 only, making"/>
   <result pre="of candidates, reviewed in Refs. 28, 29. However, boceprevir and" exact="telaprevir" post="act on HCV genotype 1 only, making development of"/>
   <result pre="minigenome system was established by tagging the coding sequence of" exact="chloramphenicol" post="acetyl-transferase (cat) with the 5′ leader and the 3′"/>
   <result pre="replacing the region coding for the structural polyprotein with the" exact="chloramphenicol" post="transferase (cat) gene [58]. However, replicons of the SINV"/>
   <result pre="members. Lead compounds identified in the past years include abamectin," exact="ivermectin" post="and berberine – a plant-derived isoquinoline alkaloid [64]. Abamectin"/>
   <result pre="and berberine – a plant-derived isoquinoline alkaloid [64]. Abamectin and" exact="ivermectin" post="are widely used antihelminthics but no follow-up studies were"/>
   <result pre="II/III trial is ongoing to assess safety and efficacy of" exact="ivermectin" post="use in DENV infections [65]. In a follow-up study,"/>
   <result pre="encephalitis virus replicons in mammalian cellsJ. Virol.7920057597760815919912 64VargheseF.S.Discovery of berberine," exact="abamectin" post="and ivermectin as antivirals against chikungunya and other alphavirusesAntiviral"/>
   <result pre="replicons in mammalian cellsJ. Virol.7920057597760815919912 64VargheseF.S.Discovery of berberine, abamectin and" exact="ivermectin" post="as antivirals against chikungunya and other alphavirusesAntiviral Res.126201611712426752081 65Efficacy"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7138017\results\search\drugs\results.xml">
   <result pre="National Health Commission suggests taking an anti-HIV drug combination of" exact="lopinavir" post="and ritonavir and inhaling a dose of nebulised interferon"/>
   <result pre="Commission suggests taking an anti-HIV drug combination of lopinavir and" exact="ritonavir" post="and inhaling a dose of nebulised interferon α for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7138382\results\search\drugs\results.xml">
   <result pre="with lopinavir/ritonavir (Chan et al., 2015; Sheahan et al., 2020)," exact="ribavirin" post="(Chen et al., 2004; Morgenstern et al., 2005; Omrani"/>
   <result pre="(Sheahan et al., 2020), while a combination of IFNα2a with" exact="ribavirin" post="delayed mortality without decreasing it on the long run"/>
   <result pre="(Omrani et al., 2014). Similarly, the combination of IFNα2b with" exact="ribavirin" post="gave excellent results in the rhesus macaque (Falzarano et"/>
   <result pre="in pulmonary endothelial cells, resulting in the secretion of anti-inflammatory" exact="adenosine" post="and the maintenance of endothelial barrier function. This process"/>
   <result pre="inhalation twice a day to the patients, in combination with" exact="ribavirin" post="(Dong et al., 2020; Lu, 2020). Clinical trials have"/>
   <result pre="lopinavir/ritonavir and IFNα2b (ChiCTR2000029387) or a combination of lopinavir/ritonavir with" exact="ribavirin" post="and IFNβ1b administered subcutanously (NCT04276688) for the treatment of"/>
   <result pre="(Mager and Jusko, 2002). The combination of IFN-I with lopinavir/ritonavir," exact="ribavirin" post="or remdesivir could improve its efficacy, because of the"/>
   <result pre="syndrome coronavirus: an observational studyInt. J. Infect. Dis.202014424610.1016/j.ijid.2013.12.00324406736 ArabiY.M.ShalhoubS.Al-OmariA.MandourahY.Al-HameedF.SindiA.AlraddadiB.Al-MotairiA.Al-KhatibK.Abdul-MomminA.QushmaqI.A.MadyA.SolaimanO.Al-AithanA.BalkhyH.H.Al-RaddadiR.RajabA.Al-MekhlafiG.A.Al-HarthyA.KharabaA.Al-JabbaryA.PintoR.SadatM.Al-MutairiH.Al-QasimE.JoseJ.DeebA.M.MersonL.HaydenF.G.FowlerR.AldawoodA.S.Effect of" exact="ribavirin" post="and interferon on the outcome of critically ill patients"/>
   <result pre="prevent acute viral respiratory infections in military recruitsVaccine2820104445445110.1016/j.vaccine.2010.03.06220394720 HartB.J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR.F.OlingerG.G.FriemanM.B.HolbrookM.R.JahrlingP.B.HensleyL.Interferon-β and" exact="mycophenolic acid" post="are potent inhibitors of middle east respiratory syndrome coronavirus"/>
   <result pre="host defensesAnnu. Rev. Immunol.32201451354510.1146/annurev-immunol-032713-12023124555472 ShalhoubS.FarahatF.Al-JiffriA.SimhairiR.ShammaO.SiddiqiN.MushtaqA.IFN-α2a or IFN-β1a in combination with" exact="ribavirin" post="to treat Middle East respiratory syndrome coronavirus pneumonia: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7138655\results\search\drugs\results.xml">
   <result pre="be reduced and overall survival would increase. The effect of" exact="hydroxychloroquine" post="on hepatic tissue seems ambiguous, since it is used"/>
   <result pre="al. 2020). Furthermore, azithromycin-induced hepatotoxicity only appears 1–3 weeks after" exact="azithromycin" post="initiation (Martinez et al. 2015). Patients suffering either from"/>
   <result pre="(NAFLD). NAFLD can sensitize the liver for hepatotoxicants such as" exact="acetaminophen" post="(Michaut et al. 2014; Massart et al. 2017), which"/>
   <result pre="such as intake of steatosis-inducing drugs (e.g. sodium valproate, amiodarone," exact="tamoxifen" post="and methotrexate) (Boeckmans et al. 2018), could play a"/>
   <result pre="have been used to assess the pharmacological effects of remdesivir," exact="chloroquine" post="and hydroxychloroquine, all potential anti-COVID-19 treatments under study (Liu"/>
   <result pre="nonalcoholic fatty liver disease: friend or foe?Gastroenterology20161501704170910.1053/j.gastro.2016.01.02526826669 GautretPLagierJParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="injury using human hepatic cell systemsToxicol Lett2016240505910.1016/j.toxlet.2015.10.01426497421 WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-NCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7139247\results\search\drugs\results.xml">
   <result pre="immature, non-infectious virus particles [68,69]. It has been reported that" exact="ritonavir" post="and lopinavir can bind to the endopeptidase C30 of"/>
   <result pre="virus particles [68,69]. It has been reported that ritonavir and" exact="lopinavir" post="can bind to the endopeptidase C30 of SARS-CoV-2 protease"/>
   <result pre="of RNA and DNA viruses by suppressing the activity of" exact="inosine" post="monophosphate dehydrogenase, which is required for the synthesis of"/>
   <result pre="outbreak of SARS in Hong Kong [74], [75], [76]. Thus," exact="ribavirin" post="could be considered as a treatment option for COVID-19"/>
   <result pre="is a widely used antimalarial and autoimmune disease drug. Recently," exact="chloroquine" post="has been reported as a potential broad-spectrum antiviral drug"/>
   <result pre="potential broad-spectrum antiviral drug [77,78]. Wang et al. found that" exact="chloroquine" post="effectively suppresses the recently emerged novel CoV (SARS-CoV-2) in"/>
   <result pre="in severe acute respiratory syndrome: a preliminary studyJAMA29020033222322810.1001/jama.290.24.322214693875 68WalmsleySBernsteinBKingMArribasJBeallGRuanePLopinavir–ritonavir versus" exact="nelfinavir" post="for the initial treatment of HIV infectionN Engl J"/>
   <result pre="of HIVAIDS222008F1F910.1097/QAD.0b013e3282f4243b 70LinSShenRGuoXMolecular modeling evaluation of the binding abilities of" exact="ritonavir" post="and lopinavir to Wuhan pneumonia coronavirus proteasesbioRxiv2020 Feb 310.1101/2020.01.31.929695"/>
   <result pre="70LinSShenRGuoXMolecular modeling evaluation of the binding abilities of ritonavir and" exact="lopinavir" post="to Wuhan pneumonia coronavirus proteasesbioRxiv2020 Feb 310.1101/2020.01.31.929695 71ChuCMChengVCHungIFWongMMChanKHChanKSRole of"/>
   <result pre="in patients with severe acute respiratory syndrome (SARS) treated with" exact="ribavirin" post="and steroidsClin Exp Immunol135200446747310.1111/j.1365-2249.2003.02391.x15008980 76PeirisJSLaiSTPoonLLGuanYYamLYLimWCoronavirus as a possible cause"/>
   <result pre="into the antiviral effects of chloroquineLancet Infect Dis62006676910.1016/S1473-3099(06)70361-916439323 78YanYZouZSunYLiXXuKFWeiYAnti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="H5N1 virus infection in an animal modelCell Res23201330030210.1038/cr.2012.16523208422 79WangMCaoRZhangLYangXLiuJXuMRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7139252\results\search\drugs\results.xml">
   <result pre="one minute. In contrast, other biocidal agents, such as 0.05–0.2%" exact="benzalkonium chloride," post="or 0.02% chlorhexidine digluconate, are less effective [24]. The"/>
   <result pre="other biocidal agents, such as 0.05–0.2% benzalkonium chloride, or 0.02%" exact="chlorhexidine" post="digluconate, are less effective [24]. The avoidance of these"/>
   <result pre="the virus entry into the host cells 5.2.1 Chloroquine and" exact="hydroxychloroquine" post="These viral entry blockages include chloroquine, hydroxychloroquine umifenovir, and"/>
   <result pre="5.2.1 Chloroquine and hydroxychloroquine These viral entry blockages include chloroquine," exact="hydroxychloroquine" post="umifenovir, and interferon [112]. A cell line study reported"/>
   <result pre="umifenovir, and interferon [112]. A cell line study reported that" exact="chloroquine" post="significantly decreased the human coronavirus-229E replication at a lower"/>
   <result pre="the clinical safety profiles, that justify future clinical research of" exact="chloroquine" post="and hydroxychloroquine in patients with COVID-19 [114]. There are"/>
   <result pre="safety profiles, that justify future clinical research of chloroquine and" exact="hydroxychloroquine" post="in patients with COVID-19 [114]. There are currently several"/>
   <result pre="with COVID-19 [114]. There are currently several clinical trials of" exact="chloroquine" post="for COVID-19, either as monotherapy or in combination with"/>
   <result pre="as monotherapy or in combination with other medications such as" exact="azithromycin" post="[112]. A non-randomized clinical trial reported the reduction of"/>
   <result pre="report the critical clinical outcomes, including death [115]. Chloroquine and" exact="hydroxychloroquine" post="are the immunomodulatory drugs with potential antiviral effects. However,"/>
   <result pre="medications. It is still premature to conclude the role of" exact="chloroquine" post="and hydroxychloroquine in COVID-19, while several clinical trials are"/>
   <result pre="is still premature to conclude the role of chloroquine and" exact="hydroxychloroquine" post="in COVID-19, while several clinical trials are on their"/>
   <result pre="pathway, including Janus-associated kinase (JAK) inhibitors through baricitinib, ruxolitinib, and" exact="imatinib" post="[119,120]. Currently, some of these drugs are being tested"/>
   <result pre="of HIV infection [137]. The cytochrome P450 inhibitory effects of" exact="ritonavir" post="prolonged the half-life of Lopinavir and extended its protease"/>
   <result pre="uses in combination with other cytochrome P450 inhibitors, such as" exact="ritonavir" post="or cobicistat, for the treatment of HIV infection [143]."/>
   <result pre="for the efficacy against COVID-19 [112]. 5.4.3 Viperin, emodin, and" exact="promazine" post="There was the in-vitro evidence of inhibitory action on"/>
   <result pre="Res.77200815015218055026 114CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.005(Epub ahead of"/>
   <result pre="treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.005(Epub ahead of print) 115GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.DupontH.HonoréS.ColsonP.ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="treatment of hemorrhagic fever virus infectionsChem. Asian J.1420193962396831389664 133WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="(2019-nCoV)Nat. Rev. Drug Discov.19202014915032127666 135WangY.FanG.SalamA.HorbyP.HaydenF.G.ChenC.PanJ.ZhengJ.LuB.GuoL.Comparative effectiveness of combined favipiravir and" exact="oseltamivir" post="therapy versus oseltamivir monotherapy in critically ill patients with"/>
   <result pre="Discov.19202014915032127666 135WangY.FanG.SalamA.HorbyP.HaydenF.G.ChenC.PanJ.ZhengJ.LuB.GuoL.Comparative effectiveness of combined favipiravir and oseltamivir therapy versus" exact="oseltamivir" post="monotherapy in critically ill patients with influenza virus infectionJ."/>
   <result pre="SARS: initial virological and clinical findingsThorax59200425225610.1136/thorax.2003.01265814985565 141KimU.J.WonE.-J.KeeS.-J.JungS.-I.JangH.-C.Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-α for Middle East respiratory syndromeAntivir. Ther.21201645545910.3851/IMP300226492219 142ArabiY.M.AsiriA.Y.AssiriA.M.JokhdarH.A."/>
   <result pre="for a recursive two-stage group sequential randomized controlled trialTrials212020810.1186/s13063-019-3846-x31900204 143BalayanT.HorvathH.RutherfordG.W.Ritonavir-boosted" exact="darunavir" post="plus two nucleoside reverse transcriptase inhibitors versus other regimens"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7140116\results\search\drugs\results.xml">
   <result pre="for the improvement of current antimetabolite-based treatments. SAMHD1 antimetabolite CDK4/6" exact="pemetrexed" post="HIV cancer 1. Introduction Sterile alpha motif and histidine-aspartic"/>
   <result pre="inactivation of a number of different nucleoside analogues [30,31], including" exact="cytarabine" post="(Cytosar-U®,Ara-C), a first line therapeutic agent for acute myelogenous"/>
   <result pre="degradation either enhanced (cladribine, clofarabine, and nelarabine) or decreased (capecitabine," exact="floxuridine" post="and fluorouracil) the potency of the nucleoside analogues tested"/>
   <result pre="degradation dramatically impaired the efficacy of anti-folate inhibitors such as" exact="pemetrexed" post="and methotrexate (Figure 2B). Calculation of 50% effective concentrations"/>
   <result pre="impaired the efficacy of anti-folate inhibitors such as pemetrexed and" exact="methotrexate" post="(Figure 2B). Calculation of 50% effective concentrations (EC50) of"/>
   <result pre="SAMHD1 also affected the efficacy of anti-folate drugs such as" exact="pemetrexed" post="and methotrexate (Table 1). 2.2. SAMHD1 Is Required for"/>
   <result pre="affected the efficacy of anti-folate drugs such as pemetrexed and" exact="methotrexate" post="(Table 1). 2.2. SAMHD1 Is Required for Antiviral Activity"/>
   <result pre="[14]. The antiviral activity of the highly selective CDK4/6 inhibitor" exact="palbociclib" post="is dependent on SAMHD1 expression [14,19] (Figure 3A). Thus,"/>
   <result pre="SAMHD1. The three agents were tested at the concentration where" exact="palbociclib" post="showed the highest efficacy in cell culture (1 μM,"/>
   <result pre="3B). Interestingly, similar results were obtained when the multi-kinase inhibitor" exact="midostaurin" post="was evaluated (Figure S1A), suggesting that activity of multiple"/>
   <result pre="SAMHD1 expression and phosphorylation was measured by Western blot. Both" exact="palbociclib" post="and midostaurin blocked SAMHD1 phosphorylation, whereas SAMHD1 protein expression"/>
   <result pre="and phosphorylation was measured by Western blot. Both palbociclib and" exact="midostaurin" post="blocked SAMHD1 phosphorylation, whereas SAMHD1 protein expression was not"/>
   <result pre="decreased expression of Rb, a substrate of CDK6, suggesting that" exact="palbociclib" post="and midostaurin also affect CDK6-mediated CDK2 phosphorylation of SAMHD1"/>
   <result pre="of Rb, a substrate of CDK6, suggesting that palbociclib and" exact="midostaurin" post="also affect CDK6-mediated CDK2 phosphorylation of SAMHD1 (Figure 3C,"/>
   <result pre="inhibition of its phosphorylation. Thus, we evaluated the capacity of" exact="palbociclib" post="to modify the activity of antimetabolites. Antiviral activity of"/>
   <result pre="palbociclib to modify the activity of antimetabolites. Antiviral activity of" exact="pemetrexed" post="and fluorouracil were evaluated alone or in combination with"/>
   <result pre="modify the activity of antimetabolites. Antiviral activity of pemetrexed and" exact="fluorouracil" post="were evaluated alone or in combination with palbociclib in"/>
   <result pre="pemetrexed and fluorouracil were evaluated alone or in combination with" exact="palbociclib" post="in primary macrophages. Pemetrexed inhibited HIV-1 replication in a"/>
   <result pre="(EC50 = 0.1 µM, Figure 4A, black line). Combination of" exact="pemetrexed" post="with increasing concentrations of palbociclib (EC50 = 0.12 µM)"/>
   <result pre="4A, black line). Combination of pemetrexed with increasing concentrations of" exact="palbociclib" post="(EC50 = 0.12 µM) enhanced the antiviral potency of"/>
   <result pre="combination index (CI) indicated strong synergy (CI ≤ 0.041 for" exact="palbociclib" post="at 0.04 µM combined with different concentrations of pemetrexed,"/>
   <result pre="µM combined with different concentrations of pemetrexed, Table 2). Interestingly," exact="pemetrexed" post="and palbociclib activity, as well as the synergistic effect"/>
   <result pre="with different concentrations of pemetrexed, Table 2). Interestingly, pemetrexed and" exact="palbociclib" post="activity, as well as the synergistic effect observed in"/>
   <result pre="of SAMHD1, (Figure 4A,B, right panels). Furthermore, the combination of" exact="pemetrexed" post="with the multi-kinase inhibitor midostaurin (EC50 = 0.62 µM)"/>
   <result pre="panels). Furthermore, the combination of pemetrexed with the multi-kinase inhibitor" exact="midostaurin" post="(EC50 = 0.62 µM) also showed a highly synergistic"/>
   <result pre="panels). On the other hand, combination of the nucleoside analogue" exact="fluorouracil" post="or the multikinase inhibitor midostaurin with palbociclib showed more"/>
   <result pre="combination of the nucleoside analogue fluorouracil or the multikinase inhibitor" exact="midostaurin" post="with palbociclib showed more limited effects, i.e., palbociclib partially"/>
   <result pre="the nucleoside analogue fluorouracil or the multikinase inhibitor midostaurin with" exact="palbociclib" post="showed more limited effects, i.e., palbociclib partially enhanced the"/>
   <result pre="multikinase inhibitor midostaurin with palbociclib showed more limited effects, i.e.," exact="palbociclib" post="partially enhanced the antiviral potency of fluorouracil or midostaurin"/>
   <result pre="limited effects, i.e., palbociclib partially enhanced the antiviral potency of" exact="fluorouracil" post="or midostaurin in the presence of SAMHD1 (Figure S2)."/>
   <result pre="i.e., palbociclib partially enhanced the antiviral potency of fluorouracil or" exact="midostaurin" post="in the presence of SAMHD1 (Figure S2). Combination index"/>
   <result pre="cell growth, thus we evaluated cytotoxic efficacy of the antimetabolites" exact="pemetrexed" post="and fluorouracil in combination with the CDK4/6 inhibitor palbociblib"/>
   <result pre="thus we evaluated cytotoxic efficacy of the antimetabolites pemetrexed and" exact="fluorouracil" post="in combination with the CDK4/6 inhibitor palbociblib in the"/>
   <result pre="showed significant differences between them (Table S1). The combination of" exact="pemetrexed" post="with palbociclib enhanced the cytotoxicity of the antimetabolite in"/>
   <result pre="differences between them (Table S1). The combination of pemetrexed with" exact="palbociclib" post="enhanced the cytotoxicity of the antimetabolite in all cell"/>
   <result pre="when antiviral efficacy was measured (Table 3). The combination of" exact="fluorouracil" post="with palbociclib enhanced fluorouracil potency in TZM-bl and T47D"/>
   <result pre="efficacy was measured (Table 3). The combination of fluorouracil with" exact="palbociclib" post="enhanced fluorouracil potency in TZM-bl and T47D cells but"/>
   <result pre="measured (Table 3). The combination of fluorouracil with palbociclib enhanced" exact="fluorouracil" post="potency in TZM-bl and T47D cells but not in"/>
   <result pre="inhibitor palbociclib, protein expression in primary macrophages treated with pemetrexed," exact="fluorouracil" post="and palbociclib, alone or in combination was evaluated (Figure"/>
   <result pre="alone or in combination was evaluated (Figure 6A). As expected," exact="palbociclib" post="alone inhibited phosphorylation of pRb and SAMHD1, therefore activating"/>
   <result pre="triphosphohydrolase function and subsequently reducing the intracellular dNTP pool. Interestingly," exact="pemetrexed" post="and fluorouracil treatment resulted in different effects, i.e., while"/>
   <result pre="and subsequently reducing the intracellular dNTP pool. Interestingly, pemetrexed and" exact="fluorouracil" post="treatment resulted in different effects, i.e., while fluorouracil acts"/>
   <result pre="pemetrexed and fluorouracil treatment resulted in different effects, i.e., while" exact="fluorouracil" post="acts similarly to palbociclib, pemetrexed did not decrease the"/>
   <result pre="in different effects, i.e., while fluorouracil acts similarly to palbociclib," exact="pemetrexed" post="did not decrease the phosphorylation of pRb and SAMHD1."/>
   <result pre="did not decrease the phosphorylation of pRb and SAMHD1. Although" exact="pemetrexed" post="activity is dependent on SAMHD1, its mechanisms of action"/>
   <result pre="pemetrexed–palbociclib drug combination compared to fluorouracil–palbociblib. Thus, antifolates such as" exact="pemetrexed" post="inhibit the dNTP pool by a mechanism not directly"/>
   <result pre="other hand, when two compounds directly affecting SAMHD1 phosphorylation (i.e.," exact="fluorouracil" post="and palbociclib) are combined, the synergic effect is less"/>
   <result pre="analogues but also anti-folate drugs. Interestingly, antifolate drugs such as" exact="pemetrexed" post="or methotrexate showed increased potency in SAMHD1-expressing cells, whereas"/>
   <result pre="also anti-folate drugs. Interestingly, antifolate drugs such as pemetrexed or" exact="methotrexate" post="showed increased potency in SAMHD1-expressing cells, whereas nucleoside analogues"/>
   <result pre="(AraC and clofarabine) and other types of hematological cancers like" exact="nelarabine" post="for T-lymphoblastic lymphoma, cladribine used in the treatment of"/>
   <result pre="other types of hematological cancers like nelarabine for T-lymphoblastic lymphoma," exact="cladribine" post="used in the treatment of hairy cell leukemia and"/>
   <result pre="serum (FBS; Thermo Fisher Scientific, Waltham, MA, USA), penicillin and" exact="streptomycin" post="(Thermo Fisher Scientific, Waltham, MA, USA) and differentiated to"/>
   <result pre="technique as described elsewhere (22). 4.2. Drugs 33-Azido-3-deoxythymidine (zidovudine, AZT)," exact="nevirapine" post="(NVP), 1-beta-D-Arabinofuranosylcytosine (AraC), 9-beta-D-Arabinofuranosyl-2-fluoroadenine (fludarabine), 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine (nelarabine), 2-Chloro-2′-deoxyadenosine (cladribine),"/>
   <result pre="2-Chloro-2′-deoxyadenosine (cladribine), 2-chloro-9-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine (clofarabine), 2′,2′-Difluorodeoxycytidine (gemcitabine), 5-Fluoro-2-desoxyuridine (floxuridine), 5-Fluoropyrimidine-2,4-dione (fluorouracil)," exact="pemetrexed" post="and 4′-N-benzoylstaurosporine (midostaurin) were purchased from Sigma-Aldrich (Madrid, Spain)."/>
   <result pre="online at https://www.mdpi.com/2072-6694/12/3/713/s1, Figure S1: Efficacy of the multi-kinase inhibitor" exact="midostaurin" post="depends on SAMHD1 expression, Figure S2: Relative effect of"/>
   <result pre="Cycle2017161029103810.1080/15384101.2017.131440728436707 28.HeroldN.RuddS.G.LjungbladL.SanjivK.MyrbergI.H.PaulinC.B.J.HeshmatiY.HagenkortA.KutznerJ.PageB.D.G.et al.Targeting SAMHD1 with the Vpx protein to improve" exact="cytarabine" post="therapy for hematological malignanciesNat. Med.20172325626310.1038/nm.426528067901 29.SchneiderC.OellerichT.BaldaufH.-M.SchwarzS.-M.ThomasD.FlickR.BohnenbergerH.KaderaliL.StegmannL.CremerA.et al.SAMHD1 is a"/>
   <result pre="for hematological malignanciesNat. Med.20172325626310.1038/nm.426528067901 29.SchneiderC.OellerichT.BaldaufH.-M.SchwarzS.-M.ThomasD.FlickR.BohnenbergerH.KaderaliL.StegmannL.CremerA.et al.SAMHD1 is a biomarker for" exact="cytarabine" post="response and a therapeutic target in acute myeloid leukemiaNat."/>
   <result pre="and drug resistance activities of SAMHD1Exp. Hematol.201752323910.1016/j.exphem.2017.05.00128502830 36.JoergerM.OmlinA.CernyT.FrühM.The role of" exact="pemetrexed" post="in advanced non small-cell lung cancer: Special focus on"/>
   <result pre="of untreated MDMs (no drug, ND) or macrophages treated with" exact="palbociclib" post="at the indicated doses. Membranes were blotted with an"/>
   <result pre="antiviral activity. Inhibition of HIV infection with increasing doses of" exact="palbociclib" post="and pemetrexed was measured. Percentage of GFP+ cells relative"/>
   <result pre="Inhibition of HIV infection with increasing doses of palbociclib and" exact="pemetrexed" post="was measured. Percentage of GFP+ cells relative to the"/>
   <result pre="duplicate is shown. (B) As in (A), relative effect of" exact="pemetrexed" post="alone (white bars) or in combination with a fixed"/>
   <result pre="(white bars) or in combination with a fixed dose of" exact="palbociclib" post="0.04 µM (black bars), in the presence (left panel)"/>
   <result pre="antiviral activity. Inhibition of HIV infection with increasing doses of" exact="midostaurin" post="and pemetrexed was measured. Percentage of GFP+ cells relative"/>
   <result pre="Inhibition of HIV infection with increasing doses of midostaurin and" exact="pemetrexed" post="was measured. Percentage of GFP+ cells relative to the"/>
   <result pre="duplicate is shown. (D) As in (C), relative effect of" exact="pemetrexed" post="(PTX) alone (white bars) or in combination with a"/>
   <result pre="(white bars) or in combination with a fixed dose of" exact="midostaurin" post="0.2 µM (black bars), in the presence (left panel)"/>
   <result pre="and MDA-MB-468 cell lines, respectively. Left panels, cytotoxic activity of" exact="palbociclib" post="alone (5 µM, white bars), pemetrexed alone (black bars"/>
   <result pre="panels, cytotoxic activity of palbociclib alone (5 µM, white bars)," exact="pemetrexed" post="alone (black bars at 0.2, 1 or 0.04 µM"/>
   <result pre="the same concentration (grey bars). Right panels, cytotoxic activity of" exact="palbociclib" post="alone (5 µM, white bars), fluorouracil alone (5 µM,"/>
   <result pre="panels, cytotoxic activity of palbociclib alone (5 µM, white bars)," exact="fluorouracil" post="alone (5 µM, black bars) or the combination of"/>
   <result pre="for drug synergy. (A) Protein expression in MDMs treated with" exact="palbociclib" post="(PD) at 1 µM, pemetrexed (PTX) and fluorouracil (FU),"/>
   <result pre="expression in MDMs treated with palbociclib (PD) at 1 µM," exact="pemetrexed" post="(PTX) and fluorouracil (FU), both at 5µM and the"/>
   <result pre="treated with palbociclib (PD) at 1 µM, pemetrexed (PTX) and" exact="fluorouracil" post="(FU), both at 5µM and the corresponding drug combinations"/>
   <result pre="model of drug interactions. Antimetabolites affecting dNTP synthesis such as" exact="pemetrexed" post="inhibit dNTP pool by a mechanism not directly affecting"/>
   <result pre="and thus synergy with anticancer drugs affecting SAMHD1 phosphorylation as" exact="palbociclib" post="is higher compared to compounds also targeting SAMHD1 function"/>
   <result pre="of antimetabolites (AraC, fludarabine, nelarabine, cladribine, clofarabine, gemcitabine, floxuridine, fluorouracil," exact="pemetrexed" post="and methotrexate) and antiretrovirals (AZT and NVP) in macrophages"/>
   <result pre="or inversely (+/-). cancers-12-00713-t002_Table 2Table 2 Combination index values for" exact="pemetrexed" post="and fluorouracil combinations with palbociclib and midostaurin. Macrophages were"/>
   <result pre="(+/-). cancers-12-00713-t002_Table 2Table 2 Combination index values for pemetrexed and" exact="fluorouracil" post="combinations with palbociclib and midostaurin. Macrophages were treated with"/>
   <result pre="2 Combination index values for pemetrexed and fluorouracil combinations with" exact="palbociclib" post="and midostaurin. Macrophages were treated with the different at"/>
   <result pre="different at indicated concentrations in combination with 0.04 µM of" exact="palbociclib" post="or 0.2 µM of midostaurin and infected with HIV-1"/>
   <result pre="combination with 0.04 µM of palbociclib or 0.2 µM of" exact="midostaurin" post="and infected with HIV-1 for 48 h. Drug efficacy was"/>
   <result pre="= 1, additive. cancers-12-00713-t003_Table 3Table 3 Combination index values for" exact="pemetrexed" post="and fluorouracil combinations with palbociclib. TZM-bl, MDA-MB-468 and T47D"/>
   <result pre="additive. cancers-12-00713-t003_Table 3Table 3 Combination index values for pemetrexed and" exact="fluorouracil" post="combinations with palbociclib. TZM-bl, MDA-MB-468 and T47D cells were"/>
   <result pre="MDA-MB-468 and T47D cells were treated with indicated concentrations of" exact="pemetrexed" post="or fluorouracil in combination with 5 µM of palbociclib."/>
   <result pre="T47D cells were treated with indicated concentrations of pemetrexed or" exact="fluorouracil" post="in combination with 5 µM of palbociclib. Cytotoxic effect"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral1\PMC7140361\results\search\drugs\results.xml">
   <result pre="Finally, in Schuierer’s report [1], the treated patients required lower" exact="norepinephrine" post="doses than untreated patients on baseline, and the treated"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
